0001814287-23-000007.txt : 20230814 0001814287-23-000007.hdr.sgml : 20230814 20230814083210 ACCESSION NUMBER: 0001814287-23-000007 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 119 CONFORMED PERIOD OF REPORT: 20230630 FILED AS OF DATE: 20230814 DATE AS OF CHANGE: 20230814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Abacus Life, Inc. CENTRAL INDEX KEY: 0001814287 STANDARD INDUSTRIAL CLASSIFICATION: INVESTMENT ADVICE [6282] IRS NUMBER: 851210472 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39403 FILM NUMBER: 231166515 BUSINESS ADDRESS: STREET 1: 2101 PARK CENTER DRIVE, SUITE 170 CITY: ORLANDO STATE: FL ZIP: 32835 BUSINESS PHONE: (800) 561-4148 MAIL ADDRESS: STREET 1: 2101 PARK CENTER DRIVE, SUITE 170 CITY: ORLANDO STATE: FL ZIP: 32835 FORMER COMPANY: FORMER CONFORMED NAME: East Resources Acquisition Co DATE OF NAME CHANGE: 20200605 10-Q 1 abl-20230630.htm 10-Q abl-20230630
000181428712-312023Q2falseP1MP3MP1MP3M100018142872023-01-012023-06-300001814287us-gaap:CommonStockMember2023-01-012023-06-300001814287us-gaap:WarrantMember2023-01-012023-06-3000018142872023-08-14xbrli:shares00018142872023-06-30iso4217:USD00018142872022-12-310001814287us-gaap:NonrelatedPartyMember2023-06-300001814287us-gaap:NonrelatedPartyMember2022-12-310001814287us-gaap:RelatedPartyMember2023-06-300001814287us-gaap:RelatedPartyMember2022-12-310001814287srt:AffiliatedEntityMember2023-06-300001814287srt:AffiliatedEntityMember2022-12-310001814287abl:OwnersMember2023-06-300001814287abl:OwnersMember2022-12-310001814287us-gaap:CommonClassAMember2022-12-31iso4217:USDxbrli:shares0001814287us-gaap:CommonClassAMember2023-06-300001814287us-gaap:RelatedPartyMember2023-04-012023-06-300001814287us-gaap:RelatedPartyMember2022-04-012022-06-300001814287us-gaap:RelatedPartyMember2023-01-012023-06-300001814287us-gaap:RelatedPartyMember2022-01-012022-06-300001814287us-gaap:NonrelatedPartyMember2023-04-012023-06-300001814287us-gaap:NonrelatedPartyMember2022-04-012022-06-300001814287us-gaap:NonrelatedPartyMember2023-01-012023-06-300001814287us-gaap:NonrelatedPartyMember2022-01-012022-06-3000018142872023-04-012023-06-3000018142872022-04-012022-06-3000018142872022-01-012022-06-300001814287us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-03-310001814287us-gaap:AdditionalPaidInCapitalMember2022-03-310001814287us-gaap:RetainedEarningsMember2022-03-310001814287us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001814287us-gaap:NoncontrollingInterestMember2022-03-3100018142872022-03-310001814287us-gaap:RetainedEarningsMember2022-04-012022-06-300001814287us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-012022-06-300001814287us-gaap:NoncontrollingInterestMember2022-04-012022-06-300001814287us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-06-300001814287us-gaap:AdditionalPaidInCapitalMember2022-06-300001814287us-gaap:RetainedEarningsMember2022-06-300001814287us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300001814287us-gaap:NoncontrollingInterestMember2022-06-3000018142872022-06-300001814287us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-03-310001814287us-gaap:AdditionalPaidInCapitalMember2023-03-310001814287us-gaap:RetainedEarningsMember2023-03-310001814287us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001814287us-gaap:NoncontrollingInterestMember2023-03-3100018142872023-03-310001814287us-gaap:RetainedEarningsMember2023-04-012023-06-300001814287us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300001814287us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-04-012023-06-300001814287us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300001814287us-gaap:NoncontrollingInterestMember2023-04-012023-06-300001814287us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-06-300001814287us-gaap:AdditionalPaidInCapitalMember2023-06-300001814287us-gaap:RetainedEarningsMember2023-06-300001814287us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300001814287us-gaap:NoncontrollingInterestMember2023-06-300001814287us-gaap:CommonStockMemberus-gaap:CommonClassAMember2021-12-310001814287us-gaap:AdditionalPaidInCapitalMember2021-12-310001814287us-gaap:RetainedEarningsMember2021-12-310001814287us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001814287us-gaap:NoncontrollingInterestMember2021-12-3100018142872021-12-310001814287us-gaap:RetainedEarningsMember2022-01-012022-06-300001814287us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-06-300001814287us-gaap:NoncontrollingInterestMember2022-01-012022-06-300001814287us-gaap:CommonStockMemberus-gaap:CommonClassAMember2022-12-310001814287us-gaap:AdditionalPaidInCapitalMember2022-12-310001814287us-gaap:RetainedEarningsMember2022-12-310001814287us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001814287us-gaap:NoncontrollingInterestMember2022-12-310001814287us-gaap:RetainedEarningsMember2023-01-012023-06-300001814287us-gaap:AdditionalPaidInCapitalMember2023-01-012023-06-300001814287us-gaap:CommonStockMemberus-gaap:CommonClassAMember2023-01-012023-06-300001814287us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-06-300001814287us-gaap:NoncontrollingInterestMember2023-01-012023-06-300001814287abl:LongevityMarketAssetsLLCMember2023-06-30xbrli:pure0001814287us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2023-06-300001814287us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2022-12-3100018142872021-01-01abl:provider0001814287abl:ExpenseSupportAgreementMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-04-012023-06-300001814287abl:ExpenseSupportAgreementMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2022-04-012022-06-300001814287abl:ExpenseSupportAgreementMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-01-012023-06-300001814287abl:ExpenseSupportAgreementMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2022-01-012022-06-300001814287abl:ProviderOneMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-06-300001814287us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberabl:ProviderTwoMember2023-06-300001814287abl:ProviderOneMemberus-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2022-12-310001814287us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMemberabl:ProviderTwoMember2022-12-3100018142872021-10-04abl:investor0001814287abl:LMXSeriesLLCMemberus-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-10-042021-10-040001814287us-gaap:VariableInterestEntityPrimaryBeneficiaryMember2021-10-042021-10-040001814287us-gaap:VariableInterestEntityPrimaryBeneficiaryMemberabl:LongevityMarketAdvisorsLLCMember2022-03-032022-03-030001814287abl:RegionalInvestmentServicesIncMember2022-03-032022-03-030001814287abl:RegionalInvestmentServicesIncMemberabl:LongevityMarketAdvisorsLLCMember2023-06-300001814287us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberus-gaap:RelatedPartyMemberabl:Customer1Member2023-01-012023-06-300001814287us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberabl:Customer2Memberus-gaap:RelatedPartyMember2023-01-012023-06-300001814287us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberus-gaap:RelatedPartyMemberabl:Customer1Member2022-01-012022-12-310001814287us-gaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMemberabl:Customer2Memberus-gaap:RelatedPartyMember2022-01-012022-12-310001814287us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberabl:ActiveManagementSegmentMemberus-gaap:NonrelatedPartyMemberabl:Customer1Member2023-04-012023-06-300001814287us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberabl:PortfolioServicingSegmentMemberabl:Customer1Memberus-gaap:RelatedPartyMember2023-04-012023-06-300001814287us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberabl:Customer2Memberabl:PortfolioServicingSegmentMemberus-gaap:RelatedPartyMember2023-04-012023-06-300001814287us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberus-gaap:NonrelatedPartyMemberabl:Customer1Member2022-04-012022-06-300001814287us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberabl:ActiveManagementSegmentMemberus-gaap:NonrelatedPartyMemberabl:Customer1Member2023-01-012023-06-300001814287us-gaap:CustomerConcentrationRiskMemberabl:InvestmentMethodRevenueBenchmarkMemberus-gaap:NonrelatedPartyMemberabl:Customer1Member2023-01-012023-06-300001814287us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberabl:PortfolioServicingSegmentMemberabl:Customer1Memberus-gaap:RelatedPartyMember2023-01-012023-06-300001814287us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberabl:Customer2Memberabl:PortfolioServicingSegmentMemberus-gaap:RelatedPartyMember2023-01-012023-06-300001814287us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMemberus-gaap:NonrelatedPartyMemberabl:Customer1Member2022-01-012022-06-300001814287abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember2023-06-302023-06-300001814287us-gaap:MeasurementInputDiscountRateMemberabl:LongevityMarketAssetsLLCMember2023-06-300001814287abl:AbacusSettlementsLLCMemberus-gaap:MeasurementInputDiscountRateMember2023-06-300001814287us-gaap:ValuationTechniqueDiscountedCashFlowMemberabl:LongevityMarketAssetsLLCMembersrt:MinimumMember2023-06-300001814287us-gaap:ValuationTechniqueDiscountedCashFlowMemberabl:LongevityMarketAssetsLLCMembersrt:MaximumMember2023-06-300001814287abl:AbacusSettlementsLLCMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MinimumMember2023-06-300001814287abl:AbacusSettlementsLLCMemberus-gaap:ValuationTechniqueDiscountedCashFlowMembersrt:MaximumMember2023-06-300001814287abl:LongevityMarketAssetsLLCMembersrt:MinimumMemberus-gaap:MarketApproachValuationTechniqueMember2023-06-300001814287abl:LongevityMarketAssetsLLCMembersrt:MaximumMemberus-gaap:MarketApproachValuationTechniqueMember2023-06-300001814287abl:AbacusSettlementsLLCMembersrt:MinimumMemberus-gaap:MarketApproachValuationTechniqueMember2023-06-300001814287abl:AbacusSettlementsLLCMembersrt:MaximumMemberus-gaap:MarketApproachValuationTechniqueMember2023-06-300001814287abl:AbacusSettlementsLLCMember2023-06-300001814287abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember2023-06-300001814287abl:AbacusSettlementsLLCMember2023-06-302023-06-300001814287abl:LongevityMarketAssetsLLCMember2023-06-302023-06-300001814287abl:CustomerRelationshipAgentsMemberabl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember2023-06-300001814287abl:CustomerRelationshipAgentsMemberabl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember2023-06-302023-06-300001814287abl:CustomerRelationshipsFinancialRelationshipsMemberabl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember2023-06-300001814287abl:CustomerRelationshipsFinancialRelationshipsMemberabl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember2023-06-302023-06-300001814287abl:APATechnologyMemberabl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember2023-06-300001814287abl:APATechnologyMemberabl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember2023-06-302023-06-300001814287abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMemberabl:MarketPlaceTechnologyMember2023-06-300001814287abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMemberabl:MarketPlaceTechnologyMember2023-06-302023-06-300001814287abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMemberus-gaap:TradeNamesMember2023-06-300001814287abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMemberus-gaap:NoncompeteAgreementsMember2023-06-300001814287abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMemberus-gaap:NoncompeteAgreementsMember2023-06-302023-06-300001814287us-gaap:LicensingAgreementsMemberabl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember2023-06-300001814287abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember2023-04-012023-06-300001814287abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember2022-04-012022-06-300001814287abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember2023-01-012023-06-300001814287abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember2022-01-012022-06-30abl:insurance_contract0001814287us-gaap:ComputerEquipmentMember2023-06-300001814287us-gaap:ComputerEquipmentMember2022-12-310001814287us-gaap:FurnitureAndFixturesMember2023-06-300001814287us-gaap:FurnitureAndFixturesMember2022-12-310001814287us-gaap:LeaseholdImprovementsMember2023-06-300001814287us-gaap:LeaseholdImprovementsMember2022-12-310001814287abl:AbacusSettlementsLLCMember2021-12-310001814287abl:AbacusSettlementsLLCMember2022-01-012022-06-300001814287abl:AbacusSettlementsLLCMember2022-06-300001814287abl:AbacusSettlementsLLCMember2022-12-310001814287abl:AbacusSettlementsLLCMember2023-01-012023-06-300001814287abl:AbacusSettlementsLLCMember2023-06-300001814287abl:CustomerRelationshipAgentsMember2023-06-300001814287abl:CustomerRelationshipsFinancialRelationshipsMember2023-06-300001814287abl:APATechnologyMember2023-06-300001814287abl:MarketPlaceTechnologyMember2023-06-300001814287us-gaap:TradeNamesMember2023-06-300001814287us-gaap:NoncompeteAgreementsMember2023-06-300001814287us-gaap:LicensingAgreementsMember2023-06-3000018142872021-11-012021-11-3000018142872022-01-012022-01-3100018142872021-11-3000018142872022-10-012022-10-3100018142872022-10-31abl:entity0001814287abl:SeriesSeedPreferredUnitsMember2020-07-222020-07-220001814287abl:SeriesSeedPreferredUnitsMember2020-07-220001814287abl:SeriesSeedPreferredUnitsMember2022-12-012022-12-310001814287abl:SeriesSeedPreferredUnitsMember2022-12-31abl:payment0001814287abl:SeriesSeedPreferredUnitsMember2023-03-310001814287abl:SeriesSeedPreferredUnitsMember2023-06-300001814287abl:SeriesB1PreferredStockMember2020-12-212020-12-210001814287abl:SeriesB1PreferredStockMember2020-12-210001814287us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-06-300001814287us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2022-12-31abl:segment0001814287abl:PortfolioServicingSegmentMember2023-04-012023-06-300001814287abl:PortfolioServicingSegmentMember2022-04-012022-06-300001814287abl:PortfolioServicingSegmentMember2023-01-012023-06-300001814287abl:PortfolioServicingSegmentMember2022-01-012022-06-300001814287abl:ActiveManagementSegmentMember2023-04-012023-06-300001814287abl:ActiveManagementSegmentMember2022-04-012022-06-300001814287abl:ActiveManagementSegmentMember2023-01-012023-06-300001814287abl:ActiveManagementSegmentMember2022-01-012022-06-300001814287us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-06-300001814287us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-06-300001814287us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2023-06-300001814287us-gaap:FairValueMeasurementsRecurringMember2023-06-300001814287us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310001814287us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001814287us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel3Member2022-12-310001814287us-gaap:FairValueMeasurementsRecurringMember2022-12-310001814287us-gaap:MeasurementInputDiscountRateMember2023-06-300001814287us-gaap:MeasurementInputDiscountRateMember2022-12-310001814287us-gaap:SubsequentEventMember2023-07-012023-08-140001814287abl:LifeInsuranceCarrierConcentrationRiskMemberabl:LifeSettlementContractsFaceValueMemberabl:AmericanGeneralLifeInsuranceCompanyMember2023-01-012023-06-300001814287abl:LifeInsuranceCarrierConcentrationRiskMemberabl:AmericanGeneralLifeInsuranceCompanyMemberabl:LifeSettlementContractsFairValueMember2023-01-012023-06-300001814287abl:LifeInsuranceCarrierConcentrationRiskMemberabl:LifeSettlementContractsFaceValueMemberabl:ReliaStarLifeInsuranceCompanyMember2023-01-012023-06-300001814287abl:LifeInsuranceCarrierConcentrationRiskMemberabl:LifeSettlementContractsFairValueMemberabl:ReliaStarLifeInsuranceCompanyMember2023-01-012023-06-300001814287abl:LincolnNationalLifeInsuranceCompanyMemberabl:LifeInsuranceCarrierConcentrationRiskMemberabl:LifeSettlementContractsFaceValueMember2023-01-012023-06-300001814287abl:LincolnNationalLifeInsuranceCompanyMemberabl:LifeInsuranceCarrierConcentrationRiskMemberabl:LifeSettlementContractsFairValueMember2023-01-012023-06-300001814287abl:LifeSettlementContractMember2022-12-310001814287abl:LifeSettlementContractMember2023-01-012023-06-300001814287abl:LifeSettlementContractMember2023-06-300001814287abl:PrivatePlacementWarrantMember2023-06-300001814287abl:PrivatePlacementWarrantMember2020-08-250001814287us-gaap:MeasurementInputRiskFreeInterestRateMemberabl:PrivatePlacementWarrantMember2023-06-300001814287abl:PrivatePlacementWarrantMemberus-gaap:MeasurementInputExpectedTermMember2023-06-300001814287us-gaap:MeasurementInputExercisePriceMemberabl:PrivatePlacementWarrantMember2023-06-300001814287us-gaap:MeasurementInputSharePriceMemberabl:PrivatePlacementWarrantMember2023-06-300001814287us-gaap:MeasurementInputExpectedDividendRateMemberabl:PrivatePlacementWarrantMember2023-06-3000018142872021-01-012021-12-3100018142872022-01-072022-01-070001814287us-gaap:NotesPayableOtherPayablesMemberabl:LMATTSeries2024IncMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300001814287us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:NotesPayableOtherPayablesMemberabl:LMATTSeries2024IncMember2023-06-300001814287us-gaap:NotesPayableOtherPayablesMemberabl:LMATTSeries2024IncMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001814287us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:NotesPayableOtherPayablesMemberabl:LMATTSeries2024IncMember2022-12-310001814287abl:LMATTSeries22024IncMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300001814287abl:LMATTSeries22024IncMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:NotesPayableOtherPayablesMember2023-06-300001814287abl:LMATTSeries22024IncMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001814287abl:LMATTSeries22024IncMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:NotesPayableOtherPayablesMember2022-12-310001814287abl:LMATTGrowthIncomeSeries12026IncMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300001814287us-gaap:EstimateOfFairValueFairValueDisclosureMemberabl:LMATTGrowthIncomeSeries12026IncMemberus-gaap:NotesPayableOtherPayablesMember2023-06-300001814287abl:LMATTGrowthIncomeSeries12026IncMemberus-gaap:NotesPayableOtherPayablesMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001814287us-gaap:EstimateOfFairValueFairValueDisclosureMemberabl:LMATTGrowthIncomeSeries12026IncMemberus-gaap:NotesPayableOtherPayablesMember2022-12-310001814287us-gaap:SecuredDebtMemberabl:LMATTIncomeSeriesLPMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300001814287us-gaap:SecuredDebtMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberabl:LMATTIncomeSeriesLPMember2023-06-300001814287us-gaap:SecuredDebtMemberabl:LMATTIncomeSeriesLPMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001814287us-gaap:SecuredDebtMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberabl:LMATTIncomeSeriesLPMember2022-12-310001814287us-gaap:SecuredDebtMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberabl:LMATTIncomeSeriesIILPMember2023-06-300001814287us-gaap:SecuredDebtMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberabl:LMATTIncomeSeriesIILPMember2023-06-300001814287us-gaap:SecuredDebtMemberus-gaap:CarryingReportedAmountFairValueDisclosureMemberabl:LMATTIncomeSeriesIILPMember2022-12-310001814287us-gaap:SecuredDebtMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberabl:LMATTIncomeSeriesIILPMember2022-12-310001814287us-gaap:UnsecuredDebtMemberabl:SponsorPIKNoteMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300001814287us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:UnsecuredDebtMemberabl:SponsorPIKNoteMember2023-06-300001814287us-gaap:UnsecuredDebtMemberabl:SponsorPIKNoteMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001814287us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:UnsecuredDebtMemberabl:SponsorPIKNoteMember2022-12-310001814287us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300001814287us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-06-300001814287us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001814287us-gaap:EstimateOfFairValueFairValueDisclosureMember2022-12-310001814287us-gaap:LineOfCreditMemberabl:SPVInvestmentFacilityMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2023-06-300001814287us-gaap:LineOfCreditMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberabl:SPVInvestmentFacilityMember2023-06-300001814287us-gaap:LineOfCreditMemberabl:SPVInvestmentFacilityMemberus-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310001814287us-gaap:LineOfCreditMemberus-gaap:EstimateOfFairValueFairValueDisclosureMemberabl:SPVInvestmentFacilityMember2022-12-310001814287us-gaap:UnsecuredDebtMemberabl:SponsorPIKNoteMember2023-06-300001814287us-gaap:NotesPayableOtherPayablesMemberabl:LMATTSeries2024IncMember2022-03-310001814287us-gaap:AssetPledgedAsCollateralMemberus-gaap:NotesPayableOtherPayablesMemberabl:LMATTSeries2024IncMember2023-06-300001814287abl:LMATTSeries22024IncMember2022-09-160001814287abl:LMATTSeries22024IncMemberus-gaap:NotesPayableOtherPayablesMember2022-09-160001814287abl:LMATTSeries22024IncMemberus-gaap:AssetPledgedAsCollateralMemberus-gaap:NotesPayableOtherPayablesMember2023-06-300001814287abl:LMATTGrowthIncomeSeries12026IncMember2022-09-160001814287us-gaap:NotesPayableOtherPayablesMemberabl:LMATTGrowthIncomeSeries12026IncMember2022-09-160001814287us-gaap:AssetPledgedAsCollateralMemberabl:LMATTGrowthIncomeSeries12026IncMemberus-gaap:NotesPayableOtherPayablesMember2023-06-300001814287us-gaap:SecuredDebtMemberabl:LMATTIncomeSeriesLPMember2023-01-012023-06-300001814287us-gaap:SecuredDebtMemberabl:LMATTIncomeSeriesLPMember2023-06-30abl:option0001814287us-gaap:SecuredDebtMemberus-gaap:GeneralPartnerMemberabl:LMATTIncomeSeriesLPMember2023-06-300001814287us-gaap:SecuredDebtMemberus-gaap:LimitedPartnerMemberabl:LMATTIncomeSeriesLPMember2023-06-300001814287us-gaap:SecuredDebtMemberabl:LMATTIncomeSeriesIILPMember2023-01-012023-06-300001814287us-gaap:SecuredDebtMemberabl:LMATTIncomeSeriesIILPMember2023-06-300001814287us-gaap:SecuredDebtMemberabl:CapitalCommitmentThresholdOneMemberus-gaap:LimitedPartnerMembersrt:MaximumMemberabl:LMATTIncomeSeriesIILPMember2023-01-012023-06-300001814287us-gaap:SecuredDebtMemberabl:CapitalCommitmentThresholdOneMemberus-gaap:LimitedPartnerMemberabl:LMATTIncomeSeriesIILPMember2023-06-300001814287us-gaap:SecuredDebtMemberabl:CapitalCommitmentThresholdTwoMemberus-gaap:LimitedPartnerMembersrt:MinimumMemberabl:LMATTIncomeSeriesIILPMember2023-01-012023-06-300001814287us-gaap:SecuredDebtMemberabl:CapitalCommitmentThresholdTwoMemberus-gaap:LimitedPartnerMembersrt:MaximumMemberabl:LMATTIncomeSeriesIILPMember2023-01-012023-06-300001814287abl:CapitalCommitmentThresholdTwoMemberus-gaap:SecuredDebtMemberus-gaap:LimitedPartnerMemberabl:LMATTIncomeSeriesIILPMember2023-06-300001814287us-gaap:SecuredDebtMemberus-gaap:LimitedPartnerMemberabl:CapitalCommitmentThresholdThreeMembersrt:MinimumMemberabl:LMATTIncomeSeriesIILPMember2023-01-012023-06-300001814287us-gaap:SecuredDebtMemberabl:CapitalCommitmentThresholdThreeMemberus-gaap:LimitedPartnerMemberabl:LMATTIncomeSeriesIILPMember2023-06-300001814287us-gaap:SecuredDebtMemberus-gaap:GeneralPartnerMemberabl:LMATTIncomeSeriesIILPMember2023-06-300001814287us-gaap:SubsequentEventMemberabl:PolicyAPAMember2023-07-050001814287us-gaap:LineOfCreditMemberus-gaap:SubsequentEventMemberabl:SPVInvestmentFacilityMember2023-07-050001814287us-gaap:LineOfCreditMemberus-gaap:SubsequentEventMemberabl:SPVInvestmentFacilityMemberus-gaap:SecuredDebtMember2023-07-050001814287us-gaap:LineOfCreditMemberus-gaap:SubsequentEventMemberabl:SPVInvestmentFacilityMemberus-gaap:LineOfCreditMember2023-07-050001814287us-gaap:LineOfCreditMemberus-gaap:SubsequentEventMemberabl:SPVInvestmentFacilityMember2023-07-052023-07-05abl:extensionabl:vote0001814287abl:PublicWarrantsMember2023-06-300001814287abl:PublicWarrantsMember2023-01-012023-06-300001814287abl:PublicWarrantsMember2022-08-300001814287us-gaap:MeasurementInputRiskFreeInterestRateMemberabl:PublicWarrantsMemberabl:BinomialLatticeModelMember2023-06-300001814287abl:PublicWarrantsMemberabl:BinomialLatticeModelMember2023-06-300001814287abl:PublicWarrantsMemberus-gaap:MeasurementInputExercisePriceMemberabl:BinomialLatticeModelMember2023-06-300001814287abl:PublicWarrantsMemberabl:BinomialLatticeModelMemberus-gaap:MeasurementInputSharePriceMember2023-06-3000018142872022-01-012022-12-310001814287us-gaap:LineOfCreditMemberabl:SPVInvestmentFacilityMemberus-gaap:RelatedPartyMember2023-06-300001814287abl:ServiceFeeAgreementMemberus-gaap:RelatedPartyMember2023-04-012023-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:AffiliatedEntityMember2023-04-012023-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:AffiliatedEntityMember2022-04-012022-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:AffiliatedEntityMember2023-01-012023-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:AffiliatedEntityMember2022-01-012022-06-300001814287srt:AffiliatedEntityMember2023-04-012023-06-300001814287srt:AffiliatedEntityMember2023-01-012023-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:AffiliatedEntityMemberabl:ExpenseReimbursementsMember2023-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:AffiliatedEntityMemberabl:ExpenseReimbursementsMember2022-12-310001814287abl:PrivatePlacementWarrantMember2023-04-012023-06-300001814287abl:PrivatePlacementWarrantMember2023-01-012023-06-300001814287us-gaap:LineOfCreditMemberus-gaap:SubsequentEventMemberabl:OwlRockCreditFacilityMemberus-gaap:SecuredDebtMember2023-07-050001814287us-gaap:LineOfCreditMemberus-gaap:SubsequentEventMemberabl:OwlRockCreditFacilityMember2023-07-050001814287us-gaap:LineOfCreditMemberus-gaap:SubsequentEventMemberabl:OwlRockCreditFacilityMember2023-07-052023-07-050001814287us-gaap:LineOfCreditMemberus-gaap:SubsequentEventMemberabl:OwlRockCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMemberabl:VariableRateComponentOneMember2023-07-052023-07-050001814287us-gaap:LineOfCreditMemberabl:VariableRateComponentTwoMemberus-gaap:SubsequentEventMemberabl:OwlRockCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-07-052023-07-050001814287us-gaap:LineOfCreditMemberus-gaap:SubsequentEventMemberabl:OwlRockCreditFacilityMemberabl:VariableRateComponentThreeMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-07-052023-07-050001814287us-gaap:LineOfCreditMemberus-gaap:BaseRateMemberus-gaap:SubsequentEventMemberabl:OwlRockCreditFacilityMember2023-07-050001814287us-gaap:LineOfCreditMemberus-gaap:SubsequentEventMemberabl:OwlRockCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-07-050001814287srt:SubsidiariesMemberus-gaap:NonrelatedPartyMember2023-04-012023-06-300001814287srt:SubsidiariesMemberus-gaap:NonrelatedPartyMember2022-04-012022-06-300001814287srt:SubsidiariesMemberus-gaap:NonrelatedPartyMember2023-01-012023-06-300001814287srt:SubsidiariesMemberus-gaap:NonrelatedPartyMember2022-01-012022-06-300001814287srt:SubsidiariesMemberus-gaap:RelatedPartyMember2023-04-012023-06-300001814287srt:SubsidiariesMemberus-gaap:RelatedPartyMember2022-04-012022-06-300001814287srt:SubsidiariesMemberus-gaap:RelatedPartyMember2023-01-012023-06-300001814287srt:SubsidiariesMemberus-gaap:RelatedPartyMember2022-01-012022-06-300001814287srt:SubsidiariesMember2023-04-012023-06-300001814287srt:SubsidiariesMember2022-04-012022-06-300001814287srt:SubsidiariesMember2023-01-012023-06-300001814287srt:SubsidiariesMember2022-01-012022-06-300001814287us-gaap:CommonStockMembersrt:SubsidiariesMember2023-03-310001814287srt:SubsidiariesMemberus-gaap:AdditionalPaidInCapitalMember2023-03-310001814287us-gaap:RetainedEarningsMembersrt:SubsidiariesMember2023-03-310001814287srt:SubsidiariesMember2023-03-310001814287us-gaap:RetainedEarningsMembersrt:SubsidiariesMember2023-04-012023-06-300001814287us-gaap:CommonStockMembersrt:SubsidiariesMember2023-06-300001814287srt:SubsidiariesMemberus-gaap:AdditionalPaidInCapitalMember2023-06-300001814287us-gaap:RetainedEarningsMembersrt:SubsidiariesMember2023-06-300001814287srt:SubsidiariesMember2023-06-300001814287us-gaap:CommonStockMembersrt:SubsidiariesMember2022-12-310001814287srt:SubsidiariesMemberus-gaap:AdditionalPaidInCapitalMember2022-12-310001814287us-gaap:RetainedEarningsMembersrt:SubsidiariesMember2022-12-310001814287srt:SubsidiariesMember2022-12-310001814287us-gaap:RetainedEarningsMembersrt:SubsidiariesMember2023-01-012023-06-300001814287us-gaap:CommonStockMembersrt:SubsidiariesMember2021-12-310001814287srt:SubsidiariesMemberus-gaap:AdditionalPaidInCapitalMember2021-12-310001814287us-gaap:RetainedEarningsMembersrt:SubsidiariesMember2021-12-310001814287srt:SubsidiariesMember2021-12-310001814287us-gaap:RetainedEarningsMembersrt:SubsidiariesMember2022-01-012022-06-300001814287us-gaap:CommonStockMembersrt:SubsidiariesMember2022-06-300001814287srt:SubsidiariesMemberus-gaap:AdditionalPaidInCapitalMember2022-06-300001814287us-gaap:RetainedEarningsMembersrt:SubsidiariesMember2022-06-300001814287srt:SubsidiariesMember2022-06-300001814287srt:SubsidiariesMemberabl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember2023-06-292023-06-290001814287srt:SubsidiariesMemberabl:ERESClassACommonStockMemberabl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember2023-06-290001814287srt:SubsidiariesMemberabl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember2023-06-290001814287srt:SubsidiariesMemberabl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMembersrt:MinimumMember2023-06-292023-06-290001814287us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembersrt:SubsidiariesMember2023-01-012023-06-300001814287us-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMembersrt:SubsidiariesMember2022-01-012022-06-300001814287abl:LifeSettlementCommissionExpenseBenchmarkMembersrt:SubsidiariesMemberabl:BrokerConcentrationRiskMemberabl:TwoBrokersMember2023-01-012023-06-300001814287srt:SubsidiariesMemberabl:AgentMember2023-04-012023-06-300001814287srt:SubsidiariesMemberabl:AgentMember2022-04-012022-06-300001814287srt:SubsidiariesMemberabl:AgentMember2023-01-012023-06-300001814287srt:SubsidiariesMemberabl:AgentMember2022-01-012022-06-300001814287srt:SubsidiariesMemberabl:BrokerMember2023-04-012023-06-300001814287srt:SubsidiariesMemberabl:BrokerMember2022-04-012022-06-300001814287srt:SubsidiariesMemberabl:BrokerMember2023-01-012023-06-300001814287srt:SubsidiariesMemberabl:BrokerMember2022-01-012022-06-300001814287srt:SubsidiariesMemberabl:ClientDirectMember2023-04-012023-06-300001814287srt:SubsidiariesMemberabl:ClientDirectMember2022-04-012022-06-300001814287srt:SubsidiariesMemberabl:ClientDirectMember2023-01-012023-06-300001814287srt:SubsidiariesMemberabl:ClientDirectMember2022-01-012022-06-300001814287srt:SubsidiariesMemberabl:NovaTradingUSLLCAndNovaHoldingUSLPMember2023-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:SubsidiariesMemberus-gaap:RelatedPartyMember2023-04-012023-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:SubsidiariesMemberus-gaap:RelatedPartyMember2022-04-012022-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:SubsidiariesMemberus-gaap:RelatedPartyMember2023-01-012023-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:SubsidiariesMemberus-gaap:RelatedPartyMember2022-01-012022-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:SubsidiariesMemberus-gaap:RelatedPartyMember2023-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:SubsidiariesMemberabl:OriginationFeeMemberus-gaap:RelatedPartyMember2023-04-012023-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:SubsidiariesMemberabl:OriginationFeeMemberus-gaap:RelatedPartyMember2022-04-012022-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:SubsidiariesMemberabl:OriginationFeeMemberus-gaap:RelatedPartyMember2023-01-012023-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:SubsidiariesMemberabl:OriginationFeeMemberus-gaap:RelatedPartyMember2022-01-012022-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:SubsidiariesMemberabl:ExpenseReimbursementsMemberus-gaap:RelatedPartyMember2023-04-012023-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:SubsidiariesMemberabl:ExpenseReimbursementsMemberus-gaap:RelatedPartyMember2022-04-012022-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:SubsidiariesMemberabl:ExpenseReimbursementsMemberus-gaap:RelatedPartyMember2023-01-012023-06-300001814287abl:NovaTradingUSLLCAndNovaHoldingUSLPMembersrt:SubsidiariesMemberabl:ExpenseReimbursementsMemberus-gaap:RelatedPartyMember2022-01-012022-06-300001814287srt:SubsidiariesMembersrt:AffiliatedEntityMember2023-04-012023-06-300001814287srt:SubsidiariesMembersrt:AffiliatedEntityMember2022-04-012022-06-300001814287srt:SubsidiariesMembersrt:AffiliatedEntityMemberabl:LongevityMarketAssetsLLCMember2023-04-012023-06-300001814287srt:SubsidiariesMembersrt:AffiliatedEntityMemberabl:LongevityMarketAssetsLLCMember2022-04-012022-06-300001814287srt:SubsidiariesMembersrt:AffiliatedEntityMember2023-01-012023-06-300001814287srt:SubsidiariesMembersrt:AffiliatedEntityMember2022-01-012022-06-300001814287srt:SubsidiariesMembersrt:AffiliatedEntityMemberabl:LongevityMarketAssetsLLCMember2023-01-012023-06-300001814287srt:SubsidiariesMembersrt:AffiliatedEntityMemberabl:LongevityMarketAssetsLLCMember2022-01-012022-06-300001814287srt:SubsidiariesMemberabl:LongevityMarketAssetsLLCMemberus-gaap:RelatedPartyMember2023-06-300001814287srt:SubsidiariesMemberabl:LongevityMarketAssetsLLCMemberus-gaap:RelatedPartyMember2022-06-30
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 2023
OR
o
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _____  to _____
Commission file number 001-39403

Abacus Life, Inc.
(Exact name of registrant as specified in its charter)
Delaware
85-1210472
(State or other jurisdiction of incorporation or organization)
(I.R.S. Employer Identification No.)
2101 Park Center Drive, Suite 170
Orlando Florida
32835
(Address of Principal Executive Offices)
(Zip Code)
(800) 561-4148
Registrant's telephone number, including area code
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common stock, par value $0.0001 per shareABLThe NASDAQ Stock Market LLC
Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per shareABLLWThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports); and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).     Yes  x   No  o 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filer
o
Accelerated filer
o
Non-accelerated filer  
x
Smaller reporting company
x
Emerging growth company
x
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
o
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).     Yes   o     No  x
APPLICABLE ONLY TO REGISTRANTS INVOLVED IN BANKRUPTCY
PROCEEDINGS DURING THE PRECEDING FIVE YEARS:
Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.
o  Yes o No
APPLICABLE ONLY TO CORPORATE ISSUERS:
The registrant had 62,961,688 shares of common stock, $0.0001 par value per share, outstanding as of August 14, 2023.


ABACUS LIFE, INC.
TABLE OF CONTENTS
Page
937
Condensed Consolidated Balance Sheets


Part I - Financial Information
Item 1. Financial Statements

1

ABACUS LIFE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF JUNE 30, 2023 AND DECEMBER 31, 2022
June 30,
2023
(unaudited)
December 31,
2022 (unaudited)
ASSETS
CURRENT ASSETS:
Cash and cash equivalents$20,611,122 $30,052,823 
Accounts receivable192,595 10,448 
Related party receivable78,310 198,364 
Due from affiliates10,473,748 2,904,646 
Other receivables21,252 - 
Prepaid expenses and other current assets829,595 116,646 
Total current assets32,206,622 33,282,927 
Property and equipment, net177,931 18,617 
Intangible assets, net32,900,000 - 
Goodwill140,287,000 - 
Operating right-of-use assets240,816 77,011 
Life settlement policies, at cost9,889,610 8,716,111 
Life settlement policies, at fair value56,685,617 13,809,352 
Available for sale securities, at fair value1,000,000 1,000,000 
Other investments1,600,000 1,300,000 
Due from members and affiliates75,582 - 
State security deposit206,873 - 
Certificate of deposit262,500 - 
Other assets, at fair value1,801,886 890,829 
TOTAL ASSETS$277,334,437 $59,094,847 
LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES:
Accrued expenses$524,400 $- 
Accounts payable401,500 40,014 
Operating lease liabilities - current portion227,561 48,127 
Due to members and affiliates10,415,154 263,785 
Due to owners717,429 - 
Contract liabilities - deposits on pending settlements981,217 - 
Accrued transaction costs182,571 908,256 
Other current liabilities258,759 42,227 
Income taxes payable185,831 - 
Total current liabilities13,894,422 1,302,409 
2

ABACUS LIFE, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
AS OF JUNE 30, 2023 AND DECEMBER 31, 2022 (CONT.)
SPV purchase and sale note25,000,000 - 
Long-term debt, at fair value66,165,396 28,249,653 
Operating lease liabilities - noncurrent portion16,864 29,268 
Deferred tax liability9,320,240 1,363,820 
Warrant liability2,438,600 - 
TOTAL LIABILITIES116,835,522 30,945,150 
COMMITMENTS AND CONTINGENCIES (11)
SHAREHOLDERS' EQUITY (DEFICIT)
Class A common stock, $0.0001 par value; 200,000,000 authorized shares; 62,961,688 and 50,369,350 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively
6,296 5,037 
Additional paid-in capital188,641,886 704,963 
Retained earnings/(accumulated deficit)(29,382,362)25,487,323 
Accumulated other comprehensive income877,306 1,052,836 
Non-controlling interest355,789 899,538 
Total shareholders' equity (deficit)160,498,915 28,149,697 
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)$277,334,437 $59,094,847 
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
3

ABACUS LIFE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2023 AND 2022
Three Months Ended
June 30,
Six Months Ended
June 30,
2023202220232022
REVENUES:
Portfolio servicing revenue
Related party servicing revenue$329,629 $419,253 $543,076 $620,159 
Portfolio Servicing revenue24,737 169 46,981 370,169 
Total portfolio servicing revenue354,366 419,422 590,057 990,328 
Active management revenue
Investment Income from life insurance policies held using investment method8,263,499 5,965,466 16,655,833 13,980,466 
Change in fair value of life insurance policies (policies held using fair value method)2,760,900 2,014,013 4,339,084 3,305,505 
Total active management revenue11,024,399 7,979,479 20,994,917 17,285,971 
Total revenues11,378,765 8,398,901 21,584,974 18,276,299 
COST OF REVENUES (excluding depreciation stated below)
Cost of revenue973,400 666,119 1,462,950 2,086,075 
Total cost of revenue973,400 666,119 1,462,950 2,086,075 
Gross Profit10,405,365 7,732,782 20,122,024 16,190,224 
OPERATING EXPENSES:
Sales and marketing683,841 1,019,498 1,412,845 1,649,498 
General and administrative expenses577,539 5,499 1,274,431 646,705 
Loss on change in fair value of debt1,445,229 333,879 2,398,662 375,513 
Unrealized loss (gain) on investments(672,936)1,039,022 (798,156)1,054,975 
Depreciation1,098 1,098 2,141 2,141 
Total operating expenses2,034,771 2,398,996 4,289,923 3,728,832 
Operating Income$8,370,594 $5,333,786 $15,832,101 $12,461,392 
4

ABACUS LIFE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
FOR THE THREE MONTHS AND SIX MONTHS ENDED JUNE 30, 2023 AND 2022 (CONT.)
OTHER INCOME (EXPENSE)
Interest (expense)(584,075)- (941,458)- 
Interest income- - 7,457 - 
Other income (expense)121,601 (127,455)(21,651)(242,247)
Total other income (expense)(462,474)(127,455)(955,652)(242,247)
Net income before provision for income taxes7,908,120 5,206,331 14,876,449 12,219,145 
Provision for income taxes(1,184,571)(120,132)(528,104)(296,806)
NET INCOME6,723,549 5,086,199 14,348,345 11,922,339 
LESS: NET INCOME (LOSS) ATTRIBUTABLE TO NONCONTROLLING INTEREST(26,596)406,641 (487,303)406,641 
NET INCOME ATTRIBUTABLE TO SHAREHOLDERS6,750,145 4,679,558 14,835,648 11,515,698 
EARNINGS PER SHARE:
Basic and diluted weighted average shares outstanding(1)
50,507,728 50,369,350 50,438,921 50,369,350 
Basic and diluted net income per share0.13 0.09 0.29 0.23 
NET INCOME6,723,549 5,086,199 14,348,345 11,922,339 
Other comprehensive income, net of tax:
Change in fair value of debt(119,663)2,017,559 (231,976)2,017,559 
Comprehensive income 6,603,886 7,103,758 14,116,369 13,939,898 
Comprehensive income (loss) attributable to non-controlling interests(56,111)1,011,909 (543,749)1,011,909 
Comprehensive income attributable to Abacus Life Inc.6,659,997 6,091,849 14,660,118 12,927,989 
(1) Both the number of shares outstanding and their par value have been retrospectively recast for all prior periods presented to reflect the par value of the outstanding stock of the Abacus Life Inc. as a result of Business Combination.
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
5

ABACUS LIFE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
FOR THE THREE MONTHS ENDED JUNE 30, 2023 AND 2022
Class A Common StockAdditional
Paid-In
Capital
Retained EarningsAccumulated
Other
Comprehensive
Income
Non-
Controlling
Interests
Total
Shareholders’
Equity
SharesAmount
BALANCE AS OF MARCH 31, 2022 (1)
50,369,350 $5,037 $704,963 $4,951,188 $ $(148,155)$5,513,033 
Distributions— — — (310,000)— — (310,000)
Other Comprehensive Income— — — — 1,412,291 605,268 2,017,559 
Net Income— — — 4,679,558 — 406,641 5,086,199 
BALANCE AS OF JUNE 30, 2022 (1)
50,369,350 $5,037 $704,963 $9,320,746 $1,412,291 $863,754 $12,306,791 
Class A Common StockAdditional
Paid-In
Capital
Accumulated DeficitAccumulated Other Comprehensive LossNon-
Controlling
Interests
Total
Shareholders’
Equity
SharesAmount
BALANCE AS OF MARCH 31, 2023 (1)
50,369,350 $5,037 $704,963 $33,572,826 $967,454 $411,900 $35,662,180 
Distributions— — — (34,451,607)— — (34,451,607)
Deferred transaction costs— — — (10,841,551)— — (10,841,551)
Public warrants— — 4,726,500 (3,765,600)— — 960,900 
Merger with East Resources Acquisition Company12,592,338 1,259 17,849,091 (20,646,575)— — (2,796,225)
Acquisition of Abacus Settlements, LLC— — 165,361,332 — — — 165,361,332 
Other Comprehensive Income— — — — (90,148)(29,515)(119,663)
Net Income— — — 6,750,145 — (26,596)6,723,549 
BALANCE AS OF JUNE 30, 202362,961,688$6,296 $188,641,886 $(29,382,362)$877,306 $355,789 $160,498,915 
(1) Both the number of shares outstanding and their par value have been retrospectively recast for all prior periods presented to reflect the par value of the outstanding stock of the Abacus Life Inc. as a result of the successful Business Combination.
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
6

ABACUS LIFE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
Class A Common StockAdditional
Paid-In
Capital
Retained EarningsAccumulated
Other
Comprehensive
Income
Non-
Controlling
Interests
Total
Shareholders’
Equity
SharesAmount
BALANCE AS OF DECEMBER 31, 2021(1)
50,369,350 $5,037 $704,963 $205,048 $ $(148,155)$766,893 
Distributions— — — (2,400,000)— — (2,400,000)
Other comprehensive income— — — — 1,412,291 605,268 2,017,559 
Net Income— — — 11,515,698 — 406,641 11,922,339 
BALANCE AS OF JUNE 30, 2022(1)
50,369,350 $5,037 $704,963 $9,320,746 $1,412,291 $863,754 $12,306,791 

Class A Common StockAdditional
Paid-In
Capital
Accumulated DeficitAccumulated
Other
Comprehensive
Loss
Non-
Controlling
Interests
Total
Shareholders’
Equity
SharesAmount
BALANCE AS OF DECEMBER 31, 2022 (1)
50,369,350 $5,037 $704,963 $25,487,323 $1,052,836 $899,538 $28,149,697 
Distributions— — — (34,451,607)— — (34,451,607)
Deferred transaction costs— — — (10,841,551)— — (10,841,551)
Public warrants— — 4,726,500 (3,765,600)— — 960,900 
Merger with East Resources Acquisition Company12,592,338 1,259 17,849,091 (20,646,575)— (2,796,225)
Acquisition of Abacus Settlements, LLC— — 165,361,332 — — — 165,361,332 
Other Comprehensive Income— — — — (175,530)(56,446)(231,976)
Net Income— — — 14,835,648 — (487,303)14,348,345 
BALANCE AS OF JUNE 30, 202362,961,688$6,296 $188,641,886 $(29,382,362)$877,306 $355,789 $160,498,915 
(1) Both the number of shares outstanding and their par value have been retrospectively recast for all prior periods presented to reflect the par value of the outstanding stock of the Abacus Life Inc. as a result of the successful Business Combination.

The accompanying notes are an integral part of these interim condensed consolidated financial statements.
7

ABACUS LIFE, INC.
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE SIX MONTHS ENDED JUNE 30, 2023 AND 2022
Six Months Ended June 30,
20232022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income$14,348,345 $11,922,339 
Adjustments to reconcile net income to net cash
provided by (used in) operating activities:
Depreciation2,141 2,141 
Unrealized (gain) loss on investments(798,156)1,054,975 
Unrealized gain on policies(3,319,588)(3,305,505)
Loss on change in fair value of debt2,398,662 375,513 
Deferred income taxes252,659 999,927 
Non-cash lease expense384  
Changes in operating assets and liabilities:
Accounts receivable(182,147) 
Related party receivable125,764 (77,657)
Prepaid expenses and other current assets(193,462)(1,379,579)
Other noncurrent assets(105,655) 
Accounts payable361,486  
Accrued transaction costs(725,685) 
Other current liabilities402,363 72,938 
Life Settlement Policies purchased, at fair value(39,556,677)(7,211,509)
Life Settlement Policies purchased, at cost(11,374,605)(7,204,753)
Net cash used in operating activities(38,364,171)(4,751,170)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of investments(300,000)(250,000)
Due from affiliates(6,760,627) 
Net cash used in investing activities(7,060,627)(250,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of debt certificates35,206,351 9,463,779 
Transaction costs(10,841,551) 
Capital distribution to members(23,533,072)(2,400,000)
Proceeds from receipt of SPV purchase and sale note25,000,000  
Due to members and affiliates10,151,369 680,375 
Net cash provided by financing activities35,983,097 7,744,154 
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS(9,441,701)2,742,984 
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD30,052,823 102,421 
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD$20,611,122 $2,845,405 
The accompanying notes are an integral part of these interim condensed consolidated financial statements.
8

ABACUS LIFE, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1.DESCRIPTION OF BUSINESS
Organization and Merger
Abacus Life, Inc. (“the Company”) was formerly known as East Resources Acquisition Company ("ERES”), a blank check company incorporated in Delaware on May 22, 2020. Abacus Life, Inc. conducts its business through its wholly-owned, consolidated subsidiaries, primarily Abacus Settlements LLC (“Abacus”) and Longevity Market Assets, LLC (“LMA”), which are incorporated in the state of Delaware (collectively, the “Companies”). On June 30, 2023, (the “Closing Date”), ERES, Longevity Market Assets, LLC and Abacus Settlements, LLC consummated the combining of the Companies as contemplated by the Merger Agreement dated as of August 30, 2022 (as amended on October 14, 2022 and April 20, 2023) with LMA Merger Sub, LLC, a wholly owned subsidiary of ERES (“LMA Merger Sub”), Abacus Merger Sub, LLC, a wholly owned subsidiary of ERES (“Abacus Merger Sub”), Longevity Market Assets, LLC (“LMA”) and Abacus Settlements, LLC (“Legacy Abacus” and, together with LMA, the “Legacy Companies”). Pursuant to the Merger Agreement, on June 30, 2023, (i) LMA Merger Sub merged with and into LMA, with LMA surviving such merger (the “LMA Merger”) and (ii) Abacus Merger Sub merged with and into Legacy Abacus, with Legacy Abacus surviving such merger (the “Abacus Merger” and, together with the LMA Merger, the “Mergers” and, along with the other transactions contemplated by the Merger Agreement, the “Business Combination”) and the Legacy Companies became direct wholly owned subsidiaries of Abacus and ERES changed its name to Abacus Life, Inc.
The condensed consolidated assets, liabilities and statements of operations and comprehensive income prior to the Business Combination are those of legacy LMA. The stocks and corresponding capital amounts and income per stock, prior to the Business Combination, have been retroactively restated based on stocks reflecting the exchange ratio established in the Business Combination.
The equity structure has been recast in all comparative periods up to the Closing Date to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to legacy LMA’s stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to legacy LMA common stock prior to the Business Combination have been retroactively recast as shares reflecting the exchange ratio of 0.8 established in the Business Combination.
Business Activity
The Company, through its LMA subsidiary, is a provider of services pertaining to life insurance settlements and offers policy servicing to owners and purchasers of life settlement assets, as well as consulting, valuation, and actuarial services. The Company is also engaged in buying and selling of life settlement policies in which it uses its own capital, and purchases life settlement contracts with the intent to either hold to maturity to receive the associated death claim payout or to sell to another purchaser of life settlement contracts for a gain on the sale.
The Company, through its Abacus subsidiary, also is an originator of outstanding life insurance policies as a licensed life settlement provider on behalf of investors (“Financing Entities”). Abacus locates and screens policies for eligibility as a commercially desirable life settlement, including verifying that the policy is in force, obtaining consents and disclosures, and submitting cases for life expectancy estimates, also known, collectively, as origination services. When the sale of a policy is completed, this is deemed “settled” and the policy is then referred to as either a “life settlement” in which the insured’s life expectancy is greater than two years or “viatical settlement,” in which the insured’s life expectancy is less
9

than two years. The Company is not an insurance company, and therefore the Company does not underwrite insurable risks for its own account.
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation—In connection with the Business Combination, the Merger is accounted for as a reverse recapitalization with ERES in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Under U.S. GAAP, ERES has been treated as the “acquired” company for financial reporting purposes. This determination was primarily based on the LMA shareholders having a relative majority of the voting power of the Company, the LMA shareholders having the authority to appoint a majority of directors on the Board of Directors, and senior management of LMA comprising the majority of the senior management of the post-combination Company. LMA was then determined to be the “acquirer” for financial reporting purposes based on the relative size of LMA as compared to Abacus, represented by their revenue, equity, gross profit and net income. Accordingly, for accounting purposes, the financial statements of the combined entity will represent a continuation of the financial statements of LMA with the LMA Merger being treated as the equivalent of LMA issuing stock for the net assets of ERES, accompanied by a recapitalization. The net assets of ERES will be stated at historical cost, with no goodwill or other intangible assets recorded.
The Abacus Merger will be accounted for using the acquisition method of accounting. Under the acquisition method of accounting, the assets and liabilities of Abacus will be recorded at estimated fair value as of the acquisition date. The excess of the purchase price over the estimated fair values of the net assets acquired, if applicable, will be recognized as goodwill.
As a result of the Business Combination, the Company evaluated if ERES, Abacus, or LMA is the predecessor for accounting purposes.
In considering the foregoing principles of predecessor determination and in light of the Company's specific facts and circumstances, management determined that LMA and Abacus are dual predecessors for accounting purposes. The financial statement presentation for Abacus Life, Inc. includes the purchase accounting effects of the Abacus Merger as of the Closing Date with the financial statements of LMA as the comparative period. The predecessor financial statements for Abacus are included separately within this report.
The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and are prepared in accordance with U.S. GAAP.
Unaudited Condensed Consolidated Financial Statements—The condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2023, and the condensed consolidated statements of operations and comprehensive income for the three months and six months ended June 30, 2023 and 2022, respectively, and the condensed consolidated statements of cash flows for the six months ended June 30, 2023 and 2022, respectively. The condensed consolidated statements of operations and comprehensive income for the three months and six months ended June 30, 2023, are not necessarily indicative of the results to be expected for the full year ending December 31, 2023, or any other period. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes for Abacus for the year ended December 31, 2022, and the financial statements and notes for LMA for the year ended December 31, 2022. All references to financial information as of and for the periods ended June 30, 2023, and 2022 in the notes to condensed consolidated financial statements are unaudited.
10

Refer to this note in the LMA annual financial statements for the full list of the Company’s significant accounting policies. The details in those notes have not changed, except as discussed below and as a result of normal adjustments in the interim periods.
Consolidation of Variable Interest Entities—For entities in which the Company has variable interests, the Company first evaluates whether the entity meets the definition of a variable interest entity (“VIE”) or a voting interest entity (“VOE”). If the entity is a VIE, the Company focuses on identifying whether it has the power to direct the activities that most significantly impact the VIE’s economic performance and whether it has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company is the primary beneficiary of a VIE, the assets, liabilities, and results of operations of the VIE will be included in the Company’s condensed consolidated financial statements. The proportionate share not owned by the Company is recognized as noncontrolling interest and net income attributable to noncontrolling interest on the condensed consolidated balance sheets and condensed consolidated statements of operations and comprehensive income, respectively. If the entity is a VOE, the Company evaluates whether it has the power to control the VOE through a majority voting interest or through other arrangements.
Accounting Standards Codification (“ASC”) Topic 810, Consolidations, requires the Company to separately disclose on its condensed consolidated balance sheets the assets of consolidated VIEs and liabilities of consolidated VIEs as to which there is no recourse against the Company. As of June 30, 2023, total assets and liabilities of consolidated VIEs were $57,577,034 and $52,474,820, respectively. As of December 31, 2022, total assets and liabilities of consolidated VIEs were $30,073,972 and $27,116,762, respectively.
On January 1, 2021, the Company entered into an option agreement with two commonly owned full-service origination, servicing, and investment providers (the “Providers”), in which the Company agreed to fund certain capital needs with an option to purchase the outstanding equity ownership of the Providers (the “Option Agreement”).
The Company accounted for its investment in the call options under the Option Agreement as an equity security, pursuant to ASC 321. In arriving at this accounting conclusion, the Company first considered whether the call options met the definition of a derivative pursuant to ASC 815 and concluded that the options do not provide for net settlement and accordingly are not a derivative. The Company also concluded that the call options do not provide the Company with a controlling financial interest in the legal entity pursuant to ASC 810. The call options include material contingencies prior to exercisability that the Company does not anticipate will be resolved; additionally, the call options are in a legal entity for which the share price has no readily determinable fair value. The Company’s basis in the call options, pursuant to ASC 321, is zero and accordingly the call options are not reflected in the statement of financial position.
The Company provided $0 and $127,455 of funding for the three months ended June 30, 2023 and June 30, 2022, respectively and provided $29,721 and $242,247 of funding for the six months ended June 30, 2023 and June 30, 2022, respectively which is included in other (expense) income on the condensed consolidated statements of operations and comprehensive income. See Note 11, Commitments and Contingencies.
For the period ended June 30, 2023, and for the year ended December 31, 2022, the Providers were considered to be VIEs, but were not consolidated in the Company’s condensed consolidated financial statements due to a lack of the power criterion or the losses/benefits criterion. As of June 30, 2023, the unaudited financial information for the unconsolidated VIEs are as follows: held assets of $318,178 and liabilities of $450 and held assets of $483,167 and liabilities of $184,621, respectively. As of December 31, 2022, the unaudited financial information for the unconsolidated VIEs are as follows: held assets of $126,040 and liabilities of $0 and held assets of $861,924 and liabilities of $358,586, respectively.
On October 4, 2021, the Company entered into an operating agreement with LMX Series, LLC (“LMX”) and three other unaffiliated investors to obtain a 70% ownership interest in LMX, which was newly formed in August 2021. LMX had no operating activity prior to the operating agreement being signed.
11

LMX has a wholly owned subsidiary, LMATT Series 2024, Inc., a Delaware C corporation. While the Company and three other investors each contributed $100 to LMX, the Company directs the most significant activities by managing the investment offerings, and sponsoring and creating structured investment grade insurance liabilities, and thus was provided a 70% ownership interest. LMX is a VIE and the Company is the primary beneficiary of LMX. The Company has included the results of LMX and its subsidiaries in its condensed consolidated financial statements for the period ended June 30, 2023.
On March 3, 2022, the Company obtained an 80% ownership interest in Longevity Market Advisors, LLC (“Longevity Market Advisors”). The Longevity Market Advisors legal entity was established primarily for the purpose of acquiring the assets of a broker/dealer, Regional Investment Services, Inc. (“RIS”), an Ohio corporation. Longevity Market Advisors is a VIE and the Company is the primary beneficiary of Longevity Market Advisors. The purchase price payable in exchange for RIS was $60,000. The Company evaluated whether this represented a business combination or an asset acquisition under ASC 805. While the purchase of the RIS represents a business, it was further determined that as RIS was purchased for the primary reason of being registered by the Financial Industry Regulatory Authority (“FINRA”). As there are no tangible or intangible assets of value from the RIS that would meet the capitalization criteria that have standalone value, the Company has expensed the purchase in general and administrative costs. Upon closing of the transaction, Longevity Market Advisors will comprise 100% of the ownership structure of RIS, and RIS will be a wholly owned subsidiary. The Company has included the results of Longevity Market Advisors in its condensed consolidated financial statements for the period ended June 30, 2023.
On November 30, 2022, LMA Series, LLC, a wholly owned subsidiary of the Company, signed an Operating Agreement to be the sole member of a newly created general partnership, LMA Income Series, GP, LLC. Subsequent to that, LMA Income Series, GP, LLC formed a limited partnership, LMA Income Series, LP and issued partnership interests to limited partners in a private placement offering. It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series, LP and thus has fully consolidated the limited partnership in its condensed consolidated financial statements for the six months ended June 30, 2023.
On January 31, 2023, LMA Series, LLC, a wholly owned subsidiary of the Company, signed an Operating Agreement to be the sole member of a newly created general partnership, LMA Income Series II, GP, LLC. Subsequent to that, LMA Income Series II, GP, LLC formed a limited partnership, LMA Income Series II, LP and issued partnership interests to limited partners in a private placement offering. It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series II, LP and thus has fully consolidated the limited partnership in its condensed consolidated financial statements for the six months ended June 30, 2023.
Noncontrolling Interest—Noncontrolling interest represents the share of consolidated entities owned by third parties. At the date of formation or upon acquisition, the Company recognizes noncontrolling interest on the condensed consolidated balance sheets at an amount equal to the noncontrolling interest’s proportionate share of the relative fair value of any assets and liabilities acquired. Noncontrolling interest is subsequently adjusted for the noncontrolling shareholder’s additional contributions, distributions, and the shareholder’s share of the net earnings or losses of each respective consolidated entity.
Net income of a consolidated entity is allocated to noncontrolling interests based on the noncontrolling shareholder’s ownership interest during the period. The net income or loss that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the condensed consolidated statements of operations and comprehensive income.
Use of Estimates—The preparation of U.S. GAAP financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, disclosure of contingent assets and liabilities at the date of financial statements, and the reports amounts of revenue and expenses during the reporting periods. Company’s estimates, judgments, and
12

assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from the estimates. Estimates are used when accounting for revenue recognition and related costs, purchase price allocation, the selection of useful lives of property and equipment, valuation of other receivables, valuation of life settlement policies, valuation of other investments and available-for-sale securities, valuation of long-term debt, impairment testing, income taxes, and legal reserves.
Life Insurance Settlement Policies—The Company accounts for its holdings of life insurance settlement policies in accordance with ASC 325-30, Investments in Insurance Contracts. The Company accounts for life settlement policies purchased that we intend to hold to maturity at fair value and life settlement policies that we intend to trade in the near term at cost plus premiums paid.
The Company follows ASC 820, Fair Value Measurements and Disclosures, in estimating the fair value of its life insurance policies held at fair value. ASC 820 defines fair value as an exit price representing the amount that would be received if an asset were sold or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-level, fair value hierarchy that prioritizes the inputs used to measure fair value. Level 1 relates to quoted prices in active markets for identical assets or liabilities. Level 2 relates to observable inputs other than quoted prices included in Level 1. Level 3 relates to unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s valuation of life settlements is considered to be Level 3, as there is currently no active market where we are able to observe quoted prices for identical assets. The Company’s valuation model incorporates significant inputs that are not observable. See Note 10, “Fair Value Measurements.” For policies held at fair value, changes in fair value are reflected in operations in the period the change is calculated.
For policies held under the investment method, the Company tests the impairment if we become aware of information indicating that the carrying value plus undiscounted future premiums of a policy may not be recoverable. This information is gathered initially through extensive underwriting procedures at purchase of the settlement contract, as well as through periodic underwriting review that include medical reports and life expectancy evaluations. The policies held by the Company using the investment method are expected to be owned for a shorter-term, and are actively marketed to potential buyers. The market feedback received through these interactions provides the Company with information related to a potential impairment. If a policy is determined to be impaired, the Company will adjust the carrying value to the fair value determined through the impairment analysis.
The Company accounts for cash proceeds from sale and maturity of life insurance settlement policies, as well as cash outflows for premium payments, as operating activities within the condensed consolidated statements of cash flows.

Cost of Revenues—Cost of revenue represents the direct costs associated with fulfilling the Company’s obligations to its customers, primarily policy servicing and consulting expense.

Income Taxes—The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, the provision for income taxes represents income taxes paid or payable (or received or receivable) for the current year plus the change in deferred taxes during the year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid, and result from differences between the financial and tax bases of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when enacted.

13

Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not (greater than 50%) that a tax benefit will not be realized. In evaluating the need for a valuation allowance, management considers all potential sources of taxable income, including income available in carryback periods, future reversals of taxable temporary differences, projections of taxable income, and income from tax planning strategies, as well as all available positive and negative evidence. Positive evidence includes factors such as a history of profitable operations, projections of future profitability within the carryforward period, including from tax planning strategies, and the Company’s experience with similar operations. Existing favorable contracts are additional positive evidence. Negative evidence includes items such as cumulative losses, projections of future losses, or carryforward periods that are not long enough to allow for the utilization of a deferred tax asset based on existing projections of income. Deferred tax assets for which no valuation allowance is recorded may not be realized upon changes in facts and circumstances, resulting in a future charge to establish a valuation allowance. Existing valuation allowances are re-examined under the same standards of positive and negative evidence. If it is determined that it is more likely than not that a deferred tax asset will be realized, the appropriate amount of the valuation allowance, if any, is released. Deferred tax assets and liabilities are also remeasured to reflect changes in underlying tax rates due to law changes and the granting and lapse of tax holidays.

Tax benefits related to uncertain tax positions taken or expected to be taken on a tax return are recorded when such benefits meet a more likely than not threshold. Otherwise, these tax benefits are recorded when a tax position has been effectively settled, which means that the statute of limitations has expired or the appropriate taxing authority has completed their examination even though the statute of limitations remains open. Interest and penalties related to uncertain tax positions are recognized as part of the provision for income taxes and are accrued beginning in the period that such interest and penalties would be applicable under relevant tax law until such time that the related tax benefits are recognized.
Concentrations—Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, accounts receivable, and available-for-sale securities. The Company maintains its cash in bank deposit accounts with high-quality financial institutions, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on its cash and cash equivalents. For accounts receivable, the Company is exposed to credit risk in the event of nonpayment by customers to the extent of the amounts recorded on the accompanying condensed consolidated balance sheets. The Company extends different levels of credit to its customers and maintains allowance for doubtful accounts based upon the expected collectability of accounts receivable. The Company’s procedures for determining this allowance includes evaluating individual customer receivables, considering a customer’s financial condition, monitoring credit history and current economic conditions, and using historical experience applied to an aging of accounts.
Two related party customers accounted for 12% and 13% of the total balance of accounts receivable and related party receivables as of June 30, 2023, and two related party customers accounted for 75% and 16% of the total accounts receivable as of December 31, 2022, respectively. The largest receivables balances are from related parties where exposed credit risk is low. As such, there is no allowance for doubtful accounts as of June 30, 2023, and December 31, 2022.
One customer accounted for 27% of active management revenue for the three months ended June 30, 2023. Two related party customers each accounted for 20% and 20% of the portfolio servicing revenue for the three months ended June 30, 2023. One customer accounted for 26% of the total revenues for the three months ended June 30, 2022.
One customer accounted for 29% of active management revenue, while 16% of revenue related to 2 policies that matured that were accounted for under the investment method and 1 policy that matured that was accounted for under the fair-value method for the six months ended June 30, 2023. Two related party customers each accounted for 25% and 27% of the portfolio servicing revenue for the six months
14

ended June 30, 2023. One customer accounted for 71% of the total revenues for the six months ended June 30, 2022.

Warrants—The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480 Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the condensed consolidated statements of operations and comprehensive income.
3.BUSINESS COMBINATION
Merger consideration conveyed of $531.8 million was allocated between the Companies based on relative values derived through both the discounted cash flow method within the income approach and the guideline public company method within the market approach. Within the discounted cash flow method, the present values of cash flows reasonably expected to be produced by the Companies from their operations were summed to produce an estimate of the Companies’ business enterprise values on a controlling, marketable basis. The cash flows used in the discounted cash flow analysis were discounted at the weighted average cost of capital of 14.5% for LMA and 16.5% for Abacus. The discounted cash flow method resulted in a business enterprise value range of $380.0 million to $460.0 million for LMA and $180.0 million to $195.0 million for Abacus. Within the market approach, Company applied the guideline public company method, which employs market multiples derived from market prices of stocks of Companies that are engaged in the same or similar lines of business as the Companies and that are actively traded on a free and open market. The guideline public company method resulted in a business enterprise value range of $400.0 million to $440.0 million for LMA and $180.0 million to $190.0 million for Abacus. Management concluded on a business enterprise value of $165.4 million for Abacus and $366.4 million for LMA based upon the relative fair value of the Companies allocated to the consideration transferred.
The preliminary purchase price was allocated among the identified assets to be acquired. The primary area of the acquisition accounting that is not yet finalized is our estimate of the impact of acquisition accounting on deferred income taxes. An estimate of deferred income taxes has been recorded in the Company’s books based on information available as of June 30, 2023. As the initial acquisition accounting is based on our preliminary assessments, actual values may differ when final information becomes available. We believe that the information gathered to date provides a reasonable basis for estimating the preliminary values of deferred taxes recorded. We will continue to evaluate this item until it is satisfactorily resolved and adjust our acquisition accounting accordingly, within the allowable measurement period, as defined by ASC 805, Business Combinations. Transaction costs incurred as a result of the Business Combination were recognized within retained earnings/(accumulated deficit) on the condensed consolidated balance sheet ending June 30, 2023.

All valuation procedures related to existing assets as no new assets were identified as a result of procedures performed. Goodwill was recognized as a result of the acquisition, which represents the
15

excess fair value of consideration over the fair value of the underlying net assets, largely arising from the extensive industry expertise that has been established by Abacus. This was considered appropriate based on the determination that the Abacus Merger would be accounted for as a business acquisition under ASC 805.
Net Assets IdentifiedFair Value
Intangibles$32,900,000 
Goodwill140,287,000 
Current Assets1,280,100 
Non-Current Assets901,337 
Deferred Tax Liabilities(8,310,966)
Accrued Expenses(524,400)
Other Liabilities(1,171,739)
Total Fair Value$165,361,332 
Value ConveyedAmount
Abacus Purchase Consideration$165,361,332 
LMA Business Enterprise Value $366,388,668 
Total Consideration$531,750,000 
Intangible assets were comprised of the following:
Asset TypeFair ValueUseful LifeValuation Methodology
Customer Relationships-Agents$12,600,000 5 yearsMulti-period excess earnings method
Customer Relationships-Financing Entities11,000,000 8 yearsMulti-period excess earnings method
Internally Developed and Used Technology-APA1,600,000 2 yearsRelief from royalty method
Internally Developed and Used Technology-Marketplace100,000 3 yearsReplacement cost method
Trade Name900,000 IndefiniteRelief from royalty method
Non-Compete Agreements4,000,000 2 yearsWith and without method
State Insurance Licenses2,700,000 IndefiniteReplacement cost method
Total Fair Value$32,900,000 
Useful lives for customer relationships were developed using attrition data for agents and financing entities which resulted in a useful life of 5 years and 8 years, respectively. Estimates over the useful lives of internally developed and used technology contemplates the period in which the Company expects to utilize the technology and the length of time the technology is expected to maintain recognition and value in the market without significant investment.Non-compete agreements have a useful life commensurate with the executed non-compete agreements in place as a result of the Business Combination.
The supplemental pro forma financial information in the table below summarizes the combined results of operations for the Business Combination as if the Companies were combined as of
16

January 1, 2022. The unaudited supplemental pro forma financial information as presented below is for illustrative purposes and does not purport to represent what the results of operations would actually have been if the business combinations occurred as of the date indicated or what the results would be for any future periods.

Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Proforma revenue$18,263,455 $14,090,817 $34,769,650 $31,290,963 
Proforma net income6,432,047 4,589,315 13,373,444 11,788,486 



4.LIFE INSURANCE SETTLEMENT POLICIES
As of June 30, 2023, the Company holds 167 life settlement policies, of which 122 are accounted for under the fair value method and 45 are accounted for using the investment method (cost, plus premiums paid). Aggregate face value of policies held at fair value is $195,205,585 as of June 30, 2023, with a corresponding fair value of $56,685,617. Aggregate face value of policies accounted for using the investment method is $39,520,877 as of June 30, 2023, with a corresponding carrying value of $9,889,610.
As of December 31, 2022, the Company held 53 life settlement policies, of which 35 were accounted for under the fair value method and 18 were accounted for using the investment method (cost, plus premiums paid). Aggregate face value of policies held at fair value was $40,092,154 as of December 31, 2022, with a corresponding fair value of $13,809,352. Aggregate face value of policies accounted for using the investment method was $42,330,000 as of December 31, 2022, with a corresponding carrying value of $8,716,111.
At June 30, 2023, the Company did not have any contractual restrictions on its ability to sell policies, including those held as collateral for the issuance of long-term debt. See footnote 11 Long-Term Debt.
Life expectancy reflects the probable number of years remaining in the life of a class of persons determined statistically, affected by such factors as heredity, physical condition, nutrition, and occupation. It is not an estimate or an indication of the actual expected maturity date or indication of the timing of expected cash flows from death benefits. The following tables summarize the Company’s life insurance policies grouped by remaining life expectancy as of June 30, 2023:
Policies Carried at Fair Value
Remaining Life Expectancy (Years)PoliciesFace ValueFair Value
0-1
0$ $ 
1-2
1012,314,000 6,855,769 
2-3
1116,886,778 10,530,949 
3-4
1033,631,467 9,174,200 
4-5
1318,755,193 7,564,469 
Thereafter78113,618,147 22,560,230 
122$195,205,585 $56,685,617 
17

Policies accounted for using the investment method—
Remaining Life Expectancy (Years)Number of Life
Insurance
Policies
Face ValueCarrying Value
0-1
0$ $ 
1-2
0  
2-3
24,400,000 2,131,679 
3-4
44,100,000 1,281,524 
4-5
41,362,000 518,736 
Thereafter35 29,658,877 5,957,671 
45$39,520,877 $9,889,610 
Estimated premiums to be paid by the Company for its portfolio accounted for using the investment method during each of the five succeeding calendar years and thereafter as of June 30, 2023, are as follows:
2023 remaining$1,024,151 
20241,243,423 
20251,310,936 
20261,044,640 
Thereafter3,288,619 
Total$7,911,769 
The Company is required to pay premiums to keep its portion of life insurance policies in force. The estimated total future premium payments could increase or decrease significantly to the extent that actual mortalities of insureds differ from the estimated life expectancies.
For policies accounted for under the investment method, the Company has not been made aware of information causing a material change to assumptions relating to the timing of realization of life insurance settlement proceeds. We have also not been made aware of information indicating impairment to the carrying value of policies.
5.PROPERTY AND EQUIPMENT—NET
Property and equipment—net composed of the following:
June 30,
2023
December 31,
2022
Computer equipment$144,202 $ 
Furniture and fixtures34,300 19,444 
Leasehold improvements8,299 5,902 
Property and equipment—gross186,801 25,346 
18

Less: accumulated depreciation(8,870)(6,729)
Property and equipment—net$177,931 $18,617 
Depreciation expense for the three months ended June 30, 2023 and 2022, was $1,098 and $1,098, respectively and depreciation expense for the six months ended June 30, 2023, and 2022, was $2,141 and $2,141, respectively.
6.GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill of $140,287,000 was recognized as a result of the Business Combination, which represents the excess fair value of consideration over the fair value of the underlying net assets, largely arising from the extensive industry expertise that has been established by Abacus. This was considered appropriate based on the determination that the Abacus Merger would be accounted for as a business acquisition under ASC 805. The estimates of fair value are based upon preliminary valuation assumptions believed to be reasonable, but which are inherently uncertain and unpredictable. Refer to footnote 3 for further details.

The changes in goodwill by reportable segments were as follows:

Abacus Settlements, LLC
Goodwill at January 1, 2022$ 
Additions 
Goodwill at June 30, 2022$ 
Goodwill at January 1, 2023$ 
Additions140,287,000 
Goodwill at June 30, 2023$140,287,000 
Intangible Assets Acquired comprised of the following:
Asset TypeFair ValueUseful LifeValuation Methodology
Customer Relationships - Agents$12,600,000 5 yearsMulti-period excess-earnings method
Customer Relationships - Financial Relationships11,000,000 8 yearsMulti-period excess-earnings method
Internally Developed and Used Technology—APA1,600,000 2 yearsRelief from Royalty Method
Internally Developed and Used Technology—Market Place100,000 3 yearsReplacement Cost Method
Trade Name900,000 IndefiniteRelief from Royalty Method
Non-Compete Agreements4,000,000 2 yearsWith or Without Method
State Insurance Licenses2,700,000 IndefiniteReplacement Cost Method
$32,900,000 

7.AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE
Convertible Promissory Note—The Company holds a convertible promissory note in a separate unrelated insurance technology company. In November 2021, the Company purchased a $250,000 note and then purchased an additional note in January 2022 for $250,000 as part of the Tranche 5 offering (“Tranche 5
19

Promissory Note”). The Tranche 5 Promissory Note pays 6% interest per annum. The Tranche 5 Promissory Note matures on November 12, 2023 (“Maturity Date”) and will be paid in full as to outstanding principal and accrued interest on the Maturity Date unless the Tranche 5 Promissory Note converts prior to the 2023 Maturity Date. Conversion into preferred shares occurs if the technology company engages in an additional equity financing event that yields gross cash proceeds in excess of $1,000,000 (“Next Equity Financing”).
In October 2022, the Company purchased an additional convertible promissory note in the same unrelated insurance technology company for $500,000 as part of the Tranche 6 offering (“Tranche 6 Promissory Note” and collectively, the “Convertible Promissory Notes”). The Tranche 6 Promissory Note pays eight percent (8)% interest per annum and matures September 30, 2024 (“2024 Maturity Date”) and will be paid in full as to outstanding principal and accrued interest on the 2024 Maturity Date unless the Tranche 6 Promissory Note converts prior to the 2024 Maturity Date. Conversion into preferred shares occurs if the technology company engages in an additional equity financing event that yields gross cash proceeds in excess of $5,000,000 (“Next Round Securities”).
The Company applies the available-for-sale method of accounting for its investment in the Convertible Promissory Note, which is a debt investment. The Convertible Promissory Note does not qualify for either the held-to-maturity method due to the Convertible Promissory Note’s conversion rights or the trading securities method because the Company holds the Convertible Promissory Note as a long-term investment. The Convertible Promissory Notes are measured at fair value at each reporting period-end. Unrealized gains and losses are reported in other comprehensive income until realized. As of December 31, 2022 and June 30, 2023, the Company evaluated the fair value of its investment and determined that the fair value approximates the carrying value of $1,000,000 and there was no unrealized gain or loss recorded.
8.OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS
Other Investments:
Convertible Preferred Stock Ownership—The Company owns convertible preferred stock in two entities, further described below.
On July 22, 2020, the Company purchased 224,551 units of an unrelated insurance technology company’s Series Seed Preferred units for $750,000 (“Seed Units”). During December 2022, the Company agreed to purchase 119,760 Series Seed Preferred Units for $400,000 in cash consideration by way of eight monthly payments of $50,000 starting December 15, 2022, resulting in a total of $950,000 investment as of March 31, 2023 and $1,100,000 investment as of June 30, 2023. Upon conversion, the Seed Units held by the Company would represent 8.6% control in the technology company.
On December 21, 2020, the Company purchased 207,476 shares of a separate unrelated insurance technology company’s Series B-1 preferred stock for $500,000 (“Preferred Shares”). The Preferred Shares are convertible into voting common stock of insured consent at the option of the Company. Upon conversion, the Preferred Shares would represent less than 1% control in the technology company.
The Company applies the measurement alternative for its investments in the Seed Units and Preferred Shares because these investments are of an equity nature, and the Company does not have the ability to exercise significant influence over operating and financial policies of entities even in the event of conversion of the Seed Units or Preferred Shares. Under the measurement alternative, the Company records the investment based on original cost, less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the investee. The Company’s share of income or loss of such companies is not included in the Company’s condensed consolidated statements of operations and comprehensive income. The Company tests its investments for impairment whenever circumstances indicate that the carrying value of the investment
20

may not be recoverable. No impairment of investments occurred for the three and six months ended June 30, 2023 and 2022.
Other Noncurrent Assets- at fair value:
S&P OptionsThe Company is long S&P 500 call options and short S&P 500 put options which were purchased and sold through a broker as an economic hedge related to the market-indexed debt instruments included in the long-term debt note. The value is based on shares owned and quoted market prices in active markets. Changes in fair value are recorded in the Unrealized Loss on Investments line item on the condensed consolidated statements of operations and comprehensive income.
9.CONSOLIDATION OF VARIABLE INTEREST ENTITIES
The Company consolidates VIEs for which it is the primary beneficiary or VOEs for which it controls through a majority voting interest or other arrangement. See Note 2 for more information on how the Company evaluates an entity for consolidation.
The Company evaluated any entity in which it had a variable interest upon formation to determine whether the entity should be consolidated. The Company also evaluated the consolidation conclusion during each reconsideration event, such as changes in the governing documents or additional equity contributions to the entity. During the six months ended June 30, 2023, the Company’s consolidated VIEs, LMA Income Series II LP, LMX Series LLC (LMATT Series 2024, Inc.), Longevity Market Advisors, Regional Investment Services and LMA Income Series, LP, had total assets of $57,577,034 and liabilities of $52,474,820. For the year ended December 31, 2022, the Company’s consolidated VIEs, LMATT Series 2024, Inc., Longevity Market Advisors, Regional Investment Services and LMA Income Series, LP, had total assets and liabilities of $30,073,972 and $27,116,762, respectively. The Company did not deconsolidate any entities during the period ended June 30, 2023, or during the year ended December 31, 2022.
As of June 30, 2023, the Company held total assets of $801,345 and liabilities of $185,071, in unconsolidated VIEs. As of December 31, 2022, the Company held total assets of $987,964 and liabilities of $358,586 in unconsolidated VIEs.
10.SEGMENT REPORTING
Segment Information—The Company organizes its business into two reportable segments (1) Portfolio Servicing and (2) Active Management, which generate revenue in different manners.
This segment structure reflects the financial information and reports used by the Company’s management, specifically its chief operating decision maker (CODM), to make decisions regarding the Company’s business, including resource allocations and performance assessments, as well as the current operating focus in compliance with ASC 280, Segment Reporting. The Company’s CODM is the President and Chief Executive Officer.
The Portfolio Servicing segment generates revenues by providing policy services to customers on a contract basis.
The Active Management segment generates revenues by buying, selling, and trading policies and maintaining policies until receipt of death benefits. The Company’s reportable segments are not aggregated.
The Company’s method for measuring profitability on a reportable segment basis is gross profit. The CODM does not review asset information related to investments nor expenditures incurred for long-lived assets given the Company’s investments are recognized using the measurement alternative, and the Company’s long-lived assets are immaterial to the condensed consolidated financial statements.
21

Revenue related to the Company’s reporting segments for the three-month and six-month periods ended June 30, 2023, and June 30, 2022, is as follows:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Portfolio servicing$354,366 $419,422 $590,057 $990,328 
Active management11,024,399 7,979,479 20,994,917 17,285,971 
Total revenue$11,378,765 $8,398,901 $21,584,974 $18,276,299 
Information related to the Company’s reporting segments for the three-month and six-month periods ended June 30, 2023 and June 30, 2022 is as follows:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Portfolio servicing$(76,705)$280,303 $(166,128)$668,752 
Active management10,482,070 7,452,479 20,288,152 15,521,472 
Total gross profit10,405,365 7,732,782 20,122,024 16,190,224 
Sales and marketing(683,841)(1,019,498)(1,412,845)(1,649,498)
General, administrative and other(577,539)(5,499)(1,274,431)(646,705)
Depreciation(1,098)(1,098)(2,141)(2,141)
Other (expense) income121,601 (127,455)(21,651)(242,247)
Interest expense(584,075)- (934,001)- 
Loss on change in fair value of debt(1,445,229)(333,879)(2,398,662)(375,513)
Unrealized gain (loss) on investments672,936 (1,039,022)798,156 (1,054,975)
Provision for income taxes(1,184,571)(120,132)(528,104)(296,806)
Less: Net loss attributable to non-controlling interests26,596 (406,641)487,303 (406,641)
Net income attributable to Abacus Life, Inc.$6,750,145 $4,679,558 $14,835,648 $11,515,698 
11.COMMITMENTS AND CONTINGENCIES
Legal Proceedings—Occasionally, the Company may be subject to various proceedings such as lawsuits, disputes, or claims. The Company assesses these proceedings as they arise and accrues a liability when losses are probable and reasonably estimable. Although legal proceedings are inherently unpredictable, the Company is currently not aware of any matters that, if determined adversely to the Company, would individually, or taken together, have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows.
Commitment—The Company has entered into a Strategic Services and Expenses Support Agreement (“Expense Support Agreement”) with two commonly owned full-service origination, servicing, and investment Providers in exchange for an option to purchase the outstanding equity ownership of the Providers. Pursuant to the Expense Support Agreement, Abacus Life, Inc. provides financial support and advice for the expenses of the Providers incurred in connection with their life settlement transactions
22

businesses and the Providers are required to hire a life settlement transactions operations employee of an affiliate of Abacus Life, Inc. No later than December 1 of each calendar year, Abacus Life, Inc. provides a budget for the Providers, in which Abacus Life, Inc. commits to extend financial support for all operating expenses up to the budgeted amount. “Operating Expenses” for purposes of the Expense Support Agreement means all annual operating expenses of the Providers incurred in the ordinary course of business, excluding the premiums paid for the Providers insurance coverages that are allocable to the insurance coverage provided to Institutional Life Holdings, LLC, which owns all the outstanding membership interests of the Providers if unrelated to the Providers settlement business.
For the three months ended June 30, 2023, Abacus Life, Inc. did not incur expenses related to the Expense Support Agreement. For the six months ended June 30, 2023, Abacus Life, Inc. incurred $29,721 of expenses, related to the Expense Support Agreement, which is included in the Other (expense) line of the condensed consolidated statements of operations and comprehensive income and have not been reimbursed by the Providers.
12.FAIR VALUE MEASUREMENTS
The Company determines fair value based on assumptions that market participants would use in pricing an asset or a liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:
Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.
Level 2 inputs: Other than quoted prices in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.
Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.
23

Recurring Fair Value MeasurementsThe assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy are presented in the tables below.
Fair Value Hierarchy
As of June 30, 2023Level 1Level 2Level 3Total
Assets:
Life settlement policies$ $ $56,685,617 $56,685,617 
Available-for-sale securities, at fair value  1,000,000 1,000,000 
Other investments  1,600,000 1,600,000 
S&P 500 options1,794,640   1,794,640 
Other assets7,246   7,246 
Total assets held at fair value$1,801,886 $ $59,285,617 $61,087,503 
Liabilities:
Long-term debt$ $ $66,165,396 $66,165,396 
Private placement warrants  2,438,600 2,438,600 
Total liabilities held at fair value:$ $ $68,603,996 $68,603,996 
Fair Value Hierarchy
As of December 31, 2022Level 1Level 2Level 3Total
Assets:
Life settlement policies$ $ $13,809,352 $13,809,352 
Available-for-sale securities, at fair value  1,000,000 1,000,000 
Other investments  1,300,000 1,300,000 
S&P 500 options890,829   890,829 
Total assets held at fair value$890,829 $ $16,109,352 $17,000,181 
Liabilities:
Long-term debt$ $ $28,249,653 $28,249,653 
Total liabilities held at fair value:$ $ $28,249,653 $28,249,653 
Life Settlement PoliciesThe Company separately accounts for each owned life settlement policy using either the fair value method, or investment method (cost, plus premiums paid). The valuation method is chosen upon contract acquisition and is irrevocable.
For policies carried at fair value, the Company utilizes valuation services of a third-party actuarial firm, who values the contracts using Level 3 unobservable inputs, including actuarial assumptions, such as life expectancies and cash flow discount rates. The valuation model is based on a discounted cash flow analysis and is sensitive to changes in the discount rate used. The Company utilized a discount rate of 16% at June 30,2023 and 12% at December 31, 2022, respectively, for policy valuation, which is based on economic and company-specific factors.
24

Subsequent to the reporting date, the Company sold 3 policies carried at fair value. As of June 30, 2023, the Company valued these 3 policies using the price at the time of sale. Valuing these 3 policies using the takeout price resulted in a decrease in valuation of $231,775 compared to the third-party valuation.
For life settlement policies carried using the investment method, the Company measures these at the cost of the policy plus premiums paid. The policies accounted for using the investment method totaled $9,889,610 at June 30, 2023 and $8,716,111 at December 31, 2022, respectively.
Discount Rate Sensitivity—Changes in the 16% discount rate on the death benefit and premiums used to estimate the policies issued under LMATT Series 2024 Inc., LMATT Growth Series 2.2024 Inc., LMATT Growth and Income Series 1.2026, Inc., LMA Income Series, LP and LMA Income Series II, LP (“LMATT Policies”) fair value has been analyzed. If the discount rate increased or decreased by 2 percentage points and the other assumptions used to estimate fair value remained the same, the change in estimated fair value as of June 30, 2023, would be as follows:
As of June 30, 2023Fair ValueChange in
Fair Value
Rate Adjustment
+2%$53,987,508 $(2,698,109)
No change56,685,617 
-2%59,857,879 3,172,262 
Credit Exposure to Insurance CompaniesThe following table provides information about the life insurance issuer concentrations that exceed 10% of total face value or 10% of total fair value of the Company’s life insurance policies as of June 30, 2023:
CarrierPercentage of
Face Value
Percentage of
Fair Value
Carrier
Rating
American General Life Insurance Company14.0 %11.0 %A
ReliaStar Life Insurance Company6.0 %12.0 %A
Lincoln National Life Insurance Company14.0 %12.0 %A
The following table provides a roll forward of the fair value of life insurance policies for the six months-ended June 30, 2023:
Fair value at December 31, 2022$13,809,352 
Policies purchased58,543,580 
Realized gain (loss) on matured/sold policies1,898,958 
Premiums paid(879,462)
Unrealized gain(loss) on held policies3,319,588 
Change in estimated fair value4,339,084 
Matured/sold policies(20,885,861)
Premiums paid879,462 
Fair value at June 30, 2023$56,685,617 
25

Long-Term Debt—See Note 13. “Long-Term Debt” for background information on the market-indexed debt. The Company has elected the fair value option in accounting for the instruments. Fair value is determined using Level 3 inputs. The valuation methodology is based on the Black-Scholes-Merton option-pricing formula and a discounted cash flow analysis. Inputs to the Black-Scholes-Merton model include (i) the S&P 500 Index price, (ii) S&P 500 Index volatility, (iii) a risk-free rate based on data published by the US Treasury, and (iv) a term assumption based on the contractual term of the LMATT Notes. The discounted cash flow analysis includes a discount rate that is based on the implied discount rate developed by calibrating a valuation model to the purchase price on the initial investment date. The implied discount rate is evaluated for reasonableness by benchmarking it to yields on actively traded comparable securities.
The total change in fair value of the debt resulted in a gain of $1,602,042. This gain is comprised of $90,148, net of tax, which is included within accumulated other comprehensive income and $29,515 net of tax, which is included in equity of noncontrolling interests resulting from risk-adjusted valuation scenarios. The Company recognized a loss of $1,445,229 on the change in fair value of the debt resulting from risk-free valuation scenarios, which is included within Change in fair value of debt within the condensed consolidated statement of operations and comprehensive income for the three months ended June 30, 2023.
The total change in fair value of the debt resulted in a gain of $2,705,918. This gain is comprised of $175,530, net of tax, which is included within accumulated other comprehensive income and $56,446 net of tax, which is included in equity of noncontrolling interests resulting from risk-adjusted valuation scenarios. The Company recognized a loss of $2,398,662 on the change in fair value of the debt resulting from risk-free valuation scenarios, which is included within Change in fair value of debt within the condensed consolidated statement of operations and comprehensive income for the six months ended June 30, 2023.
The following table provides a roll forward of the fair value of the issued notes for the six months ended June 30, 2023:
Fair value at December 31, 2022$28,249,653 
Debt issued to third parties35,209,825 
Unrealized loss on change in fair value (risk-free)2,398,662 
Unrealized gain on change in fair value (credit-adjusted)307,256 
Change in estimated fair value2,705,918 
Fair value at June 30, 2023$66,165,396 
Private Placement Warrants—Simultaneously with the closing of the Initial Public Offering, ERES consummated the sale of 8,900,000 warrants (the “Private Placement Warrants”) to East Sponsor, LLC (the “Sponsor”), which included the sale of an additional 900,000 Private Placement Warrants in connection with the full exercise by the underwriters of their over-allotment option on August 25, 2020, at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of $8,900,000. Each Private Placement Warrant is exercisable for one share of Class A common stock at a price of $11.50 per share, subject to adjustment.

The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that (x) the Private Placement Warrants and the shares of Class A common stock issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or
26

salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions, (y) the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees and (z) the Private Placement Warrants and the shares of Class A common stock issuable upon exercise of the Private Placement Warrants will be entitled to registration rights. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.
Private Placement Warrants were accounted for as liabilities in accordance with ASC 815-40. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented separately in the condensed consolidated statements of operations.

The Private Placement Warrants were considered a Level 3 fair value measurement using a binomial lattice model in a risk-neutral framework. The binomial lattice model’s primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the expected volatility of the common stock. The implied volatility as of the reporting date was derived from observable public warrant traded price provided by Bloomberg LP.

The following table presents the key assumptions in the analysis:
Private Placement Warrants
Expected implied volatility de minimis
Risk-free interest rate 4.09%
Term to expiration 5.0 years
Exercise price$11.50
Common Stock Price $10.03
Dividend Yield%
Other Noncurrent Assets: S&P 500 Options—In February 2022, LMATT Series 2024, Inc., which the Company consolidates for financial reporting, purchased and sold S&P 500 call and put options through a broker. The Company purchased and sold additional S&P 500 call options through a broker in June 2022 through their 100% owned and fully consolidated subsidiaries LMATT Growth Series 2.2024, Inc. and LMATT Growth and Income Series 1.2026, Inc. The options are exchange traded, and fair value is determined using Level 1 inputs of quoted market prices as of the condensed consolidated balance sheets dates. Changes in fair value are classified as unrealized (gain)/loss on investments within the condensed consolidated statements of operations and comprehensive income.
Financial Instruments Measured at Fair Value on a Nonrecurring Basis—The following financial assets, composed of equity securities without readily determinable fair values, are adjusted to fair value when observable price changes are identified, or an impairment charge is recognized. Such fair value measurements are based predominantly on Level 3 inputs.
Available-for-Sale Investment—The Convertible Promissory Note is classified as an available-for-sale security. Available-for-sale investments are subsequently measured at fair value. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income until realized. The Company determines fair value of its available-for-sale investments using unobservable inputs by considering the initial investment value, next round financing, and the likelihood of conversion or settlement based on the contractual terms in the agreement. The Company initially purchased a $250,000 convertible promissory note from the issuer in 2021 and then on January 7, 2022, the Company purchased an additional $250,000 convertible promissory note from the same issuer and then an additional $500,000 in October 2022. As of June 30, 2023 and December 31, 2022, the Company
27

evaluated the fair value of its Promissory Note and determined that the fair value approximates the carrying value of $1,000,000 and $1,000,000, respectively.
Other Investments—The Company determines fair value using Level 3 inputs under the measurement alternative. These investments are recorded at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Impairment is assessed qualitatively. As of June 30, 2023, and December 31, 2022, the Company did not identify any impairment indicators and determined that the carrying value of $1,600,000 and $1,300,000 is the fair value for these equity investments in privately held companies, given that there have been no observable price changes.
Financial Instruments Where Carrying Value Approximates Fair Value—The carrying value of cash, cash equivalents, accounts receivables, and due to affiliates approximates fair value due to the short-term nature of their maturities.

13.LONG-TERM DEBT
Long-term debt comprises of the following:
Six Months Ended
June 30, 2023
Year Ended
December 31, 2022
CostFair valueCostFair value
Market-indexed notes:
LMATT Series 2024, Inc.$9,866,900 $9,621,141 $9,866,900 $8,067,291 
LMATT Series 2.2024, Inc.2,333,391 3,446,527 2,333,391 2,354,013 
LMATT Growth & Income Series 1.2026, Inc400,000 459,553 400,000 400,000 
Secured borrowing:
LMATT Income Series, LP21,889,444 22,124,676 17,428,349 17,428,349 
LMATT Income Series II, LP20,041,851 20,041,851   
Unsecured borrowing:
Sponsor PIK Note10,471,648 10,471,648   
Total long-term debt$65,003,234 $66,165,396 $30,028,640 $28,249,653 
SPV purchase and sale note$25,000,000 $25,000,000   
Sponsor PIK Note
On the June 30, 2023, in connection with the consummation of the Business Combination and as contemplated by the Merger Agreement, East Sponsor, LLC, a Delaware limited liability company (“Sponsor”), made an unsecured loan to the Company in the aggregate amount of $10,471,648 (the “Sponsor PIK Note”). The Sponsor PIK Note matures on June 30, 2028 (the “Maturity Date”) and may be prepaid at any time in accordance with its terms without any premium or penalty.
LMATT Series 2024, Inc. Market-Indexed Notes:
On March 31, 2022, LMATT Series 2024, Inc., which the Company consolidates for financial reporting, issued $10,166,900 in market-indexed private placement notes. The note, titled the Longevity Market Assets Target-Term Series (LMATTS) 2024, is a market-indexed instrument designed to provide upside performance exposure of the S&P 500 Index, while limiting downward exposure. Upon maturity of the note in 2024, the principal, plus the return based upon the S&P 500 Index must be paid. The note has a
28

feature to protect debt holders from market downturns, up to 40%. Any subsequent losses below the 40% threshold will reduce the note on a one-to-one basis. As of June 30, 2023, $9,866,900 of the principal amount remained outstanding.
The notes are held at fair value, which represents the exit price, or anticipated price to transfer the liability to a third party. As of June 30, 2023, the fair value of the LMATT Series 2024, Inc. notes were $9,621,141.
The notes are secured by the assets of the issuing entities, which includes cash, S&P 500 options, and life settlement policies totaling $11,195,701 as of June 30, 2023. The notes’ agreements do not restrict the trading of life settlement contracts prior to maturity of the note, as total assets of the issuing companies are considered as collateral. There are also no restrictive covenants associated with the notes with which the entities must comply.
LMATT Series 2.2024, Inc. Market-Indexed Notes:
On September 16, 2022, LMATTS Series 2.2024, Inc., a 100% owned subsidiary which the Company consolidates for financial reporting issued $2,333,391 in market-indexed private placement notes. The note, titled the Longevity Market Assets Target-Term Growth Series 2.2024, Inc. (“LMATTSTM Series 2.2024, Inc.”) is a market-indexed instrument designed to provide upside performance exposure of the S&P 500 Index, while limiting downward exposure. Upon maturity of the note in 2024, the principal, plus the return based upon the S&P 500 Index must be paid. The note has a feature to provide upside performance participation that is capped at 120% of the performance of the S&P 500. A separate layer of the note has a feature to protect debt holders from market downturns by up to 20% if the index price experiences a loss during the investment period. After the underlying index has decreased in value by more than 20%, the investment will experience all subsequent losses on a one-to-one basis. . As of June 30, 2023, the entire principal amount remained outstanding.
The notes are held at fair value, which represents the exit price, or anticipated price to transfer the liability to a third party. As of June 30, 2023, the fair value of the LMATT Series 2.2024, Inc. notes were $3,446,527.
The notes are secured by the assets of the issuing entity, LMATT Series 2.2024, Inc., which includes cash, S&P 500 options, and life settlement policies totaling $3,331,872 as of June 30, 2023. The note agreements do not restrict the trading of life settlement contracts prior to maturity of the note, as total assets of the issuing company are considered as collateral. There are also no restrictive covenants associated with the note with which the entity must comply.
LMATT Growth and Income Series 1.2026, Inc. Market-Indexed Notes:
Additionally, on September 16, 2022, LMATTS Growth and Income Series 1.2026, Inc., a 100% owned subsidiary which the Company consolidates for financial reporting issued $400,000 in market-indexed private placement notes. The note, titled the Longevity Market Assets Target-Term Growth and Income Series 1.2026, Inc (“LMATTSTM Growth and Income Series 1.2026, Inc.”) is a market-indexed instrument designed to provide upside performance exposure of the S&P 500 Index, while limiting downward exposure. Upon maturity of the note in 2026, the principal, plus the return based upon the S&P 500 Index must be paid. The note has a feature to provide upside performance participation that is capped at 140% of the performance of the S&P 500. A separate layer of the note has a feature to protect debt holders from market downturns by up to 10% if the index price experiences a loss during the investment period. After the underlying index has decreased in value by more than 10%, the investment will experience all subsequent losses on a one-to-one basis. This note also includes 4% dividend feature that will be paid annually. As of June 30, 2023, the entire principal amount remained outstanding.
29

The notes are held at fair value, which represents the exit price, or anticipated price to transfer the liability to a third party. As of June 30, 2023, the fair value of the LMATT Growth and Income Series 1.2026, Inc., notes were $459,553.
The notes are secured by the assets of the issuing entity, LMATTS Growth and Income Series 1.2026, Inc., which includes cash, S&P 500 options, and life settlement policies totaling $517,218 as of June 30, 2023. The note agreements do not restrict the trading of life settlement contracts prior to maturity of the note, as total assets of the issuing company are considered as collateral. There are also no restrictive covenants associated with the note with which the entity must comply.
See additional fair value considerations within footnote 12.
LMA Income Series, LP and LMA Income Series, GP LLC Secured Borrowing
LMA Income Series, GP, LLC, wholly owned and controlled by that LMA Series, LLC, formed a limited partnership, LMA Income Series, LP and issued partnership interests to limited partners in a private placement offering. The initial term of the offering is three years with the ability to extend for two additional one-year periods at the discretion of the general partner, LMA Income Series, GP, LLC. The limited partners will receive an annual dividend of 6.5% paid quarterly and 25% of returns in excess of a 6.5% internal rate of return capped at 9% which would require a 15% net internal rate of return. The General Partner will receive 75% of returns in excess of a 6.5% internal rate of return to limited partners then 100% in excess of a 15% net internal rate of return.
It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series, LP and thus has fully consolidated the limited partnership in its consolidated financial statements for the six months ended June 30, 2023.
The private placement offerings proceeds will be used to acquire an actively managed large and diversified portfolio of financial assets. LMA, through its consolidated subsidiaries, serves as the portfolio manager for the financial asset portfolio, which includes investment sourcing and monitoring. In this role, LMA has the unilateral ability to acquire and dispose of any of the above investments. As the partnership does not represent a business in accordance with ASC 810 and is a consolidated subsidiary that only holds financial assets, this represents a transfer subject to ASC 860-10. As the financial assets are not transferred outside the consolidated group, the proceeds from the offering shall be classified as a liability unless it meets the definition of a participating interest and the derecognition criteria in ASC 860 are met. The transferred interest did not meet the definition of a participating interest as LMA possesses the unilateral ability to direct the sale of the financial assets (ASC 860-10-50-6A(d)). In accordance with ASC 860-30-25-2, as the transfer of the financial assets did not meet the definition of a participating interest, LMA shall recognize the proceeds received from the offering as a secured borrowing.
LMA elected to account for the secured borrowing at fair value under the collateralized financing entity guidance within ASC 810-10-30. As of June 30, 2023, the fair value of the secured borrowing was $22,124,676.
LMA Income Series II, LP and LMA Income Series II, GP LLC Secured Borrowing
LMA Income Series II, GP, LLC, wholly owned and controlled by that LMA Series, LLC, formed a limited partnership, LMA Income Series II, LP and issued partnership interests to limited partners in a private placement offering. The initial term of the offering is three years with the ability to extend for two additional one-year periods at the discretion of the general partner, LMA Income Series II, GP, LLC. The limited partners will receive annual dividends equal to the Preferred Return Amounts as follows: Capital commitment less than $500,000, 7.5%; between $500,000 and $1,000,000, 7.75%; over $1,000,000, 8%. Thereafter, 100% of the excess to be paid to the General Partner.
30

It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series, LP and thus has fully consolidated the limited partnership in its consolidated financial statements for the three and six months ended June 30, 2023.
The private placement offerings proceeds will be used to acquire an actively managed large and diversified portfolio of financial assets. LMA, through its consolidated subsidiaries, serves as the portfolio manager for the financial asset portfolio, which includes investment sourcing and monitoring. In this role, LMA has the unilateral ability to acquire and dispose of any of the above investments. As the partnership does not represent a business in accordance with ASC 810 and is a consolidated subsidiary that only holds financial assets, this represents a transfer subject to ASC 860-10. As the financial assets are not transferred outside the consolidated group, the proceeds from the offering shall be classified as a liability unless it meets the definition of a participating interest and the derecognition criteria in ASC 860 are met. The transferred interest did not meet the definition of a participating interest as LMA possesses the unilateral ability to direct the sale of the financial assets (ASC 860-10-50-6A(d)). In accordance with ASC 860-30-25-2, as the transfer of the financial assets did not meet the definition of a participating interest, LMA shall recognize the proceeds received from the offering as a secured borrowing.
LMA elected to account for the secured borrowing at fair value under the collateralized financing entity guidance within ASC 810-10-30. As of June 30, 2023, the fair value of the secured borrowing was $20,041,851.

SPV Purchase and Sale

On July 5, 2023, the Company entered into an Asset Purchase Agreement (the “Policy APA”) to acquire certain insurance policies with an aggregate fair market value of $10.0 million from Abacus Investment SPV, LLC, a Delaware limited liability company (“SPV”), in exchange for a payable obligation owing by the Company to the SPV (such acquisition transaction under the Policy APA, the “SPV Purchase and Sale”).
The payable obligation owing by the Company to the SPV in connection with the SPV Purchase and Sale is evidenced by a note issued by the Company under the SPV Investment Facility (the “SPV Purchase and Sale Note”) in an original principal amount equal to the aggregate fair market value of the acquired insurance policies. The SPV Purchase and Sale Note has the same material terms and conditions as the other credit extensions under the SPV Investment Facility (as defined below).
SPV Investment Facility
On July 5, 2023, the Company entered into that certain SPV Investment Facility (the “SPV Investment Facility”), between the Company, as borrower, and the SPV, as lender.
The SPV Investment Facility, among other things:
requires certain subsidiaries of the Company to guarantee the credit extensions provided under the SPV Investment Facility pursuant to separate documentation
is unsecured without collateral security provided in favor of the SPV and subordinated in right of payment to the Company’s obligations under the Owl Rock Credit Facility, subject to limited specified exceptions and circumstances for permitting early payment;
provides for certain credit extensions in an aggregate principal amount of $25.0 million, including: (i) an initial credit extension in an original principal amount of $15.0 million that was funded upon the closing of the SPV Investment Facility, and (ii) the SPV Purchase and Sale Note in favor of the SPV in an original principal amount of $10.0 million to finance the purchase of the insurance policies under the Policy APA;
provides proceeds from the SPV Investment Facility for payment of certain transaction expenses, general corporate purposes and any other purposes not prohibited by the agreement or applicable law;
31

matures on July 5, 2026, three years after the closing of the SPV Investment Facility, subject to two automatic extensions of one year each without any amendment of the relevant documentation, but also subject to applicable subordination restrictions in relation to the Owl Rock Credit Facility;
provides for interest to accrue on the SPV Investment Facility at a rate of 12.00% per annum, payable quarterly, all of which is to be paid in-kind by the Company by increasing the principal amount of the SPV Investment Facility owing to the SPV on each interest payment date;
provides a default rate that will accrue at 2.00% per annum (subject to applicable subordination restrictions) over the rate otherwise applicable. If cash payment is not permitted due to applicable subordination restrictions or otherwise, such default interest shall be paid in-kind;
provides that no amortization payments shall be required prior to maturity;
contains financial and other covenants substantially similar and not materially worse than those contained in the Owl Rock Credit Facility from the perspective of the Company; and
provides for certain specified events of default (including certain events of default subject to grace or cure periods), with the occurrence and during the continuance of such events of default enabling the lender under the SPV Investment Facility to accelerate the obligations under the SPV Investment Facility, among other rights or remedies, subject to applicable subordination restrictions.

The SPV’s investment resulting from credit extensions under the SPV Investment Facility is treated by the Company as debt for U.S. GAAP accounting purposes. While the timing of the Policy APA and SPV Investment Facility occurred on July 5, 2023, such amounts are included within the condensed consolidated balance sheet as cash was received prior to June 30, 2023.
14.SHAREHOLDERS’ EQUITY
The Company is authorized to issue up to 200,000,000 shares of common stock, par value $0.0001 per share, and 1,000,000 shares of preferred stock, par value $0.0001 per share. No shares of preferred stock are issued or outstanding. Holders of the Company’s common stock are entitled to one vote for each share. As of June 30, 2023, there were 62,961,688 shares of common stock issued and outstanding. Holders of shares were entitled to receive, in the event of a liquidation, dissolution or winding up, ratably the assets available for distribution to the shareholders after payment of all liabilities.
The equity structure has been recast in all comparative periods up to the Closing Date to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to legacy LMA’s stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to legacy LMA common stock prior to the Business Combination have been retroactively recast as shares reflecting the exchange ratio of 0.8 established in the Business Combination. As of December 31, 2022, this resulted in 50,369,350 shares of common stock issued and outstanding.

Public Warrants

As of June 30, 2023, the Company has 17,250,000 Public Warrants outstanding. Each redeemable whole Public Warrant entitles the holder thereof to purchase one share of common stock at a price of $11.50 per full share, subject to adjustment as described. The Public Warrants represent a freestanding financial instrument as it is traded on the Nasdaq under the symbol “ABLLW” and legally detachable and separately exercisable from the related underlying shares of the Company’s common stock. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination and (b) 12 months from the closing of the Proposed
32

Offering. The Public Warrants will expire five years from the completion of a Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.

The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act with respect to the shares of Class A common stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable and the Company will not be obligated to issue a share of Class A common stock upon exercise of a warrant unless the share of Class A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.

Redemption of Warrants for Cash - Once the warrants become exercisable, the Company may redeem the outstanding Public Warrants for cash:
in whole and not in part;
at a price of $0.01 per Public Warrant;
upon not less than 30 days’ prior written notice of redemption to each warrant holder; and
if, and only if, the last sale price of the Class A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

If and when the Public warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. However, the Company will not redeem the warrants unless an effective registration statement under the Securities Act covering the shares of Class A common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of Class A common stock is available throughout the 30-day redemption period, except if the warrants may be exercised on a cashless basis and such cashless exercise is exempt from registration under the Securities Act.

Redemption of Warrants for Shares of Class A Common Stock - Once the Public warrants become exercisable, the Company may redeem the outstanding warrants for shares of Class A common stock:
in whole and not in part;
at a price equal to a number of shares of Class A common stock to be determined by reference to the agreed table set forth in the warrant agreement based on the redemption date and the “fair market value” of the Class A common stock;
upon not less than 30 days’ prior written notice of redemption to each warrant holder; and
if, and only if, the last sale price of the Class A common stock equals or exceeds $10.00 per share (as adjusted per share splits, share dividends, reorganizations, recapitalizations and the like) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of the Company’s initial Business Combination at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective issue price to be determined in good faith by our board of directors), (y) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Price”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of Market Price and the newly issued price. Further, the $10.00 and
33

$18.00 per share redemption trigger prices will be adjusted to be equal to 100% and 180%, respectively, of the higher of the market value and the newly issued price.

If the Company elects to redeem all of the Public Warrants or the common stock is at the time of any exercise of a Public Warrant not listed on a national securities exchange, management has the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. In such event, each holder would pay the exercise price by surrendering the whole warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. However, in no instance can the warrant holder unilaterally decide to exercise its Public Warrant on a cashless basis.

Upon the Business Combination, the Company accounted for the Public Warrants issued with the IPO as equity instruments. The Company accounted for the warrant as an expense of the IPO resulting in a charge directly to stockholders’ equity. The Company estimates that the fair value of the warrants upon the Business Combination is approximately $4.73 million, or $0.274 per Public Warrant, using the binomial lattice model. The fair value of the warrants is estimated as of the date of grant using the following assumptions: (1) risk-free interest rate of 4.09%, (2) term to expiration of 5.0 years, (3) exercise price of $11.50 and (4) stock price of $10.03.
15.EMPLOYEE BENEFIT PLAN
The Company has a defined contribution plan in the U.S. intended to qualify under Section 401(k) of the Internal Revenue Code (the “401(k) Plan”). The 401(k) Plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer up to 100% of their annual compensation on a pretax basis. For the year ended December 31, 2022, the Company elected to match 50% of employee contributions up to a maximum of 4% of eligible employee compensation. For the three months ended June 30, 2023 and 2022, the Company recognized expenses related to the 401(k) Plan amounting to $13,075 and $2,577, respectively and for the six months ended June 30, 2023 and 2022, the Company recognized expenses related to the 401(k) Plan amounting to $25,315 and $8,048, respectively.
16.INCOME TAXES
Before June 30, 2023, the Company elected to file as an S corporation for Federal and state income tax purposes, the Company incurred no Federal or state income taxes, except for income taxes recorded related to some of their consolidated variable interest entities and subsidiaries which are taxable C corporations. These VIE’s and subsidiaries include LMATT Series 2024, Inc., the wholly owned subsidiary of LMX, which is consolidated into LMA as a VIE, as well as LMATT Growth Series 2.2024, Inc., a wholly owned subsidiary of LMATT Growth Series, Inc., and LMATTS Growth and Income Series 1.2026, Inc., a wholly owned subsidiary of LMATT Growth and Income Series, Inc., all of which are 100% owned subsidiaries and fully consolidated. Accordingly, the provision for income taxes was attributable to amounts for LMATT Series 2024, Inc, LMATT Growth Series, Inc. and LMATT Growth and Income Series, Inc.
For the three months ended June 30, 2023 and 2022, the Company recorded provision for income taxes of $1,184,571 and $120,132, respectively. The effective tax rate is 15.0% for the three months ended June 30, 2023. The effective rate for the three months ended June 30, 2022 was 12.0% due to the impact of state income taxes and the release of the Company’s valuation allowance, as there was sufficient evidence of the Company’s ability to generate future taxable income at June 30, 2022.
34

For the six months ended June 30, 2023 and 2022, the Company recorded provision for income taxes of $528,104 and $296,806, respectively. The effective tax rate is 3.6% for the six months ended June 30, 2023. The existence of non-taxable flow-through entities within the Company as well as a change in tax status of certain entities upon the Business Combination caused the effective tax rate to be significantly lower than the statutory rate. The effective rate for the six months ended June 30, 2022 was 18% due to the impact of state income taxes and the release of the Company’s valuation allowance, as there was sufficient evidence of the Company’s ability to generate future taxable income at June 30, 2022.
The Company did not have any unrecognized tax benefits relating to uncertain tax positions as of June 30, 2023, and December 31, 2022, and did not recognize any interest or penalties related to uncertain tax positions as of June 30, 2023, and December 31, 2022.
17.RELATED-PARTY TRANSACTIONS
As of June 30, 2023 and December 31, 2022, $10,415,154 and $263,785, respectively, were due to members and affiliates primarily for reimbursable transaction costs as well as distributions to owners of $717,429 as a part of the Business Combination as of June 30, 2023. As of June 30, 2023 and December 31, 2022, $10,473,748 and $2,904,646 was due from affiliates, respectively. The amount to be received as of June 30, 2023 is due from the Sponsor as part of the Sponsor PIK Note. Additionally, the SPV purchase and sale note for $25,000,000 as of June 30, 2023 was also recorded as a related party transaction given the transfer of cash and policies between the Company and the SPV. Refer to footnote 13 for more information.
The Company has a related-party relationship with Nova Trading (US), LLC (“Nova Trading”), a Delaware limited liability company and Nova Holding (US) LP, a Delaware limited partnership (“Nova Holding” and collectively with Nova Trading, the “Nova Funds”). The Company also earns service revenue related to policy and administrative services on behalf of Nova Funds. The servicing fee is equal to 50 basis points (0.50%) times the monthly invested amount in policies held by Nova Funds divided by 12. The Company earned $197,629 and $205,224, respectively, in service revenue related to Nova Funds for the three months ended June 30, 2023 and 2022 and earned $411,076 and $406,129, respectively, in service revenue related to Nova Funds for the six months ended June 30, 2023 and 2022.
Prior to the Merger, LMA used Abacus to originate life settlement policies that it accounts for under the investment method. For the three and six months ended June 30, 2023, the Company incurred $837,975 and $1,627,975, respectively in origination costs for life settlement policies that were originated by Abacus. These costs are capitalized on the condensed consolidated balance sheets as life settlement policies, at cost.
As of June 30, 2023, and December 31, 2022, there were $72,600 and $196,289, respectively owed from the Nova Funds, which are included as related-party receivables in the accompanying condensed consolidated balance sheets.

18.LEASES
The Company’s right-of-use assets and lease liabilities for its operating lease consisted of the following amounts as of June 30, 2023 and December 31, 2022:
Six Months Ended
June 30, 2023
Year Ended
December 31, 2022
Assets:
Operating lease right-of-use assets$240,816 $77,011 
Liabilities:
35

Operating lease liability, current227,561 48,127 
Operating lease liability, non-current16,864 29,268 
Total lease liability$244,425 $77,395 
The Company recognizes lease expense for its operating leases within general, administrative, and other expenses on the Company’s condensed consolidated statements of operations and comprehensive income. The Company’s lease expense for the periods presented consisted of the following:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Operating lease cost$12,471 $11,921 $24,942 $23,842 
Variable lease cost7,704 612 8,925 1,223 
Total lease cost$20,175 $12,533 $33,867 $25,065 
The following table shows supplemental cash flow information related to lease activities for the periods presented:
Six Months Ended June 30,
20232022
Cash paid for amounts included in the measurement of the lease liability
Operating cash flows from operating leases$24,557 $23,842 
ROU assets obtained in exchange for new lease liabilities  
The table below shows a weighted-average analysis for lease terms and discount rates for all operating leases for the periods presented:
Six Months Ended
June 30, 2023
Year Ended December 31, 2022
Weighted-average remaining lease term (in years)1.001.58
Weighted-average discount rate3.54 %3.36 %
Future minimum noncancellable lease payments under the Company’s operating leases on an undiscounted basis reconciled to the respective lease liability at June 30, 2023 are as follows:
Operating leases
Remaining of 2023$130,176 
2024118,057 
2025 
2026 
2027 
Thereafter 
Total operating lease payments (undiscounted)248,233 
Less: Imputed interest(3,808)
Lease liability as of June 30, 2023$244,425 

19. EARNINGS PER SHARE
36

Basic earnings per share represents income available to ordinary shareholders divided by the weighted average number of ordinary shares outstanding during the reported period. Net income per ordinary share is computed by dividing net income by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the Public and Private Placement Warrants to purchase an aggregate of 26,150,000 shares in the calculation of diluted income per ordinary share, since the average market price of the Company’s Class A common shares for the three and six months ended June 30, 2023 was below the warrants’ $11.50 exercise price. As a result, diluted income per share is the same as basic net income per share for the period presented.

Basic and diluted weighted average shares outstanding and earnings per share were as follows:

Three Months EndedSix Months Ended
June 30, 2023June 30, 2022June 30, 2023June 30, 2022
Net income attributable to Longevity Market Assets$6,750,145 $4,679,558 $14,835,648 $11,515,698 
Weighted-average shares used in computing net income per share, basic and diluted50,507,728 50,369,350 50,438,921 50,369,350 
Basic and diluted earnings per share:$0.13 $0.09 $0.29 $0.23 

20. SUBSEQUENT EVENTS
The Company evaluated subsequent events and transactions from the condensed consolidated balance sheet date through the date at which the condensed consolidated financial statements were issued.
Owl Rock Credit Facility
On July 5, 2023 (the “Owl Rock Closing Date”), the Company entered into that certain Credit Agreement (the “Owl Rock Credit Facility”), among the Company, as borrower, the several banks and other persons from time to time party thereto (the “Owl Rock Lenders”), and Owl Rock Capital Corporation, as administrative and collateral agent for the Owl Rock Lenders thereunder.
The Owl Rock Credit Facility, among other things:
requires the Company and certain subsidiaries of the Company to guarantee the loans provided under the Owl Rock Credit Facility pursuant to separate loan documentation;
provides credit extensions for (i) an initial term loan in an aggregate principal amount of $25.0 million upon the closing of the Owl Rock Credit Facility and (ii) optional delayed draw term loans (which can be drawn on multiple drawing dates) in an aggregate principal amount of up to $25.0 million available for one hundred eighty (180) days after the Owl Rock Closing Date (the “Delayed Draw Term Loan Availability Period”), subject to the requirement that on each delayed draw date, the liquid asset coverage ratio shall not be less than 1.80 to 1.00, together with other specified conditions to drawings, the proceeds of which may be used for working capital and the business requirements of the enterprise, and to fund acquisitions, investments and other transactions permitted by the loan documentation;
provides a delayed draw commitment fee rate of 0.50% per annum applicable to undrawn commitments during the Delayed Draw Term Loan Availability Period
37

matures on July 5, 2028, the date that is five years after the closing of the Owl Rock Credit Facility;
is secured by a first-priority security interest in substantially all of the assets of the Company and the subsidiary guarantors. No pledge of any equity interests in the Company is required by any holder of such equity interests;
provides for interest to accrue on the loans drawn under the Owl Rock Credit Facility at the election of the Company, by reference to either (i) an alternative base rate (such loans, “ABR Loans”) or (ii) an adjusted term SOFR rate (such loans, “SOFR Loans”) plus an applicable margin. The adjusted term SOFR rate is determined by the applicable term SOFR for a relevant interest period plus a credit spread adjustment of 0.10%, 0.15% and 0.25% per annum for interest periods of one, three and six months, respectively. The applicable margin for each type of loan is (i) 6.25% per annum for any ABR Loans and (ii) 7.25% per annum for any SOFR Loans, with interest periods for SOFR Loans of one, three or six months (or other periods if agreed by all lenders);
provides a default rate that will accrue at 2.00% per annum over the rate otherwise applicable;
provides for amortization payments based on the initial principal amount of the loans outstanding of 1.0% per year (0.25% due per quarter), with adjustments made to the overall amortization amount upon the incurrence of any delayed draw loans;
contains provisions requiring mandatory prepayment of the initial term loans and delayed draw term loans with 100% of the proceeds of (a) indebtedness not permitted by the Owl Rock Credit Facility and (b) certain specified asset dispositions and payments (including in respect of settlements) in respect of property, casualty insurance claims or condemnation proceedings, with the proceeds received under this clause (b) subject to certain specified reinvestment rights and procedures set forth in the Owl Rock Credit Facility. The Owl Rock Credit Facility permits voluntary prepayments of outstanding loans at any time;
provides for a prepayment premium equal to (a) 4.00% of the principal amount of such loans prepaid on or prior to the first anniversary of the closing of the Owl Rock Credit Facility, (b) 3.00% of the principal amount of such loans prepaid after the first anniversary of the closing of the Owl Rock Credit Facility but on or prior to the second anniversary of the closing of the Owl Rock Credit Facility and (c) 2.00% of the principal amount of such loans prepaid after the second anniversary of the closing of the Owl Rock Credit Facility but on or prior to the third anniversary of the closing of the Owl Rock Credit Facility. No prepayment premium will be applicable for any such prepayment made after the third anniversary of the closing of the Owl Rock Credit Facility. The prepayment premium is applicable to voluntary prepayments and certain specified mandatory prepayment during such applicable periods;
provides for financial covenants such that (i) a consolidated net leverage ratio cannot exceed 2.50 to 1.00 as of the last day of any fiscal quarter and (ii) a liquid asset coverage ratio cannot be less than 1.80 to 1.00;
contains affirmative covenants related to, among other things, delivery of certain financial reports and compliance certificates, maintenance of existence, compliance with laws, material contracts, payment of taxes, property and insurance matters, inspection of property, books and records, notices, collateral matters and future subsidiaries, in each case, subject to specified limitations and exceptions;
contains an affirmative representation and corresponding covenant that the Company and certain subsidiaries of the Company do not, and will not during the term of the Owl Rock Facility (or if the term of the Owl Rock Credit Facility continues for longer than a year, during the Company’s and certain subsidiaries of the Company’s most recent fiscal year), derive more than fifteen percent (15%) of their aggregate gross revenues from securities related activities;
contains negative covenants related to, among other things, incurrence of debt, creation of liens, mergers, acquisitions and certain other fundamental changes, conditions concerning the creation of new subsidiaries, conditions concerning opening of new accounts, disposition of assets, dividends and other restricted payments, prepayment of certain indebtedness, transactions with
38

affiliates, investments and limitations on lines of business, in each case, subject to specified limitations and exceptions; and
provides for certain specified events of default upon the occurrence and during the continuation of certain events or conditions (subject to specified exceptions, grace periods or cure rights, as applicable) each as set forth in the Owl Rock Credit Facility, which includes among other things, defaults with respect to nonpayment, breaches of representations and warranties, failure to comply with covenants, cross-default to other material indebtedness, bankruptcy and insolvency matters, ERISA matters, material judgments, collateral and perfection matters, the occurrence of a change of control and subordination matters with respect to certain specified indebtedness. The occurrence and continuance of an event of default that is not cured or waived will enable the agent and/or the lenders, as applicable, to accelerate the loans or take other remedial steps as provided in the Owl Rock Credit Facility and the other loan documents.



















*****
39

ABACUS SETTLEMENTS, LLC
40

ABACUS SETTLEMENTS, LLC
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND 2022
Three Months Ended
June 30
Six Months Ended
June 30
2023202220232022
Origination revenue$1,689,088 $743,388 $3,252,738 $3,185,068 
Related party revenue5,195,602 4,948,528 9,931,938 9,829,596 
Total revenue6,884,690 5,691,916 13,184,676 13,014,664 
Cost of revenue1,505,333 956,625 2,734,949 3,265,313 
Related party cost of revenue3,392,647 2,615,307 6,558,354 5,522,312 
Total cost of revenue4,897,980 3,571,932 9,293,303 8,787,625 
Gross Profit1,986,710 2,119,984 3,891,373 4,227,039 
OPERATING EXPENSES:
General and administrative expenses2,297,577 2,208,051 4,848,580 3,948,358 
Depreciation2,561 3,048 5,597 5,988 
Total operating expenses2,300,138 2,211,099 4,854,177 3,954,346 
Income (Loss) from operations(313,428)(91,115)(962,804)272,693 
OTHER INCOME (EXPENSE)
Interest income1,193 599 1,917 1,147 
Interest (expense)(5,863)- (11,725)- 
Other income- 273 - 273 
Total other income (expense)(4,670)872 (9,808)1,420 
Income (Loss) before provision for income taxes(318,098)(90,243)(972,612)274,113 
Provision for income taxes- - 2,289 1,325 
NET INCOME (LOSS) AND COMPREHENSIVE$(318,098)$(90,243)$(974,901)$272,788 
WEIGHTED-AVERAGE UNITS USED IN COMPUTING NET INCOME (LOSS) PER UNIT:
Basic$400 400400400
Diluted$400 400400400
NET INCOME/(LOSS) PER UNIT:
Basic earnings per unit$(795.25)$(225.61)$(2,437.25)$681.97 
Diluted earnings per unit$(795.25)$(225.61)$(2,437.25)$681.97 
See accompanying notes to interim condensed consolidated financial statements.

41

Table of Contents
ABACUS SETTLEMENTS, LLC
UNAUDITED CONDENSED STATEMENTS OF CHANGES IN MEMBERS' EQUITY
FOR THREE MONTHS ENDED JUNE 30, 2023 AND 2022
Common unitsAdditional
Paid-In Capital
Retained
Earnings
Total
UnitsAmount
BALANCE—March 31, 2023400$4,000 $80,000 $1,270,334 $1,354,334 
Net income-(318,098)(318,098)
Distributions-(442,283)(442,283)
BALANCE—June 30, 2023400$4,000 $80,000 $509,953 $593,953 
Common unitsAdditional
Paid-In Capital
Retained
Earnings
Total
UnitsAmount
BALANCE—December 31, 2022400$4,000 $80,000 $1,927,137 2,011,137 
Net loss-(974,901)(974,901)
Distributions-(442,283)(442,283)
BALANCE—June 30, 2023400$4,000 $80,000 $509,953 $593,953 
See accompanying notes to interim condensed financial statements.
42

ABACUS SETTLEMENTS, LLC
UNAUDITED CONDENSED STATEMENTS OF CHANGES IN MEMBERS' EQUITY
FOR SIX MONTHS ENDED JUNE 30, 2023 AND 2022
Common unitsAdditional
Paid-In Capital
Retained
Earnings
Total
UnitsAmount
BALANCE—December 31, 2021400$4,000 $80,000 $2,638,995 $2,722,995 
Net income-272,788 272,788 
Distributions-(659,869)(659,869)
BALANCE—June 30, 2022400$4,000 $80,000 $2,251,914 $2,335,914 
Common unitsAdditional
Paid-In Capital
Retained
Earnings
Total
UnitsAmount
BALANCE—December 31, 2022400$4,000 $80,000 $1,927,137 2,011,137 
Net loss---$(974,901)(974,901)
Distributions---$(442,283)(442,283)
BALANCE—June 30, 2023400$4,000 $80,000 $509,953 $593,953 
See accompanying notes to interim condensed financial statements.
43

ABACUS SETTLEMENTS, LLC
UNAUDITED INTERIM CONDENSED STATEMENTS OF CASH FLOWS
FOR SIX MONTHS ENDED JUNE 30, 2023 AND 2022
Six Months Ended June 30,
20232022
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income (loss)$(974,901)$272,788 
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation expense19,157 10,751 
Amortization expense40,278 37,952 
Amortization of deferred financing fees11,725  
Non-cash lease expense1,210  
Changes in operating assets and liabilities:
Related party receivables397,039  
Other receivables101,203 (202,491)
Prepaid expenses(198,643)71,038 
Other current assets(26,211)(20,111)
Certificate of deposit 656,250 
Accrued payroll and other expenses(17,466)155,994 
Contract liability—deposits on pending settlements659,067 (1,427,291)
Accounts payable(36,750)(7,247)
Net cash used in operating activities(24,292)(452,367)
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures(108,394)(32,212)
Purchase of intangible asset (15,000)
Due to/from members and affiliates(74,134)11,525 
Net cash used in investing activities(182,528)(35,687)
CASH FLOWS FROM FINANCING ACTIVITIES:
Due to members(1,411)(11,857)
Distributions to members(442,283)(659,869)
Net cash used in financing activities(443,694)(671,726)
NET DECREASE IN CASH AND CASH EQUIVALENTS(650,514)(1,159,780)
CASH AND CASH EQUIVALENTS:
Beginning of period1,458,740 2,599,302 
End of period$808,226 $1,439,522 
See accompanying notes to interim condensed financial statements.
44

ABACUS SETTLEMENTS, LLC
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
1.DESCRIPTION OF THE BUSINESS
Abacus Settlements, LLC d/b/a Abacus Life (the “Company”) was formed in 2004 in the state of New York. In 2016, the Company obtained its licensure in Florida and re-domesticated to that state. On June 13, 2023, the Company re-domesticated to Delaware.
The Company acts as a purchaser of outstanding life insurance policies (“Provider”) on behalf of investors (“Financing Entities”) by locating policies and screening them for eligibility for a life settlement, including verifying that the policy is in force, obtaining consents and disclosures, and submitting cases for life expectancy estimates, also known as origination services. When the sale of a policy is completed, this is deemed “settled” and the policy is then referred to as either a “life settlement” in which the insured’s life expectancy is greater than two years or “viatical settlement,” in which the insured’s life expectancy is less than two years.
The Company is not an insurance company, and therefore the Company does not underwrite insurable risks for its own account. On August 30, 2022, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with East Resources Acquisition Company (“ERES”), which was subsequently amended on October 14, 2022. As part of the Merger Agreement, the holders of the Company’s common units together with the holders of Longevity Markets Assets, LLC (“LMA”), a commonly owned affiliate, will receive aggregate consideration of approximately $531,750,000, payable in a number of newly issued shares of ERES Class A common stock, par value $0.0001 per share (“ERES Class A common stock”), with a value ascribed to each share of ERES Class A common stock of $10.00 and, to the extent the aggregate transaction proceeds exceed $200.0 million, at the election of the Company’s and LMA’s members, up to $20.0 million of the aggregate consideration will be payable in cash to the Company’s and LMA’s members. The transaction closed on June 30, 2023 upon shareholder approval and customary closing conditions.
2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The condensed balance sheet as of June 30, 2023, was derived from amounts included in the Company’s annual financial statements for the year ended December 31, 2022. Such amounts are included within the condensed consolidated financial statements of Abacus Life, Inc. Capitalized terms used herein without definition have the meanings ascribed to them in the Company’s financial statements for the year ended December 31, 2022. Refer to this note in the annual financial statements for the full list of the Company’s significant accounting policies. The details in those notes have not changed except as discussed below and as a result of normal adjustments in the interim periods.
Basis of Presentation—The accompanying condensed financial statements are presented in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).
Unaudited Condensed Financial Statements—The condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2023, and the condensed results of its operations and comprehensive income/(loss) and cash flows for the three and six months ended June 30, 2023 and 2022. The condensed results of operations and comprehensive income/(loss) and cash flows for the period January 1, 2023 to June 30, 2023, are not necessarily indicative of the results to be expected for the full year ending December 31, 2023, or any other period.
45

Use of Estimates—The preparation of US GAAP financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, and disclosure of contingent assets and liabilities at the date of financial statements and the reports amounts of revenue and expenses during the reporting periods. Company’s estimates, judgments, and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from the estimates. Estimates are used when accounting for revenue recognition and related costs, the selection of useful lives of property and equipment, impairment testing, valuation of other receivables from clients, income taxes, and legal reserves.
Going Concern—Management evaluates at each annual and interim period whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Management’s evaluation is based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. Management has concluded that there are no conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements were issued.
Other receivables—Other receivables include origination fees for policies in which the recission period has ended, but the funds have not been received yet from financing entities. These fees were collected in the subsequent month.
The Company provides an allowance for credit losses equal to the estimated collection losses that will be incurred in collection of all receivables. Management determines the allowance for credit losses based on a review of outstanding receivables, historical collection experience, current economic conditions, and reasonable and supportable forecasts. Account balances are charged off against the allowance for credit losses after all means of collection have been exhausted and the potential for recovery is deemed remote. The Company does not have any material allowance for credit losses as of June 30, 2023 or December 31, 2022.
If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. The Company did not record material allowance for credit losses as of June 30, 2023, and December 31, 2022, respectively.
Concentrations—All of the Company’s revenues are derived from life settlement transactions in which the Company represents Financing Entities that purchased existing life insurance policies. One financing entity, a company in which the Company’s members own interests, represented 23% and 66% of the Company’s revenues in six months ended June 30, 2023 and 2022, respectively. The Company originates policies through three different channels: Direct to Consumer, Agent, and Broker. Two brokers represented the sellers for over 10% of the Company’s life settlement commission expense during the period six months ended June 30, 2023. No brokers represented the sellers for over 10% of the Company’s life settlement commission expense during the period six months ended June 30, 2022. The Company maintains cash deposits with a major financial institution, which from time to time may exceed federally insured limits. The Company periodically assesses the financial condition of the institution and believes that the risk of loss is minimal.
Advertising—All advertising expenditures incurred by the Company are charged to expense in the period to which they relate and are included in general and administrative expenses on the accompanying condensed statements of operations and comprehensive income/(loss). Advertising expense totaled $367,418 and $286,695 for three months ended June 30, 2023 and 2022, respectively. Advertising expense totaled $741,789 and $554,802 for six months ended June 30, 2023 and 2022, respectively.
46

3.SEGMENT REPORTING
Operating as a centrally led life insurance policy intermediary, the Company’s president and chief executive officer is the chief operating decision maker who allocates resources and assesses financial performance based on financial information presented for the Company as a whole. As a result of this management approach, the Company is organized as a single operating segment.
4.REVENUE
Disaggregated Revenue—The following table presents a disaggregation of the Company’s revenue by major sources for three months ended June 30, 2023 and 2022, and for six months ended June 30, 2023 and 2022:
Three Months Ended
June 30,
Six Months Ended
June 30,
2023202220232022
Agent$3,334,402 $2,717,512 $7,143,016 $5,690,701 
Broker2,809,499 2,247,953 4,675,973 5,727,970 
Client direct740,789 726,451 1,365,687 1,595,993 
Total$6,884,690 $5,691,916 $13,184,676 $13,014,664 
5.INCOME TAXES
Since the Company elected to file as an S corporation for federal and State income tax purposes, the Company incurred no federal or state income taxes. Accordingly, provision for income taxes is attributable to minimum state tax payments that are due regardless of their S corporation status and income position.
For the three months ended June 30, 2023 and 2022, the company did not record provision for income taxes. For the six months ended June 30, 2023 and 2022, the company recorded provision for income taxes of $2,289 and $1,325, respectively, which consist of state minimum taxes for state taxes that have been paid and settled during the period. The effective tax rate was approximately (0.24%) for the six months ended June 30, 2023, compared to 0.48% for the six months ended June 30, 2022.
Given the company's S Corporation status, temporary book and tax differences do not create a deferred tax asset or liability on the balance sheets. Accordingly, an assessment of realizability of any deferred tax asset balances is not relevant.
6.RETIREMENT PLAN
The Company provides a defined contribution plan to its employees, Abacus Settlements LLC 401(k) Profit Sharing Plan & Trust (the “Plan”). All eligible employees are able to participate in voluntary salary reduction contributions to the Profit-Sharing Plan. All employees who have completed one year of service with the Company are eligible to receive employer-matching contributions. The Company may match contributions to the Plan, up to 4% of compensation. For the three months ended June 30, 2023 and 2022, and for six months ended June 30, 2023 and 2022, the Company made no discretionary contribution to the Plan.
7.RELATED-PARTY TRANSACTIONS
The Company has a related-party relationship with Nova Trading (US), LLC (“Nova Trading”), a Delaware limited liability company and Nova Holding (US) LP, a Delaware limited partnership (“Nova Holding” and collectively with Nova Trading, the “Nova Funds”) as the owners of Abacus jointly own 11% of the Nova
47

Funds. For the three months ended June 30, 2023 and 2022, the Company originated 38 and 92 policies, respectively, for the Nova Funds with a total value of $56,688,680 and $102,307,954, respectively. For six months ended June 30, 2023 and 2022, the Company originated 72 and 183 policies, respectively, for the Nova Funds with a total value of $96,674,080 and $282,804,838, respectively. For its origination services to the Nova Funds, the Company earns origination fees equal to the lesser of (i) 2% of the net death benefit for the policy or (ii) $20,000. For three months ended June 30, 2023 and 2022, and for six months ended June 30, 2023 and 2022, revenue earned, and contracts originated are as follows:
Three Months Ended
June 30,
Six Months Ended
June 30,
2023202220232022
Origination fee revenue$1,504,532 $4,164,107 $2,952,837 $8,569,034 
Transaction reimbursement revenue75,332 152,221 140,960 306,361 
Total$1,579,864 $4,316,328 $3,093,797 $8,875,395 
Cost$5,290,504 $25,201,256 $11,656,637 $50,738,202 
Face value56,688,680 102,307,954 96,674,080 282,804,838 
Total policies38 92 72 183 
Average Age017575
In addition to the Nova Funds, the Company also has another affiliated investor that they provide origination services for. Total revenue earned related to the other affiliated investor was $3,615,738 and $589,700, of which $3,615,739 and $470,200 related to Longevity Market Assets, LLC (“LMA”) for the three months ended June 30, 2023 and 2022, respectively. Total cost of sales related to the other affiliated investor was $2,623,201 and $363,700, of which $2,623,201 and $326,200 related to LMA for three months ended June 30, 2023 and 2022, respectively.

Total revenue earned related to the other affiliated investor was $6,838,141 and $911,700, of which $6,794,641 and $470,200 related to LMA, for the six months ended June 30, 2023 and 2022, respectively. Total cost of sales related to the other affiliated investor was $5,020,603 and $612,700, of which $5,012,103 and $326,200 related to LMA for the six months ended June 30, 2023 and 2022, respectively. In addition, there is a related party receivable due from LMA related to transaction expenses of $19,246 and $0 as of June 30, 2023 and 2022, respectively, which is included as due from members and affiliates in the accompanying condensed balance sheets.

8. SUBSEQUENT EVENT

On June 30, 2023, the Company consummated the merger with LMA. The Company has evaluated its subsequent events through August 14, 2023, the date that the financial statements were issued and determined that there were no events that occurred that required disclosure.
48

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations Add from Filing
49

ABACUS LIFE, INC. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis provides information that management believes is relevant to an assessment and understanding of Abacus Life, Inc.’s financial condition and results of operations. This discussion should be read in conjunction with Abacus Life, Inc.’s financial statements and related notes thereto that appear elsewhere in this quarterly Quarterly Report on Form 10-Q.

The statements contained in this Quarterly Report on Form 10-Q that are not purely historical are forward-looking statements within the meaning of Section27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding our expectations, hopes, intentions or strategies regarding the future. In addition to historical financial analysis, this discussion and analysis contains forward-looking statements based upon current expectations that involve risks, uncertainties, and assumptions, as described under the heading “Cautionary Note Regarding Forward-Looking Statements.All forward-looking statements included in this document are based on information available to us on the date hereof, and we assume no obligation to update any such forward-looking statements. Actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of various factors, including, but not limited to: the potential impact of our business relationships, including with our employees, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; weakness or adverse changes in the level of activity in our sector or the sectors of our affiliated companies, which may be caused by, among other things, high or increasing interest rates, or a weak U.S. economy; significant competition that our operating subsidiaries face; compliance with extensive government regulation; and other risks detailed in the those set forth under “Risk Factors” or elsewhere in this quarterly statement. Unless the context otherwise requires, references in this “Abacus Life, Inc. Management’s Discussion and Analysis of Financial Condition and Results of Operations” to “we,” “us,” “our,” and “Abacus Life, Inc.” are intended to mean the business and operations of Abacus Life, Inc..
Overview

Abacus Life, Inc. directly acquires life insurance policies in a mutual beneficial transaction for both us and the underlying insured. With meaningful support from our proprietary risk rating heat map, we consistently evaluate policies (at origination and throughout the lifecycle) to generate essentially uncorrelated risk adjusted returns. Additionally, we provide a range of services for owners of life settlement assets.

Upon acquiring a policy, we have the option to either (i) trade that policy to a third-party institutional investor (i.e., generating a spread on each trade) or (ii) hold that policy on our balance sheet until maturity (i.e., paying the premiums over time and receiving the final claim / payout). This process is predicated on driving the best economics for Abacus Life, Inc. and we categorize this revenue as “Trading” or “Active management revenue.”    

Additionally, Abacus Life, Inc. provides a wide range of services to owners and purchasers of life settlements assets (i.e., acquired policies). More specifically, Abacus Life, Inc. provides consulting, valuation, actuarial services, and perform administrative work involved in keeping a policy in force and at the premium level most advantageous to the owner. We have experience servicing a large number of policies for highly sophisticated institutions, including policies for large institutional life settlement funds. We generate revenue on these services by charging a base servicing fee of approximately 0.5% of total asset value of the portfolio or flat rate per policy. We categorize this revenue as “Servicing” or “Portfolio servicing revenue.”

In 2021, we shifted our focus from a service based only business model and began directly acquiring life insurance policies. We have seen rapid growth in this segment as we have continued to dedicate capital and resources towards our marketing and diversified origination channels. Such items are appropriately
50

reflected in the operating expenses section of the accompanying financial statements for the period ended June 30, 2023.

Abacus Life, Inc. was formed as Abacus Life Services, LLC in the state of Florida in February 2017. Subsequently, in February 2022, we changed our name to Longevity Market Assets, LLC. We are headquartered in Orlando, Florida.

Our Business Model

As mentioned in the above Overview section, Abacus Life, Inc. generates revenue in two main ways. The first channel is through our active portfolio management strategy (“Active management revenue”), whereby we can (i) generate a spread on traded policies, (ii) hold policies on our balance sheet (paying premiums over time and receiving the payout/claim), or (iii) generate unrealized gains or losses on policies purchased by our Structured Note Offerings (LMATT Series 2024, Inc., LMATT Growth Series 2.2024, Inc., and LMATT Growth and Income Series 1.2026, Inc.) and Income Funds (LMA Income Series, LP, and the LMA Income Series II, LP). The second channel is portfolio and policy servicing activities (“Portfolio servicing revenue”), whereby we provide a range of services to life settlement asset owners.

Active management revenue derives from buying and selling policies; and the receipt of death benefits proceeds on policies we hold where the insured dies. Of the purchased policies, some are purchased with the intent to hold to maturity, while others are held for trading to be sold for a gain. We elected to account for each investment in life settlement contracts using either the investment method or the fair value method. Once the accounting method is elected for each policy, it cannot be changed. Abacus Life, Inc. accounts for life settlement policies purchased through the structured note and fund offerings on a fair value basis, and life settlement policies that we intend to trade in the near term at cost plus premiums paid. At the time that this election was made, this was the result of a cost-benefit analysis: because of our intention to hold the instruments for a relatively short period, we believed that the investment method provided a more cost effective method of accounting for the instruments and did not believe that, in the course of the short period, the fair value would differ materially from the accumulated cost. For the life settlement policies accounted for under the fair value method, these policies are part of the collateral consideration for the market linked structured notes issued under LMX Series, LLC and LMA Series, LLC subsidiaries where quarterly valuations are a condition of the private placement memorandum. Given that there is a valuation requirement stipulated in the notes, management has elected to use the fair value method for these policies as the information is readily available and also captures the change in fair value within the income statement when those changes occur as opposed to when the policies are sold or mature. For policies held at fair value, changes in fair value are reflected in operations in the period the change is calculated. Under the investment method, investments in contracts are recorded at investment price plus all initial direct costs. Continuing costs (e.g., policy premiums, statutory interest and direct external costs, if any) to keep the policy in force are capitalized. Gains/losses on sales of such are recorded at the time of sale or maturity. Under the fair value method, we record the initial investment of the transaction price and remeasure the investment at fair value at each subsequent reporting period. Changes in fair value are reported in revenue when they occur including those related to life insurance proceeds (policy maturities) and premium payments. Upon sale of a life settlement contract, we record revenue (gain/loss) for the difference between the agreed-upon purchase price with the buyer, and the carrying value of the contract.

Generating Portfolio servicing revenue involves the provision of services to one affiliate by common ownership, and third parties, which own life insurance policies. Portfolio servicing revenue is derived from services related to maintaining these settled policies pursuant to agreement with investors in settled policies (“Service Agreement(s)”). Additionally, also included in servicing revenue are fees for limited consulting services related to the evaluation of policies that we perform for third parties. Portfolio servicing revenue is recognized ratably over the life of the Service Agreements, which range from one month to ten years. The duties performed by the company under these arrangements are considered a single
51

performance obligation that is satisfied ratably as the customer simultaneously receives and consumes the benefit provided by us. As such, revenue is recognized for services provided for the corresponding month.

Portfolio servicing revenue also consists of revenue related to consulting engagements. We provide consulting services for the owners of life settlement contracts who are often customers of the servicing business line, or customers of Abacus, an affiliated entity. These consulting engagements are comprised of valuation, actuarial services, and overall policy assessments related to life settlement contracts and are short-term in nature. The performance obligations are typically identified as separate services with a specific deliverable or a group of deliverables to be provided in tandem, as agreed to in the engagement letter or contract. Each service provided under a contract is considered as a performance obligation and revenue is recognized at a point in time when the deliverable or group of deliverables is transferred to the customer.

Key Factors Affecting Our Performance

The markets for our consulting and portfolio servicing are affected by economic, regulatory, and legislative changes, technological developments, and increased competition from established and new competitors. We believe that the primary factors in selecting Abacus Life, Inc. include reputation, the ability to provide measurable increases to shareholder value and return on investment, global scale, quality of service and the ability to tailor services to each client’s specific needs. In that regard, with our ability to leverage the technology developed by the Companies, we are focused on developing and implementing data and analytic solutions for both internal operations and for maintaining industry standards and meeting client needs.

Results of Operations

The following tables set forth our results of operations for the periods presented. The period-to-period comparison of financial results is not indicative of future results:
52

Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Portfolio Servicing Revenue
Related party servicing revenue$329,629$419,253$543,076$620,159
Portfolio servicing revenue 24,737 169 46,981 370,169
Total portfolio servicing revenue 354,366 419,422 590,057 990,328
Active management revenue
Investment income from life insurance policies held using investment method8,263,4995,965,466 16,655,833 13,980,466
Change in fair value of life insurance policies (policies held using fair value method)2,760,900 2,014,013  4,339,084  3,305,505
Total active management revenue 11,024,399 7,979,479 20,994,917 17,285,971
Total Revenue11,378,7658,398,90121,584,97418,276,299
Cost of revenues (excluding depreciation stated below)973,400666,119 1,462,950 2,086,075
Gross profit 10,405,365 7,732,782 20,122,024 16,190,224
Operating expenses
Sales and marketing 683,841 1,019,498 1,412,845 1,649,498
General, administrative and other 577,539 5,499 1,274,431 646,705
Unrealized loss (gain) on investments (672,936)1,039,022 (798,156)1,054,975
Loss on change in fair value of debt 1,445,229 333,879 2,398,662 375,513
Depreciation expense1,0981,098 2,141 2,141
Total operating expenses 2,034,771 2,398,996 4,289,923 3,728,832
Operating income8,370,594 5,333,78615,832,101 12,461,392
Other (expense) income
Other income (expense) 121,601 (127,455) (21,651)(242,247)
Interest (expense) (584,075)- (941,458)-
Interest income-- 7,457 -
Net income before provision for income taxes 7,908,120 5,206,331 14,876,449 12,219,145
Provision for income taxes(1,184,571)(120,132) (528,104)(296,806)
Net income 6,723,549 5,086,199 14,348,345 11,922,339
Less: Net income (loss) attributable to noncontrolling interest (26,596)406,641 (487,303)406,641
Net income attributable to Abacus Life, Inc.$6,750,145$4,679,558$14,835,648$11,515,698



53


Revenue

Related Party Services

We have a related-party relationship with Nova Trading (US), LLC (“Nova Trading”), a Delaware limited liability company and Nova Holding (US) LP, a Delaware limited partnership (“Nova Holding” and collectively with Nova Trading, the “Nova Funds”) as some of the owners of Abacus Life, Inc. and certain members of management jointly own 11% of the Nova Funds. We enter into service agreements with the owners of life settlement contracts and are responsible for maintaining the policies, managing processing of claims in the event of death of the insured and ensuring timely payment of optimized premiums computed to derive maximum return on maturity of the policy. We neither assume the ownership of the contracts nor undertake the responsibility to make the associated premium payments. The duties that we perform under these arrangements are considered a single performance obligation that is satisfied over time and revenue is recognized for services provided for the corresponding time period. We earn servicing revenue related to policy and administrative services on behalf of Nova Funds portfolio (the “Nova Portfolio”). The servicing fee is equal to 50 basis points (0.50%) times the monthly invested amount in policies held by Nova Funds divided by 12.

Three Months Ended June 30,$ Change% Change
20232022
Related party servicing revenue$329,629$419,253$(89,624)(21.4)%

Related party servicing revenue decreased by $89,624, or 21%, for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. The decrease in related party servicing revenue is primarily due to the joint venture (“JV”) owning less policies at June 30, 2023. Total policy count for the Nova Portfolio was 353 and 413 for the periods ended June 30, 2023 and June 30, 2022, respectively. This translated to total invested dollars of $151,738,261 and $162,162,124 as of June 30, 2023 and June 30, 2022, respectively.
   Six Months Ended June 30,
20232022$ Change% Change
Related party servicing revenue$543,076$620,159$(77,083)(12.4)%

Three Months Ended June 30,
20232022$ Change% Change
Portfolio servicing revenue$24,737$169$24,56814,537.3%

Portfolio servicing revenue increased by $24,568, or 14,537%, for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. The increase in portfolio servicing revenue is primarily attributable to servicing more external funds during the three months ended June 30, 2023 compared to the three months ended June 30, 2022. There were zero non-recurring consulting projects in Q2, 2023.

Six Months Ended June 30,
20232022$ Change% Change
Portfolio servicing revenue$46,981$370,169$(323,188)(87.3)%

54

Portfolio servicing revenue decreased by $323,188, or 87%, for the six months ended June 30, 2023 compared to the six months ended June 30, 2022. The decrease in portfolio servicing revenue is primarily attributable to a reduction in the non-recurring consulting projects in 2023.

Active management revenue

Active management revenue is generated by buying, selling, and trading policies and maintaining policies through to receipt of maturity or death benefits. Policies are accounted for under both the investment method and fair value method. We have elected on an instrument-by-instrument basis to account for these policies under the investment method, pursuant to ASC 323-30-25-2. Abacus Life, Inc. engages in direct buying and selling of life settlement policies whereby each potential policy is independently researched to determine if it would be a profitable investment. Policies purchased under Abacus Life, Inc. are typically purchased with the intention to sell within twelve months and are measured for under the investment method given that the purchase dates are recent, and policies turn fairly quickly. Policies purchased under LMATT Series 2024, Inc. or LMATT Growth Series 2.2024, Inc. (the “LMATT subsidiaries”) are measured under the fair value method and will either be sold or held until the policies mature. Upon sale of a life settlement contract, the company will record revenue (gain/loss) for the difference between the agreed-upon purchase price with the buyer, and the carrying value of the contract.

Three Months Ended June 30,$ Change% Change
20232022
Active management revenue
Policies accounted for under the investment method$8,263,499$5,965,466$2,298,03338.5%
Policies accounted for under the fair value method 2,760,900  2,014,013  746,887 37.1%
Total active management revenue$11,024,399$7,979,479$3,044,92038.2%

Total active management revenue increased by $3,044,920, or 38%, for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. The increase in active management revenue was primarily attributable to maturities of policies accounted for under the investment method. As of June 30, 2023, Abacus Life, Inc. holds 167 policies, of which 122 are accounted for under the fair value method and 45 are accounted for using the investment method (cost, plus premiums paid). Policies recorded under the investment method represent those policies purchased by Abacus Life, Inc. with the intent to sell within the next 12 months. Policies recorded under the investment method resulted in a revenue increase in of $2,298,033, or 39%. Aggregate face value of policies accounted for using the investment method is $39,592,392 as of June 30, 2023, with a corresponding carrying value of approximately $9,889,610. Additional information regarding policies accounted for under the investment method is as follows:
Three Months Ended June 30,
20232022
Investment method:
Policies bought7952
Policies sold
8820
Policies matured
00
Average realized gain (loss) on policies sold
16.7%11.1%
Number of external counter parties that purchased policies
113

Policies accounted for under the fair value method, resulted in a revenue increase of $746,887, which was driven primarily by a realized gain on the sale of 22 policies of $1,297,702 for the three months ended June 30, 2023. In the three months period ended June 30, 2023, an unrealized gain of $2,126,723 was
55

recorded on 54 policies purchased. For the policies held at fair value, the unrealized gain on policies of $2,126,723 represents a change in fair value of the aforementioned policies. Abacus Life, Inc. realized a gain of $1,297,702 for the three months ended June 30, 2023 for 9 policies that sold that were included in the change in fair value of life insurance policies held using the fair value method and made premium payments of $663,424, which were also included in the same line item. Additional information regarding policies accounted for under the fair value method is as follows:

Three Months Ended June 30,
20232022
Fair value method:
Policies bought5431
Policies sold
9-
Policies matured
1-
Average realized gain (loss) on policies sold
14.7%-
Number of external counter parties that purchased policies
3-

Six Months Ended June 30,$ Change% Change
20232022
Active management revenue
Policies accounted for under the investment method$16,655,833$13,980,466$2,675,36719 %
Policies accounted for under the fair value method 4,339,084  3,305,505  1,033,579 31 %
Total active management revenue$20,994,917$17,285,971$3,708,94621 %

Total active management revenue increased by $3,708,946, or 21%, for the six months ended June 30, 2023 compared to the six months ended June 30, 2022. The increase in active management revenue was primarily attributable to an increase in policy sales and maturities. As of June 30, 2023, Abacus Life, Inc. holds 167 policies, of which 122 are accounted for under the fair value method and 45 are accounted for using the investment method (cost, plus premiums paid). Policies recorded under the investment method represent those policies purchased by Abacus Life, Inc. with the intent to sell within the next 12 months. Policies recorded under the investment method resulted in an increase of $2,675,367, or 19%. Aggregate face value of policies accounted for using the investment method is $39,520,877 as of June 30, 2023, with a corresponding carrying value of approximately $9,889,610. Additional information regarding policies accounted for under the investment method is as follows:

Six Months Ended June 30,
20232022
Investment method:
Policies bought16580
Policies sold
12748
Policies matured
20
Average realized gain (loss) on policies sold
16.3%13.5%
Number of external counter parties that purchased policies
154

Policies accounted for under the fair value method, with the intention to hold to maturity, resulted in an increase in revenue of $1,033,579 driven primarily by a realized gain on life settlement policies of $1,898,958 for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. Aggregate face value of policies held at fair value is $195,205,585 as of June 30, 2023, with a corresponding
56

fair value of $56,685,617. For the policies held at fair value, the unrealized gain recorded on 69 purchased policies as of $3,319,588 represents a change in fair value of the aforementioned policies. Abacus Life, Inc. realized a gain of $ 1,898,958 for the six months ended June 30, 2023 for 11 sold policies that were included in the change in fair value of life insurance policies held using the fair value method and made premium payments of $879,461, which were also included in the same line item. Additional information regarding policies accounted for under the fair value method is as follows:

      Six Months Ended June 30,
20232022
Fair value method:
Policies bought6932
Policies sold
11-
Policies matured
1-
Average realized gain (loss) on policies sold
10.4%-
Number of external counter parties that purchased policies
5-

Cost of Revenues (Excluding Depreciation) and Gross Profit

Cost of revenues (excluding depreciation) primarily consists of payroll costs for employees who service policies and consulting expenses for discretionary commissions directly related to active management trading revenue. Cost of revenues excludes depreciation expense as Abacus Life, Inc. does not hold any material property and equipment that is directly used to support the servicing or trading of life settlement policies. The payroll costs related to policy servicing are for recurring and non-recurring projects where the time incurred for servicing policies is measurable and directly correlates to revenue earned. Similarly, consulting expenses are for discretionary commissions earned directly related to revenue generated as part of the Active management revenue stream.

Three Months Ended June 30,
20232022$ Change% Change
Cost of revenue (excluding depreciation)$973,400$666,119$307,28146 %

Cost of revenues (excluding depreciation) increased by $307,281, or 46%, for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. The increase in cost of revenues is primarily due to an increase of payroll expenses related to increased headcount and changes to various benefit packages in 2023.

Six Months Ended June 30,
20232022$ Change% Change
Cost of revenue (excluding depreciation)$1,462,950$2,086,075$(623,125)(30)%

Cost of revenues (excluding depreciation) decreased by $623,125, or 30%, for the six months ended June 30, 2023 compared to the six months ended June 30, 2022. The decrease in cost of revenues is primarily due to a $1,057,735 decrease in consulting expenses primarily represents discretionary commissions for individuals directly related to active management trading revenue and bonuses paid out during the first quarter of 2022. The bonuses and commissions did not recur during 2023. The decrease in consulting expenses offset by a $427,380 increase in wages related to policy servicing activity as a result of increased headcount of 4 people and changes to various benefit packages in 2023.

57

Three Months Ended June 30,
20232022$ Change% Change
Gross profit$10,405,366$7,732,782$2,672,584(35)%

Gross profit increased by $2,672,584, or 35%, for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. The increase in gross profit is due to the decrease in the cost of revenue by $307,281, or 46% which was attributable to reductions in consulting expenses. The expansion of the active management business resulted in increased revenues of $3,044,920, or 38%, of the total increase in revenues of $2,979,864 or 35%.

Six Months Ended June 30,
20232022$ Change% Change
Gross profit$20,122,024$16,190,224$3,931,80024 %

Gross profit increased by $3,931,800, or 24%, for the six months ended June 30, 2023 compared to the six months ended June 30, 2022. The increase in gross profit is primarily due to decrease of cost of revenue by $623,125, or 30% and the expansion of the active management business which resulted in increased revenues of $ 3,708,946 , or 21%, of the total increase in revenues of $3,308,675, or 18%, offset by a decrease of portfolio servicing revenue of $323,188, or 87%.

Operating Expenses

Sales and Marketing Expenses

Sales and marketing expenses primarily consist of advertising and marketing related expenses.

Three Months Ended June 30,$ Change% Change
20232022
Sales and marketing expenses$683,841$1,019,498$(335,657)(33)%

Sales and marketing expenses decreased by $335,657 or 333% for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. The decrease in sales and marketing expense was attributable to reduction in advertising costs.

Six Months Ended June 30,$ Change% Change
20232022
Sales and marketing expenses$1,412,845$1,649,498$(236,653)(14)%

Sales and marketing expenses decreased by $236,653, or 14% for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. The decrease is attributable to reduction in advertising costs. The increase in 2022 was attributable to marketing of the new active management segment. Sales and marketing expense relates to sponsoring a sports organization and are not directly attributable to revenue generating activity, therefore these expenses do not represent cost of revenue.

General, Administrative, and Other

General, administrative, and other primarily consists of compensation and benefits related costs associated with our finance, legal, human resources, information technology, and administrative functions. General, administrative and other costs also consist of third-party professional service fees for external
58

legal, accounting and other consulting services, rent and lease charges, insurance costs, and software expense.

Three Months Ended June 30,$ Change% Change
20232022
General, administrative and other$577,539$5,499$572,04010,403 %

General, administrative, and other increased by $572,040, or 10,403%, for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. The increase of $284,588 and $40,060 in general, administrative and other of is related to launching the new income funds: LMA Income Series, LP and LMA Income Series II GP LLC, respectively, which did not exist during the three months ended June 30, 2022. The remaining difference is attributable to other various consolidated entities pertaining to policy servicing and administrator expenses, accounting, legal, and bank fees as we finalized the SPAC.

Six Months Ended June 30,
20232022$ Change% Change
General, administrative and other$1,274,431$646,705$627,72697 %

General, administrative, and other increased by $627,726, or 97%, for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. The increase in general, administrative and other is related to various expenses, including but not limited to increases in payroll related expense (excluding payroll expenses wages) of $245,842, an increase in Errors and Omissions insurance of $55,250, an increase in medical record consulting expense of $132,688 and an increase of $31,000 in software expenses. Additionally, $341,064 in general, administrative and other expenses were recorded in LMA Income Series, LP and LMA Income Series II GP LL pertaining to policy servicing and administrator expenses, accounting, legal, and bank fees.

Depreciation

Depreciation expense consists primarily of depreciation on property and equipment purchased and leasehold improvements made. The property at Abacus Life, Inc. currently consists of furniture, fixtures and leasehold improvements for the office and are not directly used to support the servicing or trading of life settlement policies.

Three Months Ended June 30,$ Change% Change
20232022
Depreciation$1,098$1,098$— %

Depreciation is consistent for the three months ended June 30, 2023 and June 30, 2022 as no purchases of property and equipment were made in 2023.

Six Months Ended June 30,$ Change% Change
20232022
Depreciation$2,141$2,141$— %

Depreciation is consistent for the six months ended June 30, 2023 and June 30, 2022 as no purchases of property and equipment were made in 2023.

Unrealized Loss (Gain) on Investments
59


Three Months Ended June 30,$ Change% Change
20232022
Unrealized loss (gain) on investments$(672,936)$1,039,022$(1,711,958)(165)%

Unrealized loss on investments increased by $1,711,958 for the three months ended June 30, 2023, compared to the three months ended June 30, 2022. The primary cause of this increase driven by changes in fair value of put and call options. During the three months ended June 30, 2023, the unrealized loss was $467,701, $186,470, $15,289, and $3,475 for LMATT Series 2024 Inc., LMATT Growth Series Inc., and LMATT Growth, Income Series Inc. and Longevity Market Assets, LLC, respectively.

Six Months Ended June 30,$ Change% Change
20232022
Unrealized loss (gain) on investments$(798,156)$1,054,975$(1,853,131)(176)%

Unrealized loss (gain) on investments increased by $1,853,131 for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. During the first and third quarters of 2022, Abacus Life, Inc., through three subsidiaries, LMATT Series 2024 Inc., LMATT Growth Series Inc., LMATT Growth and Income Series Inc., and purchased S&P 500 call options and sold S&P 500 put options through a broker as an economic hedge related to the market-indexed instruments described below. The primary cause of this decrease pertains to $540,818, $230,231, $23,632, and $3,475 respectively, which represents a change in fair value of those options and is classified as an unrealized loss on investments within the results of operations.

Loss on Change in Fair Value of Debt

Three Months Ended June 30,
20232022$ Change% Change
Loss on change in fair value of debt$1,445,229$333,879$1,111,350333 %

Loss on change in fair value of debt increased by $1,111,350 for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. The increase is primarily attributable to changes in the risk-free fair value of LMATT debt.

Six Months Ended June 30,$ Change% Change
20232022
Loss on change in fair value of debt$2,398,662$375,513$2,023,149539 %

Loss on change in fair value of debt increased by $2,023,149 for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. The increase is primarily attributable to changes in the risk-free fair value of LMATT debt.

On March 31, 2022, LMATT Series 2024, Inc., which the Company consolidates for financial reporting, issued $10,166,900 in market-indexed private placement notes. The notes, titled the Longevity Market Assets Target-Term Series (LMATTS) 2024, are market-indexed instruments designed to provide upside performance exposure of the S&P 500 Index, while limiting downward exposure. Upon maturity of the notes in 2024, the principal, plus the return based upon the S&P 500 Index must be paid. The notes haves a
60

feature to protect debt holders from market downturns, up to 40%. Any subsequent losses below the 40% threshold will reduce the notes on a one-to-one basis. As of June 30, 2023, $9,866,900 of the principal amount remained outstanding. The notes are held at fair value, which represents the exit price, or anticipated price to transfer the liability to a third party. As of June 30, 2023, the fair value of the LMATT Series 2024, Inc. notes was $9,621,141. The notes are secured by the assets of the issuing entities, which includes cash, S&P 500 options, and life settlement policies totaling $11,195,701 as of June 30, 2023. The note agreements do not restrict the trading of life settlement contracts prior to maturity of the note, as total assets of the issuing companies are considered as collateral. There are also no restrictive covenants associated with the notes with which the entities must comply.

On September 16, 2022, LMATTS Series 2.2024, Inc., a 100% owned subsidiary which the Company consolidates for financial reporting issued $2,333,391 in market-indexed private placement notes. The notes, titled the Longevity Market Assets Target-Term Growth Series 2.2024, Inc. (“LMATTSTM Series 2.2024, Inc.”) are market-indexed instruments designed to provide upside performance exposure of the S&P 500 Index, while limiting downward exposure. Upon maturity of the notes in 2024, the principal, plus the return based upon the S&P 500 Index must be paid. The notes have a feature to provide upside performance participation that is capped at 120% of the performance of the S&P 500. A separate layer of the notes has a feature to protect debt holders from market downturns by up to 20% if the index price experiences a loss during the investment period. After the underlying index has decreased in value by more than 20%, the investments will experience all subsequent losses on a one-to-one basis. As of June 30, 2023, the entire principal amount remained outstanding. The notes are held at fair value, which represents the exit price, or anticipated price to transfer the liability to a third party. As of June 30, 2023, the fair value of the LMATT Series 2.2024, Inc. notes was $3,446,527. The notes are secured by the assets of the issuing entity, LMATT Series 2.2024, Inc., which includes cash, S&P 500 options, and life settlement policies totaling $3,331,872 as of June 30, 2023. The notes agreement do not restrict the trading of life settlement contracts prior to maturity of the notes, as total assets of the issuing company are considered as collateral. There are also no restrictive covenants associated with the notes with which the entity must comply.

Additionally, on September 16, 2022, LMATT Growth and Income Series 1.2026, Inc., a 100% owned subsidiary which the Company consolidates for financial reporting issued $400,000 in market-indexed private placement notes. The notes, titled the Longevity Market Assets Target-Term Growth and Income Series 1.2026, Inc (“LMATTSTM Growth and Income Series 1.2026, Inc.”) are market-indexed instruments designed to provide upside performance exposure of the S&P 500 Index, while limiting downward exposure. Upon maturity of the notes in 2026, the principal, plus the return based upon the S&P 500 Index must be paid. The notes have a feature to provide upside performance participation that is capped at 140% of the performance of the S&P 500. A separate layer of the notes has a feature to protect debt holders from market downturns by up to 10% if the index price experiences a loss during the investment period. After the underlying index has decreased in value by more than 10%, the investments will experience all subsequent losses on a one-to-one basis. These notes also include a 4% dividend feature that will be paid annually. As of June 30, 2023, the entire principal amount remained outstanding. The notes are held at fair value, which represents the exit price, or anticipated price to transfer the liability to a third party. As of June 30, 2023, the fair value of the LMATT Growth and Income Series 1.2026, Inc., notes was $459,533. The notes are secured by the assets of the issuing entity, LMATT Growth and Income Series 1.2026, Inc., which includes cash, S&P 500 options, and life settlement policies totaling $517,218 as of June 30, 2023. The notes agreement does not restrict the trading of life settlement contracts prior to maturity of the note, as total assets of the issuing company are considered as collateral. There are also no restrictive covenants associated with the notes with which the entity must comply. See additional fair value considerations within the Fair Value footnote.

Other Income (Expense)

Other income (expense) consists of working capital support that Abacus Life, Inc. provides to two life settlement Providers through a contractual agreement (the “Strategic Services and Expenses Support
61

Agreement” or “SSES”). Abacus Life, Inc. entered into the SSES with the Providers and simultaneously acquired an option to purchase the outstanding equity ownership of the Providers, upon the achievement by the Providers of certain financial targets. For the years ended December 31, 2022 and December 31, 2021, the Providers were considered to be VIEs, but were not consolidated in our interim condensed consolidated financial statements as we do not hold a controlling financial interest in the Providers.

Three Months Ended June 30,$ Change% Change
20232022

Other income (expense)
$121,601$(127,455)$249,056(195.4)%
Interest (expense) (584,075)- (584,075)— %
Interest income---— %

Other income (expense) decreased by $249,056, for the three months ended June 30, 2023, compared to the three months ended June 30, 2022. The increase in other income is driven by reduction of excess return expense of $117,616 and fund management fee of $67,180 at LMA Income Series, LP for the three months ended June 30, 2023. As noted above, LMA Income Series, LP did not exist during the three months ended June 30, 2022. The remaining difference is attributable to dividend income of $4,063 at LMA Income Series GP and other income at Regional Investment Services for the three months ended June 30, 2023.

Interest (expense) increased by $584,075, for the three months ended June 30, 2023, compared to the three months ended June 30, 2022. The increase in interest expense is driven by the dividend of 6.5% required to be paid out by the LMA Income Series to its limited partner investors. The remaining increase is attributable to interest expense at LMATT Growth & Income Series Inc.


Six Months Ended June 30,$ Change% Change
20232022

Other income (expense)
$(21,651)$(242,247)$220,596(91.1)%
Interest (expense) (941,458)-(941,458)100 %
Interest income 7,457 - 7,457 100%

Other income (expense) decreased by $220,596, for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. The increase in other income is driven by reduction of excess return expense of $212,526. $29,721 was paid to the Providers during the six months ended June 30, 2023, compared to $242,247 paid during the six months ended June 30, 2022. The remaining difference is attributable to dividend income of $8,125 at LMA Income Series GP and other income at Regional Investment Services for the six months ended June 30, 2023.

Interest (expense) increased by $941,458, for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. The increase in interest expense is driven primarily by $713,149 and $220,309 accrued interest payments relating to LMA Income Series LP LLC and LMA Income Series II LP, respectively, along with $8,000 in interest expense for LMATT Growth & Income Series, Inc. for the six months ended June 30, 2022.

Interest income increased by $7,457, for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. The increase in interest income is driven by interest on proceeds from policies that matured in the first three months of 2023.

Provision for income taxes

62

As the Company elected to file as an S corporation for federal and Florida state income tax purposes, the Company incurred no federal or Florida state income taxes, except for income taxes recorded related to LMATT Series 2024, Inc. (“LMATT”), a Delaware C corporation and wholly owned subsidiary of LMX Series, LLC (“LMX”), which Abacus Life, Inc. consolidates. Accordingly, tax expense has historically been attributable to tax expense for LMATT Series 2024, Inc. However, the Business Combination resulted in changes to the tax status of certain entities which impacted the provision for income taxes by $1,383,692.

Three Months Ended June 30,$ Change% Change
20232022
Provision for income taxes$(1,184,571)$(120,132)$(1,064,439)886 %

Provision for income taxes increased by $1,064,439, or 886% for the three months ended June 30, 2023, compared to the three months ended June 30, 2022. Our effective income tax rate for the three months ended June 30, 2023 and three months June 30, 2022, was 15% and 12%, respectively. The Company's effective tax rate as of June 30, 2022 differed from the statutory rate of 21% due to state taxes and the release of the valuation allowance. The higher provision for income taxes for the three months ended June 30, 2023 is mainly related to Longevity Market Assets LLC taxable income of $7,081,252 resulting in $1,203,190 of provision for income taxes from the change in tax status upon the Business Combination.

Six Months Ended June 30,$ Change% Change
20232022
Provision for income taxes$(528,104)$(296,806)$(231,298)78 %

Provision for income taxes increased by $231,298, or 78% for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. Our effective income tax rate for the six months ended June 30, 2023, and six months ended June 30, 2022, was 3.6% and 18%, respectively. The Company's effective tax rate as of June 30, 2022 differed from the statutory rate of 21% due to the impact of state income taxes and valuation allowance released, as there was sufficient evidence of the Company’s ability to generate future taxable income at June 30, 2022. The existence of non-taxable flow-through entities within the Company as well as a change in tax status of certain entities upon the Business Combination caused the effective tax rate to be significantly lower than the statutory rate. The higher provision for income taxes for the six months ended June 30, 2023 is related to Longevity Market Assets LLC (LMA) taxable income of $13,876,206 resulting in $1,203,190 of provision for income taxes, offset by LMATT Series 2024, Inc. net taxable loss of $2,118,344 resulting in $536,894 of income tax benefit and LMATT Growth & Income Series, Inc. net taxable loss of $303,328 resulting in $76,878 of income tax benefit and LMATT Growth Series, Inc. net taxable loss of $954,095 resulting in $241,815 of income tax benefit.

Results of Operations—Segment Results

Abacus Life, Inc. organizes its business into two reportable segments (i) portfolio servicing and (ii) active management, which generate revenue in different manners. During 2021, we primarily focused on the Portfolio Servicing business. At the end of June 2021, we underwent a change in our business to focus on active management services in addition to portfolio servicing.

This segment structure reflects the financial information and reports used by Abacus Life, Inc.'s management, specifically its chief operating decision maker (CODM), to make decisions regarding Abacus Life, Inc.’s business, including resource allocations and performance assessments as well as the current operating focus in accordance with ASC 280, Segment Reporting. Abacus Life, Inc.'s CODM is the Chief Executive Officer of Abacus Life, Inc.

63

The portfolio servicing segment generates revenues by providing policy services to customers on a contract basis. The active management segment generates revenues by buying, selling and trading policies and maintaining policies through to death benefit. Abacus Life, Inc.'s reportable segments are not aggregated.

The following tables provides supplemental information of revenue and profitability by operating segment:

Portfolio Servicing

Three Months Ended June 30,$ Change% Change
20232022
Total revenue$354,366 $419,422(65,056)(16)%
Gross profit (143,885)280,303(424,188)(151)%

Total revenue for the portfolio servicing segment decreased by $65,056, or 16% for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. The decrease in portfolio servicing revenue is primarily attributable to a decrease in the non-recurring consulting projects in Portfolio servicing revenue. Gross profit from our portfolio servicing segment decreased by $424,188 or 151%, for the three months ended June 30, 2023, compared to the three months ended June 30, 2022. The decrease in gross margin is primarily due to increases in total cost of revenue of $359,132, or 258% and the reduction of revenue by $65,056, or 16%.
Six Months Ended June 30,$ Change% Change
20232022
Total revenue $590,057  $990,327  $(400,270)(40)%
Gross profit (166,128)668,752 (834,880)(125)%

Total revenue for the portfolio servicing segment decreased by $400,270 or 40% for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. The decrease in portfolio servicing revenue is primarily attributable to decrease in the non-recurring consulting projects in Portfolio servicing revenue. Gross profit from our portfolio servicing segment decreased by $834,880, or 125%, for the six months ended June 30, 2023, compared to the six months ended June 30, 2022.The decrease in gross margin is primarily due to increases in total cost of revenue of $434,610, or 135% and the reduction of revenue by $400,270, or 40%.

Active Management

Three Months Ended June 30,$ Change% Change
20232022
Total revenue $ 11,024,399  $7,979,479 3,044,92038.2%
Gross profit 10,482,070  7,452,479 3,029,59140.7%

Total revenue for the active management segment increased by $3,044,920, or 38% for the three months ended June 30, 2023, compared to the three months ended June 30, 2022. Gross profit from our active management segment increased $3,029,591, or 41% for the three months ended June 30, 2023, compared to the three months ended June 30, 2022. The increase in active management revenue and gross profit was primarily attributable to the increase in revenue of $3,044,920 and decrease in cost of revenue from 7% of revenue to 5% of revenue.
64

Six Months Ended June 30,$ Change% Change
20232022
Total revenue$20,994,917 $17,285,9713,708,94621.5%
Gross profit20,288,152 15,521,471 4,766,68130.7%

Total revenue for the active management segment increased by $3,708,946, or 22% for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. Gross profit from our active management segment increased $4,766,681, or 31% for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. The increase in Active management revenue and gross profit was primarily attributable to _ the increase in revenue of $3,708,946 and decrease in cost of revenue from 10% of revenue to 3% of revenue. The decrease in cost of revenue of approximately $1,073,064 was related to the decrease in consulting bonus expenses.

Key Business Metrics and Non-GAAP Financial Measures

The consolidated financial statements of Abacus Life, Inc. have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and are prepared in accordance with U.S. GAAP. We monitor key business metrics and non-GAAP financial measures that assist us in evaluating our business, measuring our performance, identifying trends and making strategic decisions. We have presented the following non-GAAP measures, their most directly comparable GAAP measure, and key business metrics:

Adjusted EBITDA

Non-GAAP Measure    Comparable GAAP Measure
Adjusted EBITDA     Net Income

Adjusted EBITDA is net income adjusted for depreciation expense, income tax and other non-cash and non-recurring items that in our judgement significantly impact the period-over-period assessment of performance and operating results that do not directly relate to business performance within Abacus Life, Inc.'s control. These unusual items may include proceeds from the PPP loan, payments made as part of Abacus Life, Inc.'s expense support commitment, loss on the change in fair value of debt, S&P 500 put and call options that were entered into as an economic hedge related to the debt (described as the unrealized loss on investments), and other non-recurring items. Management plans to terminate the agreement for the expense support commitment within the next twelve months. As such, management has deemed this to be non-recurring item. Adjusted EBITDA should not be determined as substitution for net income (loss), cash flows provided (used in) operating, investing, and financing activities, operating income (loss), or other metrics prepared in accordance with U.S. GAAP.

Management believes the use of Adjusted EBITDA assists investors in understanding the ongoing operating performance by presenting comparable financial results between periods. We believe that by removing the impact of depreciation and amortization and excluding certain non-cash charges, amounts spent on interest and taxes and certain other non-recurring charges that are highly variable from year to year, Adjusted EBITDA provides our investors with performance measures that reflect the impact to operations from trends in changes in revenue, policy values and operating expenses, providing a perspective not immediately apparent from net income and operating income. The adjustments we make to derive the non-GAAP measure of Adjusted EBITDA exclude items which may cause short-term fluctuations in net income and operating income and which we do not consider to be the fundamental attributes or primary drivers of our business.

The following table presents a reconciliation of Adjusted EBITDA to the most comparable GAAP financial measure, net income (loss), on a historical basis for the periods indicated below:
65


Three Months Ended June 30, 
Six Months Ended June 30, 
2023202220232022
Net income$6,723,549$5,086,199$14,348,345$11,922,339
Depreciation expense 1,098 1,098 2,141 2,141
 Interest Income 584,075  934,001
Income tax 1,184,571120,132 528,104296,806
Other income (expense) (121,601)127,455 21,651 242,247
Loss on change in fair value of debt 1,445,229 333,879 2,398,662 375,513
Unrealized gain (loss) on investments (672,936)1,039,022 (798,156) 1,054,975
Adjusted EBITDA$9,143,985$6,707,785$17,434,748$13,894,021
Adjusted EBITDA Margin80.4 %79.9 %80.8 %76.0 %
Net Income Margin59.1 %60.6 %66.5 %65.2 %

Adjusted EBITDA for the three months ended June 30, 2023 was $9,143,985 compared to $6,707,785 for the three months ended June 30, 2022. The increase of $2,436,200, or 36% in adjusted EBITDA is primarily due to the increase of $1,637,350, or 32% in net and comprehensive income and the increase of $1,111,350, or 333% in gain on change in fair value of debt. There is an offset in unrealized loss on investments of $672,936.

Adjusted EBITDA for the six months ended June 30, 2023 was $17,434,748 compared to $13,894,021 for the six months ended June 30, 2022. The increase of $3,540,727, or 25% in adjusted EBITDA is primarily due to the expansion of the active management services which resulted in increased revenues of $3,708,946, or 21% and the increase of $2,023,149, or 539% in gain on change in fair value of debt.

We monitor the following key business metrics: (i) number of policies serviced, (ii) value of policies serviced, and (iii) total invested dollars. Servicing revenue involves the provision of services to one affiliate by common ownership and third parties which own life insurance policies. The number of policies and the value of policies serviced represents the volume and dollar value of policies over which the above services are performed. Total invested dollars represent the acquisition cost plus premiums paid by the policy. We use the aforementioned metrics to assess business operations and provide concrete benchmarks that provide a clear snapshot of growth between the periods under consideration. Please refer to the following Key Business Metrics below:

Six Months Ended June 30,$ Change% Change
20232022
Key business metric
Number of policies serviced81944137885.7%
Value of policies serviced ($)1,823,437,795 650,461,869 1,172,975,926 180.3%
Total invested dollars ($)678,400,432 167,374,107511,026,325 305.3%

Liquidity and Capital Resources

Abacus Life, Inc. has financed operations since our inception primarily through customer payments, debt issuances, and net proceeds from equity financings in the form of capital contributions from our limited liability company members. Our principal uses of cash and cash equivalents in recent periods have
66

been funding our operations as Abacus Life, Inc. must actively manage its working capital and the associated cash requirements when servicing policies while also effectively utilizing cash and other sources of liquidity to purchase additional policies. As of June 30, 2023, our principal sources of liquidity was cash totaling $20,611,122. During the six months ended June 30, 2023, Abacus Life, Inc. had a net income attributable to Abacus Life, Inc. of $14,348,345 and during the six months ended June 30, 2022, Abacus Life, Inc. had a net income attributable to Abacus Life, Inc. of $11,515,698. During the six months ended June 30, 2023, and 2022, Abacus Life, Inc. had a net cash used in operations of $38,364,171 and $4,751,170, respectively.

As described above, Abacus Life, Inc. has entered into an SSES with the Providers. Since inception of the SSES on January 1, 2021 through December 31, 2021, Abacus Life, Inc. had incurred $120,000 related to initial funding of operations, and $0 related to expenses. As of June 30, 2023, Abacus Life, Inc. did not incurred related expenses to fund the deficits. Additionally, the Providers reimbursed Abacus Life, Inc. for the initial funding of $120,000 but have not reimbursed other expenses paid by Abacus Life, Inc. on behalf of the Providers in 2022. For the three months and six months ended June 30, 2023, the Providers were considered to be VIEs, but were not consolidated in our consolidated financial statements due to a lack of the power criterion or the losses/benefits criterion.

Our future capital requirements will depend on many factors, including our revenue growth rate and, the expansion of our active management and portfolio activities. Abacus Life, Inc. may, in the future, enter into arrangements to acquire or invest in complementary businesses, products and technologies. Abacus Life, Inc. may be required to seek additional equity or debt financing.

Cash Flows from our operations

The following table summarizes our cash flows for the periods presented:

Six Months Ended June 30,
20232022
Net cash used in operating activities$(38,364,171)$(4,751,170)
Net cash used in investing activities(7,060,627)(250,000)
Net cash provided by financing activities35,983,097 7,744,154

Operating Activities

During the six months ended June 30, 2023, our operating activities used $38,364,171 of net cash as compared to $4,751,170 of net cash used from operating activities during the six months ended June 30, 2022. The increase in net cash used from operating activities during the six months ended June 30, 2023 compared to the six months ended June 30, 2022, was primarily due to purchases of $39,556,677 life settlement policies at fair value and $11,374,605 life settlement policies at cost during the six months ended June 30, 2023 compared to purchases of $7,211,509 life settlement polices at fair value and $7,204,753 life settlement polices at cost during the six months ended in June 30, 2022.

Investing Activities

During the six months ended June 30, 2023, investing activities used $7,060,627 of net cash as compared to $250,000 net cash used during the six months ended June 30, 2022. $7,060,627 of net cash used in investing activities during the six months ended June 30, 2023 was related to payments of $6,760,627 due from affiliates and $300,000 of net cash was used for the purchase of other investments. $250,000 of net cash used in investing activities during the six months ended June 30, 2022 was related to the purchase of other investments.

67

Financing Activities

During the six months ended June 30, 2023, financing activities generated $35,983,097 of net cash as compared to $7,744,154 of net cash generated during the six months ended June 30, 2022. The increase of $28,238,943 in net cash generated in financing activities during the six months ended June 30, 2023 compared to June 30, 2022, was related to the proceeds of $25,000,000 received from the SPV Purchase and Sale Note as well as $35,206,351 from the issuance of debt certificates, offset by $23,533,072 of capital distributions to members during June 30, 2023.

Contractual Obligations and Commitments

Our significant contractual obligations as of June 30, 2023, include three notes, LMATTSTM 2024, LMATTSTM 2.2024, and LMATTSTM 1.2026. The $10,166,900 LMATTSTM 2024 notes are a market-indexed instrument designed to provide upside performance exposure of the S&P 500 Index, while limiting downward exposure. Upon maturity of the notes in 2024, the principal, plus the return based upon the S&P 500 Index must be paid. The notes have a feature to protect debt holders from market downturns, up to 40%. Any subsequent losses below the 40% threshold will reduce the notes. The notes do not pay interest to the holders. As of June 30, 2023, $9,866,900 of the principal amount remained outstanding.

The $2,333,391 LMATTSTM 2.2024 notes are market-indexed instruments designed to provide upside performance exposure of the S&P 500 Index, while limiting downward exposure. Upon maturity of the notes in 2024, the principal, plus the return based upon the S&P 500 Index must be paid. The notes have a feature to protect debt holders from market downturns, up to 20%. Any subsequent losses below the 20% threshold will reduce the notes. The notes do not pay interest to the holders. As of June 30, 2023, the entire principal amount remained outstanding.

The $400,000 LMATTSTM 1.2026 notes are market-indexed instruments designed to provide upside performance exposure of the S&P 500 Index, while limiting downward exposure. Upon maturity of the notes in 2026, the principal, plus the return based upon the S&P 500 Index must be paid. The notes have a feature to protect debt holders from market downturns, up to 10%. Any subsequent losses below the 10% threshold will reduce the notes. The notes pay annual interest of 4% on invested capital to the holders. As of June 30, 2023, the entire principal amount remained outstanding.

Additionally, LMA Income Series, GP, LLC, wholly owned and controlled by that LMA Series, LLC, formed a limited partnership, LMA Income Series, LP and issued partnership interests to limited partners in a private placement offering. The initial term of the offering is three years with the ability to extend for two additional one-year periods at the discretion of the general partner, LMA Income Series, GP, LLC. The limited partners will receive an annual dividend of 6.5% paid quarterly and 25% of returns in excess of a 6.5% internal rate of return capped at a 15% net internal rate of return. The General Partner will receive 75% of returns in excess of a 6.5% internal rate of return to limited partners then 100% in excess of a 15% net internal rate of return. It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series, LP and thus has fully consolidated the limited partnership in its consolidated financial statements for the year ended December 31, 2022, and interim condensed consolidated financial statements for the three and six months ended June 30, 2023.

During the three months ended March 31, 2023, LMA Income Series II, GP, LLC, wholly owned and controlled by that LMA Series, LLC, formed a limited partnership, LMA Income Series II, LP and issued partnership interests to limited partners in a private placement offering. The initial term of the offering is three years with the ability to extend for two additional one-year periods at the discretion of the general partner, LMA Income Series II, GP, LLC. The limited partners will receive annual dividends equal to the Preferred Return Amounts as follows: Capital commitment less than $500,000, 7.5%; between $500,000 and $1,000,000, 7.75%; over $1,000,000, 8%. Thereafter, 100% of the excess to be paid to the General Partner. It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series, LP and thus has
68

fully consolidated the limited partnership in its consolidated financial statements for the three and six months ended June 30, 2023.

The private placement offerings proceeds for both LMA Income Series, LP and LMA Income Series II, LP will be used to acquire an actively managed large and diversified portfolio of financial assets. Abacus Life, Inc. elected to account for the secured borrowings at fair value under the collateralized financing entity guidance within ASC 810-10-30. As of June 30, 2023, the fair value of the LMA Income Series, LP secured borrowing was $22,124,676. As of June 30, 2023, the fair value of the LMA Income Series II, LP secured borrowing was $20,041,851.

Additionally, Abacus Life, Inc. has operating lease obligations, which are included as liabilities on our balance sheet, for our office space. As of June 30, 2023, operating lease obligations were $244,425 with $227,561 due in less than one year and $16,864 due within one to three years, which are comprised of the minimum commitments for our office space.

Critical Accounting Policies and Estimates

Abacus Life, Inc. has prepared our consolidated financial statements in accordance with GAAP. Our preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets, liabilities and related disclosures at the date of the financial statements, as well as revenue and expense recorded during the reporting periods. Abacus Life, Inc. evaluates our estimates and judgments on an ongoing basis. Abacus Life, Inc. bases our estimates on historical experience and or other relevant assumptions that Abacus Life, Inc. believes to be reasonable under the circumstances. Actual results may differ materially from management’s estimates.

While our significant accounting policies are described in more detail in Note 2 to our consolidated financial statements included in this Quarterly Report on Form 10-Q, Abacus Life, Inc. believes the following accounting policies to be critical to the judgments and estimates used in the preparation of our financial statements.

Longevity Market Assets Target-Term Series (LMATTSTM) Note

On March 31, 2022, LMATT Series 2024, Inc., which Abacus Life, Inc. consolidates for financial reporting, issued approximately $10,166,900 in market-indexed private placement notes. The notes, LMATTSTM 2024, are market-indexed instruments designed to provide upside performance exposure of the S&P 500 Index, while limiting downward exposure. Upon maturity of the notes in 2024, the principal, plus the return based upon the S&P 500 Index must be paid. The notes have a feature to protect debt holders from market downturns, up to 40%. Any subsequent losses below the 40% threshold will reduce the notes. The notes do not pay interest to the holders. As of June 30, 2023, $9,866,900 of the principal amount remained outstanding.

On September 16, 2022, LMATT Growth Series, Inc., which Abacus Life, Inc. consolidates for financial reporting, issued approximately $2,333,391 in market-indexed private placement notes. The notes, LMATTSTM 2.2024, are market-indexed instruments designed to provide upside performance exposure of the S&P 500 Index, while limiting downward exposure. Upon maturity of the notes in 2024, the principal, plus the return based upon the S&P 500 Index must be paid. The notes have a feature to protect debt holders from market downturns, up to 20%. Any subsequent losses below the 20% threshold will reduce the notes. The notes do not pay interest to the holders. As of June 30, 2023, the entire principal amount remained outstanding.

On September 16, 2022, LMATT Growth and Income Series, Inc., which Abacus Life, Inc. consolidates for financial reporting, issued approximately $400,000 in market-indexed private placement notes. The notes, LMATTSTM 1.2026, are market-indexed instruments designed to provide upside performance exposure of
69

the S&P 500 Index, while limiting downward exposure. Upon maturity of the notes in 2024, the principal, plus the return based upon the S&P 500 Index must be paid. The notes have a feature to protect debt holders from market downturns, up to 10%. Any subsequent losses below the 10% threshold will reduce the notes. The notes pay an annual 4% interest rate on invested capital to the holders. As of June 30, 2023, the entire principal amount remained outstanding.

Abacus Life, Inc. has elected the fair value option in accounting for the instruments. Fair value is determined using Level 3 inputs. The valuation methodology is based on the Black-Scholes-Merton option-pricing formula and a discounted cash flow analysis. Inputs to the Black-Scholes-Merton model include (i) the S&P 500 Index price, (ii) S&P 500 Index volatility, (iii) a risk-free rate based on data published by the US Treasury, and (iv) a term assumption based on the contractual term of the LMATTTM note. The discounted cash flow analysis includes a discount rate that is based on the implied discount rate assumption developed by calibrating a valuation model to the purchase price on the initial investment date. The implied discount rate is evaluated for reasonableness by benchmarking it to yields on actively traded comparable securities.

For the three months ended June 30, 2023, Abacus Life, Inc. has recognized a loss of $620,085 and a loss of $765,591 for the LMATTSTM 2024, Inc. notes and LMATTSTM Growth Series, Inc. notes respectively on the change in fair value fair value of the debt resulting from risk-free valuation scenarios, which is included within loss on change in fair value of debt within the interim Condensed Consolidated Statement of Operations. For the six months ended June 30, 2023, Abacus Life, Inc. has recognized a loss of $1,305,293 and a loss of $1,033,816 for the LMATTSTM 2024, Inc. notes and LMATTSTM Growth Series, Inc. notes, respectively on the change in fair value fair value of the debt resulting from risk-free valuation scenarios, which is included within loss on change in fair value of debt within the interim Condensed Consolidated Statement of Operations.

Longevity Market Assets Income Series, LP

On November 30, 2022, LMA Income Series, GP, LLC, wholly owned and controlled by that LMA Series, LLC, which Abacus Life, Inc. consolidates, formed a limited partnership, LMA Income Series, LP and issued partnership interests to limited partners in a private placement offering. It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series, LP and thus has fully consolidated the limited partnership in its consolidated financial statements for the year ended December 31, 2022. The limited partners will receive an annual dividend of 6.5% paid quarterly and 25% of returns in excess of a 6.5% internal rate of return capped at 9% which would require a 15% net internal rate of return. The General Partner will receive 75% of returns in excess of a 6.5% internal rate of return to limited partners then 100% in excess of a 15% net internal rate of return. The general partner committed $250,000, with the limited partners contributing $17,428,349. Additional limited partner contributions of $4,461,095 were raised in the first quarter of 2023 bringing the total deposit amount to $22,139,444.

The private placement offerings proceeds were used to acquire an actively managed large and diversified portfolio of financial assets. Abacus Life, Inc. , through its consolidated subsidiaries, serves as the portfolio manager for the financial asset portfolio, which includes investment sourcing and monitoring. In this role, Abacus Life, Inc. has the unilateral ability to acquire and dispose of any of the above investments. Abacus Life, Inc. elected to account for the secured borrowing at fair value under the collateralized financing entity guidance within ASC 810-10-30. As of June 30, 2023, the fair value of the secured borrowing, not including the $250,000 committed from the general partner, was $22,124,676 and there was no gain or loss recognized.

Longevity Market Assets Income Series II, LP

On January 31, 2023, LMA Series, LLC, a wholly owned subsidiary of the Company, signed an Operating Agreement to be the sole member of a newly created general partnership, LMA Income Series II, GP, LLC. Subsequent to that, LMA Income Series II, GP, LLC formed a limited partnership, LMA Income Series II, LP
70

and issued partnership interests to limited partners in a private placement offering. It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series II, LP and thus has fully consolidated the limited partnership in its consolidated financial statements for the three months ended June 30, 2023. The limited partners will receive annual dividends equal to the preferred return amounts as follows: Capital commitment less than $500,000, 7.5%; between $500,000 and $1,000,000, 7.75%; over $1,000,000, 8%. Thereafter, 100% of the excess to be paid to the General Partner.

The private placement offerings proceeds were used to acquire an actively managed large and diversified portfolio of financial assets. Abacus Life, Inc. , through its consolidated subsidiaries, serves as the portfolio manager for the financial asset portfolio, which includes investment sourcing and monitoring. In this role, Abacus Life, Inc. has the unilateral ability to acquire and dispose of any of the above investments. Abacus Life, Inc. elected to account for the secured borrowing at fair value under the collateralized financing entity guidance within ASC 810-10-30. As of June 30, 2023, the fair value of the secured borrowing, not including the commitment from the general partner, was $20,041,851 and there was no gain or loss recognized.

Valuation of Life Insurance Policies

Abacus Life, Inc. accounts for its holdings of life insurance settlement policies at fair value in accordance with ASC 325-30, Investments in Insurance Contracts. Any resulting changes in estimates are reflected in operations in the period the change becomes apparent.

Abacus Life, Inc. follows ASC 820, Fair Value Measurements and Disclosures, in estimating the fair value of its life insurance policies, which defines fair value as an exit price representing the amount that would be received if an asset were sold or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-level, fair value hierarchy that prioritizes the inputs used to measure fair value. Level 1 relates to quoted prices in active markets for identical assets or liabilities. Level 2 relates to observable inputs other than quoted prices included in Level 1. Level 3 relates to unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Abacus Life, Inc.'s valuation of life settlements is considered to be Level 3, as there is currently no active market where Abacus Life, Inc. is able to observe quoted prices for identical assets. Abacus Life, Inc.'s valuation model incorporates significant inputs that are not observable.

The aggregate face value of policies held at fair value is approximately $195,205,585 as of June 30, 2023, with a corresponding fair value of approximately $56,685,617. Aggregate face value of policies accounted for using the investment method is $39,520,877 as of June 30, 2023, with a corresponding carrying value of approximately $9,889,610.

Equity Investments in Privately-Held Companies

Equity investments without readily determinable fair values include our investments in privately-held companies in which Abacus Life, Inc. holds less than a 20% ownership interest and does not have the ability to exercise significant influence. Abacus Life, Inc. determines fair value using level 3 inputs under the measurement alternative. These investments are recorded at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.

In addition, Abacus Life, Inc. monitors these investments to determine if impairment charges are required based primarily on the financial condition and near-term prospects of these companies. As of June 30, 2023, Abacus Life, Inc. did not identify any impairment indicators and determined that the carrying value
71

of $1,600,000 is the fair value for these equity investments in privately held companies, given that there have been no observable price changes.

Available-For-Sale Securities

Abacus Life, Inc. has investments in securities that are classified as available-for-sale securities, and which are reflected on the Consolidated Balance Sheets at fair value. These securities solely consist of a convertible promissory note in a private company that was entered into an arms-length. Abacus Life, Inc. determines the fair value using unobservable inputs by considering the initial investment value, next round financing, and the likelihood of conversion or settlement based on the contractual terms in the agreement. Unrealized gains and losses on these investments are included as a separate component of accumulated other comprehensive loss, net of tax, on the Consolidated Balance Sheets. Abacus Life, Inc. classifies its available-for-sale securities as short-term or long-term based on the nature of the investment, its maturity date and its availability for use in current operations. Abacus Life, Inc. monitors its available-for-sale securities for possible other-than-temporary impairment when business events or changes in circumstances indicate that the carrying value of the investment may not be recoverable. As of June 30, 2023, Abacus Life, Inc. evaluated the fair value of its investment and determined that the fair value approximates the carrying value of $1,000,000, and no unrealized gains and losses were recorded.

Quantitative and Qualitative Disclosures About Market Risk

Not required for smaller reporting companies.

JOBS Act Election

Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable.

Abacus Life, Inc. has irrevocably elected to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, Abacus Life, Inc., as an emerging growth company, will adopt the new or revised standard at the time public companies adopt the new or revised standard. As a result, following the consummation of the Business Combination, Abacus Life, Inc. will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies.


72


ABACUS MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

The following discussion and analysis provide information that management believes is relevant to an assessment and understanding of Abacus’ financial condition and results of operations. This discussion should be read in conjunction with Abacus’ financial statements and related notes thereto that appear elsewhere in this Quarterly Report.

In addition to historical financial analysis, this discussion and analysis contains forward-looking statements based upon current expectations that involve risks, uncertainties and assumptions, as described under the heading “Cautionary Note Regarding Forward-Looking Statements.” Actual results and timing of selected events may differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth under “Risk Factors” or elsewhere in this quarterly statement. Unless the context otherwise requires, references in this “Abacus Management’s Discussion and Analysis of Financial Condition and Results of Operations” to “we,” “us,” “our,” and “Abacus” are intended to mean the business and operations of Abacus Settlements, LLC.

Overview

Abacus originates life insurance policy settlement contracts as a licensed life settlement provider on behalf of third-party institutional investors (“Financing Entities”) interested in investing in the life settlement asset class. Specifically, Abacus originates policies through three primary origination channels (Agents/Financial Advisors, Direct-to-Consumers, Life Settlement Brokers) and Third-Party Intermediaries, screens them for eligibility by verifying that the policy is in force, obtaining consents and disclosures, and submitting cases for life expectancy estimates. This process is characterized as our origination services, which averages a fee of approximately 2% of face value (“Origination Revenue”).

Our Business Model

As a life settlement provider, Abacus serves as a purchaser of outstanding life insurance policies. When serving as a purchaser, Abacus’ primary purpose in the transaction is to connect buyers and sellers through an origination process. The origination process is core to Abacus’ business and drives its economics. Abacus averages approximately 2% of face value in origination fees on policies and has developed three high quality origination channels which include agents and Financial Advisors, direct to consumer and Life Settlements Brokers. Abacus also originates policies with Third-Party Intermediaries. Generally, diversification across multiple origination channels lowers average policy acquisition cost and increases estimated returns. Abacus finds sellers through its origination channels using strategic marketing practices in its core markets, with the purpose of finding policy owners who want to capitalize on their investments prior to death by extracting value from their policies through the sale of such policies to Financing Entities.

Key Factors Affecting Our Performance

Our operations and financial performance are impacted by economic factors affecting the industry, including:

Opportunities in the Life Settlements Industry

Within the life settlements industry, there is significant policy value that lapses on an annual basis. Currently, the life settlements industry only captures a narrow portion of the potential market leaving significant runway for future growth for industry participants. With the anticipation of growth in total face value of life insurance policies, we believe we are well positioned to capitalize on the overall market growth. Abacus is currently conducting business in 49 states and the District of Columbia. The company holds viatical settlement and or life settlement provider licenses in forty-three (43) of those jurisdictions. Abacus also conducts business in seven (7) jurisdictions which do not currently have life and or viatical settlement provider licensing requirements. Abacus conducts business where is it legally allowed to across the United States. The
73

only state Abacus is not currently conducting business in is Alaska and there are no current plans to procure a license.
Our ability to originate policies is essential to scale our business over time. In order to support this expected growth, we continue to invest in our technology and marketing infrastructure. In general, we expect our efforts will continue to focus on driving education and awareness of life settlements. In order to meet this growing demand, we have increased our total headcount by 18% since December, 2022, and anticipate a total of 36% growth of our total headcount from December 31, 2022 to December 31, 2024, of which 18% has already been captured.

Macroeconomic Changes

Global macroeconomic factors, including regulatory policies, unemployment, changes in retirement savings, the cost of healthcare, inflation, and tax rate changes impact demand for our origination services. These factors evolve over time and while these changes have not currently made any significant impact on performance, these trends may shift the timing and volume of transactions, or the number of customers using our origination services.

Components of Results of Operations

Results of Operations

The following tables set forth our results of operations for each of the periods indicated, and we presented and expressed the relationship of certain line items as a percentage of revenue for those periods. The period-to-period comparison of financial results is not necessarily indicative of future results.

The following tables set forth our historical results for the periods indicated, and the changes between periods:

Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Origination revenue$1,689,088 $743,388 $3,252,738 $3,185,068 
Related-party revenue5,195,602 4,948,528 9,931,938 9,829,596
Total revenue6,884,6905,691,916 13,184,67613,014,664
Cost of revenue1,505,333 956,625 2,734,949 3,265,313
Related party cost of revenue3,392,647 2,615,307 6,558,354 5,522,312
Gross profit1,986,7102,119,984 3,891,373 4,227,039
Operating expenses
General and administrative expenses2,297,5772,208,051 4,848,5803,948,358
Depreciation expense2,5613,048 5,5975,988
Total operating expenses2,300,1382,211,099 4,854,1773,954,346
Income (loss) from operations(313,428)(91,115)(962,804)272,693
Other income (expense)
Interest income 1,193599 1,9171,147
Interest (expense)(5,863)— (11,725)— 
Other income— 273 — 273 
Total other income (expense)(4,670)872 (9,808)1,420
Income (loss) before income taxes(318,098)(90,243)(972,612)274,113
74

Provision for income taxes— — 2,2891,325
Net income (loss) and comprehensive income$(318,098)$(90,243)$(974,901)$272,788 

Origination Revenue

Abacus recognizes revenue from origination activities by acting as a provider of life settlements and viatical settlements by representing investors that are interested in purchasing life settlements on the secondary or tertiary market. Revenue from origination services consists of fees negotiated for each purchase and sale of a policy to an investor, which also include any agent and broker commissions received and the reimbursement of transaction costs.
Three Months Ended June 30,
20232022$ Change% Change
Origination revenue$1,689,088 $743,388 $945,700 127 %

Revenue increased by $945,700, or 127%, for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. This increase was primarily attributable to higher pricing on the sale of broker policies arising from various factors such as policy death benefits, cash surrender values, life expectancy and policyholder age pertaining to the policies sold. These factors resulted in an increase of the commission fee paid to Abacus.

Six Months Ended June 30,
20232022$ Change% Change
Origination revenue$3,252,738 $3,185,068 $67,670 %

Revenue increased by $67,670, or 2%, for the six months ended June 30, 2023 compared to the six months ended June 30, 2022. The increase in revenue is primarily attributable to an increase in agent and client direct sales during 2023, which is driven by higher face values on the policies originated and higher commission flows, partially offset by a decrease in broker sales. The agent, broker, and client direct sales are all in line with normal, recurring business.

Related Party Revenue

Abacus has a related party relationship with Nova Trading (US), LLC (“Nova Trading”), a Delaware limited liability company and Nova Holding (US) LP, a Delaware limited partnership (“Nova Holding” and collectively with Nova Trading, the “Nova Funds”) as the owners of Abacus jointly own 11% of the Nova Funds. Pricing for origination fees are governed by origination contracts that have been negotiated by both parties and are considered to be arms-length and consistent with origination fees charged to third party customers. For its origination services to the Nova Funds, Abacus earns origination fees equal to the lesser of (i) 2% of the net death benefit for the policy or (ii) $20,000.
Three Months Ended June 30,
20232022$ Change% Change
Related Party Revenue$5,195,602 $4,948,529 $247,073 %

For the three months ended June 30, 2023 and June 30, 2022, Abacus has originated 38 and 92 policies, respectively, for the Nova Funds with a total value of approximately $56,688,680 and $102,307,954 respectively. This decrease in the origination of Nova Fund policies was partially offset by increases in origination services to Longevity Market Assets, LLC (“LMA”). For the three months ended June 30, 2023 and
75

June 30, 2022, Abacus has originated 69 and 8 policies, respectively, for LMA with a total value of approximately $114,999,768 and $31,200,000, respectively.

Related party revenue decreased by $247,073, or 5%, for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. The decrease in related party revenue is primarily attributable to decrease in Nova origination sales and transaction fee reimbursement of $2,176,724 and $1,196,167, partially offset by increased LMA originations services of $3,438,539.
Six Months Ended June 30,
20232022$ Change% Change
Related Party Revenue$9,931,938 $9,829,596 $102,342 %

For the six months ended June 30, 2023 and June 30, 2022, Abacus has originated 72 and 183 policies, respectively, for the Nova Funds with a total value of approximately $96,674,080 and $282,804,838, respectively. This decrease in the origination of Nova Fund policies was partially offset by increases in origination services to Longevity Market Assets, LLC (“LMA”). For the six months ended June 30, 2023 and June 30, 2022, Abacus has originated 103 and 8 policies, respectively, for LMA with a total value of approximately $192,685,578 and $31,200,000, respectively.

Related party revenue decreased by $102,342 or 1%, for the six months ended June 30, 2023 compared to the six months ended June 30, 2022. The decrease in related party revenue is primarily attributable to a decrease in Nova origination sales and transaction fee reimbursement of $4,770,057 and $1,284,679, partially offset by increased LMA originations services of $6,324,441.

Cost of Revenue, Related Party Cost of Revenue, and Gross Margin

Cost of revenue is primarily comprised of third-party commissions, which includes third-party sales and marketing commission fees, as well as transaction costs that are reimbursed as part of the origination activity and depreciation and amortization expense. Abacus receives an origination fee plus any commission to be paid from the purchaser for its part in arranging the life settlement transactions. Out of that fee income, Abacus pays commissions to the licensed representative of the seller, if one is required. Commission expense is recorded at the same time revenue is recognized and is included within cost of revenue. Depreciation expense consists of depreciation of property and equipment assets, which are computer equipment. Amortization expense consists primarily of amortization of capitalized costs incurred for the development of internal use software. The costs incurred exclusively consist of fees incurred from an external consulting firm during the development stage of the project and is amortized on the straight-line basis over an estimated useful life of three years.
Three Months Ended June 30,
20232022$ Change% Change
Cost of revenue$1,505,333 $956,625 $548,708 57 %
Related party cost of revenue3,392,647 2,615,307777,340 30 %
Gross Profit1,986,7102,119,984(133,274)(6)%
Gross Margin29%37%

Cost of revenue increased by $548,708 or 57%, for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. The increase in cost of revenue is primarily due to increases in sales-agents commission expenses of $838,577, partially offset by a decrease in marketing origination payout and consulting fees.

Related party cost of revenue increased by $777,340 or 30%, for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. The increase in related party cost of revenue is primarily
76

attributable to an increase in LMA agent commission expenses of $2,245,314 partially offset by a decrease in the originations of policies sold to Nova Fund of $1,478,661.

Gross profit decreased by $133,274 or 6%, for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. Gross margin decreased to 29% for the three months ended June 30, 2023 compared to 37% for the three months ended June 30, 2022. The decrease in gross profit and gross margin is primarily due to the increased commission expense per related party policy and correspondingly the decrease in gross margin due to a greater portion of the profit margin allocated to the licensed agent or broker.

Six Months Ended June 30,
20232022$ Change% Change
Cost of revenue$2,734,949$3,265,313$(530,364)(16)%
Related party cost of revenue6,558,3545,522,3121,036,042 19 %
Gross Profit3,891,3734,227,039(335,666)(8)%
Gross Margin30%32%

Cost of revenue decreased by $530,364, or 16%, for the six months ended June 30, 2023 compared to the six months ended June 30, 2022. The decrease in cost of revenue is primarily due to decreases in sales-agents commission expenses and marketing origination payout.

Related party cost of revenue increased by $1,036,042, or 19%, for the six months ended June 30, 2023 compared to the six months ended June 30, 2022. The increase in related party cost of revenue is primarily attributable to increase in LMA agent commission expenses of $4,634,216 partially offset by a decrease in the originations of policies sold to Nova Fund of $3,368,361.

Gross profit decreased by $335,666, or 8%, for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. Gross margin decreased to 30% for the six months ended June 30, 2023, compared to 32% for the six months ended June 30, 2022. The decrease in gross profit and gross margin is primarily due to the increased commission expense per related party policy and correspondingly the decrease in gross margin due to a greater part of the profit margin allocated to the licensed agent or broker.

Operating Expenses

Operating expenses is comprised of general and administrative expenses as well as depreciation expense.

General and administrative expenses include compensation, payroll, advertising, marketing, rent, insurance, recruitment, trade shows, telephone & internet, licenses, and other professional fees.

Depreciation expense consists of depreciation of property and equipment assets, which are computer equipment, office furniture and lease improvement.
Three Months Ended June 30,
20232022$ Change% Change
General and administrative expenses$2,297,577 $2,208,444 $89,133 4%
Depreciation expense2,5613,048(487)(16)%

General and administrative expenses increased by $89,133, or 4%, for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. The increase in general and administrative expenses are primarily due to increases in payroll expenses of $180,520 for administration support as a result of higher employee headcounts, and compensation raises, partially offset by a decrease in payroll expenses of $11,963 for the sales department. There was an increase in marketing expenses of $80,723 due to increased spending in internet advertising. There was also an increase of $57,000 in sponsorships. Rent and office
77

expense also increased by $15,508 and $34,812 respectively. Salaries and payroll expense, as a percentage of total revenue, represented 23% and 25% for the three months ended June 30, 2023 and 2022, respectively.

Depreciation expense decreased by $487, or 16%, for the three months ended June 30, 2023 compared to the three months ended June 30, 2022. The decrease in depreciation expense is primarily due to the declining book value of obsolescent furniture in normal course of business operations.
Six Months Ended June 30,
20232022$ Change% Change
General and administrative expenses$4,848,580 $3,948,358 $900,222 23%
Depreciation expense5,597 5,988 (391)(7)%

General and administrative expenses increased by $900,222, or 23%, for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. The increase in general and administrative expenses are primarily due to increases in payroll expenses of $138,944 for the sales department and $479,068 for administration support as a result of higher employee headcounts, and compensation raises. There was an increase in marketing expenses of $186,987 due to increased spending in internet advertising. There was also an increase of $125,500 in sponsorships. Rent and office expense also increased by $41,271 and $71,688 respectively. Salaries and payroll expense, as a percentage of total revenue, represented 24% and 19% for the six months ended June 30, 2023 and 2022, respectively.

Depreciation expense decreased by $391, or 7%, for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. The decrease in the expense is primarily due to the declining book value of obsolescent furniture in normal course of business operations.

Other income (expense)

Other income (expense) includes interest income, consulting income, and other income. Interest income represents the interest earned on Abacus’ certificates of deposits. Consulting income represents income earned on various origination consulting services performed. Other income comprises of income from credit card cash rewards.
Three Months Ended June 30,
20232022$ Change% Change
Interest income$1,193 $599 $594 99 %
Interest (expense)(5,863)— (5,863)(100)%
Other income— 273 (273)(100)%

Interest income increased by $594, or 99%, for the three months ended June 30, 2023, compared to the three months ended June 30, 2022. The increase in interest income is primarily due to favorable changes in interest rate terms for the Abacus certificate of deposit.

Interest expense increased by $5,863, or 100% for the three months ended June 30, 2023, compared to the three months ended June 30, 2022. The increase in interest expense is primarily due to the amortization of the deferred financing fees.

Other income decreased by $273, or 100% for the three months ended June 30, 2023, compared to the three months ended June 30, 2022. The decrease in other income is primarily due to none collected credit card cash rewards during 2023.

Six Months Ended June 30,
20232022$ Change% Change
78

Interest income$1,917 $1,147 $770 67 %
Interest (expense)(11,725)— (11,725)(100)%
Other income— 273 (273)(100)%

Interest income increased by $770, or 67%, for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. The increase in interest income is primarily due to favorable changes in interest rate terms for the Abacus certificate of deposit.

Interest expense increased by $11,725, or 100% for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. The increase in interest expense is primarily due to the amortization of the deferred financing fees.

Other income decreased by $273 or 100% for the six months ended June 30, 2023, compared to the six months ended June 30, 2022. The decrease in other income is primarily due to none collected credit card cash rewards during 2023.

Provision for Income Taxes
Three Months Ended June 30,
20232022$ Change% Change
Provision for income taxes$— $— $— — %

Provision for income taxes reflected no change for the three months ended June 30, 2023 compared to the three months ended June 30, 2022.

Six Months Ended June 30,
20232022$ Change% Change
Provision for income taxes$2,289 $1,325 $964 73%

Provision for income taxes increased by $964, or 73%, for the six months ended June 30, 2023 compared to the six months ended June 30, 2022. These amounts are primarily LLC annual report filing fees within the various states.

Business Segments

Operating as a centrally led life insurance policy intermediary, Abacus’ Chief Executive Officer is the Chief Operating Decision Maker (CODM) who allocates resources and assesses financial performance. As a result of this management approach, Abacus is organized as a single operating segment. The CODM reviews performance and allocates resources based on the total originations, total corresponding revenue generated for the period, gross profit, and adjusted EBITDA.

Key Business Metrics and Non-GAAP Financial Measures

Management uses non-GAAP financial measures, in conjunction with GAAP financial measures, as an integral part of managing our business and to, among other things: (i) monitor and evaluate the performance of our business operations and financial performance; (ii) facilitate internal comparisons of the historical operating performance of our business operations; (iii) review and assess the operating performance of our management team; (iv) analyze and evaluate financial and strategic planning decisions regarding future operating investments; and (v) plan for and prepare future annual operating budgets and determine appropriate levels of operating investments.

We monitor the following key business metrics and non-GAAP financial measures that assist us in evaluating our business, measuring our performance, identifying trends and making strategic decisions. As
79

such, we have presented the following non-GAAP measure, their most directly comparable U.S. GAAP measure, and key business metrics:

Non-GAAP MeasureComparable U.S. GAAP Measure
Adjusted EBITDANet Income

Adjusted EBITDA is net income adjusted for depreciation expense, provision for income taxes, interest income, and non-recurring items that in our judgement significantly impact the period-over-period assessment of performance and operating results. Adjusted EBITDA should not be construed as an indicator of our operating performance, liquidity, or cash flows provided by or used in operating, investing, and financing activities, as there may be significant factors or trends that it fails to address. We caution investors that non-GAAP financial information departs from traditional accounting conventions. Therefore, its use can make it difficult to compare current results with results from other reporting periods and with the results of other companies.

Management believes the use of Adjusted EBITDA measures assists investors in understanding the ongoing operating performance by presenting comparable financial results between periods. We believe that by removing the impact of depreciation and amortization, amounts spent on interest and taxes and certain other non-recurring income and charges that are highly variable from year to year, Adjusted EBITDA provides our investors with performance measures that reflect the impact to operations from trends in changes in revenue and operating expenses, providing a perspective not immediately apparent from net income and operating income. The adjustments we make to derive the non-GAAP measure of Adjusted EBITDA exclude items which may cause short-term fluctuations in net income and operating income and which we do not consider to be the fundamental attributes or primary drivers of our business

The following table illustrates the reconciliations from net income to adjusted EBITDA for the three months ended June 30, 2023, and 2022 and for the six months ended June 30, 2023, and 2022:

Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Net income (loss) and comprehensive income$(318,098)$(90,243)$(974,901)$272,788 
Depreciation expense2,5613,0485,5975,988
Provision for income taxes— — 2,2891,325
Interest income(1,193)(599)(1,917)(1,147)
Interest expense5,863— 11,725— 
Adjusted EBITDA$(310,867)$(87,794)$(957,207)$278,954 

Adjusted EBITDA for the three months ended June 30, 2023 was $(310,867) compared to $(87,794) for the three months ended June 30, 2022. This decrease was attributable to lower revenues and gross profit during second quarter of 2023 as well as increased general and administrative costs including payroll, legal and marketing expenses for three months ended June 30, 2023.

Adjusted EBITDA for the six months ended June 30, 2023, was $(957,207), compared to $278,594 for the six months ended June 30, 2022. This decrease was attributable to higher costs of revenue primarily driven by higher commission expense during 2023 as well as increased general and administrative costs and interest expense for the six months ended June 30, 2023.

We monitor the following key business metrics such as the number of policies originated year-over-year in measuring our performance. Origination revenues represent fees negotiated for each purchase and sale of a policy to an investor. The number of policy originations represents the volume of policies over which the above origination services are performed. The number of policy originations directly correlates with
80

origination revenues allowing management to evaluate fees earned upon each transaction. There are no estimates, assumptions, or limitations specific to the number of policy originations.
Three Months Ended June 30,% ChangeSix Months Ended June 30,% Change
2023202220232022
Number of Policy Originations141 135 %253 259 (2)%

Liquidity and Capital Resources

We have financed operations since our inception primarily through customer payments and net proceeds from equity financings in the form of capital contributions from our members. Our principal (uses) of cash and cash equivalents in recent periods have been funding our operations. As of June 30, 2023 and June 30, 2022, our principal sources of liquidity were cash, cash equivalents, and restricted cash totaling $808,226 and $1,439,522, respectively, and we had retained earnings of $509,953 and $2,251,914, respectively. During the three months ended June 30, 2023, we had a net (loss) of $(318.098), and net cash provided by operations of $20,655. During the six months ended June 30, 2023, we had a net (loss) of $(974,901), and net cash (used) by operations of $24,292. We believe our existing cash, cash equivalents, restricted cash, proceeds from equity financings will be sufficient to fund anticipated cash requirements for the next twelve months.

Our future capital requirements will depend on many factors, including our revenue growth rate, the expansion of our sales and marketing activities, the timing and extent of spending to support product development efforts. We may, in the future, enter into arrangements to acquire or invest in complementary businesses, products and technologies. We may be required to seek additional equity or debt financing. The additional debt financing would result in debt service obligations, and any future instruments governing such debt could provide for operating and financing covenants that could restrict our operations.

Cash Flows

Cash Flows for the Six Months Ended June 30, 2023 and 2022:

The following table summarizes our cash flows for the six months ended June 30, 2023 and 2022:
Six Months Ended June 30,
20232022
Net cash (used) in operating activities(24,292)(452,367)
Net cash (used) in investing activities(182,528)(35,687)
Net cash (used) in financing activities(443,694)(671,726)

Operating Activities

During the six months ended June 30, 2023, our operating activities (used) $(24,292) of net cash as compared to net cash (used) in operating activities of $(452,367) during the six months ended June 30, 2022. The decrease in net cash from operating activities during six months ended June 30, 2023, compared to six months ended June 30, 2022, was primarily due to decreases in contract liabilities. The timing of revenue recognition, customer billing, and cash collection can result in billed accounts receivable, unbilled revenue (contract assets), and deferred revenues (contract liabilities). This decrease in contract liabilities was partially offset by decreases in net income and certificate of deposit.

Investing Activities

During the six months ended June 30, 2023, investing activities (used) $(182,528) of net cash as compared to net cash (used) in investing activities of $(35,687) during the six months ended June 30, 2022. The change in cash (used) in investing activities was primarily attributable to the purchases of property, plant, and
81

equipment for $108,394. Net cash (used) in investing activities also increased due to an increase in accounts receivable for expenses related to the Merger and payments to members / affiliates as a result of payroll true up with the LMA entity for shared employees.

Financing Activities

During the six months ended June 30, 2023, financing activities (used) $(443,694) of net cash as compared to $(671,726) during the six months ended June 30, 2022. Net cash (used) in financing activities during the six months ended June 30, 2023, was primarily related to the distribution to members of $442,283. Net cash (used) in financing activities for the six months ended June 30, 2022, was primarily related to a distribution to members of $659,869, offset by a $11,857 change in due from members and affiliates.

Contractual Obligations and Commitments

Our contractual obligations as of June 30, 2023, which are included as liabilities on our balance sheet, include operating lease obligations of $190,521 with $177,873 due in less than one year and $12,648 due within one to three years, which are comprised of the minimum commitments for our office space.

Critical Accounting Policies and Estimates

We have prepared our financial statements in accordance with GAAP. Our significant accounting policies are described in more detail in Note 2 to our financial statements included in this quarterly filing statement. While our preparation of these financial statements requires us to make estimates, assumptions and judgments from time to time that may affect the reported amounts of assets, liabilities and related disclosures, as of the date of these financial statements, we have not identified any estimates made in accordance with generally accepted accounting principles that involve a significant level of estimation uncertainty which have had or are reasonably likely to have a material impact on the financial condition or results of operations.

Related Party Receivables

Related party receivables include fees to be reimbursed to Abacus from life expectancy reports, assisted physician services and escrow services incurred on policies that related party financing entities purchase as part of the origination agreement with Abacus. Related party receivables are stated at their net realizable value. All of the outstanding receivables of $5,710 as of June 30, 2023 were collected in July, 2023 and 55% of these fees as of June 30, 2022 were collected in July, 2022. Abacus provides an allowance for doubtful accounts equal to the estimated collection losses that will be incurred in collection of all receivables. The estimated losses are based upon historical collection experience coupled with a review of the current status of all existing receivables. Account balances are charged off against the allowance for doubtful accounts after all means of collection have been exhausted and the potential for recovery is remote. There is no allowance for doubtful accounts as of, June 30, 2023, or June 30, 2022.

Intangible Assets

Intangible assets are stated at cost, less accumulated amortization, and consist of capitalized costs incurred for the development of internal use software. The costs incurred exclusively consist of fees incurred from an external consulting firm during the development stage of the project and are subject to capitalization under ASC 350-40, Internal-Use Software. The software is amortized on the straight-line basis over an estimated useful life of 3 years. Abacus reviews definite-lived intangible assets and other long-lived assets for impairment at least annually or whenever an event occurs that indicates the carrying amount of an asset may not be recoverable. No impairment was recorded for the three months ending June 30, 2023, and 2022 or for the six months ending June 30, 2023, and 2022.





82

Revenue Recognition

Abacus recognizes revenue from origination activities by acting as a provider of life settlements and viatical settlements representing investors that are interested in purchasing life settlements on the secondary or tertiary market. Revenue from origination services consists of fees negotiated for each purchase and sale of a policy to an investor, which also include any agent and broker commissions received and the reimbursement of transaction costs.

Abacus’ revenue-generating arrangements are within the scope of Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers. Abacus originates life settlements policies with third parties that include settlement brokers, life insurance agents, and direct consumers or policyholders. Abacus then provides the administration services needed to initiate the transfer of the life settlement policies to investors in exchange for an origination fee. Such transactions are entirely performed through an escrow agent. In these arrangements, the customer is the investor, and Abacus has a single performance obligation to originate a life settlement policy for the investor. The consideration transferred upon each policy is negotiated directly with the investor by Abacus and is dependent upon the policy death benefits held by each life settlement policy. The revenue is recognized when the performance obligation under the terms of the contracts with customers are satisfied. Abacus recognizes revenue from life settlement transactions when the closing has occurred and any right of rescission under applicable state law has expired (i.e., the customer obtains control over the policy and has the right to use and obtain the benefits from the policy). While rescission periods may vary by state, most states grant the owner the right to rescind the contract before the earlier of 30 calendar days after the execution date of the contract or 15 calendar days after life settlement proceeds have been sent to the owner. Purchase and sale of the policies generally occurs simultaneously, and only the fees received, including any agent and broker commissions and transaction costs reimbursed, are recorded as gross revenue.

For agent and broker commissions received and transaction costs reimbursed, Abacus has determined that they are acting as the principal in the relationship as they maintain control of the services being performed as part of performance obligation prior to facilitating the transfer of the life settlement policy to the investor.

While the origination fees are fixed amounts based on the face value of the policy death benefit, there is variable consideration present due to the owners rescission right. When variable consideration is present in a contract, Abacus estimates the amount of variable consideration to which it expects to be entitled at contract inception and again at each reporting period until the amount is known. Abacus applies the variable consideration constraint so that variable consideration is included in the transaction price only to the extent it is probable that a subsequent change in estimate will not result in a significant revenue reversal. While origination fees are variable due to the rescission periods, given the that the rescission periods are relatively short in nature, Abacus has concluded that such fees are fully constrained until the rescission period lapses and thus records revenue at a fixed amount based on the face value of the policy death benefit after the rescission period is over.
Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not required for smaller reporting companies.

JOBS Act Election

Section 102(b)(1) of the JOBS Act exempts emerging growth companies from being required to comply with new or revised financial accounting standards until private companies (that is, those that have not had a Securities Act registration statement declared effective or do not have a class of securities registered under the Exchange Act) are required to comply with the new or revised financial accounting standards. The JOBS Act provides that an emerging growth company can elect to opt out of the extended transition period and comply with the requirements that apply to non-emerging growth companies but any such election to opt out is irrevocable.

83

Abacus Settlement, LLC. has irrevocably elected to opt out of such extended transition period, which means that when a standard is issued or revised and it has different application dates for public or private companies, Abacus Settlement, LLC., as an emerging growth company, will adopt the new or revised standard at the time public companies adopt the new or revised standard. As a result, following the consummation of the Business Combination, Abacus Life, Inc. will comply with new or revised accounting standards on the relevant dates on which adoption of such standards is required for non-emerging growth companies.
Item 4. Controls and Procedures

There were no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) during the most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. In light of the restatement of our financial statements included in this Annual Report on Form 10-K, we plan to enhance our processes to identify and appropriately apply applicable accounting requirements to better evaluate and understand the nuances of the complex accounting standards that apply to our financial statements. Our plans at this time include providing enhanced access to accounting literature, research materials and documents and increased communication among our personnel and third-party professionals with whom we consult regarding complex accounting applications. The elements of our remediation plan can only be accomplished over time, and we can offer no assurance that these initiatives will ultimately have the intended effects.
84

Part II Other Information
Item 1. Legal Proceedings

From time-to-time, the Company is involved in various civil actions as part of its normal course of business. The Company is not a party to any litigation that is material to ongoing operations as defined in Item 103 of Regulation S-K as of the period ended June 30, 2023.
Item 1A. Risk Factors
Factors that could cause our actual results to differ materially from those in this report include the risk factors described in our Annual Report on Form 10-K filed with the SEC on April 18, 2023. As of the date of this Report, other than material weakness related to financial instruments and accounting for accruals, there have been no material changes to the risk factors disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None
Item 3. Defaults Upon Senior Securities
None
Item 4. Mine Safety Disclosures
None
Item 5. Other Information
None
Item 6. Exhibits
The following exhibits are filed as part of, or incorporated by reference into, this Quarterly Report on Form 10-Q.
Exhibit
Number
Description
3.1
3.2
4.3
4.4
4.5
4.6
4.7
85

4.8
4.9
4.1
10.1
10.2
10.3
10.4
10.5
10.6
10.7
10.8
14.1
21.1
31.1
31.2
32.1
32.2
104*
* Filed herewith












86


EXHIBIT 31.1
CERTIFICATION OF CHIEF EXECUTIVE OFFICER
PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jay Jackson, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Abacus Life, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
87

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 14, 2023
/s/ Jay Jackson
Jay Jackson
Chief Executive Officer
(Principal Executive Officer)











































88

EXHIBIT 31.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO RULE 13A-14(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, William McCauley, certify that:
1.I have reviewed this quarterly report on Form 10-Q of Abacus Life, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:
a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant, is made known to us by others within those entities, particularly during the period in which this report is being prepared; and
b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
89

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
Date: August 14, 2023
/s/ William McCauley
William McCauley
Chief Financial Officer
(Principal Accounting and Financial Officer)



















































90

EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Abacus Life, Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, Jay Jackson, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.




Dated: August 14, 2023


/s/ Jay Jackson
Jay Jackson
Chief Executive Officer
(Principal Executive Officer)


























91

EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Abacus Life, Inc. (the “Company”) on Form 10-Q for the quarterly period ended June 30, 2023, as filed with the Securities and Exchange Commission (the “Report”), I, William McCauley, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as added by §906 of the Sarbanes-Oxley Act of 2002, that:

1.
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
2.
To my knowledge, the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of and for the period covered by the Report.







Dated: August 14, 2023

/s/ William McCauley
William McCauley
Chief Financial Officer
(Principal Accounting and Financial Officer)
92

Signatures
93
EX-101.SCH 2 abl-20230630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - COVER link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED CONSOLIDATE BALANCE SHEETS (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000007 - Statement - Abacus Settlements LLC - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME link:presentationLink link:calculationLink link:definitionLink 0000008 - Statement - Abacus Settlements LLC - UNAUDITED CONDENSED STATEMENTS OF CHANGES IN MEMBERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000009 - Statement - Abacus Settlements LLC - UNAUDITED INTERIM CONDENSED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - DESCRIPTION OF BUSINESS link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - BUSINESS COMBINATION link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - PROPERTY AND EQUIPMENT—NET link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - CONSOLIDATION OF VARIABLE INTEREST ENTITIES link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - SEGMENT REPORTING link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - LONG-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - SHAREHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - EMPLOYEE BENEFIT PLAN link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - EARNINGS PER SHARE link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Abacus Settlements LLC - DESCRIPTION OF THE BUSINESS link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Abacus Settlements LLC - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 0000032 - Disclosure - Abacus Settlements LLC - SEGMENT REPORTING link:presentationLink link:calculationLink link:definitionLink 0000033 - Disclosure - Abacus Settlements LLC - REVENUE link:presentationLink link:calculationLink link:definitionLink 0000034 - Disclosure - Abacus Settlements LLC - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 0000035 - Disclosure - Abacus Settlements LLC - RETIREMENT PLAN link:presentationLink link:calculationLink link:definitionLink 0000036 - Disclosure - Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 0000037 - Disclosure - Abacus Settlements LLC - SUBSEQUENT EVENT link:presentationLink link:calculationLink link:definitionLink 9954701 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 9954702 - Disclosure - BUSINESS COMBINATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954703 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954704 - Disclosure - PROPERTY AND EQUIPMENT—NET (Tables) link:presentationLink link:calculationLink link:definitionLink 9954705 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954706 - Disclosure - SEGMENT REPORTING (Tables) link:presentationLink link:calculationLink link:definitionLink 9954707 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954708 - Disclosure - LONG-TERM DEBT (Tables) link:presentationLink link:calculationLink link:definitionLink 9954709 - Disclosure - LEASES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954710 - Disclosure - EARNINGS PER SHARE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954711 - Disclosure - Abacus Settlements LLC - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954712 - Disclosure - Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954713 - Disclosure - DESCRIPTION OF BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 9954714 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Consolidation of Variable Interest Entities (Details) link:presentationLink link:calculationLink link:definitionLink 9954715 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentrations (Details) link:presentationLink link:calculationLink link:definitionLink 9954716 - Disclosure - BUSINESS COMBINATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954717 - Disclosure - BUSINESS COMBINATION - Purchase Price Allocation (Details) link:presentationLink link:calculationLink link:definitionLink 9954718 - Disclosure - BUSINESS COMBINATION - Value Conveyed (Details) link:presentationLink link:calculationLink link:definitionLink 9954719 - Disclosure - BUSINESS COMBINATION - Intangible Assets Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 9954720 - Disclosure - BUSINESS COMBINATION - Pro Forma Financial Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954721 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954722 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES - Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 9954723 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES - Investment Method (Details) link:presentationLink link:calculationLink link:definitionLink 9954724 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES - Estimated Premiums (Details) link:presentationLink link:calculationLink link:definitionLink 9954725 - Disclosure - PROPERTY AND EQUIPMENT—NET (Details) link:presentationLink link:calculationLink link:definitionLink 9954726 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Changes in Goodwill by Reportable Segments (Details) link:presentationLink link:calculationLink link:definitionLink 9954727 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Intangible Assets Acquired (Details) link:presentationLink link:calculationLink link:definitionLink 9954728 - Disclosure - AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE (Details) link:presentationLink link:calculationLink link:definitionLink 9954729 - Disclosure - OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS (Details) link:presentationLink link:calculationLink link:definitionLink 9954730 - Disclosure - CONSOLIDATION OF VARIABLE INTEREST ENTITIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954731 - Disclosure - SEGMENT REPORTING - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954732 - Disclosure - SEGMENT REPORTING - Revenue by Segment (Details) link:presentationLink link:calculationLink link:definitionLink 9954733 - Disclosure - SEGMENT REPORTING - Reconciliation of Net Income (Details) link:presentationLink link:calculationLink link:definitionLink 9954734 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954735 - Disclosure - FAIR VALUE MEASUREMENTS - Recurring Fair Value Measurements (Details) link:presentationLink link:calculationLink link:definitionLink 9954736 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954737 - Disclosure - FAIR VALUE MEASUREMENTS - Discount Rate Sensitivity (Details) link:presentationLink link:calculationLink link:definitionLink 9954738 - Disclosure - FAIR VALUE MEASUREMENTS - Credit Exposure to Insurance Companies (Details) link:presentationLink link:calculationLink link:definitionLink 9954739 - Disclosure - FAIR VALUE MEASUREMENTS - Life Insurance Policies (Details) link:presentationLink link:calculationLink link:definitionLink 9954740 - Disclosure - FAIR VALUE MEASUREMENTS - Issued Notes (Details) link:presentationLink link:calculationLink link:definitionLink 9954741 - Disclosure - FAIR VALUE MEASUREMENTS - Assumptions (Details) link:presentationLink link:calculationLink link:definitionLink 9954742 - Disclosure - LONG-TERM DEBT - Long-Term Debt (Details) link:presentationLink link:calculationLink link:definitionLink 9954743 - Disclosure - LONG-TERM DEBT - Sponsor PIK Note (Details) link:presentationLink link:calculationLink link:definitionLink 9954744 - Disclosure - LONG-TERM DEBT - LMATT Series 2024, Inc. Market-Indexed Notes (Details) link:presentationLink link:calculationLink link:definitionLink 9954745 - Disclosure - LONG-TERM DEBT - LMATT Series 2.2024, Inc. Market-Indexed Notes (Details) link:presentationLink link:calculationLink link:definitionLink 9954746 - Disclosure - LONG-TERM DEBT - LMATT Growth and Income Series 1.2026, Inc. Market-Indexed Notes (Details) link:presentationLink link:calculationLink link:definitionLink 9954747 - Disclosure - LONG-TERM DEBT - LMA Income Series, LP and LMA Income Series, GP LLC Secured Borrowing (Details) link:presentationLink link:calculationLink link:definitionLink 9954748 - Disclosure - LONG-TERM DEBT - LMA Income Series II, LP and LMA Income Series II, GP LLC Secured Borrowing (Details) link:presentationLink link:calculationLink link:definitionLink 9954749 - Disclosure - LONG-TERM DEBT - SPV Purchase and Sale and SPV Investment Facility (Details) link:presentationLink link:calculationLink link:definitionLink 9954750 - Disclosure - SHAREHOLDERS' EQUITY (Details) link:presentationLink link:calculationLink link:definitionLink 9954751 - Disclosure - EMPLOYEE BENEFIT PLAN (Details) link:presentationLink link:calculationLink link:definitionLink 9954752 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 9954753 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) link:presentationLink link:calculationLink link:definitionLink 9954754 - Disclosure - LEASES - ROU Assets and Lease Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954755 - Disclosure - LEASES - Lease Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954756 - Disclosure - LEASES - Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954757 - Disclosure - LEASES - Lease Terms and Discount Rates (Details) link:presentationLink link:calculationLink link:definitionLink 9954758 - Disclosure - LEASES - Future Minimum Noncancellable Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954758 - Disclosure - LEASES - Future Minimum Noncancellable Lease Payments (Details) link:presentationLink link:calculationLink link:definitionLink 9954759 - Disclosure - EARNINGS PER SHARE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954760 - Disclosure - EARNINGS PER SHARE - Basic and Diluted (Details) link:presentationLink link:calculationLink link:definitionLink 9954761 - Disclosure - SUBSEQUENT EVENTS (Details) link:presentationLink link:calculationLink link:definitionLink 9954762 - Disclosure - Abacus Settlements LLC - DESCRIPTION OF THE BUSINESS (Details) link:presentationLink link:calculationLink link:definitionLink 9954763 - Disclosure - Abacus Settlements LLC - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954764 - Disclosure - Abacus Settlements LLC - SEGMENT REPORTING (Details) link:presentationLink link:calculationLink link:definitionLink 9954765 - Disclosure - Abacus Settlements LLC - REVENUE (Details) link:presentationLink link:calculationLink link:definitionLink 9954766 - Disclosure - Abacus Settlements LLC - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 9954767 - Disclosure - Abacus Settlements LLC - RETIREMENT PLAN (Details) link:presentationLink link:calculationLink link:definitionLink 9954768 - Disclosure - Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954769 - Disclosure - Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS - Revenue Earned and Contracts Originated (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 3 abl-20230630_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 4 abl-20230630_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 abl-20230630_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Consolidated Entities [Axis] Consolidated Entities [Axis] Variable Rate [Domain] Variable Rate [Domain] LESS: NET INCOME (LOSS) ATTRIBUTABLE TO NONCONTROLLING INTEREST Less: Net loss attributable to non-controlling interests Net Income (Loss) Attributable to Noncontrolling Interest Accrued expenses Accrued Liabilities, Current Statistical Measurement [Domain] Statistical Measurement [Domain] Common stock price threshold for redemption for common stock (in dollars per share) Class Of Warrant Or Right, Redemption For Common Stock, Price Per Share Threshold Class Of Warrant Or Right, Redemption For Common Stock, Price Per Share Threshold Debt issued to third parties Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Matured/sold policies Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales Life settlement policies, at cost Carrying Value Life Settlement Contracts, Investment Method, Carrying Amount Nova Funds Nova Trading (US), LLC And Nova Holding (US) LP [Member] Nova Trading (US), LLC And Nova Holding (US) LP Statement of Stockholders' Equity [Abstract] 3-4 Life Settlement Contract, Fair Value Method, Number of Contracts, Maturity, Year Three Purchase price allocation Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block] Total policies Life Settlement Contracts, Number Of Contracts Originated Life Settlement Contracts, Number Of Contracts Originated Investments, Debt and Equity Securities [Abstract] Variable Interest Entity, Primary Beneficiary Variable Interest Entity, Primary Beneficiary [Member] Life Settlement Commission Expense Benchmark Life Settlement Commission Expense Benchmark [Member] Life Settlement Commission Expense Benchmark American General Life Insurance Company American General Life Insurance Company [Member] American General Life Insurance Company Mandatory prepayment percentage Debt Instrument, Covenant, Mandatory Prepayment Percentage Debt Instrument, Covenant, Mandatory Prepayment Percentage Deferred tax liability Deferred Income Tax Liabilities, Net Segment Reporting [Abstract] Accounts payable Accounts Payable, Current Aggregate consideration election Business Combination, Aggregate Consideration Receivable Election Business Combination, Aggregate Consideration Receivable Election Computer equipment Computer Equipment [Member] Price per warrant (in dollars per share) Class Of Warrant Or Right, Price Per Warrant Class Of Warrant Or Right, Price Per Warrant Fair value at beginning of period Fair value at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value ROU Assets and Lease Liabilities Assets And Liabilities, Lessee [Table Text Block] Assets And Liabilities, Lessee Total other income (expense) Nonoperating Income (Expense) Accrued Expenses Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Interest rate per annum Debt Securities, Available-for-Sale, Weighted Average Yield Policies Life Settlement Contracts, Fair Value Method, Number of Contracts, Fiscal Year Maturity [Abstract] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Option agreement, number of providers Number Of Providers Involved In Option Agreement Number Of Providers Involved In Option Agreement Public Warrants Public Warrants [Member] Public Warrants Active management Active Management Segment [Member] Active Management Segment SHAREHOLDERS' EQUITY Equity [Text Block] General Partner General Partner [Member] Other noncurrent assets Increase (Decrease) in Other Noncurrent Assets Schedule of Goodwill [Table] Schedule of Goodwill [Table] Ownership percentage Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage Warrants Warrants [Policy Text Block] Warrants Provider Two Provider Two [Member] Provider Two INCOME TAXES Income Tax Disclosure [Text Block] Contract liability—deposits on pending settlements Increase (Decrease) in Contract with Customer, Liability Variable Interest Entity [Line Items] Variable Interest Entity [Line Items] Ownership [Axis] Ownership [Axis] Merger with East Resources Acquisition Company (in shares) Stock Issued During Period, Shares, Reverse Recapitalization Stock Issued During Period, Shares, Reverse Recapitalization Broker Broker [Member] Broker Concentration Risk [Line Items] Concentration Risk [Line Items] Debt Instrument extension options Debt Instrument, Extension Options Debt Instrument, Extension Options Gain on change in fair value of debt, included within other comprehensive income Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) Customer [Axis] Customer [Axis] CURRENT LIABILITIES: Liabilities, Current [Abstract] LMATT Income Series, LP LMATT Income Series, LP [Member] LMATT Income Series, LP Broker Axis [Domain] Broker Axis [Domain] Broker Axis [Domain] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Business Acquisition [Line Items] Business Acquisition [Line Items] Subsequent Event Type [Domain] Subsequent Event Type [Domain] CASH AND CASH EQUIVALENTS: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect [Abstract] Capital Commitment Threshold One Capital Commitment Threshold One [Member] Capital Commitment Threshold One Diluted net income per share (in dollars per share) Diluted earnings per unit (in dollars per share) Earnings Per Share, Diluted Unrealized loss (gain) on investments Unrealized (gain) loss on investments Unrealized gain (loss) on investments Unrealized Gain (Loss) on Investments Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Units purchased (in shares) Equity Securities Without Readily Determinable Fair Value, Number Of Securities Purchased Equity Securities Without Readily Determinable Fair Value, Number Of Securities Purchased ERES Class A Common Stock ERES Class A Common Stock [Member] ERES Class A Common Stock Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Goodwill [Roll Forward] Goodwill [Roll Forward] Share price (in dollars per share) Business Acquisition, Share Price Net internal rate of return at cap Debt Instrument, Net Internal Rate Of Return At Cap Debt Instrument, Net Internal Rate Of Return At Cap Sponsor PIK Note Sponsor PIK Note [Member] Sponsor PIK Note Level 3 Fair Value, Inputs, Level 3 [Member] Line of Credit Line of Credit [Member] LMATT Series 2024, Inc. LMATT Series 2024, Inc. [Member] LMATT Series 2024, Inc. 3-4 Life Settlement Contract, Fair Value Method, Face Value, Maturity, Year Three Variable Rate Component Three Variable Rate Component Three [Member] Variable Rate Component Three Trading Symbol Trading Symbol Non-Compete Agreements Noncompete Agreements [Member] 4-5 Life Settlement Contract, Investment Method, Amount, Maturity, Year Four Market approach Valuation, Market Approach [Member] Long-term debt Long-term debt, fair value Long-Term Debt, Fair Value NET INCOME ATTRIBUTABLE TO SHAREHOLDERS Net income (loss) Net income attributable to Longevity Market Assets Net Income (Loss) Origination fee revenue Origination Fee [Member] Origination Fee Redemption price per warrant (in dollars per share) Class Of Warrant Or Right, Redemption Price Per Warrant Class Of Warrant Or Right, Redemption Price Per Warrant Total current liabilities Liabilities, Current Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member] Fair Value Disclosures [Abstract] Distributions to members Payments of Distributions to Affiliates Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-Lived Intangible Assets, Major Class Name [Domain] LEASES Lessee, Operating Leases [Text Block] Customer Relationships - Financial Relationships Customer Relationships, Financial Relationships [Member] Customer Relationships, Financial Relationships COST OF REVENUES (excluding depreciation stated below) Cost of Revenue [Abstract] Number of monthly payments Number Of Monthly Payments To Acquire Equity Securities Without Readily Determinable Fair Value Number Of Monthly Payments To Acquire Equity Securities Without Readily Determinable Fair Value LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Liabilities and Equity [Abstract] Entity Ex Transition Period Entity Ex Transition Period Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Impairment of investments Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Other Receivables Receivable [Policy Text Block] Income Tax Contingency [Table] Income Tax Contingency [Table] Useful Life Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life Schedule of Indefinite-Lived Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Other Commitments [Table] Other Commitments [Table] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Significant Accounting Policies [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Cost Reported Value Measurement [Member] 2-3 Life Settlement Contract, Fair Value Method, Face Value, Maturity, Year Two Dividend percentage Debt Instrument, Dividend Feature Percentage Debt Instrument, Dividend Feature Percentage Public warrants Adjustments to Additional Paid in Capital, Warrant Issued Goodwill Goodwill at beginning of period Goodwill at end of period Goodwill Summary of Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Equity Components [Axis] Equity Components [Axis] Exercise price of warrants (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Financial Instruments [Domain] Financial Instruments [Domain] Capital Commitment Threshold Three Capital Commitment Threshold Three [Member] Capital Commitment Threshold Three Accrued transaction costs Accrued payroll and other expenses Increase (Decrease) in Accrued Liabilities Life settlement policies, fair value, impact of +2% discount rate adjustment Sensitivity Analysis Of Fair Value, Life Settlement Contracts Fair Value, Impact Of 2 Percent Positive Change In Discount Rate Sensitivity Analysis Of Fair Value, Life Settlement Contracts Fair Value, Impact Of 2 Percent Positive Change In Discount Rate Measurement Basis [Axis] Measurement Basis [Axis] Due to members Payments Due To Members Payments Due To Members Summary of Revenue by Segment Reconciliation of Revenue from Segments to Consolidated [Table Text Block] Customer 1 Customer 1 [Member] Customer 1 Entity Small Business Entity Small Business Local Phone Number Local Phone Number Accounts receivable Increase (Decrease) in Accounts Receivable Fair Value Measurement [Domain] Fair Value Measurement [Domain] Abacus Settlements, LLC Subsidiaries [Member] Number of life settlement policies accounted for under investment method Number of Life Insurance Policies Life Settlement Contracts, Investment Method, Number of Contracts Accounts Receivable Accounts Receivable [Member] Measurement Frequency [Axis] Measurement Frequency [Axis] Long-term debt, at fair value Other Long-Term Debt, Noncurrent Warrant Warrant [Member] Maximum securities related activities percentage of aggregate gross revenues Debt Instrument, Covenant, Securities Percentage Of Gross Revenue, Maximum Debt Instrument, Covenant, Securities Percentage Of Gross Revenue, Maximum Operating lease liabilities - noncurrent portion Operating lease liability, non-current Operating Lease, Liability, Noncurrent Net income before provision for income taxes Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax Class of Warrant or Right [Table] Class of Warrant or Right [Table] Debt instrument term Debt Instrument, Term Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Fair Value Measurement Inputs and Valuation Techniques [Table] Fair Value Measurement Inputs and Valuation Techniques [Table] Depreciation expense Depreciation Depreciation Retirement Benefits [Abstract] 3-4 Life Settlement Contract, Fair Value, Maturity, Year Three Conversion of Stock [Line Items] Conversion of Stock [Line Items] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Portion at Fair Value Measurement Portion at Fair Value Measurement [Member] Variable Rate Component One Variable Rate Component One [Member] Variable Rate Component One Asset Pledged as Collateral Asset Pledged as Collateral [Member] Future Minimum Noncancellable Lease Payments Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Value conveyed Schedule of Business Acquisitions, by Acquisition [Table Text Block] Capital commitment threshold to determine dividend rate Debt Instrument, Capital Commitment Thresholds To Determine Dividends Debt Instrument, Capital Commitment Thresholds To Determine Dividends Defined Contribution Plan [Table] Defined Contribution Plan [Table] Pledged Status [Axis] Pledged Status [Axis] Consolidation of Variable Interest Entities Consolidation, Variable Interest Entity, Policy [Policy Text Block] Total revenues Revenues Income taxes payable Accrued Income Taxes, Current Risk-free interest rate Measurement Input, Risk Free Interest Rate [Member] Life Insurance Settlement Policies Life Settlement Contracts, Policy [Policy Text Block] Origination revenue percent Life Settlement Contract, Origination Revenue, Percent Life Settlement Contract, Origination Revenue, Percent Product and Service [Domain] Product and Service [Domain] Lease Expense Lease, Cost [Table Text Block] CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Loss on change in fair value of debt Loss on change in fair value of debt Unrealized loss on change in fair value (risk-free) Fair Value, Option, Changes in Fair Value, Gain (Loss) Monthly payment amount Monthly Payments To Acquire, Equity Securities Without Readily Determinable Fair Value Monthly Payments To Acquire, Equity Securities Without Readily Determinable Fair Value Antidilutive securities (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount RIS Regional Investment Services, Inc [Member] Regional Investment Services, Inc 4-5 Life Settlement Contract, Fair Value Method, Face Value, Maturity, Year Four Document Quarterly Report Document Quarterly Report Market downturn protection percentage Debt Instrument, Maximum Market Downturn Protection Percentage Debt Instrument, Maximum Market Downturn Protection Percentage Trading day period Class Of Warrant Or Right, Redemption, Trading Day Period Class Of Warrant Or Right, Redemption, Trading Day Period Private Placement Warrant Private Placement Warrant [Member] Private Placement Warrant Interest (expense) Interest (expense) Interest Expense Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] 0-1 Life Settlement Contract, Investment Method, Number of Contracts, Maturity, Remainder of Fiscal Year Market-indexed notes Notes Payable, Other Payables [Member] Goodwill [Line Items] Goodwill [Line Items] Property and equipment—gross Property, Plant and Equipment, Gross ROU assets obtained in exchange for new lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability RELATED-PARTY TRANSACTIONS Related Party Transactions Disclosure [Text Block] Less: Imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Use of Estimates Use of Estimates, Policy [Policy Text Block] Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] 2-3 Life Settlement Contract, Fair Value Method, Number of Contracts, Maturity, Year Two Life settlement policies, change in fair value, impact of +2% discount rate adjustment Sensitivity Analysis Of Fair Value, Change In Life Settlement Contracts Fair Value, Impact Of 2 Percent Positive Change In Discount Rate Sensitivity Analysis Of Fair Value, Change In Life Settlement Contracts Fair Value, Impact Of 2 Percent Positive Change In Discount Rate Entity File Number Entity File Number Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Liquid asset minimum coverage ratio Debt Instrument, Covenant, Liquid Asset Coverage Ratio, Minimum Debt Instrument, Covenant, Liquid Asset Coverage Ratio, Minimum Discount rate Measurement Input, Discount Rate [Member] Total active management revenue Insurance Services Revenue Operating lease liabilities - current portion Operating lease liability, current Operating Lease, Liability, Current Number of unaffiliated investors Number Of Unaffiliated Investors Involved In Variable Interest Entity Ownership Number of Unaffiliated Investors Entity Shell Company Entity Shell Company 2026 Lessee, Operating Lease, Liability, to be Paid, Year Three 1-2 Life Settlement Contract, Investment Method, Amount, Maturity, Year One Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Prepaid expenses Increase (Decrease) in Prepaid Expense Counterparty Name [Domain] Counterparty Name [Domain] CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Asset Class [Axis] Asset Class [Axis] 2025 Lessee, Operating Lease, Liability, to be Paid, Year Two Warrant redemption notice period Class Of Warrant Or Right, Redemption Notice Period Class Of Warrant Or Right, Redemption Notice Period Term to expiration Measurement Input, Expected Term [Member] Interest income Interest earned on marketable securities held in Trust Account Investment Income, Interest Variable lease cost Variable Lease, Cost Operating lease cost Operating Lease, Cost Longevity Market Advisors Longevity Market Advisors, LLC [Member] Longevity Market Advisors, LLC WEIGHTED-AVERAGE UNITS USED IN COMPUTING NET INCOME (LOSS) PER UNIT: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Consideration paid to acquire business Consideration Business Combination, Consideration Transferred Gross Profit Total gross profit Gross Profit Contract liabilities - deposits on pending settlements Contract with Customer, Liability, Current Security Exchange Name Security Exchange Name Total assets held at fair value Assets, Fair Value Disclosure Accumulated other comprehensive income Accumulated Other Comprehensive Income (Loss), Net of Tax Aggregate transaction proceeds threshold Business Combination, Aggregate Transaction Proceeds Threshold Business Combination, Aggregate Transaction Proceeds Threshold Employer match (as a percent) Defined Contribution Plan, Employer Matching Contribution, Percent of Match Class A Common Stock Common Class A [Member] Total Life Settlement Contracts, Investment Method, Premiums to be Paid Maximum Maximum [Member] Comprehensive income attributable to Abacus Life Inc. Comprehensive Income (Loss), Net of Tax, Attributable to Parent Document Type Document Type Schedule of Related Party Transactions Schedule of Related Party Transactions [Table Text Block] Additions Goodwill, Acquired During Period Measurement input Business Combination, Measurement Input Business Combination, Measurement Input Marger/Acquisition Stock Issued During Period, Value, Acquisitions LMATT Series 2.2024, Inc. LMATT Series 2.2024, Inc. [Member] LMATT Series 2.2024, Inc. Entity Address, Address Line One Entity Address, Address Line One Abacus Abacus Settlements, LLC Abacus Settlements LLC [Member] Abacus Settlements LLC Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Subsequent Event [Table] Subsequent Event [Table] Ownership percentage Subsidiary, Ownership Percentage, Parent Basis of Presentation and Unaudited Condensed Consolidated Financial Statements Basis of Accounting, Policy [Policy Text Block] Common Stock Price Measurement Input, Share Price [Member] Purchase of investments Purchase of convertible promissory note Payments to Acquire Debt Securities, Available-for-Sale Business Acquisition [Axis] Business Acquisition [Axis] Gain on change in fair value of debt, included within equity of noncontrolling interests Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included In Equity, Attributable To Noncontrolling Interest Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included In Equity, Attributable To Noncontrolling Interest Allowance for doubtful accounts Accounts Receivable, Allowance for Credit Loss, Current Related party transaction rate Related Party Transaction, Rate Subsequent Event Subsequent Event [Member] Life Insurance Carrier [Axis] Life Insurance Carrier [Axis] Life Insurance Carrier Customer Concentration Risk Customer Concentration Risk [Member] Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Other current liabilities Other Liabilities, Current Variable Rate [Axis] Variable Rate [Axis] Income Statement [Abstract] Return rate in excess of minimum internal rate of return Debt Instrument, Return Rate In Excess Of Minimum Internal Rate Of Return Threshold Debt Instrument, Return Rate In Excess Of Minimum Internal Rate Of Return Threshold Active management Net Investment Income Title of 12(b) Security Title of 12(b) Security Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Thereafter Life Settlement Contract, Investment Method, Number Of Contracts, Maturity, After Year Four Life Settlement Contract, Investment Method, Number Of Contracts, Maturity, After Year Four Related Party, Type [Domain] Related Party, Type [Domain] Number of securities called by each warrant (in shares) Class of Warrant or Right, Number of Securities Called by Each Warrant or Right Owners Owners [Member] Owners Two Brokers Two Brokers [Member] Two Brokers LMATT Income Series II, LP LMATT Income Series II, LP [Member] LMATT Income Series II, LP Proforma net income Business Acquisition, Pro Forma Net Income (Loss) Realized gain (loss) on matured/sold policies Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Realized Gain (Loss) Included in Earnings Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Realized Gain (Loss) Included In Earnings Thereafter Life Settlement Contract, Fair Value Method, Face Value, Maturity, After Year Four Life Settlement Contract, Fair Value Method, Face Value, Maturity, After Year Four Income Tax Disclosure [Abstract] 2025 Life Settlement Contract, Investment Method, Premium to be Paid, Year Two Number of life settlement policies Life Settlement Contracts, Number Of Contracts Life Settlement Contracts, Number Of Contracts Entity Tax Identification Number Entity Tax Identification Number Other Commitments [Domain] Other Commitments [Domain] Equity financing threshold Debt Securities, Available-For-Sale, Equity Financing Threshold In Which Shares Convert Debt Securities, Available-For-Sale, Equity Financing Threshold In Which Shares Convert Total lease cost Lease, Cost Statistical Measurement [Axis] Statistical Measurement [Axis] Other current assets Increase (Decrease) in Other Current Assets Financial Instrument [Axis] Financial Instrument [Axis] 1-2 Life Settlement Contract, Fair Value Method, Face Value, Maturity, Year One Noncontrolling Interest Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block] Entity Interactive Data Current Entity Interactive Data Current Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] LONG-TERM DEBT Long-Term Debt [Text Block] Non-Current Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets Advertising Advertising Cost [Policy Text Block] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding BUSINESS COMBINATION Mergers, Acquisitions and Dispositions Disclosures [Text Block] Origination revenue Life Settlement Contract, Origination Revenue Life Settlement Contract, Origination Revenue Segments [Domain] Segments [Domain] Enterprise value Business Combination, Enterprise Value Business Combination, Enterprise Value Variable Interest Entity, Not Primary Beneficiary Variable Interest Entity, Not Primary Beneficiary [Member] Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Certificate of deposit Certificates Of Deposit, Noncurrent Certificates Of Deposit, Noncurrent Retained earnings/(accumulated deficit) Retained Earnings (Accumulated Deficit) Commitments and Contingencies Disclosure [Abstract] Cost of Revenues Revenue from Contract with Customer [Policy Text Block] Face amount Debt Instrument, Face Amount Investment Method Revenue Benchmark Investment Method Revenue Benchmark [Member] Investment Method Revenue Benchmark Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code CURRENT ASSETS: Assets, Current [Abstract] Average Age Life Settlement Contracts, Average Age Life Settlement Contracts, Average Age Assets: Operating Lease, Asset [Abstract] Operating Lease, Asset Leases [Abstract] Advertising expense Advertising Expense Other Commitments [Line Items] Other Commitments [Line Items] Entity Address, State or Province Entity Address, State or Province Counterparty Name [Axis] Counterparty Name [Axis] Schedule of Carrying Values and Estimated Fair Values of Debt Instruments Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block] CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Schedule of Related Party Transactions, by Related Party [Table] Schedule of Related Party Transactions, by Related Party [Table] Class of Warrant or Right [Domain] Class of Warrant or Right [Domain] Operating cash flows from operating leases Operating Lease, Payments Common stock, shares outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Common Stock, Shares, Outstanding Maximum leverage ratio Debt Instrument, Covenant, Leverage Ratio, Maximum Debt Instrument, Covenant, Leverage Ratio, Maximum Additional borrowing capacity availability period Line of Credit Facility, Remaining Borrowing Capacity, Term Line of Credit Facility, Remaining Borrowing Capacity, Term Distributions Distributions Dividends Internally Developed and Used Technology—Market Place Market Place Technology [Member] Market Place Technology Premiums paid Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Premiums Paid Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Premiums Paid Subsidiary of Limited Liability Company or Limited Partnership [Line Items] Subsidiary of Limited Liability Company or Limited Partnership [Line Items] Concentrations Concentration Risk, Credit Risk, Policy [Policy Text Block] RETIREMENT PLAN Retirement Benefits [Text Block] Asset Class [Domain] Asset Class [Domain] Defined Contribution Plan Disclosure [Line Items] Defined Contribution Plan Disclosure [Line Items] Schedule of Variable Interest Entities [Table] Schedule of Variable Interest Entities [Table] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Maximum annual contributions (as a percent) Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Class of Stock [Domain] Class of Stock [Domain] Customer [Domain] Customer [Domain] Debt Instrument [Axis] Debt Instrument [Axis] Effective tax rate percentage Effective Income Tax Rate Reconciliation, Percent Current Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets Total lease liability Lease liability as of June 30, 2023 Operating Lease, Liability Measurement Input Type [Domain] Measurement Input Type [Domain] Credit Facility [Axis] Credit Facility [Axis] TOTAL LIABILITIES Liabilities Liabilities Variable Rate Component [Domain] Variable Rate Component [Domain] Variable Rate Component [Domain] Return Rate in excess of capped internal rate of return threshold Debt Instrument, Return Rate In Excess Of Capped Internal Rate Of Return Threshold Debt Instrument, Return Rate In Excess Of Capped Internal Rate Of Return Threshold Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Accumulated Other Comprehensive Income AOCI Attributable to Parent [Member] 2-3 Life Settlement Contract, Investment Method, Face Value, Maturity, Year Two Benefit plan expense Defined Contribution Plan, Cost Measurement Frequency [Domain] Measurement Frequency [Domain] PROPERTY AND EQUIPMENT—NET Property, Plant and Equipment Disclosure [Text Block] Warrant price adjustment percentage Class Of Warrant Or Right, Issuance Of Common Stock, Warrant Price Adjustment Percentage Class Of Warrant Or Right, Issuance Of Common Stock, Warrant Price Adjustment Percentage Debt Disclosure [Abstract] Broker Concentration Risk Broker Concentration Risk [Member] Broker Concentration Risk Related Party Transaction [Domain] Related Party Transaction [Domain] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Number of reportable segments Number of Reportable Segments 0-1 Life Settlement Contract, Investment Method, Amount, Maturity, Remainder of Fiscal Year 4-5 Life Settlement Contract, Fair Value Method, Number of Contracts, Maturity, Year Four LMA and Abacus Longevity Market Assets, LLC And Abacus Settlements LLC [Member] Longevity Market Assets, LLC And Abacus Settlements LLC Default rate Debt Instrument, Default Rate Debt Instrument, Default Rate Due to/from members and affiliates Payments for (Proceeds from) Businesses and Interest in Affiliates EARNINGS PER SHARE: NET INCOME/(LOSS) PER UNIT: Earnings Per Share [Abstract] Subsequent Event [Line Items] Subsequent Event [Line Items] 2-3 Life Settlement Contract, Investment Method, Number of Contracts, Maturity, Year Two Sales and marketing Sales and marketing Selling and Marketing Expense Class A common stock, $0.0001 par value; 200,000,000 authorized shares; 62,961,688 and 50,369,350 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively Common Stock, Value, Issued Affiliated Entity Affiliated Entity [Member] General and administrative expenses General, administrative and other General and Administrative Expense Note reduction ratio for losses below threshold Debt Instrument, Note Reduction Ratio For Losses Below Threshold Debt Instrument, Note Reduction Ratio For Losses Below Threshold Organization, Consolidation and Presentation of Financial Statements [Abstract] Trade Name Trade Names [Member] Non-cash lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Thereafter Lessee, Operating Lease, Liability, To Be Paid, Due After Year Four Lessee, Operating Lease, Liability, To Be Paid, Due After Year Four 3-4 Life Settlement Contract, Investment Method, Amount, Maturity, Year Three Redemption trigger price adjustment percentage Class Of Warrant Or Right, Issuance Of Common Stock, Redemption, Trigger Price Adjustment Percent Class Of Warrant Or Right, Issuance Of Common Stock, Redemption, Trigger Price Adjustment Percent Origination expenses for life settlement policies Cost Life Settlement Contracts, Origination Expense Life Settlement Contracts, Origination Expense Capital Commitment Threshold Two Capital Commitment Threshold Two [Member] Capital Commitment Threshold Two Total current assets Assets, Current Schedules of Concentration of Risk, by Risk Factor Schedules of Concentration of Risk, by Risk Factor [Table Text Block] Revenue from Contract with Customer [Abstract] Basis spread on variable rate, term Debt Instrument, Basis Spread on Variable Rate, Term Debt Instrument, Basis Spread on Variable Rate, Term 3-4 Life Settlement Contract, Investment Method, Number of Contracts, Maturity, Year Three Amortization expense Amortization Other income (expense) Other (expense) income Other Nonoperating Income (Expense) Entity Filer Category Entity Filer Category Proceeds from Issuance of Secured Debt Proceeds from Issuance of Secured Debt Carrying Value Life Settlement Contracts, Investment Method, Carrying Amount, Fiscal Year Maturity [Abstract] Unrealized gain on policies Life Settlement Contracts, Fair Value Method, Unrealized Gain (Loss) Statement [Table] Statement [Table] SPV purchase and sale note Secured Long-Term Debt, Noncurrent Current Fiscal Year End Date Current Fiscal Year End Date Policy APA Policy APA [Member] Policy APA Limited Partner Limited Partner [Member] GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Contribution amount Variable Interest Entity, Financial or Other Support, Amount Provider One Provider One [Member] Provider One 1-2 Life Settlement Contract, Fair Value, Maturity, Year One Warrant outstanding fair value per share (in dollars per share) Warrants and Rights Outstanding, Fair Value Per Share Warrants and Rights Outstanding, Fair Value Per Share Dividend Yield Measurement Input, Expected Dividend Rate [Member] Concentration risk percentage Concentration Risk, Percentage Fair value at beginning of period Fair value at end of period Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value 0-1 Life Settlement Contract, Fair Value Method, Face Value, Maturity, Remainder of Fiscal Year Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Warrants outstanding (in shares) Class of Warrant or Right, Outstanding Life settlement policies, at fair value Fair Value Life settlement policies Life Settlement Contracts, Fair Value Base Rate Base Rate [Member] LMATT Growth & Income Series 1.2026, Inc LMATT Growth & Income Series 1.2026, Inc [Member] LMATT Growth & Income Series 1.2026, Inc Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] Schedule of Goodwill Schedule of Goodwill [Table Text Block] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Exchange ratio Business Acquisition, Exchange Ratio Business Acquisition, Exchange Ratio Warrants, common stock issuance threshold price (in dollars per share) Class Of Warrant Or Right, Common Stock Issuance Threshold Price Per Share Class Of Warrant Or Right, Common Stock Issuance Threshold Price Per Share Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Life settlement policies, change in fair value, impact of -2% discount rate adjustment Sensitivity Analysis Of Fair Value, Change In Life Settlement Contracts Fair Value, Impact Of 2 Percent Adverse Change In Discount Rate Sensitivity Analysis Of Fair Value, Change In Life Settlement Contracts Fair Value, Impact Of 2 Percent Adverse Change In Discount Rate Class of Stock [Axis] Class of Stock [Axis] Depreciation expense Depreciation, Depletion and Amortization DESCRIPTION OF BUSINESS DESCRIPTION OF THE BUSINESS Nature of Operations [Text Block] LMX LMX Series, LLC [Member] LMX Series, LLC Variable Rate Component [Axis] Variable Rate Component [Axis] Variable Rate Component Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items] Change in fair value of life insurance policies (policies held using fair value method) Decrease in valuation compared to third-party valuation Life Settlement Contracts, Fair Value Method, Gain (Loss) Furniture and fixtures Furniture and Fixtures [Member] Interest rate (as a percent) Debt Instrument, Interest Rate, Stated Percentage Statement of Financial Position [Abstract] Postemployment Benefits [Abstract] Business Combination and Asset Acquisition [Abstract] Face Value Life Settlement Contracts, Investment Method, Face Value, Fiscal Year Maturity [Abstract] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Proforma revenue Business Acquisition, Pro Forma Revenue Face value Life Settlement Contracts Originated, Value Life Settlement Contracts Originated, Value ReliaStar Life Insurance Company ReliaStar Life Insurance Company [Member] ReliaStar Life Insurance Company Fair Value Measurement Inputs and Valuation Techniques Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] Agent Agent [Member] Agent Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Concentration Risk Type [Axis] Concentration Risk Type [Axis] Life Insurance Carrier [Domain] Life Insurance Carrier [Domain] Life Insurance Carrier [Domain] Subsequent Events [Abstract] Other Liabilities Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Other Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Other CONSOLIDATION OF VARIABLE INTEREST ENTITIES Variable Interest Entity Disclosure [Text Block] Warrants and rights outstanding, measurement input Warrants and Rights Outstanding, Measurement Input Face value of policies held at fair value Face Value Life Settlement Contracts, Fair Value Method, Face Value Deferred Tax Liabilities Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities Number of votes per share Number Of Votes Per Common Share Number Of Votes Per Common Share Expense Support Agreement Expense Support Agreement [Member] Expense Support Agreement Purchase of intangible asset Payments to Acquire Intangible Assets Other investments Equity securities without readily determinable fair value, amount Equity Securities without Readily Determinable Fair Value, Amount Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table] Fair Value, Concentration of Risk [Table] Fair Value, Concentration of Risk [Table] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Depreciation Depreciation Depreciation, Depletion and Amortization, Nonproduction Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS Other Assets Disclosure [Text Block] Level 2 Fair Value, Inputs, Level 2 [Member] Schedule of Life Settlement Contracts, Fair Value Method Schedule of Life Settlement Contracts, Fair Value Method [Table Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Variable Rate Component Two Variable Rate Component Two [Member] Variable Rate Component Two Capital expenditures Payments to Acquire Productive Assets Life Settlement Policies purchased, at cost Life Settlement Contract Purchased, Investment Method Life Settlement Contract Purchased, Investment Method Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table] Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table] Intangible assets, net Intangible Assets, Net (Excluding Goodwill) Issuance of debt certificates Proceeds from Issuance of Other Long-Term Debt Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] 2023 remaining Life Settlement Contract, Investment Method, Premium to be Paid, Remainder of Fiscal Year Document Fiscal Period Focus Document Fiscal Period Focus Debt Instrument, Private Placement Offering, Capital Commitment Thresholds [Domain] Debt Instrument, Private Placement Offering, Capital Commitment Thresholds [Domain] Debt Instrument, Private Placement Offering, Capital Commitment Thresholds [Domain] 2024 Lessee, Operating Lease, Liability, to be Paid, Year One Useful Life Finite-Lived Intangible Asset, Useful Life 0-1 Life Settlement Contract, Fair Value Method, Number of Contracts, Maturity, Remainder of Fiscal Year Additional borrowing capacity Line of Credit Facility, Remaining Borrowing Capacity Antidilutive Securities [Axis] Antidilutive Securities [Axis] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Four Life settlement policies, fair value, impact of -2% discount rate adjustment Sensitivity Analysis Of Fair Value, Life Settlement Contracts Fair Value, Impact Of 2 Percent Adverse Change In Discount Rate Sensitivity Analysis Of Fair Value, Life Settlement Contracts Fair Value, Impact Of 2 Percent Adverse Change In Discount Rate Common Stock Common units Common Stock [Member] Expense Reimbursements Transaction reimbursement revenue Expense Reimbursements [Member] Expense Reimbursements Available for sale securities, at fair value Debt Securities, Available-for-Sale, Noncurrent City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Product and Service [Axis] Product and Service [Axis] EARNINGS PER SHARE Earnings Per Share [Text Block] Investments, All Other Investments [Abstract] Discounted cash flow method Valuation Technique, Discounted Cash Flow [Member] 1-2 Life Settlement Contract, Investment Method, Number of Contracts, Maturity, Year One Fair Value Measurements, Recurring and Nonrecurring Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Total shareholders' equity (deficit) Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Minimum Minimum [Member] Property and equipment, net Property and equipment—net Property, Plant and Equipment, Net Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Other Comprehensive Income Other Comprehensive Income (Loss), Net of Tax Statement of Cash Flows [Abstract] ASSETS Assets [Abstract] Accrued transaction costs Accrued Transaction Costs, Current Accrued Transaction Costs, Current Goodwill and Intangible Assets Disclosure [Abstract] SPV Investment Facility SPV Investment Facility [Member] SPV Investment Facility Exercise price Measurement Input, Exercise Price [Member] Total liabilities held at fair value: Liabilities, Fair Value Disclosure Nonrelated Party Nonrelated Party [Member] Schedule of Subsidiary of Limited Liability Company or Limited Partnership [Table] Schedule of Subsidiary of Limited Liability Company or Limited Partnership [Table] Amortization payment per quarter Debt Instrument, Amortization Payment, Percentage Per Quarter Debt Instrument, Amortization Payment, Percentage Per Quarter Warrants, business combination exercisable term Warrants and Rights Outstanding, Exercisable Term, Business Combination Warrants and Rights Outstanding, Exercisable Term, Business Combination NET INCOME NET INCOME Net Income Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Client direct Client Direct [Member] Client Direct COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Number of extensions Debt Instrument, Number Of Extensions Debt Instrument, Number Of Extensions Retained Earnings (Accumulated Deficit) Retained Earnings Retained Earnings [Member] Owl Rock Credit Facility Owl Rock Credit Facility [Member] Owl Rock Credit Facility TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) Liabilities and Equity OTHER INCOME (EXPENSE) Nonoperating Income (Expense) [Abstract] Other assets, at fair value Other Assets, Noncurrent Ownership [Domain] Ownership [Domain] Basic net income per share (in dollars per share) Basic earnings per unit (in dollars per share) Earnings Per Share, Basic Operating right-of-use assets Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Interest expense Interest Revenue (Expense), Net Thereafter Life Settlement Contract, Investment Method, Face Value, Maturity, After Year Four Life Settlement Contract, Investment Method, Face Value, Maturity, After Year Four Schedule of Long-Term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Accounting Policies [Abstract] Thereafter Life Settlement Contract, Fair Value Method, Number of Contracts, Maturity, After Year Four Life Settlement Contract, Fair Value Method, Number of Contracts, Maturity, After Year Four Warrants term Warrants and Rights Outstanding, Term Common stock price threshold (in dollars per share) Class Of Warrant Or Right, Redemption, Price Per Share Threshold Class Of Warrant Or Right, Redemption, Price Per Share Threshold Indefinite-Lived Intangible Assets [Line Items] Indefinite-Lived Intangible Assets [Line Items] 4-5 Life Settlement Contract, Investment Method, Face Value, Maturity, Year Four Remaining of 2023 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Customer Relationships - Agents Customer Relationship, Agents [Member] Customer Relationship, Agents State security deposit State Security Deposits, Noncurrent State Security Deposits, Noncurrent Entity Address, City or Town Entity Address, City or Town Summary of Segment Information Schedule of Segment Reporting Information, by Segment [Table Text Block] Related Party Related Party [Member] Portfolio servicing Portfolio Servicing Segment [Member] Portfolio Servicing Segment Unaudited Condensed Consolidated Financial Statements Consolidation, Policy [Policy Text Block] Lincoln National Life Insurance Company Lincoln National Life Insurance Company [Member] Lincoln National Life Insurance Company Warrant liability Private placement warrants Warrant Liabilities, Noncurrent Warrant Liabilities, Noncurrent LMA Longevity Market Assets, LLC [Member] Longevity Market Assets, LLC Equity ownership percentage Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage Document Transition Report Document Transition Report Unsecured borrowing Unsecured Debt [Member] Schedule of Business Acquisitions, by Acquisition [Table] Schedule of Business Acquisitions, by Acquisition [Table] Accounts payable Increase (Decrease) in Accounts Payable Common stock, shares authorized (in shares) Common Stock, Shares Authorized Available-for-sale securities, at fair value Debt Securities, Available-for-Sale Document Information [Table] Document Information [Table] Customer 2 Customer 2 [Member] Customer 2 Trading days Class Of Warrant Or Right, Redemption, Number Of Trading Days Class Of Warrant Or Right, Redemption, Number Of Trading Days Due to members and affiliates Proceeds from Contributions from Affiliates Indefinite-Lived Intangible Assets [Axis] Indefinite-Lived Intangible Assets [Axis] Property, Plant and Equipment [Abstract] Other assets Other Assets, Fair Value Disclosure Binomial Lattice Model Binomial Lattice Model [Member] Binomial Lattice Model Adjustments to reconcile net income to net cash provided by/(used in) operating activities: Adjustments to reconcile net income to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Related Party Transactions [Abstract] Measurement Input Type [Axis] Measurement Input Type [Axis] 2024 Life Settlement Contract, Investment Method, Premium to be Paid, Year One Debt Instrument, Private Placement Offering, Capital Commitment Thresholds [Axis] Debt Instrument, Private Placement Offering, Capital Commitment Thresholds [Axis] Debt Instrument, Private Placement Offering, Capital Commitment Thresholds Intangible assets acquired Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block] Unrealized gain on change in fair value (credit-adjusted) Fair Value, Option, Credit Risk, Gains (Losses) on Assets 1-2 Life Settlement Contract, Fair Value Method, Number of Contracts, Maturity, Year One Warrants, proposed offering exercisable term Warrants and Rights Outstanding, Exercisable Term, Proposed Offering Warrants and Rights Outstanding, Exercisable Term, Proposed Offering Comprehensive income (loss) attributable to non-controlling interests Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest Other Commitments [Axis] Other Commitments [Axis] Additional paid-in capital Additional Paid in Capital Internal rate of return cap Debt Instrument, Internal Rate Of Return Cap Debt Instrument, Internal Rate Of Return Threshold Cap S&P 500 options Derivative Asset Broker Axis [Axis] Broker Axis [Axis] Broker Axis 2026 Life Settlement Contract, Investment Method, Premium to be Paid, Year Three Deferred income taxes Deferred Income Tax Expense (Benefit) Document Information [Line Items] Document Information [Line Items] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Life Settlement Policies purchased, at fair value Life Settlement Contract Purchased, Fair Value Method Life Settlement Contract Purchased, Fair Value Method Due from members and affiliates Other Receivable, after Allowance for Credit Loss, Noncurrent Pledged Status [Domain] Pledged Status [Domain] Life settlement policies, measurement input Life Settlement Contracts, Measurement Input Life Settlement Contracts, Measurement Input Change in fair value of debt Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment, Attributable to Parent Prepayment premium prior to second anniversary Debt Instrument, Covenant, Prepayment Premium Prior To Second Anniversary Debt Instrument, Covenant, Prepayment Premium Prior To Second Anniversary Income Taxes Income Tax, Policy [Policy Text Block] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Insurance policies fair value Life Settlement Contracts, Special Purchase Vehicle, Fair Value Life Settlement Contracts, Special Purchase Vehicle, Fair Value Percent of employees gross pay (as a percent) Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay Fair Value, Concentration of Risk, Financial Statement Captions [Line Items] Fair Value, Concentration of Risk, Financial Statement Captions [Line Items] Unrealized gain(loss) on held policies Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Unrealized Gain (Loss) Included In Earnings Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Unrealized Gain (Loss) Included In Earnings 2-3 Life Settlement Contract, Investment Method, Amount, Maturity, Year Two Related Party, Type [Axis] Related Party, Type [Axis] Schedule of Segment Reporting Information, by Segment [Table] Schedule of Segment Reporting Information, by Segment [Table] Entity Registrant Name Entity Registrant Name Warrants outstanding Warrants and Rights Outstanding Other current liabilities Increase (Decrease) in Other Current Liabilities Non-controlling interest Equity, Attributable to Noncontrolling Interest Number of life settlement policies accounted for under fair value method Policies Life Settlement Contracts, Fair Value Method, Number of Contracts Document Period End Date Document Period End Date Partner Type of Partners' Capital Account, Name [Domain] Partner Type of Partners' Capital Account, Name [Domain] Life Insurance Carrier Concentration Risk Life Insurance Carrier Concentration Risk [Member] Life Insurance Carrier Concentration Risk Warrants, common stock issuance trading day period Class Of Warrant Or Right, Common Stock Issuance Trading Day Period Class Of Warrant Or Right, Common Stock Issuance Trading Day Period Less: accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Conversion of Stock [Table] Conversion of Stock [Table] Pro forma financial information Business Acquisition, Pro Forma Information [Table Text Block] Entity Central Index Key Entity Central Index Key Liabilities: Liabilities, Fair Value Disclosure [Abstract] Segment Reporting Information [Line Items] Segment Reporting Information [Line Items] Class of Warrant or Right [Axis] Class of Warrant or Right [Axis] Change in estimated fair value Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings Thereafter Life Settlement Contract, Investment Method, Premium To Be Paid, After Year Three Life Settlement Contract, Investment Method, Premium To Be Paid, After Year Three Provision for income taxes Provision for income taxes Provision for income taxes Income Tax Expense (Benefit) 0-1 Life Settlement Contract, Fair Value, Maturity, Remainder of Fiscal Year Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Number of operating segment Number of Operating Segments Revenue Benchmark Revenue Benchmark [Member] LIFE INSURANCE SETTLEMENT POLICIES Life Settlement Contracts, Disclosure [Text Block] Number of Life Insurance Policies Life Settlement Contracts, Investment Method, Number of Contracts, Fiscal Year Maturity [Abstract] Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Equity [Abstract] Weighted-average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Thereafter Life Settlement Contract, Fair Value, Maturity, After Year Four Life Settlement Contract, Fair Value, Maturity, After Year Four Total Fair Value Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net Total portfolio servicing revenue Origination revenue Portfolio servicing Revenue from Contract with Customer, Excluding Assessed Tax Other receivables Other Receivables, Net, Current Entity [Domain] Entity [Domain] Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Amendment Flag Amendment Flag Legal Entity [Axis] Legal Entity [Axis] Fair Value Life Settlement Contracts, Fair Value, Fiscal Year Maturity [Abstract] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent State Insurance Licenses Licensing Agreements [Member] Merger with East Resources Acquisition Company Stock Issued During Period, Value, Reverse Recapitalization Stock Issued During Period, Value, Reverse Recapitalization Comprehensive income Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest Face Value Life Settlement Contracts, Fair Value Method, Face Value, Fiscal Year Maturity [Abstract] Investment Income from life insurance policies held using investment method Insurance Investment Income Assets: Assets, Fair Value Disclosure [Abstract] Credit Facility [Domain] Credit Facility [Domain] Life Insurance Contract, Fair Value Life Settlement Contracts, Fair Value [Member] Life Settlement Contracts, Fair Value Number of entities, convertible preferred stock ownership Number Of Entities In Which Equity Securities Without Readily Determinable Fair Value Are Held Number Of Entities In Which Equity Securities Without Readily Determinable Fair Value Are Held Amortization payment percentage Debt Instrument, Amortization Payment, Percentage Debt Instrument, Amortization Payment, Percentage Basis spread on variable rate Debt Instrument, Basis Spread on Variable Rate Leasehold improvements Leasehold Improvements [Member] 4-5 Life Settlement Contract, Investment Method, Number of Contracts, Maturity, Year Four Diluted weighted average shares outstanding (in shares) Weighted-average shares used in computing net income per share, diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Intangibles Fair Value Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill Series Seed Preferred Units Series Seed Preferred Units [Member] Series Seed Preferred Units Prepayment premium after second anniversary Debt Instrument, Covenant, Prepayment Premium After Second Anniversary Debt Instrument, Covenant, Prepayment Premium After Second Anniversary OPERATING EXPENSES: Operating Expenses [Abstract] REVENUE Revenue from Contract with Customer [Text Block] 3-4 Life Settlement Contract, Investment Method, Face Value, Maturity, Year Three Additional Paid-In Capital Additional Paid-in Capital [Member] Life settlement policies sold Life Settlement Contracts, Number Of Contracts Sold Life Settlement Contracts, Number Of Contracts Sold TOTAL ASSETS Assets Assets Cover [Abstract] SUBSEQUENT EVENTS SUBSEQUENT EVENT Subsequent Events [Text Block] Amortization of deferred financing fees Amortization of Debt Issuance Costs Minimum internal rate of return threshold Debt Instrument, Minimum Internal Rate Of Return Debt Instrument, Minimum Internal Rate Of Return Threshold Upside performance participation cap Debt Instrument, Maximum Upside Performance Participation Percentage Debt Instrument, Maximum Upside Performance Participation Percentage Fair Value, Recurring Fair Value, Recurring [Member] EMPLOYEE BENEFIT PLAN Defined Contribution Plan [Text Block] Service Fee Agreement Service Fee Agreement [Member] Service Fee Agreement Deferred transaction costs Stockholders Equity, Deferred Transaction Costs Stockholders Equity, Deferred Transaction Costs Fair Value Measurement Inputs and Valuation Techniques [Line Items] Fair Value Measurement Inputs and Valuation Techniques [Line Items] Total operating lease payments (undiscounted) Lessee, Operating Lease, Liability, to be Paid Series B-1 Preferred Stock Series B-1 Preferred Stock [Member] Series B-1 Preferred Stock Income Tax Contingency [Line Items] Income Tax Contingency [Line Items] Liabilities: Operating Lease, Liability [Abstract] Policies purchased Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases Total operating expenses Operating Expenses SEGMENT REPORTING Segment Reporting Disclosure [Text Block] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] 2-3 Life Settlement Contract, Fair Value, Maturity, Year Two Secured borrowing Secured Debt [Member] 4-5 Life Settlement Contract, Fair Value, Maturity, Year Four Equity Component [Domain] Equity Component [Domain] Thereafter Life Settlement Contract, Investment Method, Amount, Maturity, After Year Four Life Settlement Contract, Investment Method, Amount, Maturity, After Year Four Debt Instrument [Line Items] Debt Instrument [Line Items] Basic weighted average shares outstanding (in shares) Weighted-average shares used in computing net income per share, basic (in shares) Weighted Average Number of Shares Outstanding, Basic Entity Current Reporting Status Entity Current Reporting Status Total change in fair value of debt Change in estimated fair value Fair Value, Option, Change In Fair Value Gain (Loss) And Credit Risk, Gains (Losses) On Assets Fair Value, Option, Change In Fair Value Gain (Loss) And Credit Risk, Gains (Losses) On Assets Concentration Risk Type [Domain] Concentration Risk Type [Domain] Due from affiliates Proceeds Due From (Payments) Due To Affiliates Proceeds Due From (Payments) Due To Affiliates Operating Income Operating Income (Loss) Life Insurance Contract, Face Value Life Settlement Contracts, Face Value [Member] Life Settlement Contracts, Face Value Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Debt instrument extension term Debt Instrument, Extension Term Debt Instrument, Extension Term Schedule of Indefinite-Lived Intangible Assets [Table] Schedule of Indefinite-Lived Intangible Assets [Table] Transaction costs Payments of Merger Related Costs, Financing Activities REVENUES: Revenues [Abstract] Consolidated Entities [Domain] Consolidated Entities [Domain] Total cost of revenue Cost of Revenue Redemption for common stock trigger price adjustment percentage Class Of Warrant Or Right, Issuance Of Common Stock, Redemption For Common Stock, Trigger Price Adjustment Percent Class Of Warrant Or Right, Issuance Of Common Stock, Redemption For Common Stock, Trigger Price Adjustment Percent Related Party Transaction [Axis] Related Party Transaction [Axis] Commitment fee Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Segments [Axis] Segments [Axis] Statement [Line Items] Statement [Line Items] Prepayment premium prior to first anniversary Debt Instrument, Covenant, Prepayment Premium Prior To First Anniversary Debt Instrument, Covenant, Prepayment Premium Prior To First Anniversary Life Insurance Policies Life Settlement Contract [Member] Life Settlement Contract Internally Developed and Used Technology—APA APA Technology [Member] APA Technology Fair value Estimate of Fair Value Measurement [Member] Concentration Risk [Table] Concentration Risk [Table] Schedule of Life Settlement Contracts, Investment Method Schedule of Life Settlement Contracts, Investment Method [Table Text Block] Other comprehensive income, net of tax: Other Comprehensive Income (Loss), Net of Tax [Abstract] Partner Type [Axis] Partner Type [Axis] Face value of policies accounted for using investment method Face Value Life Settlement Contracts, Investment Method, Face Value 0-1 Life Settlement Contract, Investment Method, Face Value, Maturity, Remainder of Fiscal Year 1-2 Life Settlement Contract, Investment Method, Face Value, Maturity, Year One Certificate of deposit Increase (Decrease) in Deposit Assets SHAREHOLDERS' EQUITY (DEFICIT) Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Non- Controlling Interests Noncontrolling Interest [Member] EX-101.PRE 6 abl-20230630_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
COVER - shares
6 Months Ended
Jun. 30, 2023
Aug. 14, 2023
Document Information [Line Items]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Jun. 30, 2023  
Document Transition Report false  
Entity File Number 001-39403  
Entity Registrant Name Abacus Life, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 85-1210472  
Entity Address, Address Line One 2101 Park Center Drive, Suite 170  
Entity Address, City or Town Orlando  
Entity Address, State or Province FL  
Entity Address, Postal Zip Code 32835  
City Area Code 800  
Local Phone Number 561-4148  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   62,961,688
Entity Central Index Key 0001814287  
Current Fiscal Year End Date --12-31  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q2  
Amendment Flag false  
Common Stock    
Document Information [Line Items]    
Title of 12(b) Security Common stock, par value $0.0001 per share  
Trading Symbol ABL  
Security Exchange Name NASDAQ  
Warrant    
Document Information [Line Items]    
Title of 12(b) Security Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share  
Trading Symbol ABLLW  
Security Exchange Name NASDAQ  
XML 8 R2.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
Jun. 30, 2023
Dec. 31, 2022
CURRENT ASSETS:    
Cash and cash equivalents $ 20,611,122 $ 30,052,823
Prepaid expenses and other current assets 829,595 116,646
Total current assets 32,206,622 33,282,927
Property and equipment, net 177,931 18,617
Intangible assets, net 32,900,000 0
Goodwill 140,287,000 0
Operating right-of-use assets 240,816 77,011
Life settlement policies, at cost 9,889,610 8,716,111
Life settlement policies, at fair value 56,685,617 13,809,352
Available for sale securities, at fair value 1,000,000 1,000,000
Other investments 1,600,000 1,300,000
Due from members and affiliates 75,582 0
State security deposit 206,873 0
Certificate of deposit 262,500 0
Other assets, at fair value 1,801,886 890,829
TOTAL ASSETS 277,334,437 59,094,847
CURRENT LIABILITIES:    
Accrued expenses 524,400 0
Accounts payable 401,500 40,014
Operating lease liabilities - current portion 227,561 48,127
Accrued transaction costs 182,571 908,256
Contract liabilities - deposits on pending settlements 981,217 0
Income taxes payable 185,831 0
Total current liabilities 13,894,422 1,302,409
SPV purchase and sale note 25,000,000 0
Long-term debt, at fair value 66,165,396 28,249,653
Operating lease liabilities - noncurrent portion 16,864 29,268
Deferred tax liability 9,320,240 1,363,820
Warrant liability 2,438,600 0
TOTAL LIABILITIES 116,835,522 30,945,150
COMMITMENTS AND CONTINGENCIES
SHAREHOLDERS' EQUITY (DEFICIT)    
Additional paid-in capital 188,641,886 704,963
Retained earnings/(accumulated deficit) (29,382,362) 25,487,323
Accumulated other comprehensive income 877,306 1,052,836
Non-controlling interest 355,789 899,538
Total shareholders' equity (deficit) 160,498,915 28,149,697 [1]
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT) 277,334,437 59,094,847
Class A Common Stock    
SHAREHOLDERS' EQUITY (DEFICIT)    
Class A common stock, $0.0001 par value; 200,000,000 authorized shares; 62,961,688 and 50,369,350 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively 6,296 5,037
Nonrelated Party    
CURRENT ASSETS:    
Accounts receivable 192,595 10,448
Other receivables 21,252 0
CURRENT LIABILITIES:    
Other current liabilities 258,759 42,227
Affiliated Entity    
CURRENT ASSETS:    
Other receivables 10,473,748 2,904,646
CURRENT LIABILITIES:    
Other current liabilities 10,415,154 263,785
Related Party    
CURRENT ASSETS:    
Accounts receivable 78,310 198,364
Owners    
CURRENT LIABILITIES:    
Other current liabilities $ 717,429 $ 0
[1] Both the number of shares outstanding and their par value have been retrospectively recast for all prior periods presented to reflect the par value of the outstanding stock of the Abacus Life Inc. as a result of the successful Business Combination.
XML 9 R3.htm IDEA: XBRL DOCUMENT v3.23.2
CONDENSED CONSOLIDATE BALANCE SHEETS (Parenthetical) - $ / shares
Jun. 30, 2023
Dec. 31, 2022
Common stock, par value (in dollars per share) $ 0.0001  
Common stock, shares authorized (in shares) 200,000,000  
Common stock, shares issued (in shares) 62,961,688  
Common stock, shares outstanding (in shares) 62,961,688  
Class A Common Stock    
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 200,000,000 200,000,000
Common stock, shares issued (in shares) 62,961,688 50,369,350
Common stock, shares outstanding (in shares) 62,961,688 50,369,350
XML 10 R4.htm IDEA: XBRL DOCUMENT v3.23.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
REVENUES:        
Total portfolio servicing revenue $ 354,366 $ 419,422 $ 590,057 $ 990,328
Investment Income from life insurance policies held using investment method 8,263,499 5,965,466 16,655,833 13,980,466
Change in fair value of life insurance policies (policies held using fair value method) 2,760,900 2,014,013 4,339,084 3,305,505
Total active management revenue 11,024,399 7,979,479 20,994,917 17,285,971
Total revenues 11,378,765 8,398,901 21,584,974 18,276,299
COST OF REVENUES (excluding depreciation stated below)        
Total cost of revenue 973,400 666,119 1,462,950 2,086,075
Gross Profit 10,405,365 7,732,782 20,122,024 16,190,224
OPERATING EXPENSES:        
Sales and marketing 683,841 1,019,498 1,412,845 1,649,498
General and administrative expenses 577,539 5,499 1,274,431 646,705
Loss on change in fair value of debt 1,445,229 333,879 2,398,662 375,513
Unrealized loss (gain) on investments (672,936) 1,039,022 (798,156) 1,054,975
Depreciation 1,098 1,098 2,141 2,141
Total operating expenses 2,034,771 2,398,996 4,289,923 3,728,832
Operating Income 8,370,594 5,333,786 15,832,101 12,461,392
OTHER INCOME (EXPENSE)        
Interest (expense) (584,075) 0 (941,458) 0
Interest income 0 0 7,457 0
Other income (expense) 121,601 (127,455) (21,651) (242,247)
Total other income (expense) (462,474) (127,455) (955,652) (242,247)
Net income before provision for income taxes 7,908,120 5,206,331 14,876,449 12,219,145
Provision for income taxes (1,184,571) (120,132) (528,104) (296,806)
NET INCOME 6,723,549 5,086,199 14,348,345 11,922,339
LESS: NET INCOME (LOSS) ATTRIBUTABLE TO NONCONTROLLING INTEREST (26,596) 406,641 (487,303) 406,641
NET INCOME ATTRIBUTABLE TO SHAREHOLDERS $ 6,750,145 $ 4,679,558 $ 14,835,648 $ 11,515,698
EARNINGS PER SHARE:        
Basic weighted average shares outstanding (in shares) [1] 50,507,728 50,369,350 50,438,921 50,369,350
Diluted weighted average shares outstanding (in shares) [1] 50,507,728 50,369,350 50,438,921 50,369,350
Basic net income per share (in dollars per share) $ 0.13 $ 0.09 $ 0.29 $ 0.23
Diluted net income per share (in dollars per share) $ 0.13 $ 0.09 $ 0.29 $ 0.23
NET INCOME $ 6,723,549 $ 5,086,199 $ 14,348,345 $ 11,922,339
Other comprehensive income, net of tax:        
Change in fair value of debt (119,663) 2,017,559 (231,976) 2,017,559
Comprehensive income 6,603,886 7,103,758 14,116,369 13,939,898
Comprehensive income (loss) attributable to non-controlling interests 56,111 (1,011,909) 543,749 (1,011,909)
Comprehensive income attributable to Abacus Life Inc. 6,659,997 6,091,849 14,660,118 12,927,989
Related Party        
REVENUES:        
Total portfolio servicing revenue 329,629 419,253 543,076 620,159
Nonrelated Party        
REVENUES:        
Total portfolio servicing revenue $ 24,737 $ 169 $ 46,981 $ 370,169
[1] Both the number of shares outstanding and their par value have been retrospectively recast for all prior periods presented to reflect the par value of the outstanding stock of the Abacus Life Inc. as a result of Business Combination.
XML 11 R5.htm IDEA: XBRL DOCUMENT v3.23.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS’ EQUITY - USD ($)
Total
Class A Common Stock
Common Stock
Class A Common Stock
Additional Paid-In Capital
Retained Earnings (Accumulated Deficit)
Accumulated Other Comprehensive Income
Non- Controlling Interests
Beginning balance (in shares) at Dec. 31, 2021 [1]     50,369,350        
Beginning balance at Dec. 31, 2021 [1] $ 766,893   $ 5,037 $ 704,963 $ 205,048 $ 0 $ (148,155)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Distributions (2,400,000)       (2,400,000)    
Other Comprehensive Income 2,017,559         1,412,291 605,268
Net Income 11,922,339       11,515,698   406,641
Ending balance (in shares) at Jun. 30, 2022 [1]     50,369,350        
Ending balance at Jun. 30, 2022 [1] 12,306,791   $ 5,037 704,963 9,320,746 1,412,291 863,754
Beginning balance (in shares) at Mar. 31, 2022 [1]     50,369,350        
Beginning balance at Mar. 31, 2022 [1] 5,513,033   $ 5,037 704,963 4,951,188 0 (148,155)
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Distributions (310,000)       (310,000)    
Other Comprehensive Income 2,017,559         1,412,291 605,268
Net Income 5,086,199       4,679,558   406,641
Ending balance (in shares) at Jun. 30, 2022 [1]     50,369,350        
Ending balance at Jun. 30, 2022 [1] 12,306,791   $ 5,037 704,963 9,320,746 1,412,291 863,754
Beginning balance (in shares) at Dec. 31, 2022   50,369,350 50,369,350 [1]        
Beginning balance at Dec. 31, 2022 [1] 28,149,697   $ 5,037 704,963 25,487,323 1,052,836 899,538
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Distributions (34,451,607)       (34,451,607)    
Deferred transaction costs (10,841,551)       (10,841,551)    
Public warrants 960,900     4,726,500 (3,765,600)    
Merger with East Resources Acquisition Company (in shares)     12,592,338        
Merger with East Resources Acquisition Company (2,796,225)   $ 1,259 17,849,091 (20,646,575)    
Marger/Acquisition 165,361,332     165,361,332      
Other Comprehensive Income (231,976)         (175,530) (56,446)
Net Income $ 14,348,345       14,835,648   (487,303)
Ending balance (in shares) at Jun. 30, 2023 62,961,688 62,961,688 62,961,688        
Ending balance at Jun. 30, 2023 $ 160,498,915   $ 6,296 188,641,886 (29,382,362) 877,306 355,789
Beginning balance (in shares) at Mar. 31, 2023 [1]     50,369,350        
Beginning balance at Mar. 31, 2023 [1] 35,662,180   $ 5,037 704,963 33,572,826 967,454 411,900
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Distributions (34,451,607)       (34,451,607)    
Deferred transaction costs (10,841,551)       (10,841,551)    
Public warrants 960,900     4,726,500 (3,765,600)    
Merger with East Resources Acquisition Company (in shares)     12,592,338        
Merger with East Resources Acquisition Company (2,796,225)   $ 1,259 17,849,091 (20,646,575)    
Marger/Acquisition 165,361,332     165,361,332      
Other Comprehensive Income (119,663)         (90,148) (29,515)
Net Income $ 6,723,549       6,750,145   (26,596)
Ending balance (in shares) at Jun. 30, 2023 62,961,688 62,961,688 62,961,688        
Ending balance at Jun. 30, 2023 $ 160,498,915   $ 6,296 $ 188,641,886 $ (29,382,362) $ 877,306 $ 355,789
[1] Both the number of shares outstanding and their par value have been retrospectively recast for all prior periods presented to reflect the par value of the outstanding stock of the Abacus Life Inc. as a result of the successful Business Combination.
XML 12 R6.htm IDEA: XBRL DOCUMENT v3.23.2
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net Income $ 14,348,345 $ 11,922,339
Adjustments to reconcile net income to net cash provided by/(used in) operating activities:    
Depreciation 2,141 2,141
Unrealized (gain) loss on investments (798,156) 1,054,975
Unrealized gain on policies (3,319,588) (3,305,505)
Loss on change in fair value of debt 2,398,662 375,513
Deferred income taxes 252,659 999,927
Non-cash lease expense 384 0
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets (193,462) (1,379,579)
Other noncurrent assets (105,655) 0
Accounts payable 361,486 0
Accrued transaction costs (725,685) 0
Other current liabilities 402,363 72,938
Life Settlement Policies purchased, at fair value (39,556,677) (7,211,509)
Life Settlement Policies purchased, at cost (11,374,605) (7,204,753)
Net cash used in operating activities (38,364,171) (4,751,170)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Purchase of investments (300,000) (250,000)
Due from affiliates (6,760,627) 0
Net cash used in investing activities (7,060,627) (250,000)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Issuance of debt certificates 35,206,351 9,463,779
Transaction costs (10,841,551) 0
Distributions to members (23,533,072) (2,400,000)
Proceeds from Issuance of Secured Debt 25,000,000 0
Due to members and affiliates 10,151,369 680,375
Net cash provided by financing activities 35,983,097 7,744,154
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (9,441,701) 2,742,984
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD 30,052,823 102,421
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD 20,611,122 2,845,405
Nonrelated Party    
Changes in operating assets and liabilities:    
Accounts receivable (182,147) 0
Related Party    
Changes in operating assets and liabilities:    
Accounts receivable $ 125,764 $ (77,657)
XML 13 R7.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Origination revenue $ 354,366 $ 419,422 $ 590,057 $ 990,328
Total revenues 11,378,765 8,398,901 21,584,974 18,276,299
Total cost of revenue 973,400 666,119 1,462,950 2,086,075
Total gross profit 10,405,365 7,732,782 20,122,024 16,190,224
OPERATING EXPENSES:        
General and administrative expenses 577,539 5,499 1,274,431 646,705
Depreciation 1,098 1,098 2,141 2,141
Total operating expenses 2,034,771 2,398,996 4,289,923 3,728,832
Operating Income 8,370,594 5,333,786 15,832,101 12,461,392
OTHER INCOME (EXPENSE)        
Interest earned on marketable securities held in Trust Account 0 0 7,457 0
Interest (expense) (584,075) 0 (941,458) 0
Other income (expense) 121,601 (127,455) (21,651) (242,247)
Total other income (expense) (462,474) (127,455) (955,652) (242,247)
Net income before provision for income taxes 7,908,120 5,206,331 14,876,449 12,219,145
Provision for income taxes 1,184,571 120,132 528,104 296,806
NET INCOME ATTRIBUTABLE TO SHAREHOLDERS $ 6,750,145 $ 4,679,558 $ 14,835,648 $ 11,515,698
WEIGHTED-AVERAGE UNITS USED IN COMPUTING NET INCOME (LOSS) PER UNIT:        
Weighted-average shares used in computing net income per share, basic (in shares) [1] 50,507,728 50,369,350 50,438,921 50,369,350
Diluted weighted average shares outstanding (in shares) [1] 50,507,728 50,369,350 50,438,921 50,369,350
NET INCOME/(LOSS) PER UNIT:        
Basic earnings per unit (in dollars per share) $ 0.13 $ 0.09 $ 0.29 $ 0.23
Diluted earnings per unit (in dollars per share) $ 0.13 $ 0.09 $ 0.29 $ 0.23
Nonrelated Party        
Origination revenue $ 24,737 $ 169 $ 46,981 $ 370,169
Related Party        
Origination revenue 329,629 419,253 543,076 620,159
Abacus Settlements, LLC        
Origination revenue 6,884,690 5,691,916 13,184,676 13,014,664
Total revenues 6,884,690 5,691,916 13,184,676 13,014,664
Total cost of revenue 4,897,980 3,571,932 9,293,303 8,787,625
Total gross profit 1,986,710 2,119,984 3,891,373 4,227,039
OPERATING EXPENSES:        
General and administrative expenses 2,297,577 2,208,051 4,848,580 3,948,358
Depreciation 2,561 3,048 5,597 5,988
Total operating expenses 2,300,138 2,211,099 4,854,177 3,954,346
Operating Income (313,428) (91,115) (962,804) 272,693
OTHER INCOME (EXPENSE)        
Interest earned on marketable securities held in Trust Account 1,193 599 1,917 1,147
Interest (expense) (5,863) 0 (11,725) 0
Other income (expense) 0 273 0 273
Total other income (expense) (4,670) 872 (9,808) 1,420
Net income before provision for income taxes (318,098) (90,243) (972,612) 274,113
Provision for income taxes 0 0 2,289 1,325
NET INCOME ATTRIBUTABLE TO SHAREHOLDERS $ (318,098) $ (90,243) $ (974,901) $ 272,788
WEIGHTED-AVERAGE UNITS USED IN COMPUTING NET INCOME (LOSS) PER UNIT:        
Weighted-average shares used in computing net income per share, basic (in shares) 400 400 400 400
Diluted weighted average shares outstanding (in shares) 400 400 400 400
NET INCOME/(LOSS) PER UNIT:        
Basic earnings per unit (in dollars per share) $ (795.25) $ (225.61) $ (2,437.25) $ 681.97
Diluted earnings per unit (in dollars per share) $ (795.25) $ (225.61) $ (2,437.25) $ 681.97
Abacus Settlements, LLC | Nonrelated Party        
Origination revenue $ 1,689,088 $ 743,388 $ 3,252,738 $ 3,185,068
Total cost of revenue 1,505,333 956,625 2,734,949 3,265,313
Abacus Settlements, LLC | Related Party        
Origination revenue 5,195,602 4,948,528 9,931,938 9,829,596
Total cost of revenue $ 3,392,647 $ 2,615,307 $ 6,558,354 $ 5,522,312
[1] Both the number of shares outstanding and their par value have been retrospectively recast for all prior periods presented to reflect the par value of the outstanding stock of the Abacus Life Inc. as a result of Business Combination.
XML 14 R8.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - UNAUDITED CONDENSED STATEMENTS OF CHANGES IN MEMBERS' EQUITY - USD ($)
Total
Additional Paid-In Capital
Retained Earnings
Abacus Settlements, LLC
Abacus Settlements, LLC
Common units
Abacus Settlements, LLC
Additional Paid-In Capital
Abacus Settlements, LLC
Retained Earnings
Beginning balance (in shares) at Dec. 31, 2021         400    
Beginning balance at Dec. 31, 2021 $ 766,893 [1] $ 704,963 [1] $ 205,048 [1] $ 2,722,995 $ 4,000 $ 80,000 $ 2,638,995
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) 11,515,698     272,788     272,788
Distributions (2,400,000)   (2,400,000) (659,869)     (659,869)
Ending balance (in shares) at Jun. 30, 2022         400    
Ending balance at Jun. 30, 2022 12,306,791 [1] 704,963 [1] 9,320,746 [1] 2,335,914 $ 4,000 80,000 2,251,914
Beginning balance at Mar. 31, 2022 [1] 5,513,033 704,963 4,951,188        
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) 4,679,558     (90,243)      
Distributions (310,000)   (310,000)        
Ending balance (in shares) at Jun. 30, 2022         400    
Ending balance at Jun. 30, 2022 12,306,791 [1] 704,963 [1] 9,320,746 [1] 2,335,914 $ 4,000 80,000 2,251,914
Beginning balance (in shares) at Dec. 31, 2022         400    
Beginning balance at Dec. 31, 2022 28,149,697 [1] 704,963 [1] 25,487,323 [1] 2,011,137 $ 4,000 80,000 1,927,137
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) 14,835,648     (974,901)     (974,901)
Distributions $ (34,451,607)   (34,451,607) (442,283)     (442,283)
Ending balance (in shares) at Jun. 30, 2023 62,961,688       400    
Ending balance at Jun. 30, 2023 $ 160,498,915 188,641,886 (29,382,362) 593,953 $ 4,000 80,000 509,953
Beginning balance (in shares) at Mar. 31, 2023         400    
Beginning balance at Mar. 31, 2023 35,662,180 [1] 704,963 [1] 33,572,826 [1] 1,354,334 $ 4,000 80,000 1,270,334
Increase (Decrease) in Stockholders' Equity [Roll Forward]              
Net income (loss) 6,750,145     (318,098)     (318,098)
Distributions $ (34,451,607)   (34,451,607) (442,283)     (442,283)
Ending balance (in shares) at Jun. 30, 2023 62,961,688       400    
Ending balance at Jun. 30, 2023 $ 160,498,915 $ 188,641,886 $ (29,382,362) $ 593,953 $ 4,000 $ 80,000 $ 509,953
[1] Both the number of shares outstanding and their par value have been retrospectively recast for all prior periods presented to reflect the par value of the outstanding stock of the Abacus Life Inc. as a result of the successful Business Combination.
XML 15 R9.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - UNAUDITED INTERIM CONDENSED STATEMENTS OF CASH FLOWS - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) $ 14,835,648 $ 11,515,698
Adjustments to reconcile net income to net cash used in operating activities:    
Depreciation expense 2,141 2,141
Non-cash lease expense 384 0
Changes in operating assets and liabilities:    
Accrued payroll and other expenses (725,685) 0
Accounts payable 361,486 0
Net cash used in operating activities (38,364,171) (4,751,170)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Net cash used in investing activities (7,060,627) (250,000)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Distributions to members (23,533,072) (2,400,000)
Net cash provided by financing activities 35,983,097 7,744,154
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (9,441,701) 2,742,984
CASH AND CASH EQUIVALENTS:    
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD 30,052,823 102,421
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD 20,611,122 2,845,405
Related Party    
Changes in operating assets and liabilities:    
Accounts receivable 125,764 (77,657)
Nonrelated Party    
Changes in operating assets and liabilities:    
Accounts receivable (182,147) 0
Abacus Settlements, LLC    
CASH FLOWS FROM OPERATING ACTIVITIES:    
Net income (loss) (974,901) 272,788
Adjustments to reconcile net income to net cash used in operating activities:    
Depreciation expense 19,157 10,751
Amortization expense 40,278 37,952
Amortization of deferred financing fees 11,725 0
Non-cash lease expense 1,210 0
Changes in operating assets and liabilities:    
Prepaid expenses (198,643) 71,038
Other current assets (26,211) (20,111)
Certificate of deposit 0 656,250
Accrued payroll and other expenses (17,466) 155,994
Contract liability—deposits on pending settlements 659,067 (1,427,291)
Accounts payable (36,750) (7,247)
Net cash used in operating activities (24,292) (452,367)
CASH FLOWS FROM INVESTING ACTIVITIES:    
Capital expenditures (108,394) (32,212)
Purchase of intangible asset 0 (15,000)
Due to/from members and affiliates (74,134) 11,525
Net cash used in investing activities (182,528) (35,687)
CASH FLOWS FROM FINANCING ACTIVITIES:    
Due to members (1,411) (11,857)
Distributions to members (442,283) (659,869)
Net cash provided by financing activities (443,694) (671,726)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS (650,514) (1,159,780)
CASH AND CASH EQUIVALENTS:    
CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD 1,458,740 2,599,302
CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD 808,226 1,439,522
Abacus Settlements, LLC | Related Party    
Changes in operating assets and liabilities:    
Accounts receivable 397,039 0
Abacus Settlements, LLC | Nonrelated Party    
Changes in operating assets and liabilities:    
Accounts receivable $ 101,203 $ (202,491)
XML 16 R10.htm IDEA: XBRL DOCUMENT v3.23.2
DESCRIPTION OF BUSINESS
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
DESCRIPTION OF BUSINESS DESCRIPTION OF BUSINESS
Organization and Merger
Abacus Life, Inc. (“the Company”) was formerly known as East Resources Acquisition Company ("ERES”), a blank check company incorporated in Delaware on May 22, 2020. Abacus Life, Inc. conducts its business through its wholly-owned, consolidated subsidiaries, primarily Abacus Settlements LLC (“Abacus”) and Longevity Market Assets, LLC (“LMA”), which are incorporated in the state of Delaware (collectively, the “Companies”). On June 30, 2023, (the “Closing Date”), ERES, Longevity Market Assets, LLC and Abacus Settlements, LLC consummated the combining of the Companies as contemplated by the Merger Agreement dated as of August 30, 2022 (as amended on October 14, 2022 and April 20, 2023) with LMA Merger Sub, LLC, a wholly owned subsidiary of ERES (“LMA Merger Sub”), Abacus Merger Sub, LLC, a wholly owned subsidiary of ERES (“Abacus Merger Sub”), Longevity Market Assets, LLC (“LMA”) and Abacus Settlements, LLC (“Legacy Abacus” and, together with LMA, the “Legacy Companies”). Pursuant to the Merger Agreement, on June 30, 2023, (i) LMA Merger Sub merged with and into LMA, with LMA surviving such merger (the “LMA Merger”) and (ii) Abacus Merger Sub merged with and into Legacy Abacus, with Legacy Abacus surviving such merger (the “Abacus Merger” and, together with the LMA Merger, the “Mergers” and, along with the other transactions contemplated by the Merger Agreement, the “Business Combination”) and the Legacy Companies became direct wholly owned subsidiaries of Abacus and ERES changed its name to Abacus Life, Inc.
The condensed consolidated assets, liabilities and statements of operations and comprehensive income prior to the Business Combination are those of legacy LMA. The stocks and corresponding capital amounts and income per stock, prior to the Business Combination, have been retroactively restated based on stocks reflecting the exchange ratio established in the Business Combination.
The equity structure has been recast in all comparative periods up to the Closing Date to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to legacy LMA’s stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to legacy LMA common stock prior to the Business Combination have been retroactively recast as shares reflecting the exchange ratio of 0.8 established in the Business Combination.
Business Activity
The Company, through its LMA subsidiary, is a provider of services pertaining to life insurance settlements and offers policy servicing to owners and purchasers of life settlement assets, as well as consulting, valuation, and actuarial services. The Company is also engaged in buying and selling of life settlement policies in which it uses its own capital, and purchases life settlement contracts with the intent to either hold to maturity to receive the associated death claim payout or to sell to another purchaser of life settlement contracts for a gain on the sale.
The Company, through its Abacus subsidiary, also is an originator of outstanding life insurance policies as a licensed life settlement provider on behalf of investors (“Financing Entities”). Abacus locates and screens policies for eligibility as a commercially desirable life settlement, including verifying that the policy is in force, obtaining consents and disclosures, and submitting cases for life expectancy estimates, also known, collectively, as origination services. When the sale of a policy is completed, this is deemed “settled” and the policy is then referred to as either a “life settlement” in which the insured’s life expectancy is greater than two years or “viatical settlement,” in which the insured’s life expectancy is less
than two years. The Company is not an insurance company, and therefore the Company does not underwrite insurable risks for its own account.
XML 17 R11.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Jun. 30, 2023
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation—In connection with the Business Combination, the Merger is accounted for as a reverse recapitalization with ERES in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Under U.S. GAAP, ERES has been treated as the “acquired” company for financial reporting purposes. This determination was primarily based on the LMA shareholders having a relative majority of the voting power of the Company, the LMA shareholders having the authority to appoint a majority of directors on the Board of Directors, and senior management of LMA comprising the majority of the senior management of the post-combination Company. LMA was then determined to be the “acquirer” for financial reporting purposes based on the relative size of LMA as compared to Abacus, represented by their revenue, equity, gross profit and net income. Accordingly, for accounting purposes, the financial statements of the combined entity will represent a continuation of the financial statements of LMA with the LMA Merger being treated as the equivalent of LMA issuing stock for the net assets of ERES, accompanied by a recapitalization. The net assets of ERES will be stated at historical cost, with no goodwill or other intangible assets recorded.
The Abacus Merger will be accounted for using the acquisition method of accounting. Under the acquisition method of accounting, the assets and liabilities of Abacus will be recorded at estimated fair value as of the acquisition date. The excess of the purchase price over the estimated fair values of the net assets acquired, if applicable, will be recognized as goodwill.
As a result of the Business Combination, the Company evaluated if ERES, Abacus, or LMA is the predecessor for accounting purposes.
In considering the foregoing principles of predecessor determination and in light of the Company's specific facts and circumstances, management determined that LMA and Abacus are dual predecessors for accounting purposes. The financial statement presentation for Abacus Life, Inc. includes the purchase accounting effects of the Abacus Merger as of the Closing Date with the financial statements of LMA as the comparative period. The predecessor financial statements for Abacus are included separately within this report.
The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and are prepared in accordance with U.S. GAAP.
Unaudited Condensed Consolidated Financial Statements—The condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2023, and the condensed consolidated statements of operations and comprehensive income for the three months and six months ended June 30, 2023 and 2022, respectively, and the condensed consolidated statements of cash flows for the six months ended June 30, 2023 and 2022, respectively. The condensed consolidated statements of operations and comprehensive income for the three months and six months ended June 30, 2023, are not necessarily indicative of the results to be expected for the full year ending December 31, 2023, or any other period. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes for Abacus for the year ended December 31, 2022, and the financial statements and notes for LMA for the year ended December 31, 2022. All references to financial information as of and for the periods ended June 30, 2023, and 2022 in the notes to condensed consolidated financial statements are unaudited.
Refer to this note in the LMA annual financial statements for the full list of the Company’s significant accounting policies. The details in those notes have not changed, except as discussed below and as a result of normal adjustments in the interim periods.
Consolidation of Variable Interest Entities—For entities in which the Company has variable interests, the Company first evaluates whether the entity meets the definition of a variable interest entity (“VIE”) or a voting interest entity (“VOE”). If the entity is a VIE, the Company focuses on identifying whether it has the power to direct the activities that most significantly impact the VIE’s economic performance and whether it has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company is the primary beneficiary of a VIE, the assets, liabilities, and results of operations of the VIE will be included in the Company’s condensed consolidated financial statements. The proportionate share not owned by the Company is recognized as noncontrolling interest and net income attributable to noncontrolling interest on the condensed consolidated balance sheets and condensed consolidated statements of operations and comprehensive income, respectively. If the entity is a VOE, the Company evaluates whether it has the power to control the VOE through a majority voting interest or through other arrangements.
Accounting Standards Codification (“ASC”) Topic 810, Consolidations, requires the Company to separately disclose on its condensed consolidated balance sheets the assets of consolidated VIEs and liabilities of consolidated VIEs as to which there is no recourse against the Company. As of June 30, 2023, total assets and liabilities of consolidated VIEs were $57,577,034 and $52,474,820, respectively. As of December 31, 2022, total assets and liabilities of consolidated VIEs were $30,073,972 and $27,116,762, respectively.
On January 1, 2021, the Company entered into an option agreement with two commonly owned full-service origination, servicing, and investment providers (the “Providers”), in which the Company agreed to fund certain capital needs with an option to purchase the outstanding equity ownership of the Providers (the “Option Agreement”).
The Company accounted for its investment in the call options under the Option Agreement as an equity security, pursuant to ASC 321. In arriving at this accounting conclusion, the Company first considered whether the call options met the definition of a derivative pursuant to ASC 815 and concluded that the options do not provide for net settlement and accordingly are not a derivative. The Company also concluded that the call options do not provide the Company with a controlling financial interest in the legal entity pursuant to ASC 810. The call options include material contingencies prior to exercisability that the Company does not anticipate will be resolved; additionally, the call options are in a legal entity for which the share price has no readily determinable fair value. The Company’s basis in the call options, pursuant to ASC 321, is zero and accordingly the call options are not reflected in the statement of financial position.
The Company provided $0 and $127,455 of funding for the three months ended June 30, 2023 and June 30, 2022, respectively and provided $29,721 and $242,247 of funding for the six months ended June 30, 2023 and June 30, 2022, respectively which is included in other (expense) income on the condensed consolidated statements of operations and comprehensive income. See Note 11, Commitments and Contingencies.
For the period ended June 30, 2023, and for the year ended December 31, 2022, the Providers were considered to be VIEs, but were not consolidated in the Company’s condensed consolidated financial statements due to a lack of the power criterion or the losses/benefits criterion. As of June 30, 2023, the unaudited financial information for the unconsolidated VIEs are as follows: held assets of $318,178 and liabilities of $450 and held assets of $483,167 and liabilities of $184,621, respectively. As of December 31, 2022, the unaudited financial information for the unconsolidated VIEs are as follows: held assets of $126,040 and liabilities of $0 and held assets of $861,924 and liabilities of $358,586, respectively.
On October 4, 2021, the Company entered into an operating agreement with LMX Series, LLC (“LMX”) and three other unaffiliated investors to obtain a 70% ownership interest in LMX, which was newly formed in August 2021. LMX had no operating activity prior to the operating agreement being signed.
LMX has a wholly owned subsidiary, LMATT Series 2024, Inc., a Delaware C corporation. While the Company and three other investors each contributed $100 to LMX, the Company directs the most significant activities by managing the investment offerings, and sponsoring and creating structured investment grade insurance liabilities, and thus was provided a 70% ownership interest. LMX is a VIE and the Company is the primary beneficiary of LMX. The Company has included the results of LMX and its subsidiaries in its condensed consolidated financial statements for the period ended June 30, 2023.
On March 3, 2022, the Company obtained an 80% ownership interest in Longevity Market Advisors, LLC (“Longevity Market Advisors”). The Longevity Market Advisors legal entity was established primarily for the purpose of acquiring the assets of a broker/dealer, Regional Investment Services, Inc. (“RIS”), an Ohio corporation. Longevity Market Advisors is a VIE and the Company is the primary beneficiary of Longevity Market Advisors. The purchase price payable in exchange for RIS was $60,000. The Company evaluated whether this represented a business combination or an asset acquisition under ASC 805. While the purchase of the RIS represents a business, it was further determined that as RIS was purchased for the primary reason of being registered by the Financial Industry Regulatory Authority (“FINRA”). As there are no tangible or intangible assets of value from the RIS that would meet the capitalization criteria that have standalone value, the Company has expensed the purchase in general and administrative costs. Upon closing of the transaction, Longevity Market Advisors will comprise 100% of the ownership structure of RIS, and RIS will be a wholly owned subsidiary. The Company has included the results of Longevity Market Advisors in its condensed consolidated financial statements for the period ended June 30, 2023.
On November 30, 2022, LMA Series, LLC, a wholly owned subsidiary of the Company, signed an Operating Agreement to be the sole member of a newly created general partnership, LMA Income Series, GP, LLC. Subsequent to that, LMA Income Series, GP, LLC formed a limited partnership, LMA Income Series, LP and issued partnership interests to limited partners in a private placement offering. It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series, LP and thus has fully consolidated the limited partnership in its condensed consolidated financial statements for the six months ended June 30, 2023.
On January 31, 2023, LMA Series, LLC, a wholly owned subsidiary of the Company, signed an Operating Agreement to be the sole member of a newly created general partnership, LMA Income Series II, GP, LLC. Subsequent to that, LMA Income Series II, GP, LLC formed a limited partnership, LMA Income Series II, LP and issued partnership interests to limited partners in a private placement offering. It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series II, LP and thus has fully consolidated the limited partnership in its condensed consolidated financial statements for the six months ended June 30, 2023.
Noncontrolling Interest—Noncontrolling interest represents the share of consolidated entities owned by third parties. At the date of formation or upon acquisition, the Company recognizes noncontrolling interest on the condensed consolidated balance sheets at an amount equal to the noncontrolling interest’s proportionate share of the relative fair value of any assets and liabilities acquired. Noncontrolling interest is subsequently adjusted for the noncontrolling shareholder’s additional contributions, distributions, and the shareholder’s share of the net earnings or losses of each respective consolidated entity.
Net income of a consolidated entity is allocated to noncontrolling interests based on the noncontrolling shareholder’s ownership interest during the period. The net income or loss that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the condensed consolidated statements of operations and comprehensive income.
Use of Estimates—The preparation of U.S. GAAP financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, disclosure of contingent assets and liabilities at the date of financial statements, and the reports amounts of revenue and expenses during the reporting periods. Company’s estimates, judgments, and
assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from the estimates. Estimates are used when accounting for revenue recognition and related costs, purchase price allocation, the selection of useful lives of property and equipment, valuation of other receivables, valuation of life settlement policies, valuation of other investments and available-for-sale securities, valuation of long-term debt, impairment testing, income taxes, and legal reserves.
Life Insurance Settlement Policies—The Company accounts for its holdings of life insurance settlement policies in accordance with ASC 325-30, Investments in Insurance Contracts. The Company accounts for life settlement policies purchased that we intend to hold to maturity at fair value and life settlement policies that we intend to trade in the near term at cost plus premiums paid.
The Company follows ASC 820, Fair Value Measurements and Disclosures, in estimating the fair value of its life insurance policies held at fair value. ASC 820 defines fair value as an exit price representing the amount that would be received if an asset were sold or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-level, fair value hierarchy that prioritizes the inputs used to measure fair value. Level 1 relates to quoted prices in active markets for identical assets or liabilities. Level 2 relates to observable inputs other than quoted prices included in Level 1. Level 3 relates to unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s valuation of life settlements is considered to be Level 3, as there is currently no active market where we are able to observe quoted prices for identical assets. The Company’s valuation model incorporates significant inputs that are not observable. See Note 10, “Fair Value Measurements.” For policies held at fair value, changes in fair value are reflected in operations in the period the change is calculated.
For policies held under the investment method, the Company tests the impairment if we become aware of information indicating that the carrying value plus undiscounted future premiums of a policy may not be recoverable. This information is gathered initially through extensive underwriting procedures at purchase of the settlement contract, as well as through periodic underwriting review that include medical reports and life expectancy evaluations. The policies held by the Company using the investment method are expected to be owned for a shorter-term, and are actively marketed to potential buyers. The market feedback received through these interactions provides the Company with information related to a potential impairment. If a policy is determined to be impaired, the Company will adjust the carrying value to the fair value determined through the impairment analysis.
The Company accounts for cash proceeds from sale and maturity of life insurance settlement policies, as well as cash outflows for premium payments, as operating activities within the condensed consolidated statements of cash flows.

Cost of Revenues—Cost of revenue represents the direct costs associated with fulfilling the Company’s obligations to its customers, primarily policy servicing and consulting expense.

Income Taxes—The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, the provision for income taxes represents income taxes paid or payable (or received or receivable) for the current year plus the change in deferred taxes during the year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid, and result from differences between the financial and tax bases of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when enacted.
Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not (greater than 50%) that a tax benefit will not be realized. In evaluating the need for a valuation allowance, management considers all potential sources of taxable income, including income available in carryback periods, future reversals of taxable temporary differences, projections of taxable income, and income from tax planning strategies, as well as all available positive and negative evidence. Positive evidence includes factors such as a history of profitable operations, projections of future profitability within the carryforward period, including from tax planning strategies, and the Company’s experience with similar operations. Existing favorable contracts are additional positive evidence. Negative evidence includes items such as cumulative losses, projections of future losses, or carryforward periods that are not long enough to allow for the utilization of a deferred tax asset based on existing projections of income. Deferred tax assets for which no valuation allowance is recorded may not be realized upon changes in facts and circumstances, resulting in a future charge to establish a valuation allowance. Existing valuation allowances are re-examined under the same standards of positive and negative evidence. If it is determined that it is more likely than not that a deferred tax asset will be realized, the appropriate amount of the valuation allowance, if any, is released. Deferred tax assets and liabilities are also remeasured to reflect changes in underlying tax rates due to law changes and the granting and lapse of tax holidays.

Tax benefits related to uncertain tax positions taken or expected to be taken on a tax return are recorded when such benefits meet a more likely than not threshold. Otherwise, these tax benefits are recorded when a tax position has been effectively settled, which means that the statute of limitations has expired or the appropriate taxing authority has completed their examination even though the statute of limitations remains open. Interest and penalties related to uncertain tax positions are recognized as part of the provision for income taxes and are accrued beginning in the period that such interest and penalties would be applicable under relevant tax law until such time that the related tax benefits are recognized.
Concentrations—Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, accounts receivable, and available-for-sale securities. The Company maintains its cash in bank deposit accounts with high-quality financial institutions, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on its cash and cash equivalents. For accounts receivable, the Company is exposed to credit risk in the event of nonpayment by customers to the extent of the amounts recorded on the accompanying condensed consolidated balance sheets. The Company extends different levels of credit to its customers and maintains allowance for doubtful accounts based upon the expected collectability of accounts receivable. The Company’s procedures for determining this allowance includes evaluating individual customer receivables, considering a customer’s financial condition, monitoring credit history and current economic conditions, and using historical experience applied to an aging of accounts.
Two related party customers accounted for 12% and 13% of the total balance of accounts receivable and related party receivables as of June 30, 2023, and two related party customers accounted for 75% and 16% of the total accounts receivable as of December 31, 2022, respectively. The largest receivables balances are from related parties where exposed credit risk is low. As such, there is no allowance for doubtful accounts as of June 30, 2023, and December 31, 2022.
One customer accounted for 27% of active management revenue for the three months ended June 30, 2023. Two related party customers each accounted for 20% and 20% of the portfolio servicing revenue for the three months ended June 30, 2023. One customer accounted for 26% of the total revenues for the three months ended June 30, 2022.
One customer accounted for 29% of active management revenue, while 16% of revenue related to 2 policies that matured that were accounted for under the investment method and 1 policy that matured that was accounted for under the fair-value method for the six months ended June 30, 2023. Two related party customers each accounted for 25% and 27% of the portfolio servicing revenue for the six months
ended June 30, 2023. One customer accounted for 71% of the total revenues for the six months ended June 30, 2022.

Warrants—The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480 Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the condensed consolidated statements of operations and comprehensive income.
XML 18 R12.htm IDEA: XBRL DOCUMENT v3.23.2
BUSINESS COMBINATION
6 Months Ended
Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
BUSINESS COMBINATION BUSINESS COMBINATION
Merger consideration conveyed of $531.8 million was allocated between the Companies based on relative values derived through both the discounted cash flow method within the income approach and the guideline public company method within the market approach. Within the discounted cash flow method, the present values of cash flows reasonably expected to be produced by the Companies from their operations were summed to produce an estimate of the Companies’ business enterprise values on a controlling, marketable basis. The cash flows used in the discounted cash flow analysis were discounted at the weighted average cost of capital of 14.5% for LMA and 16.5% for Abacus. The discounted cash flow method resulted in a business enterprise value range of $380.0 million to $460.0 million for LMA and $180.0 million to $195.0 million for Abacus. Within the market approach, Company applied the guideline public company method, which employs market multiples derived from market prices of stocks of Companies that are engaged in the same or similar lines of business as the Companies and that are actively traded on a free and open market. The guideline public company method resulted in a business enterprise value range of $400.0 million to $440.0 million for LMA and $180.0 million to $190.0 million for Abacus. Management concluded on a business enterprise value of $165.4 million for Abacus and $366.4 million for LMA based upon the relative fair value of the Companies allocated to the consideration transferred.
The preliminary purchase price was allocated among the identified assets to be acquired. The primary area of the acquisition accounting that is not yet finalized is our estimate of the impact of acquisition accounting on deferred income taxes. An estimate of deferred income taxes has been recorded in the Company’s books based on information available as of June 30, 2023. As the initial acquisition accounting is based on our preliminary assessments, actual values may differ when final information becomes available. We believe that the information gathered to date provides a reasonable basis for estimating the preliminary values of deferred taxes recorded. We will continue to evaluate this item until it is satisfactorily resolved and adjust our acquisition accounting accordingly, within the allowable measurement period, as defined by ASC 805, Business Combinations. Transaction costs incurred as a result of the Business Combination were recognized within retained earnings/(accumulated deficit) on the condensed consolidated balance sheet ending June 30, 2023.

All valuation procedures related to existing assets as no new assets were identified as a result of procedures performed. Goodwill was recognized as a result of the acquisition, which represents the
excess fair value of consideration over the fair value of the underlying net assets, largely arising from the extensive industry expertise that has been established by Abacus. This was considered appropriate based on the determination that the Abacus Merger would be accounted for as a business acquisition under ASC 805.
Net Assets IdentifiedFair Value
Intangibles$32,900,000 
Goodwill140,287,000 
Current Assets1,280,100 
Non-Current Assets901,337 
Deferred Tax Liabilities(8,310,966)
Accrued Expenses(524,400)
Other Liabilities(1,171,739)
Total Fair Value$165,361,332 
Value ConveyedAmount
Abacus Purchase Consideration$165,361,332 
LMA Business Enterprise Value $366,388,668 
Total Consideration$531,750,000 
Intangible assets were comprised of the following:
Asset TypeFair ValueUseful LifeValuation Methodology
Customer Relationships-Agents$12,600,000 5 yearsMulti-period excess earnings method
Customer Relationships-Financing Entities11,000,000 8 yearsMulti-period excess earnings method
Internally Developed and Used Technology-APA1,600,000 2 yearsRelief from royalty method
Internally Developed and Used Technology-Marketplace100,000 3 yearsReplacement cost method
Trade Name900,000 IndefiniteRelief from royalty method
Non-Compete Agreements4,000,000 2 yearsWith and without method
State Insurance Licenses2,700,000 IndefiniteReplacement cost method
Total Fair Value$32,900,000 
Useful lives for customer relationships were developed using attrition data for agents and financing entities which resulted in a useful life of 5 years and 8 years, respectively. Estimates over the useful lives of internally developed and used technology contemplates the period in which the Company expects to utilize the technology and the length of time the technology is expected to maintain recognition and value in the market without significant investment.Non-compete agreements have a useful life commensurate with the executed non-compete agreements in place as a result of the Business Combination.
The supplemental pro forma financial information in the table below summarizes the combined results of operations for the Business Combination as if the Companies were combined as of
January 1, 2022. The unaudited supplemental pro forma financial information as presented below is for illustrative purposes and does not purport to represent what the results of operations would actually have been if the business combinations occurred as of the date indicated or what the results would be for any future periods.

Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Proforma revenue$18,263,455 $14,090,817 $34,769,650 $31,290,963 
Proforma net income6,432,047 4,589,315 13,373,444 11,788,486 
XML 19 R13.htm IDEA: XBRL DOCUMENT v3.23.2
LIFE INSURANCE SETTLEMENT POLICIES
6 Months Ended
Jun. 30, 2023
Investments, All Other Investments [Abstract]  
LIFE INSURANCE SETTLEMENT POLICIES LIFE INSURANCE SETTLEMENT POLICIES
As of June 30, 2023, the Company holds 167 life settlement policies, of which 122 are accounted for under the fair value method and 45 are accounted for using the investment method (cost, plus premiums paid). Aggregate face value of policies held at fair value is $195,205,585 as of June 30, 2023, with a corresponding fair value of $56,685,617. Aggregate face value of policies accounted for using the investment method is $39,520,877 as of June 30, 2023, with a corresponding carrying value of $9,889,610.
As of December 31, 2022, the Company held 53 life settlement policies, of which 35 were accounted for under the fair value method and 18 were accounted for using the investment method (cost, plus premiums paid). Aggregate face value of policies held at fair value was $40,092,154 as of December 31, 2022, with a corresponding fair value of $13,809,352. Aggregate face value of policies accounted for using the investment method was $42,330,000 as of December 31, 2022, with a corresponding carrying value of $8,716,111.
At June 30, 2023, the Company did not have any contractual restrictions on its ability to sell policies, including those held as collateral for the issuance of long-term debt. See footnote 11 Long-Term Debt.
Life expectancy reflects the probable number of years remaining in the life of a class of persons determined statistically, affected by such factors as heredity, physical condition, nutrition, and occupation. It is not an estimate or an indication of the actual expected maturity date or indication of the timing of expected cash flows from death benefits. The following tables summarize the Company’s life insurance policies grouped by remaining life expectancy as of June 30, 2023:
Policies Carried at Fair Value
Remaining Life Expectancy (Years)PoliciesFace ValueFair Value
0-1
0$— $— 
1-2
1012,314,000 6,855,769 
2-3
1116,886,778 10,530,949 
3-4
1033,631,467 9,174,200 
4-5
1318,755,193 7,564,469 
Thereafter78113,618,147 22,560,230 
122$195,205,585 $56,685,617 
Policies accounted for using the investment method—
Remaining Life Expectancy (Years)Number of Life
Insurance
Policies
Face ValueCarrying Value
0-1
0$— $— 
1-2
0— — 
2-3
24,400,000 2,131,679 
3-4
44,100,000 1,281,524 
4-5
41,362,000 518,736 
Thereafter35 29,658,877 5,957,671 
45$39,520,877 $9,889,610 
Estimated premiums to be paid by the Company for its portfolio accounted for using the investment method during each of the five succeeding calendar years and thereafter as of June 30, 2023, are as follows:
2023 remaining$1,024,151 
20241,243,423 
20251,310,936 
20261,044,640 
Thereafter3,288,619 
Total$7,911,769 
The Company is required to pay premiums to keep its portion of life insurance policies in force. The estimated total future premium payments could increase or decrease significantly to the extent that actual mortalities of insureds differ from the estimated life expectancies.
For policies accounted for under the investment method, the Company has not been made aware of information causing a material change to assumptions relating to the timing of realization of life insurance settlement proceeds. We have also not been made aware of information indicating impairment to the carrying value of policies.
XML 20 R14.htm IDEA: XBRL DOCUMENT v3.23.2
PROPERTY AND EQUIPMENT—NET
6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
PROPERTY AND EQUIPMENT—NET PROPERTY AND EQUIPMENT—NET
Property and equipment—net composed of the following:
June 30,
2023
December 31,
2022
Computer equipment$144,202 $— 
Furniture and fixtures34,300 19,444 
Leasehold improvements8,299 5,902 
Property and equipment—gross186,801 25,346 
Less: accumulated depreciation(8,870)(6,729)
Property and equipment—net$177,931 $18,617 
Depreciation expense for the three months ended June 30, 2023 and 2022, was $1,098 and $1,098, respectively and depreciation expense for the six months ended June 30, 2023, and 2022, was $2,141 and $2,141, respectively.
XML 21 R15.htm IDEA: XBRL DOCUMENT v3.23.2
GOODWILL AND OTHER INTANGIBLE ASSETS
6 Months Ended
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL AND OTHER INTANGIBLE ASSETS GOODWILL AND OTHER INTANGIBLE ASSETS
Goodwill of $140,287,000 was recognized as a result of the Business Combination, which represents the excess fair value of consideration over the fair value of the underlying net assets, largely arising from the extensive industry expertise that has been established by Abacus. This was considered appropriate based on the determination that the Abacus Merger would be accounted for as a business acquisition under ASC 805. The estimates of fair value are based upon preliminary valuation assumptions believed to be reasonable, but which are inherently uncertain and unpredictable. Refer to footnote 3 for further details.

The changes in goodwill by reportable segments were as follows:

Abacus Settlements, LLC
Goodwill at January 1, 2022$— 
Additions— 
Goodwill at June 30, 2022$— 
Goodwill at January 1, 2023$— 
Additions140,287,000 
Goodwill at June 30, 2023$140,287,000 
Intangible Assets Acquired comprised of the following:
Asset TypeFair ValueUseful LifeValuation Methodology
Customer Relationships - Agents$12,600,000 5 yearsMulti-period excess-earnings method
Customer Relationships - Financial Relationships11,000,000 8 yearsMulti-period excess-earnings method
Internally Developed and Used Technology—APA1,600,000 2 yearsRelief from Royalty Method
Internally Developed and Used Technology—Market Place100,000 3 yearsReplacement Cost Method
Trade Name900,000 IndefiniteRelief from Royalty Method
Non-Compete Agreements4,000,000 2 yearsWith or Without Method
State Insurance Licenses2,700,000 IndefiniteReplacement Cost Method
$32,900,000 
XML 22 R16.htm IDEA: XBRL DOCUMENT v3.23.2
AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE
6 Months Ended
Jun. 30, 2023
Investments, Debt and Equity Securities [Abstract]  
AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUEConvertible Promissory Note—The Company holds a convertible promissory note in a separate unrelated insurance technology company. In November 2021, the Company purchased a $250,000 note and then purchased an additional note in January 2022 for $250,000 as part of the Tranche 5 offering (“Tranche 5
Promissory Note”). The Tranche 5 Promissory Note pays 6% interest per annum. The Tranche 5 Promissory Note matures on November 12, 2023 (“Maturity Date”) and will be paid in full as to outstanding principal and accrued interest on the Maturity Date unless the Tranche 5 Promissory Note converts prior to the 2023 Maturity Date. Conversion into preferred shares occurs if the technology company engages in an additional equity financing event that yields gross cash proceeds in excess of $1,000,000 (“Next Equity Financing”).
In October 2022, the Company purchased an additional convertible promissory note in the same unrelated insurance technology company for $500,000 as part of the Tranche 6 offering (“Tranche 6 Promissory Note” and collectively, the “Convertible Promissory Notes”). The Tranche 6 Promissory Note pays eight percent (8)% interest per annum and matures September 30, 2024 (“2024 Maturity Date”) and will be paid in full as to outstanding principal and accrued interest on the 2024 Maturity Date unless the Tranche 6 Promissory Note converts prior to the 2024 Maturity Date. Conversion into preferred shares occurs if the technology company engages in an additional equity financing event that yields gross cash proceeds in excess of $5,000,000 (“Next Round Securities”).
The Company applies the available-for-sale method of accounting for its investment in the Convertible Promissory Note, which is a debt investment. The Convertible Promissory Note does not qualify for either the held-to-maturity method due to the Convertible Promissory Note’s conversion rights or the trading securities method because the Company holds the Convertible Promissory Note as a long-term investment. The Convertible Promissory Notes are measured at fair value at each reporting period-end. Unrealized gains and losses are reported in other comprehensive income until realized. As of December 31, 2022 and June 30, 2023, the Company evaluated the fair value of its investment and determined that the fair value approximates the carrying value of $1,000,000 and there was no unrealized gain or loss recorded.
XML 23 R17.htm IDEA: XBRL DOCUMENT v3.23.2
OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS
6 Months Ended
Jun. 30, 2023
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]  
OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS
Other Investments:
Convertible Preferred Stock Ownership—The Company owns convertible preferred stock in two entities, further described below.
On July 22, 2020, the Company purchased 224,551 units of an unrelated insurance technology company’s Series Seed Preferred units for $750,000 (“Seed Units”). During December 2022, the Company agreed to purchase 119,760 Series Seed Preferred Units for $400,000 in cash consideration by way of eight monthly payments of $50,000 starting December 15, 2022, resulting in a total of $950,000 investment as of March 31, 2023 and $1,100,000 investment as of June 30, 2023. Upon conversion, the Seed Units held by the Company would represent 8.6% control in the technology company.
On December 21, 2020, the Company purchased 207,476 shares of a separate unrelated insurance technology company’s Series B-1 preferred stock for $500,000 (“Preferred Shares”). The Preferred Shares are convertible into voting common stock of insured consent at the option of the Company. Upon conversion, the Preferred Shares would represent less than 1% control in the technology company.
The Company applies the measurement alternative for its investments in the Seed Units and Preferred Shares because these investments are of an equity nature, and the Company does not have the ability to exercise significant influence over operating and financial policies of entities even in the event of conversion of the Seed Units or Preferred Shares. Under the measurement alternative, the Company records the investment based on original cost, less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the investee. The Company’s share of income or loss of such companies is not included in the Company’s condensed consolidated statements of operations and comprehensive income. The Company tests its investments for impairment whenever circumstances indicate that the carrying value of the investment
may not be recoverable. No impairment of investments occurred for the three and six months ended June 30, 2023 and 2022.
Other Noncurrent Assets- at fair value:
S&P OptionsThe Company is long S&P 500 call options and short S&P 500 put options which were purchased and sold through a broker as an economic hedge related to the market-indexed debt instruments included in the long-term debt note. The value is based on shares owned and quoted market prices in active markets. Changes in fair value are recorded in the Unrealized Loss on Investments line item on the condensed consolidated statements of operations and comprehensive income.
XML 24 R18.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATION OF VARIABLE INTEREST ENTITIES
6 Months Ended
Jun. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
CONSOLIDATION OF VARIABLE INTEREST ENTITIES CONSOLIDATION OF VARIABLE INTEREST ENTITIES
The Company consolidates VIEs for which it is the primary beneficiary or VOEs for which it controls through a majority voting interest or other arrangement. See Note 2 for more information on how the Company evaluates an entity for consolidation.
The Company evaluated any entity in which it had a variable interest upon formation to determine whether the entity should be consolidated. The Company also evaluated the consolidation conclusion during each reconsideration event, such as changes in the governing documents or additional equity contributions to the entity. During the six months ended June 30, 2023, the Company’s consolidated VIEs, LMA Income Series II LP, LMX Series LLC (LMATT Series 2024, Inc.), Longevity Market Advisors, Regional Investment Services and LMA Income Series, LP, had total assets of $57,577,034 and liabilities of $52,474,820. For the year ended December 31, 2022, the Company’s consolidated VIEs, LMATT Series 2024, Inc., Longevity Market Advisors, Regional Investment Services and LMA Income Series, LP, had total assets and liabilities of $30,073,972 and $27,116,762, respectively. The Company did not deconsolidate any entities during the period ended June 30, 2023, or during the year ended December 31, 2022.
As of June 30, 2023, the Company held total assets of $801,345 and liabilities of $185,071, in unconsolidated VIEs. As of December 31, 2022, the Company held total assets of $987,964 and liabilities of $358,586 in unconsolidated VIEs.
XML 25 R19.htm IDEA: XBRL DOCUMENT v3.23.2
SEGMENT REPORTING
6 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
SEGMENT REPORTING SEGMENT REPORTING
Segment Information—The Company organizes its business into two reportable segments (1) Portfolio Servicing and (2) Active Management, which generate revenue in different manners.
This segment structure reflects the financial information and reports used by the Company’s management, specifically its chief operating decision maker (CODM), to make decisions regarding the Company’s business, including resource allocations and performance assessments, as well as the current operating focus in compliance with ASC 280, Segment Reporting. The Company’s CODM is the President and Chief Executive Officer.
The Portfolio Servicing segment generates revenues by providing policy services to customers on a contract basis.
The Active Management segment generates revenues by buying, selling, and trading policies and maintaining policies until receipt of death benefits. The Company’s reportable segments are not aggregated.
The Company’s method for measuring profitability on a reportable segment basis is gross profit. The CODM does not review asset information related to investments nor expenditures incurred for long-lived assets given the Company’s investments are recognized using the measurement alternative, and the Company’s long-lived assets are immaterial to the condensed consolidated financial statements.
Revenue related to the Company’s reporting segments for the three-month and six-month periods ended June 30, 2023, and June 30, 2022, is as follows:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Portfolio servicing$354,366 $419,422 $590,057 $990,328 
Active management11,024,399 7,979,479 20,994,917 17,285,971 
Total revenue$11,378,765 $8,398,901 $21,584,974 $18,276,299 
Information related to the Company’s reporting segments for the three-month and six-month periods ended June 30, 2023 and June 30, 2022 is as follows:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Portfolio servicing$(76,705)$280,303 $(166,128)$668,752 
Active management10,482,070 7,452,479 20,288,152 15,521,472 
Total gross profit10,405,365 7,732,782 20,122,024 16,190,224 
Sales and marketing(683,841)(1,019,498)(1,412,845)(1,649,498)
General, administrative and other(577,539)(5,499)(1,274,431)(646,705)
Depreciation(1,098)(1,098)(2,141)(2,141)
Other (expense) income121,601 (127,455)(21,651)(242,247)
Interest expense(584,075)(934,001)
Loss on change in fair value of debt(1,445,229)(333,879)(2,398,662)(375,513)
Unrealized gain (loss) on investments672,936 (1,039,022)798,156 (1,054,975)
Provision for income taxes(1,184,571)(120,132)(528,104)(296,806)
Less: Net loss attributable to non-controlling interests26,596 (406,641)487,303 (406,641)
Net income attributable to Abacus Life, Inc.$6,750,145 $4,679,558 $14,835,648 $11,515,698 
XML 26 R20.htm IDEA: XBRL DOCUMENT v3.23.2
COMMITMENTS AND CONTINGENCIES
6 Months Ended
Jun. 30, 2023
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIES
Legal Proceedings—Occasionally, the Company may be subject to various proceedings such as lawsuits, disputes, or claims. The Company assesses these proceedings as they arise and accrues a liability when losses are probable and reasonably estimable. Although legal proceedings are inherently unpredictable, the Company is currently not aware of any matters that, if determined adversely to the Company, would individually, or taken together, have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows.
Commitment—The Company has entered into a Strategic Services and Expenses Support Agreement (“Expense Support Agreement”) with two commonly owned full-service origination, servicing, and investment Providers in exchange for an option to purchase the outstanding equity ownership of the Providers. Pursuant to the Expense Support Agreement, Abacus Life, Inc. provides financial support and advice for the expenses of the Providers incurred in connection with their life settlement transactions
businesses and the Providers are required to hire a life settlement transactions operations employee of an affiliate of Abacus Life, Inc. No later than December 1 of each calendar year, Abacus Life, Inc. provides a budget for the Providers, in which Abacus Life, Inc. commits to extend financial support for all operating expenses up to the budgeted amount. “Operating Expenses” for purposes of the Expense Support Agreement means all annual operating expenses of the Providers incurred in the ordinary course of business, excluding the premiums paid for the Providers insurance coverages that are allocable to the insurance coverage provided to Institutional Life Holdings, LLC, which owns all the outstanding membership interests of the Providers if unrelated to the Providers settlement business.
For the three months ended June 30, 2023, Abacus Life, Inc. did not incur expenses related to the Expense Support Agreement. For the six months ended June 30, 2023, Abacus Life, Inc. incurred $29,721 of expenses, related to the Expense Support Agreement, which is included in the Other (expense) line of the condensed consolidated statements of operations and comprehensive income and have not been reimbursed by the Providers.
XML 27 R21.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE MEASUREMENTS
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTS
The Company determines fair value based on assumptions that market participants would use in pricing an asset or a liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:
Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.
Level 2 inputs: Other than quoted prices in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.
Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.
Recurring Fair Value Measurements—The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy are presented in the tables below.
Fair Value Hierarchy
As of June 30, 2023Level 1Level 2Level 3Total
Assets:
Life settlement policies$— $— $56,685,617 $56,685,617 
Available-for-sale securities, at fair value— — 1,000,000 1,000,000 
Other investments— — 1,600,000 1,600,000 
S&P 500 options1,794,640 — — 1,794,640 
Other assets7,246 — — 7,246 
Total assets held at fair value$1,801,886 $— $59,285,617 $61,087,503 
Liabilities:
Long-term debt$— $— $66,165,396 $66,165,396 
Private placement warrants— — 2,438,600 2,438,600 
Total liabilities held at fair value:$— $— $68,603,996 $68,603,996 
Fair Value Hierarchy
As of December 31, 2022Level 1Level 2Level 3Total
Assets:
Life settlement policies$— $— $13,809,352 $13,809,352 
Available-for-sale securities, at fair value— — 1,000,000 1,000,000 
Other investments— — 1,300,000 1,300,000 
S&P 500 options890,829 — — 890,829 
Total assets held at fair value$890,829 $— $16,109,352 $17,000,181 
Liabilities:
Long-term debt$— $— $28,249,653 $28,249,653 
Total liabilities held at fair value:$— $— $28,249,653 $28,249,653 
Life Settlement PoliciesThe Company separately accounts for each owned life settlement policy using either the fair value method, or investment method (cost, plus premiums paid). The valuation method is chosen upon contract acquisition and is irrevocable.
For policies carried at fair value, the Company utilizes valuation services of a third-party actuarial firm, who values the contracts using Level 3 unobservable inputs, including actuarial assumptions, such as life expectancies and cash flow discount rates. The valuation model is based on a discounted cash flow analysis and is sensitive to changes in the discount rate used. The Company utilized a discount rate of 16% at June 30,2023 and 12% at December 31, 2022, respectively, for policy valuation, which is based on economic and company-specific factors.
Subsequent to the reporting date, the Company sold 3 policies carried at fair value. As of June 30, 2023, the Company valued these 3 policies using the price at the time of sale. Valuing these 3 policies using the takeout price resulted in a decrease in valuation of $231,775 compared to the third-party valuation.
For life settlement policies carried using the investment method, the Company measures these at the cost of the policy plus premiums paid. The policies accounted for using the investment method totaled $9,889,610 at June 30, 2023 and $8,716,111 at December 31, 2022, respectively.
Discount Rate Sensitivity—Changes in the 16% discount rate on the death benefit and premiums used to estimate the policies issued under LMATT Series 2024 Inc., LMATT Growth Series 2.2024 Inc., LMATT Growth and Income Series 1.2026, Inc., LMA Income Series, LP and LMA Income Series II, LP (“LMATT Policies”) fair value has been analyzed. If the discount rate increased or decreased by 2 percentage points and the other assumptions used to estimate fair value remained the same, the change in estimated fair value as of June 30, 2023, would be as follows:
As of June 30, 2023Fair ValueChange in
Fair Value
Rate Adjustment
+2%$53,987,508 $(2,698,109)
No change56,685,617 
-2%59,857,879 3,172,262 
Credit Exposure to Insurance Companies—The following table provides information about the life insurance issuer concentrations that exceed 10% of total face value or 10% of total fair value of the Company’s life insurance policies as of June 30, 2023:
CarrierPercentage of
Face Value
Percentage of
Fair Value
Carrier
Rating
American General Life Insurance Company14.0 %11.0 %A
ReliaStar Life Insurance Company6.0 %12.0 %A
Lincoln National Life Insurance Company14.0 %12.0 %A
The following table provides a roll forward of the fair value of life insurance policies for the six months-ended June 30, 2023:
Fair value at December 31, 2022$13,809,352 
Policies purchased58,543,580 
Realized gain (loss) on matured/sold policies1,898,958 
Premiums paid(879,462)
Unrealized gain(loss) on held policies3,319,588 
Change in estimated fair value4,339,084 
Matured/sold policies(20,885,861)
Premiums paid879,462 
Fair value at June 30, 2023$56,685,617 
Long-Term Debt—See Note 13. “Long-Term Debt” for background information on the market-indexed debt. The Company has elected the fair value option in accounting for the instruments. Fair value is determined using Level 3 inputs. The valuation methodology is based on the Black-Scholes-Merton option-pricing formula and a discounted cash flow analysis. Inputs to the Black-Scholes-Merton model include (i) the S&P 500 Index price, (ii) S&P 500 Index volatility, (iii) a risk-free rate based on data published by the US Treasury, and (iv) a term assumption based on the contractual term of the LMATT Notes. The discounted cash flow analysis includes a discount rate that is based on the implied discount rate developed by calibrating a valuation model to the purchase price on the initial investment date. The implied discount rate is evaluated for reasonableness by benchmarking it to yields on actively traded comparable securities.
The total change in fair value of the debt resulted in a gain of $1,602,042. This gain is comprised of $90,148, net of tax, which is included within accumulated other comprehensive income and $29,515 net of tax, which is included in equity of noncontrolling interests resulting from risk-adjusted valuation scenarios. The Company recognized a loss of $1,445,229 on the change in fair value of the debt resulting from risk-free valuation scenarios, which is included within Change in fair value of debt within the condensed consolidated statement of operations and comprehensive income for the three months ended June 30, 2023.
The total change in fair value of the debt resulted in a gain of $2,705,918. This gain is comprised of $175,530, net of tax, which is included within accumulated other comprehensive income and $56,446 net of tax, which is included in equity of noncontrolling interests resulting from risk-adjusted valuation scenarios. The Company recognized a loss of $2,398,662 on the change in fair value of the debt resulting from risk-free valuation scenarios, which is included within Change in fair value of debt within the condensed consolidated statement of operations and comprehensive income for the six months ended June 30, 2023.
The following table provides a roll forward of the fair value of the issued notes for the six months ended June 30, 2023:
Fair value at December 31, 2022$28,249,653 
Debt issued to third parties35,209,825 
Unrealized loss on change in fair value (risk-free)2,398,662 
Unrealized gain on change in fair value (credit-adjusted)307,256 
Change in estimated fair value2,705,918 
Fair value at June 30, 2023$66,165,396 
Private Placement Warrants—Simultaneously with the closing of the Initial Public Offering, ERES consummated the sale of 8,900,000 warrants (the “Private Placement Warrants”) to East Sponsor, LLC (the “Sponsor”), which included the sale of an additional 900,000 Private Placement Warrants in connection with the full exercise by the underwriters of their over-allotment option on August 25, 2020, at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of $8,900,000. Each Private Placement Warrant is exercisable for one share of Class A common stock at a price of $11.50 per share, subject to adjustment.

The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that (x) the Private Placement Warrants and the shares of Class A common stock issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or
salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions, (y) the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees and (z) the Private Placement Warrants and the shares of Class A common stock issuable upon exercise of the Private Placement Warrants will be entitled to registration rights. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.
Private Placement Warrants were accounted for as liabilities in accordance with ASC 815-40. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented separately in the condensed consolidated statements of operations.

The Private Placement Warrants were considered a Level 3 fair value measurement using a binomial lattice model in a risk-neutral framework. The binomial lattice model’s primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the expected volatility of the common stock. The implied volatility as of the reporting date was derived from observable public warrant traded price provided by Bloomberg LP.

The following table presents the key assumptions in the analysis:
Private Placement Warrants
Expected implied volatility de minimis
Risk-free interest rate 4.09%
Term to expiration 5.0 years
Exercise price$11.50
Common Stock Price $10.03
Dividend Yield—%
Other Noncurrent Assets: S&P 500 Options—In February 2022, LMATT Series 2024, Inc., which the Company consolidates for financial reporting, purchased and sold S&P 500 call and put options through a broker. The Company purchased and sold additional S&P 500 call options through a broker in June 2022 through their 100% owned and fully consolidated subsidiaries LMATT Growth Series 2.2024, Inc. and LMATT Growth and Income Series 1.2026, Inc. The options are exchange traded, and fair value is determined using Level 1 inputs of quoted market prices as of the condensed consolidated balance sheets dates. Changes in fair value are classified as unrealized (gain)/loss on investments within the condensed consolidated statements of operations and comprehensive income.
Financial Instruments Measured at Fair Value on a Nonrecurring Basis—The following financial assets, composed of equity securities without readily determinable fair values, are adjusted to fair value when observable price changes are identified, or an impairment charge is recognized. Such fair value measurements are based predominantly on Level 3 inputs.
Available-for-Sale Investment—The Convertible Promissory Note is classified as an available-for-sale security. Available-for-sale investments are subsequently measured at fair value. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income until realized. The Company determines fair value of its available-for-sale investments using unobservable inputs by considering the initial investment value, next round financing, and the likelihood of conversion or settlement based on the contractual terms in the agreement. The Company initially purchased a $250,000 convertible promissory note from the issuer in 2021 and then on January 7, 2022, the Company purchased an additional $250,000 convertible promissory note from the same issuer and then an additional $500,000 in October 2022. As of June 30, 2023 and December 31, 2022, the Company
evaluated the fair value of its Promissory Note and determined that the fair value approximates the carrying value of $1,000,000 and $1,000,000, respectively.
Other Investments—The Company determines fair value using Level 3 inputs under the measurement alternative. These investments are recorded at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Impairment is assessed qualitatively. As of June 30, 2023, and December 31, 2022, the Company did not identify any impairment indicators and determined that the carrying value of $1,600,000 and $1,300,000 is the fair value for these equity investments in privately held companies, given that there have been no observable price changes.
Financial Instruments Where Carrying Value Approximates Fair Value—The carrying value of cash, cash equivalents, accounts receivables, and due to affiliates approximates fair value due to the short-term nature of their maturities.
XML 28 R22.htm IDEA: XBRL DOCUMENT v3.23.2
LONG-TERM DEBT
6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
LONG-TERM DEBT LONG-TERM DEBT
Long-term debt comprises of the following:
Six Months Ended
June 30, 2023
Year Ended
December 31, 2022
CostFair valueCostFair value
Market-indexed notes:
LMATT Series 2024, Inc.$9,866,900 $9,621,141 $9,866,900 $8,067,291 
LMATT Series 2.2024, Inc.2,333,391 3,446,527 2,333,391 2,354,013 
LMATT Growth & Income Series 1.2026, Inc400,000 459,553 400,000 400,000 
Secured borrowing:
LMATT Income Series, LP21,889,444 22,124,676 17,428,349 17,428,349 
LMATT Income Series II, LP20,041,851 20,041,851 — — 
Unsecured borrowing:
Sponsor PIK Note10,471,648 10,471,648 — — 
Total long-term debt$65,003,234 $66,165,396 $30,028,640 $28,249,653 
SPV purchase and sale note$25,000,000 $25,000,000 — — 
Sponsor PIK Note
On the June 30, 2023, in connection with the consummation of the Business Combination and as contemplated by the Merger Agreement, East Sponsor, LLC, a Delaware limited liability company (“Sponsor”), made an unsecured loan to the Company in the aggregate amount of $10,471,648 (the “Sponsor PIK Note”). The Sponsor PIK Note matures on June 30, 2028 (the “Maturity Date”) and may be prepaid at any time in accordance with its terms without any premium or penalty.
LMATT Series 2024, Inc. Market-Indexed Notes:
On March 31, 2022, LMATT Series 2024, Inc., which the Company consolidates for financial reporting, issued $10,166,900 in market-indexed private placement notes. The note, titled the Longevity Market Assets Target-Term Series (LMATTS) 2024, is a market-indexed instrument designed to provide upside performance exposure of the S&P 500 Index, while limiting downward exposure. Upon maturity of the note in 2024, the principal, plus the return based upon the S&P 500 Index must be paid. The note has a
feature to protect debt holders from market downturns, up to 40%. Any subsequent losses below the 40% threshold will reduce the note on a one-to-one basis. As of June 30, 2023, $9,866,900 of the principal amount remained outstanding.
The notes are held at fair value, which represents the exit price, or anticipated price to transfer the liability to a third party. As of June 30, 2023, the fair value of the LMATT Series 2024, Inc. notes were $9,621,141.
The notes are secured by the assets of the issuing entities, which includes cash, S&P 500 options, and life settlement policies totaling $11,195,701 as of June 30, 2023. The notes’ agreements do not restrict the trading of life settlement contracts prior to maturity of the note, as total assets of the issuing companies are considered as collateral. There are also no restrictive covenants associated with the notes with which the entities must comply.
LMATT Series 2.2024, Inc. Market-Indexed Notes:
On September 16, 2022, LMATTS Series 2.2024, Inc., a 100% owned subsidiary which the Company consolidates for financial reporting issued $2,333,391 in market-indexed private placement notes. The note, titled the Longevity Market Assets Target-Term Growth Series 2.2024, Inc. (“LMATTSTM Series 2.2024, Inc.”) is a market-indexed instrument designed to provide upside performance exposure of the S&P 500 Index, while limiting downward exposure. Upon maturity of the note in 2024, the principal, plus the return based upon the S&P 500 Index must be paid. The note has a feature to provide upside performance participation that is capped at 120% of the performance of the S&P 500. A separate layer of the note has a feature to protect debt holders from market downturns by up to 20% if the index price experiences a loss during the investment period. After the underlying index has decreased in value by more than 20%, the investment will experience all subsequent losses on a one-to-one basis. . As of June 30, 2023, the entire principal amount remained outstanding.
The notes are held at fair value, which represents the exit price, or anticipated price to transfer the liability to a third party. As of June 30, 2023, the fair value of the LMATT Series 2.2024, Inc. notes were $3,446,527.
The notes are secured by the assets of the issuing entity, LMATT Series 2.2024, Inc., which includes cash, S&P 500 options, and life settlement policies totaling $3,331,872 as of June 30, 2023. The note agreements do not restrict the trading of life settlement contracts prior to maturity of the note, as total assets of the issuing company are considered as collateral. There are also no restrictive covenants associated with the note with which the entity must comply.
LMATT Growth and Income Series 1.2026, Inc. Market-Indexed Notes:
Additionally, on September 16, 2022, LMATTS Growth and Income Series 1.2026, Inc., a 100% owned subsidiary which the Company consolidates for financial reporting issued $400,000 in market-indexed private placement notes. The note, titled the Longevity Market Assets Target-Term Growth and Income Series 1.2026, Inc (“LMATTSTM Growth and Income Series 1.2026, Inc.”) is a market-indexed instrument designed to provide upside performance exposure of the S&P 500 Index, while limiting downward exposure. Upon maturity of the note in 2026, the principal, plus the return based upon the S&P 500 Index must be paid. The note has a feature to provide upside performance participation that is capped at 140% of the performance of the S&P 500. A separate layer of the note has a feature to protect debt holders from market downturns by up to 10% if the index price experiences a loss during the investment period. After the underlying index has decreased in value by more than 10%, the investment will experience all subsequent losses on a one-to-one basis. This note also includes 4% dividend feature that will be paid annually. As of June 30, 2023, the entire principal amount remained outstanding.
The notes are held at fair value, which represents the exit price, or anticipated price to transfer the liability to a third party. As of June 30, 2023, the fair value of the LMATT Growth and Income Series 1.2026, Inc., notes were $459,553.
The notes are secured by the assets of the issuing entity, LMATTS Growth and Income Series 1.2026, Inc., which includes cash, S&P 500 options, and life settlement policies totaling $517,218 as of June 30, 2023. The note agreements do not restrict the trading of life settlement contracts prior to maturity of the note, as total assets of the issuing company are considered as collateral. There are also no restrictive covenants associated with the note with which the entity must comply.
See additional fair value considerations within footnote 12.
LMA Income Series, LP and LMA Income Series, GP LLC Secured Borrowing
LMA Income Series, GP, LLC, wholly owned and controlled by that LMA Series, LLC, formed a limited partnership, LMA Income Series, LP and issued partnership interests to limited partners in a private placement offering. The initial term of the offering is three years with the ability to extend for two additional one-year periods at the discretion of the general partner, LMA Income Series, GP, LLC. The limited partners will receive an annual dividend of 6.5% paid quarterly and 25% of returns in excess of a 6.5% internal rate of return capped at 9% which would require a 15% net internal rate of return. The General Partner will receive 75% of returns in excess of a 6.5% internal rate of return to limited partners then 100% in excess of a 15% net internal rate of return.
It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series, LP and thus has fully consolidated the limited partnership in its consolidated financial statements for the six months ended June 30, 2023.
The private placement offerings proceeds will be used to acquire an actively managed large and diversified portfolio of financial assets. LMA, through its consolidated subsidiaries, serves as the portfolio manager for the financial asset portfolio, which includes investment sourcing and monitoring. In this role, LMA has the unilateral ability to acquire and dispose of any of the above investments. As the partnership does not represent a business in accordance with ASC 810 and is a consolidated subsidiary that only holds financial assets, this represents a transfer subject to ASC 860-10. As the financial assets are not transferred outside the consolidated group, the proceeds from the offering shall be classified as a liability unless it meets the definition of a participating interest and the derecognition criteria in ASC 860 are met. The transferred interest did not meet the definition of a participating interest as LMA possesses the unilateral ability to direct the sale of the financial assets (ASC 860-10-50-6A(d)). In accordance with ASC 860-30-25-2, as the transfer of the financial assets did not meet the definition of a participating interest, LMA shall recognize the proceeds received from the offering as a secured borrowing.
LMA elected to account for the secured borrowing at fair value under the collateralized financing entity guidance within ASC 810-10-30. As of June 30, 2023, the fair value of the secured borrowing was $22,124,676.
LMA Income Series II, LP and LMA Income Series II, GP LLC Secured Borrowing
LMA Income Series II, GP, LLC, wholly owned and controlled by that LMA Series, LLC, formed a limited partnership, LMA Income Series II, LP and issued partnership interests to limited partners in a private placement offering. The initial term of the offering is three years with the ability to extend for two additional one-year periods at the discretion of the general partner, LMA Income Series II, GP, LLC. The limited partners will receive annual dividends equal to the Preferred Return Amounts as follows: Capital commitment less than $500,000, 7.5%; between $500,000 and $1,000,000, 7.75%; over $1,000,000, 8%. Thereafter, 100% of the excess to be paid to the General Partner.
It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series, LP and thus has fully consolidated the limited partnership in its consolidated financial statements for the three and six months ended June 30, 2023.
The private placement offerings proceeds will be used to acquire an actively managed large and diversified portfolio of financial assets. LMA, through its consolidated subsidiaries, serves as the portfolio manager for the financial asset portfolio, which includes investment sourcing and monitoring. In this role, LMA has the unilateral ability to acquire and dispose of any of the above investments. As the partnership does not represent a business in accordance with ASC 810 and is a consolidated subsidiary that only holds financial assets, this represents a transfer subject to ASC 860-10. As the financial assets are not transferred outside the consolidated group, the proceeds from the offering shall be classified as a liability unless it meets the definition of a participating interest and the derecognition criteria in ASC 860 are met. The transferred interest did not meet the definition of a participating interest as LMA possesses the unilateral ability to direct the sale of the financial assets (ASC 860-10-50-6A(d)). In accordance with ASC 860-30-25-2, as the transfer of the financial assets did not meet the definition of a participating interest, LMA shall recognize the proceeds received from the offering as a secured borrowing.
LMA elected to account for the secured borrowing at fair value under the collateralized financing entity guidance within ASC 810-10-30. As of June 30, 2023, the fair value of the secured borrowing was $20,041,851.

SPV Purchase and Sale

On July 5, 2023, the Company entered into an Asset Purchase Agreement (the “Policy APA”) to acquire certain insurance policies with an aggregate fair market value of $10.0 million from Abacus Investment SPV, LLC, a Delaware limited liability company (“SPV”), in exchange for a payable obligation owing by the Company to the SPV (such acquisition transaction under the Policy APA, the “SPV Purchase and Sale”).
The payable obligation owing by the Company to the SPV in connection with the SPV Purchase and Sale is evidenced by a note issued by the Company under the SPV Investment Facility (the “SPV Purchase and Sale Note”) in an original principal amount equal to the aggregate fair market value of the acquired insurance policies. The SPV Purchase and Sale Note has the same material terms and conditions as the other credit extensions under the SPV Investment Facility (as defined below).
SPV Investment Facility
On July 5, 2023, the Company entered into that certain SPV Investment Facility (the “SPV Investment Facility”), between the Company, as borrower, and the SPV, as lender.
The SPV Investment Facility, among other things:
requires certain subsidiaries of the Company to guarantee the credit extensions provided under the SPV Investment Facility pursuant to separate documentation
is unsecured without collateral security provided in favor of the SPV and subordinated in right of payment to the Company’s obligations under the Owl Rock Credit Facility, subject to limited specified exceptions and circumstances for permitting early payment;
provides for certain credit extensions in an aggregate principal amount of $25.0 million, including: (i) an initial credit extension in an original principal amount of $15.0 million that was funded upon the closing of the SPV Investment Facility, and (ii) the SPV Purchase and Sale Note in favor of the SPV in an original principal amount of $10.0 million to finance the purchase of the insurance policies under the Policy APA;
provides proceeds from the SPV Investment Facility for payment of certain transaction expenses, general corporate purposes and any other purposes not prohibited by the agreement or applicable law;
matures on July 5, 2026, three years after the closing of the SPV Investment Facility, subject to two automatic extensions of one year each without any amendment of the relevant documentation, but also subject to applicable subordination restrictions in relation to the Owl Rock Credit Facility;
provides for interest to accrue on the SPV Investment Facility at a rate of 12.00% per annum, payable quarterly, all of which is to be paid in-kind by the Company by increasing the principal amount of the SPV Investment Facility owing to the SPV on each interest payment date;
provides a default rate that will accrue at 2.00% per annum (subject to applicable subordination restrictions) over the rate otherwise applicable. If cash payment is not permitted due to applicable subordination restrictions or otherwise, such default interest shall be paid in-kind;
provides that no amortization payments shall be required prior to maturity;
contains financial and other covenants substantially similar and not materially worse than those contained in the Owl Rock Credit Facility from the perspective of the Company; and
provides for certain specified events of default (including certain events of default subject to grace or cure periods), with the occurrence and during the continuance of such events of default enabling the lender under the SPV Investment Facility to accelerate the obligations under the SPV Investment Facility, among other rights or remedies, subject to applicable subordination restrictions.
The SPV’s investment resulting from credit extensions under the SPV Investment Facility is treated by the Company as debt for U.S. GAAP accounting purposes. While the timing of the Policy APA and SPV Investment Facility occurred on July 5, 2023, such amounts are included within the condensed consolidated balance sheet as cash was received prior to June 30, 2023.
XML 29 R23.htm IDEA: XBRL DOCUMENT v3.23.2
SHAREHOLDERS' EQUITY
6 Months Ended
Jun. 30, 2023
Equity [Abstract]  
SHAREHOLDERS' EQUITY SHAREHOLDERS’ EQUITY
The Company is authorized to issue up to 200,000,000 shares of common stock, par value $0.0001 per share, and 1,000,000 shares of preferred stock, par value $0.0001 per share. No shares of preferred stock are issued or outstanding. Holders of the Company’s common stock are entitled to one vote for each share. As of June 30, 2023, there were 62,961,688 shares of common stock issued and outstanding. Holders of shares were entitled to receive, in the event of a liquidation, dissolution or winding up, ratably the assets available for distribution to the shareholders after payment of all liabilities.
The equity structure has been recast in all comparative periods up to the Closing Date to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to legacy LMA’s stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to legacy LMA common stock prior to the Business Combination have been retroactively recast as shares reflecting the exchange ratio of 0.8 established in the Business Combination. As of December 31, 2022, this resulted in 50,369,350 shares of common stock issued and outstanding.

Public Warrants

As of June 30, 2023, the Company has 17,250,000 Public Warrants outstanding. Each redeemable whole Public Warrant entitles the holder thereof to purchase one share of common stock at a price of $11.50 per full share, subject to adjustment as described. The Public Warrants represent a freestanding financial instrument as it is traded on the Nasdaq under the symbol “ABLLW” and legally detachable and separately exercisable from the related underlying shares of the Company’s common stock. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination and (b) 12 months from the closing of the Proposed
Offering. The Public Warrants will expire five years from the completion of a Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.

The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act with respect to the shares of Class A common stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable and the Company will not be obligated to issue a share of Class A common stock upon exercise of a warrant unless the share of Class A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.

Redemption of Warrants for Cash - Once the warrants become exercisable, the Company may redeem the outstanding Public Warrants for cash:
in whole and not in part;
at a price of $0.01 per Public Warrant;
upon not less than 30 days’ prior written notice of redemption to each warrant holder; and
if, and only if, the last sale price of the Class A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

If and when the Public warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. However, the Company will not redeem the warrants unless an effective registration statement under the Securities Act covering the shares of Class A common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of Class A common stock is available throughout the 30-day redemption period, except if the warrants may be exercised on a cashless basis and such cashless exercise is exempt from registration under the Securities Act.

Redemption of Warrants for Shares of Class A Common Stock - Once the Public warrants become exercisable, the Company may redeem the outstanding warrants for shares of Class A common stock:
in whole and not in part;
at a price equal to a number of shares of Class A common stock to be determined by reference to the agreed table set forth in the warrant agreement based on the redemption date and the “fair market value” of the Class A common stock;
upon not less than 30 days’ prior written notice of redemption to each warrant holder; and
if, and only if, the last sale price of the Class A common stock equals or exceeds $10.00 per share (as adjusted per share splits, share dividends, reorganizations, recapitalizations and the like) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.

In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of the Company’s initial Business Combination at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective issue price to be determined in good faith by our board of directors), (y) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Price”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of Market Price and the newly issued price. Further, the $10.00 and
$18.00 per share redemption trigger prices will be adjusted to be equal to 100% and 180%, respectively, of the higher of the market value and the newly issued price.

If the Company elects to redeem all of the Public Warrants or the common stock is at the time of any exercise of a Public Warrant not listed on a national securities exchange, management has the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. In such event, each holder would pay the exercise price by surrendering the whole warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. However, in no instance can the warrant holder unilaterally decide to exercise its Public Warrant on a cashless basis.

Upon the Business Combination, the Company accounted for the Public Warrants issued with the IPO as equity instruments. The Company accounted for the warrant as an expense of the IPO resulting in a charge directly to stockholders’ equity. The Company estimates that the fair value of the warrants upon the Business Combination is approximately $4.73 million, or $0.274 per Public Warrant, using the binomial lattice model. The fair value of the warrants is estimated as of the date of grant using the following assumptions: (1) risk-free interest rate of 4.09%, (2) term to expiration of 5.0 years, (3) exercise price of $11.50 and (4) stock price of $10.03.
XML 30 R24.htm IDEA: XBRL DOCUMENT v3.23.2
EMPLOYEE BENEFIT PLAN
6 Months Ended
Jun. 30, 2023
Postemployment Benefits [Abstract]  
EMPLOYEE BENEFIT PLAN EMPLOYEE BENEFIT PLANThe Company has a defined contribution plan in the U.S. intended to qualify under Section 401(k) of the Internal Revenue Code (the “401(k) Plan”). The 401(k) Plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer up to 100% of their annual compensation on a pretax basis. For the year ended December 31, 2022, the Company elected to match 50% of employee contributions up to a maximum of 4% of eligible employee compensation. For the three months ended June 30, 2023 and 2022, the Company recognized expenses related to the 401(k) Plan amounting to $13,075 and $2,577, respectively and for the six months ended June 30, 2023 and 2022, the Company recognized expenses related to the 401(k) Plan amounting to $25,315 and $8,048, respectively.
XML 31 R25.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES
6 Months Ended
Jun. 30, 2023
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXES
Before June 30, 2023, the Company elected to file as an S corporation for Federal and state income tax purposes, the Company incurred no Federal or state income taxes, except for income taxes recorded related to some of their consolidated variable interest entities and subsidiaries which are taxable C corporations. These VIE’s and subsidiaries include LMATT Series 2024, Inc., the wholly owned subsidiary of LMX, which is consolidated into LMA as a VIE, as well as LMATT Growth Series 2.2024, Inc., a wholly owned subsidiary of LMATT Growth Series, Inc., and LMATTS Growth and Income Series 1.2026, Inc., a wholly owned subsidiary of LMATT Growth and Income Series, Inc., all of which are 100% owned subsidiaries and fully consolidated. Accordingly, the provision for income taxes was attributable to amounts for LMATT Series 2024, Inc, LMATT Growth Series, Inc. and LMATT Growth and Income Series, Inc.
For the three months ended June 30, 2023 and 2022, the Company recorded provision for income taxes of $1,184,571 and $120,132, respectively. The effective tax rate is 15.0% for the three months ended June 30, 2023. The effective rate for the three months ended June 30, 2022 was 12.0% due to the impact of state income taxes and the release of the Company’s valuation allowance, as there was sufficient evidence of the Company’s ability to generate future taxable income at June 30, 2022.
For the six months ended June 30, 2023 and 2022, the Company recorded provision for income taxes of $528,104 and $296,806, respectively. The effective tax rate is 3.6% for the six months ended June 30, 2023. The existence of non-taxable flow-through entities within the Company as well as a change in tax status of certain entities upon the Business Combination caused the effective tax rate to be significantly lower than the statutory rate. The effective rate for the six months ended June 30, 2022 was 18% due to the impact of state income taxes and the release of the Company’s valuation allowance, as there was sufficient evidence of the Company’s ability to generate future taxable income at June 30, 2022.
The Company did not have any unrecognized tax benefits relating to uncertain tax positions as of June 30, 2023, and December 31, 2022, and did not recognize any interest or penalties related to uncertain tax positions as of June 30, 2023, and December 31, 2022.
XML 32 R26.htm IDEA: XBRL DOCUMENT v3.23.2
RELATED-PARTY TRANSACTIONS
6 Months Ended
Jun. 30, 2023
Related Party Transactions [Abstract]  
RELATED-PARTY TRANSACTIONS RELATED-PARTY TRANSACTIONS
As of June 30, 2023 and December 31, 2022, $10,415,154 and $263,785, respectively, were due to members and affiliates primarily for reimbursable transaction costs as well as distributions to owners of $717,429 as a part of the Business Combination as of June 30, 2023. As of June 30, 2023 and December 31, 2022, $10,473,748 and $2,904,646 was due from affiliates, respectively. The amount to be received as of June 30, 2023 is due from the Sponsor as part of the Sponsor PIK Note. Additionally, the SPV purchase and sale note for $25,000,000 as of June 30, 2023 was also recorded as a related party transaction given the transfer of cash and policies between the Company and the SPV. Refer to footnote 13 for more information.
The Company has a related-party relationship with Nova Trading (US), LLC (“Nova Trading”), a Delaware limited liability company and Nova Holding (US) LP, a Delaware limited partnership (“Nova Holding” and collectively with Nova Trading, the “Nova Funds”). The Company also earns service revenue related to policy and administrative services on behalf of Nova Funds. The servicing fee is equal to 50 basis points (0.50%) times the monthly invested amount in policies held by Nova Funds divided by 12. The Company earned $197,629 and $205,224, respectively, in service revenue related to Nova Funds for the three months ended June 30, 2023 and 2022 and earned $411,076 and $406,129, respectively, in service revenue related to Nova Funds for the six months ended June 30, 2023 and 2022.
Prior to the Merger, LMA used Abacus to originate life settlement policies that it accounts for under the investment method. For the three and six months ended June 30, 2023, the Company incurred $837,975 and $1,627,975, respectively in origination costs for life settlement policies that were originated by Abacus. These costs are capitalized on the condensed consolidated balance sheets as life settlement policies, at cost.
As of June 30, 2023, and December 31, 2022, there were $72,600 and $196,289, respectively owed from the Nova Funds, which are included as related-party receivables in the accompanying condensed consolidated balance sheets.
XML 33 R27.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES
6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
LEASES LEASES
The Company’s right-of-use assets and lease liabilities for its operating lease consisted of the following amounts as of June 30, 2023 and December 31, 2022:
Six Months Ended
June 30, 2023
Year Ended
December 31, 2022
Assets:
Operating lease right-of-use assets$240,816 $77,011 
Liabilities:
Operating lease liability, current227,561 48,127 
Operating lease liability, non-current16,864 29,268 
Total lease liability$244,425 $77,395 
The Company recognizes lease expense for its operating leases within general, administrative, and other expenses on the Company’s condensed consolidated statements of operations and comprehensive income. The Company’s lease expense for the periods presented consisted of the following:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Operating lease cost$12,471 $11,921 $24,942 $23,842 
Variable lease cost7,704 612 8,925 1,223 
Total lease cost$20,175 $12,533 $33,867 $25,065 
The following table shows supplemental cash flow information related to lease activities for the periods presented:
Six Months Ended June 30,
20232022
Cash paid for amounts included in the measurement of the lease liability
Operating cash flows from operating leases$24,557 $23,842 
ROU assets obtained in exchange for new lease liabilities— — 
The table below shows a weighted-average analysis for lease terms and discount rates for all operating leases for the periods presented:
Six Months Ended
June 30, 2023
Year Ended December 31, 2022
Weighted-average remaining lease term (in years)1.001.58
Weighted-average discount rate3.54 %3.36 %
Future minimum noncancellable lease payments under the Company’s operating leases on an undiscounted basis reconciled to the respective lease liability at June 30, 2023 are as follows:
Operating leases
Remaining of 2023$130,176 
2024118,057 
2025— 
2026— 
2027— 
Thereafter— 
Total operating lease payments (undiscounted)248,233 
Less: Imputed interest(3,808)
Lease liability as of June 30, 2023$244,425 
XML 34 R28.htm IDEA: XBRL DOCUMENT v3.23.2
EARNINGS PER SHARE
6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
EARNINGS PER SHARE EARNINGS PER SHARE
Basic earnings per share represents income available to ordinary shareholders divided by the weighted average number of ordinary shares outstanding during the reported period. Net income per ordinary share is computed by dividing net income by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the Public and Private Placement Warrants to purchase an aggregate of 26,150,000 shares in the calculation of diluted income per ordinary share, since the average market price of the Company’s Class A common shares for the three and six months ended June 30, 2023 was below the warrants’ $11.50 exercise price. As a result, diluted income per share is the same as basic net income per share for the period presented.

Basic and diluted weighted average shares outstanding and earnings per share were as follows:

Three Months EndedSix Months Ended
June 30, 2023June 30, 2022June 30, 2023June 30, 2022
Net income attributable to Longevity Market Assets$6,750,145 $4,679,558 $14,835,648 $11,515,698 
Weighted-average shares used in computing net income per share, basic and diluted50,507,728 50,369,350 50,438,921 50,369,350 
Basic and diluted earnings per share:$0.13 $0.09 $0.29 $0.23 
XML 35 R29.htm IDEA: XBRL DOCUMENT v3.23.2
SUBSEQUENT EVENTS
6 Months Ended
Jun. 30, 2023
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS SUBSEQUENT EVENTS
The Company evaluated subsequent events and transactions from the condensed consolidated balance sheet date through the date at which the condensed consolidated financial statements were issued.
Owl Rock Credit Facility
On July 5, 2023 (the “Owl Rock Closing Date”), the Company entered into that certain Credit Agreement (the “Owl Rock Credit Facility”), among the Company, as borrower, the several banks and other persons from time to time party thereto (the “Owl Rock Lenders”), and Owl Rock Capital Corporation, as administrative and collateral agent for the Owl Rock Lenders thereunder.
The Owl Rock Credit Facility, among other things:
requires the Company and certain subsidiaries of the Company to guarantee the loans provided under the Owl Rock Credit Facility pursuant to separate loan documentation;
provides credit extensions for (i) an initial term loan in an aggregate principal amount of $25.0 million upon the closing of the Owl Rock Credit Facility and (ii) optional delayed draw term loans (which can be drawn on multiple drawing dates) in an aggregate principal amount of up to $25.0 million available for one hundred eighty (180) days after the Owl Rock Closing Date (the “Delayed Draw Term Loan Availability Period”), subject to the requirement that on each delayed draw date, the liquid asset coverage ratio shall not be less than 1.80 to 1.00, together with other specified conditions to drawings, the proceeds of which may be used for working capital and the business requirements of the enterprise, and to fund acquisitions, investments and other transactions permitted by the loan documentation;
provides a delayed draw commitment fee rate of 0.50% per annum applicable to undrawn commitments during the Delayed Draw Term Loan Availability Period
matures on July 5, 2028, the date that is five years after the closing of the Owl Rock Credit Facility;
is secured by a first-priority security interest in substantially all of the assets of the Company and the subsidiary guarantors. No pledge of any equity interests in the Company is required by any holder of such equity interests;
provides for interest to accrue on the loans drawn under the Owl Rock Credit Facility at the election of the Company, by reference to either (i) an alternative base rate (such loans, “ABR Loans”) or (ii) an adjusted term SOFR rate (such loans, “SOFR Loans”) plus an applicable margin. The adjusted term SOFR rate is determined by the applicable term SOFR for a relevant interest period plus a credit spread adjustment of 0.10%, 0.15% and 0.25% per annum for interest periods of one, three and six months, respectively. The applicable margin for each type of loan is (i) 6.25% per annum for any ABR Loans and (ii) 7.25% per annum for any SOFR Loans, with interest periods for SOFR Loans of one, three or six months (or other periods if agreed by all lenders);
provides a default rate that will accrue at 2.00% per annum over the rate otherwise applicable;
provides for amortization payments based on the initial principal amount of the loans outstanding of 1.0% per year (0.25% due per quarter), with adjustments made to the overall amortization amount upon the incurrence of any delayed draw loans;
contains provisions requiring mandatory prepayment of the initial term loans and delayed draw term loans with 100% of the proceeds of (a) indebtedness not permitted by the Owl Rock Credit Facility and (b) certain specified asset dispositions and payments (including in respect of settlements) in respect of property, casualty insurance claims or condemnation proceedings, with the proceeds received under this clause (b) subject to certain specified reinvestment rights and procedures set forth in the Owl Rock Credit Facility. The Owl Rock Credit Facility permits voluntary prepayments of outstanding loans at any time;
provides for a prepayment premium equal to (a) 4.00% of the principal amount of such loans prepaid on or prior to the first anniversary of the closing of the Owl Rock Credit Facility, (b) 3.00% of the principal amount of such loans prepaid after the first anniversary of the closing of the Owl Rock Credit Facility but on or prior to the second anniversary of the closing of the Owl Rock Credit Facility and (c) 2.00% of the principal amount of such loans prepaid after the second anniversary of the closing of the Owl Rock Credit Facility but on or prior to the third anniversary of the closing of the Owl Rock Credit Facility. No prepayment premium will be applicable for any such prepayment made after the third anniversary of the closing of the Owl Rock Credit Facility. The prepayment premium is applicable to voluntary prepayments and certain specified mandatory prepayment during such applicable periods;
provides for financial covenants such that (i) a consolidated net leverage ratio cannot exceed 2.50 to 1.00 as of the last day of any fiscal quarter and (ii) a liquid asset coverage ratio cannot be less than 1.80 to 1.00;
contains affirmative covenants related to, among other things, delivery of certain financial reports and compliance certificates, maintenance of existence, compliance with laws, material contracts, payment of taxes, property and insurance matters, inspection of property, books and records, notices, collateral matters and future subsidiaries, in each case, subject to specified limitations and exceptions;
contains an affirmative representation and corresponding covenant that the Company and certain subsidiaries of the Company do not, and will not during the term of the Owl Rock Facility (or if the term of the Owl Rock Credit Facility continues for longer than a year, during the Company’s and certain subsidiaries of the Company’s most recent fiscal year), derive more than fifteen percent (15%) of their aggregate gross revenues from securities related activities;
contains negative covenants related to, among other things, incurrence of debt, creation of liens, mergers, acquisitions and certain other fundamental changes, conditions concerning the creation of new subsidiaries, conditions concerning opening of new accounts, disposition of assets, dividends and other restricted payments, prepayment of certain indebtedness, transactions with
affiliates, investments and limitations on lines of business, in each case, subject to specified limitations and exceptions; and
provides for certain specified events of default upon the occurrence and during the continuation of certain events or conditions (subject to specified exceptions, grace periods or cure rights, as applicable) each as set forth in the Owl Rock Credit Facility, which includes among other things, defaults with respect to nonpayment, breaches of representations and warranties, failure to comply with covenants, cross-default to other material indebtedness, bankruptcy and insolvency matters, ERISA matters, material judgments, collateral and perfection matters, the occurrence of a change of control and subordination matters with respect to certain specified indebtedness. The occurrence and continuance of an event of default that is not cured or waived will enable the agent and/or the lenders, as applicable, to accelerate the loans or take other remedial steps as provided in the Owl Rock Credit Facility and the other loan documents.
XML 36 R30.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - DESCRIPTION OF THE BUSINESS
6 Months Ended
Jun. 30, 2023
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
DESCRIPTION OF THE BUSINESS DESCRIPTION OF BUSINESS
Organization and Merger
Abacus Life, Inc. (“the Company”) was formerly known as East Resources Acquisition Company ("ERES”), a blank check company incorporated in Delaware on May 22, 2020. Abacus Life, Inc. conducts its business through its wholly-owned, consolidated subsidiaries, primarily Abacus Settlements LLC (“Abacus”) and Longevity Market Assets, LLC (“LMA”), which are incorporated in the state of Delaware (collectively, the “Companies”). On June 30, 2023, (the “Closing Date”), ERES, Longevity Market Assets, LLC and Abacus Settlements, LLC consummated the combining of the Companies as contemplated by the Merger Agreement dated as of August 30, 2022 (as amended on October 14, 2022 and April 20, 2023) with LMA Merger Sub, LLC, a wholly owned subsidiary of ERES (“LMA Merger Sub”), Abacus Merger Sub, LLC, a wholly owned subsidiary of ERES (“Abacus Merger Sub”), Longevity Market Assets, LLC (“LMA”) and Abacus Settlements, LLC (“Legacy Abacus” and, together with LMA, the “Legacy Companies”). Pursuant to the Merger Agreement, on June 30, 2023, (i) LMA Merger Sub merged with and into LMA, with LMA surviving such merger (the “LMA Merger”) and (ii) Abacus Merger Sub merged with and into Legacy Abacus, with Legacy Abacus surviving such merger (the “Abacus Merger” and, together with the LMA Merger, the “Mergers” and, along with the other transactions contemplated by the Merger Agreement, the “Business Combination”) and the Legacy Companies became direct wholly owned subsidiaries of Abacus and ERES changed its name to Abacus Life, Inc.
The condensed consolidated assets, liabilities and statements of operations and comprehensive income prior to the Business Combination are those of legacy LMA. The stocks and corresponding capital amounts and income per stock, prior to the Business Combination, have been retroactively restated based on stocks reflecting the exchange ratio established in the Business Combination.
The equity structure has been recast in all comparative periods up to the Closing Date to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to legacy LMA’s stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to legacy LMA common stock prior to the Business Combination have been retroactively recast as shares reflecting the exchange ratio of 0.8 established in the Business Combination.
Business Activity
The Company, through its LMA subsidiary, is a provider of services pertaining to life insurance settlements and offers policy servicing to owners and purchasers of life settlement assets, as well as consulting, valuation, and actuarial services. The Company is also engaged in buying and selling of life settlement policies in which it uses its own capital, and purchases life settlement contracts with the intent to either hold to maturity to receive the associated death claim payout or to sell to another purchaser of life settlement contracts for a gain on the sale.
The Company, through its Abacus subsidiary, also is an originator of outstanding life insurance policies as a licensed life settlement provider on behalf of investors (“Financing Entities”). Abacus locates and screens policies for eligibility as a commercially desirable life settlement, including verifying that the policy is in force, obtaining consents and disclosures, and submitting cases for life expectancy estimates, also known, collectively, as origination services. When the sale of a policy is completed, this is deemed “settled” and the policy is then referred to as either a “life settlement” in which the insured’s life expectancy is greater than two years or “viatical settlement,” in which the insured’s life expectancy is less
than two years. The Company is not an insurance company, and therefore the Company does not underwrite insurable risks for its own account.
Abacus Settlements, LLC  
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
DESCRIPTION OF THE BUSINESS DESCRIPTION OF THE BUSINESS
Abacus Settlements, LLC d/b/a Abacus Life (the “Company”) was formed in 2004 in the state of New York. In 2016, the Company obtained its licensure in Florida and re-domesticated to that state. On June 13, 2023, the Company re-domesticated to Delaware.
The Company acts as a purchaser of outstanding life insurance policies (“Provider”) on behalf of investors (“Financing Entities”) by locating policies and screening them for eligibility for a life settlement, including verifying that the policy is in force, obtaining consents and disclosures, and submitting cases for life expectancy estimates, also known as origination services. When the sale of a policy is completed, this is deemed “settled” and the policy is then referred to as either a “life settlement” in which the insured’s life expectancy is greater than two years or “viatical settlement,” in which the insured’s life expectancy is less than two years.
The Company is not an insurance company, and therefore the Company does not underwrite insurable risks for its own account. On August 30, 2022, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with East Resources Acquisition Company (“ERES”), which was subsequently amended on October 14, 2022. As part of the Merger Agreement, the holders of the Company’s common units together with the holders of Longevity Markets Assets, LLC (“LMA”), a commonly owned affiliate, will receive aggregate consideration of approximately $531,750,000, payable in a number of newly issued shares of ERES Class A common stock, par value $0.0001 per share (“ERES Class A common stock”), with a value ascribed to each share of ERES Class A common stock of $10.00 and, to the extent the aggregate transaction proceeds exceed $200.0 million, at the election of the Company’s and LMA’s members, up to $20.0 million of the aggregate consideration will be payable in cash to the Company’s and LMA’s members. The transaction closed on June 30, 2023 upon shareholder approval and customary closing conditions.
XML 37 R31.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
6 Months Ended
Jun. 30, 2023
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation—In connection with the Business Combination, the Merger is accounted for as a reverse recapitalization with ERES in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Under U.S. GAAP, ERES has been treated as the “acquired” company for financial reporting purposes. This determination was primarily based on the LMA shareholders having a relative majority of the voting power of the Company, the LMA shareholders having the authority to appoint a majority of directors on the Board of Directors, and senior management of LMA comprising the majority of the senior management of the post-combination Company. LMA was then determined to be the “acquirer” for financial reporting purposes based on the relative size of LMA as compared to Abacus, represented by their revenue, equity, gross profit and net income. Accordingly, for accounting purposes, the financial statements of the combined entity will represent a continuation of the financial statements of LMA with the LMA Merger being treated as the equivalent of LMA issuing stock for the net assets of ERES, accompanied by a recapitalization. The net assets of ERES will be stated at historical cost, with no goodwill or other intangible assets recorded.
The Abacus Merger will be accounted for using the acquisition method of accounting. Under the acquisition method of accounting, the assets and liabilities of Abacus will be recorded at estimated fair value as of the acquisition date. The excess of the purchase price over the estimated fair values of the net assets acquired, if applicable, will be recognized as goodwill.
As a result of the Business Combination, the Company evaluated if ERES, Abacus, or LMA is the predecessor for accounting purposes.
In considering the foregoing principles of predecessor determination and in light of the Company's specific facts and circumstances, management determined that LMA and Abacus are dual predecessors for accounting purposes. The financial statement presentation for Abacus Life, Inc. includes the purchase accounting effects of the Abacus Merger as of the Closing Date with the financial statements of LMA as the comparative period. The predecessor financial statements for Abacus are included separately within this report.
The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and are prepared in accordance with U.S. GAAP.
Unaudited Condensed Consolidated Financial Statements—The condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2023, and the condensed consolidated statements of operations and comprehensive income for the three months and six months ended June 30, 2023 and 2022, respectively, and the condensed consolidated statements of cash flows for the six months ended June 30, 2023 and 2022, respectively. The condensed consolidated statements of operations and comprehensive income for the three months and six months ended June 30, 2023, are not necessarily indicative of the results to be expected for the full year ending December 31, 2023, or any other period. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes for Abacus for the year ended December 31, 2022, and the financial statements and notes for LMA for the year ended December 31, 2022. All references to financial information as of and for the periods ended June 30, 2023, and 2022 in the notes to condensed consolidated financial statements are unaudited.
Refer to this note in the LMA annual financial statements for the full list of the Company’s significant accounting policies. The details in those notes have not changed, except as discussed below and as a result of normal adjustments in the interim periods.
Consolidation of Variable Interest Entities—For entities in which the Company has variable interests, the Company first evaluates whether the entity meets the definition of a variable interest entity (“VIE”) or a voting interest entity (“VOE”). If the entity is a VIE, the Company focuses on identifying whether it has the power to direct the activities that most significantly impact the VIE’s economic performance and whether it has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company is the primary beneficiary of a VIE, the assets, liabilities, and results of operations of the VIE will be included in the Company’s condensed consolidated financial statements. The proportionate share not owned by the Company is recognized as noncontrolling interest and net income attributable to noncontrolling interest on the condensed consolidated balance sheets and condensed consolidated statements of operations and comprehensive income, respectively. If the entity is a VOE, the Company evaluates whether it has the power to control the VOE through a majority voting interest or through other arrangements.
Accounting Standards Codification (“ASC”) Topic 810, Consolidations, requires the Company to separately disclose on its condensed consolidated balance sheets the assets of consolidated VIEs and liabilities of consolidated VIEs as to which there is no recourse against the Company. As of June 30, 2023, total assets and liabilities of consolidated VIEs were $57,577,034 and $52,474,820, respectively. As of December 31, 2022, total assets and liabilities of consolidated VIEs were $30,073,972 and $27,116,762, respectively.
On January 1, 2021, the Company entered into an option agreement with two commonly owned full-service origination, servicing, and investment providers (the “Providers”), in which the Company agreed to fund certain capital needs with an option to purchase the outstanding equity ownership of the Providers (the “Option Agreement”).
The Company accounted for its investment in the call options under the Option Agreement as an equity security, pursuant to ASC 321. In arriving at this accounting conclusion, the Company first considered whether the call options met the definition of a derivative pursuant to ASC 815 and concluded that the options do not provide for net settlement and accordingly are not a derivative. The Company also concluded that the call options do not provide the Company with a controlling financial interest in the legal entity pursuant to ASC 810. The call options include material contingencies prior to exercisability that the Company does not anticipate will be resolved; additionally, the call options are in a legal entity for which the share price has no readily determinable fair value. The Company’s basis in the call options, pursuant to ASC 321, is zero and accordingly the call options are not reflected in the statement of financial position.
The Company provided $0 and $127,455 of funding for the three months ended June 30, 2023 and June 30, 2022, respectively and provided $29,721 and $242,247 of funding for the six months ended June 30, 2023 and June 30, 2022, respectively which is included in other (expense) income on the condensed consolidated statements of operations and comprehensive income. See Note 11, Commitments and Contingencies.
For the period ended June 30, 2023, and for the year ended December 31, 2022, the Providers were considered to be VIEs, but were not consolidated in the Company’s condensed consolidated financial statements due to a lack of the power criterion or the losses/benefits criterion. As of June 30, 2023, the unaudited financial information for the unconsolidated VIEs are as follows: held assets of $318,178 and liabilities of $450 and held assets of $483,167 and liabilities of $184,621, respectively. As of December 31, 2022, the unaudited financial information for the unconsolidated VIEs are as follows: held assets of $126,040 and liabilities of $0 and held assets of $861,924 and liabilities of $358,586, respectively.
On October 4, 2021, the Company entered into an operating agreement with LMX Series, LLC (“LMX”) and three other unaffiliated investors to obtain a 70% ownership interest in LMX, which was newly formed in August 2021. LMX had no operating activity prior to the operating agreement being signed.
LMX has a wholly owned subsidiary, LMATT Series 2024, Inc., a Delaware C corporation. While the Company and three other investors each contributed $100 to LMX, the Company directs the most significant activities by managing the investment offerings, and sponsoring and creating structured investment grade insurance liabilities, and thus was provided a 70% ownership interest. LMX is a VIE and the Company is the primary beneficiary of LMX. The Company has included the results of LMX and its subsidiaries in its condensed consolidated financial statements for the period ended June 30, 2023.
On March 3, 2022, the Company obtained an 80% ownership interest in Longevity Market Advisors, LLC (“Longevity Market Advisors”). The Longevity Market Advisors legal entity was established primarily for the purpose of acquiring the assets of a broker/dealer, Regional Investment Services, Inc. (“RIS”), an Ohio corporation. Longevity Market Advisors is a VIE and the Company is the primary beneficiary of Longevity Market Advisors. The purchase price payable in exchange for RIS was $60,000. The Company evaluated whether this represented a business combination or an asset acquisition under ASC 805. While the purchase of the RIS represents a business, it was further determined that as RIS was purchased for the primary reason of being registered by the Financial Industry Regulatory Authority (“FINRA”). As there are no tangible or intangible assets of value from the RIS that would meet the capitalization criteria that have standalone value, the Company has expensed the purchase in general and administrative costs. Upon closing of the transaction, Longevity Market Advisors will comprise 100% of the ownership structure of RIS, and RIS will be a wholly owned subsidiary. The Company has included the results of Longevity Market Advisors in its condensed consolidated financial statements for the period ended June 30, 2023.
On November 30, 2022, LMA Series, LLC, a wholly owned subsidiary of the Company, signed an Operating Agreement to be the sole member of a newly created general partnership, LMA Income Series, GP, LLC. Subsequent to that, LMA Income Series, GP, LLC formed a limited partnership, LMA Income Series, LP and issued partnership interests to limited partners in a private placement offering. It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series, LP and thus has fully consolidated the limited partnership in its condensed consolidated financial statements for the six months ended June 30, 2023.
On January 31, 2023, LMA Series, LLC, a wholly owned subsidiary of the Company, signed an Operating Agreement to be the sole member of a newly created general partnership, LMA Income Series II, GP, LLC. Subsequent to that, LMA Income Series II, GP, LLC formed a limited partnership, LMA Income Series II, LP and issued partnership interests to limited partners in a private placement offering. It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series II, LP and thus has fully consolidated the limited partnership in its condensed consolidated financial statements for the six months ended June 30, 2023.
Noncontrolling Interest—Noncontrolling interest represents the share of consolidated entities owned by third parties. At the date of formation or upon acquisition, the Company recognizes noncontrolling interest on the condensed consolidated balance sheets at an amount equal to the noncontrolling interest’s proportionate share of the relative fair value of any assets and liabilities acquired. Noncontrolling interest is subsequently adjusted for the noncontrolling shareholder’s additional contributions, distributions, and the shareholder’s share of the net earnings or losses of each respective consolidated entity.
Net income of a consolidated entity is allocated to noncontrolling interests based on the noncontrolling shareholder’s ownership interest during the period. The net income or loss that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the condensed consolidated statements of operations and comprehensive income.
Use of Estimates—The preparation of U.S. GAAP financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, disclosure of contingent assets and liabilities at the date of financial statements, and the reports amounts of revenue and expenses during the reporting periods. Company’s estimates, judgments, and
assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from the estimates. Estimates are used when accounting for revenue recognition and related costs, purchase price allocation, the selection of useful lives of property and equipment, valuation of other receivables, valuation of life settlement policies, valuation of other investments and available-for-sale securities, valuation of long-term debt, impairment testing, income taxes, and legal reserves.
Life Insurance Settlement Policies—The Company accounts for its holdings of life insurance settlement policies in accordance with ASC 325-30, Investments in Insurance Contracts. The Company accounts for life settlement policies purchased that we intend to hold to maturity at fair value and life settlement policies that we intend to trade in the near term at cost plus premiums paid.
The Company follows ASC 820, Fair Value Measurements and Disclosures, in estimating the fair value of its life insurance policies held at fair value. ASC 820 defines fair value as an exit price representing the amount that would be received if an asset were sold or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-level, fair value hierarchy that prioritizes the inputs used to measure fair value. Level 1 relates to quoted prices in active markets for identical assets or liabilities. Level 2 relates to observable inputs other than quoted prices included in Level 1. Level 3 relates to unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s valuation of life settlements is considered to be Level 3, as there is currently no active market where we are able to observe quoted prices for identical assets. The Company’s valuation model incorporates significant inputs that are not observable. See Note 10, “Fair Value Measurements.” For policies held at fair value, changes in fair value are reflected in operations in the period the change is calculated.
For policies held under the investment method, the Company tests the impairment if we become aware of information indicating that the carrying value plus undiscounted future premiums of a policy may not be recoverable. This information is gathered initially through extensive underwriting procedures at purchase of the settlement contract, as well as through periodic underwriting review that include medical reports and life expectancy evaluations. The policies held by the Company using the investment method are expected to be owned for a shorter-term, and are actively marketed to potential buyers. The market feedback received through these interactions provides the Company with information related to a potential impairment. If a policy is determined to be impaired, the Company will adjust the carrying value to the fair value determined through the impairment analysis.
The Company accounts for cash proceeds from sale and maturity of life insurance settlement policies, as well as cash outflows for premium payments, as operating activities within the condensed consolidated statements of cash flows.

Cost of Revenues—Cost of revenue represents the direct costs associated with fulfilling the Company’s obligations to its customers, primarily policy servicing and consulting expense.

Income Taxes—The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, the provision for income taxes represents income taxes paid or payable (or received or receivable) for the current year plus the change in deferred taxes during the year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid, and result from differences between the financial and tax bases of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when enacted.
Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not (greater than 50%) that a tax benefit will not be realized. In evaluating the need for a valuation allowance, management considers all potential sources of taxable income, including income available in carryback periods, future reversals of taxable temporary differences, projections of taxable income, and income from tax planning strategies, as well as all available positive and negative evidence. Positive evidence includes factors such as a history of profitable operations, projections of future profitability within the carryforward period, including from tax planning strategies, and the Company’s experience with similar operations. Existing favorable contracts are additional positive evidence. Negative evidence includes items such as cumulative losses, projections of future losses, or carryforward periods that are not long enough to allow for the utilization of a deferred tax asset based on existing projections of income. Deferred tax assets for which no valuation allowance is recorded may not be realized upon changes in facts and circumstances, resulting in a future charge to establish a valuation allowance. Existing valuation allowances are re-examined under the same standards of positive and negative evidence. If it is determined that it is more likely than not that a deferred tax asset will be realized, the appropriate amount of the valuation allowance, if any, is released. Deferred tax assets and liabilities are also remeasured to reflect changes in underlying tax rates due to law changes and the granting and lapse of tax holidays.

Tax benefits related to uncertain tax positions taken or expected to be taken on a tax return are recorded when such benefits meet a more likely than not threshold. Otherwise, these tax benefits are recorded when a tax position has been effectively settled, which means that the statute of limitations has expired or the appropriate taxing authority has completed their examination even though the statute of limitations remains open. Interest and penalties related to uncertain tax positions are recognized as part of the provision for income taxes and are accrued beginning in the period that such interest and penalties would be applicable under relevant tax law until such time that the related tax benefits are recognized.
Concentrations—Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, accounts receivable, and available-for-sale securities. The Company maintains its cash in bank deposit accounts with high-quality financial institutions, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on its cash and cash equivalents. For accounts receivable, the Company is exposed to credit risk in the event of nonpayment by customers to the extent of the amounts recorded on the accompanying condensed consolidated balance sheets. The Company extends different levels of credit to its customers and maintains allowance for doubtful accounts based upon the expected collectability of accounts receivable. The Company’s procedures for determining this allowance includes evaluating individual customer receivables, considering a customer’s financial condition, monitoring credit history and current economic conditions, and using historical experience applied to an aging of accounts.
Two related party customers accounted for 12% and 13% of the total balance of accounts receivable and related party receivables as of June 30, 2023, and two related party customers accounted for 75% and 16% of the total accounts receivable as of December 31, 2022, respectively. The largest receivables balances are from related parties where exposed credit risk is low. As such, there is no allowance for doubtful accounts as of June 30, 2023, and December 31, 2022.
One customer accounted for 27% of active management revenue for the three months ended June 30, 2023. Two related party customers each accounted for 20% and 20% of the portfolio servicing revenue for the three months ended June 30, 2023. One customer accounted for 26% of the total revenues for the three months ended June 30, 2022.
One customer accounted for 29% of active management revenue, while 16% of revenue related to 2 policies that matured that were accounted for under the investment method and 1 policy that matured that was accounted for under the fair-value method for the six months ended June 30, 2023. Two related party customers each accounted for 25% and 27% of the portfolio servicing revenue for the six months
ended June 30, 2023. One customer accounted for 71% of the total revenues for the six months ended June 30, 2022.

Warrants—The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480 Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the condensed consolidated statements of operations and comprehensive income.
Abacus Settlements, LLC  
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
The condensed balance sheet as of June 30, 2023, was derived from amounts included in the Company’s annual financial statements for the year ended December 31, 2022. Such amounts are included within the condensed consolidated financial statements of Abacus Life, Inc. Capitalized terms used herein without definition have the meanings ascribed to them in the Company’s financial statements for the year ended December 31, 2022. Refer to this note in the annual financial statements for the full list of the Company’s significant accounting policies. The details in those notes have not changed except as discussed below and as a result of normal adjustments in the interim periods.
Basis of Presentation—The accompanying condensed financial statements are presented in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).
Unaudited Condensed Financial Statements—The condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2023, and the condensed results of its operations and comprehensive income/(loss) and cash flows for the three and six months ended June 30, 2023 and 2022. The condensed results of operations and comprehensive income/(loss) and cash flows for the period January 1, 2023 to June 30, 2023, are not necessarily indicative of the results to be expected for the full year ending December 31, 2023, or any other period.
Use of Estimates—The preparation of US GAAP financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, and disclosure of contingent assets and liabilities at the date of financial statements and the reports amounts of revenue and expenses during the reporting periods. Company’s estimates, judgments, and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from the estimates. Estimates are used when accounting for revenue recognition and related costs, the selection of useful lives of property and equipment, impairment testing, valuation of other receivables from clients, income taxes, and legal reserves.
Going Concern—Management evaluates at each annual and interim period whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Management’s evaluation is based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. Management has concluded that there are no conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements were issued.
Other receivables—Other receivables include origination fees for policies in which the recission period has ended, but the funds have not been received yet from financing entities. These fees were collected in the subsequent month.
The Company provides an allowance for credit losses equal to the estimated collection losses that will be incurred in collection of all receivables. Management determines the allowance for credit losses based on a review of outstanding receivables, historical collection experience, current economic conditions, and reasonable and supportable forecasts. Account balances are charged off against the allowance for credit losses after all means of collection have been exhausted and the potential for recovery is deemed remote. The Company does not have any material allowance for credit losses as of June 30, 2023 or December 31, 2022.
If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. The Company did not record material allowance for credit losses as of June 30, 2023, and December 31, 2022, respectively.
Concentrations—All of the Company’s revenues are derived from life settlement transactions in which the Company represents Financing Entities that purchased existing life insurance policies. One financing entity, a company in which the Company’s members own interests, represented 23% and 66% of the Company’s revenues in six months ended June 30, 2023 and 2022, respectively. The Company originates policies through three different channels: Direct to Consumer, Agent, and Broker. Two brokers represented the sellers for over 10% of the Company’s life settlement commission expense during the period six months ended June 30, 2023. No brokers represented the sellers for over 10% of the Company’s life settlement commission expense during the period six months ended June 30, 2022. The Company maintains cash deposits with a major financial institution, which from time to time may exceed federally insured limits. The Company periodically assesses the financial condition of the institution and believes that the risk of loss is minimal.
Advertising—All advertising expenditures incurred by the Company are charged to expense in the period to which they relate and are included in general and administrative expenses on the accompanying condensed statements of operations and comprehensive income/(loss). Advertising expense totaled $367,418 and $286,695 for three months ended June 30, 2023 and 2022, respectively. Advertising expense totaled $741,789 and $554,802 for six months ended June 30, 2023 and 2022, respectively.
XML 38 R32.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - SEGMENT REPORTING
6 Months Ended
Jun. 30, 2023
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
SEGMENT REPORTING SEGMENT REPORTING
Segment Information—The Company organizes its business into two reportable segments (1) Portfolio Servicing and (2) Active Management, which generate revenue in different manners.
This segment structure reflects the financial information and reports used by the Company’s management, specifically its chief operating decision maker (CODM), to make decisions regarding the Company’s business, including resource allocations and performance assessments, as well as the current operating focus in compliance with ASC 280, Segment Reporting. The Company’s CODM is the President and Chief Executive Officer.
The Portfolio Servicing segment generates revenues by providing policy services to customers on a contract basis.
The Active Management segment generates revenues by buying, selling, and trading policies and maintaining policies until receipt of death benefits. The Company’s reportable segments are not aggregated.
The Company’s method for measuring profitability on a reportable segment basis is gross profit. The CODM does not review asset information related to investments nor expenditures incurred for long-lived assets given the Company’s investments are recognized using the measurement alternative, and the Company’s long-lived assets are immaterial to the condensed consolidated financial statements.
Revenue related to the Company’s reporting segments for the three-month and six-month periods ended June 30, 2023, and June 30, 2022, is as follows:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Portfolio servicing$354,366 $419,422 $590,057 $990,328 
Active management11,024,399 7,979,479 20,994,917 17,285,971 
Total revenue$11,378,765 $8,398,901 $21,584,974 $18,276,299 
Information related to the Company’s reporting segments for the three-month and six-month periods ended June 30, 2023 and June 30, 2022 is as follows:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Portfolio servicing$(76,705)$280,303 $(166,128)$668,752 
Active management10,482,070 7,452,479 20,288,152 15,521,472 
Total gross profit10,405,365 7,732,782 20,122,024 16,190,224 
Sales and marketing(683,841)(1,019,498)(1,412,845)(1,649,498)
General, administrative and other(577,539)(5,499)(1,274,431)(646,705)
Depreciation(1,098)(1,098)(2,141)(2,141)
Other (expense) income121,601 (127,455)(21,651)(242,247)
Interest expense(584,075)(934,001)
Loss on change in fair value of debt(1,445,229)(333,879)(2,398,662)(375,513)
Unrealized gain (loss) on investments672,936 (1,039,022)798,156 (1,054,975)
Provision for income taxes(1,184,571)(120,132)(528,104)(296,806)
Less: Net loss attributable to non-controlling interests26,596 (406,641)487,303 (406,641)
Net income attributable to Abacus Life, Inc.$6,750,145 $4,679,558 $14,835,648 $11,515,698 
Abacus Settlements, LLC  
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
SEGMENT REPORTING SEGMENT REPORTINGOperating as a centrally led life insurance policy intermediary, the Company’s president and chief executive officer is the chief operating decision maker who allocates resources and assesses financial performance based on financial information presented for the Company as a whole. As a result of this management approach, the Company is organized as a single operating segment.
XML 39 R33.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - REVENUE
6 Months Ended
Jun. 30, 2023
Abacus Settlements, LLC  
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
REVENUE REVENUE
Disaggregated Revenue—The following table presents a disaggregation of the Company’s revenue by major sources for three months ended June 30, 2023 and 2022, and for six months ended June 30, 2023 and 2022:
Three Months Ended
June 30,
Six Months Ended
June 30,
2023202220232022
Agent$3,334,402 $2,717,512 $7,143,016 $5,690,701 
Broker2,809,499 2,247,953 4,675,973 5,727,970 
Client direct740,789 726,451 1,365,687 1,595,993 
Total$6,884,690 $5,691,916 $13,184,676 $13,014,664 
XML 40 R34.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - INCOME TAXES
6 Months Ended
Jun. 30, 2023
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
INCOME TAXES INCOME TAXES
Before June 30, 2023, the Company elected to file as an S corporation for Federal and state income tax purposes, the Company incurred no Federal or state income taxes, except for income taxes recorded related to some of their consolidated variable interest entities and subsidiaries which are taxable C corporations. These VIE’s and subsidiaries include LMATT Series 2024, Inc., the wholly owned subsidiary of LMX, which is consolidated into LMA as a VIE, as well as LMATT Growth Series 2.2024, Inc., a wholly owned subsidiary of LMATT Growth Series, Inc., and LMATTS Growth and Income Series 1.2026, Inc., a wholly owned subsidiary of LMATT Growth and Income Series, Inc., all of which are 100% owned subsidiaries and fully consolidated. Accordingly, the provision for income taxes was attributable to amounts for LMATT Series 2024, Inc, LMATT Growth Series, Inc. and LMATT Growth and Income Series, Inc.
For the three months ended June 30, 2023 and 2022, the Company recorded provision for income taxes of $1,184,571 and $120,132, respectively. The effective tax rate is 15.0% for the three months ended June 30, 2023. The effective rate for the three months ended June 30, 2022 was 12.0% due to the impact of state income taxes and the release of the Company’s valuation allowance, as there was sufficient evidence of the Company’s ability to generate future taxable income at June 30, 2022.
For the six months ended June 30, 2023 and 2022, the Company recorded provision for income taxes of $528,104 and $296,806, respectively. The effective tax rate is 3.6% for the six months ended June 30, 2023. The existence of non-taxable flow-through entities within the Company as well as a change in tax status of certain entities upon the Business Combination caused the effective tax rate to be significantly lower than the statutory rate. The effective rate for the six months ended June 30, 2022 was 18% due to the impact of state income taxes and the release of the Company’s valuation allowance, as there was sufficient evidence of the Company’s ability to generate future taxable income at June 30, 2022.
The Company did not have any unrecognized tax benefits relating to uncertain tax positions as of June 30, 2023, and December 31, 2022, and did not recognize any interest or penalties related to uncertain tax positions as of June 30, 2023, and December 31, 2022.
Abacus Settlements, LLC  
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
INCOME TAXES INCOME TAXES
Since the Company elected to file as an S corporation for federal and State income tax purposes, the Company incurred no federal or state income taxes. Accordingly, provision for income taxes is attributable to minimum state tax payments that are due regardless of their S corporation status and income position.
For the three months ended June 30, 2023 and 2022, the company did not record provision for income taxes. For the six months ended June 30, 2023 and 2022, the company recorded provision for income taxes of $2,289 and $1,325, respectively, which consist of state minimum taxes for state taxes that have been paid and settled during the period. The effective tax rate was approximately (0.24%) for the six months ended June 30, 2023, compared to 0.48% for the six months ended June 30, 2022.
Given the company's S Corporation status, temporary book and tax differences do not create a deferred tax asset or liability on the balance sheets. Accordingly, an assessment of realizability of any deferred tax asset balances is not relevant.
XML 41 R35.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - RETIREMENT PLAN
6 Months Ended
Jun. 30, 2023
Abacus Settlements, LLC  
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
RETIREMENT PLAN RETIREMENT PLANThe Company provides a defined contribution plan to its employees, Abacus Settlements LLC 401(k) Profit Sharing Plan & Trust (the “Plan”). All eligible employees are able to participate in voluntary salary reduction contributions to the Profit-Sharing Plan. All employees who have completed one year of service with the Company are eligible to receive employer-matching contributions. The Company may match contributions to the Plan, up to 4% of compensation. For the three months ended June 30, 2023 and 2022, and for six months ended June 30, 2023 and 2022, the Company made no discretionary contribution to the Plan.
XML 42 R36.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS
6 Months Ended
Jun. 30, 2023
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
RELATED-PARTY TRANSACTIONS RELATED-PARTY TRANSACTIONS
As of June 30, 2023 and December 31, 2022, $10,415,154 and $263,785, respectively, were due to members and affiliates primarily for reimbursable transaction costs as well as distributions to owners of $717,429 as a part of the Business Combination as of June 30, 2023. As of June 30, 2023 and December 31, 2022, $10,473,748 and $2,904,646 was due from affiliates, respectively. The amount to be received as of June 30, 2023 is due from the Sponsor as part of the Sponsor PIK Note. Additionally, the SPV purchase and sale note for $25,000,000 as of June 30, 2023 was also recorded as a related party transaction given the transfer of cash and policies between the Company and the SPV. Refer to footnote 13 for more information.
The Company has a related-party relationship with Nova Trading (US), LLC (“Nova Trading”), a Delaware limited liability company and Nova Holding (US) LP, a Delaware limited partnership (“Nova Holding” and collectively with Nova Trading, the “Nova Funds”). The Company also earns service revenue related to policy and administrative services on behalf of Nova Funds. The servicing fee is equal to 50 basis points (0.50%) times the monthly invested amount in policies held by Nova Funds divided by 12. The Company earned $197,629 and $205,224, respectively, in service revenue related to Nova Funds for the three months ended June 30, 2023 and 2022 and earned $411,076 and $406,129, respectively, in service revenue related to Nova Funds for the six months ended June 30, 2023 and 2022.
Prior to the Merger, LMA used Abacus to originate life settlement policies that it accounts for under the investment method. For the three and six months ended June 30, 2023, the Company incurred $837,975 and $1,627,975, respectively in origination costs for life settlement policies that were originated by Abacus. These costs are capitalized on the condensed consolidated balance sheets as life settlement policies, at cost.
As of June 30, 2023, and December 31, 2022, there were $72,600 and $196,289, respectively owed from the Nova Funds, which are included as related-party receivables in the accompanying condensed consolidated balance sheets.
Abacus Settlements, LLC  
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
RELATED-PARTY TRANSACTIONS RELATED-PARTY TRANSACTIONSThe Company has a related-party relationship with Nova Trading (US), LLC (“Nova Trading”), a Delaware limited liability company and Nova Holding (US) LP, a Delaware limited partnership (“Nova Holding” and collectively with Nova Trading, the “Nova Funds”) as the owners of Abacus jointly own 11% of the Nova
Funds. For the three months ended June 30, 2023 and 2022, the Company originated 38 and 92 policies, respectively, for the Nova Funds with a total value of $56,688,680 and $102,307,954, respectively. For six months ended June 30, 2023 and 2022, the Company originated 72 and 183 policies, respectively, for the Nova Funds with a total value of $96,674,080 and $282,804,838, respectively. For its origination services to the Nova Funds, the Company earns origination fees equal to the lesser of (i) 2% of the net death benefit for the policy or (ii) $20,000. For three months ended June 30, 2023 and 2022, and for six months ended June 30, 2023 and 2022, revenue earned, and contracts originated are as follows:
Three Months Ended
June 30,
Six Months Ended
June 30,
2023202220232022
Origination fee revenue$1,504,532 $4,164,107 $2,952,837 $8,569,034 
Transaction reimbursement revenue75,332 152,221 140,960 306,361 
Total$1,579,864 $4,316,328 $3,093,797 $8,875,395 
Cost$5,290,504 $25,201,256 $11,656,637 $50,738,202 
Face value56,688,680 102,307,954 96,674,080 282,804,838 
Total policies38 92 72 183 
Average Age017575
In addition to the Nova Funds, the Company also has another affiliated investor that they provide origination services for. Total revenue earned related to the other affiliated investor was $3,615,738 and $589,700, of which $3,615,739 and $470,200 related to Longevity Market Assets, LLC (“LMA”) for the three months ended June 30, 2023 and 2022, respectively. Total cost of sales related to the other affiliated investor was $2,623,201 and $363,700, of which $2,623,201 and $326,200 related to LMA for three months ended June 30, 2023 and 2022, respectively.
Total revenue earned related to the other affiliated investor was $6,838,141 and $911,700, of which $6,794,641 and $470,200 related to LMA, for the six months ended June 30, 2023 and 2022, respectively. Total cost of sales related to the other affiliated investor was $5,020,603 and $612,700, of which $5,012,103 and $326,200 related to LMA for the six months ended June 30, 2023 and 2022, respectively. In addition, there is a related party receivable due from LMA related to transaction expenses of $19,246 and $0 as of June 30, 2023 and 2022, respectively, which is included as due from members and affiliates in the accompanying condensed balance sheets.
XML 43 R37.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - SUBSEQUENT EVENT
6 Months Ended
Jun. 30, 2023
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
SUBSEQUENT EVENT SUBSEQUENT EVENTS
The Company evaluated subsequent events and transactions from the condensed consolidated balance sheet date through the date at which the condensed consolidated financial statements were issued.
Owl Rock Credit Facility
On July 5, 2023 (the “Owl Rock Closing Date”), the Company entered into that certain Credit Agreement (the “Owl Rock Credit Facility”), among the Company, as borrower, the several banks and other persons from time to time party thereto (the “Owl Rock Lenders”), and Owl Rock Capital Corporation, as administrative and collateral agent for the Owl Rock Lenders thereunder.
The Owl Rock Credit Facility, among other things:
requires the Company and certain subsidiaries of the Company to guarantee the loans provided under the Owl Rock Credit Facility pursuant to separate loan documentation;
provides credit extensions for (i) an initial term loan in an aggregate principal amount of $25.0 million upon the closing of the Owl Rock Credit Facility and (ii) optional delayed draw term loans (which can be drawn on multiple drawing dates) in an aggregate principal amount of up to $25.0 million available for one hundred eighty (180) days after the Owl Rock Closing Date (the “Delayed Draw Term Loan Availability Period”), subject to the requirement that on each delayed draw date, the liquid asset coverage ratio shall not be less than 1.80 to 1.00, together with other specified conditions to drawings, the proceeds of which may be used for working capital and the business requirements of the enterprise, and to fund acquisitions, investments and other transactions permitted by the loan documentation;
provides a delayed draw commitment fee rate of 0.50% per annum applicable to undrawn commitments during the Delayed Draw Term Loan Availability Period
matures on July 5, 2028, the date that is five years after the closing of the Owl Rock Credit Facility;
is secured by a first-priority security interest in substantially all of the assets of the Company and the subsidiary guarantors. No pledge of any equity interests in the Company is required by any holder of such equity interests;
provides for interest to accrue on the loans drawn under the Owl Rock Credit Facility at the election of the Company, by reference to either (i) an alternative base rate (such loans, “ABR Loans”) or (ii) an adjusted term SOFR rate (such loans, “SOFR Loans”) plus an applicable margin. The adjusted term SOFR rate is determined by the applicable term SOFR for a relevant interest period plus a credit spread adjustment of 0.10%, 0.15% and 0.25% per annum for interest periods of one, three and six months, respectively. The applicable margin for each type of loan is (i) 6.25% per annum for any ABR Loans and (ii) 7.25% per annum for any SOFR Loans, with interest periods for SOFR Loans of one, three or six months (or other periods if agreed by all lenders);
provides a default rate that will accrue at 2.00% per annum over the rate otherwise applicable;
provides for amortization payments based on the initial principal amount of the loans outstanding of 1.0% per year (0.25% due per quarter), with adjustments made to the overall amortization amount upon the incurrence of any delayed draw loans;
contains provisions requiring mandatory prepayment of the initial term loans and delayed draw term loans with 100% of the proceeds of (a) indebtedness not permitted by the Owl Rock Credit Facility and (b) certain specified asset dispositions and payments (including in respect of settlements) in respect of property, casualty insurance claims or condemnation proceedings, with the proceeds received under this clause (b) subject to certain specified reinvestment rights and procedures set forth in the Owl Rock Credit Facility. The Owl Rock Credit Facility permits voluntary prepayments of outstanding loans at any time;
provides for a prepayment premium equal to (a) 4.00% of the principal amount of such loans prepaid on or prior to the first anniversary of the closing of the Owl Rock Credit Facility, (b) 3.00% of the principal amount of such loans prepaid after the first anniversary of the closing of the Owl Rock Credit Facility but on or prior to the second anniversary of the closing of the Owl Rock Credit Facility and (c) 2.00% of the principal amount of such loans prepaid after the second anniversary of the closing of the Owl Rock Credit Facility but on or prior to the third anniversary of the closing of the Owl Rock Credit Facility. No prepayment premium will be applicable for any such prepayment made after the third anniversary of the closing of the Owl Rock Credit Facility. The prepayment premium is applicable to voluntary prepayments and certain specified mandatory prepayment during such applicable periods;
provides for financial covenants such that (i) a consolidated net leverage ratio cannot exceed 2.50 to 1.00 as of the last day of any fiscal quarter and (ii) a liquid asset coverage ratio cannot be less than 1.80 to 1.00;
contains affirmative covenants related to, among other things, delivery of certain financial reports and compliance certificates, maintenance of existence, compliance with laws, material contracts, payment of taxes, property and insurance matters, inspection of property, books and records, notices, collateral matters and future subsidiaries, in each case, subject to specified limitations and exceptions;
contains an affirmative representation and corresponding covenant that the Company and certain subsidiaries of the Company do not, and will not during the term of the Owl Rock Facility (or if the term of the Owl Rock Credit Facility continues for longer than a year, during the Company’s and certain subsidiaries of the Company’s most recent fiscal year), derive more than fifteen percent (15%) of their aggregate gross revenues from securities related activities;
contains negative covenants related to, among other things, incurrence of debt, creation of liens, mergers, acquisitions and certain other fundamental changes, conditions concerning the creation of new subsidiaries, conditions concerning opening of new accounts, disposition of assets, dividends and other restricted payments, prepayment of certain indebtedness, transactions with
affiliates, investments and limitations on lines of business, in each case, subject to specified limitations and exceptions; and
provides for certain specified events of default upon the occurrence and during the continuation of certain events or conditions (subject to specified exceptions, grace periods or cure rights, as applicable) each as set forth in the Owl Rock Credit Facility, which includes among other things, defaults with respect to nonpayment, breaches of representations and warranties, failure to comply with covenants, cross-default to other material indebtedness, bankruptcy and insolvency matters, ERISA matters, material judgments, collateral and perfection matters, the occurrence of a change of control and subordination matters with respect to certain specified indebtedness. The occurrence and continuance of an event of default that is not cured or waived will enable the agent and/or the lenders, as applicable, to accelerate the loans or take other remedial steps as provided in the Owl Rock Credit Facility and the other loan documents.
Abacus Settlements, LLC  
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
SUBSEQUENT EVENT SUBSEQUENT EVENTOn June 30, 2023, the Company consummated the merger with LMA. The Company has evaluated its subsequent events through August 14, 2023, the date that the financial statements were issued and determined that there were no events that occurred that required disclosure.
XML 44 R38.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
6 Months Ended
Jun. 30, 2023
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
Basis of Presentation and Unaudited Condensed Consolidated Financial Statements
Basis of Presentation—In connection with the Business Combination, the Merger is accounted for as a reverse recapitalization with ERES in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Under U.S. GAAP, ERES has been treated as the “acquired” company for financial reporting purposes. This determination was primarily based on the LMA shareholders having a relative majority of the voting power of the Company, the LMA shareholders having the authority to appoint a majority of directors on the Board of Directors, and senior management of LMA comprising the majority of the senior management of the post-combination Company. LMA was then determined to be the “acquirer” for financial reporting purposes based on the relative size of LMA as compared to Abacus, represented by their revenue, equity, gross profit and net income. Accordingly, for accounting purposes, the financial statements of the combined entity will represent a continuation of the financial statements of LMA with the LMA Merger being treated as the equivalent of LMA issuing stock for the net assets of ERES, accompanied by a recapitalization. The net assets of ERES will be stated at historical cost, with no goodwill or other intangible assets recorded.
The Abacus Merger will be accounted for using the acquisition method of accounting. Under the acquisition method of accounting, the assets and liabilities of Abacus will be recorded at estimated fair value as of the acquisition date. The excess of the purchase price over the estimated fair values of the net assets acquired, if applicable, will be recognized as goodwill.
As a result of the Business Combination, the Company evaluated if ERES, Abacus, or LMA is the predecessor for accounting purposes.
In considering the foregoing principles of predecessor determination and in light of the Company's specific facts and circumstances, management determined that LMA and Abacus are dual predecessors for accounting purposes. The financial statement presentation for Abacus Life, Inc. includes the purchase accounting effects of the Abacus Merger as of the Closing Date with the financial statements of LMA as the comparative period. The predecessor financial statements for Abacus are included separately within this report.
The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and are prepared in accordance with U.S. GAAP.
Unaudited Condensed Consolidated Financial Statements Unaudited Condensed Consolidated Financial Statements—The condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2023, and the condensed consolidated statements of operations and comprehensive income for the three months and six months ended June 30, 2023 and 2022, respectively, and the condensed consolidated statements of cash flows for the six months ended June 30, 2023 and 2022, respectively. The condensed consolidated statements of operations and comprehensive income for the three months and six months ended June 30, 2023, are not necessarily indicative of the results to be expected for the full year ending December 31, 2023, or any other period. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes for Abacus for the year ended December 31, 2022, and the financial statements and notes for LMA for the year ended December 31, 2022. All references to financial information as of and for the periods ended June 30, 2023, and 2022 in the notes to condensed consolidated financial statements are unaudited.
Consolidation of Variable Interest Entities
Consolidation of Variable Interest Entities—For entities in which the Company has variable interests, the Company first evaluates whether the entity meets the definition of a variable interest entity (“VIE”) or a voting interest entity (“VOE”). If the entity is a VIE, the Company focuses on identifying whether it has the power to direct the activities that most significantly impact the VIE’s economic performance and whether it has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company is the primary beneficiary of a VIE, the assets, liabilities, and results of operations of the VIE will be included in the Company’s condensed consolidated financial statements. The proportionate share not owned by the Company is recognized as noncontrolling interest and net income attributable to noncontrolling interest on the condensed consolidated balance sheets and condensed consolidated statements of operations and comprehensive income, respectively. If the entity is a VOE, the Company evaluates whether it has the power to control the VOE through a majority voting interest or through other arrangements.
Accounting Standards Codification (“ASC”) Topic 810, Consolidations, requires the Company to separately disclose on its condensed consolidated balance sheets the assets of consolidated VIEs and liabilities of consolidated VIEs as to which there is no recourse against the Company. As of June 30, 2023, total assets and liabilities of consolidated VIEs were $57,577,034 and $52,474,820, respectively. As of December 31, 2022, total assets and liabilities of consolidated VIEs were $30,073,972 and $27,116,762, respectively.
On January 1, 2021, the Company entered into an option agreement with two commonly owned full-service origination, servicing, and investment providers (the “Providers”), in which the Company agreed to fund certain capital needs with an option to purchase the outstanding equity ownership of the Providers (the “Option Agreement”).
The Company accounted for its investment in the call options under the Option Agreement as an equity security, pursuant to ASC 321. In arriving at this accounting conclusion, the Company first considered whether the call options met the definition of a derivative pursuant to ASC 815 and concluded that the options do not provide for net settlement and accordingly are not a derivative. The Company also concluded that the call options do not provide the Company with a controlling financial interest in the legal entity pursuant to ASC 810. The call options include material contingencies prior to exercisability that the Company does not anticipate will be resolved; additionally, the call options are in a legal entity for which the share price has no readily determinable fair value. The Company’s basis in the call options, pursuant to ASC 321, is zero and accordingly the call options are not reflected in the statement of financial position.
The Company provided $0 and $127,455 of funding for the three months ended June 30, 2023 and June 30, 2022, respectively and provided $29,721 and $242,247 of funding for the six months ended June 30, 2023 and June 30, 2022, respectively which is included in other (expense) income on the condensed consolidated statements of operations and comprehensive income. See Note 11, Commitments and Contingencies.
For the period ended June 30, 2023, and for the year ended December 31, 2022, the Providers were considered to be VIEs, but were not consolidated in the Company’s condensed consolidated financial statements due to a lack of the power criterion or the losses/benefits criterion. As of June 30, 2023, the unaudited financial information for the unconsolidated VIEs are as follows: held assets of $318,178 and liabilities of $450 and held assets of $483,167 and liabilities of $184,621, respectively. As of December 31, 2022, the unaudited financial information for the unconsolidated VIEs are as follows: held assets of $126,040 and liabilities of $0 and held assets of $861,924 and liabilities of $358,586, respectively.
On October 4, 2021, the Company entered into an operating agreement with LMX Series, LLC (“LMX”) and three other unaffiliated investors to obtain a 70% ownership interest in LMX, which was newly formed in August 2021. LMX had no operating activity prior to the operating agreement being signed.
LMX has a wholly owned subsidiary, LMATT Series 2024, Inc., a Delaware C corporation. While the Company and three other investors each contributed $100 to LMX, the Company directs the most significant activities by managing the investment offerings, and sponsoring and creating structured investment grade insurance liabilities, and thus was provided a 70% ownership interest. LMX is a VIE and the Company is the primary beneficiary of LMX. The Company has included the results of LMX and its subsidiaries in its condensed consolidated financial statements for the period ended June 30, 2023.
On March 3, 2022, the Company obtained an 80% ownership interest in Longevity Market Advisors, LLC (“Longevity Market Advisors”). The Longevity Market Advisors legal entity was established primarily for the purpose of acquiring the assets of a broker/dealer, Regional Investment Services, Inc. (“RIS”), an Ohio corporation. Longevity Market Advisors is a VIE and the Company is the primary beneficiary of Longevity Market Advisors. The purchase price payable in exchange for RIS was $60,000. The Company evaluated whether this represented a business combination or an asset acquisition under ASC 805. While the purchase of the RIS represents a business, it was further determined that as RIS was purchased for the primary reason of being registered by the Financial Industry Regulatory Authority (“FINRA”). As there are no tangible or intangible assets of value from the RIS that would meet the capitalization criteria that have standalone value, the Company has expensed the purchase in general and administrative costs. Upon closing of the transaction, Longevity Market Advisors will comprise 100% of the ownership structure of RIS, and RIS will be a wholly owned subsidiary. The Company has included the results of Longevity Market Advisors in its condensed consolidated financial statements for the period ended June 30, 2023.
On November 30, 2022, LMA Series, LLC, a wholly owned subsidiary of the Company, signed an Operating Agreement to be the sole member of a newly created general partnership, LMA Income Series, GP, LLC. Subsequent to that, LMA Income Series, GP, LLC formed a limited partnership, LMA Income Series, LP and issued partnership interests to limited partners in a private placement offering. It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series, LP and thus has fully consolidated the limited partnership in its condensed consolidated financial statements for the six months ended June 30, 2023.
On January 31, 2023, LMA Series, LLC, a wholly owned subsidiary of the Company, signed an Operating Agreement to be the sole member of a newly created general partnership, LMA Income Series II, GP, LLC. Subsequent to that, LMA Income Series II, GP, LLC formed a limited partnership, LMA Income Series II, LP and issued partnership interests to limited partners in a private placement offering. It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series II, LP and thus has fully consolidated the limited partnership in its condensed consolidated financial statements for the six months ended June 30, 2023.
Noncontrolling Interest
Noncontrolling Interest—Noncontrolling interest represents the share of consolidated entities owned by third parties. At the date of formation or upon acquisition, the Company recognizes noncontrolling interest on the condensed consolidated balance sheets at an amount equal to the noncontrolling interest’s proportionate share of the relative fair value of any assets and liabilities acquired. Noncontrolling interest is subsequently adjusted for the noncontrolling shareholder’s additional contributions, distributions, and the shareholder’s share of the net earnings or losses of each respective consolidated entity.
Net income of a consolidated entity is allocated to noncontrolling interests based on the noncontrolling shareholder’s ownership interest during the period. The net income or loss that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the condensed consolidated statements of operations and comprehensive income.
Use of Estimates Use of Estimates—The preparation of U.S. GAAP financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, disclosure of contingent assets and liabilities at the date of financial statements, and the reports amounts of revenue and expenses during the reporting periods. Company’s estimates, judgments, and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from the estimates. Estimates are used when accounting for revenue recognition and related costs, purchase price allocation, the selection of useful lives of property and equipment, valuation of other receivables, valuation of life settlement policies, valuation of other investments and available-for-sale securities, valuation of long-term debt, impairment testing, income taxes, and legal reserves.
Life Insurance Settlement Policies
Life Insurance Settlement Policies—The Company accounts for its holdings of life insurance settlement policies in accordance with ASC 325-30, Investments in Insurance Contracts. The Company accounts for life settlement policies purchased that we intend to hold to maturity at fair value and life settlement policies that we intend to trade in the near term at cost plus premiums paid.
The Company follows ASC 820, Fair Value Measurements and Disclosures, in estimating the fair value of its life insurance policies held at fair value. ASC 820 defines fair value as an exit price representing the amount that would be received if an asset were sold or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-level, fair value hierarchy that prioritizes the inputs used to measure fair value. Level 1 relates to quoted prices in active markets for identical assets or liabilities. Level 2 relates to observable inputs other than quoted prices included in Level 1. Level 3 relates to unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s valuation of life settlements is considered to be Level 3, as there is currently no active market where we are able to observe quoted prices for identical assets. The Company’s valuation model incorporates significant inputs that are not observable. See Note 10, “Fair Value Measurements.” For policies held at fair value, changes in fair value are reflected in operations in the period the change is calculated.
For policies held under the investment method, the Company tests the impairment if we become aware of information indicating that the carrying value plus undiscounted future premiums of a policy may not be recoverable. This information is gathered initially through extensive underwriting procedures at purchase of the settlement contract, as well as through periodic underwriting review that include medical reports and life expectancy evaluations. The policies held by the Company using the investment method are expected to be owned for a shorter-term, and are actively marketed to potential buyers. The market feedback received through these interactions provides the Company with information related to a potential impairment. If a policy is determined to be impaired, the Company will adjust the carrying value to the fair value determined through the impairment analysis.
The Company accounts for cash proceeds from sale and maturity of life insurance settlement policies, as well as cash outflows for premium payments, as operating activities within the condensed consolidated statements of cash flows.
Cost of Revenues Cost of Revenues—Cost of revenue represents the direct costs associated with fulfilling the Company’s obligations to its customers, primarily policy servicing and consulting expense.
Income Taxes Income Taxes—The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, the provision for income taxes represents income taxes paid or payable (or received or receivable) for the current year plus the change in deferred taxes during the year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid, and result from differences between the financial and tax bases of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when enacted.
Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not (greater than 50%) that a tax benefit will not be realized. In evaluating the need for a valuation allowance, management considers all potential sources of taxable income, including income available in carryback periods, future reversals of taxable temporary differences, projections of taxable income, and income from tax planning strategies, as well as all available positive and negative evidence. Positive evidence includes factors such as a history of profitable operations, projections of future profitability within the carryforward period, including from tax planning strategies, and the Company’s experience with similar operations. Existing favorable contracts are additional positive evidence. Negative evidence includes items such as cumulative losses, projections of future losses, or carryforward periods that are not long enough to allow for the utilization of a deferred tax asset based on existing projections of income. Deferred tax assets for which no valuation allowance is recorded may not be realized upon changes in facts and circumstances, resulting in a future charge to establish a valuation allowance. Existing valuation allowances are re-examined under the same standards of positive and negative evidence. If it is determined that it is more likely than not that a deferred tax asset will be realized, the appropriate amount of the valuation allowance, if any, is released. Deferred tax assets and liabilities are also remeasured to reflect changes in underlying tax rates due to law changes and the granting and lapse of tax holidays.

Tax benefits related to uncertain tax positions taken or expected to be taken on a tax return are recorded when such benefits meet a more likely than not threshold. Otherwise, these tax benefits are recorded when a tax position has been effectively settled, which means that the statute of limitations has expired or the appropriate taxing authority has completed their examination even though the statute of limitations remains open. Interest and penalties related to uncertain tax positions are recognized as part of the provision for income taxes and are accrued beginning in the period that such interest and penalties would be applicable under relevant tax law until such time that the related tax benefits are recognized.
Concentrations Concentrations—Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, accounts receivable, and available-for-sale securities. The Company maintains its cash in bank deposit accounts with high-quality financial institutions, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on its cash and cash equivalents. For accounts receivable, the Company is exposed to credit risk in the event of nonpayment by customers to the extent of the amounts recorded on the accompanying condensed consolidated balance sheets. The Company extends different levels of credit to its customers and maintains allowance for doubtful accounts based upon the expected collectability of accounts receivable. The Company’s procedures for determining this allowance includes evaluating individual customer receivables, considering a customer’s financial condition, monitoring credit history and current economic conditions, and using historical experience applied to an aging of accounts.
Warrants
Warrants—The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480 Distinguishing Liabilities from Equity (“ASC 480”) and ASC 815, Derivatives and Hedging (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding.

For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the condensed consolidated statements of operations and comprehensive income.
Abacus Settlements, LLC  
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
Basis of Presentation and Unaudited Condensed Consolidated Financial Statements
Basis of Presentation—The accompanying condensed financial statements are presented in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).
Unaudited Condensed Financial Statements—The condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2023, and the condensed results of its operations and comprehensive income/(loss) and cash flows for the three and six months ended June 30, 2023 and 2022. The condensed results of operations and comprehensive income/(loss) and cash flows for the period January 1, 2023 to June 30, 2023, are not necessarily indicative of the results to be expected for the full year ending December 31, 2023, or any other period.
Use of Estimates Use of Estimates—The preparation of US GAAP financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, and disclosure of contingent assets and liabilities at the date of financial statements and the reports amounts of revenue and expenses during the reporting periods. Company’s estimates, judgments, and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from the estimates. Estimates are used when accounting for revenue recognition and related costs, the selection of useful lives of property and equipment, impairment testing, valuation of other receivables from clients, income taxes, and legal reserves.
Other Receivables
Other receivables—Other receivables include origination fees for policies in which the recission period has ended, but the funds have not been received yet from financing entities. These fees were collected in the subsequent month.
The Company provides an allowance for credit losses equal to the estimated collection losses that will be incurred in collection of all receivables. Management determines the allowance for credit losses based on a review of outstanding receivables, historical collection experience, current economic conditions, and reasonable and supportable forecasts. Account balances are charged off against the allowance for credit losses after all means of collection have been exhausted and the potential for recovery is deemed remote. The Company does not have any material allowance for credit losses as of June 30, 2023 or December 31, 2022.
If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. The Company did not record material allowance for credit losses as of June 30, 2023, and December 31, 2022, respectively.
Concentrations Concentrations—All of the Company’s revenues are derived from life settlement transactions in which the Company represents Financing Entities that purchased existing life insurance policies. One financing entity, a company in which the Company’s members own interests, represented 23% and 66% of the Company’s revenues in six months ended June 30, 2023 and 2022, respectively. The Company originates policies through three different channels: Direct to Consumer, Agent, and Broker. Two brokers represented the sellers for over 10% of the Company’s life settlement commission expense during the period six months ended June 30, 2023. No brokers represented the sellers for over 10% of the Company’s life settlement commission expense during the period six months ended June 30, 2022. The Company maintains cash deposits with a major financial institution, which from time to time may exceed federally insured limits. The Company periodically assesses the financial condition of the institution and believes that the risk of loss is minimal.
Advertising Advertising—All advertising expenditures incurred by the Company are charged to expense in the period to which they relate and are included in general and administrative expenses on the accompanying condensed statements of operations and comprehensive income/(loss).
XML 45 R39.htm IDEA: XBRL DOCUMENT v3.23.2
BUSINESS COMBINATION (Tables)
6 Months Ended
Jun. 30, 2023
Business Combination and Asset Acquisition [Abstract]  
Purchase price allocation
Net Assets IdentifiedFair Value
Intangibles$32,900,000 
Goodwill140,287,000 
Current Assets1,280,100 
Non-Current Assets901,337 
Deferred Tax Liabilities(8,310,966)
Accrued Expenses(524,400)
Other Liabilities(1,171,739)
Total Fair Value$165,361,332 
Value conveyed
Value ConveyedAmount
Abacus Purchase Consideration$165,361,332 
LMA Business Enterprise Value $366,388,668 
Total Consideration$531,750,000 
Intangible assets acquired
Intangible assets were comprised of the following:
Asset TypeFair ValueUseful LifeValuation Methodology
Customer Relationships-Agents$12,600,000 5 yearsMulti-period excess earnings method
Customer Relationships-Financing Entities11,000,000 8 yearsMulti-period excess earnings method
Internally Developed and Used Technology-APA1,600,000 2 yearsRelief from royalty method
Internally Developed and Used Technology-Marketplace100,000 3 yearsReplacement cost method
Trade Name900,000 IndefiniteRelief from royalty method
Non-Compete Agreements4,000,000 2 yearsWith and without method
State Insurance Licenses2,700,000 IndefiniteReplacement cost method
Total Fair Value$32,900,000 
Pro forma financial information The supplemental pro forma financial information in the table below summarizes the combined results of operations for the Business Combination as if the Companies were combined as of
January 1, 2022. The unaudited supplemental pro forma financial information as presented below is for illustrative purposes and does not purport to represent what the results of operations would actually have been if the business combinations occurred as of the date indicated or what the results would be for any future periods.

Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Proforma revenue$18,263,455 $14,090,817 $34,769,650 $31,290,963 
Proforma net income6,432,047 4,589,315 13,373,444 11,788,486 
XML 46 R40.htm IDEA: XBRL DOCUMENT v3.23.2
LIFE INSURANCE SETTLEMENT POLICIES (Tables)
6 Months Ended
Jun. 30, 2023
Investments, All Other Investments [Abstract]  
Schedule of Life Settlement Contracts, Fair Value Method
Policies Carried at Fair Value
Remaining Life Expectancy (Years)PoliciesFace ValueFair Value
0-1
0$— $— 
1-2
1012,314,000 6,855,769 
2-3
1116,886,778 10,530,949 
3-4
1033,631,467 9,174,200 
4-5
1318,755,193 7,564,469 
Thereafter78113,618,147 22,560,230 
122$195,205,585 $56,685,617 
Schedule of Life Settlement Contracts, Investment Method
Policies accounted for using the investment method—
Remaining Life Expectancy (Years)Number of Life
Insurance
Policies
Face ValueCarrying Value
0-1
0$— $— 
1-2
0— — 
2-3
24,400,000 2,131,679 
3-4
44,100,000 1,281,524 
4-5
41,362,000 518,736 
Thereafter35 29,658,877 5,957,671 
45$39,520,877 $9,889,610 
Estimated premiums to be paid by the Company for its portfolio accounted for using the investment method during each of the five succeeding calendar years and thereafter as of June 30, 2023, are as follows:
2023 remaining$1,024,151 
20241,243,423 
20251,310,936 
20261,044,640 
Thereafter3,288,619 
Total$7,911,769 
XML 47 R41.htm IDEA: XBRL DOCUMENT v3.23.2
PROPERTY AND EQUIPMENT—NET (Tables)
6 Months Ended
Jun. 30, 2023
Property, Plant and Equipment [Abstract]  
Summary of Property and Equipment, Net
Property and equipment—net composed of the following:
June 30,
2023
December 31,
2022
Computer equipment$144,202 $— 
Furniture and fixtures34,300 19,444 
Leasehold improvements8,299 5,902 
Property and equipment—gross186,801 25,346 
Less: accumulated depreciation(8,870)(6,729)
Property and equipment—net$177,931 $18,617 
XML 48 R42.htm IDEA: XBRL DOCUMENT v3.23.2
GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)
6 Months Ended
Jun. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Goodwill The changes in goodwill by reportable segments were as follows:
Abacus Settlements, LLC
Goodwill at January 1, 2022$— 
Additions— 
Goodwill at June 30, 2022$— 
Goodwill at January 1, 2023$— 
Additions140,287,000 
Goodwill at June 30, 2023$140,287,000 
Schedule of Finite-Lived Intangible Assets
Intangible Assets Acquired comprised of the following:
Asset TypeFair ValueUseful LifeValuation Methodology
Customer Relationships - Agents$12,600,000 5 yearsMulti-period excess-earnings method
Customer Relationships - Financial Relationships11,000,000 8 yearsMulti-period excess-earnings method
Internally Developed and Used Technology—APA1,600,000 2 yearsRelief from Royalty Method
Internally Developed and Used Technology—Market Place100,000 3 yearsReplacement Cost Method
Trade Name900,000 IndefiniteRelief from Royalty Method
Non-Compete Agreements4,000,000 2 yearsWith or Without Method
State Insurance Licenses2,700,000 IndefiniteReplacement Cost Method
$32,900,000 
Schedule of Indefinite-Lived Intangible Assets
Intangible Assets Acquired comprised of the following:
Asset TypeFair ValueUseful LifeValuation Methodology
Customer Relationships - Agents$12,600,000 5 yearsMulti-period excess-earnings method
Customer Relationships - Financial Relationships11,000,000 8 yearsMulti-period excess-earnings method
Internally Developed and Used Technology—APA1,600,000 2 yearsRelief from Royalty Method
Internally Developed and Used Technology—Market Place100,000 3 yearsReplacement Cost Method
Trade Name900,000 IndefiniteRelief from Royalty Method
Non-Compete Agreements4,000,000 2 yearsWith or Without Method
State Insurance Licenses2,700,000 IndefiniteReplacement Cost Method
$32,900,000 
XML 49 R43.htm IDEA: XBRL DOCUMENT v3.23.2
SEGMENT REPORTING (Tables)
6 Months Ended
Jun. 30, 2023
Segment Reporting [Abstract]  
Summary of Revenue by Segment
Revenue related to the Company’s reporting segments for the three-month and six-month periods ended June 30, 2023, and June 30, 2022, is as follows:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Portfolio servicing$354,366 $419,422 $590,057 $990,328 
Active management11,024,399 7,979,479 20,994,917 17,285,971 
Total revenue$11,378,765 $8,398,901 $21,584,974 $18,276,299 
Summary of Segment Information
Information related to the Company’s reporting segments for the three-month and six-month periods ended June 30, 2023 and June 30, 2022 is as follows:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Portfolio servicing$(76,705)$280,303 $(166,128)$668,752 
Active management10,482,070 7,452,479 20,288,152 15,521,472 
Total gross profit10,405,365 7,732,782 20,122,024 16,190,224 
Sales and marketing(683,841)(1,019,498)(1,412,845)(1,649,498)
General, administrative and other(577,539)(5,499)(1,274,431)(646,705)
Depreciation(1,098)(1,098)(2,141)(2,141)
Other (expense) income121,601 (127,455)(21,651)(242,247)
Interest expense(584,075)(934,001)
Loss on change in fair value of debt(1,445,229)(333,879)(2,398,662)(375,513)
Unrealized gain (loss) on investments672,936 (1,039,022)798,156 (1,054,975)
Provision for income taxes(1,184,571)(120,132)(528,104)(296,806)
Less: Net loss attributable to non-controlling interests26,596 (406,641)487,303 (406,641)
Net income attributable to Abacus Life, Inc.$6,750,145 $4,679,558 $14,835,648 $11,515,698 
XML 50 R44.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE MEASUREMENTS (Tables)
6 Months Ended
Jun. 30, 2023
Fair Value Disclosures [Abstract]  
Fair Value Measurements, Recurring and Nonrecurring The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy are presented in the tables below.
Fair Value Hierarchy
As of June 30, 2023Level 1Level 2Level 3Total
Assets:
Life settlement policies$— $— $56,685,617 $56,685,617 
Available-for-sale securities, at fair value— — 1,000,000 1,000,000 
Other investments— — 1,600,000 1,600,000 
S&P 500 options1,794,640 — — 1,794,640 
Other assets7,246 — — 7,246 
Total assets held at fair value$1,801,886 $— $59,285,617 $61,087,503 
Liabilities:
Long-term debt$— $— $66,165,396 $66,165,396 
Private placement warrants— — 2,438,600 2,438,600 
Total liabilities held at fair value:$— $— $68,603,996 $68,603,996 
Fair Value Hierarchy
As of December 31, 2022Level 1Level 2Level 3Total
Assets:
Life settlement policies$— $— $13,809,352 $13,809,352 
Available-for-sale securities, at fair value— — 1,000,000 1,000,000 
Other investments— — 1,300,000 1,300,000 
S&P 500 options890,829 — — 890,829 
Total assets held at fair value$890,829 $— $16,109,352 $17,000,181 
Liabilities:
Long-term debt$— $— $28,249,653 $28,249,653 
Total liabilities held at fair value:$— $— $28,249,653 $28,249,653 
Fair Value Measurement Inputs and Valuation Techniques If the discount rate increased or decreased by 2 percentage points and the other assumptions used to estimate fair value remained the same, the change in estimated fair value as of June 30, 2023, would be as follows:
As of June 30, 2023Fair ValueChange in
Fair Value
Rate Adjustment
+2%$53,987,508 $(2,698,109)
No change56,685,617 
-2%59,857,879 3,172,262 
The following table presents the key assumptions in the analysis:
Private Placement Warrants
Expected implied volatility de minimis
Risk-free interest rate 4.09%
Term to expiration 5.0 years
Exercise price$11.50
Common Stock Price $10.03
Dividend Yield—%
Schedules of Concentration of Risk, by Risk Factor The following table provides information about the life insurance issuer concentrations that exceed 10% of total face value or 10% of total fair value of the Company’s life insurance policies as of June 30, 2023:
CarrierPercentage of
Face Value
Percentage of
Fair Value
Carrier
Rating
American General Life Insurance Company14.0 %11.0 %A
ReliaStar Life Insurance Company6.0 %12.0 %A
Lincoln National Life Insurance Company14.0 %12.0 %A
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation
The following table provides a roll forward of the fair value of life insurance policies for the six months-ended June 30, 2023:
Fair value at December 31, 2022$13,809,352 
Policies purchased58,543,580 
Realized gain (loss) on matured/sold policies1,898,958 
Premiums paid(879,462)
Unrealized gain(loss) on held policies3,319,588 
Change in estimated fair value4,339,084 
Matured/sold policies(20,885,861)
Premiums paid879,462 
Fair value at June 30, 2023$56,685,617 
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
The following table provides a roll forward of the fair value of the issued notes for the six months ended June 30, 2023:
Fair value at December 31, 2022$28,249,653 
Debt issued to third parties35,209,825 
Unrealized loss on change in fair value (risk-free)2,398,662 
Unrealized gain on change in fair value (credit-adjusted)307,256 
Change in estimated fair value2,705,918 
Fair value at June 30, 2023$66,165,396 
XML 51 R45.htm IDEA: XBRL DOCUMENT v3.23.2
LONG-TERM DEBT (Tables)
6 Months Ended
Jun. 30, 2023
Debt Disclosure [Abstract]  
Schedule of Carrying Values and Estimated Fair Values of Debt Instruments
Long-term debt comprises of the following:
Six Months Ended
June 30, 2023
Year Ended
December 31, 2022
CostFair valueCostFair value
Market-indexed notes:
LMATT Series 2024, Inc.$9,866,900 $9,621,141 $9,866,900 $8,067,291 
LMATT Series 2.2024, Inc.2,333,391 3,446,527 2,333,391 2,354,013 
LMATT Growth & Income Series 1.2026, Inc400,000 459,553 400,000 400,000 
Secured borrowing:
LMATT Income Series, LP21,889,444 22,124,676 17,428,349 17,428,349 
LMATT Income Series II, LP20,041,851 20,041,851 — — 
Unsecured borrowing:
Sponsor PIK Note10,471,648 10,471,648 — — 
Total long-term debt$65,003,234 $66,165,396 $30,028,640 $28,249,653 
SPV purchase and sale note$25,000,000 $25,000,000 — — 
XML 52 R46.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES (Tables)
6 Months Ended
Jun. 30, 2023
Leases [Abstract]  
ROU Assets and Lease Liabilities
The Company’s right-of-use assets and lease liabilities for its operating lease consisted of the following amounts as of June 30, 2023 and December 31, 2022:
Six Months Ended
June 30, 2023
Year Ended
December 31, 2022
Assets:
Operating lease right-of-use assets$240,816 $77,011 
Liabilities:
Operating lease liability, current227,561 48,127 
Operating lease liability, non-current16,864 29,268 
Total lease liability$244,425 $77,395 
The table below shows a weighted-average analysis for lease terms and discount rates for all operating leases for the periods presented:
Six Months Ended
June 30, 2023
Year Ended December 31, 2022
Weighted-average remaining lease term (in years)1.001.58
Weighted-average discount rate3.54 %3.36 %
Lease Expense The Company’s lease expense for the periods presented consisted of the following:
Three Months Ended June 30,Six Months Ended June 30,
2023202220232022
Operating lease cost$12,471 $11,921 $24,942 $23,842 
Variable lease cost7,704 612 8,925 1,223 
Total lease cost$20,175 $12,533 $33,867 $25,065 
The following table shows supplemental cash flow information related to lease activities for the periods presented:
Six Months Ended June 30,
20232022
Cash paid for amounts included in the measurement of the lease liability
Operating cash flows from operating leases$24,557 $23,842 
ROU assets obtained in exchange for new lease liabilities— — 
Future Minimum Noncancellable Lease Payments
Future minimum noncancellable lease payments under the Company’s operating leases on an undiscounted basis reconciled to the respective lease liability at June 30, 2023 are as follows:
Operating leases
Remaining of 2023$130,176 
2024118,057 
2025— 
2026— 
2027— 
Thereafter— 
Total operating lease payments (undiscounted)248,233 
Less: Imputed interest(3,808)
Lease liability as of June 30, 2023$244,425 
XML 53 R47.htm IDEA: XBRL DOCUMENT v3.23.2
EARNINGS PER SHARE (Tables)
6 Months Ended
Jun. 30, 2023
Earnings Per Share [Abstract]  
Schedule of Earnings Per Share, Basic and Diluted
Basic and diluted weighted average shares outstanding and earnings per share were as follows:

Three Months EndedSix Months Ended
June 30, 2023June 30, 2022June 30, 2023June 30, 2022
Net income attributable to Longevity Market Assets$6,750,145 $4,679,558 $14,835,648 $11,515,698 
Weighted-average shares used in computing net income per share, basic and diluted50,507,728 50,369,350 50,438,921 50,369,350 
Basic and diluted earnings per share:$0.13 $0.09 $0.29 $0.23 
XML 54 R48.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - REVENUE (Tables)
6 Months Ended
Jun. 30, 2023
Abacus Settlements, LLC  
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
Disaggregation of Revenue The following table presents a disaggregation of the Company’s revenue by major sources for three months ended June 30, 2023 and 2022, and for six months ended June 30, 2023 and 2022:
Three Months Ended
June 30,
Six Months Ended
June 30,
2023202220232022
Agent$3,334,402 $2,717,512 $7,143,016 $5,690,701 
Broker2,809,499 2,247,953 4,675,973 5,727,970 
Client direct740,789 726,451 1,365,687 1,595,993 
Total$6,884,690 $5,691,916 $13,184,676 $13,014,664 
XML 55 R49.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS (Tables)
6 Months Ended
Jun. 30, 2023
Subsidiary of Limited Liability Company or Limited Partnership [Line Items]  
Schedule of Related Party Transactions For three months ended June 30, 2023 and 2022, and for six months ended June 30, 2023 and 2022, revenue earned, and contracts originated are as follows:
Three Months Ended
June 30,
Six Months Ended
June 30,
2023202220232022
Origination fee revenue$1,504,532 $4,164,107 $2,952,837 $8,569,034 
Transaction reimbursement revenue75,332 152,221 140,960 306,361 
Total$1,579,864 $4,316,328 $3,093,797 $8,875,395 
Cost$5,290,504 $25,201,256 $11,656,637 $50,738,202 
Face value56,688,680 102,307,954 96,674,080 282,804,838 
Total policies38 92 72 183 
Average Age017575
XML 56 R50.htm IDEA: XBRL DOCUMENT v3.23.2
DESCRIPTION OF BUSINESS (Details)
Jun. 30, 2023
$ / shares
Business Acquisition [Line Items]  
Common stock, par value (in dollars per share) $ 0.0001
LMA  
Business Acquisition [Line Items]  
Exchange ratio 0.8
XML 57 R51.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Consolidation of Variable Interest Entities (Details)
3 Months Ended 6 Months Ended
Mar. 03, 2022
USD ($)
Oct. 04, 2021
USD ($)
investor
Jun. 30, 2023
USD ($)
provider
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
provider
Jun. 30, 2022
USD ($)
Dec. 31, 2022
USD ($)
Jan. 01, 2021
provider
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Assets     $ 277,334,437   $ 277,334,437   $ 59,094,847  
Liabilities     $ 116,835,522   $ 116,835,522   30,945,150  
Option agreement, number of providers | provider     2   2     2
Interest (expense)     $ 584,075 $ 0 $ 941,458 $ 0    
Number of unaffiliated investors | investor   3            
RIS                
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Consideration paid to acquire business $ 60,000              
Longevity Market Advisors | RIS                
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Ownership percentage     100.00%   100.00%      
Variable Interest Entity, Primary Beneficiary                
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Assets     $ 57,577,034   $ 57,577,034   30,073,972  
Liabilities     52,474,820   52,474,820   27,116,762  
Contribution amount   $ 100            
Variable Interest Entity, Primary Beneficiary | LMX                
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Ownership percentage   70.00%            
Variable Interest Entity, Primary Beneficiary | Longevity Market Advisors                
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Ownership percentage 80.00%              
Variable Interest Entity, Not Primary Beneficiary                
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Assets     801,345   801,345   987,964  
Liabilities     185,071   185,071   358,586  
Variable Interest Entity, Not Primary Beneficiary | Provider One                
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Assets     318,178   318,178   126,040  
Liabilities     450   450   0  
Variable Interest Entity, Not Primary Beneficiary | Provider Two                
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Assets     483,167   483,167   861,924  
Liabilities     184,621   184,621   $ 358,586  
Variable Interest Entity, Not Primary Beneficiary | Expense Support Agreement                
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]                
Interest (expense)     $ 0 $ 127,455 $ 29,721 $ 242,247    
XML 58 R52.htm IDEA: XBRL DOCUMENT v3.23.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentrations (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Concentration Risk [Line Items]          
Allowance for doubtful accounts $ 0   $ 0   $ 0
Customer Concentration Risk | Accounts Receivable | Customer 1 | Related Party          
Concentration Risk [Line Items]          
Concentration risk percentage     12.00%   75.00%
Customer Concentration Risk | Accounts Receivable | Customer 2 | Related Party          
Concentration Risk [Line Items]          
Concentration risk percentage     13.00%   16.00%
Customer Concentration Risk | Revenue Benchmark | Customer 1 | Related Party | Portfolio servicing          
Concentration Risk [Line Items]          
Concentration risk percentage 20.00%   25.00%    
Customer Concentration Risk | Revenue Benchmark | Customer 1 | Nonrelated Party          
Concentration Risk [Line Items]          
Concentration risk percentage   26.00%   71.00%  
Customer Concentration Risk | Revenue Benchmark | Customer 1 | Nonrelated Party | Active management          
Concentration Risk [Line Items]          
Concentration risk percentage 27.00%   29.00%    
Customer Concentration Risk | Revenue Benchmark | Customer 2 | Related Party | Portfolio servicing          
Concentration Risk [Line Items]          
Concentration risk percentage 20.00%   27.00%    
Customer Concentration Risk | Investment Method Revenue Benchmark | Customer 1 | Nonrelated Party          
Concentration Risk [Line Items]          
Concentration risk percentage     16.00%    
XML 59 R53.htm IDEA: XBRL DOCUMENT v3.23.2
BUSINESS COMBINATION - Narrative (Details)
Jun. 30, 2023
USD ($)
LMA and Abacus  
Business Acquisition [Line Items]  
Consideration $ 531,750,000
LMA and Abacus | Customer Relationships - Agents  
Business Acquisition [Line Items]  
Useful Life 5 years
LMA and Abacus | Customer Relationships - Financial Relationships  
Business Acquisition [Line Items]  
Useful Life 8 years
LMA  
Business Acquisition [Line Items]  
Consideration $ 366,388,668
Enterprise value 366,400,000
LMA | Minimum | Discounted cash flow method  
Business Acquisition [Line Items]  
Enterprise value 380,000,000
LMA | Minimum | Market approach  
Business Acquisition [Line Items]  
Enterprise value 400,000,000
LMA | Maximum | Discounted cash flow method  
Business Acquisition [Line Items]  
Enterprise value 460,000,000
LMA | Maximum | Market approach  
Business Acquisition [Line Items]  
Enterprise value $ 440,000,000
LMA | Discount rate  
Business Acquisition [Line Items]  
Measurement input 0.145
Abacus  
Business Acquisition [Line Items]  
Consideration $ 165,361,332
Enterprise value 165,400,000
Abacus | Minimum | Discounted cash flow method  
Business Acquisition [Line Items]  
Enterprise value 180,000,000
Abacus | Minimum | Market approach  
Business Acquisition [Line Items]  
Enterprise value 180,000,000
Abacus | Maximum | Discounted cash flow method  
Business Acquisition [Line Items]  
Enterprise value 195,000,000
Abacus | Maximum | Market approach  
Business Acquisition [Line Items]  
Enterprise value $ 190,000,000
Abacus | Discount rate  
Business Acquisition [Line Items]  
Measurement input 0.165
XML 60 R54.htm IDEA: XBRL DOCUMENT v3.23.2
BUSINESS COMBINATION - Purchase Price Allocation (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Business Acquisition [Line Items]    
Intangibles $ 32,900,000  
Goodwill 140,287,000 $ 0
LMA and Abacus    
Business Acquisition [Line Items]    
Intangibles 32,900,000  
Goodwill 140,287,000  
Current Assets 1,280,100  
Non-Current Assets 901,337  
Deferred Tax Liabilities (8,310,966)  
Accrued Expenses (524,400)  
Other Liabilities (1,171,739)  
Total Fair Value $ 165,361,332  
XML 61 R55.htm IDEA: XBRL DOCUMENT v3.23.2
BUSINESS COMBINATION - Value Conveyed (Details)
Jun. 30, 2023
USD ($)
Abacus  
Business Acquisition [Line Items]  
Consideration $ 165,361,332
LMA  
Business Acquisition [Line Items]  
Consideration 366,388,668
LMA and Abacus  
Business Acquisition [Line Items]  
Consideration $ 531,750,000
XML 62 R56.htm IDEA: XBRL DOCUMENT v3.23.2
BUSINESS COMBINATION - Intangible Assets Acquired (Details)
Jun. 30, 2023
USD ($)
Business Acquisition [Line Items]  
Intangibles $ 32,900,000
Trade Name  
Business Acquisition [Line Items]  
Intangibles 900,000
State Insurance Licenses  
Business Acquisition [Line Items]  
Intangibles 2,700,000
Customer Relationships - Agents  
Business Acquisition [Line Items]  
Intangibles 12,600,000
Customer Relationships - Financial Relationships  
Business Acquisition [Line Items]  
Intangibles 11,000,000
Internally Developed and Used Technology—APA  
Business Acquisition [Line Items]  
Intangibles 1,600,000
Internally Developed and Used Technology—Market Place  
Business Acquisition [Line Items]  
Intangibles 100,000
Non-Compete Agreements  
Business Acquisition [Line Items]  
Intangibles 4,000,000
LMA and Abacus  
Business Acquisition [Line Items]  
Intangibles 32,900,000
LMA and Abacus | Trade Name  
Business Acquisition [Line Items]  
Intangibles 900,000
LMA and Abacus | State Insurance Licenses  
Business Acquisition [Line Items]  
Intangibles 2,700,000
LMA and Abacus | Customer Relationships - Agents  
Business Acquisition [Line Items]  
Intangibles $ 12,600,000
Useful Life 5 years
LMA and Abacus | Customer Relationships - Financial Relationships  
Business Acquisition [Line Items]  
Intangibles $ 11,000,000
Useful Life 8 years
LMA and Abacus | Internally Developed and Used Technology—APA  
Business Acquisition [Line Items]  
Intangibles $ 1,600,000
Useful Life 2 years
LMA and Abacus | Internally Developed and Used Technology—Market Place  
Business Acquisition [Line Items]  
Intangibles $ 100,000
Useful Life 3 years
LMA and Abacus | Non-Compete Agreements  
Business Acquisition [Line Items]  
Intangibles $ 4,000,000
Useful Life 2 years
XML 63 R57.htm IDEA: XBRL DOCUMENT v3.23.2
BUSINESS COMBINATION - Pro Forma Financial Information (Details) - LMA and Abacus - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Business Acquisition [Line Items]        
Proforma revenue $ 18,263,455 $ 14,090,817 $ 34,769,650 $ 31,290,963
Proforma net income $ 6,432,047 $ 4,589,315 $ 13,373,444 $ 11,788,486
XML 64 R58.htm IDEA: XBRL DOCUMENT v3.23.2
LIFE INSURANCE SETTLEMENT POLICIES - Narrative (Details)
Jun. 30, 2023
USD ($)
insurance_contract
Dec. 31, 2022
USD ($)
insurance_contract
Investments, All Other Investments [Abstract]    
Number of life settlement policies | insurance_contract 167 53
Number of life settlement policies accounted for under fair value method | insurance_contract 122 35
Number of life settlement policies accounted for under investment method | insurance_contract 45 18
Face value of policies held at fair value $ 195,205,585 $ 40,092,154
Life settlement policies, at fair value 56,685,617 13,809,352
Face value of policies accounted for using investment method 39,520,877 42,330,000
Life settlement policies, at cost $ 9,889,610 $ 8,716,111
XML 65 R59.htm IDEA: XBRL DOCUMENT v3.23.2
LIFE INSURANCE SETTLEMENT POLICIES - Fair Value (Details)
Jun. 30, 2023
USD ($)
insurance_contract
Dec. 31, 2022
USD ($)
insurance_contract
Policies    
0-1 | insurance_contract 0  
1-2 | insurance_contract 10  
2-3 | insurance_contract 11  
3-4 | insurance_contract 10  
4-5 | insurance_contract 13  
Thereafter | insurance_contract 78  
Policies | insurance_contract 122 35
Face Value    
0-1 $ 0  
1-2 12,314,000  
2-3 16,886,778  
3-4 33,631,467  
4-5 18,755,193  
Thereafter 113,618,147  
Face Value 195,205,585 $ 40,092,154
Fair Value    
0-1 0  
1-2 6,855,769  
2-3 10,530,949  
3-4 9,174,200  
4-5 7,564,469  
Thereafter 22,560,230  
Fair Value $ 56,685,617 $ 13,809,352
XML 66 R60.htm IDEA: XBRL DOCUMENT v3.23.2
LIFE INSURANCE SETTLEMENT POLICIES - Investment Method (Details)
Jun. 30, 2023
USD ($)
insurance_contract
Dec. 31, 2022
USD ($)
insurance_contract
Number of Life Insurance Policies    
0-1 | insurance_contract 0  
1-2 | insurance_contract 0  
2-3 | insurance_contract 2  
3-4 | insurance_contract 4  
4-5 | insurance_contract 4  
Thereafter | insurance_contract 35  
Number of Life Insurance Policies | insurance_contract 45 18
Face Value    
0-1 $ 0  
1-2 0  
2-3 4,400,000  
3-4 4,100,000  
4-5 1,362,000  
Thereafter 29,658,877  
Face Value 39,520,877 $ 42,330,000
Carrying Value    
0-1 0  
1-2 0  
2-3 2,131,679  
3-4 1,281,524  
4-5 518,736  
Thereafter 5,957,671  
Carrying Value $ 9,889,610 $ 8,716,111
XML 67 R61.htm IDEA: XBRL DOCUMENT v3.23.2
LIFE INSURANCE SETTLEMENT POLICIES - Estimated Premiums (Details)
Jun. 30, 2023
USD ($)
Investments, All Other Investments [Abstract]  
2023 remaining $ 1,024,151
2024 1,243,423
2025 1,310,936
2026 1,044,640
Thereafter 3,288,619
Total $ 7,911,769
XML 68 R62.htm IDEA: XBRL DOCUMENT v3.23.2
PROPERTY AND EQUIPMENT—NET (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Property, Plant and Equipment [Line Items]          
Property and equipment—gross $ 186,801   $ 186,801   $ 25,346
Less: accumulated depreciation (8,870)   (8,870)   (6,729)
Property and equipment—net 177,931   177,931   18,617
Depreciation expense 1,098 $ 1,098 2,141 $ 2,141  
Computer equipment          
Property, Plant and Equipment [Line Items]          
Property and equipment—gross 144,202   144,202   0
Furniture and fixtures          
Property, Plant and Equipment [Line Items]          
Property and equipment—gross 34,300   34,300   19,444
Leasehold improvements          
Property, Plant and Equipment [Line Items]          
Property and equipment—gross $ 8,299   $ 8,299   $ 5,902
XML 69 R63.htm IDEA: XBRL DOCUMENT v3.23.2
GOODWILL AND OTHER INTANGIBLE ASSETS - Changes in Goodwill by Reportable Segments (Details) - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Goodwill [Roll Forward]    
Goodwill at beginning of period $ 0  
Goodwill at end of period 140,287,000  
Abacus Settlements, LLC    
Goodwill [Roll Forward]    
Goodwill at beginning of period 0 $ 0
Additions 140,287,000 0
Goodwill at end of period 140,287,000 $ 0
LMA and Abacus    
Goodwill [Roll Forward]    
Goodwill at end of period $ 140,287,000  
XML 70 R64.htm IDEA: XBRL DOCUMENT v3.23.2
GOODWILL AND OTHER INTANGIBLE ASSETS - Intangible Assets Acquired (Details)
$ in Thousands
Jun. 30, 2023
USD ($)
Finite-Lived Intangible Assets [Line Items]  
Fair Value $ 32,900
Indefinite-Lived Intangible Assets [Line Items]  
Fair Value 32,900
Trade Name  
Finite-Lived Intangible Assets [Line Items]  
Fair Value 900
Indefinite-Lived Intangible Assets [Line Items]  
Fair Value 900
State Insurance Licenses  
Finite-Lived Intangible Assets [Line Items]  
Fair Value 2,700
Indefinite-Lived Intangible Assets [Line Items]  
Fair Value 2,700
Customer Relationships - Agents  
Finite-Lived Intangible Assets [Line Items]  
Fair Value $ 12,600
Useful Life 5 years
Indefinite-Lived Intangible Assets [Line Items]  
Fair Value $ 12,600
Customer Relationships - Financial Relationships  
Finite-Lived Intangible Assets [Line Items]  
Fair Value $ 11,000
Useful Life 8 years
Indefinite-Lived Intangible Assets [Line Items]  
Fair Value $ 11,000
Internally Developed and Used Technology—APA  
Finite-Lived Intangible Assets [Line Items]  
Fair Value $ 1,600
Useful Life 2 years
Indefinite-Lived Intangible Assets [Line Items]  
Fair Value $ 1,600
Internally Developed and Used Technology—Market Place  
Finite-Lived Intangible Assets [Line Items]  
Fair Value $ 100
Useful Life 3 years
Indefinite-Lived Intangible Assets [Line Items]  
Fair Value $ 100
Non-Compete Agreements  
Finite-Lived Intangible Assets [Line Items]  
Fair Value $ 4,000
Useful Life 2 years
Indefinite-Lived Intangible Assets [Line Items]  
Fair Value $ 4,000
XML 71 R65.htm IDEA: XBRL DOCUMENT v3.23.2
AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE (Details) - USD ($)
1 Months Ended 6 Months Ended 12 Months Ended
Jan. 07, 2022
Oct. 31, 2022
Jan. 31, 2022
Nov. 30, 2021
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2021
Dec. 31, 2022
Investments, Debt and Equity Securities [Abstract]                
Purchase of convertible promissory note $ 250,000 $ 500,000 $ 250,000 $ 250,000 $ 300,000 $ 250,000 $ 250,000  
Interest rate per annum   8.00%   6.00%        
Equity financing threshold   $ 5,000,000   $ 1,000,000       $ 1,000,000
XML 72 R66.htm IDEA: XBRL DOCUMENT v3.23.2
OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Dec. 21, 2020
USD ($)
shares
Jul. 22, 2020
USD ($)
shares
Dec. 31, 2022
USD ($)
payment
shares
Jun. 30, 2023
USD ($)
entity
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
entity
Jun. 30, 2022
USD ($)
Mar. 31, 2023
USD ($)
Conversion of Stock [Line Items]                
Number of entities, convertible preferred stock ownership | entity       2   2    
Equity securities without readily determinable fair value, amount     $ 1,300,000 $ 1,600,000   $ 1,600,000    
Impairment of investments       0 $ 0 0 $ 0  
Series Seed Preferred Units                
Conversion of Stock [Line Items]                
Units purchased (in shares) | shares   224,551 119,760          
Equity securities without readily determinable fair value, amount   $ 750,000 $ 400,000 $ 1,100,000   $ 1,100,000   $ 950,000
Number of monthly payments | payment     8          
Monthly payment amount     $ 50,000          
Equity ownership percentage       8.60%   8.60%    
Series B-1 Preferred Stock                
Conversion of Stock [Line Items]                
Units purchased (in shares) | shares 207,476              
Equity securities without readily determinable fair value, amount $ 500,000              
Equity ownership percentage 1.00%              
XML 73 R67.htm IDEA: XBRL DOCUMENT v3.23.2
CONSOLIDATION OF VARIABLE INTEREST ENTITIES (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Variable Interest Entity [Line Items]    
Assets $ 277,334,437 $ 59,094,847
Liabilities 116,835,522 30,945,150
Variable Interest Entity, Primary Beneficiary    
Variable Interest Entity [Line Items]    
Assets 57,577,034 30,073,972
Liabilities 52,474,820 27,116,762
Variable Interest Entity, Not Primary Beneficiary    
Variable Interest Entity [Line Items]    
Assets 801,345 987,964
Liabilities $ 185,071 $ 358,586
XML 74 R68.htm IDEA: XBRL DOCUMENT v3.23.2
SEGMENT REPORTING - Narrative (Details)
6 Months Ended
Jun. 30, 2023
segment
Segment Reporting [Abstract]  
Number of reportable segments 2
XML 75 R69.htm IDEA: XBRL DOCUMENT v3.23.2
SEGMENT REPORTING - Revenue by Segment (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Segment Reporting Information [Line Items]        
Portfolio servicing $ 354,366 $ 419,422 $ 590,057 $ 990,328
Total revenues 11,378,765 8,398,901 21,584,974 18,276,299
Portfolio servicing        
Segment Reporting Information [Line Items]        
Portfolio servicing 354,366 419,422 590,057 990,328
Active management        
Segment Reporting Information [Line Items]        
Active management $ 11,024,399 $ 7,979,479 $ 20,994,917 $ 17,285,971
XML 76 R70.htm IDEA: XBRL DOCUMENT v3.23.2
SEGMENT REPORTING - Reconciliation of Net Income (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Segment Reporting Information [Line Items]        
Total gross profit $ 10,405,365 $ 7,732,782 $ 20,122,024 $ 16,190,224
Sales and marketing (683,841) (1,019,498) (1,412,845) (1,649,498)
General, administrative and other (577,539) (5,499) (1,274,431) (646,705)
Depreciation (1,098) (1,098) (2,141) (2,141)
Other (expense) income 121,601 (127,455) (21,651) (242,247)
Interest expense (584,075) 0 (934,001) 0
Loss on change in fair value of debt (1,445,229) (333,879) (2,398,662) (375,513)
Unrealized gain (loss) on investments 672,936 (1,039,022) 798,156 (1,054,975)
Provision for income taxes (1,184,571) (120,132) (528,104) (296,806)
Less: Net loss attributable to non-controlling interests 26,596 (406,641) 487,303 (406,641)
NET INCOME ATTRIBUTABLE TO SHAREHOLDERS 6,750,145 4,679,558 14,835,648 11,515,698
Portfolio servicing        
Segment Reporting Information [Line Items]        
Total gross profit (76,705) 280,303 (166,128) 668,752
Active management        
Segment Reporting Information [Line Items]        
Total gross profit $ 10,482,070 $ 7,452,479 $ 20,288,152 $ 15,521,472
XML 77 R71.htm IDEA: XBRL DOCUMENT v3.23.2
COMMITMENTS AND CONTINGENCIES (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2023
USD ($)
provider
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
provider
Jun. 30, 2022
USD ($)
Jan. 01, 2021
provider
Other Commitments [Line Items]          
Option agreement, number of providers | provider 2   2   2
Other income (expense) $ 121,601 $ (127,455) $ (21,651) $ (242,247)  
Expense Support Agreement | Variable Interest Entity, Not Primary Beneficiary          
Other Commitments [Line Items]          
Other income (expense) $ 0   $ 29,721    
XML 78 R72.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE MEASUREMENTS - Recurring Fair Value Measurements (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Assets:    
Life settlement policies $ 56,685,617 $ 13,809,352
Available-for-sale securities, at fair value 1,000,000 1,000,000
Other investments 1,600,000 1,300,000
Liabilities:    
Private placement warrants 2,438,600 0
Fair Value, Recurring    
Assets:    
Life settlement policies 56,685,617 13,809,352
Available-for-sale securities, at fair value 1,000,000 1,000,000
Other investments 1,600,000 1,300,000
S&P 500 options 1,794,640 890,829
Other assets 7,246  
Total assets held at fair value 61,087,503 17,000,181
Liabilities:    
Long-term debt 66,165,396 28,249,653
Private placement warrants 2,438,600  
Total liabilities held at fair value: 68,603,996 28,249,653
Fair Value, Recurring | Level 1    
Assets:    
Life settlement policies 0 0
Available-for-sale securities, at fair value 0 0
Other investments 0 0
S&P 500 options 1,794,640 890,829
Other assets 7,246  
Total assets held at fair value 1,801,886 890,829
Liabilities:    
Long-term debt 0 0
Private placement warrants 0  
Total liabilities held at fair value: 0 0
Fair Value, Recurring | Level 2    
Assets:    
Life settlement policies 0 0
Available-for-sale securities, at fair value 0 0
Other investments 0 0
S&P 500 options 0 0
Other assets 0  
Total assets held at fair value 0 0
Liabilities:    
Long-term debt 0 0
Private placement warrants 0  
Total liabilities held at fair value: 0 0
Fair Value, Recurring | Level 3    
Assets:    
Life settlement policies 56,685,617 13,809,352
Available-for-sale securities, at fair value 1,000,000 1,000,000
Other investments 1,600,000 1,300,000
S&P 500 options 0 0
Other assets 0  
Total assets held at fair value 59,285,617 16,109,352
Liabilities:    
Long-term debt 66,165,396 28,249,653
Private placement warrants 2,438,600  
Total liabilities held at fair value: $ 68,603,996 $ 28,249,653
XML 79 R73.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE MEASUREMENTS - Narrative (Details)
1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jan. 07, 2022
USD ($)
Aug. 14, 2023
USD ($)
insurance_contract
Oct. 31, 2022
USD ($)
Jan. 31, 2022
USD ($)
Nov. 30, 2021
USD ($)
Jun. 30, 2023
USD ($)
$ / shares
shares
Jun. 30, 2022
USD ($)
Jun. 30, 2023
USD ($)
$ / shares
shares
Jun. 30, 2022
USD ($)
Dec. 31, 2021
USD ($)
Dec. 31, 2022
USD ($)
Aug. 25, 2020
shares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]                        
Decrease in valuation compared to third-party valuation           $ (2,760,900) $ (2,014,013) $ (4,339,084) $ (3,305,505)      
Life settlement policies, at cost           9,889,610   9,889,610     $ 8,716,111  
Total change in fair value of debt           1,602,042   (2,705,918)        
Gain on change in fair value of debt, included within other comprehensive income           90,148   175,530        
Gain on change in fair value of debt, included within equity of noncontrolling interests           29,515   56,446        
Loss on change in fair value of debt           1,445,229 $ 333,879 2,398,662 375,513      
Purchase of convertible promissory note $ 250,000   $ 500,000 $ 250,000 $ 250,000     300,000 $ 250,000 $ 250,000    
Available-for-sale securities, at fair value           1,000,000   1,000,000     1,000,000  
Equity securities without readily determinable fair value, amount           $ 1,600,000   $ 1,600,000     $ 1,300,000  
Private Placement Warrant                        
Fair Value Measurement Inputs and Valuation Techniques [Line Items]                        
Warrants outstanding (in shares) | shares           8,900,000   8,900,000       900,000
Price per warrant (in dollars per share) | $ / shares           $ 1.00   $ 1.00        
Warrants outstanding           $ 8,900,000   $ 8,900,000        
Number of securities called by each warrant (in shares) | shares           1   1        
Exercise price of warrants (in dollars per share) | $ / shares           $ 11.50   $ 11.50        
Warrants term           30 days   30 days        
Subsequent Event                        
Fair Value Measurement Inputs and Valuation Techniques [Line Items]                        
Life settlement policies sold | insurance_contract   3                    
Decrease in valuation compared to third-party valuation   $ 231,775                    
Discount rate                        
Fair Value Measurement Inputs and Valuation Techniques [Line Items]                        
Life settlement policies, measurement input           16.00%   16.00%     12.00%  
XML 80 R74.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE MEASUREMENTS - Discount Rate Sensitivity (Details) - USD ($)
6 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Fair Value Disclosures [Abstract]    
Life settlement policies, fair value, impact of +2% discount rate adjustment $ 53,987,508  
Life settlement policies, change in fair value, impact of +2% discount rate adjustment (2,698,109)  
Life settlement policies, at fair value 56,685,617 $ 13,809,352
Life settlement policies, fair value, impact of -2% discount rate adjustment 59,857,879  
Life settlement policies, change in fair value, impact of -2% discount rate adjustment $ 3,172,262  
XML 81 R75.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE MEASUREMENTS - Credit Exposure to Insurance Companies (Details) - Life Insurance Carrier Concentration Risk
6 Months Ended
Jun. 30, 2023
Life Insurance Contract, Face Value | American General Life Insurance Company  
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]  
Concentration risk percentage 14.00%
Life Insurance Contract, Face Value | ReliaStar Life Insurance Company  
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]  
Concentration risk percentage 6.00%
Life Insurance Contract, Face Value | Lincoln National Life Insurance Company  
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]  
Concentration risk percentage 14.00%
Life Insurance Contract, Fair Value | American General Life Insurance Company  
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]  
Concentration risk percentage 11.00%
Life Insurance Contract, Fair Value | ReliaStar Life Insurance Company  
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]  
Concentration risk percentage 12.00%
Life Insurance Contract, Fair Value | Lincoln National Life Insurance Company  
Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]  
Concentration risk percentage 12.00%
XML 82 R76.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE MEASUREMENTS - Life Insurance Policies (Details) - Life Insurance Policies
6 Months Ended
Jun. 30, 2023
USD ($)
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]  
Fair value at beginning of period $ 13,809,352
Policies purchased 58,543,580
Realized gain (loss) on matured/sold policies 1,898,958
Premiums paid 879,462
Unrealized gain(loss) on held policies 3,319,588
Change in estimated fair value 4,339,084
Matured/sold policies (20,885,861)
Fair value at end of period $ 56,685,617
XML 83 R77.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE MEASUREMENTS - Issued Notes (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]        
Fair value at beginning of period     $ 28,249,653  
Debt issued to third parties     35,209,825  
Unrealized loss on change in fair value (risk-free) $ 1,445,229 $ 333,879 2,398,662 $ 375,513
Unrealized gain on change in fair value (credit-adjusted)     307,256  
Change in estimated fair value 1,602,042   (2,705,918)  
Fair value at end of period $ 66,165,396   $ 66,165,396  
XML 84 R78.htm IDEA: XBRL DOCUMENT v3.23.2
FAIR VALUE MEASUREMENTS - Assumptions (Details) - Private Placement Warrant
Jun. 30, 2023
Risk-free interest rate  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrants and rights outstanding, measurement input 0.0409
Term to expiration  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrants and rights outstanding, measurement input 5
Exercise price  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrants and rights outstanding, measurement input 11.50
Common Stock Price  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrants and rights outstanding, measurement input 10.03
Dividend Yield  
Fair Value Measurement Inputs and Valuation Techniques [Line Items]  
Warrants and rights outstanding, measurement input 0
XML 85 R79.htm IDEA: XBRL DOCUMENT v3.23.2
LONG-TERM DEBT - Long-Term Debt (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Cost    
Debt Instrument [Line Items]    
Long-term debt, fair value $ 65,003,234 $ 30,028,640
Cost | Market-indexed notes | LMATT Series 2024, Inc.    
Debt Instrument [Line Items]    
Long-term debt, fair value 9,866,900 9,866,900
Cost | Market-indexed notes | LMATT Series 2.2024, Inc.    
Debt Instrument [Line Items]    
Long-term debt, fair value 2,333,391 2,333,391
Cost | Market-indexed notes | LMATT Growth & Income Series 1.2026, Inc    
Debt Instrument [Line Items]    
Long-term debt, fair value 400,000 400,000
Cost | Secured borrowing | LMATT Income Series, LP    
Debt Instrument [Line Items]    
Long-term debt, fair value 21,889,444 17,428,349
Cost | Secured borrowing | LMATT Income Series II, LP    
Debt Instrument [Line Items]    
Long-term debt, fair value 20,041,851 0
Cost | Unsecured borrowing | Sponsor PIK Note    
Debt Instrument [Line Items]    
Long-term debt, fair value 10,471,648 0
Cost | Line of Credit | SPV Investment Facility    
Debt Instrument [Line Items]    
Long-term debt, fair value 25,000,000 0
Fair value    
Debt Instrument [Line Items]    
Long-term debt, fair value 66,165,396 28,249,653
Fair value | Market-indexed notes | LMATT Series 2024, Inc.    
Debt Instrument [Line Items]    
Long-term debt, fair value 9,621,141 8,067,291
Fair value | Market-indexed notes | LMATT Series 2.2024, Inc.    
Debt Instrument [Line Items]    
Long-term debt, fair value 3,446,527 2,354,013
Fair value | Market-indexed notes | LMATT Growth & Income Series 1.2026, Inc    
Debt Instrument [Line Items]    
Long-term debt, fair value 459,553 400,000
Fair value | Secured borrowing | LMATT Income Series, LP    
Debt Instrument [Line Items]    
Long-term debt, fair value 22,124,676 17,428,349
Fair value | Secured borrowing | LMATT Income Series II, LP    
Debt Instrument [Line Items]    
Long-term debt, fair value 20,041,851 0
Fair value | Unsecured borrowing | Sponsor PIK Note    
Debt Instrument [Line Items]    
Long-term debt, fair value 10,471,648 0
Fair value | Line of Credit | SPV Investment Facility    
Debt Instrument [Line Items]    
Long-term debt, fair value $ 25,000,000 $ 0
XML 86 R80.htm IDEA: XBRL DOCUMENT v3.23.2
LONG-TERM DEBT - Sponsor PIK Note (Details)
Jun. 30, 2023
USD ($)
Unsecured borrowing | Sponsor PIK Note  
Debt Instrument [Line Items]  
Face amount $ 10,471,648
XML 87 R81.htm IDEA: XBRL DOCUMENT v3.23.2
LONG-TERM DEBT - LMATT Series 2024, Inc. Market-Indexed Notes (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Mar. 31, 2022
Debt Instrument [Line Items]      
Assets $ 277,334,437 $ 59,094,847  
Fair value      
Debt Instrument [Line Items]      
Long-term debt, fair value 66,165,396 28,249,653  
LMATT Series 2024, Inc. | Market-indexed notes      
Debt Instrument [Line Items]      
Face amount     $ 10,166,900
Market downturn protection percentage     40.00%
Note reduction ratio for losses below threshold     100.00%
LMATT Series 2024, Inc. | Market-indexed notes | Fair value      
Debt Instrument [Line Items]      
Long-term debt, fair value 9,621,141 $ 8,067,291  
LMATT Series 2024, Inc. | Market-indexed notes | Asset Pledged as Collateral      
Debt Instrument [Line Items]      
Assets $ 11,195,701    
XML 88 R82.htm IDEA: XBRL DOCUMENT v3.23.2
LONG-TERM DEBT - LMATT Series 2.2024, Inc. Market-Indexed Notes (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Sep. 16, 2022
Debt Instrument [Line Items]      
Assets $ 277,334,437 $ 59,094,847  
Fair value      
Debt Instrument [Line Items]      
Long-term debt, fair value 66,165,396 28,249,653  
LMATT Series 2.2024, Inc. | Market-indexed notes      
Debt Instrument [Line Items]      
Face amount     $ 2,333,391
Upside performance participation cap     120.00%
Market downturn protection percentage     20.00%
Note reduction ratio for losses below threshold     100.00%
LMATT Series 2.2024, Inc. | Market-indexed notes | Asset Pledged as Collateral      
Debt Instrument [Line Items]      
Assets 3,331,872    
LMATT Series 2.2024, Inc. | Market-indexed notes | Fair value      
Debt Instrument [Line Items]      
Long-term debt, fair value $ 3,446,527 $ 2,354,013  
LMATT Series 2.2024, Inc.      
Debt Instrument [Line Items]      
Ownership percentage     100.00%
XML 89 R83.htm IDEA: XBRL DOCUMENT v3.23.2
LONG-TERM DEBT - LMATT Growth and Income Series 1.2026, Inc. Market-Indexed Notes (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Sep. 16, 2022
Debt Instrument [Line Items]      
Assets $ 277,334,437 $ 59,094,847  
Fair value      
Debt Instrument [Line Items]      
Long-term debt, fair value 66,165,396 28,249,653  
LMATT Growth & Income Series 1.2026, Inc | Market-indexed notes      
Debt Instrument [Line Items]      
Face amount     $ 400,000
Upside performance participation cap     140.00%
Market downturn protection percentage     10.00%
Note reduction ratio for losses below threshold     100.00%
Dividend percentage     4.00%
LMATT Growth & Income Series 1.2026, Inc | Market-indexed notes | Asset Pledged as Collateral      
Debt Instrument [Line Items]      
Assets 517,218    
LMATT Growth & Income Series 1.2026, Inc | Market-indexed notes | Fair value      
Debt Instrument [Line Items]      
Long-term debt, fair value $ 459,553 $ 400,000  
LMATT Growth & Income Series 1.2026, Inc      
Debt Instrument [Line Items]      
Ownership percentage     100.00%
XML 90 R84.htm IDEA: XBRL DOCUMENT v3.23.2
LONG-TERM DEBT - LMA Income Series, LP and LMA Income Series, GP LLC Secured Borrowing (Details)
6 Months Ended
Jun. 30, 2023
USD ($)
option
Dec. 31, 2022
USD ($)
Fair value    
Debt Instrument [Line Items]    
Long-term debt, fair value $ 66,165,396 $ 28,249,653
LMATT Income Series, LP | Secured borrowing    
Debt Instrument [Line Items]    
Debt instrument term 3 years  
Debt Instrument extension options | option 2  
Debt instrument extension term 1 year  
Dividend percentage 6.50%  
Return rate in excess of minimum internal rate of return 25.00%  
Minimum internal rate of return threshold 6.50%  
Internal rate of return cap 9.00%  
Net internal rate of return at cap 15.00%  
LMATT Income Series, LP | Secured borrowing | Fair value    
Debt Instrument [Line Items]    
Long-term debt, fair value $ 22,124,676 $ 17,428,349
LMATT Income Series, LP | Secured borrowing | General Partner    
Debt Instrument [Line Items]    
Return rate in excess of minimum internal rate of return 75.00%  
Minimum internal rate of return threshold 6.50%  
LMATT Income Series, LP | Secured borrowing | Limited Partner    
Debt Instrument [Line Items]    
Internal rate of return cap 15.00%  
Return Rate in excess of capped internal rate of return threshold 100.00%  
XML 91 R85.htm IDEA: XBRL DOCUMENT v3.23.2
LONG-TERM DEBT - LMA Income Series II, LP and LMA Income Series II, GP LLC Secured Borrowing (Details)
6 Months Ended
Jun. 30, 2023
USD ($)
option
Dec. 31, 2022
USD ($)
Fair value    
Debt Instrument [Line Items]    
Long-term debt, fair value $ 66,165,396 $ 28,249,653
LMATT Income Series II, LP | Secured borrowing    
Debt Instrument [Line Items]    
Debt instrument term 3 years  
Debt Instrument extension options | option 2  
Debt instrument extension term 1 year  
LMATT Income Series II, LP | Secured borrowing | Fair value    
Debt Instrument [Line Items]    
Long-term debt, fair value $ 20,041,851 $ 0
LMATT Income Series II, LP | Secured borrowing | General Partner    
Debt Instrument [Line Items]    
Dividend percentage 100.00%  
LMATT Income Series II, LP | Secured borrowing | Capital Commitment Threshold One | Limited Partner    
Debt Instrument [Line Items]    
Dividend percentage 7.50%  
LMATT Income Series II, LP | Secured borrowing | Capital Commitment Threshold One | Maximum | Limited Partner    
Debt Instrument [Line Items]    
Capital commitment threshold to determine dividend rate $ 500,000  
LMATT Income Series II, LP | Secured borrowing | Capital Commitment Threshold Two | Limited Partner    
Debt Instrument [Line Items]    
Dividend percentage 7.75%  
LMATT Income Series II, LP | Secured borrowing | Capital Commitment Threshold Two | Maximum | Limited Partner    
Debt Instrument [Line Items]    
Capital commitment threshold to determine dividend rate $ 1,000,000  
LMATT Income Series II, LP | Secured borrowing | Capital Commitment Threshold Two | Minimum | Limited Partner    
Debt Instrument [Line Items]    
Capital commitment threshold to determine dividend rate $ 500,000  
LMATT Income Series II, LP | Secured borrowing | Capital Commitment Threshold Three | Limited Partner    
Debt Instrument [Line Items]    
Dividend percentage 8.00%  
LMATT Income Series II, LP | Secured borrowing | Capital Commitment Threshold Three | Minimum | Limited Partner    
Debt Instrument [Line Items]    
Capital commitment threshold to determine dividend rate $ 1,000,000  
XML 92 R86.htm IDEA: XBRL DOCUMENT v3.23.2
LONG-TERM DEBT - SPV Purchase and Sale and SPV Investment Facility (Details) - Subsequent Event
$ in Millions
Jul. 05, 2023
USD ($)
extension
Policy APA  
Debt Instrument [Line Items]  
Insurance policies fair value $ 10.0
SPV Investment Facility | Line of Credit  
Debt Instrument [Line Items]  
Face amount $ 25.0
Debt instrument term 3 years
Number of extensions | extension 2
Debt instrument extension term 1 year
Interest rate (as a percent) 12.00%
Default rate 2.00%
SPV Investment Facility | Line of Credit | Line of Credit  
Debt Instrument [Line Items]  
Face amount $ 10.0
SPV Investment Facility | Line of Credit | Secured borrowing  
Debt Instrument [Line Items]  
Face amount $ 15.0
XML 93 R87.htm IDEA: XBRL DOCUMENT v3.23.2
SHAREHOLDERS' EQUITY (Details)
$ / shares in Units, $ in Thousands
6 Months Ended
Jun. 30, 2023
vote
$ / shares
shares
Aug. 30, 2022
USD ($)
$ / shares
Class of Warrant or Right [Line Items]    
Common stock, shares authorized (in shares) | shares 200,000,000  
Common stock, par value (in dollars per share) | $ / shares $ 0.0001  
Preferred stock, shares authorized (in shares) | shares 1,000,000  
Preferred stock, par value (in dollars per share) | $ / shares $ 0.0001  
Preferred stock, shares issued (in shares) | shares 0  
Preferred stock, shares outstanding (in shares) | shares 0  
Number of votes per share | vote 1  
Common stock, shares issued (in shares) | shares 62,961,688  
Common stock, shares outstanding (in shares) | shares 62,961,688  
Public Warrants    
Class of Warrant or Right [Line Items]    
Warrants outstanding (in shares) | shares 17,250,000  
Number of securities called by each warrant (in shares) | shares 1  
Exercise price of warrants (in dollars per share) | $ / shares $ 11.50  
Warrants, business combination exercisable term 30 days  
Warrants, proposed offering exercisable term 12 months  
Warrants term 5 years  
Redemption price per warrant (in dollars per share) | $ / shares $ 0.01  
Warrant redemption notice period 30 days  
Common stock price threshold (in dollars per share) | $ / shares $ 18.00  
Trading days 20 days  
Trading day period 30 days  
Common stock price threshold for redemption for common stock (in dollars per share) | $ / shares $ 10.00  
Warrants, common stock issuance threshold price (in dollars per share) | $ / shares $ 9.20  
Warrants, common stock issuance trading day period 20 days  
Warrant price adjustment percentage 115.00%  
Redemption trigger price adjustment percentage 100.00%  
Redemption for common stock trigger price adjustment percentage 180.00%  
Warrants outstanding | $   $ 4,730
Warrant outstanding fair value per share (in dollars per share) | $ / shares   $ 0.274
Public Warrants | Binomial Lattice Model    
Class of Warrant or Right [Line Items]    
Warrants term 5 years  
Public Warrants | Risk-free interest rate | Binomial Lattice Model    
Class of Warrant or Right [Line Items]    
Warrants and rights outstanding, measurement input 0.0409  
Public Warrants | Exercise price | Binomial Lattice Model    
Class of Warrant or Right [Line Items]    
Warrants and rights outstanding, measurement input 11.50  
Public Warrants | Common Stock Price | Binomial Lattice Model    
Class of Warrant or Right [Line Items]    
Warrants and rights outstanding, measurement input 10.03  
LMA    
Class of Warrant or Right [Line Items]    
Exchange ratio 0.8  
XML 94 R88.htm IDEA: XBRL DOCUMENT v3.23.2
EMPLOYEE BENEFIT PLAN (Details) - USD ($)
3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Postemployment Benefits [Abstract]          
Maximum annual contributions (as a percent)     100.00%    
Employer match (as a percent)         50.00%
Percent of employees gross pay (as a percent)         4.00%
Benefit plan expense $ 13,075 $ 2,577 $ 25,315 $ 8,048  
XML 95 R89.htm IDEA: XBRL DOCUMENT v3.23.2
INCOME TAXES (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Tax Disclosure [Abstract]        
Provision for income taxes $ 1,184,571 $ 120,132 $ 528,104 $ 296,806
Effective tax rate percentage 15.00% 12.00% 3.60% 18.00%
XML 96 R90.htm IDEA: XBRL DOCUMENT v3.23.2
RELATED-PARTY TRANSACTIONS (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Related Party Transaction [Line Items]          
Total portfolio servicing revenue $ 354,366 $ 419,422 $ 590,057 $ 990,328  
Affiliated Entity          
Related Party Transaction [Line Items]          
Other current liabilities 10,415,154   10,415,154   $ 263,785
Other receivables 10,473,748   10,473,748   2,904,646
Origination expenses for life settlement policies 837,975   1,627,975    
Affiliated Entity | Nova Funds          
Related Party Transaction [Line Items]          
Total portfolio servicing revenue 197,629 205,224 411,076 406,129  
Affiliated Entity | Expense Reimbursements | Nova Funds          
Related Party Transaction [Line Items]          
Accounts receivable 72,600   72,600   196,289
Owners          
Related Party Transaction [Line Items]          
Other current liabilities 717,429   717,429   0
Related Party          
Related Party Transaction [Line Items]          
Total portfolio servicing revenue 329,629 $ 419,253 543,076 $ 620,159  
Accounts receivable $ 78,310   78,310   $ 198,364
Related Party | Service Fee Agreement          
Related Party Transaction [Line Items]          
Related party transaction rate 0.50%        
Related Party | SPV Investment Facility | Line of Credit          
Related Party Transaction [Line Items]          
Face amount $ 25,000,000   $ 25,000,000    
XML 97 R91.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES - ROU Assets and Lease Liabilities (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Assets:    
Operating lease right-of-use assets $ 240,816 $ 77,011
Liabilities:    
Operating lease liability, current 227,561 48,127
Operating lease liability, non-current 16,864 29,268
Total lease liability $ 244,425 $ 77,395
XML 98 R92.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES - Lease Expense (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Leases [Abstract]        
Operating lease cost $ 12,471 $ 11,921 $ 24,942 $ 23,842
Variable lease cost 7,704 612 8,925 1,223
Total lease cost $ 20,175 $ 12,533 $ 33,867 $ 25,065
XML 99 R93.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES - Supplemental Cash Flow Information (Details) - USD ($)
6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Leases [Abstract]    
Operating cash flows from operating leases $ 24,557 $ 23,842
ROU assets obtained in exchange for new lease liabilities $ 0 $ 0
XML 100 R94.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES - Lease Terms and Discount Rates (Details)
Jun. 30, 2023
Dec. 31, 2022
Leases [Abstract]    
Weighted-average remaining lease term (in years) 1 year 1 year 6 months 29 days
Weighted-average discount rate 3.54% 3.36%
XML 101 R95.htm IDEA: XBRL DOCUMENT v3.23.2
LEASES - Future Minimum Noncancellable Lease Payments (Details) - USD ($)
Jun. 30, 2023
Dec. 31, 2022
Leases [Abstract]    
Remaining of 2023 $ 130,176  
2024 118,057  
2025 0  
2026 0  
2027 0  
Thereafter 0  
Total operating lease payments (undiscounted) 248,233  
Less: Imputed interest (3,808)  
Lease liability as of June 30, 2023 $ 244,425 $ 77,395
XML 102 R96.htm IDEA: XBRL DOCUMENT v3.23.2
EARNINGS PER SHARE - Narrative (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2023
$ / shares
shares
Jun. 30, 2023
$ / shares
shares
Private Placement Warrant    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Exercise price of warrants (in dollars per share) | $ / shares $ 11.50 $ 11.50
Private Placement Warrant    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities (in shares) | shares 26,150,000 26,150,000
XML 103 R97.htm IDEA: XBRL DOCUMENT v3.23.2
EARNINGS PER SHARE - Basic and Diluted (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Earnings Per Share [Abstract]        
Net income attributable to Longevity Market Assets $ 6,750,145 $ 4,679,558 $ 14,835,648 $ 11,515,698
Weighted-average shares used in computing net income per share, basic (in shares) [1] 50,507,728 50,369,350 50,438,921 50,369,350
Weighted-average shares used in computing net income per share, diluted (in shares) [1] 50,507,728 50,369,350 50,438,921 50,369,350
Basic net income per share (in dollars per share) $ 0.13 $ 0.09 $ 0.29 $ 0.23
Diluted net income per share (in dollars per share) $ 0.13 $ 0.09 $ 0.29 $ 0.23
[1] Both the number of shares outstanding and their par value have been retrospectively recast for all prior periods presented to reflect the par value of the outstanding stock of the Abacus Life Inc. as a result of Business Combination.
XML 104 R98.htm IDEA: XBRL DOCUMENT v3.23.2
SUBSEQUENT EVENTS (Details) - Subsequent Event - Line of Credit - Owl Rock Credit Facility
$ in Millions
Jul. 05, 2023
USD ($)
Subsequent Event [Line Items]  
Additional borrowing capacity availability period 180 days
Liquid asset minimum coverage ratio 1.80
Commitment fee 0.50%
Debt instrument term 5 years
Default rate 2.00%
Amortization payment percentage 1.00%
Amortization payment per quarter 0.25%
Mandatory prepayment percentage 100.00%
Prepayment premium prior to first anniversary 4.00%
Prepayment premium prior to second anniversary 3.00%
Prepayment premium after second anniversary 2.00%
Maximum leverage ratio 2.50
Maximum securities related activities percentage of aggregate gross revenues 15.00%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate  
Subsequent Event [Line Items]  
Interest rate (as a percent) 7.25%
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Variable Rate Component One  
Subsequent Event [Line Items]  
Basis spread on variable rate 0.10%
Basis spread on variable rate, term 1 month
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Variable Rate Component Two  
Subsequent Event [Line Items]  
Basis spread on variable rate 0.15%
Basis spread on variable rate, term 3 months
Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate | Variable Rate Component Three  
Subsequent Event [Line Items]  
Basis spread on variable rate 0.25%
Basis spread on variable rate, term 6 months
Base Rate  
Subsequent Event [Line Items]  
Interest rate (as a percent) 6.25%
Secured borrowing  
Subsequent Event [Line Items]  
Face amount $ 25.0
Additional borrowing capacity $ 25.0
XML 105 R99.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - DESCRIPTION OF THE BUSINESS (Details) - USD ($)
Jun. 30, 2023
Jun. 29, 2023
Business Acquisition [Line Items]    
Common stock, par value (in dollars per share) $ 0.0001  
LMA and Abacus    
Business Acquisition [Line Items]    
Consideration $ 531,750,000  
Abacus Settlements, LLC | LMA and Abacus    
Business Acquisition [Line Items]    
Consideration   $ 531,750,000
Share price (in dollars per share)   $ 10.00
Aggregate transaction proceeds threshold   $ 200,000,000
Abacus Settlements, LLC | LMA and Abacus | Minimum    
Business Acquisition [Line Items]    
Aggregate consideration election   $ 20,000,000
Abacus Settlements, LLC | LMA and Abacus | ERES Class A Common Stock    
Business Acquisition [Line Items]    
Common stock, par value (in dollars per share)   $ 0.0001
XML 106 R100.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - Abacus Settlements, LLC - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Concentration Risk [Line Items]        
Advertising expense $ 367,418 $ 286,695 $ 741,789 $ 554,802
Revenue Benchmark | Customer Concentration Risk        
Concentration Risk [Line Items]        
Concentration risk percentage     23.00% 66.00%
Life Settlement Commission Expense Benchmark | Broker Concentration Risk | Two Brokers        
Concentration Risk [Line Items]        
Concentration risk percentage     10.00%  
XML 107 R101.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - SEGMENT REPORTING (Details)
6 Months Ended
Jun. 30, 2023
segment
Abacus Settlements, LLC  
Segment Reporting Information [Line Items]  
Number of operating segment 1
XML 108 R102.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - REVENUE (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Disaggregation of Revenue [Line Items]        
Total portfolio servicing revenue $ 354,366 $ 419,422 $ 590,057 $ 990,328
Abacus Settlements, LLC        
Disaggregation of Revenue [Line Items]        
Total portfolio servicing revenue 6,884,690 5,691,916 13,184,676 13,014,664
Abacus Settlements, LLC | Agent        
Disaggregation of Revenue [Line Items]        
Total portfolio servicing revenue 3,334,402 2,717,512 7,143,016 5,690,701
Abacus Settlements, LLC | Broker        
Disaggregation of Revenue [Line Items]        
Total portfolio servicing revenue 2,809,499 2,247,953 4,675,973 5,727,970
Abacus Settlements, LLC | Client direct        
Disaggregation of Revenue [Line Items]        
Total portfolio servicing revenue $ 740,789 $ 726,451 $ 1,365,687 $ 1,595,993
XML 109 R103.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - INCOME TAXES (Details) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Income Tax Contingency [Line Items]        
Provision for income taxes $ 1,184,571 $ 120,132 $ 528,104 $ 296,806
Effective tax rate percentage 15.00% 12.00% 3.60% 18.00%
Abacus Settlements, LLC        
Income Tax Contingency [Line Items]        
Provision for income taxes $ 0 $ 0 $ 2,289 $ 1,325
Effective tax rate percentage     0.24% 0.48%
XML 110 R104.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - RETIREMENT PLAN (Details)
6 Months Ended 12 Months Ended
Jun. 30, 2023
Dec. 31, 2022
Defined Contribution Plan Disclosure [Line Items]    
Percent of employees gross pay (as a percent)   4.00%
Abacus Settlements, LLC    
Defined Contribution Plan Disclosure [Line Items]    
Percent of employees gross pay (as a percent) 4.00%  
XML 111 R105.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS - Narrative (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2023
USD ($)
insurance_contract
Jun. 30, 2022
USD ($)
insurance_contract
Jun. 30, 2023
USD ($)
insurance_contract
Jun. 30, 2022
USD ($)
insurance_contract
Dec. 31, 2022
USD ($)
Related Party Transaction [Line Items]          
Total portfolio servicing revenue $ 354,366 $ 419,422 $ 590,057 $ 990,328  
Total cost of revenue 973,400 666,119 1,462,950 2,086,075  
Due from members and affiliates 75,582   75,582   $ 0
Related Party          
Related Party Transaction [Line Items]          
Total portfolio servicing revenue 329,629 419,253 543,076 620,159  
Affiliated Entity | Nova Funds          
Related Party Transaction [Line Items]          
Total portfolio servicing revenue 197,629 205,224 411,076 406,129  
Abacus Settlements, LLC          
Related Party Transaction [Line Items]          
Total portfolio servicing revenue 6,884,690 5,691,916 13,184,676 13,014,664  
Total cost of revenue 4,897,980 3,571,932 9,293,303 8,787,625  
Abacus Settlements, LLC | Related Party          
Related Party Transaction [Line Items]          
Total portfolio servicing revenue 5,195,602 4,948,528 9,931,938 9,829,596  
Total cost of revenue $ 3,392,647 $ 2,615,307 $ 6,558,354 $ 5,522,312  
Abacus Settlements, LLC | Related Party | Nova Funds          
Related Party Transaction [Line Items]          
Total policies | insurance_contract 38 92 72 183  
Face value $ 56,688,680 $ 102,307,954 $ 96,674,080 $ 282,804,838  
Origination revenue percent 2.00%   2.00%    
Origination revenue     $ 20,000    
Total portfolio servicing revenue $ 1,579,864 4,316,328 3,093,797 8,875,395  
Abacus Settlements, LLC | Related Party | LMA          
Related Party Transaction [Line Items]          
Due from members and affiliates 19,246 0 19,246 0  
Abacus Settlements, LLC | Affiliated Entity          
Related Party Transaction [Line Items]          
Total portfolio servicing revenue 3,615,738 589,700 6,838,141 911,700  
Total cost of revenue 2,623,201 363,700 5,020,603 612,700  
Abacus Settlements, LLC | Affiliated Entity | LMA          
Related Party Transaction [Line Items]          
Total portfolio servicing revenue 3,615,739 470,200 6,794,641 470,200  
Total cost of revenue $ 2,623,201 $ 326,200 $ 5,012,103 $ 326,200  
Abacus Settlements, LLC | Nova Funds          
Related Party Transaction [Line Items]          
Ownership percentage 11.00%   11.00%    
XML 112 R106.htm IDEA: XBRL DOCUMENT v3.23.2
Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS - Revenue Earned and Contracts Originated (Details)
3 Months Ended 6 Months Ended
Jun. 30, 2023
USD ($)
insurance_contract
Jun. 30, 2022
USD ($)
insurance_contract
Jun. 30, 2023
USD ($)
insurance_contract
Jun. 30, 2022
USD ($)
insurance_contract
Related Party Transaction [Line Items]        
Total portfolio servicing revenue $ 354,366 $ 419,422 $ 590,057 $ 990,328
Related Party        
Related Party Transaction [Line Items]        
Total portfolio servicing revenue 329,629 419,253 543,076 620,159
Abacus Settlements, LLC        
Related Party Transaction [Line Items]        
Total portfolio servicing revenue 6,884,690 5,691,916 13,184,676 13,014,664
Abacus Settlements, LLC | Related Party        
Related Party Transaction [Line Items]        
Total portfolio servicing revenue 5,195,602 4,948,528 9,931,938 9,829,596
Abacus Settlements, LLC | Related Party | Nova Funds        
Related Party Transaction [Line Items]        
Total portfolio servicing revenue 1,579,864 4,316,328 3,093,797 8,875,395
Cost 5,290,504 25,201,256 11,656,637 50,738,202
Face value $ 56,688,680 $ 102,307,954 $ 96,674,080 $ 282,804,838
Total policies | insurance_contract 38 92 72 183
Average Age   1 year 75 years 75 years
Abacus Settlements, LLC | Related Party | Origination fee revenue | Nova Funds        
Related Party Transaction [Line Items]        
Total portfolio servicing revenue $ 1,504,532 $ 4,164,107 $ 2,952,837 $ 8,569,034
Abacus Settlements, LLC | Related Party | Transaction reimbursement revenue | Nova Funds        
Related Party Transaction [Line Items]        
Total portfolio servicing revenue $ 75,332 $ 152,221 $ 140,960 $ 306,361
XML 113 abl-20230630_htm.xml IDEA: XBRL DOCUMENT 0001814287 2023-01-01 2023-06-30 0001814287 us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001814287 us-gaap:WarrantMember 2023-01-01 2023-06-30 0001814287 2023-08-14 0001814287 2023-06-30 0001814287 2022-12-31 0001814287 us-gaap:NonrelatedPartyMember 2023-06-30 0001814287 us-gaap:NonrelatedPartyMember 2022-12-31 0001814287 us-gaap:RelatedPartyMember 2023-06-30 0001814287 us-gaap:RelatedPartyMember 2022-12-31 0001814287 srt:AffiliatedEntityMember 2023-06-30 0001814287 srt:AffiliatedEntityMember 2022-12-31 0001814287 abl:OwnersMember 2023-06-30 0001814287 abl:OwnersMember 2022-12-31 0001814287 us-gaap:CommonClassAMember 2022-12-31 0001814287 us-gaap:CommonClassAMember 2023-06-30 0001814287 us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001814287 us-gaap:RelatedPartyMember 2022-04-01 2022-06-30 0001814287 us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001814287 us-gaap:RelatedPartyMember 2022-01-01 2022-06-30 0001814287 us-gaap:NonrelatedPartyMember 2023-04-01 2023-06-30 0001814287 us-gaap:NonrelatedPartyMember 2022-04-01 2022-06-30 0001814287 us-gaap:NonrelatedPartyMember 2023-01-01 2023-06-30 0001814287 us-gaap:NonrelatedPartyMember 2022-01-01 2022-06-30 0001814287 2023-04-01 2023-06-30 0001814287 2022-04-01 2022-06-30 0001814287 2022-01-01 2022-06-30 0001814287 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-03-31 0001814287 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001814287 us-gaap:RetainedEarningsMember 2022-03-31 0001814287 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001814287 us-gaap:NoncontrollingInterestMember 2022-03-31 0001814287 2022-03-31 0001814287 us-gaap:RetainedEarningsMember 2022-04-01 2022-06-30 0001814287 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-04-01 2022-06-30 0001814287 us-gaap:NoncontrollingInterestMember 2022-04-01 2022-06-30 0001814287 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-06-30 0001814287 us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001814287 us-gaap:RetainedEarningsMember 2022-06-30 0001814287 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-06-30 0001814287 us-gaap:NoncontrollingInterestMember 2022-06-30 0001814287 2022-06-30 0001814287 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-03-31 0001814287 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001814287 us-gaap:RetainedEarningsMember 2023-03-31 0001814287 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001814287 us-gaap:NoncontrollingInterestMember 2023-03-31 0001814287 2023-03-31 0001814287 us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001814287 us-gaap:AdditionalPaidInCapitalMember 2023-04-01 2023-06-30 0001814287 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-04-01 2023-06-30 0001814287 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-01 2023-06-30 0001814287 us-gaap:NoncontrollingInterestMember 2023-04-01 2023-06-30 0001814287 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-06-30 0001814287 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001814287 us-gaap:RetainedEarningsMember 2023-06-30 0001814287 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0001814287 us-gaap:NoncontrollingInterestMember 2023-06-30 0001814287 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2021-12-31 0001814287 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001814287 us-gaap:RetainedEarningsMember 2021-12-31 0001814287 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001814287 us-gaap:NoncontrollingInterestMember 2021-12-31 0001814287 2021-12-31 0001814287 us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001814287 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-06-30 0001814287 us-gaap:NoncontrollingInterestMember 2022-01-01 2022-06-30 0001814287 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2022-12-31 0001814287 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001814287 us-gaap:RetainedEarningsMember 2022-12-31 0001814287 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001814287 us-gaap:NoncontrollingInterestMember 2022-12-31 0001814287 us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001814287 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-06-30 0001814287 us-gaap:CommonClassAMember us-gaap:CommonStockMember 2023-01-01 2023-06-30 0001814287 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-06-30 0001814287 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCMember 2023-06-30 0001814287 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2023-06-30 0001814287 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2022-12-31 0001814287 2021-01-01 0001814287 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember abl:ExpenseSupportAgreementMember 2023-04-01 2023-06-30 0001814287 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember abl:ExpenseSupportAgreementMember 2022-04-01 2022-06-30 0001814287 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember abl:ExpenseSupportAgreementMember 2023-01-01 2023-06-30 0001814287 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember abl:ExpenseSupportAgreementMember 2022-01-01 2022-06-30 0001814287 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember abl:ProviderOneMember 2023-06-30 0001814287 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember abl:ProviderTwoMember 2023-06-30 0001814287 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember abl:ProviderOneMember 2022-12-31 0001814287 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember abl:ProviderTwoMember 2022-12-31 0001814287 2021-10-04 0001814287 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember abl:LMXSeriesLLCMember 2021-10-04 2021-10-04 0001814287 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember 2021-10-04 2021-10-04 0001814287 us-gaap:VariableInterestEntityPrimaryBeneficiaryMember abl:LongevityMarketAdvisorsLLCMember 2022-03-03 2022-03-03 0001814287 abl:RegionalInvestmentServicesIncMember 2022-03-03 2022-03-03 0001814287 abl:RegionalInvestmentServicesIncMember abl:LongevityMarketAdvisorsLLCMember 2023-06-30 0001814287 abl:Customer1Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001814287 abl:Customer2Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001814287 abl:Customer1Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0001814287 abl:Customer2Member us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember us-gaap:RelatedPartyMember 2022-01-01 2022-12-31 0001814287 abl:Customer1Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:NonrelatedPartyMember abl:ActiveManagementSegmentMember 2023-04-01 2023-06-30 0001814287 abl:Customer1Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:RelatedPartyMember abl:PortfolioServicingSegmentMember 2023-04-01 2023-06-30 0001814287 abl:Customer2Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:RelatedPartyMember abl:PortfolioServicingSegmentMember 2023-04-01 2023-06-30 0001814287 abl:Customer1Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:NonrelatedPartyMember 2022-04-01 2022-06-30 0001814287 abl:Customer1Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:NonrelatedPartyMember abl:ActiveManagementSegmentMember 2023-01-01 2023-06-30 0001814287 abl:Customer1Member abl:InvestmentMethodRevenueBenchmarkMember us-gaap:CustomerConcentrationRiskMember us-gaap:NonrelatedPartyMember 2023-01-01 2023-06-30 0001814287 abl:Customer1Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:RelatedPartyMember abl:PortfolioServicingSegmentMember 2023-01-01 2023-06-30 0001814287 abl:Customer2Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:RelatedPartyMember abl:PortfolioServicingSegmentMember 2023-01-01 2023-06-30 0001814287 abl:Customer1Member us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember us-gaap:NonrelatedPartyMember 2022-01-01 2022-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember 2023-06-30 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCMember us-gaap:MeasurementInputDiscountRateMember 2023-06-30 0001814287 abl:AbacusSettlementsLLCMember us-gaap:MeasurementInputDiscountRateMember 2023-06-30 0001814287 srt:MinimumMember abl:LongevityMarketAssetsLLCMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-06-30 0001814287 srt:MaximumMember abl:LongevityMarketAssetsLLCMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-06-30 0001814287 srt:MinimumMember abl:AbacusSettlementsLLCMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-06-30 0001814287 srt:MaximumMember abl:AbacusSettlementsLLCMember us-gaap:ValuationTechniqueDiscountedCashFlowMember 2023-06-30 0001814287 srt:MinimumMember abl:LongevityMarketAssetsLLCMember us-gaap:MarketApproachValuationTechniqueMember 2023-06-30 0001814287 srt:MaximumMember abl:LongevityMarketAssetsLLCMember us-gaap:MarketApproachValuationTechniqueMember 2023-06-30 0001814287 srt:MinimumMember abl:AbacusSettlementsLLCMember us-gaap:MarketApproachValuationTechniqueMember 2023-06-30 0001814287 srt:MaximumMember abl:AbacusSettlementsLLCMember us-gaap:MarketApproachValuationTechniqueMember 2023-06-30 0001814287 abl:AbacusSettlementsLLCMember 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember 2023-06-30 0001814287 abl:AbacusSettlementsLLCMember 2023-06-30 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCMember 2023-06-30 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember abl:CustomerRelationshipAgentsMember 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember abl:CustomerRelationshipAgentsMember 2023-06-30 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember abl:CustomerRelationshipsFinancialRelationshipsMember 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember abl:CustomerRelationshipsFinancialRelationshipsMember 2023-06-30 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember abl:APATechnologyMember 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember abl:APATechnologyMember 2023-06-30 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember abl:MarketPlaceTechnologyMember 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember abl:MarketPlaceTechnologyMember 2023-06-30 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember us-gaap:TradeNamesMember 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember us-gaap:NoncompeteAgreementsMember 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember us-gaap:NoncompeteAgreementsMember 2023-06-30 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember us-gaap:LicensingAgreementsMember 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember 2023-04-01 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember 2022-04-01 2022-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember 2023-01-01 2023-06-30 0001814287 abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember 2022-01-01 2022-06-30 0001814287 us-gaap:ComputerEquipmentMember 2023-06-30 0001814287 us-gaap:ComputerEquipmentMember 2022-12-31 0001814287 us-gaap:FurnitureAndFixturesMember 2023-06-30 0001814287 us-gaap:FurnitureAndFixturesMember 2022-12-31 0001814287 us-gaap:LeaseholdImprovementsMember 2023-06-30 0001814287 us-gaap:LeaseholdImprovementsMember 2022-12-31 0001814287 abl:AbacusSettlementsLLCMember 2021-12-31 0001814287 abl:AbacusSettlementsLLCMember 2022-01-01 2022-06-30 0001814287 abl:AbacusSettlementsLLCMember 2022-06-30 0001814287 abl:AbacusSettlementsLLCMember 2022-12-31 0001814287 abl:AbacusSettlementsLLCMember 2023-01-01 2023-06-30 0001814287 abl:AbacusSettlementsLLCMember 2023-06-30 0001814287 abl:CustomerRelationshipAgentsMember 2023-06-30 0001814287 abl:CustomerRelationshipsFinancialRelationshipsMember 2023-06-30 0001814287 abl:APATechnologyMember 2023-06-30 0001814287 abl:MarketPlaceTechnologyMember 2023-06-30 0001814287 us-gaap:TradeNamesMember 2023-06-30 0001814287 us-gaap:NoncompeteAgreementsMember 2023-06-30 0001814287 us-gaap:LicensingAgreementsMember 2023-06-30 0001814287 2021-11-01 2021-11-30 0001814287 2022-01-01 2022-01-31 0001814287 2021-11-30 0001814287 2022-10-01 2022-10-31 0001814287 2022-10-31 0001814287 abl:SeriesSeedPreferredUnitsMember 2020-07-22 2020-07-22 0001814287 abl:SeriesSeedPreferredUnitsMember 2020-07-22 0001814287 abl:SeriesSeedPreferredUnitsMember 2022-12-01 2022-12-31 0001814287 abl:SeriesSeedPreferredUnitsMember 2022-12-31 0001814287 abl:SeriesSeedPreferredUnitsMember 2023-03-31 0001814287 abl:SeriesSeedPreferredUnitsMember 2023-06-30 0001814287 abl:SeriesB1PreferredStockMember 2020-12-21 2020-12-21 0001814287 abl:SeriesB1PreferredStockMember 2020-12-21 0001814287 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2023-06-30 0001814287 us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember 2022-12-31 0001814287 abl:PortfolioServicingSegmentMember 2023-04-01 2023-06-30 0001814287 abl:PortfolioServicingSegmentMember 2022-04-01 2022-06-30 0001814287 abl:PortfolioServicingSegmentMember 2023-01-01 2023-06-30 0001814287 abl:PortfolioServicingSegmentMember 2022-01-01 2022-06-30 0001814287 abl:ActiveManagementSegmentMember 2023-04-01 2023-06-30 0001814287 abl:ActiveManagementSegmentMember 2022-04-01 2022-06-30 0001814287 abl:ActiveManagementSegmentMember 2023-01-01 2023-06-30 0001814287 abl:ActiveManagementSegmentMember 2022-01-01 2022-06-30 0001814287 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001814287 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001814287 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001814287 us-gaap:FairValueMeasurementsRecurringMember 2023-06-30 0001814287 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001814287 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001814287 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001814287 us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001814287 us-gaap:MeasurementInputDiscountRateMember 2023-06-30 0001814287 us-gaap:MeasurementInputDiscountRateMember 2022-12-31 0001814287 us-gaap:SubsequentEventMember 2023-07-01 2023-08-14 0001814287 abl:AmericanGeneralLifeInsuranceCompanyMember abl:LifeSettlementContractsFaceValueMember abl:LifeInsuranceCarrierConcentrationRiskMember 2023-01-01 2023-06-30 0001814287 abl:AmericanGeneralLifeInsuranceCompanyMember abl:LifeSettlementContractsFairValueMember abl:LifeInsuranceCarrierConcentrationRiskMember 2023-01-01 2023-06-30 0001814287 abl:ReliaStarLifeInsuranceCompanyMember abl:LifeSettlementContractsFaceValueMember abl:LifeInsuranceCarrierConcentrationRiskMember 2023-01-01 2023-06-30 0001814287 abl:ReliaStarLifeInsuranceCompanyMember abl:LifeSettlementContractsFairValueMember abl:LifeInsuranceCarrierConcentrationRiskMember 2023-01-01 2023-06-30 0001814287 abl:LincolnNationalLifeInsuranceCompanyMember abl:LifeSettlementContractsFaceValueMember abl:LifeInsuranceCarrierConcentrationRiskMember 2023-01-01 2023-06-30 0001814287 abl:LincolnNationalLifeInsuranceCompanyMember abl:LifeSettlementContractsFairValueMember abl:LifeInsuranceCarrierConcentrationRiskMember 2023-01-01 2023-06-30 0001814287 abl:LifeSettlementContractMember 2022-12-31 0001814287 abl:LifeSettlementContractMember 2023-01-01 2023-06-30 0001814287 abl:LifeSettlementContractMember 2023-06-30 0001814287 abl:PrivatePlacementWarrantMember 2023-06-30 0001814287 abl:PrivatePlacementWarrantMember 2020-08-25 0001814287 abl:PrivatePlacementWarrantMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-06-30 0001814287 abl:PrivatePlacementWarrantMember us-gaap:MeasurementInputExpectedTermMember 2023-06-30 0001814287 abl:PrivatePlacementWarrantMember us-gaap:MeasurementInputExercisePriceMember 2023-06-30 0001814287 abl:PrivatePlacementWarrantMember us-gaap:MeasurementInputSharePriceMember 2023-06-30 0001814287 abl:PrivatePlacementWarrantMember us-gaap:MeasurementInputExpectedDividendRateMember 2023-06-30 0001814287 2021-01-01 2021-12-31 0001814287 2022-01-07 2022-01-07 0001814287 abl:LMATTSeries2024IncMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:NotesPayableOtherPayablesMember 2023-06-30 0001814287 abl:LMATTSeries2024IncMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NotesPayableOtherPayablesMember 2023-06-30 0001814287 abl:LMATTSeries2024IncMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001814287 abl:LMATTSeries2024IncMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001814287 abl:LMATTSeries22024IncMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:NotesPayableOtherPayablesMember 2023-06-30 0001814287 abl:LMATTSeries22024IncMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NotesPayableOtherPayablesMember 2023-06-30 0001814287 abl:LMATTSeries22024IncMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001814287 abl:LMATTSeries22024IncMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001814287 abl:LMATTGrowthIncomeSeries12026IncMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:NotesPayableOtherPayablesMember 2023-06-30 0001814287 abl:LMATTGrowthIncomeSeries12026IncMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NotesPayableOtherPayablesMember 2023-06-30 0001814287 abl:LMATTGrowthIncomeSeries12026IncMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001814287 abl:LMATTGrowthIncomeSeries12026IncMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:NotesPayableOtherPayablesMember 2022-12-31 0001814287 abl:LMATTIncomeSeriesLPMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SecuredDebtMember 2023-06-30 0001814287 abl:LMATTIncomeSeriesLPMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SecuredDebtMember 2023-06-30 0001814287 abl:LMATTIncomeSeriesLPMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SecuredDebtMember 2022-12-31 0001814287 abl:LMATTIncomeSeriesLPMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SecuredDebtMember 2022-12-31 0001814287 abl:LMATTIncomeSeriesIILPMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SecuredDebtMember 2023-06-30 0001814287 abl:LMATTIncomeSeriesIILPMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SecuredDebtMember 2023-06-30 0001814287 abl:LMATTIncomeSeriesIILPMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:SecuredDebtMember 2022-12-31 0001814287 abl:LMATTIncomeSeriesIILPMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:SecuredDebtMember 2022-12-31 0001814287 abl:SponsorPIKNoteMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:UnsecuredDebtMember 2023-06-30 0001814287 abl:SponsorPIKNoteMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:UnsecuredDebtMember 2023-06-30 0001814287 abl:SponsorPIKNoteMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:UnsecuredDebtMember 2022-12-31 0001814287 abl:SponsorPIKNoteMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:UnsecuredDebtMember 2022-12-31 0001814287 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-06-30 0001814287 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-06-30 0001814287 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2022-12-31 0001814287 us-gaap:EstimateOfFairValueFairValueDisclosureMember 2022-12-31 0001814287 abl:SPVInvestmentFacilityMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LineOfCreditMember 2023-06-30 0001814287 abl:SPVInvestmentFacilityMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LineOfCreditMember 2023-06-30 0001814287 abl:SPVInvestmentFacilityMember us-gaap:CarryingReportedAmountFairValueDisclosureMember us-gaap:LineOfCreditMember 2022-12-31 0001814287 abl:SPVInvestmentFacilityMember us-gaap:EstimateOfFairValueFairValueDisclosureMember us-gaap:LineOfCreditMember 2022-12-31 0001814287 abl:SponsorPIKNoteMember us-gaap:UnsecuredDebtMember 2023-06-30 0001814287 abl:LMATTSeries2024IncMember us-gaap:NotesPayableOtherPayablesMember 2022-03-31 0001814287 abl:LMATTSeries2024IncMember us-gaap:NotesPayableOtherPayablesMember us-gaap:AssetPledgedAsCollateralMember 2023-06-30 0001814287 abl:LMATTSeries22024IncMember 2022-09-16 0001814287 abl:LMATTSeries22024IncMember us-gaap:NotesPayableOtherPayablesMember 2022-09-16 0001814287 abl:LMATTSeries22024IncMember us-gaap:NotesPayableOtherPayablesMember us-gaap:AssetPledgedAsCollateralMember 2023-06-30 0001814287 abl:LMATTGrowthIncomeSeries12026IncMember 2022-09-16 0001814287 abl:LMATTGrowthIncomeSeries12026IncMember us-gaap:NotesPayableOtherPayablesMember 2022-09-16 0001814287 abl:LMATTGrowthIncomeSeries12026IncMember us-gaap:NotesPayableOtherPayablesMember us-gaap:AssetPledgedAsCollateralMember 2023-06-30 0001814287 abl:LMATTIncomeSeriesLPMember us-gaap:SecuredDebtMember 2023-01-01 2023-06-30 0001814287 abl:LMATTIncomeSeriesLPMember us-gaap:SecuredDebtMember 2023-06-30 0001814287 abl:LMATTIncomeSeriesLPMember us-gaap:SecuredDebtMember us-gaap:GeneralPartnerMember 2023-06-30 0001814287 abl:LMATTIncomeSeriesLPMember us-gaap:SecuredDebtMember us-gaap:LimitedPartnerMember 2023-06-30 0001814287 abl:LMATTIncomeSeriesIILPMember us-gaap:SecuredDebtMember 2023-01-01 2023-06-30 0001814287 abl:LMATTIncomeSeriesIILPMember us-gaap:SecuredDebtMember 2023-06-30 0001814287 abl:CapitalCommitmentThresholdOneMember srt:MaximumMember abl:LMATTIncomeSeriesIILPMember us-gaap:SecuredDebtMember us-gaap:LimitedPartnerMember 2023-01-01 2023-06-30 0001814287 abl:CapitalCommitmentThresholdOneMember abl:LMATTIncomeSeriesIILPMember us-gaap:SecuredDebtMember us-gaap:LimitedPartnerMember 2023-06-30 0001814287 abl:CapitalCommitmentThresholdTwoMember srt:MinimumMember abl:LMATTIncomeSeriesIILPMember us-gaap:SecuredDebtMember us-gaap:LimitedPartnerMember 2023-01-01 2023-06-30 0001814287 abl:CapitalCommitmentThresholdTwoMember srt:MaximumMember abl:LMATTIncomeSeriesIILPMember us-gaap:SecuredDebtMember us-gaap:LimitedPartnerMember 2023-01-01 2023-06-30 0001814287 abl:CapitalCommitmentThresholdTwoMember abl:LMATTIncomeSeriesIILPMember us-gaap:SecuredDebtMember us-gaap:LimitedPartnerMember 2023-06-30 0001814287 abl:CapitalCommitmentThresholdThreeMember srt:MinimumMember abl:LMATTIncomeSeriesIILPMember us-gaap:SecuredDebtMember us-gaap:LimitedPartnerMember 2023-01-01 2023-06-30 0001814287 abl:CapitalCommitmentThresholdThreeMember abl:LMATTIncomeSeriesIILPMember us-gaap:SecuredDebtMember us-gaap:LimitedPartnerMember 2023-06-30 0001814287 abl:LMATTIncomeSeriesIILPMember us-gaap:SecuredDebtMember us-gaap:GeneralPartnerMember 2023-06-30 0001814287 abl:PolicyAPAMember us-gaap:SubsequentEventMember 2023-07-05 0001814287 abl:SPVInvestmentFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-07-05 0001814287 us-gaap:SecuredDebtMember abl:SPVInvestmentFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-07-05 0001814287 us-gaap:LineOfCreditMember abl:SPVInvestmentFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-07-05 0001814287 abl:SPVInvestmentFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-07-05 2023-07-05 0001814287 abl:PublicWarrantsMember 2023-06-30 0001814287 abl:PublicWarrantsMember 2023-01-01 2023-06-30 0001814287 abl:PublicWarrantsMember 2022-08-30 0001814287 abl:PublicWarrantsMember us-gaap:MeasurementInputRiskFreeInterestRateMember abl:BinomialLatticeModelMember 2023-06-30 0001814287 abl:PublicWarrantsMember abl:BinomialLatticeModelMember 2023-06-30 0001814287 abl:PublicWarrantsMember us-gaap:MeasurementInputExercisePriceMember abl:BinomialLatticeModelMember 2023-06-30 0001814287 abl:PublicWarrantsMember us-gaap:MeasurementInputSharePriceMember abl:BinomialLatticeModelMember 2023-06-30 0001814287 2022-01-01 2022-12-31 0001814287 abl:SPVInvestmentFacilityMember us-gaap:LineOfCreditMember us-gaap:RelatedPartyMember 2023-06-30 0001814287 abl:ServiceFeeAgreementMember us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001814287 abl:NovaTradingUSLLCAndNovaHoldingUSLPMember srt:AffiliatedEntityMember 2023-04-01 2023-06-30 0001814287 abl:NovaTradingUSLLCAndNovaHoldingUSLPMember srt:AffiliatedEntityMember 2022-04-01 2022-06-30 0001814287 abl:NovaTradingUSLLCAndNovaHoldingUSLPMember srt:AffiliatedEntityMember 2023-01-01 2023-06-30 0001814287 abl:NovaTradingUSLLCAndNovaHoldingUSLPMember srt:AffiliatedEntityMember 2022-01-01 2022-06-30 0001814287 srt:AffiliatedEntityMember 2023-04-01 2023-06-30 0001814287 srt:AffiliatedEntityMember 2023-01-01 2023-06-30 0001814287 abl:NovaTradingUSLLCAndNovaHoldingUSLPMember abl:ExpenseReimbursementsMember srt:AffiliatedEntityMember 2023-06-30 0001814287 abl:NovaTradingUSLLCAndNovaHoldingUSLPMember abl:ExpenseReimbursementsMember srt:AffiliatedEntityMember 2022-12-31 0001814287 abl:PrivatePlacementWarrantMember 2023-04-01 2023-06-30 0001814287 abl:PrivatePlacementWarrantMember 2023-01-01 2023-06-30 0001814287 us-gaap:SecuredDebtMember abl:OwlRockCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-07-05 0001814287 abl:OwlRockCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-07-05 0001814287 abl:OwlRockCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2023-07-05 2023-07-05 0001814287 abl:VariableRateComponentOneMember abl:OwlRockCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-07-05 2023-07-05 0001814287 abl:VariableRateComponentTwoMember abl:OwlRockCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-07-05 2023-07-05 0001814287 abl:VariableRateComponentThreeMember abl:OwlRockCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-07-05 2023-07-05 0001814287 abl:OwlRockCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:BaseRateMember 2023-07-05 0001814287 abl:OwlRockCreditFacilityMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember 2023-07-05 0001814287 srt:SubsidiariesMember us-gaap:NonrelatedPartyMember 2023-04-01 2023-06-30 0001814287 srt:SubsidiariesMember us-gaap:NonrelatedPartyMember 2022-04-01 2022-06-30 0001814287 srt:SubsidiariesMember us-gaap:NonrelatedPartyMember 2023-01-01 2023-06-30 0001814287 srt:SubsidiariesMember us-gaap:NonrelatedPartyMember 2022-01-01 2022-06-30 0001814287 srt:SubsidiariesMember us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001814287 srt:SubsidiariesMember us-gaap:RelatedPartyMember 2022-04-01 2022-06-30 0001814287 srt:SubsidiariesMember us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001814287 srt:SubsidiariesMember us-gaap:RelatedPartyMember 2022-01-01 2022-06-30 0001814287 srt:SubsidiariesMember 2023-04-01 2023-06-30 0001814287 srt:SubsidiariesMember 2022-04-01 2022-06-30 0001814287 srt:SubsidiariesMember 2023-01-01 2023-06-30 0001814287 srt:SubsidiariesMember 2022-01-01 2022-06-30 0001814287 srt:SubsidiariesMember us-gaap:CommonStockMember 2023-03-31 0001814287 srt:SubsidiariesMember us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001814287 srt:SubsidiariesMember us-gaap:RetainedEarningsMember 2023-03-31 0001814287 srt:SubsidiariesMember 2023-03-31 0001814287 srt:SubsidiariesMember us-gaap:RetainedEarningsMember 2023-04-01 2023-06-30 0001814287 srt:SubsidiariesMember us-gaap:CommonStockMember 2023-06-30 0001814287 srt:SubsidiariesMember us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0001814287 srt:SubsidiariesMember us-gaap:RetainedEarningsMember 2023-06-30 0001814287 srt:SubsidiariesMember 2023-06-30 0001814287 srt:SubsidiariesMember us-gaap:CommonStockMember 2022-12-31 0001814287 srt:SubsidiariesMember us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001814287 srt:SubsidiariesMember us-gaap:RetainedEarningsMember 2022-12-31 0001814287 srt:SubsidiariesMember 2022-12-31 0001814287 srt:SubsidiariesMember us-gaap:RetainedEarningsMember 2023-01-01 2023-06-30 0001814287 srt:SubsidiariesMember us-gaap:CommonStockMember 2021-12-31 0001814287 srt:SubsidiariesMember us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001814287 srt:SubsidiariesMember us-gaap:RetainedEarningsMember 2021-12-31 0001814287 srt:SubsidiariesMember 2021-12-31 0001814287 srt:SubsidiariesMember us-gaap:RetainedEarningsMember 2022-01-01 2022-06-30 0001814287 srt:SubsidiariesMember us-gaap:CommonStockMember 2022-06-30 0001814287 srt:SubsidiariesMember us-gaap:AdditionalPaidInCapitalMember 2022-06-30 0001814287 srt:SubsidiariesMember us-gaap:RetainedEarningsMember 2022-06-30 0001814287 srt:SubsidiariesMember 2022-06-30 0001814287 srt:SubsidiariesMember abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember 2023-06-29 2023-06-29 0001814287 srt:SubsidiariesMember abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember abl:ERESClassACommonStockMember 2023-06-29 0001814287 srt:SubsidiariesMember abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember 2023-06-29 0001814287 srt:SubsidiariesMember srt:MinimumMember abl:LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember 2023-06-29 2023-06-29 0001814287 srt:SubsidiariesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2023-01-01 2023-06-30 0001814287 srt:SubsidiariesMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2022-01-01 2022-06-30 0001814287 abl:TwoBrokersMember srt:SubsidiariesMember abl:LifeSettlementCommissionExpenseBenchmarkMember abl:BrokerConcentrationRiskMember 2023-01-01 2023-06-30 0001814287 srt:SubsidiariesMember abl:AgentMember 2023-04-01 2023-06-30 0001814287 srt:SubsidiariesMember abl:AgentMember 2022-04-01 2022-06-30 0001814287 srt:SubsidiariesMember abl:AgentMember 2023-01-01 2023-06-30 0001814287 srt:SubsidiariesMember abl:AgentMember 2022-01-01 2022-06-30 0001814287 srt:SubsidiariesMember abl:BrokerMember 2023-04-01 2023-06-30 0001814287 srt:SubsidiariesMember abl:BrokerMember 2022-04-01 2022-06-30 0001814287 srt:SubsidiariesMember abl:BrokerMember 2023-01-01 2023-06-30 0001814287 srt:SubsidiariesMember abl:BrokerMember 2022-01-01 2022-06-30 0001814287 srt:SubsidiariesMember abl:ClientDirectMember 2023-04-01 2023-06-30 0001814287 srt:SubsidiariesMember abl:ClientDirectMember 2022-04-01 2022-06-30 0001814287 srt:SubsidiariesMember abl:ClientDirectMember 2023-01-01 2023-06-30 0001814287 srt:SubsidiariesMember abl:ClientDirectMember 2022-01-01 2022-06-30 0001814287 srt:SubsidiariesMember abl:NovaTradingUSLLCAndNovaHoldingUSLPMember 2023-06-30 0001814287 srt:SubsidiariesMember abl:NovaTradingUSLLCAndNovaHoldingUSLPMember us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001814287 srt:SubsidiariesMember abl:NovaTradingUSLLCAndNovaHoldingUSLPMember us-gaap:RelatedPartyMember 2022-04-01 2022-06-30 0001814287 srt:SubsidiariesMember abl:NovaTradingUSLLCAndNovaHoldingUSLPMember us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001814287 srt:SubsidiariesMember abl:NovaTradingUSLLCAndNovaHoldingUSLPMember us-gaap:RelatedPartyMember 2022-01-01 2022-06-30 0001814287 srt:SubsidiariesMember abl:NovaTradingUSLLCAndNovaHoldingUSLPMember us-gaap:RelatedPartyMember 2023-06-30 0001814287 srt:SubsidiariesMember abl:NovaTradingUSLLCAndNovaHoldingUSLPMember abl:OriginationFeeMember us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001814287 srt:SubsidiariesMember abl:NovaTradingUSLLCAndNovaHoldingUSLPMember abl:OriginationFeeMember us-gaap:RelatedPartyMember 2022-04-01 2022-06-30 0001814287 srt:SubsidiariesMember abl:NovaTradingUSLLCAndNovaHoldingUSLPMember abl:OriginationFeeMember us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001814287 srt:SubsidiariesMember abl:NovaTradingUSLLCAndNovaHoldingUSLPMember abl:OriginationFeeMember us-gaap:RelatedPartyMember 2022-01-01 2022-06-30 0001814287 srt:SubsidiariesMember abl:NovaTradingUSLLCAndNovaHoldingUSLPMember abl:ExpenseReimbursementsMember us-gaap:RelatedPartyMember 2023-04-01 2023-06-30 0001814287 srt:SubsidiariesMember abl:NovaTradingUSLLCAndNovaHoldingUSLPMember abl:ExpenseReimbursementsMember us-gaap:RelatedPartyMember 2022-04-01 2022-06-30 0001814287 srt:SubsidiariesMember abl:NovaTradingUSLLCAndNovaHoldingUSLPMember abl:ExpenseReimbursementsMember us-gaap:RelatedPartyMember 2023-01-01 2023-06-30 0001814287 srt:SubsidiariesMember abl:NovaTradingUSLLCAndNovaHoldingUSLPMember abl:ExpenseReimbursementsMember us-gaap:RelatedPartyMember 2022-01-01 2022-06-30 0001814287 srt:SubsidiariesMember srt:AffiliatedEntityMember 2023-04-01 2023-06-30 0001814287 srt:SubsidiariesMember srt:AffiliatedEntityMember 2022-04-01 2022-06-30 0001814287 srt:SubsidiariesMember abl:LongevityMarketAssetsLLCMember srt:AffiliatedEntityMember 2023-04-01 2023-06-30 0001814287 srt:SubsidiariesMember abl:LongevityMarketAssetsLLCMember srt:AffiliatedEntityMember 2022-04-01 2022-06-30 0001814287 srt:SubsidiariesMember srt:AffiliatedEntityMember 2023-01-01 2023-06-30 0001814287 srt:SubsidiariesMember srt:AffiliatedEntityMember 2022-01-01 2022-06-30 0001814287 srt:SubsidiariesMember abl:LongevityMarketAssetsLLCMember srt:AffiliatedEntityMember 2023-01-01 2023-06-30 0001814287 srt:SubsidiariesMember abl:LongevityMarketAssetsLLCMember srt:AffiliatedEntityMember 2022-01-01 2022-06-30 0001814287 srt:SubsidiariesMember abl:LongevityMarketAssetsLLCMember us-gaap:RelatedPartyMember 2023-06-30 0001814287 srt:SubsidiariesMember abl:LongevityMarketAssetsLLCMember us-gaap:RelatedPartyMember 2022-06-30 shares iso4217:USD iso4217:USD shares pure abl:provider abl:investor abl:insurance_contract abl:entity abl:payment abl:segment abl:option abl:extension abl:vote 0001814287 --12-31 2023 Q2 false P1M P3M P1M P3M 1 10-Q true 2023-06-30 false 001-39403 Abacus Life, Inc. DE 85-1210472 2101 Park Center Drive, Suite 170 Orlando FL 32835 800 561-4148 Common stock, par value $0.0001 per share ABL NASDAQ Warrants, each whole warrant exercisable for one share of common stock at an exercise price of $11.50 per share ABLLW NASDAQ Yes Yes Non-accelerated Filer true true false false 62961688 20611122 30052823 192595 10448 78310 198364 10473748 2904646 21252 0 829595 116646 32206622 33282927 177931 18617 32900000 0 140287000 0 240816 77011 9889610 8716111 56685617 13809352 1000000 1000000 1600000 1300000 75582 0 206873 0 262500 0 1801886 890829 277334437 59094847 524400 0 401500 40014 227561 48127 10415154 263785 717429 0 981217 0 182571 908256 258759 42227 185831 0 13894422 1302409 25000000 0 66165396 28249653 16864 29268 9320240 1363820 2438600 0 116835522 30945150 0.0001 0.0001 200000000 200000000 62961688 62961688 50369350 50369350 6296 5037 188641886 704963 -29382362 25487323 877306 1052836 355789 899538 160498915 28149697 277334437 59094847 329629 419253 543076 620159 24737 169 46981 370169 354366 419422 590057 990328 8263499 5965466 16655833 13980466 2760900 2014013 4339084 3305505 11024399 7979479 20994917 17285971 11378765 8398901 21584974 18276299 973400 666119 1462950 2086075 973400 666119 1462950 2086075 10405365 7732782 20122024 16190224 683841 1019498 1412845 1649498 577539 5499 1274431 646705 -1445229 -333879 -2398662 -375513 672936 -1039022 798156 -1054975 1098 1098 2141 2141 2034771 2398996 4289923 3728832 8370594 5333786 15832101 12461392 584075 0 941458 0 0 0 7457 0 121601 -127455 -21651 -242247 -462474 -127455 -955652 -242247 7908120 5206331 14876449 12219145 1184571 120132 528104 296806 6723549 5086199 14348345 11922339 -26596 406641 -487303 406641 6750145 4679558 14835648 11515698 50507728 50507728 50369350 50369350 50438921 50438921 50369350 50369350 0.13 0.13 0.09 0.09 0.29 0.29 0.23 0.23 6723549 5086199 14348345 11922339 -119663 2017559 -231976 2017559 6603886 7103758 14116369 13939898 -56111 1011909 -543749 1011909 6659997 6091849 14660118 12927989 50369350 5037 704963 4951188 0 -148155 5513033 310000 310000 1412291 605268 2017559 4679558 406641 5086199 50369350 5037 704963 9320746 1412291 863754 12306791 50369350 5037 704963 33572826 967454 411900 35662180 34451607 34451607 10841551 10841551 4726500 -3765600 960900 12592338 1259 17849091 -20646575 -2796225 165361332 165361332 -90148 -29515 -119663 6750145 -26596 6723549 62961688 6296 188641886 -29382362 877306 355789 160498915 50369350 5037 704963 205048 0 -148155 766893 2400000 2400000 1412291 605268 2017559 11515698 406641 11922339 50369350 5037 704963 9320746 1412291 863754 12306791 50369350 5037 704963 25487323 1052836 899538 28149697 34451607 34451607 10841551 10841551 4726500 -3765600 960900 12592338 1259 17849091 -20646575 -2796225 165361332 165361332 -175530 -56446 -231976 14835648 -487303 14348345 62961688 6296 188641886 -29382362 877306 355789 160498915 14348345 11922339 2141 2141 798156 -1054975 3319588 3305505 -2398662 -375513 252659 999927 384 0 182147 0 -125764 77657 193462 1379579 105655 0 361486 0 -725685 0 402363 72938 39556677 7211509 11374605 7204753 -38364171 -4751170 300000 250000 -6760627 0 -7060627 -250000 35206351 9463779 10841551 0 23533072 2400000 25000000 0 10151369 680375 35983097 7744154 -9441701 2742984 30052823 102421 20611122 2845405 DESCRIPTION OF BUSINESS<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Organization and Merger</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Abacus Life, Inc. (“the Company”) was formerly known as East Resources Acquisition Company ("ERES”), a blank check company incorporated in Delaware on May 22, 2020. Abacus Life, Inc. conducts its business through its wholly-owned, consolidated subsidiaries, primarily Abacus Settlements LLC (“Abacus”) and Longevity Market Assets, LLC (“LMA”), which are incorporated in the state of Delaware (collectively, the “Companies”). On June 30, 2023, (the “Closing Date”), ERES, Longevity Market Assets, LLC and Abacus Settlements, LLC consummated the combining of the Companies as contemplated by the Merger Agreement dated as of August 30, 2022 (as amended on October 14, 2022 and April 20, 2023) with LMA Merger Sub, LLC, a wholly owned subsidiary of ERES (“LMA Merger Sub”), Abacus Merger Sub, LLC, a wholly owned subsidiary of ERES (“Abacus Merger Sub”), Longevity Market Assets, LLC (“LMA”) and Abacus Settlements, LLC (“Legacy Abacus” and, together with LMA, the “Legacy Companies”). Pursuant to the Merger Agreement, on June 30, 2023, (i) LMA Merger Sub merged with and into LMA, with LMA surviving such merger (the “LMA Merger”) and (ii) Abacus Merger Sub merged with and into Legacy Abacus, with Legacy Abacus surviving such merger (the “Abacus Merger” and, together with the LMA Merger, the “Mergers” and, along with the other transactions contemplated by the Merger Agreement, the “Business Combination”) and the Legacy Companies became direct wholly owned subsidiaries of Abacus and ERES changed its name to Abacus Life, Inc. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed consolidated assets, liabilities and statements of operations and comprehensive income prior to the Business Combination are those of legacy LMA. The stocks and corresponding capital amounts and income per stock, prior to the Business Combination, have been retroactively restated based on stocks reflecting the exchange ratio established in the Business Combination. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The equity structure has been recast in all comparative periods up to the Closing Date to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to legacy LMA’s stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to legacy LMA common stock prior to the Business Combination have been retroactively recast as shares reflecting the exchange ratio of 0.8 established in the Business Combination.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Business Activity</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company, through its LMA subsidiary, is a provider of services pertaining to life insurance settlements and offers policy servicing to owners and purchasers of life settlement assets, as well as consulting, valuation, and actuarial services. The Company is also engaged in buying and selling of life settlement policies in which it uses its own capital, and purchases life settlement contracts with the intent to either hold to maturity to receive the associated death claim payout or to sell to another purchaser of life settlement contracts for a gain on the sale.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company, through its Abacus subsidiary, also is an originator of outstanding life insurance policies as a licensed life settlement provider on behalf of investors (“Financing Entities”). Abacus locates and screens policies for eligibility as a commercially desirable life settlement, including verifying that the policy is in force, obtaining consents and disclosures, and submitting cases for life expectancy estimates, also known, collectively, as origination services. When the sale of a policy is completed, this is deemed “settled” and the policy is then referred to as either a “life settlement” in which the insured’s life expectancy is greater than two years or “viatical settlement,” in which the insured’s life expectancy is less </span></div>than two years. The Company is not an insurance company, and therefore the Company does not underwrite insurable risks for its own account. 0.0001 0.8 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—In connection with the Business Combination, the Merger is accounted for as a reverse recapitalization with ERES in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Under U.S. GAAP, ERES has been treated as the “acquired” company for financial reporting purposes. This determination was primarily based on the LMA shareholders having a relative majority of the voting power of the Company, the LMA shareholders having the authority to appoint a majority of directors on the Board of Directors, and senior management of LMA comprising the majority of the senior management of the post-combination Company. LMA was then determined to be the “acquirer” for financial reporting purposes based on the relative size of LMA as compared to Abacus, represented by their revenue, equity, gross profit and net income. Accordingly, for accounting purposes, the financial statements of the combined entity will represent a continuation of the financial statements of LMA with the LMA Merger being treated as the equivalent of LMA issuing stock for the net assets of ERES, accompanied by a recapitalization. The net assets of ERES will be stated at historical cost, with no goodwill or other intangible assets recorded.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Abacus Merger will be accounted for using the acquisition method of accounting. Under the acquisition method of accounting, the assets and liabilities of Abacus will be recorded at estimated fair value as of the acquisition date. The excess of the purchase price over the estimated fair values of the net assets acquired, if applicable, will be recognized as goodwill. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a result of the Business Combination, the Company evaluated if ERES, Abacus, or LMA is the predecessor for accounting purposes. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In considering the foregoing principles of predecessor determination and in light of the Company's specific facts and circumstances, management determined that LMA and Abacus are dual predecessors for accounting purposes. The financial statement presentation for Abacus Life, Inc. includes the purchase accounting effects of the Abacus Merger as of the Closing Date with the financial statements of LMA as the comparative period. The predecessor financial statements for Abacus are included separately within this report. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and are prepared in accordance with U.S. GAAP. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unaudited Condensed Consolidated Financial Statements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2023, and the condensed consolidated statements of operations and comprehensive income for the three months and six months ended June 30, 2023 and 2022, respectively, and the condensed consolidated statements of cash flows for the six months ended June 30, 2023 and 2022, respectively. The condensed consolidated statements of operations and comprehensive income for the three months and six months ended June 30, 2023, are not necessarily indicative of the results to be expected for the full year ending December 31, 2023, or any other period. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes for Abacus for the year ended December 31, 2022, and the financial statements and notes for LMA for the year ended December 31, 2022. All references to financial information as of and for the periods ended June 30, 2023, and 2022 in the notes to condensed consolidated financial statements are unaudited. </span></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Refer to this note in the LMA annual financial statements for the full list of the Company’s significant accounting policies. The details in those notes have not changed, except as discussed below and as a result of normal adjustments in the interim periods.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidation of Variable Interest Entities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—For entities in which the Company has variable interests, the Company first evaluates whether the entity meets the definition of a variable interest entity (“VIE”) or a voting interest entity (“VOE”). If the entity is a VIE, the Company focuses on identifying whether it has the power to direct the activities that most significantly impact the VIE’s economic performance and whether it has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company is the primary beneficiary of a VIE, the assets, liabilities, and results of operations of the VIE will be included in the Company’s condensed consolidated financial statements. The proportionate share not owned by the Company is recognized as noncontrolling interest and net income attributable to noncontrolling interest on the condensed consolidated balance sheets and condensed consolidated statements of operations and comprehensive income, respectively. If the entity is a VOE, the Company evaluates whether it has the power to control the VOE through a majority voting interest or through other arrangements.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accounting Standards Codification (“ASC”) Topic 810, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Consolidations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, requires the Company to separately disclose on its condensed consolidated balance sheets the assets of consolidated VIEs and liabilities of consolidated VIEs as to which there is no recourse against the Company. As of June 30, 2023, total assets and liabilities of consolidated VIEs were</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> $57,577,034</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and $52,474,820, respectively. As of December 31, 2022, total assets and liabilities of consolidated VIEs were $30,073,972 and $27,116,762, respectively.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On January 1, 2021, the Company entered into an option agreement with two commonly owned full-service origination, servicing, and investment providers (the “Providers”), in which the Company agreed to fund certain capital needs with an option to purchase the outstanding equity ownership of the Providers (the “Option Agreement”). </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company accounted for its investment in the call options under the Option Agreement as an equity security, pursuant to ASC 321. In arriving at this accounting conclusion, the Company first considered whether the call options met the definition of a derivative pursuant to ASC 815 and concluded that the options do not provide for net settlement and accordingly are not a derivative. The Company also concluded that the call options do not provide the Company with a controlling financial interest in the legal entity pursuant to ASC 810. The call options include material contingencies prior to exercisability that the Company does not anticipate will be resolved; additionally, the call options are in a legal entity for which the share price has no readily determinable fair value. The Company’s basis in the call options, pursuant to ASC 321, is zero and accordingly the call options are not reflected in the statement of financial position.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company provided $0 and $127,455 of funding for the three months ended June 30, 2023 and June 30, 2022, respectively and provided $29,721 and $242,247 of funding for the six months ended June 30, 2023 and June 30, 2022, respectively which is included in other (expense) income on the condensed consolidated statements of operations and comprehensive income. See Note 11, Commitments and Contingencies.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the period ended June 30, 2023, and for the year ended December 31, 2022, the Providers were considered to be VIEs, but were not consolidated in the Company’s condensed consolidated financial statements due to a lack of the power criterion or the losses/benefits criterion. As of June 30, 2023, the unaudited financial information for the unconsolidated VIEs are as follows: held assets of $318,178 and liabilities of $450 and held assets of $483,167 and liabilities of $184,621, respectively. As of December 31, 2022, the unaudited financial information for the unconsolidated VIEs are as follows: held assets of $126,040 and liabilities of $0 and held assets of $861,924 and liabilities of $358,586, respectively.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On October 4, 2021, the Company entered into an operating agreement with LMX Series, LLC (“LMX”) and three other unaffiliated investors to obtain a 70% ownership interest in LMX, which was newly formed in August 2021. LMX had no operating activity prior to the operating agreement being signed. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMX has a wholly owned subsidiary, LMATT Series 2024, Inc., a Delaware C corporation. While the Company and three other investors each contributed $100 to LMX, the Company directs the most significant activities by managing the investment offerings, and sponsoring and creating structured investment grade insurance liabilities, and thus was provided a 70% ownership interest. LMX is a VIE and the Company is the primary beneficiary of LMX. The Company has included the results of LMX and its subsidiaries in its condensed consolidated financial statements for the period ended June 30, 2023.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 3, 2022, the Company obtained an 80% ownership interest in Longevity Market Advisors, LLC (“Longevity Market Advisors”). The Longevity Market Advisors legal entity was established primarily for the purpose of acquiring the assets of a broker/dealer, Regional Investment Services, Inc. (“RIS”), an Ohio corporation. Longevity Market Advisors is a VIE and the Company is the primary beneficiary of Longevity Market Advisors. The purchase price payable in exchange for RIS was $60,000. The Company evaluated whether this represented a business combination or an asset acquisition under ASC 805. While the purchase of the RIS represents a business, it was further determined that as RIS was purchased for the primary reason of being registered by the Financial Industry Regulatory Authority (“FINRA”). As there are no tangible or intangible assets of value from the RIS that would meet the capitalization criteria that have standalone value, the Company has expensed the purchase in general and administrative costs. Upon closing of the transaction, Longevity Market Advisors will comprise 100% of the ownership structure of RIS, and RIS will be a wholly owned subsidiary. The Company has included the results of Longevity Market Advisors in its condensed consolidated financial statements for the period ended June 30, 2023.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 30, 2022, LMA Series, LLC, a wholly owned subsidiary of the Company, signed an Operating Agreement to be the sole member of a newly created general partnership, LMA Income Series, GP, LLC. Subsequent to that, LMA Income Series, GP, LLC formed a limited partnership, LMA Income Series, LP and issued partnership interests to limited partners in a private placement offering. It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series, LP and thus has fully consolidated the limited partnership in its condensed consolidated financial statements for the six months ended June 30, 2023.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On January 31, 2023, LMA Series, LLC, a wholly owned subsidiary of the Company, signed an Operating Agreement to be the sole member of a newly created general partnership, LMA Income Series II, GP, LLC. Subsequent to that, LMA Income Series II, GP, LLC formed a limited partnership, LMA Income Series II, LP and issued partnership interests to limited partners in a private placement offering. It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series II, LP and thus has fully consolidated the limited partnership in its condensed consolidated financial statements for the six months ended June 30, 2023.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Noncontrolling Interest</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Noncontrolling interest represents the share of consolidated entities owned by third parties. At the date of formation or upon acquisition, the Company recognizes noncontrolling interest on the condensed consolidated balance sheets at an amount equal to the noncontrolling interest’s proportionate share of the relative fair value of any assets and liabilities acquired. Noncontrolling interest is subsequently adjusted for the noncontrolling shareholder’s additional contributions, distributions, and the shareholder’s share of the net earnings or losses of each respective consolidated entity.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net income of a consolidated entity is allocated to noncontrolling interests based on the noncontrolling shareholder’s ownership interest during the period. The net income or loss that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the condensed consolidated statements of operations and comprehensive income.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The preparation of U.S. GAAP financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, disclosure of contingent assets and liabilities at the date of financial statements, and the reports amounts of revenue and expenses during the reporting periods. Company’s estimates, judgments, and </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from the estimates. Estimates are used when accounting for revenue recognition and related costs, purchase price allocation, the selection of useful lives of property and equipment, valuation of other receivables, valuation of life settlement policies, valuation of other investments and available-for-sale securities, valuation of long-term debt, impairment testing, income taxes, and legal reserves.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Life Insurance Settlement Policies</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The Company accounts for its holdings of life insurance settlement policies in accordance with ASC 325-30, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Investments in Insurance Contracts</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company accounts for life settlement policies purchased that we intend to hold to maturity at fair value and life settlement policies that we intend to trade in the near term at cost plus premiums paid. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company follows ASC 820, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in estimating the fair value of its life insurance policies held at fair value. ASC 820 defines fair value as an exit price representing the amount that would be received if an asset were sold or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-level, fair value hierarchy that prioritizes the inputs used to measure fair value. Level 1 relates to quoted prices in active markets for identical assets or liabilities. Level 2 relates to observable inputs other than quoted prices included in Level 1. Level 3 relates to unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s valuation of life settlements is considered to be Level 3, as there is currently no active market where we are able to observe quoted prices for identical assets. The Company’s valuation model incorporates significant inputs that are not observable. See Note 10, “Fair Value Measurements.” For policies held at fair value, changes in fair value are reflected in operations in the period the change is calculated.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For policies held under the investment method, the Company tests the impairment if we become aware of information indicating that the carrying value plus undiscounted future premiums of a policy may not be recoverable. This information is gathered initially through extensive underwriting procedures at purchase of the settlement contract, as well as through periodic underwriting review that include medical reports and life expectancy evaluations. The policies held by the Company using the investment method are expected to be owned for a shorter-term, and are actively marketed to potential buyers. The market feedback received through these interactions provides the Company with information related to a potential impairment. If a policy is determined to be impaired, the Company will adjust the carrying value to the fair value determined through the impairment analysis.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company accounts for cash proceeds from sale and maturity of life insurance settlement policies, as well as cash outflows for premium payments, as operating activities within the condensed consolidated statements of cash flows.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost of Revenues</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Cost of revenue represents the direct costs associated with fulfilling the Company’s obligations to its customers, primarily policy servicing and consulting expense. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">—The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, the provision for income taxes represents income taxes paid or payable (or received or receivable) for the current year plus the change in deferred taxes during the year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid, and result from differences between the financial and tax bases of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when enacted. </span></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not (greater than 50%) that a tax benefit will not be realized. In evaluating the need for a valuation allowance, management considers all potential sources of taxable income, including income available in carryback periods, future reversals of taxable temporary differences, projections of taxable income, and income from tax planning strategies, as well as all available positive and negative evidence. Positive evidence includes factors such as a history of profitable operations, projections of future profitability within the carryforward period, including from tax planning strategies, and the Company’s experience with similar operations. Existing favorable contracts are additional positive evidence. Negative evidence includes items such as cumulative losses, projections of future losses, or carryforward periods that are not long enough to allow for the utilization of a deferred tax asset based on existing projections of income. Deferred tax assets for which no valuation allowance is recorded may not be realized upon changes in facts and circumstances, resulting in a future charge to establish a valuation allowance. Existing valuation allowances are re-examined under the same standards of positive and negative evidence. If it is determined that it is more likely than not that a deferred tax asset will be realized, the appropriate amount of the valuation allowance, if any, is released. Deferred tax assets and liabilities are also remeasured to reflect changes in underlying tax rates due to law changes and the granting and lapse of tax holidays.</span></div><div style="padding-left:22.5pt"><span><br/></span></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Tax benefits related to uncertain tax positions taken or expected to be taken on a tax return are recorded when such benefits meet a more likely than not threshold. Otherwise, these tax benefits are recorded when a tax position has been effectively settled, which means that the statute of limitations has expired or the appropriate taxing authority has completed their examination even though the statute of limitations remains open. Interest and penalties related to uncertain tax positions are recognized as part of the provision for income taxes and are accrued beginning in the period that such interest and penalties would be applicable under relevant tax law until such time that the related tax benefits are recognized.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Concentrations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, accounts receivable, and available-for-sale securities. The Company maintains its cash in bank deposit accounts with high-quality financial institutions, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on its cash and cash equivalents. For accounts receivable, the Company is exposed to credit risk in the event of nonpayment by customers to the extent of the amounts recorded on the accompanying condensed consolidated balance sheets. The Company extends different levels of credit to its customers and maintains allowance for doubtful accounts based upon the expected collectability of accounts receivable. The Company’s procedures for determining this allowance includes evaluating individual customer receivables, considering a customer’s financial condition, monitoring credit history and current economic conditions, and using historical experience applied to an aging of accounts.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Two related party customers accounted for 12% and 13% of the total balance of accounts receivable and related party receivables as of June 30, 2023, and two related party customers accounted for 75% and 16% of the total accounts receivable as of December 31, 2022, respectively. The largest receivables balances are from related parties where exposed credit risk is low. As such, there is no allowance for doubtful accounts as of June 30, 2023, and December 31, 2022.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">One customer accounted for 27% of active management revenue for the three months ended June 30, 2023. Two related party customers each accounted for 20% and 20% of the portfolio servicing revenue for the three months ended June 30, 2023. One customer accounted for 26% of the total revenues for the three months ended June 30, 2022.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">One customer accounted for 29% of active management revenue, while 16% of revenue related to 2 policies that matured that were accounted for under the investment method and 1 policy that matured that was accounted for under the fair-value method for the six months ended June 30, 2023. Two related party customers each accounted for 25% and 27% of the portfolio servicing revenue for the six months </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ended June 30, 2023. One customer accounted for 71% of the total revenues for the six months ended June 30, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Warrants</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">—The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> (“ASC 480”) and ASC 815, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. </span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the condensed consolidated statements of operations and comprehensive income.</span></div> <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—In connection with the Business Combination, the Merger is accounted for as a reverse recapitalization with ERES in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”). Under U.S. GAAP, ERES has been treated as the “acquired” company for financial reporting purposes. This determination was primarily based on the LMA shareholders having a relative majority of the voting power of the Company, the LMA shareholders having the authority to appoint a majority of directors on the Board of Directors, and senior management of LMA comprising the majority of the senior management of the post-combination Company. LMA was then determined to be the “acquirer” for financial reporting purposes based on the relative size of LMA as compared to Abacus, represented by their revenue, equity, gross profit and net income. Accordingly, for accounting purposes, the financial statements of the combined entity will represent a continuation of the financial statements of LMA with the LMA Merger being treated as the equivalent of LMA issuing stock for the net assets of ERES, accompanied by a recapitalization. The net assets of ERES will be stated at historical cost, with no goodwill or other intangible assets recorded.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Abacus Merger will be accounted for using the acquisition method of accounting. Under the acquisition method of accounting, the assets and liabilities of Abacus will be recorded at estimated fair value as of the acquisition date. The excess of the purchase price over the estimated fair values of the net assets acquired, if applicable, will be recognized as goodwill. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As a result of the Business Combination, the Company evaluated if ERES, Abacus, or LMA is the predecessor for accounting purposes. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In considering the foregoing principles of predecessor determination and in light of the Company's specific facts and circumstances, management determined that LMA and Abacus are dual predecessors for accounting purposes. The financial statement presentation for Abacus Life, Inc. includes the purchase accounting effects of the Abacus Merger as of the Closing Date with the financial statements of LMA as the comparative period. The predecessor financial statements for Abacus are included separately within this report. </span></div>The accompanying condensed consolidated financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission and are prepared in accordance with U.S. GAAP. Unaudited Condensed Consolidated Financial Statements—The condensed consolidated financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2023, and the condensed consolidated statements of operations and comprehensive income for the three months and six months ended June 30, 2023 and 2022, respectively, and the condensed consolidated statements of cash flows for the six months ended June 30, 2023 and 2022, respectively. The condensed consolidated statements of operations and comprehensive income for the three months and six months ended June 30, 2023, are not necessarily indicative of the results to be expected for the full year ending December 31, 2023, or any other period. These interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes for Abacus for the year ended December 31, 2022, and the financial statements and notes for LMA for the year ended December 31, 2022. All references to financial information as of and for the periods ended June 30, 2023, and 2022 in the notes to condensed consolidated financial statements are unaudited. <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Consolidation of Variable Interest Entities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—For entities in which the Company has variable interests, the Company first evaluates whether the entity meets the definition of a variable interest entity (“VIE”) or a voting interest entity (“VOE”). If the entity is a VIE, the Company focuses on identifying whether it has the power to direct the activities that most significantly impact the VIE’s economic performance and whether it has the obligation to absorb losses or the right to receive benefits from the VIE. If the Company is the primary beneficiary of a VIE, the assets, liabilities, and results of operations of the VIE will be included in the Company’s condensed consolidated financial statements. The proportionate share not owned by the Company is recognized as noncontrolling interest and net income attributable to noncontrolling interest on the condensed consolidated balance sheets and condensed consolidated statements of operations and comprehensive income, respectively. If the entity is a VOE, the Company evaluates whether it has the power to control the VOE through a majority voting interest or through other arrangements.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accounting Standards Codification (“ASC”) Topic 810, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Consolidations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, requires the Company to separately disclose on its condensed consolidated balance sheets the assets of consolidated VIEs and liabilities of consolidated VIEs as to which there is no recourse against the Company. As of June 30, 2023, total assets and liabilities of consolidated VIEs were</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> $57,577,034</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%"> and $52,474,820, respectively. As of December 31, 2022, total assets and liabilities of consolidated VIEs were $30,073,972 and $27,116,762, respectively.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On January 1, 2021, the Company entered into an option agreement with two commonly owned full-service origination, servicing, and investment providers (the “Providers”), in which the Company agreed to fund certain capital needs with an option to purchase the outstanding equity ownership of the Providers (the “Option Agreement”). </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company accounted for its investment in the call options under the Option Agreement as an equity security, pursuant to ASC 321. In arriving at this accounting conclusion, the Company first considered whether the call options met the definition of a derivative pursuant to ASC 815 and concluded that the options do not provide for net settlement and accordingly are not a derivative. The Company also concluded that the call options do not provide the Company with a controlling financial interest in the legal entity pursuant to ASC 810. The call options include material contingencies prior to exercisability that the Company does not anticipate will be resolved; additionally, the call options are in a legal entity for which the share price has no readily determinable fair value. The Company’s basis in the call options, pursuant to ASC 321, is zero and accordingly the call options are not reflected in the statement of financial position.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company provided $0 and $127,455 of funding for the three months ended June 30, 2023 and June 30, 2022, respectively and provided $29,721 and $242,247 of funding for the six months ended June 30, 2023 and June 30, 2022, respectively which is included in other (expense) income on the condensed consolidated statements of operations and comprehensive income. See Note 11, Commitments and Contingencies.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the period ended June 30, 2023, and for the year ended December 31, 2022, the Providers were considered to be VIEs, but were not consolidated in the Company’s condensed consolidated financial statements due to a lack of the power criterion or the losses/benefits criterion. As of June 30, 2023, the unaudited financial information for the unconsolidated VIEs are as follows: held assets of $318,178 and liabilities of $450 and held assets of $483,167 and liabilities of $184,621, respectively. As of December 31, 2022, the unaudited financial information for the unconsolidated VIEs are as follows: held assets of $126,040 and liabilities of $0 and held assets of $861,924 and liabilities of $358,586, respectively.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On October 4, 2021, the Company entered into an operating agreement with LMX Series, LLC (“LMX”) and three other unaffiliated investors to obtain a 70% ownership interest in LMX, which was newly formed in August 2021. LMX had no operating activity prior to the operating agreement being signed. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMX has a wholly owned subsidiary, LMATT Series 2024, Inc., a Delaware C corporation. While the Company and three other investors each contributed $100 to LMX, the Company directs the most significant activities by managing the investment offerings, and sponsoring and creating structured investment grade insurance liabilities, and thus was provided a 70% ownership interest. LMX is a VIE and the Company is the primary beneficiary of LMX. The Company has included the results of LMX and its subsidiaries in its condensed consolidated financial statements for the period ended June 30, 2023.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 3, 2022, the Company obtained an 80% ownership interest in Longevity Market Advisors, LLC (“Longevity Market Advisors”). The Longevity Market Advisors legal entity was established primarily for the purpose of acquiring the assets of a broker/dealer, Regional Investment Services, Inc. (“RIS”), an Ohio corporation. Longevity Market Advisors is a VIE and the Company is the primary beneficiary of Longevity Market Advisors. The purchase price payable in exchange for RIS was $60,000. The Company evaluated whether this represented a business combination or an asset acquisition under ASC 805. While the purchase of the RIS represents a business, it was further determined that as RIS was purchased for the primary reason of being registered by the Financial Industry Regulatory Authority (“FINRA”). As there are no tangible or intangible assets of value from the RIS that would meet the capitalization criteria that have standalone value, the Company has expensed the purchase in general and administrative costs. Upon closing of the transaction, Longevity Market Advisors will comprise 100% of the ownership structure of RIS, and RIS will be a wholly owned subsidiary. The Company has included the results of Longevity Market Advisors in its condensed consolidated financial statements for the period ended June 30, 2023.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On November 30, 2022, LMA Series, LLC, a wholly owned subsidiary of the Company, signed an Operating Agreement to be the sole member of a newly created general partnership, LMA Income Series, GP, LLC. Subsequent to that, LMA Income Series, GP, LLC formed a limited partnership, LMA Income Series, LP and issued partnership interests to limited partners in a private placement offering. It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series, LP and thus has fully consolidated the limited partnership in its condensed consolidated financial statements for the six months ended June 30, 2023.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On January 31, 2023, LMA Series, LLC, a wholly owned subsidiary of the Company, signed an Operating Agreement to be the sole member of a newly created general partnership, LMA Income Series II, GP, LLC. Subsequent to that, LMA Income Series II, GP, LLC formed a limited partnership, LMA Income Series II, LP and issued partnership interests to limited partners in a private placement offering. It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series II, LP and thus has fully consolidated the limited partnership in its condensed consolidated financial statements for the six months ended June 30, 2023.</span></div> 57577034 52474820 30073972 27116762 2 0 127455 29721 242247 318178 450 483167 184621 126040 0 861924 358586 3 0.70 3 100 0.70 0.80 60000 1 <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Noncontrolling Interest</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Noncontrolling interest represents the share of consolidated entities owned by third parties. At the date of formation or upon acquisition, the Company recognizes noncontrolling interest on the condensed consolidated balance sheets at an amount equal to the noncontrolling interest’s proportionate share of the relative fair value of any assets and liabilities acquired. Noncontrolling interest is subsequently adjusted for the noncontrolling shareholder’s additional contributions, distributions, and the shareholder’s share of the net earnings or losses of each respective consolidated entity.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net income of a consolidated entity is allocated to noncontrolling interests based on the noncontrolling shareholder’s ownership interest during the period. The net income or loss that is not attributable to the Company is reflected in net income (loss) attributable to noncontrolling interests in the condensed consolidated statements of operations and comprehensive income.</span></div> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The preparation of U.S. GAAP financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, disclosure of contingent assets and liabilities at the date of financial statements, and the reports amounts of revenue and expenses during the reporting periods. Company’s estimates, judgments, and </span>assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from the estimates. Estimates are used when accounting for revenue recognition and related costs, purchase price allocation, the selection of useful lives of property and equipment, valuation of other receivables, valuation of life settlement policies, valuation of other investments and available-for-sale securities, valuation of long-term debt, impairment testing, income taxes, and legal reserves. <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Life Insurance Settlement Policies</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The Company accounts for its holdings of life insurance settlement policies in accordance with ASC 325-30, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Investments in Insurance Contracts</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company accounts for life settlement policies purchased that we intend to hold to maturity at fair value and life settlement policies that we intend to trade in the near term at cost plus premiums paid. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company follows ASC 820, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">, in estimating the fair value of its life insurance policies held at fair value. ASC 820 defines fair value as an exit price representing the amount that would be received if an asset were sold or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the guidance establishes a three-level, fair value hierarchy that prioritizes the inputs used to measure fair value. Level 1 relates to quoted prices in active markets for identical assets or liabilities. Level 2 relates to observable inputs other than quoted prices included in Level 1. Level 3 relates to unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The Company’s valuation of life settlements is considered to be Level 3, as there is currently no active market where we are able to observe quoted prices for identical assets. The Company’s valuation model incorporates significant inputs that are not observable. See Note 10, “Fair Value Measurements.” For policies held at fair value, changes in fair value are reflected in operations in the period the change is calculated.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For policies held under the investment method, the Company tests the impairment if we become aware of information indicating that the carrying value plus undiscounted future premiums of a policy may not be recoverable. This information is gathered initially through extensive underwriting procedures at purchase of the settlement contract, as well as through periodic underwriting review that include medical reports and life expectancy evaluations. The policies held by the Company using the investment method are expected to be owned for a shorter-term, and are actively marketed to potential buyers. The market feedback received through these interactions provides the Company with information related to a potential impairment. If a policy is determined to be impaired, the Company will adjust the carrying value to the fair value determined through the impairment analysis.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company accounts for cash proceeds from sale and maturity of life insurance settlement policies, as well as cash outflows for premium payments, as operating activities within the condensed consolidated statements of cash flows.</span></div> Cost of Revenues—Cost of revenue represents the direct costs associated with fulfilling the Company’s obligations to its customers, primarily policy servicing and consulting expense. <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">—The provision for income taxes is determined using the asset and liability approach of accounting for income taxes. Under this approach, the provision for income taxes represents income taxes paid or payable (or received or receivable) for the current year plus the change in deferred taxes during the year. Deferred taxes represent the future tax consequences expected to occur when the reported amounts of assets and liabilities are recovered or paid, and result from differences between the financial and tax bases of the Company’s assets and liabilities and are adjusted for changes in tax rates and tax laws when enacted. </span><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Valuation allowances are recorded to reduce deferred tax assets when it is more likely than not (greater than 50%) that a tax benefit will not be realized. In evaluating the need for a valuation allowance, management considers all potential sources of taxable income, including income available in carryback periods, future reversals of taxable temporary differences, projections of taxable income, and income from tax planning strategies, as well as all available positive and negative evidence. Positive evidence includes factors such as a history of profitable operations, projections of future profitability within the carryforward period, including from tax planning strategies, and the Company’s experience with similar operations. Existing favorable contracts are additional positive evidence. Negative evidence includes items such as cumulative losses, projections of future losses, or carryforward periods that are not long enough to allow for the utilization of a deferred tax asset based on existing projections of income. Deferred tax assets for which no valuation allowance is recorded may not be realized upon changes in facts and circumstances, resulting in a future charge to establish a valuation allowance. Existing valuation allowances are re-examined under the same standards of positive and negative evidence. If it is determined that it is more likely than not that a deferred tax asset will be realized, the appropriate amount of the valuation allowance, if any, is released. Deferred tax assets and liabilities are also remeasured to reflect changes in underlying tax rates due to law changes and the granting and lapse of tax holidays.</span></div><div style="padding-left:22.5pt"><span><br/></span></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Tax benefits related to uncertain tax positions taken or expected to be taken on a tax return are recorded when such benefits meet a more likely than not threshold. Otherwise, these tax benefits are recorded when a tax position has been effectively settled, which means that the statute of limitations has expired or the appropriate taxing authority has completed their examination even though the statute of limitations remains open. Interest and penalties related to uncertain tax positions are recognized as part of the provision for income taxes and are accrued beginning in the period that such interest and penalties would be applicable under relevant tax law until such time that the related tax benefits are recognized.</span></div> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Concentrations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents, accounts receivable, and available-for-sale securities. The Company maintains its cash in bank deposit accounts with high-quality financial institutions, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on its cash and cash equivalents. For accounts receivable, the Company is exposed to credit risk in the event of nonpayment by customers to the extent of the amounts recorded on the accompanying condensed consolidated balance sheets. The Company extends different levels of credit to its customers and maintains allowance for doubtful accounts based upon the expected collectability of accounts receivable. The Company’s procedures for determining this allowance includes evaluating individual customer receivables, considering a customer’s financial condition, monitoring credit history and current economic conditions, and using historical experience applied to an aging of accounts.</span> 0.12 0.13 0.75 0.16 0 0 0.27 0.20 0.20 0.26 0.29 0.16 0.25 0.27 0.71 <div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Warrants</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">—The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480 </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Distinguishing Liabilities from Equity</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> (“ASC 480”) and ASC 815, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:107%">Derivatives and Hedging</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%"> (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. </span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the condensed consolidated statements of operations and comprehensive income.</span></div> BUSINESS COMBINATION<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Merger consideration conveyed of $531.8 million was allocated between the Companies based on relative values derived through both the discounted cash flow method within the income approach and the guideline public company method within the market approach. Within the discounted cash flow method, the present values of cash flows reasonably expected to be produced by the Companies from their operations were summed to produce an estimate of the Companies’ business enterprise values on a controlling, marketable basis. The cash flows used in the discounted cash flow analysis were discounted at the weighted average cost of capital of 14.5% for LMA and 16.5% for Abacus. The discounted cash flow method resulted in a business enterprise value range of $380.0 million to $460.0 million for LMA and $180.0 million to $195.0 million for Abacus. Within the market approach, Company applied the guideline public company method, which employs market multiples derived from market prices of stocks of Companies that are engaged in the same or similar lines of business as the Companies and that are actively traded on a free and open market. The guideline public company method resulted in a business enterprise value range of $400.0 million to $440.0 million for LMA and $180.0 million to $190.0 million for Abacus. Management concluded on a business enterprise value of $165.4 million for Abacus and $366.4 million for LMA based upon the relative fair value of the Companies allocated to the consideration transferred.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The preliminary purchase price was allocated among the identified assets to be acquired. The primary area of the acquisition accounting that is not yet finalized is our estimate of the impact of acquisition accounting on deferred income taxes. An estimate of deferred income taxes has been recorded in the Company’s books based on information available as of June 30, 2023. As the initial acquisition accounting is based on our preliminary assessments, actual values may differ when final information becomes available. We believe that the information gathered to date provides a reasonable basis for estimating the preliminary values of deferred taxes recorded. We will continue to evaluate this item until it is satisfactorily resolved and adjust our acquisition accounting accordingly, within the allowable measurement period, as defined by ASC 805, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Business Combinations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. Transaction costs incurred as a result of the Business Combination were recognized within retained earnings/(accumulated deficit) on the condensed consolidated balance sheet ending June 30, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">All valuation procedures related to existing assets as no new assets were identified as a result of procedures performed. Goodwill was recognized as a result of the acquisition, which represents the </span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">excess fair value of consideration over the fair value of the underlying net assets, largely arising from the extensive industry expertise that has been established by Abacus. This was considered appropriate based on the determination that the Abacus Merger would be accounted for as a business acquisition under ASC 805. </span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:77.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Assets Identified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Intangibles</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,900,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">140,287,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Current Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,280,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-Current Assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">901,337 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Deferred Tax Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(8,310,966)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued Expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(524,400)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,171,739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total Fair Value</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">165,361,332 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-indent:-5.15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"><tr><td style="width:1.0%"></td><td style="width:77.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Value Conveyed</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Abacus Purchase Consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">165,361,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMA Business Enterprise Value </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">366,388,668 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total Consideration</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">531,750,000 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Intangible assets were comprised of the following:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:31.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.006%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Asset Type</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Valuation Methodology</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Customer Relationships-Agents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,600,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Multi-period excess earnings method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Customer Relationships-Financing Entities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,000,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Multi-period excess earnings method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Internally Developed and Used Technology-APA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,600,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Relief from royalty method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Internally Developed and Used Technology-Marketplace</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">100,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Replacement cost method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Trade Name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">900,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Relief from royalty method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-Compete Agreements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,000,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With and without method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">State Insurance Licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,700,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Replacement cost method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total Fair Value</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,900,000 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Useful lives for customer relationships were developed using attrition data for agents and financing entities which resulted in a useful life of 5 years and 8 years, respectively. Estimates over the useful lives of internally developed and used technology contemplates the period in which the Company expects to utilize the technology and the length of time the technology is expected to maintain recognition and value in the market without significant investment.Non-compete agreements have a useful life commensurate with the executed non-compete agreements in place as a result of the Business Combination.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">The supplemental pro forma financial information in the table below summarizes the combined results of operations for the Business Combination as if the Companies were combined as of </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">January 1, 2022. The unaudited supplemental pro forma financial information as presented below is for illustrative purposes and does not purport to represent what the results of operations would actually have been if the business combinations occurred as of the date indicated or what the results would be for any future periods.</span></div><div style="padding-left:22.5pt"><span><br/></span></div><div style="padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:21.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Proforma revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,263,455 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,090,817 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,769,650 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,290,963 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Proforma net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,432,047 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,589,315 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,373,444 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,788,486 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div> 531800000 0.145 0.165 380000000 460000000 180000000 195000000 400000000 440000000 180000000 190000000 165400000 366400000 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:77.788%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.012%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Net Assets Identified</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Intangibles</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,900,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Goodwill</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">140,287,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Current Assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,280,100 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-Current Assets</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">901,337 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Deferred Tax Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(8,310,966)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Accrued Expenses</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(524,400)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other Liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,171,739)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total Fair Value</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">165,361,332 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 32900000 140287000 1280100 901337 8310966 524400 1171739 165361332 <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.060%"><tr><td style="width:1.0%"></td><td style="width:77.922%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.878%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Value Conveyed</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amount</span></td></tr><tr style="height:6pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Abacus Purchase Consideration</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">165,361,332 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMA Business Enterprise Value </span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">366,388,668 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total Consideration</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">531,750,000 </span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 165361332 366388668 531750000 <div style="margin-top:10pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">Intangible assets were comprised of the following:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:31.447%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.252%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.006%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:37.895%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Asset Type</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Useful Life</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Valuation Methodology</span></td></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Customer Relationships-Agents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,600,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5 years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Multi-period excess earnings method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Customer Relationships-Financing Entities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,000,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Multi-period excess earnings method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Internally Developed and Used Technology-APA</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,600,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2 years</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Relief from royalty method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Internally Developed and Used Technology-Marketplace</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">100,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Replacement cost method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Trade Name</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">900,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Relief from royalty method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-Compete Agreements</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,000,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2 years</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With and without method</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">State Insurance Licenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,700,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indefinite</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Replacement cost method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total Fair Value</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,900,000 </span></td><td style="border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div> 12600000 P5Y 11000000 P8Y 1600000 P2Y 100000 P3Y 900000 4000000 P2Y 2700000 32900000 P5Y P8Y The supplemental pro forma financial information in the table below summarizes the combined results of operations for the Business Combination as if the Companies were combined as of <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">January 1, 2022. The unaudited supplemental pro forma financial information as presented below is for illustrative purposes and does not purport to represent what the results of operations would actually have been if the business combinations occurred as of the date indicated or what the results would be for any future periods.</span></div><div style="padding-left:22.5pt"><span><br/></span></div><div style="padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.363%"><tr><td style="width:1.0%"></td><td style="width:21.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.510%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.868%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.871%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Proforma revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18,263,455 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14,090,817 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34,769,650 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31,290,963 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Proforma net income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,432,047 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,589,315 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13,373,444 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,788,486 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr style="height:11pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td></tr></table></div> 18263455 14090817 34769650 31290963 6432047 4589315 13373444 11788486 LIFE INSURANCE SETTLEMENT POLICIES<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2023, the Company holds 167 life settlement policies, of which 122 are accounted for under the fair value method and 45 are accounted for using the investment method (cost, plus premiums paid). Aggregate face value of policies held at fair value is $195,205,585 as of June 30, 2023, with a corresponding fair value of $56,685,617. Aggregate face value of policies accounted for using the investment method is $39,520,877 as of June 30, 2023, with a corresponding carrying value of $9,889,610. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of December 31, 2022, the Company held 53 life settlement policies, of which 35 were accounted for under the fair value method and 18 were accounted for using the investment method (cost, plus premiums paid). Aggregate face value of policies held at fair value was $40,092,154 as of December 31, 2022, with a corresponding fair value of $13,809,352. Aggregate face value of policies accounted for using the investment method was $42,330,000 as of December 31, 2022, with a corresponding carrying value of $8,716,111.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">At June 30, 2023, the Company did not have any contractual restrictions on its ability to sell policies, including those held as collateral for the issuance of long-term debt. See footnote 11 Long-Term Debt.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Life expectancy reflects the probable number of years remaining in the life of a class of persons determined statistically, affected by such factors as heredity, physical condition, nutrition, and occupation. It is not an estimate or an indication of the actual expected maturity date or indication of the timing of expected cash flows from death benefits. The following tables summarize the Company’s life insurance policies grouped by remaining life expectancy as of June 30, 2023:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Policies Carried at Fair Value</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:52.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Remaining Life Expectancy (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Policies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Face Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0-1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1-2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,314,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,855,769 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2-3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,886,778 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,530,949 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3-4</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33,631,467 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,174,200 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4-5</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18,755,193 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,564,469 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">78</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">113,618,147 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22,560,230 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">122</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">195,205,585 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56,685,617 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Policies accounted for using the investment method—</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:52.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Remaining Life Expectancy (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Number of Life<br/>Insurance<br/>Policies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Face Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Carrying Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0-1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1-2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2-3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,400,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,131,679 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3-4</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,281,524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4-5</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,362,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">518,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29,658,877 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,957,671 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,520,877 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,889,610 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Estimated premiums to be paid by the Company for its portfolio accounted for using the investment method during each of the five succeeding calendar years and thereafter as of June 30, 2023, are as follows:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:84.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023 remaining</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,024,151 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,243,423 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,310,936 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,044,640 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,288,619 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,911,769 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is required to pay premiums to keep its portion of life insurance policies in force. The estimated total future premium payments could increase or decrease significantly to the extent that actual mortalities of insureds differ from the estimated life expectancies.</span></div>For policies accounted for under the investment method, the Company has not been made aware of information causing a material change to assumptions relating to the timing of realization of life insurance settlement proceeds. We have also not been made aware of information indicating impairment to the carrying value of policies. 167 122 45 195205585 56685617 39520877 9889610 53 35 18 40092154 13809352 42330000 8716111 <div style="margin-top:10pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Policies Carried at Fair Value</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:52.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Remaining Life Expectancy (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Policies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Face Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0-1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1-2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,314,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,855,769 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2-3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,886,778 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,530,949 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3-4</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33,631,467 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,174,200 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4-5</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18,755,193 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,564,469 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">78</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">113,618,147 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22,560,230 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">122</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">195,205,585 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56,685,617 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 0 10 12314000 6855769 11 16886778 10530949 10 33631467 9174200 13 18755193 7564469 78 113618147 22560230 122 195205585 56685617 <div style="margin-top:10pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Policies accounted for using the investment method—</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:52.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.667%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Remaining Life Expectancy (Years)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Number of Life<br/>Insurance<br/>Policies</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Face Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Carrying Value</span></td></tr><tr style="height:8pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0-1</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1-2</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2-3</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,400,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,131,679 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3-4</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,100,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,281,524 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4-5</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,362,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">518,736 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29,658,877 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,957,671 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">45</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">39,520,877 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,889,610 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Estimated premiums to be paid by the Company for its portfolio accounted for using the investment method during each of the five succeeding calendar years and thereafter as of June 30, 2023, are as follows:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:84.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2023 remaining</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,024,151 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,243,423 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,310,936 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,044,640 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,288,619 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,911,769 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 0 0 0 0 0 0 2 4400000 2131679 4 4100000 1281524 4 1362000 518736 35 29658877 5957671 45 39520877 9889610 1024151 1243423 1310936 1044640 3288619 7911769 PROPERTY AND EQUIPMENT—NET<div style="margin-top:10pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment—net composed of the following:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"></td><td style="width:68.789%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Computer equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">144,202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">34,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment—gross</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">186,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"></td><td style="width:68.789%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(8,870)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(6,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment—net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">177,931 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18,617 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depreciation expense for the three months ended June 30, 2023 and 2022, was $1,098 and $1,098, respectively and depreciation expense for the six months ended June 30, 2023, and 2022, was $2,141 and $2,141, respectively.</span></div> <div style="margin-top:10pt;padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment—net composed of the following:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"></td><td style="width:68.789%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">June 30,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Computer equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">144,202 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Furniture and fixtures</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">34,300 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">19,444 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,299 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,902 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment—gross</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">186,801 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,346 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"></td><td style="width:68.789%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.638%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.433%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.640%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: accumulated depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(8,870)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(6,729)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Property and equipment—net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">177,931 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18,617 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 144202 0 34300 19444 8299 5902 186801 25346 8870 6729 177931 18617 1098 1098 2141 2141 GOODWILL AND OTHER INTANGIBLE ASSETS<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Goodwill of $140,287,000 was recognized as a result of the Business Combination, which represents the excess fair value of consideration over the fair value of the underlying net assets, largely arising from the extensive industry expertise that has been established by Abacus. This was considered appropriate based on the determination that the Abacus Merger would be accounted for as a business acquisition under ASC 805. The estimates of fair value are based upon preliminary valuation assumptions believed to be reasonable, but which are inherently uncertain and unpredictable. Refer to footnote 3 for further details.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:107%">The changes in goodwill by reportable segments were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:73.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.897%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Abacus Settlements, LLC</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Goodwill at January 1, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td colspan="4" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="5" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Goodwill at June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td colspan="4" style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Goodwill at January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td colspan="4" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="5" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">140,287,000 </span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Goodwill at June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td colspan="4" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">140,287,000 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Intangible Assets Acquired comprised of the following:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:35.090%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Asset Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Valuation Methodology</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Customer Relationships - Agents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,600,000 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5 years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Multi-period excess-earnings method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Customer Relationships - Financial Relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,000,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Multi-period excess-earnings method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Internally Developed and Used Technology—APA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,600,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Relief from Royalty Method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Internally Developed and Used Technology—Market Place</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">100,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Replacement Cost Method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Trade Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">900,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Relief from Royalty Method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-Compete Agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,000,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With or Without Method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">State Insurance Licenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,700,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Replacement Cost Method</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,900,000 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div> 140287000 The changes in goodwill by reportable segments were as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:96.666%"><tr><td style="width:1.0%"></td><td style="width:73.037%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.897%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.282%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.284%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Abacus Settlements, LLC</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Goodwill at January 1, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td colspan="4" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="5" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Goodwill at June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td colspan="4" style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:9pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Goodwill at January 1, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td colspan="4" style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additions</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="5" style="border-bottom:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">140,287,000 </span></td><td style="border-bottom:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Goodwill at June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td colspan="4" style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">140,287,000 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 0 0 0 0 140287000 140287000 <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Intangible Assets Acquired comprised of the following:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:35.090%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Asset Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Valuation Methodology</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Customer Relationships - Agents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,600,000 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5 years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Multi-period excess-earnings method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Customer Relationships - Financial Relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,000,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Multi-period excess-earnings method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Internally Developed and Used Technology—APA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,600,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Relief from Royalty Method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Internally Developed and Used Technology—Market Place</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">100,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Replacement Cost Method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Trade Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">900,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Relief from Royalty Method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-Compete Agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,000,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With or Without Method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">State Insurance Licenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,700,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Replacement Cost Method</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,900,000 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div> <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Intangible Assets Acquired comprised of the following:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:35.090%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.519%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.428%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Asset Type</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Useful Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Valuation Methodology</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Customer Relationships - Agents</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,600,000 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5 years</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Multi-period excess-earnings method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Customer Relationships - Financial Relationships</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,000,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Multi-period excess-earnings method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Internally Developed and Used Technology—APA</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,600,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Relief from Royalty Method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Internally Developed and Used Technology—Market Place</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">100,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Replacement Cost Method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Trade Name</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">900,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Relief from Royalty Method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Non-Compete Agreements</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,000,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2 years</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">With or Without Method</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">State Insurance Licenses</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,700,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Indefinite</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Replacement Cost Method</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">32,900,000 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div> 12600000 P5Y 11000000 P8Y 1600000 P2Y 100000 P3Y 900000 4000000 P2Y 2700000 32900000 AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Promissory Note</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The Company holds a convertible promissory note in a separate unrelated insurance technology company. In November 2021, the Company purchased a $250,000 note and then purchased an additional note in January 2022 for $250,000 as part of the Tranche 5 offering (“Tranche 5 </span><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Promissory Note”). The Tranche 5 Promissory Note pays 6% interest per annum. The Tranche 5 Promissory Note matures on November 12, 2023 (“Maturity Date”) and will be paid in full as to outstanding principal and accrued interest on the Maturity Date unless the Tranche 5 Promissory Note converts prior to the 2023 Maturity Date. Conversion into preferred shares occurs if the technology company engages in an additional equity financing event that yields gross cash proceeds in excess of $1,000,000 (“Next Equity Financing”).</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In October 2022, the Company purchased an additional convertible promissory note in the same unrelated insurance technology company for $500,000 as part of the Tranche 6</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">offering</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(“Tranche 6 Promissory Note” and collectively, the “Convertible Promissory Notes”). The Tranche 6 Promissory Note pays eight percent (8)% interest per annum and matures September 30, 2024 (“2024 Maturity Date”) and will be paid in full as to outstanding principal and accrued interest on the 2024 Maturity Date unless the Tranche 6 Promissory Note converts prior to the 2024 Maturity Date. Conversion into preferred shares occurs if the technology company engages in an additional equity financing event that yields gross cash proceeds in excess of $5,000,000 (“Next Round Securities”).</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company applies the available-for-sale method of accounting for its investment in the Convertible Promissory Note, which is a debt investment. The Convertible Promissory Note does not qualify for either the held-to-maturity method due to the Convertible Promissory Note’s conversion rights or the trading securities method because the Company holds the Convertible Promissory Note as a long-term investment. The Convertible Promissory Notes are measured at fair value at each reporting period-end. Unrealized gains and losses are reported in other comprehensive income until realized. As of December 31, 2022 and June 30, 2023, the Company evaluated the fair value of its investment and determined that the fair value approximates the carrying value of $1,000,000 and there was no unrealized gain or loss recorded.</span></div> 250000 250000 0.06 1000000 500000 0.08 5000000 1000000 OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Investments:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Convertible Preferred Stock Ownership</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The Company owns convertible preferred stock in two entities, further described below.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On July 22, 2020, the Company purchased 224,551 units of an unrelated insurance technology company’s Series Seed Preferred units for $750,000 (“Seed Units”). During December 2022, the Company agreed to purchase 119,760 Series Seed Preferred Units for $400,000 in cash consideration by way of eight monthly payments of $50,000 starting December 15, 2022, resulting in a total of $950,000 investment as of March 31, 2023 and $1,100,000 investment as of June 30, 2023. Upon conversion, the Seed Units held by the Company would represent 8.6% control in the technology company.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On December 21, 2020, the Company purchased 207,476 shares of a separate unrelated insurance technology company’s Series B-1 preferred stock for $500,000 (“Preferred Shares”). The Preferred Shares are convertible into voting common stock of insured consent at the option of the Company. Upon conversion, the Preferred Shares would represent less than 1% control in the technology company.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company applies the measurement alternative for its investments in the Seed Units and Preferred Shares because these investments are of an equity nature, and the Company does not have the ability to exercise significant influence over operating and financial policies of entities even in the event of conversion of the Seed Units or Preferred Shares. Under the measurement alternative, the Company records the investment based on original cost, less impairments, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the investee. The Company’s share of income or loss of such companies is not included in the Company’s condensed consolidated statements of operations and comprehensive income. The Company tests its investments for impairment whenever circumstances indicate that the carrying value of the investment </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">may not be recoverable. No impairment of investments occurred for the three and six months ended June 30, 2023 and 2022.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Noncurrent Assets- at fair value:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">S&amp;P Options</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is long S&amp;P 500 call options and short S&amp;P 500 put options which were purchased and sold through a broker as an economic hedge related to the market-indexed debt instruments included in the long-term debt note. The value is based on shares owned and quoted market prices in active markets. Changes in fair value are recorded in the Unrealized Loss on Investments line item on the condensed consolidated statements of operations and comprehensive income.</span></div> 2 224551 750000 119760 400000 8 50000 950000 1100000 0.086 207476 500000 0.01 0 0 0 0 CONSOLIDATION OF VARIABLE INTEREST ENTITIES<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company consolidates VIEs for which it is the primary beneficiary or VOEs for which it controls through a majority voting interest or other arrangement. See Note 2 for more information on how the Company evaluates an entity for consolidation.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company evaluated any entity in which it had a variable interest upon formation to determine whether the entity should be consolidated. The Company also evaluated the consolidation conclusion during each reconsideration event, such as changes in the governing documents or additional equity contributions to the entity. During the six months ended June 30, 2023, the Company’s consolidated VIEs, LMA Income Series II LP, LMX Series LLC (LMATT Series 2024, Inc.), Longevity Market Advisors, Regional Investment Services and LMA Income Series, LP, had total assets of $57,577,034 and liabilities of $52,474,820. For the year ended December 31, 2022, the Company’s consolidated VIEs, LMATT Series 2024, Inc., Longevity Market Advisors, Regional Investment Services and LMA Income Series, LP, had total assets and liabilities of $30,073,972 and $27,116,762, respectively. The Company did not deconsolidate any entities during the period ended June 30, 2023, or during the year ended December 31, 2022.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2023, the Company held total assets of $801,345 and liabilities of $185,071, in unconsolidated VIEs. As of December 31, 2022, the Company held total assets of $987,964 and liabilities of $358,586 in unconsolidated VIEs.</span></div> 57577034 52474820 30073972 27116762 801345 185071 987964 358586 SEGMENT REPORTING<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Segment Information</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The Company organizes its business into two reportable segments (1) Portfolio Servicing and (2) Active Management, which generate revenue in different manners. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">This segment structure reflects the financial information and reports used by the Company’s management, specifically its chief operating decision maker (CODM), to make decisions regarding the Company’s business, including resource allocations and performance assessments, as well as the current operating focus in compliance with ASC 280, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">. The Company’s CODM is the President and Chief Executive Officer.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Portfolio Servicing segment generates revenues by providing policy services to customers on a contract basis.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Active Management segment generates revenues by buying, selling, and trading policies and maintaining policies until receipt of death benefits. The Company’s reportable segments are not aggregated.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company’s method for measuring profitability on a reportable segment basis is gross profit. The CODM does not review asset information related to investments nor expenditures incurred for long-lived assets given the Company’s investments are recognized using the measurement alternative, and the Company’s long-lived assets are immaterial to the condensed consolidated financial statements.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revenue related to the Company’s reporting segments for the three-month and six-month periods ended June 30, 2023, and June 30, 2022, is as follows:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:37.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Portfolio servicing</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">354,366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">419,422 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">590,057 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">990,328 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Active management</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,024,399 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,979,479 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,994,917 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,285,971 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,378,765 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,398,901 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,584,974 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18,276,299 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information related to the Company’s reporting segments for the three-month and six-month periods ended June 30, 2023 and June 30, 2022 is as follows:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:37.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Portfolio servicing</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(76,705)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">280,303 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(166,128)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">668,752 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Active management</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,482,070 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,452,479 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,288,152 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15,521,472 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total gross profit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,405,365 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,732,782 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,122,024 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,190,224 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(683,841)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,019,498)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,412,845)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,649,498)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General, administrative and other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(577,539)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5,499)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,274,431)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(646,705)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,098)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,098)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2,141)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2,141)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other (expense) income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">121,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(127,455)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(21,651)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(242,247)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(584,075)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(934,001)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Loss on change in fair value of debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,445,229)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(333,879)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2,398,662)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(375,513)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unrealized gain (loss) on investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">672,936 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,039,022)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">798,156 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,054,975)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,184,571)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(120,132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(528,104)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(296,806)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: Net loss attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26,596 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(406,641)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">487,303 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(406,641)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net income attributable to Abacus Life, Inc.</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,750,145 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,679,558 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,835,648 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,515,698 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 2 <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Revenue related to the Company’s reporting segments for the three-month and six-month periods ended June 30, 2023, and June 30, 2022, is as follows:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:37.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Portfolio servicing</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">354,366 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">419,422 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">590,057 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">990,328 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Active management</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,024,399 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,979,479 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,994,917 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,285,971 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total revenue</span></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,378,765 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,398,901 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,584,974 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">18,276,299 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 354366 419422 590057 990328 11024399 7979479 20994917 17285971 11378765 8398901 21584974 18276299 <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Information related to the Company’s reporting segments for the three-month and six-month periods ended June 30, 2023 and June 30, 2022 is as follows:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:37.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Portfolio servicing</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(76,705)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">280,303 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(166,128)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">668,752 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Active management</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,482,070 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,452,479 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,288,152 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">15,521,472 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total gross profit</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,405,365 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,732,782 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,122,024 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,190,224 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sales and marketing</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(683,841)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,019,498)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,412,845)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,649,498)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">General, administrative and other</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(577,539)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(5,499)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,274,431)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(646,705)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Depreciation</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,098)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,098)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2,141)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2,141)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other (expense) income</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">121,601 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(127,455)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(21,651)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(242,247)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Interest expense</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(584,075)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(934,001)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">- </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Loss on change in fair value of debt</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,445,229)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(333,879)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2,398,662)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(375,513)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unrealized gain (loss) on investments</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">672,936 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,039,022)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">798,156 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,054,975)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Provision for income taxes</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(1,184,571)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(120,132)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(528,104)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(296,806)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: Net loss attributable to non-controlling interests</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">26,596 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(406,641)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">487,303 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(406,641)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net income attributable to Abacus Life, Inc.</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,750,145 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,679,558 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,835,648 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,515,698 </span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> -76705 280303 -166128 668752 10482070 7452479 20288152 15521472 10405365 7732782 20122024 16190224 683841 1019498 1412845 1649498 577539 5499 1274431 646705 1098 1098 2141 2141 121601 -127455 -21651 -242247 -584075 0 -934001 0 -1445229 -333879 -2398662 -375513 672936 -1039022 798156 -1054975 1184571 120132 528104 296806 -26596 406641 -487303 406641 6750145 4679558 14835648 11515698 COMMITMENTS AND CONTINGENCIES<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Legal Proceedings</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Occasionally, the Company may be subject to various proceedings such as lawsuits, disputes, or claims. The Company assesses these proceedings as they arise and accrues a liability when losses are probable and reasonably estimable. Although legal proceedings are inherently unpredictable, the Company is currently not aware of any matters that, if determined adversely to the Company, would individually, or taken together, have a material adverse effect on the Company’s business, financial position, results of operations, or cash flows.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Commitment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The Company has entered into a Strategic Services and Expenses Support Agreement (“Expense Support Agreement”) with two commonly owned full-service origination, servicing, and investment Providers in exchange for an option to purchase the outstanding equity ownership of the Providers. Pursuant to the Expense Support Agreement, Abacus Life, Inc. provides financial support and advice for the expenses of the Providers incurred in connection with their life settlement transactions </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">businesses and the Providers are required to hire a life settlement transactions operations employee of an affiliate of Abacus Life, Inc. No later than December 1 of each calendar year, Abacus Life, Inc. provides a budget for the Providers, in which Abacus Life, Inc. commits to extend financial support for all operating expenses up to the budgeted amount. “Operating Expenses” for purposes of the Expense Support Agreement means all annual operating expenses of the Providers incurred in the ordinary course of business, excluding the premiums paid for the Providers insurance coverages that are allocable to the insurance coverage provided to Institutional Life Holdings, LLC, which owns all the outstanding membership interests of the Providers if unrelated to the Providers settlement business. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended June 30, 2023, Abacus Life, Inc. did not incur expenses related to the Expense Support Agreement. For the six months ended June 30, 2023, Abacus Life, Inc. incurred $29,721 of expenses, related to the Expense Support Agreement, which is included in the Other (expense) line of the condensed consolidated statements of operations and comprehensive income and have not been reimbursed by the Providers.</span></div> 2 0 29721 FAIR VALUE MEASUREMENTS<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company determines fair value based on assumptions that market participants would use in pricing an asset or a liability in the principal or most advantageous market. When considering market participant assumptions in fair value measurements, the following fair value hierarchy distinguishes between observable and unobservable inputs, which are categorized in one of the following levels:</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.03pt">Level 1 inputs: Unadjusted quoted prices in active markets for identical assets or liabilities accessible to the reporting entity at the measurement date.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.03pt">Level 2 inputs: Other than quoted prices in Level 1 inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the asset or liability.</span></div><div style="margin-top:10pt;padding-left:45pt;text-indent:-22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:17.03pt">Level 3 inputs: Unobservable inputs for the asset or liability used to measure fair value to the extent that observable inputs are not available, thereby allowing for situations in which there is little, if any, market activity for the asset or liability at the measurement date.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Recurring Fair Value Measurements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy are presented in the tables below.</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:41.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value Hierarchy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Life settlement policies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56,685,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56,685,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Available-for-sale securities, at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,600,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,600,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S&amp;P 500 options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,794,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,794,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total assets held at fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,801,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">59,285,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">61,087,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">66,165,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">66,165,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Private placement warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,438,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,438,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total liabilities held at fair value:</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">68,603,996 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">68,603,996 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:40.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value Hierarchy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Life settlement policies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,809,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,809,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Available-for-sale securities, at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S&amp;P 500 options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">890,829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">890,829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total assets held at fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">890,829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,109,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,000,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,249,653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,249,653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total liabilities held at fair value:</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,249,653 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,249,653 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Life Settlement Policies</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-style:italic;font-weight:700;line-height:120%">—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company separately accounts for each owned life settlement policy using either the fair value method, or investment method (cost, plus premiums paid). The valuation method is chosen upon contract acquisition and is irrevocable.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For policies carried at fair value, the Company utilizes valuation services of a third-party actuarial firm, who values the contracts using Level 3 unobservable inputs, including actuarial assumptions, such as life expectancies and cash flow discount rates. The valuation model is based on a discounted cash flow analysis and is sensitive to changes in the discount rate used. The Company utilized a discount rate of 16% at June 30,2023 and 12% at December 31, 2022, respectively, for policy valuation, which is based on economic and company-specific factors.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Subsequent to the reporting date, the Company sold 3 policies carried at fair value. As of June 30, 2023, the Company valued these 3 policies using the price at the time of sale. Valuing these 3 policies using the takeout price resulted in a decrease in valuation of $231,775 compared to the third-party valuation.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For life settlement policies carried using the investment method, the Company measures these at the cost of the policy plus premiums paid. The policies accounted for using the investment method totaled $9,889,610 at June 30, 2023 and $8,716,111 at December 31, 2022, respectively.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Discount Rate Sensitivity</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Changes in the 16% discount rate on the death benefit and premiums used to estimate the policies issued under LMATT Series 2024 Inc., LMATT Growth Series 2.2024 Inc., LMATT Growth and Income Series 1.2026, Inc., LMA Income Series, LP and LMA Income Series II, LP (“LMATT Policies”) fair value has been analyzed. If the discount rate increased or decreased by 2 percentage points and the other assumptions used to estimate fair value remained the same, the change in estimated fair value as of June 30, 2023, would be as follows:</span></div><div style="margin-top:10pt;padding-left:22.5pt;padding-right:-7.2pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"><tr><td style="width:1.0%"></td><td style="width:65.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.595%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Change in <br/>Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Rate Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">+2%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">53,987,508 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2,698,109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56,685,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-2%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">59,857,879 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,172,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Credit Exposure to Insurance Companies</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The following table provides information about the life insurance issuer concentrations that exceed 10% of total face value or 10% of total fair value of the Company’s life insurance policies as of June 30, 2023: </span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:53.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Carrier</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Percentage of<br/>Face Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Percentage of<br/>Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Carrier<br/>Rating</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">American General Life Insurance Company</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ReliaStar Life Insurance Company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lincoln National Life Insurance Company</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A</span></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table provides a roll forward of the fair value of life insurance policies for the six months-ended June 30, 2023:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"></td><td style="width:84.161%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,809,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Policies purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">58,543,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Realized gain (loss) on matured/sold policies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,898,958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Premiums paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(879,462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unrealized gain(loss) on held policies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,319,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Change in estimated fair value</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,339,084 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Matured/sold policies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(20,885,861)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Premiums paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">879,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value at June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56,685,617 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Long-Term Debt</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—See Note 13. “Long-Term Debt” for background information on the market-indexed debt. The Company has elected the fair value option in accounting for the instruments. Fair value is determined using Level 3 inputs. The valuation methodology is based on the Black-Scholes-Merton option-pricing formula and a discounted cash flow analysis. Inputs to the Black-Scholes-Merton model include (i) the S&amp;P 500 Index price, (ii) S&amp;P 500 Index volatility, (iii) a risk-free rate based on data published by the US Treasury, and (iv) a term assumption based on the contractual term of the LMATT Notes. The discounted cash flow analysis includes a discount rate that is based on the implied discount rate developed by calibrating a valuation model to the purchase price on the initial investment date. The implied discount rate is evaluated for reasonableness by benchmarking it to yields on actively traded comparable securities.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The total change in fair value of the debt resulted in a gain of $1,602,042. This gain is comprised of $90,148, net of tax, which is included within accumulated other comprehensive income and $29,515 net of tax, which is included in equity of noncontrolling interests resulting from risk-adjusted valuation scenarios. The Company recognized a loss of $1,445,229 on the change in fair value of the debt resulting from risk-free valuation scenarios, which is included within Change in fair value of debt within the condensed consolidated statement of operations and comprehensive income for the three months ended June 30, 2023. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The total change in fair value of the debt resulted in a gain of $2,705,918. This gain is comprised of $175,530, net of tax, which is included within accumulated other comprehensive income and $56,446 net of tax, which is included in equity of noncontrolling interests resulting from risk-adjusted valuation scenarios. The Company recognized a loss of $2,398,662 on the change in fair value of the debt resulting from risk-free valuation scenarios, which is included within Change in fair value of debt within the condensed consolidated statement of operations and comprehensive income for the six months ended June 30, 2023. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table provides a roll forward of the fair value of the issued notes for the six months ended June 30, 2023:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:84.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,249,653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Debt issued to third parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35,209,825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unrealized loss on change in fair value (risk-free)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,398,662 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unrealized gain on change in fair value (credit-adjusted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">307,256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Change in estimated fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,705,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value at June 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">66,165,396 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Private Placement Warrants</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Simultaneously with the closing of the Initial Public Offering, ERES consummated the sale of 8,900,000 warrants (the “Private Placement Warrants”) to East Sponsor, LLC (the “Sponsor”), which included the sale of an additional 900,000 Private Placement Warrants in connection with the full exercise by the underwriters of their over-allotment option on August 25, 2020, at a price of $1.00 per Private Placement Warrant, for an aggregate purchase price of $8,900,000. Each Private Placement Warrant is exercisable for one share of Class A common stock at a price of $11.50 per share, subject to adjustment. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Private Placement Warrants are identical to the Public Warrants underlying the Units sold in the Initial Public Offering, except that (x) the Private Placement Warrants and the shares of Class A common stock issuable upon the exercise of the Private Placement Warrants will not be transferable, assignable or </span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">salable until 30 days after the completion of a Business Combination, subject to certain limited exceptions, (y) the Private Placement Warrants will be exercisable on a cashless basis and be non-redeemable so long as they are held by the initial purchasers or their permitted transferees and (z) the Private Placement Warrants and the shares of Class A common stock issuable upon exercise of the Private Placement Warrants will be entitled to registration rights. If the Private Placement Warrants are held by someone other than the initial purchasers or their permitted transferees, the Private Placement Warrants will be redeemable by the Company and exercisable by such holders on the same basis as the Public Warrants.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Private Placement Warrants were accounted for as liabilities in accordance with ASC 815-40. The warrant liabilities are measured at fair value at inception and on a recurring basis, with changes in fair value presented separately in the condensed consolidated statements of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Private Placement Warrants were considered a Level 3 fair value measurement using a binomial lattice model in a risk-neutral framework. The binomial lattice model’s primary unobservable input utilized in determining the fair value of the Private Placement Warrants is the expected volatility of the common stock. The implied volatility as of the reporting date was derived from observable public warrant traded price provided by Bloomberg LP.</span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents the key assumptions in the analysis:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.303%"><tr><td style="width:1.0%"></td><td style="width:68.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Private Placement Warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Expected implied volatility </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">de minimis </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.09%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Term to expiration </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$11.50</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Common Stock Price </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$10.03</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dividend Yield</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Noncurrent Assets: S&amp;P 500 Options</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—In February 2022, LMATT Series 2024, Inc., which the Company consolidates for financial reporting, purchased and sold S&amp;P 500 call and put options through a broker. The Company purchased and sold additional S&amp;P 500 call options through a broker in June 2022 through their 100% owned and fully consolidated subsidiaries LMATT Growth Series 2.2024, Inc. and LMATT Growth and Income Series 1.2026, Inc. The options are exchange traded, and fair value is determined using Level 1 inputs of quoted market prices as of the condensed consolidated balance sheets dates. Changes in fair value are classified as unrealized (gain)/loss on investments within the condensed consolidated statements of operations and comprehensive income.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Instruments Measured at Fair Value on a Nonrecurring Basis</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The following financial assets, composed of equity securities without readily determinable fair values, are adjusted to fair value when observable price changes are identified, or an impairment charge is recognized. Such fair value measurements are based predominantly on Level 3 inputs.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Available-for-Sale Investment</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The Convertible Promissory Note is classified as an available-for-sale security. Available-for-sale investments are subsequently measured at fair value. Unrealized holding gains and losses are excluded from earnings and reported in other comprehensive income until realized. The Company determines fair value of its available-for-sale investments using unobservable inputs by considering the initial investment value, next round financing, and the likelihood of conversion or settlement based on the contractual terms in the agreement. The Company initially purchased a $250,000 convertible promissory note from the issuer in 2021 and then on January 7, 2022, the Company purchased an additional $250,000 convertible promissory note from the same issuer and then an additional $500,000 in October 2022. As of June 30, 2023 and December 31, 2022, the Company </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">evaluated the fair value of its Promissory Note and determined that the fair value approximates the carrying value of $1,000,000 and $1,000,000, respectively.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other Investments</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The Company determines fair value using Level 3 inputs under the measurement alternative. These investments are recorded at cost, minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer. Impairment is assessed qualitatively. As of June 30, 2023, and December 31, 2022, the Company did not identify any impairment indicators and determined that the carrying value of $1,600,000 and $1,300,000 is the fair value for these equity investments in privately held companies, given that there have been no observable price changes.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Financial Instruments Where Carrying Value Approximates Fair Value</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Th</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">e carrying value of cash, cash equivalents, accounts receivables, and due to affiliates approximates fair value due to the short-term nature of their maturities.</span></div> The assets and liabilities measured at estimated fair value on a recurring basis and their corresponding placement in the fair value hierarchy are presented in the tables below.<div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:41.915%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.757%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value Hierarchy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Life settlement policies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56,685,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56,685,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Available-for-sale securities, at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,600,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,600,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S&amp;P 500 options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,794,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,794,640 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,246 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total assets held at fair value</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,801,886 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">59,285,617 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">61,087,503 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Long-term debt</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">66,165,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">66,165,396 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Private placement warrants</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,438,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,438,600 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total liabilities held at fair value:</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">68,603,996 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">68,603,996 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:40.646%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.233%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value Hierarchy</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">As of December 31, 2022</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Level 3</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Total</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Life settlement policies</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,809,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,809,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Available-for-sale securities, at fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,000,000 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Other investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,300,000 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">S&amp;P 500 options</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">890,829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">890,829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total assets held at fair value</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">890,829 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,109,352 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,000,181 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Long-term debt</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,249,653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,249,653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total liabilities held at fair value:</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,249,653 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,249,653 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 0 0 56685617 56685617 0 0 1000000 1000000 0 0 1600000 1600000 1794640 0 0 1794640 7246 0 0 7246 1801886 0 59285617 61087503 0 0 66165396 66165396 0 0 2438600 2438600 0 0 68603996 68603996 0 0 13809352 13809352 0 0 1000000 1000000 0 0 1300000 1300000 890829 0 0 890829 890829 0 16109352 17000181 0 0 28249653 28249653 0 0 28249653 28249653 0.16 0.12 3 3 3 -231775 9889610 8716111 0.16 If the discount rate increased or decreased by 2 percentage points and the other assumptions used to estimate fair value remained the same, the change in estimated fair value as of June 30, 2023, would be as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"><tr><td style="width:1.0%"></td><td style="width:65.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.790%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.595%"></td><td style="width:0.1%"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">As of June 30, 2023</span></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair Value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Change in <br/>Fair Value</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Rate Adjustment</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">+2%</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">53,987,508 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(2,698,109)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">No change</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56,685,617 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">-2%</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">59,857,879 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,172,262 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents the key assumptions in the analysis:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.303%"><tr><td style="width:1.0%"></td><td style="width:68.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:28.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Private Placement Warrants</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Expected implied volatility </span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">de minimis </span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Risk-free interest rate </span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4.09%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Term to expiration </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5.0 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Exercise price</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$11.50</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Common Stock Price </span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$10.03</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Dividend Yield</span></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—%</span></td></tr></table></div> 53987508 -2698109 56685617 59857879 3172262 The following table provides information about the life insurance issuer concentrations that exceed 10% of total face value or 10% of total fair value of the Company’s life insurance policies as of June 30, 2023: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:53.344%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.666%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Carrier</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Percentage of<br/>Face Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Percentage of<br/>Fair Value</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Carrier<br/>Rating</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">American General Life Insurance Company</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11.0 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ReliaStar Life Insurance Company</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.0 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lincoln National Life Insurance Company</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12.0 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">A</span></td></tr></table> 0.140 0.110 0.060 0.120 0.140 0.120 <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table provides a roll forward of the fair value of life insurance policies for the six months-ended June 30, 2023:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.606%"><tr><td style="width:1.0%"></td><td style="width:84.161%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.639%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,809,352 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Policies purchased</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">58,543,580 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Realized gain (loss) on matured/sold policies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,898,958 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Premiums paid</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(879,462)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unrealized gain(loss) on held policies</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,319,588 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Change in estimated fair value</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,339,084 </span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Matured/sold policies</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(20,885,861)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Premiums paid</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">879,462 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value at June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56,685,617 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 13809352 58543580 1898958 879462 3319588 4339084 20885861 879462 56685617 1602042 90148 29515 -1445229 -2705918 175530 56446 -2398662 <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table provides a roll forward of the fair value of the issued notes for the six months ended June 30, 2023:</span></div><div style="margin-top:10pt;padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:84.138%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.662%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value at December 31, 2022</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,249,653 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Debt issued to third parties</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">35,209,825 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unrealized loss on change in fair value (risk-free)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,398,662 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unrealized gain on change in fair value (credit-adjusted)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">307,256 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Change in estimated fair value</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,705,918 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Fair value at June 30, 2023</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">66,165,396 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 28249653 35209825 -2398662 -307256 -2705918 66165396 8900000 900000 1.00 8900000 1 11.50 P30D 0.0409 5 11.50 10.03 0 250000 250000 500000 1000000 1000000 1600000 1300000 LONG-TERM DEBT<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Long-term debt comprises of the following:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:37.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Year Ended<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Market-indexed notes:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMATT Series 2024, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,866,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,621,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,866,900 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,067,291 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMATT Series 2.2024, Inc.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,333,391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,446,527 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,333,391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,354,013 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMATT Growth &amp; Income Series 1.2026, Inc</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">400,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">459,553 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">400,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">400,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Secured borrowing:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMATT Income Series, LP</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,889,444 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22,124,676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,428,349 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,428,349 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMATT Income Series II, LP</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,041,851 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,041,851 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unsecured borrowing:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sponsor PIK Note</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,471,648 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,471,648 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total long-term debt</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">65,003,234 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">66,165,396 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,028,640 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,249,653 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SPV purchase and sale note</span></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,000,000 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,000,000 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:107%">Sponsor PIK Note</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On the June 30, 2023, in connection with the consummation of the Business Combination and as contemplated by the Merger Agreement, East Sponsor, LLC, a Delaware limited liability company (“Sponsor”), made an unsecured loan to the Company in the aggregate amount of $10,471,648 (the “Sponsor PIK Note”). The Sponsor PIK Note matures on June 30, 2028 (the “Maturity Date”) and may be prepaid at any time in accordance with its terms without any premium or penalty.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LMATT Series 2024, Inc. Market-Indexed Notes:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On March 31, 2022, LMATT Series 2024, Inc., which the Company consolidates for financial reporting, issued $10,166,900 in market-indexed private placement notes. The note, titled the Longevity Market Assets Target-Term Series (LMATTS) 2024, is a market-indexed instrument designed to provide upside performance exposure of the S&amp;P 500 Index, while limiting downward exposure. Upon maturity of the note in 2024, the principal, plus the return based upon the S&amp;P 500 Index must be paid. The note has a </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">feature to protect debt holders from market downturns, up to 40%. Any subsequent losses below the 40% threshold will reduce the note on a one-to-one basis. As of June 30, 2023, $9,866,900 of the principal amount remained outstanding.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The notes are held at fair value, which represents the exit price, or anticipated price to transfer the liability to a third party. As of June 30, 2023, the fair value of the LMATT Series 2024, Inc. notes were $9,621,141.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The notes are secured by the assets of the issuing entities, which includes cash, S&amp;P 500 options, and life settlement policies totaling $11,195,701 as of June 30, 2023. The notes’ agreements do not restrict the trading of life settlement contracts prior to maturity of the note, as total assets of the issuing companies are considered as collateral. There are also no restrictive covenants associated with the notes with which the entities must comply.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LMATT Series 2.2024, Inc. Market-Indexed Notes:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On September 16, 2022, LMATTS Series 2.2024, Inc., a 100% owned subsidiary which the Company consolidates for financial reporting issued $2,333,391 in market-indexed private placement notes. The note, titled the Longevity Market Assets Target-Term Growth Series 2.2024, Inc. (“LMATTSTM Series 2.2024, Inc.”) is a market-indexed instrument designed to provide upside performance exposure of the S&amp;P 500 Index, while limiting downward exposure. Upon maturity of the note in 2024, the principal, plus the return based upon the S&amp;P 500 Index must be paid. The note has a feature to provide upside performance participation that is capped at 120% of the performance of the S&amp;P 500. A separate layer of the note has a feature to protect debt holders from market downturns by up to 20% if the index price experiences a loss during the investment period. After the underlying index has decreased in value by more than 20%, the investment will experience all subsequent losses on a one-to-one basis. . As of June 30, 2023, the entire principal amount remained outstanding.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The notes are held at fair value, which represents the exit price, or anticipated price to transfer the liability to a third party. As of June 30, 2023, the fair value of the LMATT Series 2.2024, Inc. notes were $3,446,527.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The notes are secured by the assets of the issuing entity, LMATT Series 2.2024, Inc., which includes cash, S&amp;P 500 options, and life settlement policies totaling $3,331,872 as of June 30, 2023. The note agreements do not restrict the trading of life settlement contracts prior to maturity of the note, as total assets of the issuing company are considered as collateral. There are also no restrictive covenants associated with the note with which the entity must comply.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LMATT Growth and Income Series 1.2026, Inc. Market-Indexed Notes:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Additionally, on September 16, 2022, LMATTS Growth and Income Series 1.2026, Inc., a 100% owned subsidiary which the Company consolidates for financial reporting issued $400,000 in market-indexed private placement notes. The note, titled the Longevity Market Assets Target-Term Growth and Income Series 1.2026, Inc (“LMATTSTM Growth and Income Series 1.2026, Inc.”) is a market-indexed instrument designed to provide upside performance exposure of the S&amp;P 500 Index, while limiting downward exposure. Upon maturity of the note in 2026, the principal, plus the return based upon the S&amp;P 500 Index must be paid. The note has a feature to provide upside performance participation that is capped at 140% of the performance of the S&amp;P 500. A separate layer of the note has a feature to protect debt holders from market downturns by up to 10% if the index price experiences a loss during the investment period. After the underlying index has decreased in value by more than 10%, the investment will experience all subsequent losses on a one-to-one basis. This note also includes 4% dividend feature that will be paid annually. As of June 30, 2023, the entire principal amount remained outstanding.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The notes are held at fair value, which represents the exit price, or anticipated price to transfer the liability to a third party. As of June 30, 2023, the fair value of the LMATT Growth and Income Series 1.2026, Inc., notes were $459,553.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The notes are secured by the assets of the issuing entity, LMATTS Growth and Income Series 1.2026, Inc., which includes cash, S&amp;P 500 options, and life settlement policies totaling $517,218 as of June 30, 2023. The note agreements do not restrict the trading of life settlement contracts prior to maturity of the note, as total assets of the issuing company are considered as collateral. There are also no restrictive covenants associated with the note with which the entity must comply.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">See additional fair value considerations within footnote 12.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LMA Income Series, LP and LMA Income Series, GP LLC Secured Borrowing</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMA Income Series, GP, LLC, wholly owned and controlled by that LMA Series, LLC, formed a limited partnership, LMA Income Series, LP and issued partnership interests to limited partners in a private placement offering. The initial term of the offering is three years with the ability to extend for two additional one-year periods at the discretion of the general partner, LMA Income Series, GP, LLC. The limited partners will receive an annual dividend of 6.5% paid quarterly and 25% of returns in excess of a 6.5% internal rate of return capped at 9% which would require a 15% net internal rate of return. The General Partner will receive 75% of returns in excess of a 6.5% internal rate of return to limited partners then 100% in excess of a 15% net internal rate of return.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series, LP and thus has fully consolidated the limited partnership in its consolidated financial statements for the six months ended June 30, 2023.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The private placement offerings proceeds will be used to acquire an actively managed large and diversified portfolio of financial assets. LMA, through its consolidated subsidiaries, serves as the portfolio manager for the financial asset portfolio, which includes investment sourcing and monitoring. In this role, LMA has the unilateral ability to acquire and dispose of any of the above investments. As the partnership does not represent a business in accordance with ASC 810 and is a consolidated subsidiary that only holds financial assets, this represents a transfer subject to ASC 860-10. As the financial assets are not transferred outside the consolidated group, the proceeds from the offering shall be classified as a liability unless it meets the definition of a participating interest and the derecognition criteria in ASC 860 are met. The transferred interest did not meet the definition of a participating interest as LMA possesses the unilateral ability to direct the sale of the financial assets (ASC 860-10-50-6A(d)). In accordance with ASC 860-30-25-2, as the transfer of the financial assets did not meet the definition of a participating interest, LMA shall recognize the proceeds received from the offering as a secured borrowing. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMA elected to account for the secured borrowing at fair value under the collateralized financing entity guidance within ASC 810-10-30. As of June 30, 2023, the fair value of the secured borrowing was $22,124,676. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">LMA Income Series II, LP and LMA Income Series II, GP LLC Secured Borrowing</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMA Income Series II, GP, LLC, wholly owned and controlled by that LMA Series, LLC, formed a limited partnership, LMA Income Series II, LP and issued partnership interests to limited partners in a private placement offering. The initial term of the offering is three years with the ability to extend for two additional one-year periods at the discretion of the general partner, LMA Income Series II, GP, LLC. The limited partners will receive annual dividends equal to the Preferred Return Amounts as follows: Capital commitment less than $500,000, 7.5%; between $500,000 and $1,000,000, 7.75%; over $1,000,000, 8%. Thereafter, 100% of the excess to be paid to the General Partner. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">It was determined that LMA Series, LLC is the primary beneficiary of LMA Income Series, LP and thus has fully consolidated the limited partnership in its consolidated financial statements for the three and six months ended June 30, 2023.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The private placement offerings proceeds will be used to acquire an actively managed large and diversified portfolio of financial assets. LMA, through its consolidated subsidiaries, serves as the portfolio manager for the financial asset portfolio, which includes investment sourcing and monitoring. In this role, LMA has the unilateral ability to acquire and dispose of any of the above investments. As the partnership does not represent a business in accordance with ASC 810 and is a consolidated subsidiary that only holds financial assets, this represents a transfer subject to ASC 860-10. As the financial assets are not transferred outside the consolidated group, the proceeds from the offering shall be classified as a liability unless it meets the definition of a participating interest and the derecognition criteria in ASC 860 are met. The transferred interest did not meet the definition of a participating interest as LMA possesses the unilateral ability to direct the sale of the financial assets (ASC 860-10-50-6A(d)). In accordance with ASC 860-30-25-2, as the transfer of the financial assets did not meet the definition of a participating interest, LMA shall recognize the proceeds received from the offering as a secured borrowing. </span></div><div style="margin-top:10pt;padding-left:21.6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMA elected to account for the secured borrowing at fair value under the collateralized financing entity guidance within ASC 810-10-30. As of June 30, 2023, the fair value of the secured borrowing was $20,041,851. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">SPV Purchase and Sale</span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On July 5, 2023, the Company entered into an Asset Purchase Agreement (the “Policy APA”) to acquire certain insurance policies with an aggregate fair market value of $10.0 million from Abacus Investment SPV, LLC, a Delaware limited liability company (“SPV”), in exchange for a payable obligation owing by the Company to the SPV (such acquisition transaction under the Policy APA, the “SPV Purchase and Sale”).</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The payable obligation owing by the Company to the SPV in connection with the SPV Purchase and Sale is evidenced by a note issued by the Company under the SPV Investment Facility (the “SPV Purchase and Sale Note”) in an original principal amount equal to the aggregate fair market value of the acquired insurance policies. The SPV Purchase and Sale Note has the same material terms and conditions as the other credit extensions under the SPV Investment Facility (as defined below).</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:112%">SPV Investment Facility</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">On July 5, 2023, the Company entered into that certain SPV Investment Facility (the “SPV Investment Facility”), between the Company, as borrower, and the SPV, as lender.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">The SPV Investment Facility, among other things:</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">requires certain subsidiaries of the Company to guarantee the credit extensions provided under the SPV Investment Facility pursuant to separate documentation</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">is unsecured without collateral security provided in favor of the SPV and subordinated in right of payment to the Company’s obligations under the Owl Rock Credit Facility, subject to limited specified exceptions and circumstances for permitting early payment;</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">provides for certain credit extensions in an aggregate principal amount of $25.0 million, including: (i) an initial credit extension in an original principal amount of $15.0 million that was funded upon the closing of the SPV Investment Facility, and (ii) the SPV Purchase and Sale Note in favor of the SPV in an original principal amount of $10.0 million to finance the purchase of the insurance policies under the Policy APA;</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">provides proceeds from the SPV Investment Facility for payment of certain transaction expenses, general corporate purposes and any other purposes not prohibited by the agreement or applicable law;</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">matures on July 5, 2026, three years after the closing of the SPV Investment Facility, subject to two automatic extensions of one year each without any amendment of the relevant documentation, but also subject to applicable subordination restrictions in relation to the Owl Rock Credit Facility;</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">provides for interest to accrue on the SPV Investment Facility at a rate of 12.00% per annum, payable quarterly, all of which is to be paid in-kind by the Company by increasing the principal amount of the SPV Investment Facility owing to the SPV on each interest payment date;</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">provides a default rate that will accrue at 2.00% per annum (subject to applicable subordination restrictions) over the rate otherwise applicable. If cash payment is not permitted due to applicable subordination restrictions or otherwise, such default interest shall be paid in-kind;</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">provides that no amortization payments shall be required prior to maturity;</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">contains financial and other covenants substantially similar and not materially worse than those contained in the Owl Rock Credit Facility from the perspective of the Company; and</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%;padding-left:12.53pt">provides for certain specified events of default (including certain events of default subject to grace or cure periods), with the occurrence and during the continuance of such events of default enabling the lender under the SPV Investment Facility to accelerate the obligations under the SPV Investment Facility, among other rights or remedies, subject to applicable subordination restrictions.</span></div>The SPV’s investment resulting from credit extensions under the SPV Investment Facility is treated by the Company as debt for U.S. GAAP accounting purposes. While the timing of the Policy APA and SPV Investment Facility occurred on July 5, 2023, such amounts are included within the condensed consolidated balance sheet as cash was received prior to June 30, 2023. <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Long-term debt comprises of the following:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:37.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Year Ended<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair value</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Fair value</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Market-indexed notes:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMATT Series 2024, Inc.</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,866,900 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,621,141 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">9,866,900 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,067,291 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMATT Series 2.2024, Inc.</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,333,391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,446,527 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,333,391 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,354,013 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMATT Growth &amp; Income Series 1.2026, Inc</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">400,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">459,553 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">400,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">400,000 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Secured borrowing:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMATT Income Series, LP</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">21,889,444 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">22,124,676 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,428,349 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">17,428,349 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">LMATT Income Series II, LP</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,041,851 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,041,851 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Unsecured borrowing:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Sponsor PIK Note</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,471,648 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">10,471,648 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total long-term debt</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">65,003,234 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">66,165,396 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">30,028,640 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">28,249,653 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">SPV purchase and sale note</span></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,000,000 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,000,000 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 9866900 9621141 9866900 8067291 2333391 3446527 2333391 2354013 400000 459553 400000 400000 21889444 22124676 17428349 17428349 20041851 20041851 0 0 10471648 10471648 0 0 65003234 66165396 30028640 28249653 25000000 25000000 0 0 10471648 10166900 0.40 0.40 1 9866900 9621141 11195701 1 2333391 1.20 0.20 0.20 1 3446527 3331872 1 400000 1.40 0.10 0.10 1 0.04 459553 517218 P3Y 2 P1Y 0.065 0.25 0.065 0.09 0.15 0.75 0.065 1 0.15 22124676 P3Y 2 P1Y 500000 0.075 500000 1000000 0.0775 1000000 0.08 1 20041851 10000000 25000000 15000000 10000000 P3Y 2 P1Y 0.1200 0.0200 SHAREHOLDERS’ EQUITY<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is authorized to issue up to 200,000,000 shares of common stock, par value $0.0001 per share, and 1,000,000 shares of preferred stock, par value $0.0001 per share. No shares of preferred stock are issued or outstanding. Holders of the Company’s common stock are entitled to one vote for each share. As of June 30, 2023, there were 62,961,688 shares of common stock issued and outstanding. Holders of shares were entitled to receive, in the event of a liquidation, dissolution or winding up, ratably the assets available for distribution to the shareholders after payment of all liabilities.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The equity structure has been recast in all comparative periods up to the Closing Date to reflect the number of shares of the Company’s common stock, $0.0001 par value per share, issued to legacy LMA’s stockholders in connection with the Business Combination. As such, the shares and corresponding capital amounts and earnings per share related to legacy LMA common stock prior to the Business Combination have been retroactively recast as shares reflecting the exchange ratio of 0.8 established in the Business Combination. As of December 31, 2022, this resulted in 50,369,350 shares of common stock issued and outstanding.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Public Warrants</span></div><div><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2023, the Company has 17,250,000 Public Warrants outstanding. Each redeemable whole Public Warrant entitles the holder thereof to purchase one share of common stock at a price of $11.50 per full share, subject to adjustment as described. The Public Warrants represent a freestanding financial instrument as it is traded on the Nasdaq under the symbol “ABLLW” and legally detachable and separately exercisable from the related underlying shares of the Company’s common stock. Public Warrants may only be exercised for a whole number of shares. No fractional shares will be issued upon exercise of the Public Warrants. The Public Warrants will become exercisable on the later of (a) 30 days after the completion of a Business Combination and (b) 12 months from the closing of the Proposed </span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Offering. The Public Warrants will expire five years from the completion of a Business Combination, at 5:00 p.m., New York City time, or earlier upon redemption or liquidation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company will not be obligated to deliver any shares of Class A common stock pursuant to the exercise of a Public Warrant and will have no obligation to settle such Public Warrant exercise unless a registration statement under the Securities Act with respect to the shares of Class A common stock underlying the warrants is then effective and a prospectus relating thereto is current, subject to the Company satisfying its obligations with respect to registration, or a valid exemption from registration is available. No warrant will be exercisable and the Company will not be obligated to issue a share of Class A common stock upon exercise of a warrant unless the share of Class A common stock issuable upon such warrant exercise has been registered, qualified or deemed to be exempt under the securities laws of the state of residence of the registered holder of the warrants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Redemption of Warrants for Cash - Once the warrants become exercisable, the Company may redeem the outstanding Public Warrants for cash:</span></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">in whole and not in part;</span></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">at a price of $0.01 per Public Warrant;</span></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">upon not less than 30 days’ prior written notice of redemption to each warrant holder; and</span></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">if, and only if, the last sale price of the Class A common stock equals or exceeds $18.00 per share (as adjusted for stock splits, stock dividends, reorganizations, recapitalizations and the like) for any 20 trading days within a 30-trading day period ending on the third trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.</span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If and when the Public warrants become redeemable by the Company, the Company may exercise its redemption right even if it is unable to register or qualify the underlying securities for sale under all applicable state securities laws. However, the Company will not redeem the warrants unless an effective registration statement under the Securities Act covering the shares of Class A common stock issuable upon exercise of the warrants is effective and a current prospectus relating to those shares of Class A common stock is available throughout the 30-day redemption period, except if the warrants may be exercised on a cashless basis and such cashless exercise is exempt from registration under the Securities Act.</span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Redemption of Warrants for Shares of Class A Common Stock - Once the Public warrants become exercisable, the Company may redeem the outstanding warrants for shares of Class A common stock:</span></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">in whole and not in part;</span></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">at a price equal to a number of shares of Class A common stock to be determined by reference to the agreed table set forth in the warrant agreement based on the redemption date and the “fair market value” of the Class A common stock;</span></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">upon not less than 30 days’ prior written notice of redemption to each warrant holder; and</span></div><div style="padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">if, and only if, the last sale price of the Class A common stock equals or exceeds $10.00 per share (as adjusted per share splits, share dividends, reorganizations, recapitalizations and the like) on the trading day prior to the date on which the Company sends the notice of redemption to the warrant holders.</span></div><div style="padding-left:22.5pt;text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition, if (x) the Company issues additional shares of common stock or equity-linked securities for capital raising purposes in connection with the closing of the Company’s initial Business Combination at an issue price or effective issue price of less than $9.20 per share (with such issue price or effective issue price to be determined in good faith by our board of directors), (y) the volume weighted average trading price of the Company’s common stock during the 20 trading day period starting on the trading day prior to the day on which the Company consummates its initial Business Combination (such price, the “Market Price”) is below $9.20 per share, the exercise price of the warrants will be adjusted (to the nearest cent) to be equal to 115% of the higher of Market Price and the newly issued price. Further, the $10.00 and </span></div><div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$18.00 per share redemption trigger prices will be adjusted to be equal to 100% and 180%, respectively, of the higher of the market value and the newly issued price.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the Company elects to redeem all of the Public Warrants or the common stock is at the time of any exercise of a Public Warrant not listed on a national securities exchange, management has the option to require all holders that wish to exercise the Public Warrants to do so on a “cashless basis,” as described in the warrant agreement. In such event, each holder would pay the exercise price by surrendering the whole warrants for that number of shares of common stock equal to the quotient obtained by dividing (x) the product of the number of shares of common stock underlying the warrants, multiplied by the difference between the exercise price of the warrants and the “fair market value” (defined below) by (y) the fair market value. The “fair market value” shall mean the average reported last sale price of the common stock for the 10 trading days ending on the third trading day prior to the date on which the notice of redemption is sent to the holders of warrants. However, in no instance can the warrant holder unilaterally decide to exercise its Public Warrant on a cashless basis.</span></div><div style="padding-left:22.5pt"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Upon the Business Combination, the Company accounted for the Public Warrants issued with the IPO as equity instruments. The Company accounted for the warrant as an expense of the IPO resulting in a charge directly to stockholders’ equity. The Company estimates that the fair value of the warrants upon the Business Combination is approximately $4.73 million, or $0.274 per Public Warrant, using the binomial lattice model. The fair value of the warrants is estimated as of the date of grant using the following assumptions: (1) risk-free interest rate of 4.09%, (2) term to expiration of 5.0 years, (3) exercise price of $11.50 and (4) stock price of $10.03.</span></div> 200000000 0.0001 1000000 0.0001 0 0 1 62961688 62961688 0.0001 0.8 50369350 17250000 1 11.50 P30D P12M P5Y 0.01 P30D 18.00 P20D P30D P30D P30D 10.00 9.20 P20D 9.20 1.15 10.00 18.00 1 1.80 4730000 0.274 0.0409 P5Y 11.50 10.03 EMPLOYEE BENEFIT PLANThe Company has a defined contribution plan in the U.S. intended to qualify under Section 401(k) of the Internal Revenue Code (the “401(k) Plan”). The 401(k) Plan covers substantially all employees who meet minimum age and service requirements and allows participants to defer up to 100% of their annual compensation on a pretax basis. For the year ended December 31, 2022, the Company elected to match 50% of employee contributions up to a maximum of 4% of eligible employee compensation. For the three months ended June 30, 2023 and 2022, the Company recognized expenses related to the 401(k) Plan amounting to $13,075 and $2,577, respectively and for the six months ended June 30, 2023 and 2022, the Company recognized expenses related to the 401(k) Plan amounting to $25,315 and $8,048, respectively. 1 0.50 0.04 13075 2577 25315 8048 INCOME TAXES<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Before June 30, 2023, the Company elected to file as an S corporation for Federal and state income tax purposes, the Company incurred no Federal or state income taxes, except for income taxes recorded related to some of their consolidated variable interest entities and subsidiaries which are taxable C corporations. These VIE’s and subsidiaries include LMATT Series 2024, Inc., the wholly owned subsidiary of LMX, which is consolidated into LMA as a VIE, as well as LMATT Growth Series 2.2024, Inc., a wholly owned subsidiary of LMATT Growth Series, Inc., and LMATTS Growth and Income Series 1.2026, Inc., a wholly owned subsidiary of LMATT Growth and Income Series, Inc., all of which are 100% owned subsidiaries and fully consolidated. Accordingly, the provision for income taxes was attributable to amounts for LMATT Series 2024, Inc, LMATT Growth Series, Inc. and LMATT Growth and Income Series, Inc.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended June 30, 2023 and 2022, the Company recorded provision for income taxes of $1,184,571 and $120,132, respectively. The effective tax rate is 15.0% for the three months ended June 30, 2023. The effective rate for the three months ended June 30, 2022 was 12.0% due to the impact of state income taxes and the release of the Company’s valuation allowance, as there was sufficient evidence of the Company’s ability to generate future taxable income at June 30, 2022.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the six months ended June 30, 2023 and 2022, the Company recorded provision for income taxes of $528,104 and $296,806, respectively. The effective tax rate is 3.6% for the six months ended June 30, 2023. The existence of non-taxable flow-through entities within the Company as well as a change in tax status of certain entities upon the Business Combination caused the effective tax rate to be significantly lower than the statutory rate. The effective rate for the six months ended June 30, 2022 was 18% due to the impact of state income taxes and the release of the Company’s valuation allowance, as there was sufficient evidence of the Company’s ability to generate future taxable income at June 30, 2022. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company did not have any unrecognized tax benefits relating to uncertain tax positions as of June 30, 2023, and December 31, 2022, and did not recognize any interest or penalties related to uncertain tax positions as of June 30, 2023, and December 31, 2022.</span></div> 1184571 120132 0.150 0.120 528104 296806 0.036 0.18 RELATED-PARTY TRANSACTIONS<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">As of June 30, 2023 and December 31, 2022, $10,415,154 and $263,785, respectively, were due to members and affiliates primarily for reimbursable transaction costs as well as distributions to owners of $717,429 as a part of the Business Combination as of June 30, 2023. As of June 30, 2023 and December 31, 2022, $10,473,748 and $2,904,646 was due from affiliates, respectively. The amount to be received as of June 30, 2023 is due from the Sponsor as part of the Sponsor PIK Note. Additionally, the SPV purchase and sale note for $25,000,000 as of June 30, 2023 was also recorded as a related party transaction given the transfer of cash and policies between the Company and the SPV. Refer to footnote 13 for more information.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company has a related-party relationship with Nova Trading (US), LLC (“Nova Trading”), a Delaware limited liability company and Nova Holding (US) LP, a Delaware limited partnership (“Nova Holding” and collectively with Nova Trading, the “Nova Funds”). The Company also earns service revenue related to policy and administrative services on behalf of Nova Funds. The servicing fee is equal to 50 basis points (0.50%) times the monthly invested amount in policies held by Nova Funds divided by 12. The Company earned $197,629 and $205,224, respectively, in service revenue related to Nova Funds for the three months ended June 30, 2023 and 2022 and earned $411,076 and $406,129, respectively, in service revenue related to Nova Funds for the six months ended June 30, 2023 and 2022.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Prior to the Merger, LMA used Abacus to originate life settlement policies that it accounts for under the investment method. For the three and six months ended June 30, 2023, the Company incurred $837,975 and $1,627,975, respectively in origination costs for life settlement policies that were originated by Abacus. These costs are capitalized on the condensed consolidated balance sheets as life settlement policies, at cost.</span></div>As of June 30, 2023, and December 31, 2022, there were $72,600 and $196,289, respectively owed from the Nova Funds, which are included as related-party receivables in the accompanying condensed consolidated balance sheets. 10415154 263785 717429 10473748 2904646 25000000 0.0050 0.0050 197629 205224 411076 406129 837975 1627975 72600 196289 LEASES<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company’s right-of-use assets and lease liabilities for its operating lease consisted of the following amounts as of June 30, 2023 and December 31, 2022: </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:56.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Year Ended<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">240,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">77,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:56.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease liability, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">227,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">48,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease liability, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29,268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">244,425 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">77,395 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company recognizes lease expense for its operating leases within general, administrative, and other expenses on the Company’s condensed consolidated statements of operations and comprehensive income. The Company’s lease expense for the periods presented consisted of the following:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:37.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,921 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24,942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,533 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33,867 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,065 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table shows supplemental cash flow information related to lease activities for the periods presented:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:70.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash paid for amounts included in the measurement of the lease liability</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24,557 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for new lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The table below shows a weighted-average analysis for lease terms and discount rates for all operating leases for the periods presented:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:57.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Year Ended December 31, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.58</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.54 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.36 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr></table></div><div style="margin-top:10pt;padding-left:21.6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum noncancellable lease payments under the Company’s operating leases on an undiscounted basis reconciled to the respective lease liability at June 30, 2023 are as follows:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:79.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Operating leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Remaining of 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">130,176 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">118,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total operating lease payments (undiscounted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">248,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3,808)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lease liability as of June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">244,425 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company’s right-of-use assets and lease liabilities for its operating lease consisted of the following amounts as of June 30, 2023 and December 31, 2022: </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:56.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Year Ended<br/>December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Assets:</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease right-of-use assets</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">240,816 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">77,011 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr></table></div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:56.201%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.011%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.854%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease liability, current</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">227,561 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">48,127 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease liability, non-current</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">16,864 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">29,268 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 31pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease liability</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">244,425 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">77,395 </span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The table below shows a weighted-average analysis for lease terms and discount rates for all operating leases for the periods presented:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:57.630%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:19.058%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.069%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.743%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Year Ended December 31, 2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average remaining lease term (in years)</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.00</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1.58</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average discount rate</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.54 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3.36 </span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">%</span></td></tr></table></div> 240816 77011 227561 48127 16864 29268 244425 77395 The Company’s lease expense for the periods presented consisted of the following:<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:37.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating lease cost</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,471 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,921 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24,942 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Variable lease cost</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,704 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">612 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,925 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,223 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total lease cost</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">20,175 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">12,533 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">33,867 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,065 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table shows supplemental cash flow information related to lease activities for the periods presented:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:70.169%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.550%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.704%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.077%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Cash paid for amounts included in the measurement of the lease liability</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Operating cash flows from operating leases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">24,557 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">23,842 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">ROU assets obtained in exchange for new lease liabilities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr></table></div> 12471 11921 24942 23842 7704 612 8925 1223 20175 12533 33867 25065 24557 23842 0 0 P1Y P1Y6M29D 0.0354 0.0336 <div style="margin-top:10pt;padding-left:21.6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Future minimum noncancellable lease payments under the Company’s operating leases on an undiscounted basis reconciled to the respective lease liability at June 30, 2023 are as follows:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:79.376%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.424%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Operating leases</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Remaining of 2023</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">130,176 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2024</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">118,057 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2025</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2026</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2027</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Thereafter</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">— </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total operating lease payments (undiscounted)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">248,233 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Less: Imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">(3,808)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Lease liability as of June 30, 2023</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">244,425 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 130176 118057 0 0 0 0 248233 3808 244425 EARNINGS PER SHARE <div style="text-indent:-4.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Basic earnings per share represents income available to ordinary shareholders divided by the weighted average number of ordinary shares outstanding during the reported period. Net income per ordinary share is computed by dividing net income by the weighted-average number of ordinary shares outstanding during the period. The Company has not considered the effect of the Public and Private Placement Warrants to purchase an aggregate of 26,150,000 shares in the calculation of diluted income per ordinary share, since the average market price of the Company’s Class A common shares for the three and six months ended June 30, 2023 was below the warrants’ $11.50 exercise price. As a result, diluted income per share is the same as basic net income per share for the period presented.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Basic and diluted weighted average shares outstanding and earnings per share were as follows:</span></div><div style="padding-left:22.5pt"><span><br/></span></div><div style="padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:36.360%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net income attributable to Longevity Market Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,750,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,679,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,835,648 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,515,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average shares used in computing net income per share, basic and diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50,507,728 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50,369,350 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50,438,921 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50,369,350 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Basic and diluted earnings per share:</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.09 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.23 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 26150000 26150000 11.50 <div style="padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Basic and diluted weighted average shares outstanding and earnings per share were as follows:</span></div><div style="padding-left:22.5pt"><span><br/></span></div><div style="padding-left:22.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:36.360%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.911%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.979%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.503%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.142%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">June 30, 2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">June 30, 2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">June 30, 2022</span></td></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Net income attributable to Longevity Market Assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,750,145 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,679,558 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">14,835,648 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,515,698 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Weighted-average shares used in computing net income per share, basic and diluted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50,507,728 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50,369,350 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50,438,921 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50,369,350 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:11pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Basic and diluted earnings per share:</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.13 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.09 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.29 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0.23 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> 6750145 4679558 14835648 11515698 50507728 50507728 50369350 50369350 50438921 50438921 50369350 50369350 0.13 0.13 0.09 0.09 0.29 0.29 0.23 0.23 SUBSEQUENT EVENTS<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company evaluated subsequent events and transactions from the condensed consolidated balance sheet date through the date at which the condensed consolidated financial statements were issued. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Owl Rock Credit Facility</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">On July 5, 2023 (the “Owl Rock Closing Date”), the Company entered into that certain Credit Agreement (the “Owl Rock Credit Facility”), among the Company, as borrower, the several banks and other persons from time to time party thereto (the “Owl Rock Lenders”), and Owl Rock Capital Corporation, as administrative and collateral agent for the Owl Rock Lenders thereunder.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Owl Rock Credit Facility, among other things:</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">requires the Company and certain subsidiaries of the Company to guarantee the loans provided under the Owl Rock Credit Facility pursuant to separate loan documentation;</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">provides credit extensions for (i) an initial term loan in an aggregate principal amount of $25.0 million upon the closing of the Owl Rock Credit Facility and (ii) optional delayed draw term loans (which can be drawn on multiple drawing dates) in an aggregate principal amount of up to $25.0 million available for one hundred eighty (180) days after the Owl Rock Closing Date (the “Delayed Draw Term Loan Availability Period”), subject to the requirement that on each delayed draw date, the liquid asset coverage ratio shall not be less than 1.80 to 1.00, together with other specified conditions to drawings, the proceeds of which may be used for working capital and the business requirements of the enterprise, and to fund acquisitions, investments and other transactions permitted by the loan documentation;</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%;padding-left:12.53pt">provides a delayed draw commitment fee rate of 0.50% per annum applicable to undrawn commitments during the Delayed Draw Term Loan Availability Period</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">matures on July 5, 2028, the date that is five years after the closing of the Owl Rock Credit Facility; </span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">is secured by a first-priority security interest in substantially all of the assets of the Company and the subsidiary guarantors. No pledge of any equity interests in the Company is required by any holder of such equity interests; </span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">provides for interest to accrue on the loans drawn under the Owl Rock Credit Facility at the election of the Company, by reference to either (i) an alternative base rate (such loans, “ABR Loans”) or (ii) an adjusted term SOFR rate (such loans, “SOFR Loans”) plus an applicable margin. The adjusted term SOFR rate is determined by the applicable term SOFR for a relevant interest period plus a credit spread adjustment of 0.10%, 0.15% and 0.25% per annum for interest periods of <span style="-sec-ix-hidden:f-1137">one</span>, <span style="-sec-ix-hidden:f-1138">three</span> and six months, respectively. The applicable margin for each type of loan is (i) 6.25% per annum for any ABR Loans and (ii) 7.25% per annum for any SOFR Loans, with interest periods for SOFR Loans of <span style="-sec-ix-hidden:f-1142">one</span>, <span style="-sec-ix-hidden:f-1143">three</span> or six months (or other periods if agreed by all lenders); </span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">provides a default rate that will accrue at 2.00% per annum over the rate otherwise applicable; </span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">provides for amortization payments based on the initial principal amount of the loans outstanding of 1.0% per year (0.25% due per quarter), with adjustments made to the overall amortization amount upon the incurrence of any delayed draw loans; </span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">contains provisions requiring mandatory prepayment of the initial term loans and delayed draw term loans with 100% of the proceeds of (a) indebtedness not permitted by the Owl Rock Credit Facility and (b) certain specified asset dispositions and payments (including in respect of settlements) in respect of property, casualty insurance claims or condemnation proceedings, with the proceeds received under this clause (b) subject to certain specified reinvestment rights and procedures set forth in the Owl Rock Credit Facility. The Owl Rock Credit Facility permits voluntary prepayments of outstanding loans at any time; </span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">provides for a prepayment premium equal to (a) 4.00% of the principal amount of such loans prepaid on or prior to the first anniversary of the closing of the Owl Rock Credit Facility, (b) 3.00% of the principal amount of such loans prepaid after the first anniversary of the closing of the Owl Rock Credit Facility but on or prior to the second anniversary of the closing of the Owl Rock Credit Facility and (c) 2.00% of the principal amount of such loans prepaid after the second anniversary of the closing of the Owl Rock Credit Facility but on or prior to the third anniversary of the closing of the Owl Rock Credit Facility. No prepayment premium will be applicable for any such prepayment made after the third anniversary of the closing of the Owl Rock Credit Facility. The prepayment premium is applicable to voluntary prepayments and certain specified mandatory prepayment during such applicable periods; </span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">provides for financial covenants such that (i) a consolidated net leverage ratio cannot exceed 2.50 to 1.00 as of the last day of any fiscal quarter and (ii) a liquid asset coverage ratio cannot be less than 1.80 to 1.00;</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">contains affirmative covenants related to, among other things, delivery of certain financial reports and compliance certificates, maintenance of existence, compliance with laws, material contracts, payment of taxes, property and insurance matters, inspection of property, books and records, notices, collateral matters and future subsidiaries, in each case, subject to specified limitations and exceptions;</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">contains an affirmative representation and corresponding covenant that the Company and certain subsidiaries of the Company do not, and will not during the term of the Owl Rock Facility (or if the term of the Owl Rock Credit Facility continues for longer than a year, during the Company’s and certain subsidiaries of the Company’s most recent fiscal year), derive more than fifteen percent (15%) of their aggregate gross revenues from securities related activities;</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">contains negative covenants related to, among other things, incurrence of debt, creation of liens, mergers, acquisitions and certain other fundamental changes, conditions concerning the creation of new subsidiaries, conditions concerning opening of new accounts, disposition of assets, dividends and other restricted payments, prepayment of certain indebtedness, transactions with </span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">affiliates, investments and limitations on lines of business, in each case, subject to specified limitations and exceptions; and</span></div><div style="margin-top:10pt;padding-left:58.5pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%">•</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:107%;padding-left:12.53pt">provides for certain specified events of default upon the occurrence and during the continuation of certain events or conditions (subject to specified exceptions, grace periods or cure rights, as applicable) each as set forth in the Owl Rock Credit Facility, which includes among other things, defaults with respect to nonpayment, breaches of representations and warranties, failure to comply with covenants, cross-default to other material indebtedness, bankruptcy and insolvency matters, ERISA matters, material judgments, collateral and perfection matters, the occurrence of a change of control and subordination matters with respect to certain specified indebtedness. The occurrence and continuance of an event of default that is not cured or waived will enable the agent and/or the lenders, as applicable, to accelerate the loans or take other remedial steps as provided in the Owl Rock Credit Facility and the other loan documents.</span></div> 25000000 25000000 P180D 1.80 0.0050 P5Y 0.0010 0.0015 0.0025 P6M 0.0625 0.0725 P6M 0.0200 0.010 0.0025 1 0.0400 0.0300 0.0200 2.50 1.80 0.15 1689088 743388 3252738 3185068 5195602 4948528 9931938 9829596 6884690 5691916 13184676 13014664 1505333 956625 2734949 3265313 3392647 2615307 6558354 5522312 4897980 3571932 9293303 8787625 1986710 2119984 3891373 4227039 2297577 2208051 4848580 3948358 2561 3048 5597 5988 2300138 2211099 4854177 3954346 -313428 -91115 -962804 272693 1193 599 1917 1147 5863 0 11725 0 0 273 0 273 -4670 872 -9808 1420 -318098 -90243 -972612 274113 0 0 2289 1325 -318098 -90243 -974901 272788 400 400 400 400 400 400 400 400 -795.25 -225.61 -2437.25 681.97 -795.25 -225.61 -2437.25 681.97 400 4000 80000 1270334 1354334 -318098 -318098 442283 442283 400 4000 80000 509953 593953 400 4000 80000 1927137 2011137 -974901 -974901 442283 442283 400 4000 80000 509953 593953 400 4000 80000 2638995 2722995 272788 272788 659869 659869 400 4000 80000 2251914 2335914 400 4000 80000 1927137 2011137 -974901 -974901 442283 442283 400 4000 80000 509953 593953 -974901 272788 19157 10751 40278 37952 11725 0 1210 0 -397039 0 -101203 202491 198643 -71038 26211 20111 0 -656250 -17466 155994 659067 -1427291 -36750 -7247 -24292 -452367 108394 32212 0 15000 74134 -11525 -182528 -35687 1411 11857 442283 659869 -443694 -671726 -650514 -1159780 1458740 2599302 808226 1439522 DESCRIPTION OF THE BUSINESS<div style="padding-left:22.5pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:112%">Abacus Settlements, LLC d/b/a Abacus Life (the “Company”) was formed in 2004 in the state of New York. In 2016, the Company obtained its licensure in Florida and re-domesticated to that state. On June 13, 2023, the Company re-domesticated to Delaware.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company acts as a purchaser of outstanding life insurance policies (“Provider”) on behalf of investors (“Financing Entities”) by locating policies and screening them for eligibility for a life settlement, including verifying that the policy is in force, obtaining consents and disclosures, and submitting cases for life expectancy estimates, also known as origination services. When the sale of a policy is completed, this is deemed “settled” and the policy is then referred to as either a “life settlement” in which the insured’s life expectancy is greater than two years or “viatical settlement,” in which the insured’s life expectancy is less than two years.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company is not an insurance company, and therefore the Company does not underwrite insurable risks for its own account. On August 30, 2022, the Company entered into an Agreement and Plan of Merger (the “Merger Agreement”) with East Resources Acquisition Company (“ERES”), which was subsequently amended on October 14, 2022. As part of the Merger Agreement, the holders of the Company’s common units together with the holders of Longevity Markets Assets, LLC (“LMA”), a commonly owned affiliate, will receive aggregate consideration of approximately $531,750,000, payable in a number of newly issued shares of ERES Class A common stock, par value $0.0001 per share (“ERES Class A common stock”), with a value ascribed to each share of ERES Class A common stock of $10.00 and, to the extent the aggregate transaction proceeds exceed $200.0 million, at the election of the Company’s and LMA’s members, up to $20.0 million of the aggregate consideration will be payable in cash to the Company’s and LMA’s members. The transaction closed on June 30, 2023 upon shareholder approval and customary closing conditions.</span></div> 531750000 0.0001 10.00 200000000 20000000 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The condensed balance sheet as of June 30, 2023, was derived from amounts included in the Company’s annual financial statements for the year ended December 31, 2022. Such amounts are included within the condensed consolidated financial statements of Abacus Life, Inc. Capitalized terms used herein without definition have the meanings ascribed to them in the Company’s financial statements for the year ended December 31, 2022. Refer to this note in the annual financial statements for the full list of the Company’s significant accounting policies. The details in those notes have not changed except as discussed below and as a result of normal adjustments in the interim periods.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The accompanying condensed financial statements are presented in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unaudited Condensed Financial Statements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2023, and the condensed results of its operations and comprehensive income/(loss) and cash flows for the three and six months ended June 30, 2023 and 2022. The condensed results of operations and comprehensive income/(loss) and cash flows for the period January 1, 2023 to June 30, 2023, are not necessarily indicative of the results to be expected for the full year ending December 31, 2023, or any other period.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The preparation of US GAAP financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, and disclosure of contingent assets and liabilities at the date of financial statements and the reports amounts of revenue and expenses during the reporting periods. Company’s estimates, judgments, and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from the estimates. Estimates are used when accounting for revenue recognition and related costs, the selection of useful lives of property and equipment, impairment testing, valuation of other receivables from clients, income taxes, and legal reserves.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Going Concern</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Management evaluates at each annual and interim period whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Management’s evaluation is based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued. Management has concluded that there are no conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date these financial statements were issued.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other receivables</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Other receivables include origination fees for policies in which the recission period has ended, but the funds have not been received yet from financing entities. These fees were collected in the subsequent month. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company provides an allowance for credit losses equal to the estimated collection losses that will be incurred in collection of all receivables. Management determines the allowance for credit losses based on a review of outstanding receivables, historical collection experience, current economic conditions, and reasonable and supportable forecasts. Account balances are charged off against the allowance for credit losses after all means of collection have been exhausted and the potential for recovery is deemed remote. The Company does not have any material allowance for credit losses as of June 30, 2023 or December 31, 2022.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. The Company did not record material allowance for credit losses as of June 30, 2023, and December 31, 2022, respectively.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Concentrations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—All of the Company’s revenues are derived from life settlement transactions in which the Company represents Financing Entities that purchased existing life insurance policies. One financing entity, a company in which the Company’s members own interests, represented 23% and 66% of the Company’s revenues in six months ended June 30, 2023 and 2022, respectively. The Company originates policies through three different channels: Direct to Consumer, Agent, and Broker. Two brokers represented the sellers for over 10% of the Company’s life settlement commission expense during the period six months ended June 30, 2023. No brokers represented the sellers for over 10% of the Company’s life settlement commission expense during the period six months ended June 30, 2022. The Company maintains cash deposits with a major financial institution, which from time to time may exceed federally insured limits. The Company periodically assesses the financial condition of the institution and believes that the risk of loss is minimal.</span></div>Advertising—All advertising expenditures incurred by the Company are charged to expense in the period to which they relate and are included in general and administrative expenses on the accompanying condensed statements of operations and comprehensive income/(loss). Advertising expense totaled $367,418 and $286,695 for three months ended June 30, 2023 and 2022, respectively. Advertising expense totaled $741,789 and $554,802 for six months ended June 30, 2023 and 2022, respectively. <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Basis of Presentation</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The accompanying condensed financial statements are presented in accordance with the rules and regulations of the Securities and Exchange Commission (“SEC”) and are prepared in accordance with generally accepted accounting principles in the United States of America (“US GAAP”).</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Unaudited Condensed Financial Statements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year ended December 31, 2022, and, in the opinion of management, reflect all adjustments, consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of June 30, 2023, and the condensed results of its operations and comprehensive income/(loss) and cash flows for the three and six months ended June 30, 2023 and 2022. The condensed results of operations and comprehensive income/(loss) and cash flows for the period January 1, 2023 to June 30, 2023, are not necessarily indicative of the results to be expected for the full year ending December 31, 2023, or any other period.</span></div> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—The preparation of US GAAP financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and changes therein, and disclosure of contingent assets and liabilities at the date of financial statements and the reports amounts of revenue and expenses during the reporting periods. Company’s estimates, judgments, and assumptions are continually evaluated based on available information and experience. Because of the use of estimates inherent in the financial reporting process, actual results could differ from the estimates. Estimates are used when accounting for revenue recognition and related costs, the selection of useful lives of property and equipment, impairment testing, valuation of other receivables from clients, income taxes, and legal reserves.</span> <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Other receivables</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—Other receivables include origination fees for policies in which the recission period has ended, but the funds have not been received yet from financing entities. These fees were collected in the subsequent month. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The Company provides an allowance for credit losses equal to the estimated collection losses that will be incurred in collection of all receivables. Management determines the allowance for credit losses based on a review of outstanding receivables, historical collection experience, current economic conditions, and reasonable and supportable forecasts. Account balances are charged off against the allowance for credit losses after all means of collection have been exhausted and the potential for recovery is deemed remote. The Company does not have any material allowance for credit losses as of June 30, 2023 or December 31, 2022.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">If the financial condition of the Company’s customers were to deteriorate, resulting in an impairment of their ability to make payments, additional allowances may be required. The Company did not record material allowance for credit losses as of June 30, 2023, and December 31, 2022, respectively.</span></div> <span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Concentrations</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">—All of the Company’s revenues are derived from life settlement transactions in which the Company represents Financing Entities that purchased existing life insurance policies. One financing entity, a company in which the Company’s members own interests, represented 23% and 66% of the Company’s revenues in six months ended June 30, 2023 and 2022, respectively. The Company originates policies through three different channels: Direct to Consumer, Agent, and Broker. Two brokers represented the sellers for over 10% of the Company’s life settlement commission expense during the period six months ended June 30, 2023. No brokers represented the sellers for over 10% of the Company’s life settlement commission expense during the period six months ended June 30, 2022. The Company maintains cash deposits with a major financial institution, which from time to time may exceed federally insured limits. The Company periodically assesses the financial condition of the institution and believes that the risk of loss is minimal.</span> 0.23 0.66 0.10 Advertising—All advertising expenditures incurred by the Company are charged to expense in the period to which they relate and are included in general and administrative expenses on the accompanying condensed statements of operations and comprehensive income/(loss). 367418 286695 741789 554802 SEGMENT REPORTINGOperating as a centrally led life insurance policy intermediary, the Company’s president and chief executive officer is the chief operating decision maker who allocates resources and assesses financial performance based on financial information presented for the Company as a whole. As a result of this management approach, the Company is organized as a single operating segment. REVENUE<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Disaggregated Revenue—</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">The following table presents a disaggregation of the Company’s revenue by major sources for three months ended June 30, 2023 and 2022, and for six months ended June 30, 2023 and 2022:</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:37.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Agent</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,334,402 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,717,512 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,143,016 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,690,701 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Broker</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,809,499 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,247,953 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,675,973 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,727,970 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Client direct</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">740,789 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">726,451 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,365,687 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,595,993 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,884,690 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,691,916 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,184,676 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,014,664 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div> The following table presents a disaggregation of the Company’s revenue by major sources for three months ended June 30, 2023 and 2022, and for six months ended June 30, 2023 and 2022:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:95.454%"><tr><td style="width:1.0%"></td><td style="width:37.947%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.661%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.434%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.668%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended<br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Agent</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,334,402 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,717,512 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">7,143,016 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,690,701 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Broker</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,809,499 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,247,953 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,675,973 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,727,970 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Client direct</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">740,789 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">726,451 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,365,687 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,595,993 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">6,884,690 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,691,916 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,184,676 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-bottom:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">13,014,664 </span></td><td style="border-bottom:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 3334402 2717512 7143016 5690701 2809499 2247953 4675973 5727970 740789 726451 1365687 1595993 6884690 5691916 13184676 13014664 INCOME TAXES<div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Since the Company elected to file as an S corporation for federal and State income tax purposes, the Company incurred no federal or state income taxes. Accordingly, provision for income taxes is attributable to minimum state tax payments that are due regardless of their S corporation status and income position.</span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">For the three months ended June 30, 2023 and 2022, the company did not record provision for income taxes. For the six months ended June 30, 2023 and 2022, the company recorded provision for income taxes of $2,289 and $1,325, respectively, which consist of state minimum taxes for state taxes that have been paid and settled during the period. The effective tax rate was approximately (0.24%) for the six months ended June 30, 2023, compared to 0.48% for the six months ended June 30, 2022. </span></div><div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Given the company's S Corporation status, temporary book and tax differences do not create a deferred tax asset or liability on the balance sheets. Accordingly, an assessment of realizability of any deferred tax asset balances is not relevant.</span></div> 2289 1325 0.0024 0.0048 RETIREMENT PLANThe Company provides a defined contribution plan to its employees, Abacus Settlements LLC 401(k) Profit Sharing Plan &amp; Trust (the “Plan”). All eligible employees are able to participate in voluntary salary reduction contributions to the Profit-Sharing Plan. All employees who have completed one year of service with the Company are eligible to receive employer-matching contributions. The Company may match contributions to the Plan, up to 4% of compensation. For the three months ended June 30, 2023 and 2022, and for six months ended June 30, 2023 and 2022, the Company made no discretionary contribution to the Plan. 0.04 RELATED-PARTY TRANSACTIONSThe Company has a related-party relationship with Nova Trading (US), LLC (“Nova Trading”), a Delaware limited liability company and Nova Holding (US) LP, a Delaware limited partnership (“Nova Holding” and collectively with Nova Trading, the “Nova Funds”) as the owners of Abacus jointly own 11% of the Nova <div style="margin-top:10pt;padding-left:22.5pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Funds. For the three months ended June 30, 2023 and 2022, the Company originated 38 and 92 policies, respectively, for the Nova Funds with a total value of $56,688,680 and $102,307,954, respectively. For six months ended June 30, 2023 and 2022, the Company originated 72 and 183 policies, respectively, for the Nova Funds with a total value of $96,674,080 and $282,804,838, respectively. For its origination services to the Nova Funds, the Company earns origination fees equal to the lesser of (i) 2% of the net death benefit for the policy or (ii) $20,000. For three months ended June 30, 2023 and 2022, and for six months ended June 30, 2023 and 2022, revenue earned, and contracts originated are as follows:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"><tr><td style="width:1.0%"></td><td style="width:36.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended <br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Origination fee revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,504,532 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,164,107 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,952,837 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,569,034 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Transaction reimbursement revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">75,332 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">152,221 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">140,960 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">306,361 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,579,864 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,316,328 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,093,797 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,875,395 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cost</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,290,504 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,201,256 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,656,637 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50,738,202 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Face value</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56,688,680 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">102,307,954 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">96,674,080 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">282,804,838 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total policies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">92 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">183 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average Age</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></td></tr></table></div><div style="margin-top:10pt;padding-left:21.6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">In addition to the Nova Funds, the Company also has another affiliated investor that they provide origination services for. Total revenue earned related to the other affiliated investor was $3,615,738 and $589,700, of which $3,615,739 and $470,200 related to Longevity Market Assets, LLC (“LMA”) for the three months ended June 30, 2023 and 2022, respectively. Total cost of sales related to the other affiliated investor was $2,623,201 and $363,700, of which $2,623,201 and $326,200 related to LMA for three months ended June 30, 2023 and 2022, respectively. </span></div>Total revenue earned related to the other affiliated investor was $6,838,141 and $911,700, of which $6,794,641 and $470,200 related to LMA, for the six months ended June 30, 2023 and 2022, respectively. Total cost of sales related to the other affiliated investor was $5,020,603 and $612,700, of which $5,012,103 and $326,200 related to LMA for the six months ended June 30, 2023 and 2022, respectively. In addition, there is a related party receivable due from LMA related to transaction expenses of $19,246 and $0 as of June 30, 2023 and 2022, respectively, which is included as due from members and affiliates in the accompanying condensed balance sheets. 0.11 38 92 56688680 102307954 72 183 96674080 282804838 0.02 20000 For three months ended June 30, 2023 and 2022, and for six months ended June 30, 2023 and 2022, revenue earned, and contracts originated are as follows:<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:94.393%"><tr><td style="width:1.0%"></td><td style="width:36.299%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.148%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.442%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.831%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Three Months Ended <br/>June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">Six Months Ended<br/>June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:120%">2022</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Origination fee revenue</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,504,532 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,164,107 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">2,952,837 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,569,034 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Transaction reimbursement revenue</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">75,332 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">152,221 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">140,960 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">306,361 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total</span></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1,579,864 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">4,316,328 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">3,093,797 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">8,875,395 </span></td><td style="border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Cost</span></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">5,290,504 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">25,201,256 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">11,656,637 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">50,738,202 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Face value</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">56,688,680 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">102,307,954 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">96,674,080 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">282,804,838 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">Total policies</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">38 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">92 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">72 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">183 </span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Average Age</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">0</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:400;line-height:120%">1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></td></tr></table> 1504532 4164107 2952837 8569034 75332 152221 140960 306361 1579864 4316328 3093797 8875395 5290504 25201256 11656637 50738202 56688680 102307954 96674080 282804838 38 92 72 183 P1Y P75Y P75Y 3615738 589700 3615739 470200 2623201 363700 2623201 326200 6838141 911700 6794641 470200 5020603 612700 5012103 326200 19246 0 SUBSEQUENT EVENTOn June 30, 2023, the Company consummated the merger with LMA. The Company has evaluated its subsequent events through August 14, 2023, the date that the financial statements were issued and determined that there were no events that occurred that required disclosure. Both the number of shares outstanding and their par value have been retrospectively recast for all prior periods presented to reflect the par value of the outstanding stock of the Abacus Life Inc. as a result of Business Combination. Both the number of shares outstanding and their par value have been retrospectively recast for all prior periods presented to reflect the par value of the outstanding stock of the Abacus Life Inc. as a result of the successful Business Combination. EXCEL 114 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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
!;\(%:<--F#NLO1@ L7H:!XJV@H5S4=%"U#10BRT+D%;Z9;KI=NCJ4(^ M5#S'4H7Z4+,)A;IB%Q7-G]XH 6K@$ NMRY96:^5''N(P*U7( 3UR)%6HCSN; M.JAK?5'1_.F-$J &#K'0NM1I15JN%VDGI KY4-H$4X7Z2+/)@BK/ G6 4X6 MX4BJ$+6 (19:EP:M\,KUPBMNJE ?;/:$"%6]Y="Z7S!5B!K71T4+4-%"++0N M^5J1E^M%WN]/%7) ?(13A?JBS"83($ /4X5 Z492A6 ]X%0A:D5"++0N UJ) ME^LEWFFI0@XL,1U)%>KCS>YF3+35]&KXJ($#5+00"ZW[.+U6[Q5ZO7=>JE M BFEKM47,9;ZJ'.)@XJV0D7S4=$"J(%=@_:33B%DQUR3CCU>L965A5[UU6<* MQ?!9!I;-N"GZ=S?JH\SN?]1UM:AHOAAJSI9MJB[KGVE0PX9 V%,U$7='4L6B M%6R%7EO]SC2A&&J-(VG"R9;>9,N5OFZSNQ;U^0FH:"$66IJ=-_=M\ M9M6+'*H7,M0%:)%5&:H=AP4HZD>_-S]_K"YW";G<%:K>15%-;>[B-*HFPZ\@ZB\.'M>_K:Z@JM=#%&2=[=*R M:L2#O?M74%S6;VKH[??HZ[?0_@LA7@="@+^8ZI?ZC0F+-O3+NS"JJ7R<%B21 M]ZH8QBM;=6K^\GJ)ER]E]E2_2. N*\ML6V\^RF@C\\I _7Z?9>77+U6 _4L^ MSO\/4$L#!!0 ( -$#E>ZL#DWBP< *PA 8 >&PO=V]R:W-H965T M&ULM5IM<^(V$/XK&MKIW,TTAR59?DD39@B0.SHYH(%+DMK.1 M1?.2O7UAA$$GU!3Q*LO_@M9"U.B#8)Y)OB\$*P3:,\U_ZO7#$T0"E1S\ M%0-0?8#=,@ 7 W!F:(XL,VM()>W="/X*1"JMM*4'F6^RT+T1 ,II/A:#+/C^;3A_&PGUZ>+]3/U]%D,0?3>S#HS[^ ^X?I MGW-P!9[F0_#AYX\W7:F I.JZ0?'0N_RAJ.6A#OC*8[E)P"A>L55U?%<9<+ " MO5EQAXP*?]_'GP"V?@7(0EB#9W#^<&2 @P].Q9D^W*+OR$OWC].O8#H;/?87 MX\EGT!\LQM_&B_%H?JUS6Z[6UJM-(_HZV=& W794R"9,O+!.[Y>?H&/]IK/Y M0LHJ'K /'K!-VGL3E8#&<<"W3&=F/M;)QJ9YYJ4';6Q[V"8WW9=C$S2"T$<( M8_\@6(%'#O"(<8+ZJ[]4:*EL)!,@N4I' 8^#,&(@5KC##'=Z/3T+:+(!.\%? M0K54P?)']\,^40=A_!&H7"JH#./G/!F%,F2)=EK)):?U0LHJ?G,.?G.,TSID M2FD0TC0#ZPS-1Y.C^4+0AK5)/2%4 >8>@+E&8$^QXK H_%?-S(=GFDY.Q),$ M*)X(XQ=63+4.L=L <^7Z'B1.#713#EK$]EVBQ^T=<'OGXDYAIX!W/ H#M9)T M:+TF6HRA3SRO!E#U#WA](]Z'PJO!AL;/3#D7K&DHP N-]@SPM2+0 MI=0!]YMSCGW/<5 -=U,.NX1 K$<-K9+EK!,+=\V$R.(V#V[Z7>_A0D\%*4$. M\6M -7*^^D-N"](C/H;FS,GCJRSG1$Q5)X!]5P5;HLVBA:**LSR[CK,I9+5 M1"5$9*:W;/*3=/:/4F"2,)5-:;P"44B78=2>#@OU%\J'E])6=49)]=#(H[V9 M8#L:KMXF*O< EQLF5/FFEEPL"]=H/8&;<0I];#?B0BN(79^X+4P(2Z:&9JJ> M9EAC18"GX=H:%!9Q2)VW-8)MJZZD;&ADMEX_"/@^)>P=_4&7D3XD2#,D'&A[ M]6RND6O#5U(C-'.CPB?V*L-(0>.$YDU*P),63S9)\,I%Q/$:GFP*MB$MN1*: MR7):69U'T:I%VF0^6Q79#JX#;"]B2(*&9(1_"-0.JFY012TD'/B&.X[IU.S2B+H*06&V15G(G/$&>YYF2+AJM M$4URO((J"=B.U5@U&E$76;9+6I@4E4R*S$PZ>:N)BS)86P7KX*,F8UYA#SLV M=.L5HDY488?0;5G[J*17!-_5FHTGWT;S:JM-FI7_U2=,((E(1K*(M*1:9*7:H:LNUX%M UVN5J:AL66 : MCG12ESD?CTC+C2DZEI:V!I)HX=+;D7F?K@>%??C M27\R.""!XRMDCSO'"^,.5.% MDXKP84NGBS2M;A:CS839E&S!C4MVQB?ZW#T[\F_6BYB3)FY2+;2@ZKB=>L>K MD70\"[?M@."2DO&)CE>SRP;68:P\?CI[8DT33'P/6WX]>VHD7==6(6"W&%"R M*3:SZ62T4'7$X''4GX_ A^$H/_JHKN7[Y?W),#\8_?$T_M9_2#?3M;9H&-17 M"%VK'J0:2>3:R/?:;#G:N39S;2M@T%^ Q9<1N!M]'D\F*35,[[,+L]'C>#K4 MVM.D654Y$.2A>O.@D806LE'+KB N61F;6?FD.2-U[[0A3>)561Y"B.HI22?I MV<1NVW?#)45C<_L[X;%@D0KC%9A1(7]H<5Z4C2^EK6IPR<;8^5]WF;"1[-_M MC MIJSJC9'EL9OG#YH=@ 0M?VO8_L([G/03M1C(\F^5QR?+8S/*/)Y>G/WGMOF7C./@=(0(8E?WE\N'KXY*"?O6BO7;^#UX/\PX%23?X= MPU3 M] &'#S1Z_P%02P,$% @ T0.5_=>R\H15;]:'NKKJU/23J+$B-H'(AU8@I"W1U=8$.T?WUV?WX')5/W[%EU/)^@F1C>WT=W9]%(!T-EUA?QV>Q=]5_GHQ*=>G5!8QFS65>;"Z3=%PF1=^R5?E1N[SO:CY3+MGXC M[WZ[($["OZ]71XAZOR#B$0I# M-BRV84)XE(1;6,MBMK68.2V>9F6R>+>U@(S=M.<[Y\68!F'@<\-<&QA2$0H/ M&_;:.()YR$3 #(N!,X/:0F9[-L7Z3&/ M4ZNW;6 04!*$YNBV<<3#1,U7L[>!,_M8J'G-8+N#K=U!W9)VS>G-@G[]!47_ MN*V6_\DQ9'C@G/[E3]CW_@:MF4.214.2Q0.1 MM7HBW/9$Z!R!7^1*YFH,)JLY2N9* Z1%F2>5($/RAU*8!;P A=; X$' J3&] MQ@","7,.VB!, L:HL4;%-LYG?N!U3$&Q=8!P.F LE5=G:7U_@2P5P.03H6%G M'U!D@PAFII%[0"T3L:=UF-=CG5$10]6UJR=GUS94[=6!LB P+G4, :N;BS#N MN1$ 9$3A*G71,AX TH"$(24=#M@1HM@M(K:F7ZYFV1*\LS04[9NE&E^"F8;; M0$ZINO]:AMM =5>E!)OWWQA"$N9C*KI,)]ITXEYKIU^CNW>5_*E9;V&53(9< M;P=EBP9EBX=B:W>)5K38+6DO5Z54O"622;Z25A(5,C9.D_+ M5!;H62[F*%VA::Z"-70VFV7K%2@1FA/NCA]3$>V'1 D8);H=1*U/:(5+W9+ MWJU'/C5+$SQ ;?5YJ%3JK@QK;+6!EJT EV"8\= TU\75-E>+7>Q6NS?EL\Q5 MQU9+T1Z3 85*U$"T%F,;=UC=1CDW[0: BI!;*Q*$4X$2"SJ,UYH7]Q&]67\7 MV"KT4(ET9L8F8P@(^P "LY]3DPG $"G$[0 QDY5=WHMRW?C'^1CELM*_[^F M=4Y-?7W_K4Q^=-RE WNJ"B_$Q)KV-I 3SZ>FO(H (&8JI&1,F%X!D(1@H29/ MAUNT&L5N.7K[,2< TA&':L6R9@>D,3U,S< (P'$2JFC+]("-(\(//;_#?BU& ML5N-7D?3]UOUV71Z=WE^/ST[OXK0] 9-OI[=15]OKL;1W01TAK"2$7[ O=U. M:9QA Y6.5N/?%*P 4(T(RGUFK9$ $G/,?=&1"B%:NA+/*5]^BRZ_?)U&X\.S M7U7,^"5"]]>7TPFZKU*&E]=U+O"^CB1W7/?IZF8R^2M206:-!F-+XE3,'Q4[ M@[)%@[+%0[&U.U!+;^*6WK_5^7E09_4OKF.5'G0>M"UMI&3?&7=2W- M5WI-5')]@_NE2NVG,_1)(3<-H7O$^9YK^"?^%S@& "'O<2\(B!G@@4CJ"VIF MBB(0R6@HB'F'[&M\CP_?9NBQ*%?)77M_G6?>9 MNCQ+>GL60L*>A9"P9WMPMCVKI3NASN5(KS*C7JN,,Q#X\"HS)%LT*%L\%%N[ M7W0 0=P!Q'F]2E3QE!K31;U^K%=I68_N>;98)'FA%Q509C8G"'=U_A&FYG"% M4)Z9T@)1Q-11,(IV#%$=7!!WK7"Z2RA^W25[^#AKKI/CP)!V2+1J4+1Z*K=T9.N@A[J"GYU9>P[*K)E7$ M10-S]-DP[%N#SP8QI4JM.X8-HX&W2]T*'5L0=6O4=?'8&GJK8SEROQ@".84$X-0>@C>.,>H%OCD ;YZL0E7>, M0*H#*.K._=M%&+]451C@'OJ@,=&@;-&@;/%0;.T^T3$1W;,=T;.FP8X0_#!4 MZY>9Y & *O;& IL[$@ 04ZPHK?$((CW,?+]C[Y?JZ(2Z8X;]]0W4%O =A@-* M'S;A"$1HV6\#*0^PL#); % 00:EG[L$! MP+"J+"$=N3VJ)3KM4]:RK]B! A4F(O0#;)D.U:Q@(4)FFFX#5="(:6"9;@,9 M(8%'N]9@+"BV=G_HJ("ZHX(_6/5 @<(9 M(@(>F-(4!'JA9^ZR1 "0A2SDYD2/ 2 553*V(\%*M2BG;E&^KP""VME^PGTS MPPZ@J&?FB2, Q;FPJNH E B[#-52G+JE^$>*("B0X*>>AZF9OH* :AGRK"H7 M *CZF6%S[,0 D HE&5G'Y@+5"ICN4< ]BB"H+4,/*:;,RMM!0($Q-O?:0)Q/ M0FM/!0"2@/BB(P7 M !F[AV$_@40;%#].RA;-"A;/!1;NTNT_F5N_3M\ 00# MY"H69L(*0'%KID)4 IO3%#QAU[XPT]J8N;5QOT((9FO40Q[ZEKDVS$RJ0TP8 M!X2;YKJHVK9J.P],V=:>BNX_V[5_SP(#J ME*K8T30:J.\.3.D/<:E(PMS#!6"8D:Y.UM*7N;/1/UOHP( Z%!6XV368$%!X MA%EC ,*I&PTVBS\ ( D8QEV#0:M/YE:?'RMR8+;RLX;!7D@$0 @)S20\@,*T M*_)C6F*R/<4N?[RJ@=F)V8[N!X!@]T.X@%F/1,0 4.F1H$N',JU#6>C4(_^K MB@8V:"9Y4+9H4+9X*+9V!VH=S=PZ^O]1T7#!@/RR]91+'U#4!Q3O ;6?Z='2 MF[MSS\/5(5QPH(CJZ(_.Z$'9HD'9 MXJ'8VOVB53=WJ^Z?KQYH3K"[?7T8"'YD"NDQ!"2$'YD9E0@$,AI8E#& ]$-\ M)#J"$:X%.G<+]"$J"9I3]' , (0= P%AQ]A(IV.TG.=N.=^QIX;^@_K4&[C) M/SRMAV2+!F6+AV)K=]/.,Z5[RNS[;;,U+.U"@E!XH:DQ 6# *#5Q$8!3*EJ% MD6;,!0%QR#V_0V1R'6/P/D7V?9ZG!20_]ZKGF4SC;:#@OF].N@C *1CH*X.QO?=VX" M%?E8C3N/F,,3R*\+%G(S<1T!0"$H%O;D!( A$5QT).*Y#B"X.X#H/SGMNGI* M!?&9N>$$ (F/.?4"TWK@*0'.0\K-=#P Y)P0BCL>2/2KH*!]1,MB?V]Y]GE6 M/J/R6:+5>OF@!(7R"Q C5/MU"I3FZ"7)T6NR6$OTK&(*]"!E-8S*/"M>9/T^ MF<7OZOLL42ZNDBS)8H%>\E1]4FHES>;5#K0:U*MJ+2BSZBTVU=MHZ@O0S.H: MJ@.[%U"4V>S[^P_-,G.5/LIJ1^4()05*%%>Q7M0=>[XNE*%%@2ZRY4,SUH^@ MR3/:><7*4N9/]5Y1X&:(OGF)3N;+V7V4K\4YB$K MRVQ9?WR6R5SF%4#]_IAEY?N7Z@3;5QV=_A=02P,$% @ T0.5QUN4@S] M" YT, !@ !X;"]W;W)K& $EQC;-86RQ6$R65O*<3Z?#!(YDN^\I*S:,U#^1*^7/=I[.W#G/R]%>F!P=;'VGOD]%U_77V+Y;K"C+/P5#Q,_"DG,GRY[ MU_3<5974(&OQ'Y^_)GNO23J4QRCZEKYQ%I<])>T1#_A>#TA/ M>?,H2+*_Y#5OJ_3(?).(:)4;RQZL_'#[W_L[/Q%[!E1M,&"Y :L:: T&:FZ@ M=O6@Y09:Q8"9#09Z;J!W]6#D!D;5P&HP,',#LZL'*S>PJF-H.DMV;F!7#-2F M05/E;>:4BHE.FTQVDUV=;8TUF;Q--\WF>[ 55J;*D2>\JXLX>B5QVE[RTA>9 MM#-[*48_3*_">Q'+3WUI)ZZN'SWIA\BK301<7ETB(:X[)'WR]?;ZZ\AY&(_( M\+?;T?CV7KZZ?[A^&'\>WS[8>&VPZQA@X]1,(+ +-QN]GU8N&GE[47D"^> MO^@[(1EZ:Q]F3=I9=US(\,479.S%H1\^)P#".="=VFG]-3VO &AZ$H@,H]5* M!K%-Z NH>[/3J$>=1?*=BME,QRWQI#;YN^+,?IC 9D0,OG'/R MBQ^29.G%//E /$%&?'Y&5/HK80JCD"A;^>FM\#Q9>W-^V9/WNH3'+[QW]<^? MJ*'\"Y(J)FR""7,P8=,M3,]@Z=W^Y4I3E(O!R[X.,1VZ2+"2Q-2=Q-0C)=9% M5ENFL7>*3,.P;+5\ED;MKO^@?T(J ]B*9AL5]L=3V),ZFRFZHEEE]J=3V [ M-AFS;;T,G];;27E5]55O9"FU5B[@TE"M?9=>1/-ORRA8\#B1M\2_-K[X3OZXBX* R)7CJQZU%LOO%N9O?GA/%I)9091DH#+,+T6O2G5J6[8 ME8M\W.KK6"EAPISZ$&0D,:W* *:8/F>8,/?@ $K3;^RFWVB=_I&?B-A_W*0K M.6AQ.#1J;OLLC:W5N#EN]7/LU'?UZ@ -#=VV#+LRKYB]FV'"W,,C*$VLN9M8 MLW5BQ^&B98T[W81R,:)DBQ$&37LK_-@;#"9L@@ES,&%3L\,:%].ABP0KZXI<*<. M9ZJJVU2KA#"KRQJW#H/6N(!+IM-]ER5-V#M-V,?G/9^]>)?W0+*X:6?")VUH MUT:@ZU15U,ITC^OM(%5,ZLTT6Z>TNCQP6OMZ;+S A,TP82X2K"0BJA1E1N4' MIDJY,Z1;&2IM@DIS4&E35-H,E>9BT #Z9O)]$G !U.X$[".P >3N'RA@=R M. ')7&0U[8LCA8E8=I>$S[J*U)8+IBESS$J;8)*!\:C>C-K,W/=:UDA1RJ;FCRP(H-:V46D35)J# M2INBTF:H-!>+5A9H40NG[97=;@4!H/ZM6:IN5+=*C-N]':TI3)H#C*)OFYJM MT&ILP70[0Z6Y'0915D)1 :?MY>K#V;Y="[E]5=-TV56S*@/,FNZ$UFO<#8X= MJ*FF,6;5RCZH)6Q4FMMA$.7]@T5]FK66%X_(TU5P^Z!2ZYC!;(,:U6\;QNW] M.'IS(&JQ&94V!X%Q-P-WV@V,NQWX_U':945IEYVP(_BP MONJ52;E<-!BU*B=K=,!]0Y8+\,$L]R3Z!.J]JIO,8M6JVTE\!^!35==4M5IU M8YUV!P,X,!P!7IFI['LM:Z2HRK(?N4.8H6X11J5-4&D.*FV*2INATEPL6EF@ M15F8(6P59O4*IF'J"M5J2Q34HBXJS0$&T5=EU*WN=YZBNIVATMP.@R@+H:C9 MLG=N&F;UNF)3DMONZF@9 +MI&Y)T?AI:@TJ; .0&6O:AU42Q:641%792]9Y,P+)SZ-M?&)!=HVI3D MUILV)KGUIG"2VVD_+M *7%4"3MN2W+0>6?YI8E&]4MNK5W(U?1.))1%+3L+- MZI'')'K*KVT2;40BO.VLR7]I(S\F:R\F+UZPX63IO7#RR'GZ5 411\F:9T]& M"+[+]W,O$>0IBHDGEZ;KV)>OUES^6R0D$U9"6;0+RU23;S.4^2ITU ;C:)''>2I#]^ M?O1#+[U5G4&:'NS]'G[%X^?L*0\)F4>;4&Q_1K,[NGN2Q$WV$_S*\2$]'T'' MQ_3\(W1\0L\_0<>OF7T^8S;TB:JS*I2!O(SY^B2+R]21WLGNUQ]3]02P,$ M% @ T0.5R?S23,J"0 3S0 !@ !X;"]W;W)K>NDV8?ZR&+0)>\BR[-[&#Z)._[*X=Y_T M+^-=%@81NT] NMML_.3UFH7QRU4'=MYN/ 1/ZRR_T>M?;OTG-F/9Y^U]PC_U M#EJ6P89%:1!'(&&KJ\X 7@SM8D A\25@+^G1-8SC/_,/D^55Q\HM8B%; M9+D*G_]Y9D,6AKDF;L=?>Z6=PV_F X^OW[3?%,YS9Q[]E WC\(]@F:VO.FX' M+-G*WX790_SRD>T=HKF^11RFQ?_@92]K=#SZ/)?#P"D^E\_#"Y!<.[ MZ6@\G?$[L_E@/KX=3^Z/63YL-@+O_O/+92_CQN4_T5OL M#;DN#4$:0VQP&T?9.@7C:,F6U?$][M3!,_3FV34R*OQ]%[T'V/H5( MAA3W# MTX;A[A;3+Y/Y9#R[4$U;J9:H MU>:K_"+=^@MVU>'+.&7),^OT?_X)VM9O*I];4E:9 7*8 6+2WI_RHA1$BWC# MP+LP3E-EDI0J[$)%7H*>^Y"XF-K$O>P]'WNB$(044ML3@A4KZ<%*:HS38/D_ MONK*E9#%O%(MXF@1A Q$PGQ^/_^T\-,UV*5LR>\#7E@3/PNBI[(R!5G 4F4\ M:9OQ;$E99:;LPTS9QGB.&%>Z"/RB'+.O'%A2IG*XU$*/(H4@@;5P-@A5#'0. M!CKFA(NC;A&CD/%";S+1D7X=NZ1FH2QCJ])\>@ZB-HNK<5-EM/$#5H",ZTF@^-=7B"XQ?YCJ$RIO8I*3MF\EMDU\Q1R M.ON.,!TV5MK&XJ0T&LJ3BEUL$^C4%ZQ*E#@40D=G/A+FH[.@$H(C1SB[!"VI*TZ"X)*0"/^]D=!FB7!XRY'R()-;-CFD27JJ%%% M+##%V')0/6PJ46(9XB8@'9HQ_9!TVR1^#C@1!X^O8!5$/N= S8DG@SBFGHLM M3TH\6=)Q"(&4:!P0D \;,'\\Y_5B^# >S,;@W6A<7OW"[Y7[E,%T5%Z,__MY M\F7P*=_$*'V1X;[K<0L=2RJ$LB1R"/)\+-S[2?:J--(X_MPT;$M;U5O!1% #$_E.BHY:)21M::M.AB DR$Q(#JR7 M[_I8\*PCOD@F%1!1QZ[OIQ1R7<>QJ:-)4<$]4$.?(8Z2QBQME6:TI:WJL* 9 MR-RR^.XL;;4ET9:VZF0(!H/,#.;4+)492!>Z")(Z55$(:E@6$B0%F4F*W'3] M->^Z*NTT:CH[-BUIJ_HM" TZ@=!\2P\4M LV/K_-D*QD3.=W=EN25MUM@0OPF9>=&HS%,MM$^A! M6J\Z*C'+H1HBB@6AP4:.T!]LXB0+_FXV$TF_3RR>574S93'L>!1IS#PZ*VF@ M&L=FQJO\7(XE"<\OL15=,?4F%"OH!W10O2NH$-.4=2R(!VXD'B?VF_>*JAP) M6G4;92F=C8(KX!_+%7"K7*$M;=7)$%P!F[G"?<*V?K TMIFQBBAXKDWJFT>% MH ,MK*O#@BQ@,UFX*SKABQW/_RC;ATIIJ*)C@6P$ZX"AE+,@U-46@>[8B)O] M(>-K=A4L./,NU^PV3H-,::IK2.R]E;*(36U$=0M H"_^$8<-6 ''T"%VO9NO MD(.4>IZF%T0$&I.&#D(<90D'U,,"??WY)TY7T6_[:4X!KY3<_F6^GE-!+)5G MK')WP*:>9==!2"'7A82S"T^3*T3 )3'#Y2DG*$1U&&$[M)XJ*CD'$491 M1/W5BM;OFD\_22*N[YK:T56=!X#8QXW:9=J83-*+":"+Q'Z48='5] M1RH@FIHA^IS3/JJ 5D(06WR'%=34ZG :WH"7I]\TD=; M!>FVM%5=%R!-&T"ZQ9,^JMA6$^HZI Z."D'$63JV-$A.CYX>-"-Y.R=]5 9O MUW(1JF\W%'*08(\BG1\"Y6E#&UW=H@;_@,830+/FL].S)6W5>1"\@3H_M%]" M6^W?MZ6M.AF"B5#S#O_$LQ4J[]VQYUC8JV>OJ0U0-5'0!-JPO=?F[2G'@F;E M9T>K)6W5IW,%'['-#?SO35V[U?Y\6]JJDR'8CGUBP\&D=O9JQ8OX<6P?+=%J"E? MM;GUDZ> ,\Z0K;A*Z[W#%U12OKU2?LCB;?$"R&.<9?&FN%PS?\F27(!_OXKC M[.U#_@.'=XCZ_P)02P,$% @ T0.5^G1)Z'6!P P10 !D !X;"]W M;W)K&ULI5AK;QLW%OTKA+HH7$ KR;*;!HEM0'8< MU(53&U:Z_;#8#]0,I2',(:>^^!<;(Q] M=H40GGTKE7:7@\+[ZL-X[+)"E-R-3"4TWBR-+;G'HUV-764%S\.A4HVGD\F[ M<W5A:J^D%H^6N;HLN=U>"V4VEX/30;/P)%>%IX7QU47%5V(N M_&_5H\73N)62RU)H)XUF5BPO![/3#]?GM#]L^)<4&]?[S//6MP(I4@0S/@CR1RT*NE@_W9I0+_[--VCL9L*QVWI3I,"PHI8Y_^;>$PUL.3-.! M:; [*@I6?N*>7UU8LV&6=D,:_0BNAM,P3FH*RMQ;O)4XYZ\^WO]X] M_,H>/K/KW^9WO][.YQ=C#^&T99PE0==1T/050>_8%Z-]X=BMSD6^>WX,HUK+ MIHUEU].C G^I]8B=389L.IF>'9%WUGIZ%N2=O2+OP:ZXEO_E1(8ANS':&25S M'KFA<_9HA1/:QP6S9)^EYCJ37+$Y%@6(Z!W[]VSAO 65_G,(H6C ^6$#*+T^ MN(IGXG)0D2Z[%H.K[[\[?3?Y>,2]\]:]\V/2_TP@CPHZ;.8KTED?U(#B%V%7 MPK+9@H.\[%XNQ9#=Z6S$3K[_[OUT.OGH"P'PRXKK;5@Y_?@#VW#'J+X(J[;L M69L-9(%(W'GV))RI;28#VZ?;>2-GR#A;**Z?&4I7AO_3 M+JDS8RMC$<4<#^R34'S#K6"0](5OV70:2#89'3 [,SJO,T1>XM^B=@#+.>8+ M:^I5$18WA5%J^T\8+?(A[4^\@BY7+YS,);=2N"&KK$3=DW QJ4'%\RH1Z_[^ MIH4HOF[1(5COC5Z)M?1;&&R?4:MGS@D/H?US]U]F'12;0F8%(R_WW:<(.*(T ML;S%X@25))3*M5#;8=B4Q$:PX4(C?,0>-$-ZBC8]A^RD?T 9X+1B*$BB,X@B M-3SN"'GZ$IOXCH"EQD%.D"X$=R$UJ8$7':E@)G$'NY&RE0K;%]NPH:'FRHH@ MF,4@830A\V:!PZ?GZ7TP%1%5>(P8@,;2%PQ! M:#3-ZT6PG7@96<("2SI>;$DU =./8>]XAUZ"Y6](?B&A$_YGV74T4.U^L>)9 MP_5TD@Z"6V8E$!#; K9#MW3N .L>:^MJCL!YD5JM,^RN (!8D*O,\*K@ETJM&:A #RE_7]:R@E2'/ML'>G M>O.4!$KRA51H/")*=]TX +48CRV/F-!+ZCE6%#2UKF/IA6;4"6,;UAX"(M1I M7Q@7:K***"!>T3X,@=ES(]ZB)U&=KDNJW4#6%0#:[7:,,(:<_O21.%V6C8M#]H_):#*9G#(H96NNZH0I21@R MZ5Q-CC]V\G1KLZ(X7$CZ]=P(8[\U>LUTW; MH]"@*5;6K&6>@HX15M($"6@\CS,#88(B "-08S'F ^W>,$: FN62PE>A' "Y M*".=I/ICXZX*LRGX2H^4N"2R$]16$*"TP;TS#28.%T9(&@96I00D6<"V1C5# M8!N+1WVO@V/*(;OTBJ\B@(MZ2S:%J@0%:1K:-R/X0-4+)^)8*#VKG8A#+4W; MB5'#'9_<"T%4].GRXSH>HY.)V)&%#%V">$^/F-1J2X$+R9@)2ELZ $P,;E5$ MS%QP2,D4ER6R;&MJSR(;R1?ZRW7L/"W*A[SKC,(5 J%?(<14J4(*<25&KU.G M;;,=>P+"A#1D6+DB0IJ@%M:!O#$!]ZC3XDLS(UYFL9F\"$/+201.%%PM2:[4 M:V2% 8&:P2E=/*'G5OO0=KH1*%FL3 8$4SO*T&ZUZZP@&(2"[:%K;:-5E/;" MTG46R9L+)RT24>S;.*3VH>K@Y!HU=KF-^(VFWZ MY-)E*,FHYRZR"B"7TOM8OUPR,Z@7WRH4#KB\I?H@:<1W*1#A+DB7JO[5A ;V M%!JJ4%VR_(ZVVX:=L.4]BZE]*.'ICN8+\L !!CB=-P-*1"'OS4%[/OLB5$&4 M!1NK*@Q)I.>-D#T\&V%MXL64(5CRMEWL@P!5F*" @B7DX='&L"WJ.[G=Z%DC M@V062D4;N[^J3%&=/?0%8MS[K!1F3_IX1DBBZ\0O3.UJ^WUN%C]+==OCQSW< M*Q PTK7$T M_0]02P,$% @ T0.5[/B/.E''@ R&0 !D !X;"]W;W)K&ULU5U;<]M&EOXK*$TRFU3!LDA)EA(GKI(5.Z,IW\JR,[NU MM0]-H$EV# (,&A"E_/H]M[Z!@"QG,K4[+[9$ MVG3Y_+=R[=^F'7M)_L6NLN MN]U4M?WQ8-UUV^\?/[;%6F^4/6RVNH9OEDV[41W\VJX>VVVK54DO;:K'\Z.C M)X\WRM0'SWZ@S]ZUSWYH^JXRM7[79K;?;%1[]UQ7S>['@]F!^^"]6:T[_.#Q MLQ^V:J6O=?=Q^ZZ%WQ[[44JST;4U39VU>OGCP<7L^^W)\D!6][9J- MO P4;$S-_ZM;X4/TPOG1Q MS>6%.=/-$1.5/JE//?FB;7=;BTS :_D!+I;>! M.%/CIEQW+7QKX+WNV?7'UZ\OWO]7]O9E=GWU\YNKEU>7%V\^9!>7EV\_OOEP M]>;G[-W;5U>75R^N?WC,=^\4?TWC'$^-=%$73UYVI5]F[IC*% MT3;[[XN%[5H0EO\96S"/=S(^'BK0]W:K"OWC 6B(U>V-/GCVU[_,GAP]O8?: M$T_MR7VC_Y-;]6>-G3U7UMBL66;O<(EUITB[_OJ7\_EL_O2JSHJFKD7E=J9; M9]U:9\]["Q-:FUTVFX6IZ969W%09^\1ZH,36]V):J+C1_OM*U;E55W>$W>HLCJK#1V];4A=E6L-7P M+I+PL3;XS#6L1-/"+C:Z-87*OL%%S8^>?CR\/LQ^OKAX1[_/GGY[".^40+7_ M(F=BUD#U0FL8%NPCS6MI!AE'%;_UIM6E# .9A_6P*!2=[K="/>R'8P-:P%+:F"E:)C*K.$%O7I]D=FU:O6ZJ8!, M"W3=X'C(T$JA%00+\FO3FNX.EXNOW#0\8[.#9?N^8^)WJNS6/UC69 MVFX;4WLNN@;>$QJ?-ZHM\9N?W#=YINHR XDRP(Z-JL$E@/'O\!F< M')G5&NOF'"Y@]#W\ CC8/2J"V+EE'=*H.]ZAVC,7N B+6.B1?6O=OGUNO]+= M\#RWYG?M5@/3TNZW/-_%0H&MSW$L5BKX>'&'KYN6M*#N=9YI(*.#_5BUC<7- M;Y:F(Z;5X+Q!JIN-/LPN2!N G J>)$V*9%\(Y"T-2[ H^L@TZ[C&# ,JX$/D M\LY45: .-A>T'(;LF:7RTM2 Q&AG"O 74?J%IMU,=047>:.J:.>-M3T^"+ZP M^$1+PN=PSX8#-6GL55X?[#H1#K1T&6@<2"68@0K6 M:KN<5U WV:II2GH<"&F $C!>8 3KE5E4V@T+\\(FZ)+GX]UUJW93I?:N]Y)- MTF8-,7:C0;-(3<(N.N/SD&=YHX4HE)3*J(6IX 6Q=$R9(\F1C>O7M@/C0N0I M$$+8DAY'JU[<%F$2-=@J,5A 9F[8:0\D]B#32 =199P\.;6$_6%! MY&4!21K7B69@7,$.,W:$UL!.N8V%9_6J&?@@("\>+[7QN&/@I"I$E@.K_!\V MLUM=F*4I@(N%;&]AVJ+?@!"#,P2Z(VL8V[&B=:#[)*%H,NB\71U1W00JC!6_ */ M[0S3'5(,EJ1AA +7N/$0!$7J='Z<(=!J'K M*]H1/]RU+OJ6C0 ^\>(6-J%>T30;L+9.]'"5]\WCX0^:)-67!*,N_>HNX]6] M]*N[#JL3T/B!=N7A3!GA E*,;M=85CO;H3AZ;CCB5%VCD(^.RJ*%ZW8NYDZK M%AP@[O%/(!F;!4. X^^>'L\H!ID39LD=D&RVIA9W�/G?H28] ,(&FFRE\A MIJ,)J4E"(7KV1)()3?0NE1GB\=E3&RT: ME)@--R\9HBKMHRI&8=WTCJ3"V8 &B6R1_4&0IM<8L]]H@22>TF[=:@!N'!(2 MUC.W[E?F9*33M9- MYP4!P;^I2_",9-!D[]GW68&R^A:7H8-@+WL012?=9$1'Q?N8/!_:'<8YD;6T MN!+P*&;S19IKUTU?E>RZ%=D4>.?7OAZ$BY\?B%!O@_%:9)7OT=LLT=AI5Y&. MBU[C(8,"XB!XO-2M1L^+? _#FYIS9T'C8B/#3)W:;9%%9V&8-!C]2YB.(M,[ M^WR8O4JF2'-I6AC;X4V WVM-^D78F..MC48 W!&;8"^,(U'M#^Y><=F*7ZY>N#P% MJ:^+[2>??_LBY#6NEC$5F)7)8+P!^0UL@J9('N M/+DD6.-6 3'I6J 6IQ- MU#C\E\ !#!4SD(#H!H*K6�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�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�$Y:A,WX5 R#R;XI:G/D25PY*CL7#Z;,Q_3E^ MQJB:3F;'_> <.#729312XD>GJ%3O:FL^X/$J*L9AMD8=::"!VQD2:9\?9>&8 MS#E;D%/72&<]_7<@#U7+!?T_3DWHKC8Q+<= 62J7<1S MBMI!,F7A.MU17*B52HU1[%5B")/27R 7HA9Q*QFBT?-#&Q"*PJZU@Q0[) M26E_OW3M26HD;V[F^UU?V-;.6)-S[2N;RA8O;OVZ!VN9 MFGVDZ6R!=K*&V!9,+(K[]UY!<(A&S6LFT1\:3F>^=CP 94;JPE/P\X13E E( M4=E8N-D4 Q,XE2GDF*XK1>R"$HHXZ]7K3QZJZ%17AX6CWBGI2,1SKEAD V ; M7%.^WF7)Q[OUY!$O;JT!Y.0 %C&:>YA/D @,09I5=@5<'UNX+#3"%P@D:%E& MQO/) #8/@ZY+HY&6YE %;2Z63?1P_:3T $L[3](GDD^LS&/VQ=$W"-,U =\K M ]JVL$TW- .6^K-O)\PQE.VG1/JM^GV_'#L41$BX[Z$;FYF'0.,R,A_4108E M,,N*]K9P)NY4_7Z)/K"%'XB$V!^VLMO#;3 (M]E@:\9.?2\KU".=RO".N.R. M8FBDP35X,@4NO]P@#<]N2F09HP;3#X9(RN3JCM(7*!<"QB=]?IB#:(U0EVV^G$F H<>9S% M;>S?V0I&1Z)-WD&3:70L"U@(!V4T,X\%G9$'8A=KM+K3Z-]P,^YOX2IAY)K7 MPQ#1$R6?5N)9OQK+.Z+:U"7FW54D;,9N'M>XA*4NN*MB=%(>!489LB['4EA2 M9T2S=^23Z/#"14VCT.#\A>C'*1E540UFZ@Z=1J-^R*X.$S#X/&);1T(=;\]# ML"R=LJ:I,1G845VVL> T+HP _98SH]R2YG'DY<1 B.H-C=S.W _K-G/M48N[ MV+WP?J8C1759IW S0!JCC-3F)G'<9YU$)",=_GSJGZI2N[ZP"#)J,VB(C@%& M//8)SX[,BY921>X+C1RG2DH/O'P//?U^HJM=[ZAGZ2R?'\#LK 4=3J:IE"1I M HF_M_"C+4XNB=37!>"PP:6F<4RSB6R0;;2B>:I0;LFX[Q]:#.P6R=+!AN33 M",07]%]&W+=G+KC$AK)Q1)]3J=;W8F#[/OIREBH";<'40L646-7OU.>CP\CXGC!:(*22:H+6C7>17]-OC=&@7IQ":=+<6'%8^.:\9 M1 +EJC)Y'TG<$?/HJV&FC"Y82T?'.@S2A=2&M*!Q@NK-)E)N(Y#""9']4V-U MK(L2M75HB##Z6N'J*F1MZ;$&I'#;UIZKZU]O+KO;EM"G.E\F+/>_+M#XHMPB M5:MVVSW/4\2DD&5/4W&T<3?\BDJFT_35E*[[!GP(N;YBL4&[A[0&7NUX'8'5 M!VES"DC%(Q[?T3&LY/F.JPJLS)T='MF7,M?5&G MM(?4%C\[MT_;C_:7\5MUMSQ^\?^#3[,\E%]@ZW3R\_$HAEAS$VS%7Z[G-@1; M\.5*H1UWM #O%]:&YH88M/_*&PO=V]R:W-H965T2\9$GK3;LH"O1# M8LV#]W'N^\[9VMA'ERGEQ;=%7KCS7N;]\NUPZ)),+:0;F*4J\&1F[$)Z7-KY MT"VMDBD?6N3#R6AT,EQ(7?0NSOC>O;TX,Z7/=:'NK7#E8B'MYDKE9GW>&_>J M&U_T//-T8WAQMI1S]:#\+\M[BZMA3275"U4X;0IAU>R\=SE^>W5*[_,+?]5J M[5J_!6DR->:1+F[3\]Z(!%*Y2CQ1D/BS4M+0.O!FM.? )!Z8L-R!$4OY7GIY<6;-6EAZ&]3H!ZO*IR&< M+L@H#][BJ<8Y?W$YE> B +[/%<#V3MS=78N7XOW-P_67V_NOMY\_B<\?Q->? M;\35+P^WGVX>'LZ&'ISI_#")7*X"E\D>+B?BHRE\YL1-D:JT>WX(B6NQ)Y78 M5Y.#!/]2%@-Q/.J+R6AR?(#><0W#,=,[WD/OH9PZG6JXI3 S<:<7VJL4?^54 MY]IOQ+59+&6!A[9^>"^M+Y1UF5Z*O]^!GKCU:N'^L0N=P/S5;N84=V_=4B;J MO(? J+VR(9B*,??W@SF8S>^4Q54/.=\;N?Q%HZ0?%'.E#913EPFOY7::>94V>JH=_/EYJ&BTQ=23'-9/ KDM03_ MQ[=TD1B[-%:2374AWJMF2,L$(:/Q;UHZ@.6< M\)DUY3SCF^O,Y/GF)816:9_>=R;7*?-RER*R@B@\KM$A M6.],,55Q1'-18'"'- M?7'4/I ;X#07R%:J$8@LU3^L"&GZ M%)OPC("EJD)*$"\8=ZH+8@,M&J>"F.0[>!N1NLSY]>F&7ZA<0FGQ-OIC@\?A6?LZBP:([+@ '<6/M,P @5)V0< MEIW\,GB)8"]I_()3$0'3MF'K>(->A.7?H/R$0D/\CWK704/5[ZNY3"I?CR?I M('S+S!4,8FO .NX6S^WPNOO2NE+"<-[L-&B?++7ME_JG+9.(!?U, W-21!>@ MQU+4!G2E7>D5.9(+V'91N@BGG[WC/$Z+ Z #(= M:43NX!UN=2TD3%6" M*!2IMDA->UR=WJ,(#E 0*?;[)),%@4XYNB B@/QI?O_*J01A7CB\V\G>,@9! M'EL$3BV@SKDS9&VP1>]L9<"$'E+-L2JCEG854B\X(T^@JXA>NPL(SM,^,XYS M*O$5-7D)@\HI$+K67.1*5*4FFN4;+6A><77R# M=@IE'9G'>8LZ6P*'3+I*EH1: %"0>1ZJ.=%?L7;:I$Z4RTJO=LVA>U% ?E:4 M"\K=0-9E -IU*P:W(>/3=^33BT6E8E^\& U&H]%8@*E8R;R,F!*%OM#.E52( M3,M8-1TF %=-$58D/;RJB!-*'5*[\;AT'.DA<**PSS.[DI:*H6N$! 0A.CM" M=I1\AF/N]PRV#4P5Q3SL$4!\-'CS?,>H[UX20_*/KXW!^IW^*^3KJNR1:5 4 ME]:L=!J-CA964P<):+P,/0-A@B0 (9!C99$ [58S1H":V8S,MT0Z '*!1CQ) M^<>&MY;H3>&O=$F!2R0;0G4& 4IK#*6Q,7&8)D&ISUX5 Y!H =L2V0R&K20> MM+5FQ7*'Z"KFU$Z%9I:ZK:C1_4[ M.KDGA"CI6TG=<.W'J&0J5&2EN4J0W],E.K72DN$X&!-%84L'@(E)-#MFJB2H M)+G4"T39QI1>!&\D7>BO+$+EJ5'>I5TC%$8(F'X.$U.FXA"2N1KL=YVZS#;> MPP@3TJ!A]9P%Y[+3M$!1XMPD0#"6HP3EMG"-% 2#RB%['&Q9*@I[90$\ M%=!4.6T1B&I;QCZ5C[QD)5?(L;--B&<9$FD,!LV>!#8),J&95C%%KEV'3ZI= M@I2,?.Z"5P%D#-4^Y"\7Q63VZML2B0,J;R@_:&KQ730$SX(T5+5'$VK8HVDH M0S7!\BO*;FUVPE:V)*;RD2M/,YK/2 ,'&*!T6C4H 86TU0=MZ>PSSH)("S9D M50@2G5Y61+;PK(C5@1="AF!)ZW*Q#0)8H8,""I:0AT9K(S;([Z1VQ6>%"-() MIXK:=M_++*<\>V +\;K>0KP^N(78,Q#LVD <)/2=RY*36LR3_^8>Z.1/4.VT M5NWT/[D'^FYB>V>_=#@=RG:7W=T+[%O[<"V;C$:OGJPG/JFU^)NQCP-TZWAC M?-)O=VXQ^<0F/R3>DC<>XD..')%*#F.K7J;HB1U%3&R(.*4QEV:9,3ZNAL8V MBQV'JYU)MSQS">):_CQ6B1NB[*P6-9%PDZ&%3G^IR$=NTQ9-B M$6KH_T)9^'\=^#/J0)?3DP84#1FU1HT/)U5?%7$"+L:J3@2E1H6#)<9LNT93 M6 4!=2!6N\=@]:H9E4E"T*:M11XFY%J31;1U8(_+$AP'35R/I[A5*-4L> MGEO+@A!\NO=IG=Y>]+G?WR/+2+[>N\C9#*D";DDK*_3I57,OYQ!Z3GF;(I[2 M6(A+BK\E>M]O',(@\^+U\;A_^GK4QWC=I\:?_8"F_-:D7JAUOJG&[&9LY\W. M=2YI,MR:UYLYO9[OAB3!)4 M>[@X#X[Q!?Y8T-I% M+!0A"@.'50FH-D0K&OLLQ^:=JK:)D*.S>N7R/-8AA[15I0H0XJ&SK(6(!"(A M'%PV^,V*-AVT ^$OI=2V)7'70WL[CDLWV-4\#5N?3'EU2A^&*5J07,+7T_IN M_>WY,GQR;5X/'ZX1+:@SE")G.#H:G**!M>%C<+CP9LD?8*?&0TC^F2D)'>@% M/)\9XZL+8E!_D;_X%U!+ P04 " #1 Y7MC:AKFLB "J?0 &0 'AL M+W=OMSVT:2_U=0WF0OJ8)>U#-QXBI9 MD;/:\JLL.WM75_O M'S/\85TW'\U"J3:Y79:5^?')HFU7W^_MF7RAEIG9K5>J@F]F=;/,6OBSF>^9 M5:.R@EY:EGN3_?V3O66FJR?/?J#/WC;/?JB[MM25>MLDIELNL^;NN2KK]8]/ M#I[8#][I^:+%#_:>_;#*YNI:M1]6;QOX:\^-4NBEJHRNJZ11LQ^?G!]\__P4 MGZ<'?M%J;8)_)\C)M*X_XA]7Q8]/]I$@5:J\Q1$R^-^-NE!EB0,!&;_)F$_< ME/AB^&\[^@OB'7B99D9=U.4_=-$N?GQR]B0IU"SKRO9=O?Z;$GZ.<;R\+@W] M-UGSLZ!@J6N^/_9K<@A>.%L?^2%B;PP(;IY(J+RIZS-GOW0 MU.NDP:=A-/P'L4IO W&ZPD6Y;AOX5L-[[;/S:0:S)"#\ME0@[-8D+U]>)#O) M]8=7K\[?_5?RYD5R??7SZZL75Q?GK]\GYQ<7;SZ\?G_U^N?D[9N75Q=7E]<_ M[+5 " ZWE\NDSWG2R7B^63K@'_OJMWD M<#]-)ON3PRWC'3JI'-)XAR/C77=3HPL-6IK4L^2E7NI6%?#_;*I+W=XE%_5R ME57P9>.^?)LU;:4:L]"KY+]?PGC)5:N6YG^&I,.3'PU/CMOP>[/*1U5MVD;0+E3SO#$QH#(I_JBMZ):5O7JEFKIH$1LSRO.XJ M7! P6$D&'X#IN(%U4?#_/%OI-BOU[YD?^/(=4*,K>K$ILBI7_/EK!I=Y7I5*H/O(@D?*E*#:^!$$6/G2]7H/$N^0:8F^T\_[%[O M)C^?G[^EOP^>?KL+[Q1 M?LB96(60/54*1@6K"S-:V@&&2?+?^MTHPH9!B3% MNHC\SD J0%=6 K.KNF%2NV95&V5VD_<+$%"A6M4L17K)&L8&7L >:^ 4S5N1 MU,S0RU?GB5EDC5K4)9!I@*X;' \%6F9H2\$._5HWN!^ 77SEIN89ZS6P)9_) M5DFWCHG?95V[X-':.LE6JUI7+4P6SE$ WWE;PWM"X_,Z:PK\YB?[39ID59& M1FD0QS*KP+&@5:-M#).CL!IM[)Q]!@;?PR] @NU.[M7.LK5+HZYYA2HG7) B M,#%5 ^O6V'6[;[WBU7 R-_IW9;F!:6GU&YZ/;7F*8_&F@H^G=_BZ;F@75)U* M$P5DM+ >\Z8VN/CU3+.EA#[Q MU,*UG2JV=YW3;-(VHTFP2P4[B[:)7T5K?![R+"^T$(6:4HHCU&+IF#)+DB4; M^5>F!>-"Y&6@A+ D'8YDUSJR"+"!32051I MJT]V6R)8($5DMH DA7RB&1C>8+L).T* (N!*9&'A636O>SX(R O'BVT\KA@X MJ1+Q:<\J_X=)S$KE>J9SD&(NRYOK)N^6H,3@#('NP!J&]FT!RTM&"-X0#0!# ME!0=Z'I C!GG[OWP;D]6(23 MV7XEWH&RW95Y;MHI\JN4";6D& 6-9NIW%NB M>/-X!;PH:]HR@)V5MR[;3) 8&+:[;))7L#JU[-)H68>&"?A!<0DCZ+)H/%7> M$1V$*K01O\!C6\-TAQ2#7A00&\&;J"%UJ0O>"UO,L=51<+J*$090R]YC "1 MU^E0NW"%0>FZDE;$#7>M\JYA(X!/7-["(E1SFF8)UM:J'G*Y;1X'?] D95U! M,.K"<7<1%"&9 "4HQN5QO>=J9%=732L,1E585*/C@J MJQ;R;5W,G$ !RX0P2VJ!9+W2E;A#O_/0J<\P MDDT DB99\2M$AC1A:BDEWU:7J#_P9H41*_I:6"(R'=$K%6DH1C>62#*AT;Z+ M=89D?/K4!$S#)F;#S2Q#"*9<",8HK!U?D5@Y:]A!HEMD?Q"DJ05&_C=*((FC MM%TT"H ;QX^$]?2M_9.E'%%"C["0@;N5HB0 @II'$9AG9I',RGIM'!V?-"WO MXW^U3%+:DU7=.D5 \*^K CPC&319>_9]1J"LND4VE%?L60>J:+6;C.B@>A^2 MYZ-HF7!.8"T-<@(>12\?M7/-HN[*@EUW1C8%WOFUJWKAXOT#$>JM,5X+K/*6 M?9M$.W;<5<3CHM=XR*" . @>SU2CT/.BW/WPNN(,G-]QH9%AH8ZMMNBBM3!, M&HS^&*&CRG36/N\F[Y!,'(.\%(YH1V=,,&XA(_4IP7*-F1JC 94!,LDP5 CP M ]"9:XL? )%DNI0H'&"%,$?&'36HHY2792,=83 M\QD83AS8 :&4<+>.8&&G.= -C6[P)\'NA:'\1-N9X:ZD0 +W MK]ALQ2]7ES9/0=O7QO:CS[^Y]'F-JUE(!69E$ABO1WX-BZ HD@=X"T_."-98 M+B F70C4XG0"J!J'_Q(X@*%B 1(074)P%2H,VC.81YX69DBK .Q7]1+P+JP@ M[2@$(J@" S/74P#-O+"8DY@"J)LF@!B);I9T0Z@:O@72E"9$48&L4<^;>FEG M=R*QW+L@ %,O=_)2;A..@;@XB$G#D"L50,;&.785LI7@=1?>.(0I&MS?9H\P M A;BUI2KJ"L$S93.H:U6KRN7< @9C>.KJJXPZF_JLHST*#0[-5S85/7L@WE^C=ZVZ^ M"'-A_>@)NK(FL*#&$+VBRDWG8;GU]?N&W_'I!H MGIP=@!^)C)Q)D'<*JDW$'M >1#%H9DNTR+C#VU$]ZRU1D&E W!4^"4H]F'X8 M>(B\FS.K&&:AXI$F=I@*SN:9KDP;4D_Q_B:.;>L6'<%H[F-S\C7.]]7Q:7I\ M>IKN'Q[16U\=3]*CTZ/T;++?5QR>=@!B?.K40/S^Z6'ZW>F$IYZOI*^H66 \T?N(X5PX\YP,VE#XW6J+-+P)L8>Y 1 M0-^^@Y4+RMB C72Y$OZ0DDJ'[D,8H5Z<)5#CVQ3KG&-\Q?0;PEDW1]2<@P%)9*@U'XA#5 #^F M0\"$Z>#KB^1PR(_S@$PCUK4Y%9$+TAFZ"",*U4RI6-;DVMA[I^+!T%K4R+ IX/=8C1M5/ 5\ M6]!J89DKW90#YZ> W8@17 >__]C]3 S'E1Y-T1%%O.,! M[\/"^-BDD_\,#!XG/M"UI@E@4?Z>HLJ0X3^.JY.B(Y +.RW+/_J:(P+"' P[ MLEK9B(/CCST79[@'QA#,(@C<1Q(*5EA=-0"F&JK8S,#G@.P=G1^D);O&'PJ0OS-_!Y"3=/]H? MI'68N[.3@_2[R='@&X?'9^GQVOOI/V$X- MA8G8R&.!/7SN@#WGKM!(\08'Z>?&(&"30:[T8I2/ M&2@>#..L]:(N'?0TKG4GQ534^_#7VJ[B VJ,Q%:8U/TZ)I#.B-56,O.NZMK'YZ!?-XL=!UOJW%./E63Q@:4'%7< M-+#*[B3;B7E@+E.B;(!PDMY7)Q S[^_'NNE+^3[PX8JLZZX!H=F.@+ YB.H= M+-NHQ8'C.4+_^\>AK7'DBNM'NMP\)I@FQ8P14CSK&B*I7Y&'KRQ3=M"@2B"R M!&-A.$9CD]K 4AMV,)*^\X76JZH PXOO>,*< W_/'>M6E8#7ER]?G?NE??< M2-Z%T7?B.EOJH3X7H(,;0US*%%D@=M94Z<$\MB#[J(%/H$_&SU+.GP+XK*QA M9].8\29&*0R6<[9 MC7$UI^!+NL\ Y^ZC!>$!O"%QMAN_ A&P::;EM-T^8[[N$59U?"=^,;/ZNKX1 MU.:"#ZP2!3@E'6=MHY&0 0#9&0<2?&+$]]UA-1Q4AR8F \?8))=.,;O<*]^X MRV1=<91CJ?OY+5$(40J0I'[K9!)4N6W/6PP$F%XZA.^;Z.5;=G?&=/'3O@*$ M$_>'XQ!]1?D.6 F((%0$&':3*S890\T[(52\SW6/$4S884$V"=.@S*8;9HT2(^>2@\75P/R0"WZQ+W1%!V <$HF]HBO0 MC5?G'E=F:PG^+#'!C"EJ$*9$=2/#NYS)4&G1-:-( W302$I-$'=C)1+;^+FQ M+AZP%1K@S&\%)LZ$M,DQ!7I$D+H) M52@X)^$[<.+$JQ-.FOS:%?-@SE!0&:=ZZ?@!^@X?[3F=SVXR74K<?"67@ MB\#F[2;/59YU/G23?_H5TA7*TE?X!L]\-'5.T1T$$AU]PW@]I_"GT.A2?73D MQMX-](SZLPP'JU58WD-;9J4JEM[Q04:5M)[:BWI1LY@(YR_\64I@$.8"IPMK M?V/[SW%_M)PO0]5=<=\JBU5>X@P:M\J@8$WO^U+/5%C@L[U>@\/X_)9L [M< M.\#RCLE*90NCFR- @#C?05@"Z&0*5&*SD&YXCRG#AQ[$I+39K:BZ+'>\@%+D* MQ */>O*PD-)0D_]@69KI&5N!()O @3FWCE7D/I !MDTMU:'1"H3G/]( MD1 >@@/'RJE/9,";[1H[XY><(B",B57DJG46?NE%*4=WSA%-Y8LT9).R>SS* M#MO5\#VBU7?S!H&"M\%]WS9$$K/;<1H'QKT'J MPPG9ZLT[S3O-IUAQ""H)[)1@6,N(XX4&E !;18KR5-0 "_2[]$KI:M4!Q62I M<<>P-"*M>8EC)@=BG"GV^JVK6T[LYM8 R %,%(98$NJBS'W+4, W!0@\[B0< MMYZB*1,71X35DN@$Z?4G]75AH= .>1@.V56;@S(H027M5@)'('X!NEI."5:U M7597#&*(8%\+JB6"!>.-&::R>UP/-1ML\SF4D=ZH 0NCJ1S_X8XR/%O!@0,P M$*T(.F%X9LT)4(M"63"J)]BAM;N/[&5=J)(<%.?85=PMW1<[=6>Z50GK[6 > M;09WV$KNVN.J6'??8NQ2!QU!/T([UZ@8K ]AP?;N<9&76XT74OH%6(\>Q:"3+%K$6H::E%F MQL@-80^&<4U='>5NG6NBZ(OHQJK>':V"'#>\ 1G02M"1[&AFD\PSTC"4%N@P M@5/;W*EN6XDW2 )KM"P6/A;DQ-#D](H)@=?-!0*0'J\5'B4R;G!>!YW'8P-T MQ+LU.#:SW4FJ(&5U^-TZ>#XC M;2X6E<:"G)1"O8:Q/V!UTH M78;4F [^ RQ*0V@N=2?.,MO8PAN2WUS5>* +H?>TNU.V5B1;=J94,<7V"^=C MK6!:?U*%_:,KD\;]KP3%PL6T\)I:._SD7A6I;=@IB3:;!\CY6=53:ZH'<+9B M2#NN M]>>K9 MAVS).PZ.'%:WG_N@*4K/R2D$"IG0 M7-_).*EG=44("N4:?$V9%+9"B[3=UX_=D'8:/W[I$G;AB[O8BTQRZ$[R8 < O MN7.:(D@HX!N[R4_Q]_Z. MI';-CA*UH#2A>BYPZ-4IT#"1Q[/S;MTCB?H(1O M781G/'BG<1* )[;P/$XG$&0"&A$[]\_\^G3E>.Z'S&:8 0T\.H[;N(03_E5F M:\/\JBK+R4__XO )9@[6='SFN_MQ]9A&#H-@$L*DM,!4+FJS#N)%<$*T53>#BX MP8_#4_PP6Z30X*,080'7> <,RS&4^ST\Q]TF/GGH,GMLT(U>@C":@,[=Y/)6 MSEO/LIN:@)P#5M).Z&L"J[Z(,$'?$Z27FL8KHYS,\F[92=&#:P!C(K+?DH_> M$$HO$,#4%^Q9Q@ U:[QOD&RUZZZ0%O[^/O6QN;)RZ%%E<^$_#>QQWST.,=/ MOK,'QLA<1*B9=S*7LJ)88^3:"C:>O .!$1$5O-G,"2&Y<'[8 3+//"MM6L[ MZC831^I"$I,M;1\*GK-"?;]G'UW-Q.SU2Z5;C*%8OH'U\7W^+#(Y2(AN&1 & M)N8EM20N8M#Z47[I+N7E*!4N^?""#KDS.F6! 23%D6+V^?J"8.5(8B7!5N]> MI!,:O(M[U&[5>9,Q_* ILY5$./#J@M#>'6)7[PA,"+^[RIX((HL@/?ZP,[*/ MBBJDO0!#/J_$MS0*E*>*?1EY*]JJ;D+J4\K&U@L4$A.EN\D;C._6VG!SDE&A M^S(#DV01T?Y^,+[CA,,ZF&03,\+$++T:F!)M+E6?V]0F(( M<-/<4+Z*L5*"T+GDP5J-E-BU<8P.*0&S1J?,[8/+:4( 63 M !:DH&YTTU]M/3 XJYG'8V)T!(H )J?1YJ.]5L3>,D0#V0"*K"W^PU^S95(? M*WJ GMY?F(GC352,EI2#8B.< Y9DFE4?P=+1ROMIR#\O]'RQ@RT&=#0IDH=N M;>F=]D1*F6L0/5UI=$<7 B "5(7<\T<1JRI85/4D@+&)\+D7;@(]NCLF- Y-S8H^%[!/)@PG$#T'3>N M7'Q02="-&1H7F]J, N6?W ZSL8VS5M(G\)![BN*6D5[C+3N#>+^INVF*QT@F*(0Q!"69+C']>E^BE+-CT46\HV^'D;)"# MFP57<'&TH4.2'-H+ A),. (GR6=:5;/B,@ M8K,8G'1)0F9W(8)[4^ QIP:"&^P";$SVSNIOP@<6 FF!B-:ULVQHE4-EBL_! M'DR^IND.#EU++)]\MBHRO I1_9IG" 2VY5*B!Q-V>BR$G?0(&Z1F['C2YO4_ M)2)0:OORY JO;/@I<@EIU'QC .=!:1M'>]B &5H']; S4@.C);U]XT?#!/0.YR EL$>VDGY6"60K2IJ^% EN+^5>'2-3@_N4X&M M@X,"_(/NZ&CO;Q%9VP<1K6NJS_*Y_YV\A" ,< /#=Y>V#3\/@:$OJG-IW)CP MBEN9QOUC4P:^U$%LCN^^#*)+,HV7?.M!<&<)OA8=;Y0K!E(P8_8B &;A;ZH@9Q6^ M# _&YZX"X?C47WC[@5\2,M=*N7LC9H.0O'^$'B>!#>]L]2.Z%O:):[(ZRNR$4PP1$E%)]/IXVR#]!%W;+9&2QYK"NY M'42NWAVA.+%70G//6QB_".FV4HWMG@2$?6')%JDITQ/F@>A.#[S$820=+EVA M*6)9A#!$E0="XX*2TJW7%!MY1S?C2#,@IC 5W8@)>F%[$E-I-"BZ7"X+)F.B MN6_72@6[\MT559GO O9]RPE$/U@ Q;*1.X;##9AK=\ L6K'@GA,.(*3U'V^^ MIDN!,/%@7V"+WU,F=_!J5#[IYK0B&9MB\=<$&^I27@(:%W,D(_9$8D7Q0)KE M%@]'^I>@>[/S53>V;!^UJ'"<8;MB+2>\?6D]HWB('R08E\V 8(C_@U+,8OCN MXYX='TJ/9!C?[=#>P0N07./UY[[08SDFDC\@B_$+0O]TEX-^L;M!M_[(R?OQ3-GH M!:S^Y/D7NK#;PN+KRXL(3]]WB??G_[64ZXW?2MF\&_SAUX'_V6X 3_YOW?T= MG#_'M.T#,,2>/H!/D(#%MO M MM?2*,X>Z?YO,'F$JK^P41-AG>-8*:@S;AAC?+_239%@+@!?^U=DK55/3ZE ME/"OS>3"G"!9O&"%;! %J'Y7N;+V*(;AP'TW\>+QF\,OBP[2E:Z6'@B"UOC& MU[MQY(\5)IM8=?""&UC+._J0,Y;M'Z-2NA_Z5X?Z2VZ^S#(-1BJ?::FP]V10 M FL5B.#-QO80!=_\PAX0"*[\Q;YZZ>H.#C#Z"T3A=<&>HO_4E(*>G.]<9(^' MY6 'VPFRN8[@.R4=LL()=;>UOK< >402Y'+'LG<+J,^C$8H8O/:3SNK%E30I MP$G]/[KDP"=G9#9D3A[DDHF_F;UK1#&"1]$/T@]!.+E&:NAZQ.2R["UD>6=A MCW&@M0MN.8Y*S-%OE3EJO#=)[R\9NWTGV(R/>_$%L#7^C)H)KB./BY[_ M/#:+KN?>QA\K- J+^YT( SC*/;Q7MXN,VYJM<_<]O.R!J/U:3F"H)>'#9=WV M+@]VE^K2R-RN(M?T;J5R$R.C@1B(F:_ZOX#GY#N:OW95,5)O_)$$1;>!-F1? MXA[(*G2%/" @_\"8$((+#EWX-M:@\1%[9Z8^*]H3D2[DMEV,#S]9/B,EZ'XU M?;@KZMSGJ?OB/#7&OL63#\E:(DMST\ S0XOOC:(2ZV!#\7$EY5-SGD$NF)KUV/2@?;F3[] MYXU\SI.= ![I\-5H>_@(XS??X(/HOE*E^5Y^R1.U$7]TH%OB583G[(_RW%_WW.="!.%O7F#R@'N _J2T3<:Z M[2BHE0X[>T\^_]S$<%.=K78Q[*=^QIK__^C6.GOLD+-'5$\3U[;%#@:DD%JX M%CO?5DG]#M8F]X/>SE_@3@?@KX13@5"W_E+;[-+$_1'[. MO[_M'^=?,7\%7@P%6JH9O+J_>WK\A'\CQO[1UBOZ->YIW8+EIG\N5 :"P@?@ M^UD-?D?^P G&ULQ5A;4R.Y%?XK*N_4%E0UN.\7!JAB MF,F$% P4L,E#*@]RMVRKIMWR2C*&_/I\1VJW3?"PN50V#V"U6N><[]R/^G2M M]'C:ZB$X^%73>'?BS%&NSLV:DR42I[_1P MU9R-0@(D6E%;XL#Q\R0N1=L2(\#XM>YZP_T/3G?H,N%&7*KV+[*Q M\[-1.6*-F/)5:^_5^H^BUR('6XOR*'\S"T_/]5JS32=!C=:.%4=-<#)CISR8#7>2M#9\XL) MAQ0&X]M6P-C6L.OK2W;$'KY\O?GR[9'=?[F[O7^\^O;U=&PACZC&=<_[D^<= M_X!WSFY49^>&?>D:T;RF'P/G #;>@/T4O\OP3ZONF"5AP.(P3M[AEPS*)XY? M\@-^#ZN)D8U$,#(U9==R(:UH\,LGLI7VA5VJQ9)W>*F'EW=''=U1+!]72][B? M_TON>Y?%?H!O^")T9A0W[*KS)8)R[>>?RCB*/S[.Q8X-9[R3?Q>&2<389&4@ MS>"ALXK9M4*"+Y6V?-(*9CQ'PPZB0W:'W:EJI8(@_21KV\(Q<>L\>Y-!MIS%B] MJNU*$]&4BH9A%OBGLN-=+7D+'EL%"8%';-C*("XF+^YTKZW3O_AH2-0 S2Q% M+:>RYFW[XHQ0SZ68,M170"6U&KQWQ6[!OPO-#BYO/]\R3N;%M ,1UNW+GX#^UTK5@$*YJIX-Q2D"XTZJC=\: S)D^P -;HU;2+PFI M5]K9;HMVJJAPP+ UY+?2<5A+.V<7#YSAV0 MRH:H"-VEL]"79U&OG*=OI["?T)[-OLC8.',3 &83 88\M-3J23I[+$%7OS#C M"/$2-O;%%G'!R+_0JK,:/8-JOC1>XIMX^PUYD]4+A,'S,*1;D$[@NH4@A7<# MM4^+OU1FI1TN;RU0G>3$6&P[=,3+&EZT=F^R3K8?$&EQ-1J&C=JZ%.%I0_W70 MC7SNGY# 4C6&"6K*#"U5#"W5:[F[%0?D4TY\43C6Y@0>!>-7C7U+\""??_"& MN#M^.ZMM_IHA?S^P)$N#),^Q2J,J2''N \NJ, BS JL*JR0N-YFX+:\LBH(P M!FE5L2*H"I 6%>0$594&552PJ CB,L.;B#TJR]NA-7P@TJ0H@R+/\%""11E4 M881U' 59"?(BI5-E$!=Y$$/ U?ZP_3U<]-9#O[>##F"$(LP.R3ZH\DF8T&:4 MYT$4E[2;Y[!E%N_S41BD91R$10@?I5F\\5%+>1[O%Q%&' M&8(C W61Q$%1$EJ(C,Y0-OA\*JOPMG_X.\3((RQ4AQ@%"AV*I* MMTZC&/N96^=IO__5%?06&=%@ZI88#EP=<#P5O(?VG!5%D"45Z#+05(X^+M(@ M34A&GO9F^BPP/2'#7;20Z%ZL_XV#R$'J?V\]:U?PC#BD8H>>Q")8)4=('D0Q M&8ZPTD[F*-,XB-/B$%&)BH,*QWIJX$+PA@5.'[&#*L$ZC&A]348%F'K.NYF; MC:9<:O;$6Z2#:S,3ZPR39K F*98D,%U1.9R4'GD>TVX!?T7)(?NEPWVP=95T MAB;&#EI(."01NS4W+^*@2G*G>U+!9>!15.1YOY=1I@'L'75I-P=1IO06L/Q9 MT$ 81- I*YP7R?<) 0U@8MU;+RE>R=Z3\;IO_LW>G_ M[:TNH&O=OCO NXS^PTM*/L#,_Y_WK_Q_H%HQJ%;\]_>O?Y/%[3![H]YC0A4T MH=)EHH5A6H0QO4\M7 [:\D8ABXE1^X-]/Y;]Q8 MUG.UN6"X2=C?.7PA]I<+/&PGGMV[!WU9::AB[+]O.0]UMI_Z=O3PIH#@5ARS M"^.&4[-JW;ALZ7JWTW[X$IV$U_-7AB#5-G?3QG.C81#IO%6S;]W'^^)BO//M M!;>'F?O"A+N=PO3N/\,,N\-'K O_[69[W'\!N^%Z!@_"G5.0AL<%<"]X(30?P?JJ4W3R0@.'3WOD_ %!+ P04 " #1 Y7 MWMG/LST# !F!P &0 'AL+W=O]6#/DO#=OZ.%P<9#J7E>(!AZ;NM5+KS*F._=]O:NPX?I,=MC2SEZJAAMR M5>GK3B$O'*BI_2@(4K_AHO56"[=VHU8+V9M:M'BC0/=-P]73&FMY6'JA][QP M*\K*V 5_M>AXB7=HOG0WBCQ_8BE$@ZT6L@6%^Z5W&9ZO9S;>!7P5>-!'-MA* MME+>6^=]L?0"*PAKW!G+P.GS@!NL:TM$,OX;.;TII04>V\_L?[G:J98MU[B1 M]3^B,-72FWM0X)[WM;F5A[]QK,<)W,E:NU\X#+%9ZL&NUT8V(Y@4-*(=OOQQ M/(^XX:N%D@=0-IK8K.%*=6@2)UK[I]P91;N"<&9U MN>64!>CP38UTV$;#]?4&_H3;JZ]7G[Y<+7Q#66RLOQL9UP-C] IC"A]E:RH- M5VV!Q:]XG]1-$J-GB>OH).&'OCV#.& 0!5%\@B^>2HX=7_+;)3-;\TN5GB2R M]^5<=WR'2X\NA$;U@-[J[9LP#2Y.R$PFF8ECCU^1>==OM2@$W120>[@6C3!8 MT)=O12W,$VQDT_&6-M6T><.5:5'I2G3P[S7QP7N#C?[V4FG)_U#:;"IM=O(? M.-%;)X$ORQK9X)W0O"P5EMR>Q2T^8-OCVS?S*(PNX'.%L)"U[M4--S(H "A&:H??1 M]CY0Y^+4N<#;PAH1%'UF5)]<$?$+,X M3E@21&1'+ LS-@NMG;$PB5D0IF3/6)H'+ M"6"MYCXH"YT'.DCPG*THREL]B M2%B:S5B>Q12>1;26!;"IAS,BAY" M5#: ]O=2FF?')IB>UM4/4$L#!!0 ( -$#E?*N\L%9@8 %P4 9 M>&PO=V]R:W-H965T7\2# ME=*?3 9@V7612W/8RZPM7PX&)LZ@X*:O2I"XDRI=<(NO>CDPI0:>.*(B'T1A M.!D47,C>[,"MO=.S U797$AXIYFIBH+KFV/(U>JP-^PU"^_%,K.T,)@=E'P) M<[!_E.\TO@U:E$04((U0DFE(#WM'PY?'^W3>'?@@8&4ZSXPT62CUB5[.DL-> M2 )!#K$E!(Y_5W ">4Y *,8_-6:O94F$W><&_8W3'759< ,G*O]3)#8[[$U[ M+(&45[E]KU:_0*W/'N'%*C?NEZW\V?U)C\65L:JHB5&"0DC_SZ]K.W0(IN$] M!%%-$#FY/2,GY6MN^>Q JQ73=!K1Z,&IZJA1."')*7.K<5<@G9T=+3AR86A\ MFP,:VQIV?G["GK.SWTY^OSAEETC,&!1&(UVX(U:O4<.;W0/WKQ:&)$(C$.F M4G8N"F$AP7^^$+FP-^Q$%267N*G;S7=<6PG:9*)D?YTC'CNS4)B_MUG',Q]O M9TZ)]M*4/(;#'F:2 7T%O=FS'X:3\-4.U<:M:N-=Z+,O>>[AU.P8,.V!H?&A M-7[ ; :M?5QZH7&L8JG(@7'#N&1S%BM=*LU=YB$&>P,):)[C9L*,Y1:8D+$J M@%E^SSTV<_3*/A_JLM("AL7B7 SB^.+B\Q"=TB&GD5EC^Z-\S?(N19;.6;[_+F>_F M>X>\I4,=W?:\V:>5,^^5FM.0.$V^GM,=I!8"M<+#MSX9AN'33;S&C6E%S+K& MZK.CF )%R&5^XXU>:G4E3!.]:T&U(HM:J\6BLL[Q:&A>J(IJ)QW>[LS@?J/= MVNP+BC)L1$XZFVD 5O@2"U1BUW/4 >!#M)Y1;3KLT [-^&08#*?C8&]_Z'"> M#*,P&(X0"U.B!-=&\QL7WPS2U"^X/-8N,]&_>WTT?_I 83>1',H#B2/GC6%$ M_)+*N8*H!.H;6]+E;K5P.M$AK F _;RN!8V1VF2]XGGEZQ=&EUIQ&8-+(3R+ M 49L396F(A98(QA[O!1?W+K[]URUC#7PMC&8%+)YXT54C3UZ+L%:;>4 MW.I<4J@M(":KQE&4 M4@<%WIA9R#ZO(89B@?X:#8,Z56BY8=_R9'[ZJ$< ]!=^ ?'.^SM[1S7[L[O 0WPV^:^G4"/G$DGK9B3_W+\GG_]>)WN&J\WIJ,=C43<'8SPDU4455'#.FGXC?_.Q*IIW;!& M-4[#DNLDIXKP6C:&^]$3<3/TVPPG0:0F-K#Y2VSO3OSMRNQ"X )+H!E78?)*YT8!FLM"NL M-/SBS*F2>QN^&X!+U.%:%/B.;?"GL!^-G_[\P!$@\ ;1/J[#_GCZP.$!^\9; ME$1VC?HC%C^,ZA.R#=(U" 1J)"FMF98HIS;8PVD%J?;'' I M00>Y02#,8GNCQ;*6E6XQPPX%@PZ@/NI4K9Y(0;MA>+L7U!+ M P04 " #1 Y7]U9NZEH# %" &0 'AL+W=OJ'S;V)%ZQ M+^[N.H%_WYEUX@L2B;@/_9!X7V:>>6;G;;BV[ME7B %>M#)^E%0AU)=IZHL* MM? ]6Z.AFX5U6@3:NF7J:X>BC$I:I7F6G:=:2).,A_%LYL9#VP0E#SUSM$L[E%)J-%Y: PX7HV32O[P^ M8_DH\*?$M=]9 WLRM_:9-W?E*,F8$"HL B,(^JSP!I5B(*+Q[P8SZ4RRXNYZ MB_Y;])U\F0N/-U;])0-'X M8/5&F1AH:=JO>-F\PX["1;9'(=\HY)%W:RBR_%4$,1XZNP;'TH3&B^AJU"9R MTG!0'H.C6TEZ83R9"[("]/A!(3UV\#"=WL )/-P^W3WX+9=/)MF :R MQCIIL4&^;I'S/RHYENJU_E!P#\:TX/3[!CR+#\] M@'?:N7X:\08?=OV8?7_/TX- 7#>7OA8%CA(J#(]NAEI(H!NX"IU#)@25\QETJ&5[BQNA:&+EUW.1,N&'2^DC7\/24\ MN NH_3_ON3;X'UP[ZUP[.QB!#^383P$\5=@]1^WL2I;H07"1DEX)!>6CD_,F MMH-:"0/!@J2,1UTK^XI(";"G'@99__/S%Y@YNY !'BOAI%G"C#&.A*ZO^ =/ MCNH5/@=B6W,=M96U<6*K%" J SY'2QE""O M*!SG%X=8%DA=*%01S+(C3^8<%DC]=(OL3JA#%A5;?<.L![M!T8)_)+>' M/O$]AJ;F_> 7IL,D:0((%NL!]>$H%RJ'"+IM+\CM!:@Y8-<<0)B2%_EQ7-'H M B]?/J80WM M$8R%4OK"(7/@&+Q)HQWFO?#L@[X5;2GHLA0M2S7I?J39<.W3:3;!U;/1S&VALQ&5%&UL[5AK;]M&%OTK ]4M'("1^*:4V 9D)T;= M=5+#=KM8%/TP(D?F-"1'Y8RL>'_]GCM\F(IE->YVL5\*Q!$?,_>>^S[#HXVJ M/^E<",,^ET6ECT>Y,:LWDXE.'-4M4E-[BM[R9Z50N>V4UE,?%= M-YZ47%:CDR/[[*H^.5)K4\A*7-5,K\N2UP^GHE";XY$WZAYW$FBH($ <;OK?6=MBRX%J*?,C/Y M\6@Z8IE8\G5AKM7F>]':$Y&\5!7:_L\VS=HD'K%TK8TJV\U 4,JJ^>6?6S\, M-DS=9S;X[0;?XFX4693ON.$G1[7:L)I60QI=6%/M;H"3%07EQM1X*['/G,P7 M'%H8G&\* 6<;S2XOS]AK=OW^]1^A_K4WROPAW4U9H'K,-_U M@SWR@MX+@947/"/O9KW0,I/(2J:6[%*6TH@,OWPA"VD>V)DJ5[S"R[I_><5K M4XE:YW+%?KF$/'9A1*E_W>6=1GFX6SF5W1N]XJDX'J&NM*COQ>CDNV^\V'V[ MQ[2P-RW<)_WD97'\L[+87)/G$!?1QX7Q*F/O1"K*A:A9X-FGOL,./-<)O\)V62[6M>:+ IMJ7FG>E'ZJ-/*::X@L"OK-I#:U7*SIK2;Y:D.Q)!,. M$B]Q0G]&RSA;(M,YR9&SIQ M&+,- 87YRUJ5 Z.WW31FMX#&2[6N#!FR$'B="KS+=F%CT>7UW\@WU41L"F+)-D,2\H-G;-U<]LM:[3'$W18M<56<-7HZ[@E-]$9J'K2C>P:C*:K9/E_ CA*9+W 0BX5,DY6S:B#RL:YG8Q\B.]U@\_> M41)1&]A(D\-;]YS=UCR3U1T[_.GFE6,;ZN%WWTQ]WWT[?&T?>6^Q@B,U"K[A M4%^T_:7HFT\ZL,%N_UX5O71V>;5S^VK0GK9TMYM;W58H9DC1Y=-3(YI@#T6< MKZM,=^"W?60#*GB-JJ)&)E-*1X1M+?K PN\V5(U!/,-0HVKDI+_;A'2I$,>< M%TN*\:/61ENSBERP%()26OR^Y@5)CER:T7BR4I)FV:$[CMQO7S$#(J&M(25- M(M@IJWNA"4];.[)ZS*!<%!E;/ STHF/<2\I1//7\;9O)7+PY\&:)$U/CL&7L M1H[OAU_V-&C9XY>!/DI'F^IY+5K0,)/&YXZ^0JW$7G100L]SW"1NH(1N['C^ M[+^&HN7GKP$R9E>U5+:^:-<'4=^)&D7P8<[6&KM:QD%-MY9WU$TT^XY$&@8QJH8[^$74<\OHKV< MX"F!M UO%[G8*^A/TJ"XAQG_/QE>_#\P+>E-2_Y"AK=7UFZDSROX>SS^T7BD M.J0%CP2S+9C?:$!!(%XPS_NV(U[#47?^TAFPWFS$TRG^W+8WNKX3N.B.4?@E-24#OG)J/ L]:2:; M-PW^ NPS8$]"Q^VP^U/?F8)N3X/I+NP2?738WWMVTLZV1X7;\!L"--P)GC)@ M*;2VP$FB8;"'\A7S^P2HA&&9X("_$)588O9UYK6L"7>'$EM ,8A;=VGRU2E" M5\N7!*9C!PVY<-J:J$#9TH%_B$FAP#C-OZ)0&_T&LXQ #8_^[ 9*MQY879:_ M/%[]N.VX'L !\YP(T8H"']>AX\7X@!A'C:C6ID7NLXL=N&$V EBC]W:]+%JDYDSC4.K-O#PUI_B.G#< M&8YNLT;ME*3-(F2!-G@ _C=S"2_APXWK.7X4DS2P"2HBBS9RG03)![O9.=IN MFZN#&AN4%QND[R!S6Y@]Q< 3%#KJAFIF?B]J?B?8''\0!HOIWP4.KNUY[H]R MV3)ZV]MQ4LJ1L?U)-&OIETT_, J\?<")7!%1WETV2+MQBW8[J8;,TW;+9S71 MJ?$@<&(O(K\U51Q-9TZ"DR:5T":7:?ZXHF7C8>+"Q>Y0S:6J[L0]#9 /O/Z$ MHINC'EORTH\$D-:^D;^8D3\YJ%O#B7<14#HLZQ?:[8.&!I1)C54!?3?9MOO+ M%7[\Q&[P\.7+.L:V&;L8RV3P ;(DPD^?636SG+WY%MD_[;_DSIL/F(_+F\_ MB 82!^15++'5'2=@C77S:;6Y,6IE/VYX#@1T *\IT-]=T,*^N_; M)_\!4$L#!!0 ( -$#E=)(4U # P #XD 9 >&PO=V]R:W-H965T M<;ZS[XM5)!?*I, M[5\^F*M*NFGME$UWBRMJV3 5[7SQNY4C M.'P[S51*7:G::UL+IY8OCJ[.GKY\3.MYP1]:;?S@LR!-%M9^H"\_ER^.9B20 M,JH(1$'BWZUZI8PA0A#C8Z)YE%G2QN'GCOI/K#MT64BO7EGS3UV&]8NC)T>B M5$O9FO#6;OZNDC[G1*^PQO-?L8EK'U\4F.+S5V!OQ -Q\_[ES>M_O'_]VSOQ^@_\?7X:P(XVG1:)],M(>GZ ](7X MU=9A[<7KNE3E>/\IQ,RRSCM97\[O)?A+6T_%P]E$S&?SA_?0>YAU?\CT'AZ@ M=],NO"XUL"CL4ESK2@=5XK]<:*/#5KRR52-KO'3YY1OI0JV<7^M&_.L:],3/ M057^W_NL$YD_VL^<@NVI;V2A7APAFKQRM^KH\H?OSBYFS^Y1[5%6[=%]U"\_ MQWM?1N%&O%NK;!)U*TTKR2(>1E0?6R '#QD_LBY%<++VD@//BZ6SE0C875@@ MH?;8A4_>&ETRB84TLBZ4B%F(GF&UL^UJS;OX@0QBL];%^CXZ2UV#CI9&^( ' M$JG(K?-T:\M<4'\CV\LI&![!\95UCG21WLV"R1*K2/M"C6\5[D*@, M[$8"(MG# "@H+/8NJRA/2Y^GC+E#UNFL$K4,:[C&/XT*7#Q#P?C8:@36R#\L M2/*([Z)?8Q'B?[@.UEBU$A@.2O$+8X%GT3A[JY'+!$LWEGX744WK? L"1,LK M6)I03&1$:8N6(,#F>I8%3L2]*"(E]2G$VN?95,?Z!.(#63H0PF')*I*#*O@K M5T#6BG@T3B,(&K)S95L( -W^-C^?SE ^C*%*V#;XPW&4 )VT/Z@+F>U80P#; MD,P@72HCMS!$Z>2FE\6+XQBD!21:*'Y;"S"K4"-U8^(3XD@!ZT\^2_:V(1.. M-9"W4ANY $$RC44:7L,E%'E]BMD"?)?P#AHPK/51F E60GLYPBC+CT=H:2K0@X%O 3%+1MY^1PV6(@.Y&B+$!)B0E9@CPHNX%S)1F$*=4+0W$J&,% MI,$A8N^8-6%!)EW:N7KYEA&4RZS@A)_(E']B#(!-.,W>_/[3V\.$^.V84F-: MSV1Z@&/Z6NDZ%M=#U.&,4M$SQ'F.OV&0Y.5D<0D[&/2$=>B-W\0 B/R[HA8G MQ\25@Y)C\6SV_83^G7_/J)I-Y^?#X!PY-=)E-%+B1Z>HU.#3WGS 0UI4C,-L M@SK200-?YTBD0WZ4A6,RYVQ!3MT@G0WT/X \5"T7]'\X-:&[VL;,0LABO&90K%,,8],'^6CO"".HWU*"$_//B+H8!N4(JX O6T]/%VJKC!Q M:3%F+&/BG3L"R-2ZB.<4M:-DRL+UNJ.X4"N5&J/8J\00)KDKR"^1"] +.96, MT6EYIXV)1>!06\&*G9&3TOYAZ3J6U$B4:@$8<*IZ@2DJ&PLW&R*D0F<*A1R3-^5(G9!"46<]1KT)W=5=*JOP\)1 M[Y1T).(E5RRR ; -KBE?'[+D_=UZ\H@7M]8 1Q:@N,BB!659TL(4S<:_JMTOTCBU\1R3$_KB5W1]NHT$X9X.]&3OU MO:S0@'0JPP?BLC^*H9$&G\&3*7#YY09I?'93(\L8-9I^,$12)E>?*,T!6N=Y MZ*$CAJY<2D]'1MNN7"VU+\ UU<1^5C Z$FWR#II,HV-9P$(XJ*"9>2+HI#T0NUBCU2>- M_@U?)L,M7"6,W/!Z&")ZHL9X500\&U9C^8FH=G6)>?<5"9NQF\&%NYF.%-5UF\+- &F,,E*;F\3)D'42D8QT]OB9_UR5 M\OK*(LBHS: A.@88\3@A/#LR+UI*%;DO-7*E;-\ M?@"SLQ9T.)FF4I*D"R2^M>%'>YQ<$ZDO"\!Q@TM-XX1F$]DAVVA%\U2EW(IQ M/SRT&-DMDJ6##W*UEZ3*"G1S'OSSDV")C@(>./E!2 M5&4?=60[8F[HH^.]XO?B3H!Q6:A^8,5N2GRQS8[GY+F>GD2[R"_HMR?IT"Y. M(33I[BTXK'QR7C>(!,I5=?(^DK@CYM%7XTP97;"1CHYU&*1+J0UI0>,$U9MM MI)PCD,()D?V@LSK618ER'1HCC&XK7-N$(I<>:T *7W/M>?WVYYNK_FLF]&=; MKA*6A[<+-+XHMTS5*F_;\3Q%3 I9]C051QMWPZ^H9#I-7UWIVC7@7<@-%8L- MV@[2.GCE\3H":PC2[A20BD<\OJ-C6,GS'5<56)D[.SJ.X7L4$#Y-5RDFWJ#L M0&N2SL&44>D$))\R8)O\H'*2J( OOCU3C2<:^;[C+Y"8CP(CH=$QK9_>++.;%__-"^>)_H-KCK-KC;[Y0_C(* M?.4*?;L+_?%-*@T']#L1KN5X'@MR#,+K7Z^FH]OH-;#:WTAKGC5V;Z6[&^6K M=M6BFSE[-.3:'\#'.?O^>^1T5)5/1[N-6,"K:MLSI0N@F 32NGS$C?)-PQYB M?&^$G Y^T\'*TR]7J#% \8\_[\A/\X]CKN)O0OKE\9+BKU7BEV ;_H7(PH9@*_ZX5AA8'2W ^Z6UH?M"#/)/AB[_"U!+ P04 M" #1 Y7UNUSG?@@ #_=@ &0 'AL+W=OESVT:6_U=0WF36J8(IDCH3)ZZ2%3FC*5]EV9G=VMH/(- D.P8!!@V( M4O[Z?5F!^>K.MZ M^]W!@4G7:I.82;E5!7RS+*M-4L.?U>K ;"N59/32)C^83Z?$^? MO:]>?%\V=:X+];Z*3+/9)-7=2Y67NQ^>S)[8#S[HU;K&#PY>?+]-5NI:U9^V M[ROXZ\"-DNF-*HPNBZA2RQ^>G,^^>SF?X@OTQ,]:[4SP[PB7LBC+S_C'5?;# MDRE2I'*5UCA$ O^Y41G3Z*T,76YD9>!@HTN^+_) MK3#B(2_,Y84YTKJXOSMQ^C\XN+=I[8E3S,?F.8D>E,6]=I$ET6FLO;[!T"RHWMN MZ7XY'QWP;TTQB0ZG<32?S@]'QCMT?#BD\0Z'^- LC,XT"&94+J/7>J-KE<%_ MDX7.=7T7792;;5+ EY7[\GU2U86JS%IOH_]Y#>-%5[7:F/_MXPY/?M0_.6K> M=V:;I.J')Z!:1E4WZLF+O_S'[&3Z?&1I1VYI1V.COWB9&&UP5>]Q[*).6!V* M+/I4)$U&:[DH85\*P_\RL,]9@A^_TD52I#K)HVMX38$VUJ9O>:,$]"^OGZJ_ M_,?9?#9_?E5$:5D4HKD[7:^C>JVBEXV!H8W!W5@ :?AM3-^\4=5*51&,F*1I MV11(/)BL*($/P'C MW^$W:HLCRMBZ6$7;2@-CMKDR^"Z2\*D@3A*C:&'G&U7I-(F>XJ+FT^>?)M>3 MZ*?S\_?T]^SY-Q-X)P.JW10S/(.$GZ:Z,KE]$.QH:U@$76L%*T;UE4\H)> MOSF/S#JIU+K,@4P#=-W@>,C0/$%C"H;HE[)"]8#EXBLW)<]8[F!9\IEH3CPZ M)GZ7-/6:1ZO+*-EN2UW4,%DX1P;K3NL2WA,:7Y9)E>$W/]IO8I)LD"@-[-@D M!;@6%%O2:I@[WR1@,N(<2Q6*OAX<8>OZXJTH&A4'"D@ MHX;]6%6EPD#4!.#D^2)@6R+P3REOHE&&8 M84 %?(A&AJ0&&U- ?XA2K]0M)MM7<%%WB1YL//: MF 8?!)>:?J8EX7.XYL08Q5.@^L6T5-QQ+]@P':E+?J[P^V'4B'&BI(] X MD$HP SFLU=0QKZ HHU599O0X$%(")6"\P @6*[W(E1T6YH5-4!G/Q[MK5VVG M:MN[QDDV29O1Q-B- LTB-?&[:(W/0Y[EC1:B4%)R\8M:+!U39DFR9./ZE:G! MN!!Y"0@A;$F#(]F]#F=&E\,K5;DV5@DE4:*? .)5%=ILP$A!F<(= ?6,+1O:]A>,D+PAD@ &*(H:T#6 M V+,\.H^]FM[M TA ;XMP[_62]BVJR*=H)W*FTR9MH0$LZCE4J7>$K65QPO@ M15Z2R@!X5MZZC)D@,3!L=]DD;V%W2M'2UK;V#1.L!]DE"T&71>.I_([H(%2A MC?B%230"!(\=$#P>!8*_&]S[ Z81X/>1.&O?2L.W>ID)\$$Q5@*^LQ]$@4?7 MJ0VKCJE1I-S66MJ2HD!![1V5Q0/EVKJ).Y54X,1PGWZ$W=TLV(T??OO\<$8Q MR)QP1VS!8+G5A;@TKSWHF)<8CD8 *Z,D^P7".YHPMI22?RISE %XL\"P$_UE MVE2D_JU7"I(R#%@LD60&6[K35G;B\>ES$RP:%)&-+R\9HBKEHBI&4O7PCK1U MHP0MH%G%AB#04FN,WV^4P I':;VN%( O#@D)K^E;^R=SN44)/<),AM5M%47R M"$P>16":F'6TS,N=<71\T;2LYW\V3V*R'D59.T% *^+#+P;&279>_9?1N"H MNL5E*"_8RP9$T4HW&<)>\3XD[T4!,&&5P.(97 EX!;UYE.::==GD&;O?A/P3 MO/-+4W1"OOL'(N1:8LP56-91O<6XNJ6VPS:_/3B:_P>/#/B!P.Y250K]*.Z MGT,7G%'SNA>:&V9ON.\R=DLU<19K<)A(F.(Q>X 2U%AK/1GQ,"?.PYR,FGYO MYL7Z_ QBB6 +G#:("""VZ!(C <"-?7[E=QOE16''IKC]-U:I^L67,-8 M^\:.HV4??7?H$PM4RI +3'Q&,UR&_!(U0%#(#CH0GEWQ#:N9M:!M>R[F%5YW<82#,BN]^V3^7>7_5&8&15S62=OY+M+=,%E MLUJ'2:>N,I(P\E/L"9.J@JC=[MJY#T VQ994F48*V:D+"3>5HW/KR^#\I99XN"D![!4?@D"'5O MG-_S$/D<9U8QGD'!(TEL,.>:K!)=F#JDG@+K?;!9ES6HP'"287_R'<[WU?%I M?'QZ&D\/C^BMKX[G\='I47PVGW8%AZ>UWCKR$.!+IP;BIZ>'\;>G8GQ71']+(. J\.SSCKR2O*%E@/-'[B.+2.#%6#"C8]?=BBS&P"% M&""0$4#\]@Q3ZI0: 1OIDA+\(65O. %PHSAV0+-RHRG[^C1(3[ZWGUJQC/L] M)M%$Z<9E@QJKJCI!],89,K L*C-,KE\'/.QB=#+W38W9!0*4K@%[H#E-7G, '^0D0([ 0YB]G!$##)OH45D+8;3H MW*BZ%V5@?NA&DA$=PLYFQ]8161"Z(9^@@0!WJ7)A09%(@ MH92PBSW"F3M;D)NR;\[6Y6L&GXA'V&3"5D"V< M6IQUA!G$2E-ZEC8)L#IJ/>"%DGR$NE55JHVM [IU6#JS4AEF!;R>ZBWGD6QB M$0^2>T6YA/2G>YP,G@F"YK87@/GC]8_?/.=!U(E8VR3#J<^D^=.$^ M&=K:$(=".#72HP2],AVC0?]-5>6>"/0N ADA20Z/@WQB#V1U/_?0EAN1!;"F M4S:J,["J1\?']&[#)J,W9!X*X,-/.G:9OO<3SK^-3^5'\WA^=-HWZP.2 M!F-S\HYJTX*+C"6>8G@.COL;B\W&,=>CD=0DN@9^O850,9K-$&ML-KKV@>Y% MJ &3Z%4K&!W(08SGR$(?VS+IY#\#@\?9"72M<018E+]'86HM^!_'U5'6$,@% M34O2S[ZXAX P!<..2RULQ,'QQX&+,]P#0PAF'833 [&^9593]("IBDHC2S!W MY-P^.S^/CLI >)O4OK$E=V]# D1FJ% M#KT-QEZ_^2]0IXK"Q->O+QRPA\\=L.?<$AHI5G#@WG()1(HT(R3! @G,5"X( M1271Z?3K N%C@X&CL5Z8+VY4+N.\637P(*YH0L2M$\Q=A0O@4/[. M.S<& ?L+Y)(J1OE8?.3!,,[:K02F#1! 4P4D5;/9M.<0'$DY8[ILP%1S?= M5$68RX#@F1+SMJH6X,-RN:1JFVTEV*(@<_X=[2K6F;F.7#5IW52JA:U759+A M:*:I*-C:RR;4:ZR44M>%^)VA/6?&VYR.RU,^++$!K[;]*FZ@]FA,A6D-G(=B M!,S+VEV5E-E(0#E8WAKW&J2#;Q((!Z+#T+2X%BM2!2K11&?#VE""IR)IAJ$^ M UH]SVZTH0:0EC8./=8.' 8?:R,RW#>8'W"6AB@Z"SIGW+*YN,GU M6:TD6E3E9U4=9"K)515'']2*H"&HC).C:P[IC)0[[7(^7%W[\ SX\VZMR[9: M#:_D2R5I:$#)4;6K\]OD3K*=6,5?8VJ$> .$$_>^.H&8>3IMRZ:OF?O ATN? MKHT%F&9+[V$7#A4EF+>M7@*.YPC]3X]#6^/(%=>/=+EY3#!-C!DCI'C95$12 MM_0-7]E%V4&#!+[P$HR%X1B-36H%6VW8P4CZSA=#KXH,##B\!/+0Y D8OCLP MZK8GRDK JZNW'\Z]\)X;R;LP^HY<"TG9UU "=' 'ADN9XA)H.3LJQV >6Y!] MJU-.H$_"SU+5E0+X)"]!LVG,MA*CN1$TF[49#Y(AK74<4F3 4^")E-*Q208D MZ],6)Y7:O&P5/%*8).7LQK"84_ E;5Z VU['' (#LC ,)/C'B&]RP9 VB M0Q.3@6-LDDI+EMWNK6^89;*N.,JQU/WTGBB$* 5(4K\V,@F*W-CS%@,!II?. MW/LF>OV>W9TQ3?MI7P'"B;O#<8B^I7P'[ 1$$*H%&";1%9N,OBZ9$"K>Y[J' M"";LL":;A/O7DAH*6/;7_X_(VGB@VTIJ^C+QOXNX15=7CY6X\)7'"AV]^V\F M=R'-_UJB-U*J/G6EZM/1:O+;=IG+EI#[RM)?-) M0;\=**<%H,-G][JU!E>[ M#BI^NF(N4X[F7-+!*!B8JG)Q./:";NG4BP-%;0?M:H7#A<+'5?QJ0F(;S'5C MMASV50+,@>%=^J:ORNF:5Z3I.6@>I5:)NZ%JC6WVG$1#C-<, MCM!_R*8[;!2T67+#I&NF<8=0^@VS*T,'S<# XTWRV3=B,XM ,9N-E 0X4*). M7-%GU'1TFV0G.!P>4&3D-L6/$N'H(K:5[L:92LY7UX.#=,QCS\J\CC)Q)J1- MSDS0(Q+-F%"V@T,;W+$UV4M..^;$T2]-M@KF'!&;;YW8?#LJ-M@0#1[')INN M?<'.GM7K$Z1_=,Q0BCH55^,*KF@CV)@M84N684XLJ"MN[9 ]!["X G7\#+V^ MSXS0HYX\K%E4U+C>6P%F>FC^OEE]X,XQ,'=I%60><0$LXC65?%&8PC,,)&H# MX^Z/5DM>4(Q] JX&H!J.B1$O@+H&':':Z&8#_TATUEZ.Y,PYHX&=#:^0DI^) MDCILD%L'Y]OK5DU12. 2-#9&MLYU M8*G\5M>2#7(@QV7!&!\$&0<^?X$-771BPF5SJ )D< _(+8?/(WN$IX598@^. M4_H[$B2$/^"@L$CIT>J[6P-,[OSJGHGL(XF7VW#&!-G)&6AA#TFUK%E.JG!A%^4] M/#*"U(<3,@I<-9HUS6KEK16O-7A!4!6I?U/] "SL;]*6I(MM M Q0WAH&%<*,E-:]QS&C&B(X[57]MRIISJ*DU '*H$)DAEH0:%E/?G1.LFP P MCSL/QRT7Z/TD"TF$E9)3!.YU)_4E6*'0#GD8#MD4^X.R;T,A;;;BU0"? UTU M9]^*TFZKJ[NPI[&O!84)P3IMQ0RSQIU5]]7U.81O2DSE1.FXG0V#!/RJ,MV M:H1TNQ*6ML$\VF1IOY6,7:Q0R @'Z&=JU0;C 8H44R\Y.D(9W(6 M''F;Y"EF=C$\V9_:]R %]20^CM<.W6I.%."#\(&NN*MIB3NS4-S3N9/0(BS- MVK,!9(I=-TY543VS =7AA!,<>MA%(922L#@9:!\]G)L!:ND(%;K14/UH[ MV.G(]80WMR4><$)0 MNVCNE"W+B,HNE$WU$CI%;\M*R\?7+_QJ^^<4DY@27<9$9N*G2M M>/$"! ($;6B*($;'-R;1C^WO_1T$9%/8R<%7) :4&D04$QKH,@42$ +9ZQ@> MGLFHG']4LFZ=A4=+V.ID>NF.BME0A8AS20N"CT CQA'^ '-'#T;2*>1"PFQG M@&YPW,KEW@O[Y3 K#!DXL,N:Z271N>Q_( M=Y'CE<10;(6,+Z-)\M:@8,P1\E9WH12@R2I_4:D_;]0A@=OZ^1 IU?.!2=L\ M*0II3P)6KKI^B4X>.TJY!?=&R9F@%2?;%:( H& 2O;??VX_\N7N\+0!KV1)? M I/YJHL[OHL +Q6A*3PTWEN/PY;\,%NDT/DA$V$#=WC'"_,QY/L]:VXWN?A\ MW"V.I%R6R>@-,*,*Z)Q$E[=R%GN9W)0$:AW(E"Y&G__?=EF$R?@.(SW7--X0 MY7B6-IM&"AR<[Q]BD?V6\,H>4SI!45ZB#RL8#Y4L\;XOL]:NJ4-.#G3UU.[ZU=NV9NDW$D;KPS"0;V_Z"Q[M0WN_1HZNEF+UNA7;$ M&(KEZ]D??[R 62;G%]$M \C!7+>DV>RM3'W6CW)M=S%O1ZYPR_LWM,^=T>$. M#*8IIA:SSU<;!#M'',L)PGOW(@W8X%W1MR)5=1-2>U0R MM%\@D)@TGD3O,-;=:<,]44:%[LOT3)*TB/;W?_$=)ASR<<"1V0Y@8+U-'I)( M0D#0<)&#*O&"@J4+2POPZ(H)S$KL=DUF:[E0*E=2U]?(N,3=)(.P'3YVH=; MM" 9>.H/;6HQ\15Q.FT!8"(G.7K YEE.^3.MF"%U7?O#R-,'S&F%K18+< KL M(KKI&;W'9!/55&+&^L--AXS@#M$'S3Z8^/<1N(US,I8I(0"VBQ^L76^X)QJ MVAX3PU601K![E3:?[;TG]BHC&LA&M&3R\1_^+B\3^^#=1PF2(+&HYAF(PS.* MX>6T7C=E&J%TUB2A%"/B'" 7BZ3X#.:6Q,]/0R!AK5?K9]C30,>R6OS0M:WU MDV+&5$J _:=[D^[H*BN$H2J3RP0IA: RUA>SWTV(IL1CE(QZ':090(LYLK2U M7UZH7(-^&O$I,DXI.7E\(LRFAIM@CPT/,9V3E;V,[U3H@PG#"43IT'K4?+%- M(5D03)FY&-VF>"@AZ-3)V=QF$>U,P.NPOB._L@^F--U2@^4/PLS0%F@5*R@W:)F?#ST.KZ$B(7 M HT)+ZF4:7R'D;W:#:5$O*+W8];M,UAU%4%05F_Q>^\SX$LW74/Z^?5+=^ ) MB\-'9U,L0>-+#:!O?/=U@!\I;+ODX]3!90CX6NO^>SC;I]MZ M!PFO1&E1QF@33]C:;CCJP?&=DG(HW7#Y8!?4+>M97\A< M[@JY=D NSQR@.+*7NJ:$FD)P(*3;NAPV;Y&7\6ET6Y*C6"Z,].BR #P=/I#P MDAZO&!T%V@>BREN9849)HQ*6'UI/UM@@Q^DFF>R!((GT460;%WW MWU[:L>-] 5""X.D9Z0[>K.+:*'_OD^)CKM5?/#X;OWE<+F/S+63SD%REDTN>*'BXW3AK5W7+C"D)R[M246Z$8&LO$,7UY<7+5@BD_-=H_^4 M:^.O]RZ-W]^SOFT*V7L/1__$:U2C_U\7J ;G S&T?( I/K#M[38R;U]AR@?F M'W&':O?ZTO[K[;Z0&H$O[;NN#M'M_E,O+XW&KRT=,ZK^_-!L_-S/0UKV'SG$ M6'O^];]\3IUF$3V=2?$TL;GOUY)5@%#(CYKYPB=8Z98.'2]XHBNI6@ MR3=H82LC75'7ZEYE90TR4[R:-->\.V&NG_>*;VD0[#2>&/)'"\Y)^"O!X'5!*V)WJ=Z#MI]O46(; MB4E./:9\Q!.HD$N:XI[]SKY0-8\CN]%WG1D8!V MIE32A)+5;IT5]%&1S(:+DP?Y$("_:[6I!((%CZ+)HEN7'5\GT9N>GR^0ZR]' MR/)Z;;M%43"#>PM;B=/6SWPX:KSBQ_Y!X3J=IUPQY"UP[X]AHT%=39) MHZ?:$*+8E'7G.D!W31Z-S$48N7AOE,I]5(4>?0\\NEMA>U+4@XDCE]8G\<9K MCQ7=[X6%ZFY[01%:+1X0L**[%5"<;=#;Z3M$@IX"K @M?#JBPR*=R?UY&%%\ M,7]8FGK@=>L>K#$+Z4^?S<:/BCV@X/B8 :QM//=9JNZ>B6N27QK!Q##"0;1@ MW;-8P8[^24N5 E,)#0;O.'H?$6.'R=]27]]FT35)I>&PO=V]R:W-H965T!DTUT731HT3ONPV =:HFRB$JF25!SOU^\,:2M.ZPCH MB\WKF9DS%X[.-TI_,VO.+3Q5I307O;6U]5F_;[(UKY@Y5367N%,H73&+4[WJ MFUISEKM+5=F/PS#M5TS(WO3GO)2[6YZ$6]_<)G ML5I;6NA/SVNVXO?]671V.:+S[L 7P3?F8 QD MR5*I;S29YQ>]D!3B)<\L(3#\>^17O"P)"-7XOL/LM2+IXN%XC_[>V8ZV+)GA M5ZK\*G*[ONB->Y#S@C6E_:PV?_.=/4/"RU1IW"]L_-GAH =98ZRJ=I=1@TI( M_\^>=CP<7!B'KUR(=Q=BI[<7Y+3\DUDV/==J YI.(QH-G*GN-BHG)#GEWFK< M%7C/3B\?[N>WU_?W[Z-JK7[Q7K_+N!/P0R-/(0D#B,,XZ\9F]C M<,48N%+54DCF0T/F,#,&4V"6?6^$$6[UG]G26(UA\^\Q'KR8P7$QE$IGIF89 MO^AAKABN'WEO^OMO41K^T6'$H#5BT(4^O6MTML90A%J+C ,K2Y4Y2XXIV@EU M7-%;8H+X,##/N;2B$#R']TQH^,+*AL-<6B97@H($WD 2!Y,P#,(PA+^4RC>B M+"$:A$$\'KG%JT9K1-E#1K@1!A%NW"IY\L/F)(R")!G!G[S@N)'#@CW!1\&6 MHD2OH+BWXR")PF"2IN_06YEN\,SU$]8H0YO#>! ,PO =?+)KKE]>C()H% 6C M9/(.%LJR\M"@-Q"EPR!)27@,'2X:MBX:=KK(PV9*/O+MCXG@_=)Y_[A?/.C5 M#A1FE6J(N27#0@%M4."^$3G7/K9?6O;Q9@9M"EQ+RS6&$-[9LY"D:9",QT&: MCG M@RH 8P4*A5FT$7)UMBL%BVW-#T/DP?"B*3&D"D^7)^2&V[7*5:E66XQS*M<8 M=I]YZ7;-6M3F9+;"^*8\B>(@W>7)$+:<:0,W^'B(DYIKH7+@3QFY!3103N!(Q_0<"7O+O@J[ M=NIN<( =S1[@WC)+1= T&EW ,28R7W_B8'1,DU?T_[D('532CMP:M;DUZGXF MM +7MD'A8P7%">D;N5<>BT[ XPFVP.0Q35V7SD(447>+Q;%+.$L]!BRI+=RU MA.(_I)"V,O-KD"%P=^SX6VY ^(PF%S-)>;'/> _*'-X' M)AOL0C&>J;6(3X'L:"1KH-Q>C3M^@?M-=;AE?N((&[Q]?6==KO:?J?,?'O^?-Q_Y&"=6PET1CK +T/[#P4^LJEVSOE06B[X;KO%;BVLZ@/N%4G8_(0'MU]OT?U!+ P04 M " #1 Y7 O"$+#4$ !J"0 &0 'AL+W=O@WE(TB!..PS#/M 2;0N51)>D MXOC?[TC9B@LD7C\,!BR1O'ON[3F>AENIONNU$ :>ZZK1(V]MS.9B,-#Y6M1< MG\N-:/!D*57-#2[5:J W2O#"*=75@/E^/*AYV7CCH=N[5^.A;$U5-N)>@6[K MFJO=E:CD=N11[[#Q4*[6QFX,QL,-7XFY,%\W]PI7@QZE*&O1Z%(VH,1RY%W2 MBZO(RCN!;Z78ZJ-WL)$LI/QN%[-BY/G6(5&)W%@$CH\G,1%598'0C1][3*\W M:16/WP_HURYVC&7!M9C(ZL^R,.N1EWI0B"5O*_,@M[^+?3S.P5Q6VOW#MI.- M$@_R5AM9[Y71@[ILNB=_WN?A2"'UWU!@>P7F_.X,.2]_XX:/ATIN05EI1+,O M+E2GC3:8PGSX^WDQOIW>/?P\9$O*J$_#0<JU0;X'O^K V1O@,=S*QJPU3)M"%#_K#]#1WEMV\/:* MG03\HVW.(? ),)\%)_""/OK X05OX,V:)Z$-GT,=S;-"B MK03()=R42P'80:82UFV88-ZMTQC6-2\5?.-5*^!6F+4L7HOCI*77X[B759F7 M0L.$*U6* K@YMO7A79/OX.-?@BO]"7J@:[2P MUSX"\L\H^/"^!WQYHV<,J ^4D8"&Q/=]B$D:122),V!G 5 *%'?2F"1)BI(D M0NID80;!66@5@X#$ 25AG$!&:!(2O,D@/(N HFY*$H2B60 )B>(0I3)X1'(( MOC1($0M(41_E:)@ 8RCD$Q98=QCZ2+,(X2(2I1&NHIC$:832"9PH?-07/OH_ M"O_"XA.%/VGI/PK/\URVC<'2XW" 5MLB8_] ^6*X=H9_G0MW;;W [!X".V*$ M9=G.JOX**_Q^=7A:/C# ,OJ^8PHC%$L?)QT9\$?H_H02EE(2L=!1 8E"@IBY MD\B2(HB/:1!$P#(21RE)DP0BDD4)@E((;=6##&%\=_(>&9:F*(FTFVI3XCC! MM&%.Z[*M-1@)"P$;7A:PV+D<3F2]XNJ*_= EP)>P!.H,# M75^X71S/A\HB]8G/,)T1M4?5 M^%]02P,$% @ T0.5YK[[T/D @ , 8 !D !X;"]W;W)K&UL?57;;MLP#/T5PAV*%C#J:Q(G30+TDF$=UB[K9<,P[$&Q MF5BH+;F2W+1_/\I.O!9(\Q*3$GEXCB0RX[54CSI'-/!2%D)/G-R8:N1Y.LVQ M9/I$5BAH9RE5R0RY:N7I2B'+FJ2R\$+?[WLEX\*9CINUN9J.96T*+G"N0-=E MR=3K.19R/7$"9[MPRU>YL0O>=%RQ%=ZA>:CFBCRO0\EXB4)S*4#A(%%88&(QM,&T^E*VL2W M]A;]$F(6QXMX4:EI?,L.E8R34H&TUHUFBD-ME$ MC@M[*7=&T2ZG/#.=WWZ?SV[O?\/9S27,?CQ'!TD8A*+ M O7QV#-4SB9YZ0;ZO(4./X#NP[44)MO*C3'C5XT4?:%;UM95Y=F!=,&& B@]E3S2MZ= ;^G"VT4?1J_NZ2 MWB+'NY%M)XUTQ5*<.-0J&M4S.M/#@Z#OG^[A'7>\XWWHT[NV@4 N82OA/7<7 M;M#L8KT7=S?K=Q5P6V'S0 1-C526E=2863HF1UC*@CJ=B]4(Z,*PN;!+3+%< MH((H<.&"$FI#3H<&GR"(8Y>NE:P--'RNE>"F5MA47O(7:VN(8C?R?0B&;AS' M\ VI(W-99,#+2LEGM' :$C<<#J'G#@EQKX"5DEI#D/3=Q \@[+E1W"=0K4&UL[5?; M;MLX$/V5@5H4NX 3RW+B9%/;@.(DK0OG@MAI'A;[0$LCB2A%JB05QW_?$64I MZ:YM-,_;%XN7F3-G;B0]7"G]S62(%IYS(F-AV[M3H^'JK2"2[S38,H\9WI]CD*M1E[/ M:Q;N>9K9:J$['A8LQ3G:A^).TZS;HL0\1VFXDJ Q&7EA[^Q\4,D[@:\<5^;5 M&"I/EDI]JR;3>.3Y%2$4&-D*@='G"2

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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 116 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 117 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 376 405 1 true 116 0 false 13 false false R1.htm 0000001 - Document - COVER Sheet http://abacuslife.com/role/COVER COVER Cover 1 false false R2.htm 0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS Sheet http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS CONDENSED CONSOLIDATED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED CONSOLIDATE BALANCE SHEETS (Parenthetical) Sheet http://abacuslife.com/role/CONDENSEDCONSOLIDATEBALANCESHEETSParenthetical CONDENSED CONSOLIDATE BALANCE SHEETS (Parenthetical) Statements 3 false false R4.htm 0000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Sheet http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Statements 4 false false R5.htm 0000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS??? EQUITY Sheet http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS??? EQUITY Statements 5 false false R6.htm 0000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Sheet http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 0000007 - Statement - Abacus Settlements LLC - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Sheet http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME Abacus Settlements LLC - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME Statements 7 false false R8.htm 0000008 - Statement - Abacus Settlements LLC - UNAUDITED CONDENSED STATEMENTS OF CHANGES IN MEMBERS' EQUITY Sheet http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY Abacus Settlements LLC - UNAUDITED CONDENSED STATEMENTS OF CHANGES IN MEMBERS' EQUITY Statements 8 false false R9.htm 0000009 - Statement - Abacus Settlements LLC - UNAUDITED INTERIM CONDENSED STATEMENTS OF CASH FLOWS Sheet http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS Abacus Settlements LLC - UNAUDITED INTERIM CONDENSED STATEMENTS OF CASH FLOWS Statements 9 false false R10.htm 0000010 - Disclosure - DESCRIPTION OF BUSINESS Sheet http://abacuslife.com/role/DESCRIPTIONOFBUSINESS DESCRIPTION OF BUSINESS Notes 10 false false R11.htm 0000011 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 11 false false R12.htm 0000012 - Disclosure - BUSINESS COMBINATION Sheet http://abacuslife.com/role/BUSINESSCOMBINATION BUSINESS COMBINATION Notes 12 false false R13.htm 0000013 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES Sheet http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIES LIFE INSURANCE SETTLEMENT POLICIES Notes 13 false false R14.htm 0000014 - Disclosure - PROPERTY AND EQUIPMENT???NET Sheet http://abacuslife.com/role/PROPERTYANDEQUIPMENTNET PROPERTY AND EQUIPMENT???NET Notes 14 false false R15.htm 0000015 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS Sheet http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETS GOODWILL AND OTHER INTANGIBLE ASSETS Notes 15 false false R16.htm 0000016 - Disclosure - AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE Sheet http://abacuslife.com/role/AVAILABLEFORSALESECURITIESATFAIRVALUE AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE Notes 16 false false R17.htm 0000017 - Disclosure - OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS Sheet http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETS OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS Notes 17 false false R18.htm 0000018 - Disclosure - CONSOLIDATION OF VARIABLE INTEREST ENTITIES Sheet http://abacuslife.com/role/CONSOLIDATIONOFVARIABLEINTERESTENTITIES CONSOLIDATION OF VARIABLE INTEREST ENTITIES Notes 18 false false R19.htm 0000019 - Disclosure - SEGMENT REPORTING Sheet http://abacuslife.com/role/SEGMENTREPORTING SEGMENT REPORTING Notes 19 false false R20.htm 0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://abacuslife.com/role/COMMITMENTSANDCONTINGENCIES COMMITMENTS AND CONTINGENCIES Notes 20 false false R21.htm 0000021 - Disclosure - FAIR VALUE MEASUREMENTS Sheet http://abacuslife.com/role/FAIRVALUEMEASUREMENTS FAIR VALUE MEASUREMENTS Notes 21 false false R22.htm 0000022 - Disclosure - LONG-TERM DEBT Sheet http://abacuslife.com/role/LONGTERMDEBT LONG-TERM DEBT Notes 22 false false R23.htm 0000023 - Disclosure - SHAREHOLDERS' EQUITY Sheet http://abacuslife.com/role/SHAREHOLDERSEQUITY SHAREHOLDERS' EQUITY Notes 23 false false R24.htm 0000024 - Disclosure - EMPLOYEE BENEFIT PLAN Sheet http://abacuslife.com/role/EMPLOYEEBENEFITPLAN EMPLOYEE BENEFIT PLAN Notes 24 false false R25.htm 0000025 - Disclosure - INCOME TAXES Sheet http://abacuslife.com/role/INCOMETAXES INCOME TAXES Notes 25 false false R26.htm 0000026 - Disclosure - RELATED-PARTY TRANSACTIONS Sheet http://abacuslife.com/role/RELATEDPARTYTRANSACTIONS RELATED-PARTY TRANSACTIONS Notes 26 false false R27.htm 0000027 - Disclosure - LEASES Sheet http://abacuslife.com/role/LEASES LEASES Notes 27 false false R28.htm 0000028 - Disclosure - EARNINGS PER SHARE Sheet http://abacuslife.com/role/EARNINGSPERSHARE EARNINGS PER SHARE Notes 28 false false R29.htm 0000029 - Disclosure - SUBSEQUENT EVENTS Sheet http://abacuslife.com/role/SUBSEQUENTEVENTS SUBSEQUENT EVENTS Notes 29 false false R30.htm 0000030 - Disclosure - Abacus Settlements LLC - DESCRIPTION OF THE BUSINESS Sheet http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESS Abacus Settlements LLC - DESCRIPTION OF THE BUSINESS Notes 30 false false R31.htm 0000031 - Disclosure - Abacus Settlements LLC - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES Abacus Settlements LLC - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 31 false false R32.htm 0000032 - Disclosure - Abacus Settlements LLC - SEGMENT REPORTING Sheet http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTING Abacus Settlements LLC - SEGMENT REPORTING Notes 32 false false R33.htm 0000033 - Disclosure - Abacus Settlements LLC - REVENUE Sheet http://abacuslife.com/role/AbacusSettlementsLLCREVENUE Abacus Settlements LLC - REVENUE Notes 33 false false R34.htm 0000034 - Disclosure - Abacus Settlements LLC - INCOME TAXES Sheet http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXES Abacus Settlements LLC - INCOME TAXES Notes 34 false false R35.htm 0000035 - Disclosure - Abacus Settlements LLC - RETIREMENT PLAN Sheet http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLAN Abacus Settlements LLC - RETIREMENT PLAN Notes 35 false false R36.htm 0000036 - Disclosure - Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS Sheet http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONS Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS Notes 36 false false R37.htm 0000037 - Disclosure - Abacus Settlements LLC - SUBSEQUENT EVENT Sheet http://abacuslife.com/role/AbacusSettlementsLLCSUBSEQUENTEVENT Abacus Settlements LLC - SUBSEQUENT EVENT Notes 37 false false R38.htm 9954701 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 38 false false R39.htm 9954702 - Disclosure - BUSINESS COMBINATION (Tables) Sheet http://abacuslife.com/role/BUSINESSCOMBINATIONTables BUSINESS COMBINATION (Tables) Tables http://abacuslife.com/role/BUSINESSCOMBINATION 39 false false R40.htm 9954703 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES (Tables) Sheet http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESTables LIFE INSURANCE SETTLEMENT POLICIES (Tables) Tables http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIES 40 false false R41.htm 9954704 - Disclosure - PROPERTY AND EQUIPMENT???NET (Tables) Sheet http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETTables PROPERTY AND EQUIPMENT???NET (Tables) Tables http://abacuslife.com/role/PROPERTYANDEQUIPMENTNET 41 false false R42.htm 9954705 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Sheet http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables GOODWILL AND OTHER INTANGIBLE ASSETS (Tables) Tables http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETS 42 false false R43.htm 9954706 - Disclosure - SEGMENT REPORTING (Tables) Sheet http://abacuslife.com/role/SEGMENTREPORTINGTables SEGMENT REPORTING (Tables) Tables http://abacuslife.com/role/SEGMENTREPORTING 43 false false R44.htm 9954707 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) Sheet http://abacuslife.com/role/FAIRVALUEMEASUREMENTSTables FAIR VALUE MEASUREMENTS (Tables) Tables http://abacuslife.com/role/FAIRVALUEMEASUREMENTS 44 false false R45.htm 9954708 - Disclosure - LONG-TERM DEBT (Tables) Sheet http://abacuslife.com/role/LONGTERMDEBTTables LONG-TERM DEBT (Tables) Tables http://abacuslife.com/role/LONGTERMDEBT 45 false false R46.htm 9954709 - Disclosure - LEASES (Tables) Sheet http://abacuslife.com/role/LEASESTables LEASES (Tables) Tables http://abacuslife.com/role/LEASES 46 false false R47.htm 9954710 - Disclosure - EARNINGS PER SHARE (Tables) Sheet http://abacuslife.com/role/EARNINGSPERSHARETables EARNINGS PER SHARE (Tables) Tables http://abacuslife.com/role/EARNINGSPERSHARE 47 false false R48.htm 9954711 - Disclosure - Abacus Settlements LLC - REVENUE (Tables) Sheet http://abacuslife.com/role/AbacusSettlementsLLCREVENUETables Abacus Settlements LLC - REVENUE (Tables) Tables http://abacuslife.com/role/AbacusSettlementsLLCREVENUE 48 false false R49.htm 9954712 - Disclosure - Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS (Tables) Sheet http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSTables Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS (Tables) Tables http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONS 49 false false R50.htm 9954713 - Disclosure - DESCRIPTION OF BUSINESS (Details) Sheet http://abacuslife.com/role/DESCRIPTIONOFBUSINESSDetails DESCRIPTION OF BUSINESS (Details) Details http://abacuslife.com/role/DESCRIPTIONOFBUSINESS 50 false false R51.htm 9954714 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Consolidation of Variable Interest Entities (Details) Sheet http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Consolidation of Variable Interest Entities (Details) Details 51 false false R52.htm 9954715 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentrations (Details) Sheet http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentrations (Details) Details 52 false false R53.htm 9954716 - Disclosure - BUSINESS COMBINATION - Narrative (Details) Sheet http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails BUSINESS COMBINATION - Narrative (Details) Details 53 false false R54.htm 9954717 - Disclosure - BUSINESS COMBINATION - Purchase Price Allocation (Details) Sheet http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails BUSINESS COMBINATION - Purchase Price Allocation (Details) Details 54 false false R55.htm 9954718 - Disclosure - BUSINESS COMBINATION - Value Conveyed (Details) Sheet http://abacuslife.com/role/BUSINESSCOMBINATIONValueConveyedDetails BUSINESS COMBINATION - Value Conveyed (Details) Details 55 false false R56.htm 9954719 - Disclosure - BUSINESS COMBINATION - Intangible Assets Acquired (Details) Sheet http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails BUSINESS COMBINATION - Intangible Assets Acquired (Details) Details 56 false false R57.htm 9954720 - Disclosure - BUSINESS COMBINATION - Pro Forma Financial Information (Details) Sheet http://abacuslife.com/role/BUSINESSCOMBINATIONProFormaFinancialInformationDetails BUSINESS COMBINATION - Pro Forma Financial Information (Details) Details 57 false false R58.htm 9954721 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES - Narrative (Details) Sheet http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESNarrativeDetails LIFE INSURANCE SETTLEMENT POLICIES - Narrative (Details) Details 58 false false R59.htm 9954722 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES - Fair Value (Details) Sheet http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails LIFE INSURANCE SETTLEMENT POLICIES - Fair Value (Details) Details 59 false false R60.htm 9954723 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES - Investment Method (Details) Sheet http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails LIFE INSURANCE SETTLEMENT POLICIES - Investment Method (Details) Details 60 false false R61.htm 9954724 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES - Estimated Premiums (Details) Sheet http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESEstimatedPremiumsDetails LIFE INSURANCE SETTLEMENT POLICIES - Estimated Premiums (Details) Details 61 false false R62.htm 9954725 - Disclosure - PROPERTY AND EQUIPMENT???NET (Details) Sheet http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETDetails PROPERTY AND EQUIPMENT???NET (Details) Details http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETTables 62 false false R63.htm 9954726 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Changes in Goodwill by Reportable Segments (Details) Sheet http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinGoodwillbyReportableSegmentsDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Changes in Goodwill by Reportable Segments (Details) Details 63 false false R64.htm 9954727 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Intangible Assets Acquired (Details) Sheet http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails GOODWILL AND OTHER INTANGIBLE ASSETS - Intangible Assets Acquired (Details) Details 64 false false R65.htm 9954728 - Disclosure - AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE (Details) Sheet http://abacuslife.com/role/AVAILABLEFORSALESECURITIESATFAIRVALUEDetails AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE (Details) Details http://abacuslife.com/role/AVAILABLEFORSALESECURITIESATFAIRVALUE 65 false false R66.htm 9954729 - Disclosure - OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS (Details) Sheet http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETSDetails OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS (Details) Details http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETS 66 false false R67.htm 9954730 - Disclosure - CONSOLIDATION OF VARIABLE INTEREST ENTITIES (Details) Sheet http://abacuslife.com/role/CONSOLIDATIONOFVARIABLEINTERESTENTITIESDetails CONSOLIDATION OF VARIABLE INTEREST ENTITIES (Details) Details http://abacuslife.com/role/CONSOLIDATIONOFVARIABLEINTERESTENTITIES 67 false false R68.htm 9954731 - Disclosure - SEGMENT REPORTING - Narrative (Details) Sheet http://abacuslife.com/role/SEGMENTREPORTINGNarrativeDetails SEGMENT REPORTING - Narrative (Details) Details 68 false false R69.htm 9954732 - Disclosure - SEGMENT REPORTING - Revenue by Segment (Details) Sheet http://abacuslife.com/role/SEGMENTREPORTINGRevenuebySegmentDetails SEGMENT REPORTING - Revenue by Segment (Details) Details 69 false false R70.htm 9954733 - Disclosure - SEGMENT REPORTING - Reconciliation of Net Income (Details) Sheet http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails SEGMENT REPORTING - Reconciliation of Net Income (Details) Details 70 false false R71.htm 9954734 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) Sheet http://abacuslife.com/role/COMMITMENTSANDCONTINGENCIESDetails COMMITMENTS AND CONTINGENCIES (Details) Details http://abacuslife.com/role/COMMITMENTSANDCONTINGENCIES 71 false false R72.htm 9954735 - Disclosure - FAIR VALUE MEASUREMENTS - Recurring Fair Value Measurements (Details) Sheet http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails FAIR VALUE MEASUREMENTS - Recurring Fair Value Measurements (Details) Details 72 false false R73.htm 9954736 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details) Sheet http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails FAIR VALUE MEASUREMENTS - Narrative (Details) Details 73 false false R74.htm 9954737 - Disclosure - FAIR VALUE MEASUREMENTS - Discount Rate Sensitivity (Details) Sheet http://abacuslife.com/role/FAIRVALUEMEASUREMENTSDiscountRateSensitivityDetails FAIR VALUE MEASUREMENTS - Discount Rate Sensitivity (Details) Details 74 false false R75.htm 9954738 - Disclosure - FAIR VALUE MEASUREMENTS - Credit Exposure to Insurance Companies (Details) Sheet http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails FAIR VALUE MEASUREMENTS - Credit Exposure to Insurance Companies (Details) Details 75 false false R76.htm 9954739 - Disclosure - FAIR VALUE MEASUREMENTS - Life Insurance Policies (Details) Sheet http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails FAIR VALUE MEASUREMENTS - Life Insurance Policies (Details) Details 76 false false R77.htm 9954740 - Disclosure - FAIR VALUE MEASUREMENTS - Issued Notes (Details) Notes http://abacuslife.com/role/FAIRVALUEMEASUREMENTSIssuedNotesDetails FAIR VALUE MEASUREMENTS - Issued Notes (Details) Details 77 false false R78.htm 9954741 - Disclosure - FAIR VALUE MEASUREMENTS - Assumptions (Details) Sheet http://abacuslife.com/role/FAIRVALUEMEASUREMENTSAssumptionsDetails FAIR VALUE MEASUREMENTS - Assumptions (Details) Details 78 false false R79.htm 9954742 - Disclosure - LONG-TERM DEBT - Long-Term Debt (Details) Sheet http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails LONG-TERM DEBT - Long-Term Debt (Details) Details 79 false false R80.htm 9954743 - Disclosure - LONG-TERM DEBT - Sponsor PIK Note (Details) Sheet http://abacuslife.com/role/LONGTERMDEBTSponsorPIKNoteDetails LONG-TERM DEBT - Sponsor PIK Note (Details) Details 80 false false R81.htm 9954744 - Disclosure - LONG-TERM DEBT - LMATT Series 2024, Inc. Market-Indexed Notes (Details) Notes http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails LONG-TERM DEBT - LMATT Series 2024, Inc. Market-Indexed Notes (Details) Details 81 false false R82.htm 9954745 - Disclosure - LONG-TERM DEBT - LMATT Series 2.2024, Inc. Market-Indexed Notes (Details) Notes http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails LONG-TERM DEBT - LMATT Series 2.2024, Inc. Market-Indexed Notes (Details) Details 82 false false R83.htm 9954746 - Disclosure - LONG-TERM DEBT - LMATT Growth and Income Series 1.2026, Inc. Market-Indexed Notes (Details) Notes http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails LONG-TERM DEBT - LMATT Growth and Income Series 1.2026, Inc. Market-Indexed Notes (Details) Details 83 false false R84.htm 9954747 - Disclosure - LONG-TERM DEBT - LMA Income Series, LP and LMA Income Series, GP LLC Secured Borrowing (Details) Sheet http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails LONG-TERM DEBT - LMA Income Series, LP and LMA Income Series, GP LLC Secured Borrowing (Details) Details 84 false false R85.htm 9954748 - Disclosure - LONG-TERM DEBT - LMA Income Series II, LP and LMA Income Series II, GP LLC Secured Borrowing (Details) Sheet http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails LONG-TERM DEBT - LMA Income Series II, LP and LMA Income Series II, GP LLC Secured Borrowing (Details) Details 85 false false R86.htm 9954749 - Disclosure - LONG-TERM DEBT - SPV Purchase and Sale and SPV Investment Facility (Details) Sheet http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails LONG-TERM DEBT - SPV Purchase and Sale and SPV Investment Facility (Details) Details 86 false false R87.htm 9954750 - Disclosure - SHAREHOLDERS' EQUITY (Details) Sheet http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails SHAREHOLDERS' EQUITY (Details) Details http://abacuslife.com/role/SHAREHOLDERSEQUITY 87 false false R88.htm 9954751 - Disclosure - EMPLOYEE BENEFIT PLAN (Details) Sheet http://abacuslife.com/role/EMPLOYEEBENEFITPLANDetails EMPLOYEE BENEFIT PLAN (Details) Details http://abacuslife.com/role/EMPLOYEEBENEFITPLAN 88 false false R89.htm 9954752 - Disclosure - INCOME TAXES (Details) Sheet http://abacuslife.com/role/INCOMETAXESDetails INCOME TAXES (Details) Details http://abacuslife.com/role/INCOMETAXES 89 false false R90.htm 9954753 - Disclosure - RELATED-PARTY TRANSACTIONS (Details) Sheet http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails RELATED-PARTY TRANSACTIONS (Details) Details http://abacuslife.com/role/RELATEDPARTYTRANSACTIONS 90 false false R91.htm 9954754 - Disclosure - LEASES - ROU Assets and Lease Liabilities (Details) Sheet http://abacuslife.com/role/LEASESROUAssetsandLeaseLiabilitiesDetails LEASES - ROU Assets and Lease Liabilities (Details) Details 91 false false R92.htm 9954755 - Disclosure - LEASES - Lease Expense (Details) Sheet http://abacuslife.com/role/LEASESLeaseExpenseDetails LEASES - Lease Expense (Details) Details 92 false false R93.htm 9954756 - Disclosure - LEASES - Supplemental Cash Flow Information (Details) Sheet http://abacuslife.com/role/LEASESSupplementalCashFlowInformationDetails LEASES - Supplemental Cash Flow Information (Details) Details 93 false false R94.htm 9954757 - Disclosure - LEASES - Lease Terms and Discount Rates (Details) Sheet http://abacuslife.com/role/LEASESLeaseTermsandDiscountRatesDetails LEASES - Lease Terms and Discount Rates (Details) Details 94 false false R95.htm 9954758 - Disclosure - LEASES - Future Minimum Noncancellable Lease Payments (Details) Sheet http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails LEASES - Future Minimum Noncancellable Lease Payments (Details) Details 95 false false R96.htm 9954759 - Disclosure - EARNINGS PER SHARE - Narrative (Details) Sheet http://abacuslife.com/role/EARNINGSPERSHARENarrativeDetails EARNINGS PER SHARE - Narrative (Details) Details 96 false false R97.htm 9954760 - Disclosure - EARNINGS PER SHARE - Basic and Diluted (Details) Sheet http://abacuslife.com/role/EARNINGSPERSHAREBasicandDilutedDetails EARNINGS PER SHARE - Basic and Diluted (Details) Details 97 false false R98.htm 9954761 - Disclosure - SUBSEQUENT EVENTS (Details) Sheet http://abacuslife.com/role/SUBSEQUENTEVENTSDetails SUBSEQUENT EVENTS (Details) Details http://abacuslife.com/role/SUBSEQUENTEVENTS 98 false false R99.htm 9954762 - Disclosure - Abacus Settlements LLC - DESCRIPTION OF THE BUSINESS (Details) Sheet http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails Abacus Settlements LLC - DESCRIPTION OF THE BUSINESS (Details) Details http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESS 99 false false R100.htm 9954763 - Disclosure - Abacus Settlements LLC - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Sheet http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails Abacus Settlements LLC - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) Details http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES 100 false false R101.htm 9954764 - Disclosure - Abacus Settlements LLC - SEGMENT REPORTING (Details) Sheet http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTINGDetails Abacus Settlements LLC - SEGMENT REPORTING (Details) Details http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTING 101 false false R102.htm 9954765 - Disclosure - Abacus Settlements LLC - REVENUE (Details) Sheet http://abacuslife.com/role/AbacusSettlementsLLCREVENUEDetails Abacus Settlements LLC - REVENUE (Details) Details http://abacuslife.com/role/AbacusSettlementsLLCREVENUETables 102 false false R103.htm 9954766 - Disclosure - Abacus Settlements LLC - INCOME TAXES (Details) Sheet http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXESDetails Abacus Settlements LLC - INCOME TAXES (Details) Details http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXES 103 false false R104.htm 9954767 - Disclosure - Abacus Settlements LLC - RETIREMENT PLAN (Details) Sheet http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLANDetails Abacus Settlements LLC - RETIREMENT PLAN (Details) Details http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLAN 104 false false R105.htm 9954768 - Disclosure - Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS - Narrative (Details) Sheet http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS - Narrative (Details) Details http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSTables 105 false false R106.htm 9954769 - Disclosure - Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS - Revenue Earned and Contracts Originated (Details) Sheet http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS - Revenue Earned and Contracts Originated (Details) Details 106 false false All Reports Book All Reports abl-20230630.htm abl-20230630.xsd abl-20230630_cal.xml abl-20230630_def.xml abl-20230630_lab.xml abl-20230630_pre.xml http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 120 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "abl-20230630.htm": { "axisCustom": 4, "axisStandard": 35, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 1219, "http://xbrl.sec.gov/dei/2023": 33 }, "contextCount": 376, "dts": { "calculationLink": { "local": [ "abl-20230630_cal.xml" ] }, "definitionLink": { "local": [ "abl-20230630_def.xml" ] }, "inline": { "local": [ "abl-20230630.htm" ] }, "labelLink": { "local": [ "abl-20230630_lab.xml" ] }, "presentationLink": { "local": [ "abl-20230630_pre.xml" ] }, "schema": { "local": [ "abl-20230630.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 696, "entityCount": 1, "hidden": { "http://abacuslife.com/20230630": 4, "http://fasb.org/us-gaap/2023": 1, "http://xbrl.sec.gov/dei/2023": 5, "total": 10 }, "keyCustom": 95, "keyStandard": 310, "memberCustom": 57, "memberStandard": 48, "nsprefix": "abl", "nsuri": "http://abacuslife.com/20230630", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - COVER", "menuCat": "Cover", "order": "1", "role": "http://abacuslife.com/role/COVER", "shortName": "COVER", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - DESCRIPTION OF BUSINESS", "menuCat": "Notes", "order": "10", "role": "http://abacuslife.com/role/DESCRIPTIONOFBUSINESS", "shortName": "DESCRIPTION OF BUSINESS", "subGroupType": "", "uniqueAnchor": null }, "R100": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-307", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954763 - Disclosure - Abacus Settlements LLC - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "menuCat": "Details", "order": "100", "role": "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "shortName": "Abacus Settlements LLC - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-307", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AdvertisingExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R101": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "9954764 - Disclosure - Abacus Settlements LLC - SEGMENT REPORTING (Details)", "menuCat": "Details", "order": "101", "role": "http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTINGDetails", "shortName": "Abacus Settlements LLC - SEGMENT REPORTING (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R102": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954765 - Disclosure - Abacus Settlements LLC - REVENUE (Details)", "menuCat": "Details", "order": "102", "role": "http://abacuslife.com/role/AbacusSettlementsLLCREVENUEDetails", "shortName": "Abacus Settlements LLC - REVENUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-341", "decimals": "0", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R103": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954766 - Disclosure - Abacus Settlements LLC - INCOME TAXES (Details)", "menuCat": "Details", "order": "103", "role": "http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXESDetails", "shortName": "Abacus Settlements LLC - INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-309", "decimals": "4", "lang": "en-US", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R104": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-278", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954767 - Disclosure - Abacus Settlements LLC - RETIREMENT PLAN (Details)", "menuCat": "Details", "order": "104", "role": "http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLANDetails", "shortName": "Abacus Settlements LLC - RETIREMENT PLAN (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-309", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R105": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954768 - Disclosure - Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS - Narrative (Details)", "menuCat": "Details", "order": "105", "role": "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "shortName": "Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-356", "decimals": "0", "lang": "en-US", "name": "abl:LifeSettlementContractOriginationRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R106": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954769 - Disclosure - Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS - Revenue Earned and Contracts Originated (Details)", "menuCat": "Details", "order": "106", "role": "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "shortName": "Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS - Revenue Earned and Contracts Originated (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-354", "decimals": "0", "lang": "en-US", "name": "abl:LifeSettlementContractsOriginationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "11", "role": "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": null }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - BUSINESS COMBINATION", "menuCat": "Notes", "order": "12", "role": "http://abacuslife.com/role/BUSINESSCOMBINATION", "shortName": "BUSINESS COMBINATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LifeSettlementContractsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES", "menuCat": "Notes", "order": "13", "role": "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIES", "shortName": "LIFE INSURANCE SETTLEMENT POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LifeSettlementContractsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - PROPERTY AND EQUIPMENT\u2014NET", "menuCat": "Notes", "order": "14", "role": "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNET", "shortName": "PROPERTY AND EQUIPMENT\u2014NET", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS", "menuCat": "Notes", "order": "15", "role": "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETS", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE", "menuCat": "Notes", "order": "16", "role": "http://abacuslife.com/role/AVAILABLEFORSALESECURITIESATFAIRVALUE", "shortName": "AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS", "menuCat": "Notes", "order": "17", "role": "http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETS", "shortName": "OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OtherAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - CONSOLIDATION OF VARIABLE INTEREST ENTITIES", "menuCat": "Notes", "order": "18", "role": "http://abacuslife.com/role/CONSOLIDATIONOFVARIABLEINTERESTENTITIES", "shortName": "CONSOLIDATION OF VARIABLE INTEREST ENTITIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:VariableInterestEntityDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - SEGMENT REPORTING", "menuCat": "Notes", "order": "19", "role": "http://abacuslife.com/role/SEGMENTREPORTING", "shortName": "SEGMENT REPORTING", "subGroupType": "", "uniqueAnchor": null }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - CONDENSED CONSOLIDATED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "shortName": "CONDENSED CONSOLIDATED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "20", "role": "http://abacuslife.com/role/COMMITMENTSANDCONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - FAIR VALUE MEASUREMENTS", "menuCat": "Notes", "order": "21", "role": "http://abacuslife.com/role/FAIRVALUEMEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - LONG-TERM DEBT", "menuCat": "Notes", "order": "22", "role": "http://abacuslife.com/role/LONGTERMDEBT", "shortName": "LONG-TERM DEBT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - SHAREHOLDERS' EQUITY", "menuCat": "Notes", "order": "23", "role": "http://abacuslife.com/role/SHAREHOLDERSEQUITY", "shortName": "SHAREHOLDERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - EMPLOYEE BENEFIT PLAN", "menuCat": "Notes", "order": "24", "role": "http://abacuslife.com/role/EMPLOYEEBENEFITPLAN", "shortName": "EMPLOYEE BENEFIT PLAN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "25", "role": "http://abacuslife.com/role/INCOMETAXES", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": null }, "R26": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - RELATED-PARTY TRANSACTIONS", "menuCat": "Notes", "order": "26", "role": "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONS", "shortName": "RELATED-PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": null }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - LEASES", "menuCat": "Notes", "order": "27", "role": "http://abacuslife.com/role/LEASES", "shortName": "LEASES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - EARNINGS PER SHARE", "menuCat": "Notes", "order": "28", "role": "http://abacuslife.com/role/EARNINGSPERSHARE", "shortName": "EARNINGS PER SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "29", "role": "http://abacuslife.com/role/SUBSEQUENTEVENTS", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": null }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONDENSED CONSOLIDATE BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://abacuslife.com/role/CONDENSEDCONSOLIDATEBALANCESHEETSParenthetical", "shortName": "CONDENSED CONSOLIDATE BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-16", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Abacus Settlements LLC - DESCRIPTION OF THE BUSINESS", "menuCat": "Notes", "order": "30", "role": "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESS", "shortName": "Abacus Settlements LLC - DESCRIPTION OF THE BUSINESS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-309", "decimals": null, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Abacus Settlements LLC - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "31", "role": "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "shortName": "Abacus Settlements LLC - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-309", "decimals": null, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000032 - Disclosure - Abacus Settlements LLC - SEGMENT REPORTING", "menuCat": "Notes", "order": "32", "role": "http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTING", "shortName": "Abacus Settlements LLC - SEGMENT REPORTING", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-309", "decimals": null, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-309", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000033 - Disclosure - Abacus Settlements LLC - REVENUE", "menuCat": "Notes", "order": "33", "role": "http://abacuslife.com/role/AbacusSettlementsLLCREVENUE", "shortName": "Abacus Settlements LLC - REVENUE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-309", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000034 - Disclosure - Abacus Settlements LLC - INCOME TAXES", "menuCat": "Notes", "order": "34", "role": "http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXES", "shortName": "Abacus Settlements LLC - INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-309", "decimals": null, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-309", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000035 - Disclosure - Abacus Settlements LLC - RETIREMENT PLAN", "menuCat": "Notes", "order": "35", "role": "http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLAN", "shortName": "Abacus Settlements LLC - RETIREMENT PLAN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-309", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R36": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000036 - Disclosure - Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS", "menuCat": "Notes", "order": "36", "role": "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONS", "shortName": "Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-309", "decimals": null, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000037 - Disclosure - Abacus Settlements LLC - SUBSEQUENT EVENT", "menuCat": "Notes", "order": "37", "role": "http://abacuslife.com/role/AbacusSettlementsLLCSUBSEQUENTEVENT", "shortName": "Abacus Settlements LLC - SUBSEQUENT EVENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-309", "decimals": null, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954701 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "38", "role": "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954702 - Disclosure - BUSINESS COMBINATION (Tables)", "menuCat": "Tables", "order": "39", "role": "http://abacuslife.com/role/BUSINESSCOMBINATIONTables", "shortName": "BUSINESS COMBINATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME", "menuCat": "Statements", "order": "4", "role": "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "lang": "en-US", "name": "us-gaap:InsuranceInvestmentIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLifeSettlementContractsFairValueMethodTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954703 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES (Tables)", "menuCat": "Tables", "order": "40", "role": "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESTables", "shortName": "LIFE INSURANCE SETTLEMENT POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfLifeSettlementContractsFairValueMethodTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R41": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954704 - Disclosure - PROPERTY AND EQUIPMENT\u2014NET (Tables)", "menuCat": "Tables", "order": "41", "role": "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETTables", "shortName": "PROPERTY AND EQUIPMENT\u2014NET (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954705 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "menuCat": "Tables", "order": "42", "role": "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R43": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954706 - Disclosure - SEGMENT REPORTING (Tables)", "menuCat": "Tables", "order": "43", "role": "http://abacuslife.com/role/SEGMENTREPORTINGTables", "shortName": "SEGMENT REPORTING (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R44": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954707 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "menuCat": "Tables", "order": "44", "role": "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSTables", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R45": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954708 - Disclosure - LONG-TERM DEBT (Tables)", "menuCat": "Tables", "order": "45", "role": "http://abacuslife.com/role/LONGTERMDEBTTables", "shortName": "LONG-TERM DEBT (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R46": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "abl:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954709 - Disclosure - LEASES (Tables)", "menuCat": "Tables", "order": "46", "role": "http://abacuslife.com/role/LEASESTables", "shortName": "LEASES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "abl:AssetsAndLiabilitiesLesseeTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R47": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954710 - Disclosure - EARNINGS PER SHARE (Tables)", "menuCat": "Tables", "order": "47", "role": "http://abacuslife.com/role/EARNINGSPERSHARETables", "shortName": "EARNINGS PER SHARE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R48": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-309", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954711 - Disclosure - Abacus Settlements LLC - REVENUE (Tables)", "menuCat": "Tables", "order": "48", "role": "http://abacuslife.com/role/AbacusSettlementsLLCREVENUETables", "shortName": "Abacus Settlements LLC - REVENUE (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-309", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R49": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954712 - Disclosure - Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS (Tables)", "menuCat": "Tables", "order": "49", "role": "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSTables", "shortName": "Abacus Settlements LLC - RELATED-PARTY TRANSACTIONS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-59", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS\u2019 EQUITY", "menuCat": "Statements", "order": "5", "role": "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SHAREHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-59", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R50": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954713 - Disclosure - DESCRIPTION OF BUSINESS (Details)", "menuCat": "Details", "order": "50", "role": "http://abacuslife.com/role/DESCRIPTIONOFBUSINESSDetails", "shortName": "DESCRIPTION OF BUSINESS (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R51": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954714 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Consolidation of Variable Interest Entities (Details)", "menuCat": "Details", "order": "51", "role": "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Consolidation of Variable Interest Entities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-90", "decimals": "INF", "lang": "en-US", "name": "abl:NumberOfUnaffiliatedInvestorsInvolvedInVariableInterestEntityOwnership", "reportCount": 1, "unique": true, "unitRef": "investor", "xsiNil": "false" } }, "R52": { "firstAnchor": { "ancestors": [ "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954715 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentrations (Details)", "menuCat": "Details", "order": "52", "role": "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Concentrations (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-6", "decimals": "0", "lang": "en-US", "name": "us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R53": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-109", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954716 - Disclosure - BUSINESS COMBINATION - Narrative (Details)", "menuCat": "Details", "order": "53", "role": "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "shortName": "BUSINESS COMBINATION - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-78", "decimals": "-5", "lang": "en-US", "name": "abl:BusinessCombinationEnterpriseValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R54": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954717 - Disclosure - BUSINESS COMBINATION - Purchase Price Allocation (Details)", "menuCat": "Details", "order": "54", "role": "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails", "shortName": "BUSINESS COMBINATION - Purchase Price Allocation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-121", "decimals": "0", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R55": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-122", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954718 - Disclosure - BUSINESS COMBINATION - Value Conveyed (Details)", "menuCat": "Details", "order": "55", "role": "http://abacuslife.com/role/BUSINESSCOMBINATIONValueConveyedDetails", "shortName": "BUSINESS COMBINATION - Value Conveyed (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R56": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954719 - Disclosure - BUSINESS COMBINATION - Intangible Assets Acquired (Details)", "menuCat": "Details", "order": "56", "role": "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "shortName": "BUSINESS COMBINATION - Intangible Assets Acquired (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-132", "decimals": "-3", "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R57": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-136", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954720 - Disclosure - BUSINESS COMBINATION - Pro Forma Financial Information (Details)", "menuCat": "Details", "order": "57", "role": "http://abacuslife.com/role/BUSINESSCOMBINATIONProFormaFinancialInformationDetails", "shortName": "BUSINESS COMBINATION - Pro Forma Financial Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-136", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:BusinessAcquisitionsProFormaRevenue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R58": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "INF", "first": true, "lang": "en-US", "name": "abl:LifeSettlementContractsNumberOfContracts", "reportCount": 1, "unique": true, "unitRef": "insurance_contract", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954721 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES - Narrative (Details)", "menuCat": "Details", "order": "58", "role": "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESNarrativeDetails", "shortName": "LIFE INSURANCE SETTLEMENT POLICIES - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "INF", "first": true, "lang": "en-US", "name": "abl:LifeSettlementContractsNumberOfContracts", "reportCount": 1, "unique": true, "unitRef": "insurance_contract", "xsiNil": "false" } }, "R59": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLifeSettlementContractsFairValueMethodTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "insurance_contract", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954722 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES - Fair Value (Details)", "menuCat": "Details", "order": "59", "role": "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails", "shortName": "LIFE INSURANCE SETTLEMENT POLICIES - Fair Value (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLifeSettlementContractsFairValueMethodTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "insurance_contract", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "shortName": "UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": "0", "lang": "en-US", "name": "us-gaap:LifeSettlementContractsFairValueMethodUnrealizedGainLoss", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R60": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLifeSettlementContractsInvestmentMethodTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "insurance_contract", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954723 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES - Investment Method (Details)", "menuCat": "Details", "order": "60", "role": "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails", "shortName": "LIFE INSURANCE SETTLEMENT POLICIES - Investment Method (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLifeSettlementContractsInvestmentMethodTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "insurance_contract", "xsiNil": "false" } }, "R61": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLifeSettlementContractsInvestmentMethodTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LifeSettlementContractsInvestmentMethodPremiumsToBePaidInRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954724 - Disclosure - LIFE INSURANCE SETTLEMENT POLICIES - Estimated Premiums (Details)", "menuCat": "Details", "order": "61", "role": "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESEstimatedPremiumsDetails", "shortName": "LIFE INSURANCE SETTLEMENT POLICIES - Estimated Premiums (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfLifeSettlementContractsInvestmentMethodTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LifeSettlementContractsInvestmentMethodPremiumsToBePaidInRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R62": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954725 - Disclosure - PROPERTY AND EQUIPMENT\u2014NET (Details)", "menuCat": "Details", "order": "62", "role": "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETDetails", "shortName": "PROPERTY AND EQUIPMENT\u2014NET (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:PropertyPlantAndEquipmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-6", "decimals": "0", "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentGross", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R63": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-6", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954726 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Changes in Goodwill by Reportable Segments (Details)", "menuCat": "Details", "order": "63", "role": "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinGoodwillbyReportableSegmentsDetails", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Changes in Goodwill by Reportable Segments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-149", "decimals": "0", "lang": "en-US", "name": "us-gaap:Goodwill", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R64": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954727 - Disclosure - GOODWILL AND OTHER INTANGIBLE ASSETS - Intangible Assets Acquired (Details)", "menuCat": "Details", "order": "64", "role": "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails", "shortName": "GOODWILL AND OTHER INTANGIBLE ASSETS - Intangible Assets Acquired (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-152", "decimals": null, "lang": "en-US", "name": "us-gaap:FiniteLivedIntangibleAssetUsefulLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R65": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-210", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954728 - Disclosure - AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE (Details)", "menuCat": "Details", "order": "65", "role": "http://abacuslife.com/role/AVAILABLEFORSALESECURITIESATFAIRVALUEDetails", "shortName": "AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-163", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleWeightedAverageYield", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R66": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "INF", "first": true, "lang": "en-US", "name": "abl:NumberOfEntitiesInWhichEquitySecuritiesWithoutReadilyDeterminableFairValueAreHeld", "reportCount": 1, "unitRef": "entity", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954729 - Disclosure - OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS (Details)", "menuCat": "Details", "order": "66", "role": "http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETSDetails", "shortName": "OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "INF", "lang": "en-US", "name": "us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R67": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954730 - Disclosure - CONSOLIDATION OF VARIABLE INTEREST ENTITIES (Details)", "menuCat": "Details", "order": "67", "role": "http://abacuslife.com/role/CONSOLIDATIONOFVARIABLEINTERESTENTITIESDetails", "shortName": "CONSOLIDATION OF VARIABLE INTEREST ENTITIES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R68": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954731 - Disclosure - SEGMENT REPORTING - Narrative (Details)", "menuCat": "Details", "order": "68", "role": "http://abacuslife.com/role/SEGMENTREPORTINGNarrativeDetails", "shortName": "SEGMENT REPORTING - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:NumberOfReportableSegments", "reportCount": 1, "unique": true, "unitRef": "segment", "xsiNil": "false" } }, "R69": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954732 - Disclosure - SEGMENT REPORTING - Revenue by Segment (Details)", "menuCat": "Details", "order": "69", "role": "http://abacuslife.com/role/SEGMENTREPORTINGRevenuebySegmentDetails", "shortName": "SEGMENT REPORTING - Revenue by Segment (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-174", "decimals": "0", "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000007 - Statement - Abacus Settlements LLC - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME", "menuCat": "Statements", "order": "7", "role": "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "shortName": "Abacus Settlements LLC - UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-307", "decimals": "0", "lang": "en-US", "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R70": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:GrossProfit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954733 - Disclosure - SEGMENT REPORTING - Reconciliation of Net Income (Details)", "menuCat": "Details", "order": "70", "role": "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails", "shortName": "SEGMENT REPORTING - Reconciliation of Net Income (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "lang": "en-US", "name": "us-gaap:InterestRevenueExpenseNet", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R71": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "INF", "first": true, "lang": "en-US", "name": "abl:NumberOfProvidersInvolvedInOptionAgreement", "reportCount": 1, "unitRef": "provider", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954734 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "menuCat": "Details", "order": "71", "role": "http://abacuslife.com/role/COMMITMENTSANDCONTINGENCIESDetails", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-82", "decimals": "0", "lang": "en-US", "name": "us-gaap:OtherNonoperatingIncomeExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R72": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954735 - Disclosure - FAIR VALUE MEASUREMENTS - Recurring Fair Value Measurements (Details)", "menuCat": "Details", "order": "72", "role": "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails", "shortName": "FAIR VALUE MEASUREMENTS - Recurring Fair Value Measurements (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-185", "decimals": "0", "lang": "en-US", "name": "us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R73": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LifeSettlementContractsFairValueMethodGainLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954736 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details)", "menuCat": "Details", "order": "73", "role": "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "shortName": "FAIR VALUE MEASUREMENTS - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R74": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "abl:SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954737 - Disclosure - FAIR VALUE MEASUREMENTS - Discount Rate Sensitivity (Details)", "menuCat": "Details", "order": "74", "role": "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSDiscountRateSensitivityDetails", "shortName": "FAIR VALUE MEASUREMENTS - Discount Rate Sensitivity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "abl:SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R75": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-193", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954738 - Disclosure - FAIR VALUE MEASUREMENTS - Credit Exposure to Insurance Companies (Details)", "menuCat": "Details", "order": "75", "role": "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails", "shortName": "FAIR VALUE MEASUREMENTS - Credit Exposure to Insurance Companies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-193", "decimals": "3", "first": true, "lang": "en-US", "name": "us-gaap:ConcentrationRiskPercentage1", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R76": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-199", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954739 - Disclosure - FAIR VALUE MEASUREMENTS - Life Insurance Policies (Details)", "menuCat": "Details", "order": "76", "role": "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails", "shortName": "FAIR VALUE MEASUREMENTS - Life Insurance Policies (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-199", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R77": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-6", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954740 - Disclosure - FAIR VALUE MEASUREMENTS - Issued Notes (Details)", "menuCat": "Details", "order": "77", "role": "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSIssuedNotesDetails", "shortName": "FAIR VALUE MEASUREMENTS - Issued Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-6", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R78": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-204", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954741 - Disclosure - FAIR VALUE MEASUREMENTS - Assumptions (Details)", "menuCat": "Details", "order": "78", "role": "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSAssumptionsDetails", "shortName": "FAIR VALUE MEASUREMENTS - Assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-204", "decimals": "4", "first": true, "lang": "en-US", "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R79": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-235", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954742 - Disclosure - LONG-TERM DEBT - Long-Term Debt (Details)", "menuCat": "Details", "order": "79", "role": "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails", "shortName": "LONG-TERM DEBT - Long-Term Debt (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-235", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-325", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000008 - Statement - Abacus Settlements LLC - UNAUDITED CONDENSED STATEMENTS OF CHANGES IN MEMBERS' EQUITY", "menuCat": "Statements", "order": "8", "role": "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY", "shortName": "Abacus Settlements LLC - UNAUDITED CONDENSED STATEMENTS OF CHANGES IN MEMBERS' EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-325", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R80": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-243", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954743 - Disclosure - LONG-TERM DEBT - Sponsor PIK Note (Details)", "menuCat": "Details", "order": "80", "role": "http://abacuslife.com/role/LONGTERMDEBTSponsorPIKNoteDetails", "shortName": "LONG-TERM DEBT - Sponsor PIK Note (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-243", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R81": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954744 - Disclosure - LONG-TERM DEBT - LMATT Series 2024, Inc. Market-Indexed Notes (Details)", "menuCat": "Details", "order": "81", "role": "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "shortName": "LONG-TERM DEBT - LMATT Series 2024, Inc. Market-Indexed Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-244", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R82": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954745 - Disclosure - LONG-TERM DEBT - LMATT Series 2.2024, Inc. Market-Indexed Notes (Details)", "menuCat": "Details", "order": "82", "role": "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "shortName": "LONG-TERM DEBT - LMATT Series 2.2024, Inc. Market-Indexed Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-247", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R83": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:Assets", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954746 - Disclosure - LONG-TERM DEBT - LMATT Growth and Income Series 1.2026, Inc. Market-Indexed Notes (Details)", "menuCat": "Details", "order": "83", "role": "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "shortName": "LONG-TERM DEBT - LMATT Growth and Income Series 1.2026, Inc. Market-Indexed Notes (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-250", "decimals": "INF", "lang": "en-US", "name": "us-gaap:DebtInstrumentFaceAmount", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R84": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-236", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954747 - Disclosure - LONG-TERM DEBT - LMA Income Series, LP and LMA Income Series, GP LLC Secured Borrowing (Details)", "menuCat": "Details", "order": "84", "role": "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "shortName": "LONG-TERM DEBT - LMA Income Series, LP and LMA Income Series, GP LLC Secured Borrowing (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-252", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtInstrumentTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R85": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-236", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LongTermDebtFairValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954748 - Disclosure - LONG-TERM DEBT - LMA Income Series II, LP and LMA Income Series II, GP LLC Secured Borrowing (Details)", "menuCat": "Details", "order": "85", "role": "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "shortName": "LONG-TERM DEBT - LMA Income Series II, LP and LMA Income Series II, GP LLC Secured Borrowing (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-256", "decimals": null, "lang": "en-US", "name": "us-gaap:DebtInstrumentTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R86": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-266", "decimals": "-5", "first": true, "lang": "en-US", "name": "abl:LifeSettlementContractsSpecialPurchaseVehicleFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954749 - Disclosure - LONG-TERM DEBT - SPV Purchase and Sale and SPV Investment Facility (Details)", "menuCat": "Details", "order": "86", "role": "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "shortName": "LONG-TERM DEBT - SPV Purchase and Sale and SPV Investment Facility (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-266", "decimals": "-5", "first": true, "lang": "en-US", "name": "abl:LifeSettlementContractsSpecialPurchaseVehicleFairValue", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R87": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954750 - Disclosure - SHAREHOLDERS' EQUITY (Details)", "menuCat": "Details", "order": "87", "role": "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails", "shortName": "SHAREHOLDERS' EQUITY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R88": { "firstAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954751 - Disclosure - EMPLOYEE BENEFIT PLAN (Details)", "menuCat": "Details", "order": "88", "role": "http://abacuslife.com/role/EMPLOYEEBENEFITPLANDetails", "shortName": "EMPLOYEE BENEFIT PLAN (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "reportCount": 1, "unique": true, "unitRef": "number", "xsiNil": "false" } }, "R89": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954752 - Disclosure - INCOME TAXES (Details)", "menuCat": "Details", "order": "89", "role": "http://abacuslife.com/role/INCOMETAXESDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R9": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000009 - Statement - Abacus Settlements LLC - UNAUDITED INTERIM CONDENSED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "9", "role": "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "shortName": "Abacus Settlements LLC - UNAUDITED INTERIM CONDENSED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-309", "decimals": "0", "lang": "en-US", "name": "us-gaap:Depreciation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R90": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954753 - Disclosure - RELATED-PARTY TRANSACTIONS (Details)", "menuCat": "Details", "order": "90", "role": "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails", "shortName": "RELATED-PARTY TRANSACTIONS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-285", "decimals": "0", "lang": "en-US", "name": "abl:LifeSettlementContractsOriginationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R91": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954754 - Disclosure - LEASES - ROU Assets and Lease Liabilities (Details)", "menuCat": "Details", "order": "91", "role": "http://abacuslife.com/role/LEASESROUAssetsandLeaseLiabilitiesDetails", "shortName": "LEASES - ROU Assets and Lease Liabilities (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R92": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954755 - Disclosure - LEASES - Lease Expense (Details)", "menuCat": "Details", "order": "92", "role": "http://abacuslife.com/role/LEASESLeaseExpenseDetails", "shortName": "LEASES - Lease Expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R93": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954756 - Disclosure - LEASES - Supplemental Cash Flow Information (Details)", "menuCat": "Details", "order": "93", "role": "http://abacuslife.com/role/LEASESSupplementalCashFlowInformationDetails", "shortName": "LEASES - Supplemental Cash Flow Information (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-1", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeasePayments", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R94": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954757 - Disclosure - LEASES - Lease Terms and Discount Rates (Details)", "menuCat": "Details", "order": "94", "role": "http://abacuslife.com/role/LEASESLeaseTermsandDiscountRatesDetails", "shortName": "LEASES - Lease Terms and Discount Rates (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R95": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954758 - Disclosure - LEASES - Future Minimum Noncancellable Lease Payments (Details)", "menuCat": "Details", "order": "95", "role": "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails", "shortName": "LEASES - Future Minimum Noncancellable Lease Payments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R96": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-202", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954759 - Disclosure - EARNINGS PER SHARE - Narrative (Details)", "menuCat": "Details", "order": "96", "role": "http://abacuslife.com/role/EARNINGSPERSHARENarrativeDetails", "shortName": "EARNINGS PER SHARE - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-289", "decimals": "0", "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R97": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-25", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954760 - Disclosure - EARNINGS PER SHARE - Basic and Diluted (Details)", "menuCat": "Details", "order": "97", "role": "http://abacuslife.com/role/EARNINGSPERSHAREBasicandDilutedDetails", "shortName": "EARNINGS PER SHARE - Basic and Diluted (Details)", "subGroupType": "details", "uniqueAnchor": null }, "R98": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-292", "decimals": null, "first": true, "lang": "en-US", "name": "abl:LineOfCreditFacilityRemainingBorrowingCapacityTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954761 - Disclosure - SUBSEQUENT EVENTS (Details)", "menuCat": "Details", "order": "98", "role": "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails", "shortName": "SUBSEQUENT EVENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-292", "decimals": null, "first": true, "lang": "en-US", "name": "abl:LineOfCreditFacilityRemainingBorrowingCapacityTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R99": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-5", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "9954762 - Disclosure - Abacus Settlements LLC - DESCRIPTION OF THE BUSINESS (Details)", "menuCat": "Details", "order": "99", "role": "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails", "shortName": "Abacus Settlements LLC - DESCRIPTION OF THE BUSINESS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "abl-20230630.htm", "contextRef": "c-334", "decimals": "0", "lang": "en-US", "name": "us-gaap:BusinessCombinationConsiderationTransferred1", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } } }, "segmentCount": 116, "tag": { "abl_APATechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "APA Technology", "label": "APA Technology [Member]", "terseLabel": "Internally Developed and Used Technology\u2014APA" } } }, "localname": "APATechnologyMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "abl_AbacusSettlementsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Abacus Settlements LLC", "label": "Abacus Settlements LLC [Member]", "terseLabel": "Abacus", "verboseLabel": "Abacus Settlements, LLC" } } }, "localname": "AbacusSettlementsLLCMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONValueConveyedDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinGoodwillbyReportableSegmentsDetails" ], "xbrltype": "domainItemType" }, "abl_AccruedTransactionCostsCurrent": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Transaction Costs, Current", "label": "Accrued Transaction Costs, Current", "terseLabel": "Accrued transaction costs" } } }, "localname": "AccruedTransactionCostsCurrent", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "abl_ActiveManagementSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Active Management Segment", "label": "Active Management Segment [Member]", "terseLabel": "Active management" } } }, "localname": "ActiveManagementSegmentMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails", "http://abacuslife.com/role/SEGMENTREPORTINGRevenuebySegmentDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "domainItemType" }, "abl_AgentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agent", "label": "Agent [Member]", "terseLabel": "Agent" } } }, "localname": "AgentMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCREVENUEDetails" ], "xbrltype": "domainItemType" }, "abl_AmericanGeneralLifeInsuranceCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "American General Life Insurance Company", "label": "American General Life Insurance Company [Member]", "terseLabel": "American General Life Insurance Company" } } }, "localname": "AmericanGeneralLifeInsuranceCompanyMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails" ], "xbrltype": "domainItemType" }, "abl_AssetsAndLiabilitiesLesseeTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Assets And Liabilities, Lessee", "label": "Assets And Liabilities, Lessee [Table Text Block]", "terseLabel": "ROU Assets and Lease Liabilities" } } }, "localname": "AssetsAndLiabilitiesLesseeTableTextBlock", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "abl_BinomialLatticeModelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Binomial Lattice Model", "label": "Binomial Lattice Model [Member]", "terseLabel": "Binomial Lattice Model" } } }, "localname": "BinomialLatticeModelMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "domainItemType" }, "abl_BrokerAxisAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Broker Axis", "label": "Broker Axis [Axis]", "terseLabel": "Broker Axis [Axis]" } } }, "localname": "BrokerAxisAxis", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "stringItemType" }, "abl_BrokerAxisDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Broker Axis [Domain]", "label": "Broker Axis [Domain]", "terseLabel": "Broker Axis [Domain]" } } }, "localname": "BrokerAxisDomain", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "abl_BrokerConcentrationRiskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Broker Concentration Risk", "label": "Broker Concentration Risk [Member]", "terseLabel": "Broker Concentration Risk" } } }, "localname": "BrokerConcentrationRiskMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "abl_BrokerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Broker", "label": "Broker [Member]", "terseLabel": "Broker" } } }, "localname": "BrokerMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCREVENUEDetails" ], "xbrltype": "domainItemType" }, "abl_BusinessAcquisitionExchangeRatio": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Acquisition, Exchange Ratio", "label": "Business Acquisition, Exchange Ratio", "terseLabel": "Exchange ratio" } } }, "localname": "BusinessAcquisitionExchangeRatio", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/DESCRIPTIONOFBUSINESSDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "pureItemType" }, "abl_BusinessCombinationAggregateConsiderationReceivableElection": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Aggregate Consideration Receivable Election", "label": "Business Combination, Aggregate Consideration Receivable Election", "terseLabel": "Aggregate consideration election" } } }, "localname": "BusinessCombinationAggregateConsiderationReceivableElection", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails" ], "xbrltype": "monetaryItemType" }, "abl_BusinessCombinationAggregateTransactionProceedsThreshold": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Aggregate Transaction Proceeds Threshold", "label": "Business Combination, Aggregate Transaction Proceeds Threshold", "terseLabel": "Aggregate transaction proceeds threshold" } } }, "localname": "BusinessCombinationAggregateTransactionProceedsThreshold", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails" ], "xbrltype": "monetaryItemType" }, "abl_BusinessCombinationEnterpriseValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Enterprise Value", "label": "Business Combination, Enterprise Value", "terseLabel": "Enterprise value" } } }, "localname": "BusinessCombinationEnterpriseValue", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "abl_BusinessCombinationMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Business Combination, Measurement Input", "label": "Business Combination, Measurement Input", "terseLabel": "Measurement input" } } }, "localname": "BusinessCombinationMeasurementInput", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails" ], "xbrltype": "decimalItemType" }, "abl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": { "order": 7.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Accrued Expenses", "negatedTerseLabel": "Accrued Expenses" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenses", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "abl_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesOther": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Other", "label": "Business Combination, Recognized Identifiable Assets Acquired And Liabilities Assumed, Liabilities, Other", "negatedTerseLabel": "Other Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedLiabilitiesOther", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "abl_CapitalCommitmentThresholdOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital Commitment Threshold One", "label": "Capital Commitment Threshold One [Member]", "terseLabel": "Capital Commitment Threshold One" } } }, "localname": "CapitalCommitmentThresholdOneMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails" ], "xbrltype": "domainItemType" }, "abl_CapitalCommitmentThresholdThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital Commitment Threshold Three", "label": "Capital Commitment Threshold Three [Member]", "terseLabel": "Capital Commitment Threshold Three" } } }, "localname": "CapitalCommitmentThresholdThreeMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails" ], "xbrltype": "domainItemType" }, "abl_CapitalCommitmentThresholdTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Capital Commitment Threshold Two", "label": "Capital Commitment Threshold Two [Member]", "terseLabel": "Capital Commitment Threshold Two" } } }, "localname": "CapitalCommitmentThresholdTwoMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails" ], "xbrltype": "domainItemType" }, "abl_CertificatesOfDepositNoncurrent": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Certificates Of Deposit, Noncurrent", "label": "Certificates Of Deposit, Noncurrent", "terseLabel": "Certificate of deposit" } } }, "localname": "CertificatesOfDepositNoncurrent", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "abl_ClassOfWarrantOrRightCommonStockIssuanceThresholdPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Common Stock Issuance Threshold Price Per Share", "label": "Class Of Warrant Or Right, Common Stock Issuance Threshold Price Per Share", "terseLabel": "Warrants, common stock issuance threshold price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightCommonStockIssuanceThresholdPricePerShare", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "perShareItemType" }, "abl_ClassOfWarrantOrRightCommonStockIssuanceTradingDayPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Common Stock Issuance Trading Day Period", "label": "Class Of Warrant Or Right, Common Stock Issuance Trading Day Period", "terseLabel": "Warrants, common stock issuance trading day period" } } }, "localname": "ClassOfWarrantOrRightCommonStockIssuanceTradingDayPeriod", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "durationItemType" }, "abl_ClassOfWarrantOrRightIssuanceOfCommonStockRedemptionForCommonStockTriggerPriceAdjustmentPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Issuance Of Common Stock, Redemption For Common Stock, Trigger Price Adjustment Percent", "label": "Class Of Warrant Or Right, Issuance Of Common Stock, Redemption For Common Stock, Trigger Price Adjustment Percent", "terseLabel": "Redemption for common stock trigger price adjustment percentage" } } }, "localname": "ClassOfWarrantOrRightIssuanceOfCommonStockRedemptionForCommonStockTriggerPriceAdjustmentPercent", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "percentItemType" }, "abl_ClassOfWarrantOrRightIssuanceOfCommonStockRedemptionTriggerPriceAdjustmentPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Issuance Of Common Stock, Redemption, Trigger Price Adjustment Percent", "label": "Class Of Warrant Or Right, Issuance Of Common Stock, Redemption, Trigger Price Adjustment Percent", "terseLabel": "Redemption trigger price adjustment percentage" } } }, "localname": "ClassOfWarrantOrRightIssuanceOfCommonStockRedemptionTriggerPriceAdjustmentPercent", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "percentItemType" }, "abl_ClassOfWarrantOrRightIssuanceOfCommonStockWarrantPriceAdjustmentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Issuance Of Common Stock, Warrant Price Adjustment Percentage", "label": "Class Of Warrant Or Right, Issuance Of Common Stock, Warrant Price Adjustment Percentage", "terseLabel": "Warrant price adjustment percentage" } } }, "localname": "ClassOfWarrantOrRightIssuanceOfCommonStockWarrantPriceAdjustmentPercentage", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "percentItemType" }, "abl_ClassOfWarrantOrRightPricePerWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Price Per Warrant", "label": "Class Of Warrant Or Right, Price Per Warrant", "terseLabel": "Price per warrant (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightPricePerWarrant", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "perShareItemType" }, "abl_ClassOfWarrantOrRightRedemptionForCommonStockPricePerShareThreshold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Redemption For Common Stock, Price Per Share Threshold", "label": "Class Of Warrant Or Right, Redemption For Common Stock, Price Per Share Threshold", "terseLabel": "Common stock price threshold for redemption for common stock (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightRedemptionForCommonStockPricePerShareThreshold", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "perShareItemType" }, "abl_ClassOfWarrantOrRightRedemptionNoticePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Redemption Notice Period", "label": "Class Of Warrant Or Right, Redemption Notice Period", "terseLabel": "Warrant redemption notice period" } } }, "localname": "ClassOfWarrantOrRightRedemptionNoticePeriod", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "durationItemType" }, "abl_ClassOfWarrantOrRightRedemptionNumberOfTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Redemption, Number Of Trading Days", "label": "Class Of Warrant Or Right, Redemption, Number Of Trading Days", "terseLabel": "Trading days" } } }, "localname": "ClassOfWarrantOrRightRedemptionNumberOfTradingDays", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "durationItemType" }, "abl_ClassOfWarrantOrRightRedemptionPricePerShareThreshold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Redemption, Price Per Share Threshold", "label": "Class Of Warrant Or Right, Redemption, Price Per Share Threshold", "terseLabel": "Common stock price threshold (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightRedemptionPricePerShareThreshold", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "perShareItemType" }, "abl_ClassOfWarrantOrRightRedemptionPricePerWarrant": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Redemption Price Per Warrant", "label": "Class Of Warrant Or Right, Redemption Price Per Warrant", "terseLabel": "Redemption price per warrant (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightRedemptionPricePerWarrant", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "perShareItemType" }, "abl_ClassOfWarrantOrRightRedemptionTradingDayPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Class Of Warrant Or Right, Redemption, Trading Day Period", "label": "Class Of Warrant Or Right, Redemption, Trading Day Period", "terseLabel": "Trading day period" } } }, "localname": "ClassOfWarrantOrRightRedemptionTradingDayPeriod", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "durationItemType" }, "abl_ClientDirectMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Client Direct", "label": "Client Direct [Member]", "terseLabel": "Client direct" } } }, "localname": "ClientDirectMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCREVENUEDetails" ], "xbrltype": "domainItemType" }, "abl_Customer1Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer 1", "label": "Customer 1 [Member]", "terseLabel": "Customer 1" } } }, "localname": "Customer1Member", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "domainItemType" }, "abl_Customer2Member": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer 2", "label": "Customer 2 [Member]", "terseLabel": "Customer 2" } } }, "localname": "Customer2Member", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "domainItemType" }, "abl_CustomerRelationshipAgentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Relationship, Agents", "label": "Customer Relationship, Agents [Member]", "terseLabel": "Customer Relationships - Agents" } } }, "localname": "CustomerRelationshipAgentsMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "abl_CustomerRelationshipsFinancialRelationshipsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Customer Relationships, Financial Relationships", "label": "Customer Relationships, Financial Relationships [Member]", "terseLabel": "Customer Relationships - Financial Relationships" } } }, "localname": "CustomerRelationshipsFinancialRelationshipsMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "abl_DebtInstrumentAmortizationPaymentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Amortization Payment, Percentage", "label": "Debt Instrument, Amortization Payment, Percentage", "terseLabel": "Amortization payment percentage" } } }, "localname": "DebtInstrumentAmortizationPaymentPercentage", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "abl_DebtInstrumentAmortizationPaymentPercentagePerQuarter": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Amortization Payment, Percentage Per Quarter", "label": "Debt Instrument, Amortization Payment, Percentage Per Quarter", "terseLabel": "Amortization payment per quarter" } } }, "localname": "DebtInstrumentAmortizationPaymentPercentagePerQuarter", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "abl_DebtInstrumentBasisSpreadOnVariableRateTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Basis Spread on Variable Rate, Term", "label": "Debt Instrument, Basis Spread on Variable Rate, Term", "terseLabel": "Basis spread on variable rate, term" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRateTerm", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "durationItemType" }, "abl_DebtInstrumentCapitalCommitmentThresholdsToDetermineDividends": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Capital Commitment Thresholds To Determine Dividends", "label": "Debt Instrument, Capital Commitment Thresholds To Determine Dividends", "terseLabel": "Capital commitment threshold to determine dividend rate" } } }, "localname": "DebtInstrumentCapitalCommitmentThresholdsToDetermineDividends", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails" ], "xbrltype": "monetaryItemType" }, "abl_DebtInstrumentCovenantLeverageRatioMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Leverage Ratio, Maximum", "label": "Debt Instrument, Covenant, Leverage Ratio, Maximum", "terseLabel": "Maximum leverage ratio" } } }, "localname": "DebtInstrumentCovenantLeverageRatioMaximum", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "pureItemType" }, "abl_DebtInstrumentCovenantLiquidAssetCoverageRatioMinimum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Liquid Asset Coverage Ratio, Minimum", "label": "Debt Instrument, Covenant, Liquid Asset Coverage Ratio, Minimum", "terseLabel": "Liquid asset minimum coverage ratio" } } }, "localname": "DebtInstrumentCovenantLiquidAssetCoverageRatioMinimum", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "pureItemType" }, "abl_DebtInstrumentCovenantMandatoryPrepaymentPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Mandatory Prepayment Percentage", "label": "Debt Instrument, Covenant, Mandatory Prepayment Percentage", "terseLabel": "Mandatory prepayment percentage" } } }, "localname": "DebtInstrumentCovenantMandatoryPrepaymentPercentage", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "abl_DebtInstrumentCovenantPrepaymentPremiumAfterSecondAnniversary": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Prepayment Premium After Second Anniversary", "label": "Debt Instrument, Covenant, Prepayment Premium After Second Anniversary", "terseLabel": "Prepayment premium after second anniversary" } } }, "localname": "DebtInstrumentCovenantPrepaymentPremiumAfterSecondAnniversary", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "abl_DebtInstrumentCovenantPrepaymentPremiumPriorToFirstAnniversary": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Prepayment Premium Prior To First Anniversary", "label": "Debt Instrument, Covenant, Prepayment Premium Prior To First Anniversary", "terseLabel": "Prepayment premium prior to first anniversary" } } }, "localname": "DebtInstrumentCovenantPrepaymentPremiumPriorToFirstAnniversary", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "abl_DebtInstrumentCovenantPrepaymentPremiumPriorToSecondAnniversary": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Prepayment Premium Prior To Second Anniversary", "label": "Debt Instrument, Covenant, Prepayment Premium Prior To Second Anniversary", "terseLabel": "Prepayment premium prior to second anniversary" } } }, "localname": "DebtInstrumentCovenantPrepaymentPremiumPriorToSecondAnniversary", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "abl_DebtInstrumentCovenantSecuritiesPercentageOfGrossRevenueMaximum": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Covenant, Securities Percentage Of Gross Revenue, Maximum", "label": "Debt Instrument, Covenant, Securities Percentage Of Gross Revenue, Maximum", "terseLabel": "Maximum securities related activities percentage of aggregate gross revenues" } } }, "localname": "DebtInstrumentCovenantSecuritiesPercentageOfGrossRevenueMaximum", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "abl_DebtInstrumentDefaultRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Default Rate", "label": "Debt Instrument, Default Rate", "terseLabel": "Default rate" } } }, "localname": "DebtInstrumentDefaultRate", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "abl_DebtInstrumentDividendFeaturePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Dividend Feature Percentage", "label": "Debt Instrument, Dividend Feature Percentage", "terseLabel": "Dividend percentage" } } }, "localname": "DebtInstrumentDividendFeaturePercentage", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails" ], "xbrltype": "percentItemType" }, "abl_DebtInstrumentExtensionOptions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Extension Options", "label": "Debt Instrument, Extension Options", "terseLabel": "Debt Instrument extension options" } } }, "localname": "DebtInstrumentExtensionOptions", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails" ], "xbrltype": "integerItemType" }, "abl_DebtInstrumentExtensionTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Extension Term", "label": "Debt Instrument, Extension Term", "terseLabel": "Debt instrument extension term" } } }, "localname": "DebtInstrumentExtensionTerm", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails" ], "xbrltype": "durationItemType" }, "abl_DebtInstrumentInternalRateOfReturnCap": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Internal Rate Of Return Threshold Cap", "label": "Debt Instrument, Internal Rate Of Return Cap", "terseLabel": "Internal rate of return cap" } } }, "localname": "DebtInstrumentInternalRateOfReturnCap", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails" ], "xbrltype": "percentItemType" }, "abl_DebtInstrumentMaximumMarketDownturnProtectionPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Maximum Market Downturn Protection Percentage", "label": "Debt Instrument, Maximum Market Downturn Protection Percentage", "terseLabel": "Market downturn protection percentage" } } }, "localname": "DebtInstrumentMaximumMarketDownturnProtectionPercentage", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails" ], "xbrltype": "percentItemType" }, "abl_DebtInstrumentMaximumUpsidePerformanceParticipationPercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Maximum Upside Performance Participation Percentage", "label": "Debt Instrument, Maximum Upside Performance Participation Percentage", "terseLabel": "Upside performance participation cap" } } }, "localname": "DebtInstrumentMaximumUpsidePerformanceParticipationPercentage", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails" ], "xbrltype": "percentItemType" }, "abl_DebtInstrumentMinimumInternalRateOfReturn": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Minimum Internal Rate Of Return Threshold", "label": "Debt Instrument, Minimum Internal Rate Of Return", "terseLabel": "Minimum internal rate of return threshold" } } }, "localname": "DebtInstrumentMinimumInternalRateOfReturn", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails" ], "xbrltype": "percentItemType" }, "abl_DebtInstrumentNetInternalRateOfReturnAtCap": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Net Internal Rate Of Return At Cap", "label": "Debt Instrument, Net Internal Rate Of Return At Cap", "terseLabel": "Net internal rate of return at cap" } } }, "localname": "DebtInstrumentNetInternalRateOfReturnAtCap", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails" ], "xbrltype": "percentItemType" }, "abl_DebtInstrumentNoteReductionRatioForLossesBelowThreshold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Note Reduction Ratio For Losses Below Threshold", "label": "Debt Instrument, Note Reduction Ratio For Losses Below Threshold", "terseLabel": "Note reduction ratio for losses below threshold" } } }, "localname": "DebtInstrumentNoteReductionRatioForLossesBelowThreshold", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails" ], "xbrltype": "percentItemType" }, "abl_DebtInstrumentNumberOfExtensions": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Number Of Extensions", "label": "Debt Instrument, Number Of Extensions", "terseLabel": "Number of extensions" } } }, "localname": "DebtInstrumentNumberOfExtensions", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails" ], "xbrltype": "integerItemType" }, "abl_DebtInstrumentPrivatePlacementOfferingCapitalCommitmentThresholdsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Private Placement Offering, Capital Commitment Thresholds", "label": "Debt Instrument, Private Placement Offering, Capital Commitment Thresholds [Axis]", "terseLabel": "Debt Instrument, Private Placement Offering, Capital Commitment Thresholds [Axis]" } } }, "localname": "DebtInstrumentPrivatePlacementOfferingCapitalCommitmentThresholdsAxis", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails" ], "xbrltype": "stringItemType" }, "abl_DebtInstrumentPrivatePlacementOfferingCapitalCommitmentThresholdsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Private Placement Offering, Capital Commitment Thresholds [Domain]", "label": "Debt Instrument, Private Placement Offering, Capital Commitment Thresholds [Domain]", "terseLabel": "Debt Instrument, Private Placement Offering, Capital Commitment Thresholds [Domain]" } } }, "localname": "DebtInstrumentPrivatePlacementOfferingCapitalCommitmentThresholdsDomain", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails" ], "xbrltype": "domainItemType" }, "abl_DebtInstrumentReturnRateInExcessOfCappedInternalRateOfReturnThreshold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Return Rate In Excess Of Capped Internal Rate Of Return Threshold", "label": "Debt Instrument, Return Rate In Excess Of Capped Internal Rate Of Return Threshold", "terseLabel": "Return Rate in excess of capped internal rate of return threshold" } } }, "localname": "DebtInstrumentReturnRateInExcessOfCappedInternalRateOfReturnThreshold", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails" ], "xbrltype": "percentItemType" }, "abl_DebtInstrumentReturnRateInExcessOfMinimumInternalRateOfReturnThreshold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt Instrument, Return Rate In Excess Of Minimum Internal Rate Of Return Threshold", "label": "Debt Instrument, Return Rate In Excess Of Minimum Internal Rate Of Return Threshold", "terseLabel": "Return rate in excess of minimum internal rate of return" } } }, "localname": "DebtInstrumentReturnRateInExcessOfMinimumInternalRateOfReturnThreshold", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails" ], "xbrltype": "percentItemType" }, "abl_DebtSecuritiesAvailableForSaleEquityFinancingThresholdInWhichSharesConvert": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debt Securities, Available-For-Sale, Equity Financing Threshold In Which Shares Convert", "label": "Debt Securities, Available-For-Sale, Equity Financing Threshold In Which Shares Convert", "terseLabel": "Equity financing threshold" } } }, "localname": "DebtSecuritiesAvailableForSaleEquityFinancingThresholdInWhichSharesConvert", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AVAILABLEFORSALESECURITIESATFAIRVALUEDetails" ], "xbrltype": "monetaryItemType" }, "abl_ERESClassACommonStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ERES Class A Common Stock", "label": "ERES Class A Common Stock [Member]", "terseLabel": "ERES Class A Common Stock" } } }, "localname": "ERESClassACommonStockMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails" ], "xbrltype": "domainItemType" }, "abl_EquitySecuritiesWithoutReadilyDeterminableFairValueNumberOfSecuritiesPurchased": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equity Securities Without Readily Determinable Fair Value, Number Of Securities Purchased", "label": "Equity Securities Without Readily Determinable Fair Value, Number Of Securities Purchased", "terseLabel": "Units purchased (in shares)" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueNumberOfSecuritiesPurchased", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETSDetails" ], "xbrltype": "sharesItemType" }, "abl_ExpenseReimbursementsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expense Reimbursements", "label": "Expense Reimbursements [Member]", "terseLabel": "Expense Reimbursements", "verboseLabel": "Transaction reimbursement revenue" } } }, "localname": "ExpenseReimbursementsMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "abl_ExpenseSupportAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Expense Support Agreement", "label": "Expense Support Agreement [Member]", "terseLabel": "Expense Support Agreement" } } }, "localname": "ExpenseSupportAgreementMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "abl_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPremiumsPaid": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails": { "order": 2.0, "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Premiums Paid", "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Premiums Paid", "terseLabel": "Premiums paid" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPremiumsPaid", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails" ], "xbrltype": "monetaryItemType" }, "abl_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRealizedGainLossIncludedInEarnings": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails": { "order": 1.0, "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Realized Gain (Loss) Included In Earnings", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Realized Gain (Loss) Included in Earnings", "terseLabel": "Realized gain (loss) on matured/sold policies" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetRealizedGainLossIncludedInEarnings", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails" ], "xbrltype": "monetaryItemType" }, "abl_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInEarnings": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails": { "order": 3.0, "parentTag": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Unrealized Gain (Loss) Included In Earnings", "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Asset, Unrealized Gain (Loss) Included In Earnings", "terseLabel": "Unrealized gain(loss) on held policies" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetUnrealizedGainLossIncludedInEarnings", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails" ], "xbrltype": "monetaryItemType" }, "abl_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEquityAttributableToNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included In Equity, Attributable To Noncontrolling Interest", "label": "Fair Value, Measurement With Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included In Equity, Attributable To Noncontrolling Interest", "terseLabel": "Gain on change in fair value of debt, included within equity of noncontrolling interests" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEquityAttributableToNoncontrollingInterest", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "abl_FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSIssuedNotesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair Value, Option, Change In Fair Value Gain (Loss) And Credit Risk, Gains (Losses) On Assets", "label": "Fair Value, Option, Change In Fair Value Gain (Loss) And Credit Risk, Gains (Losses) On Assets", "terseLabel": "Total change in fair value of debt", "totalLabel": "Change in estimated fair value" } } }, "localname": "FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSIssuedNotesDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "abl_InvestmentMethodRevenueBenchmarkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Investment Method Revenue Benchmark", "label": "Investment Method Revenue Benchmark [Member]", "terseLabel": "Investment Method Revenue Benchmark" } } }, "localname": "InvestmentMethodRevenueBenchmarkMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "domainItemType" }, "abl_LMATTGrowthIncomeSeries12026IncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LMATT Growth & Income Series 1.2026, Inc", "label": "LMATT Growth & Income Series 1.2026, Inc [Member]", "terseLabel": "LMATT Growth & Income Series 1.2026, Inc" } } }, "localname": "LMATTGrowthIncomeSeries12026IncMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "abl_LMATTIncomeSeriesIILPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LMATT Income Series II, LP", "label": "LMATT Income Series II, LP [Member]", "terseLabel": "LMATT Income Series II, LP" } } }, "localname": "LMATTIncomeSeriesIILPMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "abl_LMATTIncomeSeriesLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LMATT Income Series, LP", "label": "LMATT Income Series, LP [Member]", "terseLabel": "LMATT Income Series, LP" } } }, "localname": "LMATTIncomeSeriesLPMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "abl_LMATTSeries2024IncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LMATT Series 2024, Inc.", "label": "LMATT Series 2024, Inc. [Member]", "terseLabel": "LMATT Series 2024, Inc." } } }, "localname": "LMATTSeries2024IncMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "abl_LMATTSeries22024IncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LMATT Series 2.2024, Inc.", "label": "LMATT Series 2.2024, Inc. [Member]", "terseLabel": "LMATT Series 2.2024, Inc." } } }, "localname": "LMATTSeries22024IncMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "abl_LMXSeriesLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "LMX Series, LLC", "label": "LMX Series, LLC [Member]", "terseLabel": "LMX" } } }, "localname": "LMXSeriesLLCMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "abl_LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails": { "order": 4.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Lessee, Operating Lease, Liability, To Be Paid, Due After Year Four", "label": "Lessee, Operating Lease, Liability, To Be Paid, Due After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LesseeOperatingLeaseLiabilityToBePaidDueAfterYearFour", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "abl_LifeInsuranceCarrierAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Insurance Carrier", "label": "Life Insurance Carrier [Axis]", "terseLabel": "Life Insurance Carrier [Axis]" } } }, "localname": "LifeInsuranceCarrierAxis", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails" ], "xbrltype": "stringItemType" }, "abl_LifeInsuranceCarrierConcentrationRiskMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Insurance Carrier Concentration Risk", "label": "Life Insurance Carrier Concentration Risk [Member]", "terseLabel": "Life Insurance Carrier Concentration Risk" } } }, "localname": "LifeInsuranceCarrierConcentrationRiskMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails" ], "xbrltype": "domainItemType" }, "abl_LifeInsuranceCarrierDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Insurance Carrier [Domain]", "label": "Life Insurance Carrier [Domain]", "terseLabel": "Life Insurance Carrier [Domain]" } } }, "localname": "LifeInsuranceCarrierDomain", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails" ], "xbrltype": "domainItemType" }, "abl_LifeSettlementCommissionExpenseBenchmarkMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Settlement Commission Expense Benchmark", "label": "Life Settlement Commission Expense Benchmark [Member]", "terseLabel": "Life Settlement Commission Expense Benchmark" } } }, "localname": "LifeSettlementCommissionExpenseBenchmarkMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "abl_LifeSettlementContractFairValueMaturityAfterYearFour": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Life Settlement Contract, Fair Value, Maturity, After Year Four", "label": "Life Settlement Contract, Fair Value, Maturity, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LifeSettlementContractFairValueMaturityAfterYearFour", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "monetaryItemType" }, "abl_LifeSettlementContractFairValueMethodFaceValueMaturityAfterYearFour": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodFaceValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Life Settlement Contract, Fair Value Method, Face Value, Maturity, After Year Four", "label": "Life Settlement Contract, Fair Value Method, Face Value, Maturity, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LifeSettlementContractFairValueMethodFaceValueMaturityAfterYearFour", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "monetaryItemType" }, "abl_LifeSettlementContractFairValueMethodNumberOfContractsMaturityAfterYearFour": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 6.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodNumberOfContracts", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Life Settlement Contract, Fair Value Method, Number of Contracts, Maturity, After Year Four", "label": "Life Settlement Contract, Fair Value Method, Number of Contracts, Maturity, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LifeSettlementContractFairValueMethodNumberOfContractsMaturityAfterYearFour", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "integerItemType" }, "abl_LifeSettlementContractInvestmentMethodAmountMaturityAfterYearFour": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 4.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodCarryingAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Life Settlement Contract, Investment Method, Amount, Maturity, After Year Four", "label": "Life Settlement Contract, Investment Method, Amount, Maturity, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LifeSettlementContractInvestmentMethodAmountMaturityAfterYearFour", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "monetaryItemType" }, "abl_LifeSettlementContractInvestmentMethodFaceValueMaturityAfterYearFour": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 2.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodFaceValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Life Settlement Contract, Investment Method, Face Value, Maturity, After Year Four", "label": "Life Settlement Contract, Investment Method, Face Value, Maturity, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LifeSettlementContractInvestmentMethodFaceValueMaturityAfterYearFour", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "monetaryItemType" }, "abl_LifeSettlementContractInvestmentMethodNumberOfContractsMaturityAfterYearFour": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 6.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodNumberOfContracts", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Life Settlement Contract, Investment Method, Number Of Contracts, Maturity, After Year Four", "label": "Life Settlement Contract, Investment Method, Number Of Contracts, Maturity, After Year Four", "terseLabel": "Thereafter" } } }, "localname": "LifeSettlementContractInvestmentMethodNumberOfContractsMaturityAfterYearFour", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "integerItemType" }, "abl_LifeSettlementContractInvestmentMethodPremiumToBePaidAfterYearThree": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESEstimatedPremiumsDetails": { "order": 5.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Life Settlement Contract, Investment Method, Premium To Be Paid, After Year Three", "label": "Life Settlement Contract, Investment Method, Premium To Be Paid, After Year Three", "terseLabel": "Thereafter" } } }, "localname": "LifeSettlementContractInvestmentMethodPremiumToBePaidAfterYearThree", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESEstimatedPremiumsDetails" ], "xbrltype": "monetaryItemType" }, "abl_LifeSettlementContractMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Settlement Contract", "label": "Life Settlement Contract [Member]", "terseLabel": "Life Insurance Policies" } } }, "localname": "LifeSettlementContractMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails" ], "xbrltype": "domainItemType" }, "abl_LifeSettlementContractOriginationRevenue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Life Settlement Contract, Origination Revenue", "label": "Life Settlement Contract, Origination Revenue", "terseLabel": "Origination revenue" } } }, "localname": "LifeSettlementContractOriginationRevenue", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "abl_LifeSettlementContractOriginationRevenuePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Settlement Contract, Origination Revenue, Percent", "label": "Life Settlement Contract, Origination Revenue, Percent", "terseLabel": "Origination revenue percent" } } }, "localname": "LifeSettlementContractOriginationRevenuePercent", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails" ], "xbrltype": "percentItemType" }, "abl_LifeSettlementContractPurchasedFairValueMethod": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Life Settlement Contract Purchased, Fair Value Method", "label": "Life Settlement Contract Purchased, Fair Value Method", "negatedTerseLabel": "Life Settlement Policies purchased, at fair value" } } }, "localname": "LifeSettlementContractPurchasedFairValueMethod", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "abl_LifeSettlementContractPurchasedInvestmentMethod": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Life Settlement Contract Purchased, Investment Method", "label": "Life Settlement Contract Purchased, Investment Method", "negatedTerseLabel": "Life Settlement Policies purchased, at cost" } } }, "localname": "LifeSettlementContractPurchasedInvestmentMethod", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "abl_LifeSettlementContractsAverageAge": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Settlement Contracts, Average Age", "label": "Life Settlement Contracts, Average Age", "terseLabel": "Average Age" } } }, "localname": "LifeSettlementContractsAverageAge", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails" ], "xbrltype": "durationItemType" }, "abl_LifeSettlementContractsFaceValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Settlement Contracts, Face Value", "label": "Life Settlement Contracts, Face Value [Member]", "terseLabel": "Life Insurance Contract, Face Value" } } }, "localname": "LifeSettlementContractsFaceValueMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails" ], "xbrltype": "domainItemType" }, "abl_LifeSettlementContractsFairValueMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Settlement Contracts, Fair Value", "label": "Life Settlement Contracts, Fair Value [Member]", "terseLabel": "Life Insurance Contract, Fair Value" } } }, "localname": "LifeSettlementContractsFairValueMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails" ], "xbrltype": "domainItemType" }, "abl_LifeSettlementContractsMeasurementInput": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Settlement Contracts, Measurement Input", "label": "Life Settlement Contracts, Measurement Input", "terseLabel": "Life settlement policies, measurement input" } } }, "localname": "LifeSettlementContractsMeasurementInput", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "percentItemType" }, "abl_LifeSettlementContractsNumberOfContracts": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Settlement Contracts, Number Of Contracts", "label": "Life Settlement Contracts, Number Of Contracts", "terseLabel": "Number of life settlement policies" } } }, "localname": "LifeSettlementContractsNumberOfContracts", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESNarrativeDetails" ], "xbrltype": "integerItemType" }, "abl_LifeSettlementContractsNumberOfContractsOriginated": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Settlement Contracts, Number Of Contracts Originated", "label": "Life Settlement Contracts, Number Of Contracts Originated", "terseLabel": "Total policies" } } }, "localname": "LifeSettlementContractsNumberOfContractsOriginated", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails" ], "xbrltype": "integerItemType" }, "abl_LifeSettlementContractsNumberOfContractsSold": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Life Settlement Contracts, Number Of Contracts Sold", "label": "Life Settlement Contracts, Number Of Contracts Sold", "terseLabel": "Life settlement policies sold" } } }, "localname": "LifeSettlementContractsNumberOfContractsSold", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "integerItemType" }, "abl_LifeSettlementContractsOriginatedValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Life Settlement Contracts Originated, Value", "label": "Life Settlement Contracts Originated, Value", "terseLabel": "Face value" } } }, "localname": "LifeSettlementContractsOriginatedValue", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails" ], "xbrltype": "monetaryItemType" }, "abl_LifeSettlementContractsOriginationExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Life Settlement Contracts, Origination Expense", "label": "Life Settlement Contracts, Origination Expense", "terseLabel": "Origination expenses for life settlement policies", "verboseLabel": "Cost" } } }, "localname": "LifeSettlementContractsOriginationExpense", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "abl_LifeSettlementContractsSpecialPurchaseVehicleFairValue": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Life Settlement Contracts, Special Purchase Vehicle, Fair Value", "label": "Life Settlement Contracts, Special Purchase Vehicle, Fair Value", "terseLabel": "Insurance policies fair value" } } }, "localname": "LifeSettlementContractsSpecialPurchaseVehicleFairValue", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails" ], "xbrltype": "monetaryItemType" }, "abl_LincolnNationalLifeInsuranceCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Lincoln National Life Insurance Company", "label": "Lincoln National Life Insurance Company [Member]", "terseLabel": "Lincoln National Life Insurance Company" } } }, "localname": "LincolnNationalLifeInsuranceCompanyMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails" ], "xbrltype": "domainItemType" }, "abl_LineOfCreditFacilityRemainingBorrowingCapacityTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line of Credit Facility, Remaining Borrowing Capacity, Term", "label": "Line of Credit Facility, Remaining Borrowing Capacity, Term", "terseLabel": "Additional borrowing capacity availability period" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacityTerm", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "durationItemType" }, "abl_LongevityMarketAdvisorsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Longevity Market Advisors, LLC", "label": "Longevity Market Advisors, LLC [Member]", "terseLabel": "Longevity Market Advisors" } } }, "localname": "LongevityMarketAdvisorsLLCMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "abl_LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Longevity Market Assets,\u00a0LLC And Abacus Settlements LLC", "label": "Longevity Market Assets,\u00a0LLC And Abacus Settlements LLC [Member]", "terseLabel": "LMA and Abacus" } } }, "localname": "LongevityMarketAssetsLLCAndAbacusSettlementsLLCMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONProFormaFinancialInformationDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONValueConveyedDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinGoodwillbyReportableSegmentsDetails" ], "xbrltype": "domainItemType" }, "abl_LongevityMarketAssetsLLCMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Longevity Market Assets, LLC", "label": "Longevity Market Assets, LLC [Member]", "terseLabel": "LMA" } } }, "localname": "LongevityMarketAssetsLLCMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONValueConveyedDetails", "http://abacuslife.com/role/DESCRIPTIONOFBUSINESSDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "domainItemType" }, "abl_MarketPlaceTechnologyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Market Place Technology", "label": "Market Place Technology [Member]", "terseLabel": "Internally Developed and Used Technology\u2014Market Place" } } }, "localname": "MarketPlaceTechnologyMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "abl_MonthlyPaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Monthly Payments To Acquire, Equity Securities Without Readily Determinable Fair Value", "label": "Monthly Payments To Acquire, Equity Securities Without Readily Determinable Fair Value", "terseLabel": "Monthly payment amount" } } }, "localname": "MonthlyPaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETSDetails" ], "xbrltype": "monetaryItemType" }, "abl_NovaTradingUSLLCAndNovaHoldingUSLPMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Nova Trading (US), LLC And Nova Holding (US) LP", "label": "Nova Trading (US), LLC And Nova Holding (US) LP [Member]", "terseLabel": "Nova Funds" } } }, "localname": "NovaTradingUSLLCAndNovaHoldingUSLPMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "abl_NumberOfEntitiesInWhichEquitySecuritiesWithoutReadilyDeterminableFairValueAreHeld": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Entities In Which Equity Securities Without Readily Determinable Fair Value Are Held", "label": "Number Of Entities In Which Equity Securities Without Readily Determinable Fair Value Are Held", "terseLabel": "Number of entities, convertible preferred stock ownership" } } }, "localname": "NumberOfEntitiesInWhichEquitySecuritiesWithoutReadilyDeterminableFairValueAreHeld", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETSDetails" ], "xbrltype": "integerItemType" }, "abl_NumberOfMonthlyPaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Monthly Payments To Acquire Equity Securities Without Readily Determinable Fair Value", "label": "Number Of Monthly Payments To Acquire Equity Securities Without Readily Determinable Fair Value", "terseLabel": "Number of monthly payments" } } }, "localname": "NumberOfMonthlyPaymentsToAcquireEquitySecuritiesWithoutReadilyDeterminableFairValue", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETSDetails" ], "xbrltype": "integerItemType" }, "abl_NumberOfProvidersInvolvedInOptionAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Providers Involved In Option Agreement", "label": "Number Of Providers Involved In Option Agreement", "terseLabel": "Option agreement, number of providers" } } }, "localname": "NumberOfProvidersInvolvedInOptionAgreement", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "integerItemType" }, "abl_NumberOfUnaffiliatedInvestorsInvolvedInVariableInterestEntityOwnership": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of Unaffiliated Investors", "label": "Number Of Unaffiliated Investors Involved In Variable Interest Entity Ownership", "terseLabel": "Number of unaffiliated investors" } } }, "localname": "NumberOfUnaffiliatedInvestorsInvolvedInVariableInterestEntityOwnership", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "integerItemType" }, "abl_NumberOfVotesPerCommonShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Votes Per Common Share", "label": "Number Of Votes Per Common Share", "terseLabel": "Number of votes per share" } } }, "localname": "NumberOfVotesPerCommonShare", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "integerItemType" }, "abl_OperatingLeaseAssetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Lease, Asset", "label": "Operating Lease, Asset [Abstract]", "terseLabel": "Assets:" } } }, "localname": "OperatingLeaseAssetAbstract", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LEASESROUAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "abl_OriginationFeeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Origination Fee", "label": "Origination Fee [Member]", "terseLabel": "Origination fee revenue" } } }, "localname": "OriginationFeeMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails" ], "xbrltype": "domainItemType" }, "abl_OwlRockCreditFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Owl Rock Credit Facility", "label": "Owl Rock Credit Facility [Member]", "terseLabel": "Owl Rock Credit Facility" } } }, "localname": "OwlRockCreditFacilityMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "abl_OwnersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Owners", "label": "Owners [Member]", "terseLabel": "Owners" } } }, "localname": "OwnersMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "abl_PaymentsDueToMembers": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Payments Due To Members", "label": "Payments Due To Members", "negatedTerseLabel": "Due to members" } } }, "localname": "PaymentsDueToMembers", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "abl_PolicyAPAMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Policy APA", "label": "Policy APA [Member]", "terseLabel": "Policy APA" } } }, "localname": "PolicyAPAMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails" ], "xbrltype": "domainItemType" }, "abl_PortfolioServicingSegmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Portfolio Servicing Segment", "label": "Portfolio Servicing Segment [Member]", "terseLabel": "Portfolio servicing" } } }, "localname": "PortfolioServicingSegmentMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails", "http://abacuslife.com/role/SEGMENTREPORTINGRevenuebySegmentDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "domainItemType" }, "abl_PrivatePlacementWarrantMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Private Placement Warrant", "label": "Private Placement Warrant [Member]", "terseLabel": "Private Placement Warrant" } } }, "localname": "PrivatePlacementWarrantMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/EARNINGSPERSHARENarrativeDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSAssumptionsDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "abl_ProceedsDueFromPaymentsDueToAffiliates": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Proceeds Due From (Payments) Due To Affiliates", "label": "Proceeds Due From (Payments) Due To Affiliates", "terseLabel": "Due from affiliates" } } }, "localname": "ProceedsDueFromPaymentsDueToAffiliates", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "abl_ProviderOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Provider One", "label": "Provider One [Member]", "terseLabel": "Provider One" } } }, "localname": "ProviderOneMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "abl_ProviderTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Provider Two", "label": "Provider Two [Member]", "terseLabel": "Provider Two" } } }, "localname": "ProviderTwoMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "abl_PublicWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Public Warrants", "label": "Public Warrants [Member]", "terseLabel": "Public Warrants" } } }, "localname": "PublicWarrantsMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "domainItemType" }, "abl_RegionalInvestmentServicesIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Regional Investment Services,\u00a0Inc", "label": "Regional Investment Services,\u00a0Inc [Member]", "terseLabel": "RIS" } } }, "localname": "RegionalInvestmentServicesIncMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "abl_ReliaStarLifeInsuranceCompanyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ReliaStar Life Insurance Company", "label": "ReliaStar Life Insurance Company [Member]", "terseLabel": "ReliaStar Life Insurance Company" } } }, "localname": "ReliaStarLifeInsuranceCompanyMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails" ], "xbrltype": "domainItemType" }, "abl_SPVInvestmentFacilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SPV Investment Facility", "label": "SPV Investment Facility [Member]", "terseLabel": "SPV Investment Facility" } } }, "localname": "SPVInvestmentFacilityMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails", "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "abl_SensitivityAnalysisOfFairValueChangeInLifeSettlementContractsFairValueImpactOf2PercentAdverseChangeInDiscountRate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sensitivity Analysis Of Fair Value, Change In Life Settlement Contracts Fair Value, Impact Of 2 Percent Adverse Change In Discount Rate", "label": "Sensitivity Analysis Of Fair Value, Change In Life Settlement Contracts Fair Value, Impact Of 2 Percent Adverse Change In Discount Rate", "terseLabel": "Life settlement policies, change in fair value, impact of -2% discount rate adjustment" } } }, "localname": "SensitivityAnalysisOfFairValueChangeInLifeSettlementContractsFairValueImpactOf2PercentAdverseChangeInDiscountRate", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSDiscountRateSensitivityDetails" ], "xbrltype": "monetaryItemType" }, "abl_SensitivityAnalysisOfFairValueChangeInLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sensitivity Analysis Of Fair Value, Change In Life Settlement Contracts Fair Value, Impact Of 2 Percent Positive Change In Discount Rate", "label": "Sensitivity Analysis Of Fair Value, Change In Life Settlement Contracts Fair Value, Impact Of 2 Percent Positive Change In Discount Rate", "terseLabel": "Life settlement policies, change in fair value, impact of +2% discount rate adjustment" } } }, "localname": "SensitivityAnalysisOfFairValueChangeInLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSDiscountRateSensitivityDetails" ], "xbrltype": "monetaryItemType" }, "abl_SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentAdverseChangeInDiscountRate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sensitivity Analysis Of Fair Value, Life Settlement Contracts Fair Value, Impact Of 2 Percent Adverse Change In Discount Rate", "label": "Sensitivity Analysis Of Fair Value, Life Settlement Contracts Fair Value, Impact Of 2 Percent Adverse Change In Discount Rate", "terseLabel": "Life settlement policies, fair value, impact of -2% discount rate adjustment" } } }, "localname": "SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentAdverseChangeInDiscountRate", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSDiscountRateSensitivityDetails" ], "xbrltype": "monetaryItemType" }, "abl_SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sensitivity Analysis Of Fair Value, Life Settlement Contracts Fair Value, Impact Of 2 Percent Positive Change In Discount Rate", "label": "Sensitivity Analysis Of Fair Value, Life Settlement Contracts Fair Value, Impact Of 2 Percent Positive Change In Discount Rate", "terseLabel": "Life settlement policies, fair value, impact of +2% discount rate adjustment" } } }, "localname": "SensitivityAnalysisOfFairValueLifeSettlementContractsFairValueImpactOf2PercentPositiveChangeInDiscountRate", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSDiscountRateSensitivityDetails" ], "xbrltype": "monetaryItemType" }, "abl_SeriesB1PreferredStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series B-1 Preferred Stock", "label": "Series B-1 Preferred Stock [Member]", "terseLabel": "Series B-1 Preferred Stock" } } }, "localname": "SeriesB1PreferredStockMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETSDetails" ], "xbrltype": "domainItemType" }, "abl_SeriesSeedPreferredUnitsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Series Seed Preferred Units", "label": "Series Seed Preferred Units [Member]", "terseLabel": "Series Seed Preferred Units" } } }, "localname": "SeriesSeedPreferredUnitsMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETSDetails" ], "xbrltype": "domainItemType" }, "abl_ServiceFeeAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Service Fee Agreement", "label": "Service Fee Agreement [Member]", "terseLabel": "Service Fee Agreement" } } }, "localname": "ServiceFeeAgreementMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "abl_SponsorPIKNoteMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sponsor PIK Note", "label": "Sponsor PIK Note [Member]", "terseLabel": "Sponsor PIK Note" } } }, "localname": "SponsorPIKNoteMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails", "http://abacuslife.com/role/LONGTERMDEBTSponsorPIKNoteDetails" ], "xbrltype": "domainItemType" }, "abl_StateSecurityDepositsNoncurrent": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 11.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "State Security Deposits, Noncurrent", "label": "State Security Deposits, Noncurrent", "terseLabel": "State security deposit" } } }, "localname": "StateSecurityDepositsNoncurrent", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "abl_StockIssuedDuringPeriodSharesReverseRecapitalization": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Shares, Reverse Recapitalization", "label": "Stock Issued During Period, Shares, Reverse Recapitalization", "terseLabel": "Merger with East Resources Acquisition Company (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesReverseRecapitalization", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "abl_StockIssuedDuringPeriodValueReverseRecapitalization": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Reverse Recapitalization", "label": "Stock Issued During Period, Value, Reverse Recapitalization", "terseLabel": "Merger with East Resources Acquisition Company" } } }, "localname": "StockIssuedDuringPeriodValueReverseRecapitalization", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "abl_StockholdersEquityDeferredTransactionCosts": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Stockholders Equity, Deferred Transaction Costs", "label": "Stockholders Equity, Deferred Transaction Costs", "negatedTerseLabel": "Deferred transaction costs" } } }, "localname": "StockholdersEquityDeferredTransactionCosts", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "abl_TwoBrokersMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two Brokers", "label": "Two Brokers [Member]", "terseLabel": "Two Brokers" } } }, "localname": "TwoBrokersMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "domainItemType" }, "abl_VariableRateComponentAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Rate Component", "label": "Variable Rate Component [Axis]", "terseLabel": "Variable Rate Component [Axis]" } } }, "localname": "VariableRateComponentAxis", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "abl_VariableRateComponentDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Rate Component [Domain]", "label": "Variable Rate Component [Domain]", "terseLabel": "Variable Rate Component [Domain]" } } }, "localname": "VariableRateComponentDomain", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "abl_VariableRateComponentOneMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Rate Component One", "label": "Variable Rate Component One [Member]", "terseLabel": "Variable Rate Component One" } } }, "localname": "VariableRateComponentOneMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "abl_VariableRateComponentThreeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Rate Component Three", "label": "Variable Rate Component Three [Member]", "terseLabel": "Variable Rate Component Three" } } }, "localname": "VariableRateComponentThreeMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "abl_VariableRateComponentTwoMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Rate Component Two", "label": "Variable Rate Component Two [Member]", "terseLabel": "Variable Rate Component Two" } } }, "localname": "VariableRateComponentTwoMember", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "abl_WarrantLiabilitiesNoncurrent": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Warrant Liabilities, Noncurrent", "label": "Warrant Liabilities, Noncurrent", "terseLabel": "Warrant liability", "verboseLabel": "Private placement warrants" } } }, "localname": "WarrantLiabilitiesNoncurrent", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "abl_WarrantsAndRightsOutstandingExercisableTermBusinessCombination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants and Rights Outstanding, Exercisable Term, Business Combination", "label": "Warrants and Rights Outstanding, Exercisable Term, Business Combination", "terseLabel": "Warrants, business combination exercisable term" } } }, "localname": "WarrantsAndRightsOutstandingExercisableTermBusinessCombination", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "durationItemType" }, "abl_WarrantsAndRightsOutstandingExercisableTermProposedOffering": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants and Rights Outstanding, Exercisable Term, Proposed Offering", "label": "Warrants and Rights Outstanding, Exercisable Term, Proposed Offering", "terseLabel": "Warrants, proposed offering exercisable term" } } }, "localname": "WarrantsAndRightsOutstandingExercisableTermProposedOffering", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "durationItemType" }, "abl_WarrantsAndRightsOutstandingFairValuePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants and Rights Outstanding, Fair Value Per Share", "label": "Warrants and Rights Outstanding, Fair Value Per Share", "terseLabel": "Warrant outstanding fair value per share (in dollars per share)" } } }, "localname": "WarrantsAndRightsOutstandingFairValuePerShare", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "perShareItemType" }, "abl_WarrantsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Warrants", "label": "Warrants [Policy Text Block]", "terseLabel": "Warrants" } } }, "localname": "WarrantsPolicyTextBlock", "nsuri": "http://abacuslife.com/20230630", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]", "terseLabel": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]", "terseLabel": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r869" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r870" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r867" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]", "terseLabel": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/CONSOLIDATIONOFVARIABLEINTERESTENTITIESDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinGoodwillbyReportableSegmentsDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r867" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r872" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r867" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r871" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r867" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r867" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r867" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r867" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]", "terseLabel": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/CONSOLIDATIONOFVARIABLEINTERESTENTITIESDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinGoodwillbyReportableSegmentsDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r866" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r868" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "tradingSymbolItemType" }, "srt_AffiliatedEntityMember": { "auth_ref": [ "r759", "r813", "r858", "r946", "r958", "r959", "r960" ], "lang": { "en-us": { "role": { "label": "Affiliated Entity [Member]", "terseLabel": "Affiliated Entity" } } }, "localname": "AffiliatedEntityMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r242", "r520", "r521", "r525", "r526", "r584", "r813", "r939", "r942", "r943" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "terseLabel": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESS", "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails", "http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXES", "http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXESDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONS", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSTables", "http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLAN", "http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLANDetails", "http://abacuslife.com/role/AbacusSettlementsLLCREVENUE", "http://abacuslife.com/role/AbacusSettlementsLLCREVENUEDetails", "http://abacuslife.com/role/AbacusSettlementsLLCREVENUETables", "http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTING", "http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTINGDetails", "http://abacuslife.com/role/AbacusSettlementsLLCSUBSEQUENTEVENT", "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://abacuslife.com/role/CONSOLIDATIONOFVARIABLEINTERESTENTITIESDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r242", "r520", "r521", "r525", "r526", "r584", "r813", "r939", "r942", "r943" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Domain]", "terseLabel": "Consolidated Entities [Domain]" } } }, "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESS", "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails", "http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXES", "http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXESDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONS", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSTables", "http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLAN", "http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLANDetails", "http://abacuslife.com/role/AbacusSettlementsLLCREVENUE", "http://abacuslife.com/role/AbacusSettlementsLLCREVENUEDetails", "http://abacuslife.com/role/AbacusSettlementsLLCREVENUETables", "http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTING", "http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTINGDetails", "http://abacuslife.com/role/AbacusSettlementsLLCSUBSEQUENTEVENT", "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://abacuslife.com/role/CONSOLIDATIONOFVARIABLEINTERESTENTITIESDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "domainItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r240", "r241", "r411", "r428", "r582", "r819", "r821" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]", "terseLabel": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "srt_MajorCustomersAxis": { "auth_ref": [ "r304", "r837", "r945", "r970", "r971" ], "lang": { "en-us": { "role": { "label": "Customer [Axis]", "terseLabel": "Customer [Axis]" } } }, "localname": "MajorCustomersAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r395", "r396", "r397", "r398", "r485", "r621", "r686", "r728", "r729", "r793", "r794", "r795", "r796", "r803", "r814", "r815", "r826", "r834", "r847", "r854", "r944", "r963", "r964", "r965", "r966", "r967", "r968" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]", "terseLabel": "Maximum" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r395", "r396", "r397", "r398", "r485", "r621", "r686", "r728", "r729", "r793", "r794", "r795", "r796", "r803", "r814", "r815", "r826", "r834", "r847", "r854", "r944", "r963", "r964", "r965", "r966", "r967", "r968" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails" ], "xbrltype": "domainItemType" }, "srt_NameOfMajorCustomerDomain": { "auth_ref": [ "r304", "r837", "r945", "r970", "r971" ], "lang": { "en-us": { "role": { "label": "Customer [Domain]", "terseLabel": "Customer [Domain]" } } }, "localname": "NameOfMajorCustomerDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]", "terseLabel": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Domain]", "terseLabel": "Ownership [Domain]" } } }, "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r301", "r623", "r680", "r681", "r682", "r683", "r684", "r685", "r817", "r835", "r853", "r879", "r937", "r938", "r945", "r970" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]", "terseLabel": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCREVENUEDetails" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r301", "r623", "r680", "r681", "r682", "r683", "r684", "r685", "r817", "r835", "r853", "r879", "r937", "r938", "r945", "r970" ], "lang": { "en-us": { "role": { "label": "Product and Service [Domain]", "terseLabel": "Product and Service [Domain]" } } }, "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCREVENUEDetails" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r395", "r396", "r397", "r398", "r466", "r485", "r486", "r487", "r488", "r594", "r621", "r686", "r728", "r729", "r793", "r794", "r795", "r796", "r803", "r814", "r815", "r826", "r834", "r847", "r854", "r857", "r935", "r944", "r964", "r965", "r966", "r967", "r968" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "terseLabel": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r395", "r396", "r397", "r398", "r466", "r485", "r486", "r487", "r488", "r594", "r621", "r686", "r728", "r729", "r793", "r794", "r795", "r796", "r803", "r814", "r815", "r826", "r834", "r847", "r854", "r857", "r935", "r944", "r964", "r965", "r966", "r967", "r968" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "terseLabel": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r240", "r241", "r411", "r428", "r582", "r820", "r821" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]", "terseLabel": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "srt_SubsidiariesMember": { "auth_ref": [ "r946", "r958", "r959", "r960" ], "lang": { "en-us": { "role": { "label": "Subsidiaries [Member]", "terseLabel": "Abacus Settlements, LLC" } } }, "localname": "SubsidiariesMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESS", "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails", "http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXES", "http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXESDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONS", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSTables", "http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLAN", "http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLANDetails", "http://abacuslife.com/role/AbacusSettlementsLLCREVENUE", "http://abacuslife.com/role/AbacusSettlementsLLCREVENUEDetails", "http://abacuslife.com/role/AbacusSettlementsLLCREVENUETables", "http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTING", "http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTINGDetails", "http://abacuslife.com/role/AbacusSettlementsLLCSUBSEQUENTEVENT", "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r21", "r852" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableMember": { "auth_ref": [ "r811" ], "lang": { "en-us": { "role": { "documentation": "Due from customers or clients for goods or services that have been delivered or sold.", "label": "Accounts Receivable [Member]", "terseLabel": "Accounts Receivable" } } }, "localname": "AccountsReceivableMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AccountsReceivableNetCurrent": { "auth_ref": [ "r305", "r306" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "terseLabel": "Accounts receivable" } } }, "localname": "AccountsReceivableNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedIncomeTaxesCurrent": { "auth_ref": [ "r118", "r165" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.", "label": "Accrued Income Taxes, Current", "terseLabel": "Income taxes payable" } } }, "localname": "AccruedIncomeTaxesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r24" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued expenses" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "auth_ref": [ "r65", "r202", "r655" ], "calculation": { "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETDetails": { "order": 2.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "negatedTerseLabel": "Less: accumulated depreciation" } } }, "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r31", "r32", "r124", "r209", "r651", "r691", "r692" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r3", "r11", "r32", "r528", "r531", "r575", "r687", "r688", "r890", "r891", "r892", "r901", "r902", "r903" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Income" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": { "auth_ref": [ "r140" ], "lang": { "en-us": { "role": { "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Acquired Finite-Lived Intangible Assets, Weighted Average Useful Life", "terseLabel": "Useful Life" } } }, "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r121", "r852", "r974" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r489", "r490", "r491", "r707", "r901", "r902", "r903", "r952", "r976" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentForAmortization": { "auth_ref": [ "r7", "r63" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 22.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of recurring noncash expense charged against earnings in the period to allocate the cost of assets over their estimated remaining economic lives.", "label": "Amortization", "terseLabel": "Amortization expense" } } }, "localname": "AdjustmentForAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "auth_ref": [ "r13", "r67", "r149" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "terseLabel": "Public warrants" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net income to net cash provided by/(used in) operating activities:", "verboseLabel": "Adjustments to reconcile net income to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r178" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising Cost [Policy Text Block]", "terseLabel": "Advertising" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r492" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising Expense", "terseLabel": "Advertising expense" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": { "auth_ref": [ "r210", "r307", "r362" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.", "label": "Accounts Receivable, Allowance for Credit Loss, Current", "terseLabel": "Allowance for doubtful accounts" } } }, "localname": "AllowanceForDoubtfulAccountsReceivableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AmortizationOfFinancingCosts": { "auth_ref": [ "r126", "r423", "r561", "r894" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 17.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense attributable to debt issuance costs.", "label": "Amortization of Debt Issuance Costs", "terseLabel": "Amortization of deferred financing fees" } } }, "localname": "AmortizationOfFinancingCosts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r265" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/EARNINGSPERSHARENarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/EARNINGSPERSHARENarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/EARNINGSPERSHARENarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/EARNINGSPERSHARENarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_AssetPledgedAsCollateralMember": { "auth_ref": [ "r520", "r731", "r848", "r969" ], "lang": { "en-us": { "role": { "documentation": "Asset pledged as collateral.", "label": "Asset Pledged as Collateral [Member]", "terseLabel": "Asset Pledged as Collateral" } } }, "localname": "AssetPledgedAsCollateralMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r163", "r205", "r236", "r276", "r291", "r297", "r344", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r520", "r525", "r551", "r647", "r752", "r852", "r865", "r940", "r941", "r961" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "terseLabel": "Assets", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/CONSOLIDATIONOFVARIABLEINTERESTENTITIESDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r197", "r211", "r236", "r344", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r520", "r525", "r551", "r852", "r940", "r941", "r961" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "CURRENT ASSETS:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsFairValueDisclosure": { "auth_ref": [ "r97" ], "calculation": { "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets held at fair value" } } }, "localname": "AssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "localname": "AssetsFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r314", "r368", "r639", "r911" ], "calculation": { "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Available-for-sale securities, at fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": { "auth_ref": [ "r200", "r310", "r368" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 13.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.", "label": "Debt Securities, Available-for-Sale, Noncurrent", "terseLabel": "Available for sale securities, at fair value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_BaseRateMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Minimum rate investor will accept.", "label": "Base Rate [Member]", "terseLabel": "Base Rate" } } }, "localname": "BaseRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Unaudited Condensed Consolidated Financial Statements" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r518", "r845", "r846" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.", "label": "Business Acquisition, Acquiree [Domain]", "terseLabel": "Business Acquisition, Acquiree [Domain]" } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONProFormaFinancialInformationDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONValueConveyedDetails", "http://abacuslife.com/role/DESCRIPTIONOFBUSINESSDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinGoodwillbyReportableSegmentsDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r73", "r74", "r518", "r845", "r846" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]", "terseLabel": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONProFormaFinancialInformationDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONValueConveyedDetails", "http://abacuslife.com/role/DESCRIPTIONOFBUSINESSDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinGoodwillbyReportableSegmentsDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [ "r518" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]", "terseLabel": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONProFormaFinancialInformationDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONValueConveyedDetails", "http://abacuslife.com/role/DESCRIPTIONOFBUSINESSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": { "auth_ref": [ "r877", "r878" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.", "label": "Business Acquisition, Pro Forma Information [Table Text Block]", "terseLabel": "Pro forma financial information" } } }, "localname": "BusinessAcquisitionProFormaInformationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionSharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.", "label": "Business Acquisition, Share Price", "terseLabel": "Share price (in dollars per share)" } } }, "localname": "BusinessAcquisitionSharePrice", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": { "auth_ref": [ "r516", "r517" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.", "label": "Business Acquisition, Pro Forma Net Income (Loss)", "terseLabel": "Proforma net income" } } }, "localname": "BusinessAcquisitionsProFormaNetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONProFormaFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessAcquisitionsProFormaRevenue": { "auth_ref": [ "r516", "r517" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The pro forma revenue for a period as if the business combination or combinations had been completed at the beginning of the period.", "label": "Business Acquisition, Pro Forma Revenue", "terseLabel": "Proforma revenue" } } }, "localname": "BusinessAcquisitionsProFormaRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONProFormaFinancialInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationConsiderationTransferred1": { "auth_ref": [ "r0", "r1", "r9" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.", "label": "Business Combination, Consideration Transferred", "terseLabel": "Consideration", "verboseLabel": "Consideration paid to acquire business" } } }, "localname": "BusinessCombinationConsiderationTransferred1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONValueConveyedDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets": { "auth_ref": [ "r75" ], "calculation": { "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets", "terseLabel": "Current Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": { "auth_ref": [ "r75" ], "calculation": { "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities", "negatedTerseLabel": "Deferred Tax Liabilities" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": { "auth_ref": [ "r75" ], "calculation": { "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill", "terseLabel": "Intangibles", "verboseLabel": "Fair Value" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets": { "auth_ref": [ "r75" ], "calculation": { "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of other assets expected to be realized or consumed after one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Other Noncurrent Assets", "terseLabel": "Non-Current Assets" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "auth_ref": [ "r75" ], "calculation": { "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "totalLabel": "Total Fair Value" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "auth_ref": [ "r100", "r101" ], "lang": { "en-us": { "role": { "documentation": "Measured as reported on the statement of financial position (balance sheet).", "label": "Reported Value Measurement [Member]", "terseLabel": "Cost" } } }, "localname": "CarryingReportedAmountFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r39", "r199", "r818" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r39", "r135", "r233" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD", "periodStartLabel": "CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect [Abstract]", "terseLabel": "CASH AND CASH EQUIVALENTS:" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffectAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r2", "r135" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfStockDomain": { "auth_ref": [ "r191", "r206", "r207", "r208", "r236", "r259", "r260", "r262", "r264", "r270", "r271", "r344", "r399", "r401", "r402", "r403", "r406", "r407", "r426", "r427", "r430", "r433", "r440", "r551", "r696", "r697", "r698", "r699", "r707", "r708", "r709", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r740", "r761", "r785", "r804", "r805", "r806", "r807", "r808", "r873", "r895", "r904" ], "lang": { "en-us": { "role": { "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.", "label": "Class of Stock [Domain]", "terseLabel": "Class of Stock [Domain]" } } }, "localname": "ClassOfStockDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEBALANCESHEETSParenthetical", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/COVER", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]", "terseLabel": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/EARNINGSPERSHARENarrativeDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSAssumptionsDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]", "terseLabel": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/EARNINGSPERSHARENarrativeDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSAssumptionsDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r441" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrants (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/EARNINGSPERSHARENarrativeDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Class of Warrant or Right [Line Items]" } } }, "localname": "ClassOfWarrantOrRightLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.", "label": "Class of Warrant or Right, Number of Securities Called by Each Warrant or Right", "terseLabel": "Number of securities called by each warrant (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "Class of Warrant or Right, Outstanding", "terseLabel": "Warrants outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ClassOfWarrantOrRightTable": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.", "label": "Class of Warrant or Right [Table]", "terseLabel": "Class of Warrant or Right [Table]" } } }, "localname": "ClassOfWarrantOrRightTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r28", "r113", "r649", "r739" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r144", "r393", "r394", "r812", "r936" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/COMMITMENTSANDCONTINGENCIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonClassAMember": { "auth_ref": [ "r976" ], "lang": { "en-us": { "role": { "documentation": "Classification of common stock representing ownership interest in a corporation.", "label": "Common Class A [Member]", "terseLabel": "Class A Common Stock" } } }, "localname": "CommonClassAMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEBALANCESHEETSParenthetical", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r855", "r856", "r857", "r859", "r860", "r861", "r862", "r901", "r902", "r952", "r972", "r976" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock", "verboseLabel": "Common units" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY", "http://abacuslife.com/role/COVER", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEBALANCESHEETSParenthetical", "http://abacuslife.com/role/DESCRIPTIONOFBUSINESSDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r120", "r740" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEBALANCESHEETSParenthetical", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r120" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEBALANCESHEETSParenthetical", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r13", "r120", "r740", "r758", "r976", "r977" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEBALANCESHEETSParenthetical", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r120", "r650", "r852" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Class A common stock, $0.0001 par value; 200,000,000 authorized shares; 62,961,688 and 50,369,350 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CompensationAndRetirementDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Retirement Benefits [Abstract]" } } }, "localname": "CompensationAndRetirementDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r33", "r216", "r218", "r228", "r643", "r666" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive income attributable to Abacus Life Inc." } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r5", "r81", "r95", "r216", "r218", "r227", "r642", "r665" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest", "negatedTerseLabel": "Comprehensive income (loss) attributable to non-controlling interests" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r95", "r157", "r216", "r218", "r226", "r641", "r664" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Comprehensive income" } } }, "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComputerEquipmentMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.", "label": "Computer Equipment [Member]", "terseLabel": "Computer equipment" } } }, "localname": "ComputerEquipmentMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "auth_ref": [ "r45", "r47", "r102", "r103", "r304", "r811" ], "lang": { "en-us": { "role": { "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.", "label": "Concentration Risk Benchmark [Domain]", "terseLabel": "Concentration Risk Benchmark [Domain]" } } }, "localname": "ConcentrationRiskBenchmarkDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "auth_ref": [ "r45", "r47", "r102", "r103", "r304", "r693", "r811" ], "lang": { "en-us": { "role": { "documentation": "Information by benchmark of concentration risk.", "label": "Concentration Risk Benchmark [Axis]", "terseLabel": "Concentration Risk Benchmark [Axis]" } } }, "localname": "ConcentrationRiskByBenchmarkAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskByTypeAxis": { "auth_ref": [ "r45", "r47", "r102", "r103", "r304", "r811", "r876" ], "lang": { "en-us": { "role": { "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.", "label": "Concentration Risk Type [Axis]", "terseLabel": "Concentration Risk Type [Axis]" } } }, "localname": "ConcentrationRiskByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r115", "r181" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentrations" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskLineItems": { "auth_ref": [ "r811" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Concentration Risk [Line Items]", "terseLabel": "Concentration Risk [Line Items]" } } }, "localname": "ConcentrationRiskLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskPercentage1": { "auth_ref": [ "r45", "r47", "r102", "r103", "r304" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.", "label": "Concentration Risk, Percentage", "terseLabel": "Concentration risk percentage" } } }, "localname": "ConcentrationRiskPercentage1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ConcentrationRiskTable": { "auth_ref": [ "r44", "r45", "r47", "r48", "r102", "r160", "r811" ], "lang": { "en-us": { "role": { "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Concentration Risk [Table]", "terseLabel": "Concentration Risk [Table]" } } }, "localname": "ConcentrationRiskTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConcentrationRiskTypeDomain": { "auth_ref": [ "r45", "r47", "r102", "r103", "r304", "r811" ], "lang": { "en-us": { "role": { "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.", "label": "Concentration Risk Type [Domain]", "terseLabel": "Concentration Risk Type [Domain]" } } }, "localname": "ConcentrationRiskTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]", "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]" } } }, "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable": { "auth_ref": [ "r12", "r96" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning the effects of any changes in a parent's ownership interest in a subsidiary on the equity attributable to the parent which may have occurred during the period. The changes represented by this element did not result in the deconsolidation of the subsidiary.", "label": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]", "terseLabel": "Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Table]" } } }, "localname": "ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestEffectsOfChangesNetTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r82", "r822" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]", "terseLabel": "Unaudited Condensed Consolidated Financial Statements" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for subsidiaries or other investments that are consolidated, including the accounting treatment for intercompany accounts or transactions and any noncontrolling interest.", "label": "Consolidation, Subsidiaries or Other Investments, Consolidated Entities, Policy [Policy Text Block]", "terseLabel": "Noncontrolling Interest" } } }, "localname": "ConsolidationSubsidiariesOrOtherInvestmentsConsolidatedEntitiesPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConsolidationVariableInterestEntityPolicy": { "auth_ref": [ "r83", "r86", "r88" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for consolidation to describe the significant judgments and assumptions made in determining whether a variable interest held by the entity requires the variable interest entity to be consolidated and (or) disclose information about its involvement with the variable interest entity; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; and the significant factors considered and judgments made in determining that the power to direct the activities that significantly impact the economic performance of the variable interest entity are shared (as defined).", "label": "Consolidation, Variable Interest Entity, Policy [Policy Text Block]", "terseLabel": "Consolidation of Variable Interest Entities" } } }, "localname": "ConsolidationVariableInterestEntityPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "auth_ref": [ "r443", "r444", "r463" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.", "label": "Contract with Customer, Liability, Current", "terseLabel": "Contract liabilities - deposits on pending settlements" } } }, "localname": "ContractWithCustomerLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConversionOfStockLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Conversion of Stock [Line Items]", "terseLabel": "Conversion of Stock [Line Items]" } } }, "localname": "ConversionOfStockLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ConversionOfStockTable": { "auth_ref": [ "r40", "r41", "r42" ], "lang": { "en-us": { "role": { "documentation": "This table may be used to disclose all the information related to converting stock into another financial instrument(s) in a noncash (or part noncash) transaction. It may include a description sufficient information to understand the nature and purpose of the conversion, as well as the financial instruments converted from and to (for example, preferred, common, treasury, etc.) the amounts converted, the new shares issued, and the value of the new shares issued, if applicable. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.", "label": "Conversion of Stock [Table]", "terseLabel": "Conversion of Stock [Table]" } } }, "localname": "ConversionOfStockTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CostOfRevenue": { "auth_ref": [ "r129", "r236", "r344", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r551", "r940" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_GrossProfit", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.", "label": "Cost of Revenue", "terseLabel": "Total cost of revenue" } } }, "localname": "CostOfRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_CostOfRevenueAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cost of Revenue [Abstract]", "terseLabel": "COST OF REVENUES (excluding depreciation stated below)" } } }, "localname": "CostOfRevenueAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Axis]", "terseLabel": "Credit Facility [Axis]" } } }, "localname": "CreditFacilityAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CreditFacilityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "label": "Credit Facility [Domain]", "terseLabel": "Credit Facility [Domain]" } } }, "localname": "CreditFacilityDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_CustomerConcentrationRiskMember": { "auth_ref": [ "r46", "r304" ], "lang": { "en-us": { "role": { "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.", "label": "Customer Concentration Risk [Member]", "terseLabel": "Customer Concentration Risk" } } }, "localname": "CustomerConcentrationRiskMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Disclosure [Abstract]" } } }, "localname": "DebtDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentAxis": { "auth_ref": [ "r20", "r117", "r118", "r164", "r166", "r242", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r562", "r829", "r830", "r831", "r832", "r833", "r896" ], "lang": { "en-us": { "role": { "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "label": "Debt Instrument [Axis]", "terseLabel": "Debt Instrument [Axis]" } } }, "localname": "DebtInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails", "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/LONGTERMDEBTSponsorPIKNoteDetails", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.", "label": "Debt Instrument, Basis Spread on Variable Rate", "terseLabel": "Basis spread on variable rate" } } }, "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentFaceAmount": { "auth_ref": [ "r108", "r110", "r408", "r562", "r830", "r831" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Face (par) amount of debt instrument at time of issuance.", "label": "Debt Instrument, Face Amount", "terseLabel": "Face amount" } } }, "localname": "DebtInstrumentFaceAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/LONGTERMDEBTSponsorPIKNoteDetails", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r26", "r409" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt Instrument, Interest Rate, Stated Percentage", "terseLabel": "Interest rate (as a percent)" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DebtInstrumentLineItems": { "auth_ref": [ "r242", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r562", "r829", "r830", "r831", "r832", "r833", "r896" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Instrument [Line Items]", "terseLabel": "Debt Instrument [Line Items]" } } }, "localname": "DebtInstrumentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails", "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/LONGTERMDEBTSponsorPIKNoteDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentNameDomain": { "auth_ref": [ "r27", "r242", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r562", "r829", "r830", "r831", "r832", "r833", "r896" ], "lang": { "en-us": { "role": { "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "label": "Debt Instrument, Name [Domain]", "terseLabel": "Debt Instrument, Name [Domain]" } } }, "localname": "DebtInstrumentNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails", "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/LONGTERMDEBTSponsorPIKNoteDetails", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DebtInstrumentTable": { "auth_ref": [ "r27", "r68", "r69", "r107", "r108", "r110", "r114", "r147", "r148", "r242", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r562", "r829", "r830", "r831", "r832", "r833", "r896" ], "lang": { "en-us": { "role": { "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Schedule of Long-Term Debt Instruments [Table]", "terseLabel": "Schedule of Long-Term Debt Instruments [Table]" } } }, "localname": "DebtInstrumentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails", "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/LONGTERMDEBTSponsorPIKNoteDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtInstrumentTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Debt Instrument, Term", "terseLabel": "Debt instrument term" } } }, "localname": "DebtInstrumentTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "durationItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleWeightedAverageYield": { "auth_ref": [ "r887" ], "lang": { "en-us": { "role": { "documentation": "Weighted average yield of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Weighted Average Yield", "terseLabel": "Interest rate per annum" } } }, "localname": "DebtSecuritiesAvailableForSaleWeightedAverageYield", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AVAILABLEFORSALESECURITIESATFAIRVALUEDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]" } } }, "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r7", "r153", "r187", "r511", "r512", "r898" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Deferred Income Tax Expense (Benefit)", "terseLabel": "Deferred income taxes" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredIncomeTaxLiabilitiesNet": { "auth_ref": [ "r497", "r498", "r648" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.", "label": "Deferred Income Tax Liabilities, Net", "terseLabel": "Deferred tax liability" } } }, "localname": "DeferredIncomeTaxLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanCostRecognized": { "auth_ref": [ "r484" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost for defined contribution plan.", "label": "Defined Contribution Plan, Cost", "terseLabel": "Benefit plan expense" } } }, "localname": "DefinedContributionPlanCostRecognized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/EMPLOYEEBENEFITPLANDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedContributionPlanDisclosureLineItems": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Contribution Plan Disclosure [Line Items]", "terseLabel": "Defined Contribution Plan Disclosure [Line Items]" } } }, "localname": "DefinedContributionPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLANDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "terseLabel": "Percent of employees gross pay (as a percent)" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLANDetails", "http://abacuslife.com/role/EMPLOYEEBENEFITPLANDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Percentage employer matches of the employee's percentage contribution matched.", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Match", "terseLabel": "Employer match (as a percent)" } } }, "localname": "DefinedContributionPlanEmployerMatchingContributionPercentOfMatch", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/EMPLOYEEBENEFITPLANDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.", "label": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent", "terseLabel": "Maximum annual contributions (as a percent)" } } }, "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/EMPLOYEEBENEFITPLANDetails" ], "xbrltype": "percentItemType" }, "us-gaap_DefinedContributionPlanTable": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about defined contribution pension plans or defined contribution other postretirement plans, separately for pension plans and other postretirement benefit plans.", "label": "Defined Contribution Plan [Table]", "terseLabel": "Defined Contribution Plan [Table]" } } }, "localname": "DefinedContributionPlanTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLANDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DefinedContributionPlanTextBlock": { "auth_ref": [ "r483", "r484" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for defined contribution plan.", "label": "Defined Contribution Plan [Text Block]", "terseLabel": "EMPLOYEE BENEFIT PLAN" } } }, "localname": "DefinedContributionPlanTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/EMPLOYEEBENEFITPLAN" ], "xbrltype": "textBlockItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r7", "r64" ], "calculation": { "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 16.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "negatedTerseLabel": "Depreciation", "verboseLabel": "Depreciation expense" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r7", "r64" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation, Depletion and Amortization, Nonproduction", "terseLabel": "Depreciation", "verboseLabel": "Depreciation" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r7", "r281" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation, Depletion and Amortization", "terseLabel": "Depreciation expense" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeAssets": { "auth_ref": [ "r212", "r213", "r550", "r720", "r721", "r722", "r723", "r724", "r725", "r726", "r727", "r728", "r729", "r746", "r747", "r797", "r798", "r799", "r800", "r801", "r802", "r821", "r857", "r973" ], "calculation": { "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails": { "order": 4.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Derivative Asset", "terseLabel": "S&P 500 options" } } }, "localname": "DerivativeAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisaggregationOfRevenueLineItems": { "auth_ref": [ "r462", "r835", "r836", "r837", "r838", "r839", "r840", "r841" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Disaggregation of Revenue [Line Items]", "terseLabel": "Disaggregation of Revenue [Line Items]" } } }, "localname": "DisaggregationOfRevenueLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCREVENUEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTable": { "auth_ref": [ "r462", "r835", "r836", "r837", "r838", "r839", "r840", "r841" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table]", "terseLabel": "Disaggregation of Revenue [Table]" } } }, "localname": "DisaggregationOfRevenueTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCREVENUEDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "auth_ref": [ "r945" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.", "label": "Disaggregation of Revenue [Table Text Block]", "terseLabel": "Disaggregation of Revenue" } } }, "localname": "DisaggregationOfRevenueTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCREVENUETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_Dividends": { "auth_ref": [ "r4", "r149" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of paid and unpaid cash, stock, and paid-in-kind (PIK) dividends declared, for example, but not limited to, common and preferred stock.", "label": "Dividends", "negatedLabel": "Distributions", "negatedTerseLabel": "Distributions" } } }, "localname": "Dividends", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Abstract]", "terseLabel": "EARNINGS PER SHARE:", "verboseLabel": "NET INCOME/(LOSS) PER UNIT:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r229", "r248", "r249", "r250", "r251", "r252", "r257", "r259", "r262", "r263", "r264", "r268", "r536", "r537", "r644", "r667", "r823" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Basic net income per share (in dollars per share)", "verboseLabel": "Basic earnings per unit (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/EARNINGSPERSHAREBasicandDilutedDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r229", "r248", "r249", "r250", "r251", "r252", "r259", "r262", "r263", "r264", "r268", "r536", "r537", "r644", "r667", "r823" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted net income per share (in dollars per share)", "verboseLabel": "Diluted earnings per unit (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/EARNINGSPERSHAREBasicandDilutedDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r256", "r265", "r266", "r267" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "EARNINGS PER SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/EARNINGSPERSHARE" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r500" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective Income Tax Rate Reconciliation, Percent", "terseLabel": "Effective tax rate percentage" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXESDetails", "http://abacuslife.com/role/INCOMETAXESDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r13", "r193", "r220", "r221", "r222", "r243", "r244", "r245", "r247", "r253", "r255", "r269", "r360", "r361", "r442", "r489", "r490", "r491", "r507", "r508", "r527", "r528", "r529", "r530", "r531", "r532", "r535", "r552", "r554", "r555", "r556", "r557", "r558", "r575", "r687", "r688", "r689", "r707", "r785" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee": { "auth_ref": [ "r874" ], "lang": { "en-us": { "role": { "documentation": "Percentage of ownership of equity interest excluding interest in entity that is consolidated and equity method investee.", "label": "Equity Ownership, Excluding Consolidated Entity and Equity Method Investee, Percentage", "terseLabel": "Equity ownership percentage" } } }, "localname": "EquityOwnershipPercentageExcludingConsolidatedEntityAndEquityMethodInvestee", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETSDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueAmount": { "auth_ref": [ "r342" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails": { "order": 5.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Amount", "terseLabel": "Equity securities without readily determinable fair value, amount", "verboseLabel": "Other investments" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails", "http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount": { "auth_ref": [ "r343" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of impairment loss on investment in equity security without readily determinable fair value.", "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Annual Amount", "terseLabel": "Impairment of investments" } } }, "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossAnnualAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "auth_ref": [ "r416", "r550", "r830", "r831" ], "lang": { "en-us": { "role": { "documentation": "Measured as an estimate of fair value.", "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair value" } } }, "localname": "EstimateOfFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r16", "r97", "r99", "r159" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "terseLabel": "Fair Value Measurements, Recurring and Nonrecurring" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSAssumptionsDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSAssumptionsDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.", "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Class of asset.", "label": "Asset Class [Domain]", "terseLabel": "Asset Class [Domain]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable": { "auth_ref": [ "r15", "r99" ], "lang": { "en-us": { "role": { "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of assets using significant unobservable inputs (level 3). Such reconciliation, separately presenting changes during the period, at a minimum, may include, but is not limited to: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income, and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table]" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r15", "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of assets using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes during the period attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets) and gains or losses recognized in other comprehensive income (loss), and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs), by class of asset.", "label": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByAssetClassAxis": { "auth_ref": [ "r97", "r99" ], "lang": { "en-us": { "role": { "documentation": "Information by class of asset.", "label": "Asset Class [Axis]", "terseLabel": "Asset Class [Axis]" } } }, "localname": "FairValueByAssetClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r416", "r468", "r469", "r470", "r471", "r472", "r473", "r540", "r591", "r592", "r593", "r830", "r831", "r842", "r843", "r844" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]", "terseLabel": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementBasisAxis": { "auth_ref": [ "r18", "r97", "r416", "r830", "r831" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement basis.", "label": "Measurement Basis [Axis]", "terseLabel": "Measurement Basis [Axis]" } } }, "localname": "FairValueByMeasurementBasisAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r539", "r540", "r542", "r543", "r546" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]", "terseLabel": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]", "terseLabel": "Fair Value, Concentration of Risk, Financial Statement Captions [Line Items]" } } }, "localname": "FairValueConcentrationOfRiskFinancialStatementCaptionsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueConcentrationOfRiskTable": { "auth_ref": [ "r102", "r104", "r160", "r161" ], "lang": { "en-us": { "role": { "documentation": "Summarization of information required and determined to be disclosed concerning all significant concentrations of risk, including credit risk and market risk, arising from all financial instruments (as defined), whether from an individual counterparty or groups of counterparties. Such disclosure may also include quantitative information about the market risks of financial instruments that is consistent with the way the Company manages or adjusts those risks.", "label": "Fair Value, Concentration of Risk [Table]", "terseLabel": "Fair Value, Concentration of Risk [Table]" } } }, "localname": "FairValueConcentrationOfRiskTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSCreditExposuretoInsuranceCompaniesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosureItemAmountsDomain": { "auth_ref": [ "r416", "r830", "r831" ], "lang": { "en-us": { "role": { "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.", "label": "Fair Value Measurement [Domain]", "terseLabel": "Fair Value Measurement [Domain]" } } }, "localname": "FairValueDisclosureItemAmountsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Abstract]" } } }, "localname": "FairValueDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_FairValueDisclosuresTextBlock": { "auth_ref": [ "r538" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.", "label": "Fair Value Disclosures [Text Block]", "terseLabel": "FAIR VALUE MEASUREMENTS" } } }, "localname": "FairValueDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r416", "r468", "r473", "r540", "r591", "r842", "r843", "r844" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r416", "r468", "r473", "r540", "r592", "r830", "r831", "r842", "r843", "r844" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]", "terseLabel": "Level 2" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r416", "r468", "r469", "r470", "r471", "r472", "r473", "r540", "r593", "r830", "r831", "r842", "r843", "r844" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSIssuedNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "auth_ref": [ "r15", "r99" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "terseLabel": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]", "terseLabel": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1": { "auth_ref": [ "r544" ], "calculation": { "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from asset measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Gain (Loss) Included in Earnings", "totalLabel": "Change in estimated fair value" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases": { "auth_ref": [ "r98" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of purchases of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Purchases", "terseLabel": "Policies purchased" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales": { "auth_ref": [ "r98" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sale of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Sales", "negatedTerseLabel": "Matured/sold policies" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetSales", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue": { "auth_ref": [ "r15" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as an asset measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Value", "periodEndLabel": "Fair value at end of period", "periodStartLabel": "Fair value at beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSLifeInsurancePoliciesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": { "auth_ref": [ "r545" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)", "terseLabel": "Gain on change in fair value of debt, included within other comprehensive income" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues": { "auth_ref": [ "r98" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of issuances of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Issuances", "terseLabel": "Debt issued to third parties" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSIssuedNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r15" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "periodEndLabel": "Fair value at end of period", "periodStartLabel": "Fair value at beginning of period" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSIssuedNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r416", "r468", "r469", "r470", "r471", "r472", "r473", "r591", "r592", "r593", "r830", "r831", "r842", "r843", "r844" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]", "terseLabel": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r538", "r546" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]", "terseLabel": "Fair Value, Recurring" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOptionChangesInFairValueGainLoss1": { "auth_ref": [ "r105" ], "calculation": { "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSIssuedNotesDetails": { "order": 2.0, "parentTag": "abl_FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets", "weight": 1.0 }, "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails": { "order": 8.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 5.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "For each line item in the statement of financial position, the amounts of gains and losses from fair value changes included in earnings.", "label": "Fair Value, Option, Changes in Fair Value, Gain (Loss)", "negatedLabel": "Unrealized loss on change in fair value (risk-free)", "negatedTerseLabel": "Loss on change in fair value of debt", "verboseLabel": "Loss on change in fair value of debt" } } }, "localname": "FairValueOptionChangesInFairValueGainLoss1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSIssuedNotesDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueOptionCreditRiskGainsLossesOnAssets": { "auth_ref": [ "r106" ], "calculation": { "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSIssuedNotesDetails": { "order": 1.0, "parentTag": "abl_FairValueOptionChangeInFairValueGainLossAndCreditRiskGainsLossesOnAssets", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This item represents the estimated amount of gains or losses included in earnings during the period attributable to changes in instrument-specific credit risk arising from loans and other receivables held as assets.", "label": "Fair Value, Option, Credit Risk, Gains (Losses) on Assets", "negatedLabel": "Unrealized gain on change in fair value (credit-adjusted)" } } }, "localname": "FairValueOptionCreditRiskGainsLossesOnAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSIssuedNotesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r363", "r364", "r365", "r366", "r367", "r369", "r370", "r371", "r424", "r438", "r533", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r661", "r827", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r912", "r913", "r914", "r915" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of finite-lived and indefinite-lived intangible assets acquired as part of a business combination.", "label": "Finite-Lived and Indefinite-Lived Intangible Assets Acquired as Part of Business Combination [Table Text Block]", "terseLabel": "Intangible assets acquired" } } }, "localname": "FiniteLivedAndIndefiniteLivedIntangibleAssetsAcquiredAsPartOfBusinessCombinationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FiniteLivedIntangibleAssetUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Finite-Lived Intangible Asset, Useful Life", "terseLabel": "Useful Life" } } }, "localname": "FiniteLivedIntangibleAssetUsefulLife", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "durationItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r384", "r386", "r387", "r389", "r624", "r625" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "auth_ref": [ "r624" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Finite-Lived Intangible Assets [Line Items]", "terseLabel": "Finite-Lived Intangible Assets [Line Items]" } } }, "localname": "FiniteLivedIntangibleAssetsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r59", "r62" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]", "terseLabel": "Furniture and fixtures" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r130", "r763" ], "calculation": { "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 4.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "negatedTerseLabel": "General, administrative and other", "terseLabel": "General and administrative expenses" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralPartnerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Party to a partnership business who has unlimited liability.", "label": "General Partner [Member]", "terseLabel": "General Partner" } } }, "localname": "GeneralPartnerMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r203", "r372", "r638", "r828", "r852", "r925", "r932" ], "calculation": { "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "weight": 1.0 }, "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill", "periodEndLabel": "Goodwill at end of period", "periodStartLabel": "Goodwill at beginning of period", "terseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinGoodwillbyReportableSegmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAcquiredDuringPeriod": { "auth_ref": [ "r375", "r828" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.", "label": "Goodwill, Acquired During Period", "terseLabel": "Additions" } } }, "localname": "GoodwillAcquiredDuringPeriod", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinGoodwillbyReportableSegmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "auth_ref": [ "r139" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for goodwill and intangible assets.", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "terseLabel": "GOODWILL AND OTHER INTANGIBLE ASSETS" } } }, "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETS" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillLineItems": { "auth_ref": [ "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r828" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Goodwill [Line Items]", "terseLabel": "Goodwill [Line Items]" } } }, "localname": "GoodwillLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinGoodwillbyReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GoodwillRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Goodwill [Roll Forward]", "terseLabel": "Goodwill [Roll Forward]" } } }, "localname": "GoodwillRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinGoodwillbyReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GrossProfit": { "auth_ref": [ "r127", "r236", "r276", "r290", "r296", "r299", "r344", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r551", "r825", "r940" ], "calculation": { "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails": { "order": 4.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.", "label": "Gross Profit", "terseLabel": "Total gross profit", "totalLabel": "Gross Profit" } } }, "localname": "GrossProfit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r128", "r892" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ProfitLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of income (loss) including portion attributable to noncontrolling interest. Includes, but is not limited to, income (loss) from continuing operations, discontinued operations and equity method investments.", "label": "Income (Loss), Including Portion Attributable to Noncontrolling Interest, before Tax", "totalLabel": "Net income before provision for income taxes" } } }, "localname": "IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Contingency [Line Items]", "terseLabel": "Income Tax Contingency [Line Items]" } } }, "localname": "IncomeTaxContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxContingencyTable": { "auth_ref": [ "r10", "r72", "r151", "r152" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.", "label": "Income Tax Contingency [Table]", "terseLabel": "Income Tax Contingency [Table]" } } }, "localname": "IncomeTaxContingencyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r237", "r494", "r501", "r502", "r505", "r509", "r513", "r514", "r515", "r701" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXES", "http://abacuslife.com/role/INCOMETAXES" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r174", "r188", "r254", "r255", "r284", "r499", "r510", "r668" ], "calculation": { "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails": { "order": 7.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_ProfitLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "negatedLabel": "Provision for income taxes", "negatedTerseLabel": "Provision for income taxes", "terseLabel": "Provision for income taxes" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXESDetails", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/INCOMETAXESDetails", "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r219", "r495", "r496", "r502", "r503", "r504", "r506", "r695" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r6" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "auth_ref": [ "r6" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.", "label": "Increase (Decrease) in Accounts Receivable", "negatedTerseLabel": "Accounts receivable" } } }, "localname": "IncreaseDecreaseInAccountsReceivable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r6" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued transaction costs", "verboseLabel": "Accrued payroll and other expenses" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r622", "r893" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 21.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Contract liability\u2014deposits on pending settlements" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInDepositOtherAssets": { "auth_ref": [ "r6" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 20.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in moneys or securities given as security including, but not limited to, contract, escrow, or earnest money deposits, retainage (if applicable), deposits with clearing organizations and others, collateral, or margin deposits.", "label": "Increase (Decrease) in Deposit Assets", "negatedTerseLabel": "Certificate of deposit" } } }, "localname": "IncreaseDecreaseInDepositOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentAssets": { "auth_ref": [ "r893" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 19.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current assets classified as other.", "label": "Increase (Decrease) in Other Current Assets", "negatedTerseLabel": "Other current assets" } } }, "localname": "IncreaseDecreaseInOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r893" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Increase (Decrease) in Other Current Liabilities", "terseLabel": "Other current liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "auth_ref": [ "r893" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.", "label": "Increase (Decrease) in Other Noncurrent Assets", "negatedTerseLabel": "Other noncurrent assets" } } }, "localname": "IncreaseDecreaseInOtherNoncurrentAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r6" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r6" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 18.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedTerseLabel": "Prepaid expenses" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r385", "r388" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]", "terseLabel": "Indefinite-Lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Indefinite-Lived Intangible Assets [Line Items]", "terseLabel": "Indefinite-Lived Intangible Assets [Line Items]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r60", "r141" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.", "label": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]", "terseLabel": "Indefinite-Lived Intangible Assets, Major Class Name [Domain]" } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_InsuranceInvestmentIncome": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_InsuranceServicesRevenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment income associated with the company's insurance services.", "label": "Insurance Investment Income", "terseLabel": "Investment Income from life insurance policies held using investment method" } } }, "localname": "InsuranceInvestmentIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_InsuranceServicesRevenue": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Revenue from insurance services, including net premiums earned, gain on sale of insurance block, agency management fees and insurance contract fees and commissions.", "label": "Insurance Services Revenue", "totalLabel": "Total active management revenue" } } }, "localname": "InsuranceServicesRevenue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "auth_ref": [ "r58", "r61" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.", "label": "Intangible Assets, Net (Excluding Goodwill)", "terseLabel": "Intangible assets, net" } } }, "localname": "IntangibleAssetsNetExcludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestExpense": { "auth_ref": [ "r109", "r170", "r223", "r280", "r560", "r769", "r863", "r975" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.", "label": "Interest Expense", "negatedTerseLabel": "Interest (expense)", "terseLabel": "Interest (expense)" } } }, "localname": "InterestExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestRevenueExpenseNet": { "auth_ref": [ "r276" ], "calculation": { "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails": { "order": 9.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).", "label": "Interest Revenue (Expense), Net", "terseLabel": "Interest expense" } } }, "localname": "InterestRevenueExpenseNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeInterest": { "auth_ref": [ "r131", "r279" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.", "label": "Investment Income, Interest", "terseLabel": "Interest earned on marketable securities held in Trust Account", "verboseLabel": "Interest income" } } }, "localname": "InvestmentIncomeInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentsAllOtherInvestmentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, All Other Investments [Abstract]" } } }, "localname": "InvestmentsAllOtherInvestmentsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r162", "r171", "r172", "r192", "r308", "r311", "r547", "r548" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "AVAILABLE-FOR-SALE SECURITIES, AT FAIR VALUE" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AVAILABLEFORSALESECURITIESATFAIRVALUE" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r567", "r851" ], "calculation": { "http://abacuslife.com/role/LEASESLeaseExpenseDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "Lease, Cost", "totalLabel": "Total lease cost" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r956" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]", "terseLabel": "Lease Expense" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]", "terseLabel": "Leasehold improvements" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LeasesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "localname": "LeasesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "auth_ref": [ "r957" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "terseLabel": "Future Minimum Noncancellable Lease Payments" } } }, "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "auth_ref": [ "r574" ], "calculation": { "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails_1": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.", "label": "Lessee, Operating Lease, Liability, to be Paid", "totalLabel": "Total operating lease payments (undiscounted)" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "auth_ref": [ "r574" ], "calculation": { "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails": { "order": 5.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "terseLabel": "2024" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "auth_ref": [ "r574" ], "calculation": { "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "terseLabel": "2027" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "auth_ref": [ "r574" ], "calculation": { "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails": { "order": 3.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "terseLabel": "2026" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "auth_ref": [ "r574" ], "calculation": { "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "terseLabel": "2025" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "auth_ref": [ "r957" ], "calculation": { "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails": { "order": 6.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "terseLabel": "Remaining of 2023" } } }, "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "auth_ref": [ "r574" ], "calculation": { "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails_1": { "order": 2.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "negatedTerseLabel": "Less: Imputed interest" } } }, "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LesseeOperatingLeasesTextBlock": { "auth_ref": [ "r563" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.", "label": "Lessee, Operating Leases [Text Block]", "terseLabel": "LEASES" } } }, "localname": "LesseeOperatingLeasesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASES" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r23", "r236", "r344", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r521", "r525", "r526", "r551", "r738", "r824", "r865", "r940", "r961", "r962" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "terseLabel": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/CONSOLIDATIONOFVARIABLEINTERESTENTITIESDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r123", "r168", "r654", "r852", "r897", "r916", "r955" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND SHAREHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r25", "r198", "r236", "r344", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r521", "r525", "r526", "r551", "r852", "r940", "r961", "r962" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "CURRENT LIABILITIES:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r97" ], "calculation": { "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities held at fair value:" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "LiabilitiesFairValueDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LicensingAgreementsMember": { "auth_ref": [ "r78", "r493", "r947" ], "lang": { "en-us": { "role": { "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).", "label": "Licensing Agreements [Member]", "terseLabel": "State Insurance Licenses" } } }, "localname": "LicensingAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LifeSettlementContractsDisclosureTextBlock": { "auth_ref": [ "r345", "r354", "r355", "r359" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for life settlement contracts including the accounting policy for life settlement contracts and the classification of cash receipts and cash disbursements in the statement of cash flows and, as applicable, for (1) life settlement contracts accounted for under the investment method based on the remaining life expectancy for each of the first five succeeding years from the date of the statement of financial position and thereafter, as well as in the aggregate: (a) the number of life settlement contracts, (b) the carrying value of the life settlement contracts, and (c) the face value (death benefits) of the life insurance policies underlying the contracts, (d) the life insurance premiums anticipated to be paid for each of the five succeeding fiscal years to keep the life settlement contracts in force as of the date of the most recent statement of financial position presented, (e) the nature of the information that causes the Entity to change its expectations on the timing of the realization of proceeds from the investments in life settlement contracts and the related effect on the timing of the realization of proceeds from the life settlement contracts and for (2) life settlement contracts accounted for under the fair value method, disclosure would include, based on remaining life expectancy for each of the first five succeeding years from the date of the statement of financial position and thereafter, as well as in the aggregate: (a) the number of life settlement contracts, (b) the carrying value of the life settlement contracts, (c) the face value (death benefits) of the life insurance policies underlying the contracts, (d) the reasons for changes in the Entity's expectation of the timing of the realization of the investments in life settlement contracts, and (e) (i) the gains or losses recognized during the period on investments sold during the period and (ii) the unrealized gains or losses recognized during the period on investments that are still held at the date of the statement of financial position.", "label": "Life Settlement Contracts, Disclosure [Text Block]", "terseLabel": "LIFE INSURANCE SETTLEMENT POLICIES" } } }, "localname": "LifeSettlementContractsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_LifeSettlementContractsFairValueFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Life Settlement Contracts, Fair Value, Fiscal Year Maturity [Abstract]", "terseLabel": "Fair Value" } } }, "localname": "LifeSettlementContractsFairValueFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LifeSettlementContractsFairValueMaturingInNextTwelveMonths": { "auth_ref": [ "r357" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 6.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of life settlement contract accounted for under fair value method maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Fair Value, Maturity, Year One", "terseLabel": "1-2" } } }, "localname": "LifeSettlementContractsFairValueMaturingInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsFairValueMaturingInRemainderOfFiscalYear": { "auth_ref": [ "r922" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of life settlement contract accounted for under fair value method maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Fair Value, Maturity, Remainder of Fiscal Year", "terseLabel": "0-1" } } }, "localname": "LifeSettlementContractsFairValueMaturingInRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsFairValueMaturingInYearFour": { "auth_ref": [ "r357" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 4.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of life settlement contract accounted for under fair value method maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Fair Value, Maturity, Year Four", "terseLabel": "4-5" } } }, "localname": "LifeSettlementContractsFairValueMaturingInYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsFairValueMaturingInYearThree": { "auth_ref": [ "r357" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 5.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of life settlement contract accounted for under fair value method maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Fair Value, Maturity, Year Three", "terseLabel": "3-4" } } }, "localname": "LifeSettlementContractsFairValueMaturingInYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsFairValueMaturingInYearTwo": { "auth_ref": [ "r357" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 3.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value of life settlement contract accounted for under fair value method maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Fair Value, Maturity, Year Two", "terseLabel": "2-3" } } }, "localname": "LifeSettlementContractsFairValueMaturingInYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount": { "auth_ref": [ "r346", "r357" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 10.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails": { "order": 1.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 }, "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value amount of life settlement contracts accounted for under the fair value method.", "label": "Life Settlement Contracts, Fair Value", "terseLabel": "Life settlement policies, at fair value", "totalLabel": "Fair Value", "verboseLabel": "Life settlement policies" } } }, "localname": "LifeSettlementContractsFairValueMethodCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSDiscountRateSensitivityDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails", "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails", "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodFaceValue": { "auth_ref": [ "r358" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face value (death benefits) of the life insurance policies underlying the life settlement contracts accounted for under the fair value method.", "label": "Life Settlement Contracts, Fair Value Method, Face Value", "terseLabel": "Face value of policies held at fair value", "totalLabel": "Face Value" } } }, "localname": "LifeSettlementContractsFairValueMethodFaceValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails", "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodFaceValueFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Life Settlement Contracts, Fair Value Method, Face Value, Fiscal Year Maturity [Abstract]", "terseLabel": "Face Value" } } }, "localname": "LifeSettlementContractsFairValueMethodFaceValueFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodFaceValueMaturingInNextTwelveMonths": { "auth_ref": [ "r358" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 5.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodFaceValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face value of life insurance policy underlying life settlement contract accounted for under fair value method maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Fair Value Method, Face Value, Maturity, Year One", "terseLabel": "1-2" } } }, "localname": "LifeSettlementContractsFairValueMethodFaceValueMaturingInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodFaceValueMaturingInRemainderOfFiscalYear": { "auth_ref": [ "r923" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodFaceValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face value of life insurance policy underlying life settlement contract accounted for under fair value method maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Fair Value Method, Face Value, Maturity, Remainder of Fiscal Year", "terseLabel": "0-1" } } }, "localname": "LifeSettlementContractsFairValueMethodFaceValueMaturingInRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodFaceValueMaturingInYearFour": { "auth_ref": [ "r358" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 6.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodFaceValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face value of life insurance policy underlying life settlement contract accounted for under fair value method maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Fair Value Method, Face Value, Maturity, Year Four", "terseLabel": "4-5" } } }, "localname": "LifeSettlementContractsFairValueMethodFaceValueMaturingInYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodFaceValueMaturingInYearThree": { "auth_ref": [ "r358" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 3.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodFaceValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face value of life insurance policy underlying life settlement contract accounted for under fair value method maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Fair Value Method, Face Value, Maturity, Year Three", "terseLabel": "3-4" } } }, "localname": "LifeSettlementContractsFairValueMethodFaceValueMaturingInYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodFaceValueMaturingInYearTwo": { "auth_ref": [ "r358" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 4.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodFaceValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face value of life insurance policy underlying life settlement contract accounted for under fair value method maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Fair Value Method, Face Value, Maturity, Year Two", "terseLabel": "2-3" } } }, "localname": "LifeSettlementContractsFairValueMethodFaceValueMaturingInYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodGainLoss": { "auth_ref": [ "r347" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_InsuranceServicesRevenue", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "This item represents the gains or losses recognized and realized during the period on investments in life settlement contracts sold during the period.", "label": "Life Settlement Contracts, Fair Value Method, Gain (Loss)", "negatedLabel": "Decrease in valuation compared to third-party valuation", "terseLabel": "Change in fair value of life insurance policies (policies held using fair value method)" } } }, "localname": "LifeSettlementContractsFairValueMethodGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodNumberOfContracts": { "auth_ref": [ "r356" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Number of life settlement contracts accounted for under the fair value method.", "label": "Life Settlement Contracts, Fair Value Method, Number of Contracts", "terseLabel": "Number of life settlement policies accounted for under fair value method", "totalLabel": "Policies" } } }, "localname": "LifeSettlementContractsFairValueMethodNumberOfContracts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails", "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodNumberOfContractsFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Life Settlement Contracts, Fair Value Method, Number of Contracts, Fiscal Year Maturity [Abstract]", "terseLabel": "Policies" } } }, "localname": "LifeSettlementContractsFairValueMethodNumberOfContractsFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInNextTwelveMonths": { "auth_ref": [ "r356" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 2.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodNumberOfContracts", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of life settlement contracts accounted for under fair value method maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Fair Value Method, Number of Contracts, Maturity, Year One", "terseLabel": "1-2" } } }, "localname": "LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInRemainderOfFiscalYear": { "auth_ref": [ "r921" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 4.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodNumberOfContracts", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of life settlement contracts accounted for under fair value method maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Fair Value Method, Number of Contracts, Maturity, Remainder of Fiscal Year", "terseLabel": "0-1" } } }, "localname": "LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearFour": { "auth_ref": [ "r356" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 3.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodNumberOfContracts", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of life settlement contracts accounted for under fair value method maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Fair Value Method, Number of Contracts, Maturity, Year Four", "terseLabel": "4-5" } } }, "localname": "LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearThree": { "auth_ref": [ "r356" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 5.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodNumberOfContracts", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of life settlement contracts accounted for under fair value method maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Fair Value Method, Number of Contracts, Maturity, Year Three", "terseLabel": "3-4" } } }, "localname": "LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearTwo": { "auth_ref": [ "r356" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails": { "order": 1.0, "parentTag": "us-gaap_LifeSettlementContractsFairValueMethodNumberOfContracts", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of life settlement contracts accounted for under fair value method maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Fair Value Method, Number of Contracts, Maturity, Year Two", "terseLabel": "2-3" } } }, "localname": "LifeSettlementContractsFairValueMethodNumberOfContractsMaturingInYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESFairValueDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LifeSettlementContractsFairValueMethodUnrealizedGainLoss": { "auth_ref": [ "r348" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net change in the difference between the fair value and the carrying value, or in the comparative fair values, of investments in life settlement contracts held at each balance sheet date, that was included in earnings for the period.", "label": "Life Settlement Contracts, Fair Value Method, Unrealized Gain (Loss)", "negatedTerseLabel": "Unrealized gain on policies" } } }, "localname": "LifeSettlementContractsFairValueMethodUnrealizedGainLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodCarryingAmount": { "auth_ref": [ "r346", "r351" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 8.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of life settlement contracts accounted for under the investment method.", "label": "Life Settlement Contracts, Investment Method, Carrying Amount", "terseLabel": "Life settlement policies, at cost", "totalLabel": "Carrying Value" } } }, "localname": "LifeSettlementContractsInvestmentMethodCarryingAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails", "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodCarryingAmountFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Life Settlement Contracts, Investment Method, Carrying Amount, Fiscal Year Maturity [Abstract]", "terseLabel": "Carrying Value" } } }, "localname": "LifeSettlementContractsInvestmentMethodCarryingAmountFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInNextTwelveMonths": { "auth_ref": [ "r351" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 6.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodCarryingAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of life settlement contract accounted for under investment method maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Amount, Maturity, Year One", "terseLabel": "1-2" } } }, "localname": "LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInRemainderOfFiscalYear": { "auth_ref": [ "r918" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 1.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodCarryingAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of life settlement contract accounted for under investment method maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Amount, Maturity, Remainder of Fiscal Year", "terseLabel": "0-1" } } }, "localname": "LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearFour": { "auth_ref": [ "r351" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 3.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodCarryingAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of life settlement contract accounted for under investment method maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Amount, Maturity, Year Four", "terseLabel": "4-5" } } }, "localname": "LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearThree": { "auth_ref": [ "r351" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 2.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodCarryingAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of life settlement contract accounted for under investment method maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Amount, Maturity, Year Three", "terseLabel": "3-4" } } }, "localname": "LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearTwo": { "auth_ref": [ "r351" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 5.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodCarryingAmount", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of life settlement contract accounted for under investment method maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Amount, Maturity, Year Two", "terseLabel": "2-3" } } }, "localname": "LifeSettlementContractsInvestmentMethodCarryingAmountMaturingInYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodFaceValue": { "auth_ref": [ "r352" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face value (death benefits) of the life insurance policies underlying the life settlement contracts accounted for under the investment method.", "label": "Life Settlement Contracts, Investment Method, Face Value", "terseLabel": "Face value of policies accounted for using investment method", "totalLabel": "Face Value" } } }, "localname": "LifeSettlementContractsInvestmentMethodFaceValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails", "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodFaceValueFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Life Settlement Contracts, Investment Method, Face Value, Fiscal Year Maturity [Abstract]", "terseLabel": "Face Value" } } }, "localname": "LifeSettlementContractsInvestmentMethodFaceValueFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodFaceValueMaturingInNextTwelveMonths": { "auth_ref": [ "r352" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 3.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodFaceValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face value of life insurance policy underlying life settlement contract accounted for under investment method maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Face Value, Maturity, Year One", "terseLabel": "1-2" } } }, "localname": "LifeSettlementContractsInvestmentMethodFaceValueMaturingInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodFaceValueMaturingInRemainderOfFiscalYear": { "auth_ref": [ "r919" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 4.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodFaceValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face value of life insurance policy underlying life settlement contract accounted for under investment method maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Face Value, Maturity, Remainder of Fiscal Year", "terseLabel": "0-1" } } }, "localname": "LifeSettlementContractsInvestmentMethodFaceValueMaturingInRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFour": { "auth_ref": [ "r352" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 5.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodFaceValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face value of life insurance policy underlying life settlement contract accounted for under investment method maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Face Value, Maturity, Year Four", "terseLabel": "4-5" } } }, "localname": "LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearThree": { "auth_ref": [ "r352" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 6.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodFaceValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face value of life insurance policy underlying life settlement contract accounted for under investment method maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Face Value, Maturity, Year Three", "terseLabel": "3-4" } } }, "localname": "LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearTwo": { "auth_ref": [ "r352" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 1.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodFaceValue", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Face value of life insurance policy underlying life settlement contract accounted for under investment method maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Face Value, Maturity, Year Two", "terseLabel": "2-3" } } }, "localname": "LifeSettlementContractsInvestmentMethodFaceValueMaturingInYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid": { "auth_ref": [ "r920" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESEstimatedPremiumsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of life insurance premiums anticipated to be paid to keep the life settlement contracts accounted for under the investment method in force.", "label": "Life Settlement Contracts, Investment Method, Premiums to be Paid", "totalLabel": "Total" } } }, "localname": "LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESEstimatedPremiumsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodNumberOfContracts": { "auth_ref": [ "r350" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "lang": { "en-us": { "role": { "documentation": "Number of life settlement contracts accounted for under the investment method.", "label": "Life Settlement Contracts, Investment Method, Number of Contracts", "terseLabel": "Number of life settlement policies accounted for under investment method", "totalLabel": "Number of Life Insurance Policies" } } }, "localname": "LifeSettlementContractsInvestmentMethodNumberOfContracts", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails", "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodNumberOfContractsFiscalYearMaturityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Life Settlement Contracts, Investment Method, Number of Contracts, Fiscal Year Maturity [Abstract]", "terseLabel": "Number of Life Insurance Policies" } } }, "localname": "LifeSettlementContractsInvestmentMethodNumberOfContractsFiscalYearMaturityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInNextTwelveMonths": { "auth_ref": [ "r350" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 1.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodNumberOfContracts", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of life settlement contracts accounted for under investment method maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Number of Contracts, Maturity, Year One", "terseLabel": "1-2" } } }, "localname": "LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInRemainderOfFiscalYear": { "auth_ref": [ "r917" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 4.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodNumberOfContracts", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of life settlement contracts accounted for under investment method maturing in remainder of current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Number of Contracts, Maturity, Remainder of Fiscal Year", "terseLabel": "0-1" } } }, "localname": "LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFour": { "auth_ref": [ "r350" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 3.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodNumberOfContracts", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of life settlement contracts accounted for under investment method maturing in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Number of Contracts, Maturity, Year Four", "terseLabel": "4-5" } } }, "localname": "LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearFour", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearThree": { "auth_ref": [ "r350" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 2.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodNumberOfContracts", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of life settlement contracts accounted for under investment method maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Number of Contracts, Maturity, Year Three", "terseLabel": "3-4" } } }, "localname": "LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearTwo": { "auth_ref": [ "r350" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails": { "order": 5.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodNumberOfContracts", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Number of life settlement contracts accounted for under investment method maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Number of Contracts, Maturity, Year Two", "terseLabel": "2-3" } } }, "localname": "LifeSettlementContractsInvestmentMethodNumberOfContractsMaturingInYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESInvestmentMethodDetails" ], "xbrltype": "integerItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodPremiumsToBePaidInNextTwelveMonths": { "auth_ref": [ "r353" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESEstimatedPremiumsDetails": { "order": 4.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of life insurance premium accounted for under investment method to be paid in next fiscal year following current fiscal year to keep life settlement contract in force. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Premium to be Paid, Year One", "terseLabel": "2024" } } }, "localname": "LifeSettlementContractsInvestmentMethodPremiumsToBePaidInNextTwelveMonths", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESEstimatedPremiumsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodPremiumsToBePaidInRemainderOfFiscalYear": { "auth_ref": [ "r920" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESEstimatedPremiumsDetails": { "order": 3.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of life insurance premium accounted for under investment method to be paid in remainder of current fiscal year to keep life settlement contract in force.", "label": "Life Settlement Contract, Investment Method, Premium to be Paid, Remainder of Fiscal Year", "terseLabel": "2023 remaining" } } }, "localname": "LifeSettlementContractsInvestmentMethodPremiumsToBePaidInRemainderOfFiscalYear", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESEstimatedPremiumsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearThree": { "auth_ref": [ "r353" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESEstimatedPremiumsDetails": { "order": 1.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of life insurance premium accounted for under investment method to be paid in third fiscal year following current fiscal year to keep life settlement contract in force. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Premium to be Paid, Year Three", "terseLabel": "2026" } } }, "localname": "LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearThree", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESEstimatedPremiumsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearTwo": { "auth_ref": [ "r353" ], "calculation": { "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESEstimatedPremiumsDetails": { "order": 2.0, "parentTag": "us-gaap_LifeSettlementContractsInvestmentMethodFiveYearDisclosurePremiumsToBePaid", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of life insurance premium accounted for under investment method to be paid in second fiscal year following current fiscal year to keep life settlement contract in force. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).", "label": "Life Settlement Contract, Investment Method, Premium to be Paid, Year Two", "terseLabel": "2025" } } }, "localname": "LifeSettlementContractsInvestmentMethodPremiumsToBePaidInYearTwo", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESEstimatedPremiumsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LifeSettlementContractsPolicy": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for life settlement contracts including the classification of cash receipts and cash disbursements in the statement of cash flows.", "label": "Life Settlement Contracts, Policy [Policy Text Block]", "terseLabel": "Life Insurance Settlement Policies" } } }, "localname": "LifeSettlementContractsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_LimitedPartnerMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Party to a partnership business who has limited liability.", "label": "Limited Partner [Member]", "terseLabel": "Limited Partner" } } }, "localname": "LimitedPartnerMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": { "auth_ref": [ "r22" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).", "label": "Line of Credit Facility, Remaining Borrowing Capacity", "terseLabel": "Additional borrowing capacity" } } }, "localname": "LineOfCreditFacilityRemainingBorrowingCapacity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility.", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "terseLabel": "Commitment fee" } } }, "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "percentItemType" }, "us-gaap_LineOfCreditMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.", "label": "Line of Credit [Member]", "terseLabel": "Line of Credit" } } }, "localname": "LineOfCreditMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails", "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LongTermDebtFairValue": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.", "label": "Long-Term Debt, Fair Value", "terseLabel": "Long-term debt, fair value", "verboseLabel": "Long-term debt" } } }, "localname": "LongTermDebtFairValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LongTermDebtTextBlock": { "auth_ref": [ "r145" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-term debt.", "label": "Long-Term Debt [Text Block]", "terseLabel": "LONG-TERM DEBT" } } }, "localname": "LongTermDebtTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBT" ], "xbrltype": "textBlockItemType" }, "us-gaap_LongtermDebtTypeAxis": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-term debt.", "label": "Long-Term Debt, Type [Axis]", "terseLabel": "Long-Term Debt, Type [Axis]" } } }, "localname": "LongtermDebtTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails", "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/LONGTERMDEBTSponsorPIKNoteDetails", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LongtermDebtTypeDomain": { "auth_ref": [ "r27", "r66" ], "lang": { "en-us": { "role": { "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.", "label": "Long-Term Debt, Type [Domain]", "terseLabel": "Long-Term Debt, Type [Domain]" } } }, "localname": "LongtermDebtTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails", "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/LONGTERMDEBTSponsorPIKNoteDetails", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MarketApproachValuationTechniqueMember": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach using price and other relevant information generated by market transaction involving identical or comparable asset, liability, or group of assets and liabilities.", "label": "Valuation, Market Approach [Member]", "terseLabel": "Market approach" } } }, "localname": "MarketApproachValuationTechniqueMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputDiscountRateMember": { "auth_ref": [ "r953" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate to determine present value of future cash flows.", "label": "Measurement Input, Discount Rate [Member]", "terseLabel": "Discount rate" } } }, "localname": "MeasurementInputDiscountRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExercisePriceMember": { "auth_ref": [ "r953" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using agreed upon price for exchange of underlying asset.", "label": "Measurement Input, Exercise Price [Member]", "terseLabel": "Exercise price" } } }, "localname": "MeasurementInputExercisePriceMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSAssumptionsDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedDividendRateMember": { "auth_ref": [ "r953" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.", "label": "Measurement Input, Expected Dividend Rate [Member]", "terseLabel": "Dividend Yield" } } }, "localname": "MeasurementInputExpectedDividendRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r953" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Term to expiration" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSAssumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r953" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free interest rate" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSAssumptionsDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputSharePriceMember": { "auth_ref": [ "r953" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using share price of saleable stock.", "label": "Measurement Input, Share Price [Member]", "terseLabel": "Common Stock Price" } } }, "localname": "MeasurementInputSharePriceMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSAssumptionsDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r541" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]", "terseLabel": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSAssumptionsDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]", "terseLabel": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSAssumptionsDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "domainItemType" }, "us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock": { "auth_ref": [ "r116", "r154" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings.", "label": "Mergers, Acquisitions and Dispositions Disclosures [Text Block]", "terseLabel": "BUSINESS COMBINATION" } } }, "localname": "MergersAcquisitionsAndDispositionsDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATION" ], "xbrltype": "textBlockItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r30", "r167", "r236", "r344", "r399", "r401", "r402", "r403", "r406", "r407", "r551", "r653", "r742" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.", "label": "Equity, Attributable to Noncontrolling Interest", "terseLabel": "Non-controlling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Subsidiary, Ownership Percentage, Parent", "terseLabel": "Ownership percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r177", "r189" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "DESCRIPTION OF BUSINESS", "verboseLabel": "DESCRIPTION OF THE BUSINESS" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESS", "http://abacuslife.com/role/DESCRIPTIONOFBUSINESS" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r232" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r232" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r135", "r136", "r137" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r125", "r137", "r169", "r196", "r214", "r217", "r222", "r236", "r246", "r248", "r249", "r250", "r251", "r254", "r255", "r261", "r276", "r290", "r296", "r299", "r344", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r537", "r551", "r659", "r760", "r783", "r784", "r825", "r863", "r940" ], "calculation": { "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss)", "netLabel": "Net income attributable to Longevity Market Assets", "terseLabel": "Net income (loss)", "totalLabel": "NET INCOME ATTRIBUTABLE TO SHAREHOLDERS" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/EARNINGSPERSHAREBasicandDilutedDetails", "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "auth_ref": [ "r94", "r158", "r214", "r217", "r254", "r255", "r658", "r892" ], "calculation": { "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails": { "order": 10.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "negatedTerseLabel": "Less: Net loss attributable to non-controlling interests", "terseLabel": "LESS: NET INCOME (LOSS) ATTRIBUTABLE TO NONCONTROLLING INTEREST" } } }, "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetInvestmentIncome": { "auth_ref": [ "r175", "r662", "r663", "r770", "r863" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after investment expense, of income earned from investments in securities and real estate. Includes, but is not limited to, real estate investment, policy loans, dividends, and interest. Excludes realized gain (loss) on investments.", "label": "Net Investment Income", "verboseLabel": "Active management" } } }, "localname": "NetInvestmentIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SEGMENTREPORTINGRevenuebySegmentDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncompeteAgreementsMember": { "auth_ref": [ "r77" ], "lang": { "en-us": { "role": { "documentation": "Agreement in which one party agrees not to pursue a similar trade in competition with another party.", "label": "Noncompete Agreements [Member]", "terseLabel": "Non-Compete Agreements" } } }, "localname": "NoncompeteAgreementsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r79", "r442", "r901", "r902", "r903", "r976" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]", "terseLabel": "Non- Controlling Interests" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r132" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense)" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "OTHER INCOME (EXPENSE)" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_NonrelatedPartyMember": { "auth_ref": [ "r899", "r900" ], "lang": { "en-us": { "role": { "documentation": "Party not related to reporting entity.", "label": "Nonrelated Party [Member]", "terseLabel": "Nonrelated Party" } } }, "localname": "NonrelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "domainItemType" }, "us-gaap_NotesPayableOtherPayablesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A written promise to pay a note to a third party.", "label": "Notes Payable, Other Payables [Member]", "terseLabel": "Market-indexed notes" } } }, "localname": "NotesPayableOtherPayablesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r906" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "Number of Operating Segments", "terseLabel": "Number of operating segment" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTINGDetails" ], "xbrltype": "integerItemType" }, "us-gaap_NumberOfReportableSegments": { "auth_ref": [ "r906" ], "lang": { "en-us": { "role": { "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.", "label": "Number of Reportable Segments", "terseLabel": "Number of reportable segments" } } }, "localname": "NumberOfReportableSegments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SEGMENTREPORTINGNarrativeDetails" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "OPERATING EXPENSES:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r276", "r290", "r296", "r299", "r825" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_IncomeLossIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating Income" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r568", "r851" ], "calculation": { "http://abacuslife.com/role/LEASESLeaseExpenseDetails": { "order": 2.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating Lease, Cost", "terseLabel": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiability": { "auth_ref": [ "r565" ], "calculation": { "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails_1": { "order": 1.0, "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0 }, "http://abacuslife.com/role/LEASESROUAssetsandLeaseLiabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.", "label": "Operating Lease, Liability", "terseLabel": "Lease liability as of June 30, 2023", "totalLabel": "Total lease liability" } } }, "localname": "OperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESFutureMinimumNoncancellableLeasePaymentsDetails", "http://abacuslife.com/role/LEASESROUAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Lease, Liability [Abstract]", "terseLabel": "Liabilities:" } } }, "localname": "OperatingLeaseLiabilityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESROUAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLeaseLiabilityCurrent": { "auth_ref": [ "r565" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 }, "http://abacuslife.com/role/LEASESROUAssetsandLeaseLiabilitiesDetails": { "order": 1.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.", "label": "Operating Lease, Liability, Current", "terseLabel": "Operating lease liability, current", "verboseLabel": "Operating lease liabilities - current portion" } } }, "localname": "OperatingLeaseLiabilityCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/LEASESROUAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r565" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 }, "http://abacuslife.com/role/LEASESROUAssetsandLeaseLiabilitiesDetails": { "order": 2.0, "parentTag": "us-gaap_OperatingLeaseLiability", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Operating lease liability, non-current", "verboseLabel": "Operating lease liabilities - noncurrent portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/LEASESROUAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r566", "r570" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "Operating Lease, Payments", "terseLabel": "Operating cash flows from operating leases" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r564" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 9.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating Lease, Right-of-Use Asset", "terseLabel": "Operating lease right-of-use assets", "verboseLabel": "Operating right-of-use assets" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/LEASESROUAssetsandLeaseLiabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r894" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "terseLabel": "Non-cash lease expense" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "auth_ref": [ "r573", "r851" ], "lang": { "en-us": { "role": { "documentation": "Weighted average discount rate for operating lease calculated at point in time.", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "terseLabel": "Weighted-average discount rate" } } }, "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESLeaseTermsandDiscountRatesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "auth_ref": [ "r572", "r851" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Operating Lease, Weighted Average Remaining Lease Term", "terseLabel": "Weighted-average remaining lease term (in years)" } } }, "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESLeaseTermsandDiscountRatesDetails" ], "xbrltype": "durationItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_OtherAssetsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets.", "label": "Other Assets Disclosure [Text Block]", "terseLabel": "OTHER INVESTMENTS AND OTHER NONCURRENT ASSETS" } } }, "localname": "OtherAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETS" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAssetsFairValueDisclosure": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails": { "order": 3.0, "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Fair value portion of other assets.", "label": "Other Assets, Fair Value Disclosure", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSRecurringFairValueMeasurementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r204" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 6.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets, at fair value" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherCommitmentsAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of other commitment.", "label": "Other Commitments [Axis]", "terseLabel": "Other Commitments [Axis]" } } }, "localname": "OtherCommitmentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Other future obligation.", "label": "Other Commitments [Domain]", "terseLabel": "Other Commitments [Domain]" } } }, "localname": "OtherCommitmentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_OtherCommitmentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Other Commitments [Line Items]", "terseLabel": "Other Commitments [Line Items]" } } }, "localname": "OtherCommitmentsLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherCommitmentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about obligations resulting from other commitments.", "label": "Other Commitments [Table]", "terseLabel": "Other Commitments [Table]" } } }, "localname": "OtherCommitmentsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent": { "auth_ref": [ "r519", "r524" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) from increase (decrease) in instrument-specific credit risk of financial liability measured under fair value option, attributable to parent.", "label": "Other Comprehensive Income (Loss), Financial Liability, Fair Value Option, after Tax and Reclassification Adjustment, Attributable to Parent", "terseLabel": "Change in fair value of debt" } } }, "localname": "OtherComprehensiveIncomeLossFinancialLiabilityFairValueOptionAfterTaxAndReclassificationAdjustmentAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r13", "r19", "r215", "r218", "r225", "r552", "r553", "r558", "r640", "r660", "r890", "r891" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Other Comprehensive Income" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive Income (Loss), Net of Tax [Abstract]", "terseLabel": "Other comprehensive income, net of tax:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_OtherLiabilitiesCurrent": { "auth_ref": [ "r24", "r852" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 5.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherLongTermDebtNoncurrent": { "auth_ref": [ "r27", "r737" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term debt classified as other, payable after one year or the operating cycle, if longer.", "label": "Other Long-Term Debt, Noncurrent", "verboseLabel": "Long-term debt, at fair value" } } }, "localname": "OtherLongTermDebtNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r133" ], "calculation": { "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails": { "order": 6.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense)", "verboseLabel": "Other (expense) income" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent": { "auth_ref": [ "r888" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 7.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance for credit loss, of receivable classified as other and noncurrent.", "label": "Other Receivable, after Allowance for Credit Loss, Noncurrent", "terseLabel": "Due from members and affiliates" } } }, "localname": "OtherReceivableAfterAllowanceForCreditLossNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherReceivablesNetCurrent": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.", "label": "Other Receivables, Net, Current", "terseLabel": "Other receivables" } } }, "localname": "OtherReceivablesNetCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PartnerTypeOfPartnersCapitalAccountAxis": { "auth_ref": [ "r70", "r710" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of partner's capital account. Examples of classes of partners include, but not limited to, general partners, limited partners, preferred partners, and other ownership interests.", "label": "Partner Type [Axis]", "terseLabel": "Partner Type [Axis]" } } }, "localname": "PartnerTypeOfPartnersCapitalAccountAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PartnerTypeOfPartnersCapitalAccountNameDomain": { "auth_ref": [ "r150", "r710" ], "lang": { "en-us": { "role": { "documentation": "Capital accounts of each type or class of partner. Examples of classes of partners include, but are not limited to, general partners, limited partners, preferred partners, and other ownership interests.", "label": "Partner Type of Partners' Capital Account, Name [Domain]", "terseLabel": "Partner Type of Partners' Capital Account, Name [Domain]" } } }, "localname": "PartnerTypeOfPartnersCapitalAccountNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PaymentsForProceedsFromBusinessesAndInterestInAffiliates": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net cash outflow or inflow associated with the acquisition or sale of a business segment during the period.", "label": "Payments for (Proceeds from) Businesses and Interest in Affiliates", "negatedTerseLabel": "Due to/from members and affiliates" } } }, "localname": "PaymentsForProceedsFromBusinessesAndInterestInAffiliates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfDistributionsToAffiliates": { "auth_ref": [ "r38" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The distributions of earnings to an entity that is affiliated with the reporting entity by means of direct or indirect ownership.", "label": "Payments of Distributions to Affiliates", "negatedTerseLabel": "Distributions to members" } } }, "localname": "PaymentsOfDistributionsToAffiliates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsOfMergerRelatedCostsFinancingActivities": { "auth_ref": [ "r37" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for financing costs associated with business combinations.", "label": "Payments of Merger Related Costs, Financing Activities", "negatedTerseLabel": "Transaction costs" } } }, "localname": "PaymentsOfMergerRelatedCostsFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireAvailableForSaleSecuritiesDebt": { "auth_ref": [ "r34", "r230", "r309" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to acquire investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Payments to Acquire Debt Securities, Available-for-Sale", "negatedTerseLabel": "Purchase of investments", "terseLabel": "Purchase of convertible promissory note" } } }, "localname": "PaymentsToAcquireAvailableForSaleSecuritiesDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AVAILABLEFORSALESECURITIESATFAIRVALUEDetails", "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireIntangibleAssets": { "auth_ref": [ "r134" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.", "label": "Payments to Acquire Intangible Assets", "negatedTerseLabel": "Purchase of intangible asset" } } }, "localname": "PaymentsToAcquireIntangibleAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireProductiveAssets": { "auth_ref": [ "r173", "r948", "r949", "r950" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.", "label": "Payments to Acquire Productive Assets", "negatedTerseLabel": "Capital expenditures" } } }, "localname": "PaymentsToAcquireProductiveAssets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": { "auth_ref": [ "r465", "r466", "r467", "r473", "r474", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r484", "r844" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for retirement benefits.", "label": "Retirement Benefits [Text Block]", "terseLabel": "RETIREMENT PLAN" } } }, "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLAN" ], "xbrltype": "textBlockItemType" }, "us-gaap_PledgedStatusAxis": { "auth_ref": [ "r520", "r731", "r848" ], "lang": { "en-us": { "role": { "documentation": "Information by pledged or not pledged status of asset owned by entity.", "label": "Pledged Status [Axis]", "terseLabel": "Pledged Status [Axis]" } } }, "localname": "PledgedStatusAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PledgedStatusDomain": { "auth_ref": [ "r520", "r731", "r848" ], "lang": { "en-us": { "role": { "documentation": "Pledged or not pledged status of asset owned by entity.", "label": "Pledged Status [Domain]", "terseLabel": "Pledged Status [Domain]" } } }, "localname": "PledgedStatusDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "auth_ref": [ "r549" ], "lang": { "en-us": { "role": { "documentation": "Measured at fair value for financial reporting purposes.", "label": "Portion at Fair Value Measurement [Member]", "terseLabel": "Portion at Fair Value Measurement" } } }, "localname": "PortionAtFairValueFairValueDisclosureMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTGrowthandIncomeSeries12026IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries2024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLMATTSeries22024IncMarketIndexedNotesDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PostemploymentBenefitsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Postemployment Benefits [Abstract]" } } }, "localname": "PostemploymentBenefitsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r119", "r426" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r119", "r740" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r119", "r426" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r119", "r740", "r758", "r976", "r977" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r889" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromContributionsFromAffiliates": { "auth_ref": [ "r35" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from an entity that is affiliated with the entity by means of direct or indirect ownership.", "label": "Proceeds from Contributions from Affiliates", "terseLabel": "Due to members and affiliates" } } }, "localname": "ProceedsFromContributionsFromAffiliates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfOtherLongTermDebt": { "auth_ref": [ "r36" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of long-term debt classified as other.", "label": "Proceeds from Issuance of Other Long-Term Debt", "terseLabel": "Issuance of debt certificates" } } }, "localname": "ProceedsFromIssuanceOfOtherLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSecuredDebt": { "auth_ref": [ "r36" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from amounts received from issuance of long-term debt that is wholly or partially secured by collateral. Excludes proceeds from tax exempt secured debt.", "label": "Proceeds from Issuance of Secured Debt", "terseLabel": "Proceeds from Issuance of Secured Debt" } } }, "localname": "ProceedsFromIssuanceOfSecuredDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r196", "r214", "r217", "r231", "r236", "r246", "r254", "r255", "r276", "r290", "r296", "r299", "r344", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r519", "r522", "r523", "r537", "r551", "r645", "r657", "r706", "r760", "r783", "r784", "r825", "r849", "r850", "r864", "r892", "r940" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net Income", "totalLabel": "NET INCOME", "verboseLabel": "NET INCOME" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Abstract]" } } }, "localname": "PropertyPlantAndEquipmentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]", "terseLabel": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "auth_ref": [ "r142", "r182", "r185", "r186" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment Disclosure [Text Block]", "terseLabel": "PROPERTY AND EQUIPMENT\u2014NET" } } }, "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNET" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentGross": { "auth_ref": [ "r143", "r201", "r656" ], "calculation": { "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETDetails": { "order": 1.0, "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Gross", "terseLabel": "Property and equipment\u2014gross" } } }, "localname": "PropertyPlantAndEquipmentGross", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r8", "r646", "r656", "r852" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 12.0, "parentTag": "us-gaap_Assets", "weight": 1.0 }, "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net", "totalLabel": "Property and equipment\u2014net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table Text Block]", "terseLabel": "Summary of Property and Equipment, Net" } } }, "localname": "PropertyPlantAndEquipmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.", "label": "Long-Lived Tangible Asset [Domain]", "terseLabel": "Long-Lived Tangible Asset [Domain]" } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ReceivablesPolicyTextBlock": { "auth_ref": [ "r907", "r908", "r909", "r910" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.", "label": "Receivable [Policy Text Block]", "terseLabel": "Other Receivables" } } }, "localname": "ReceivablesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": { "auth_ref": [ "r55", "r56" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.", "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]", "terseLabel": "Summary of Revenue by Segment" } } }, "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SEGMENTREPORTINGTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r475", "r579", "r580", "r732", "r733", "r734", "r735", "r736", "r757", "r759", "r792" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Domain]", "terseLabel": "Related Party, Type [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyMember": { "auth_ref": [ "r238", "r239", "r579", "r580", "r581", "r582", "r732", "r733", "r734", "r735", "r736", "r757", "r759", "r792" ], "lang": { "en-us": { "role": { "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family.", "label": "Related Party [Member]", "terseLabel": "Related Party" } } }, "localname": "RelatedPartyMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAxis": { "auth_ref": [ "r579", "r580", "r960" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party transaction.", "label": "Related Party Transaction [Axis]", "terseLabel": "Related Party Transaction [Axis]" } } }, "localname": "RelatedPartyTransactionAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Transaction between related party.", "label": "Related Party Transaction [Domain]", "terseLabel": "Related Party Transaction [Domain]" } } }, "localname": "RelatedPartyTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [ "r764", "r765", "r768" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionRate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties.", "label": "Related Party Transaction, Rate", "terseLabel": "Related party transaction rate" } } }, "localname": "RelatedPartyTransactionRate", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "percentItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r475", "r579", "r580", "r626", "r627", "r628", "r629", "r630", "r631", "r632", "r633", "r634", "r635", "r636", "r637", "r732", "r733", "r734", "r735", "r736", "r757", "r759", "r792", "r960" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]", "terseLabel": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r576", "r577", "r578", "r580", "r583", "r702", "r703", "r704", "r766", "r767", "r768", "r789", "r791" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Related Party Transactions Disclosure [Text Block]", "terseLabel": "RELATED-PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONS", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONS" ], "xbrltype": "textBlockItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r122", "r149", "r652", "r690", "r692", "r700", "r741", "r852" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained earnings/(accumulated deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r193", "r243", "r244", "r245", "r247", "r253", "r255", "r360", "r361", "r489", "r490", "r491", "r507", "r508", "r527", "r529", "r530", "r532", "r535", "r687", "r689", "r707", "r976" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]", "terseLabel": "Retained Earnings (Accumulated Deficit)", "verboseLabel": "Retained Earnings" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer [Abstract]" } } }, "localname": "RevenueFromContractWithCustomerAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r277", "r278", "r289", "r294", "r295", "r301", "r303", "r304", "r461", "r462", "r623" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_Revenues", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "netLabel": "Origination revenue", "terseLabel": "Total portfolio servicing revenue", "verboseLabel": "Portfolio servicing" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "http://abacuslife.com/role/AbacusSettlementsLLCREVENUEDetails", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails", "http://abacuslife.com/role/SEGMENTREPORTINGRevenuebySegmentDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r190", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r816" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Cost of Revenues" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "auth_ref": [ "r190", "r445", "r446", "r447", "r448", "r449", "r450", "r451", "r452", "r464" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.", "label": "Revenue from Contract with Customer [Text Block]", "terseLabel": "REVENUE" } } }, "localname": "RevenueFromContractWithCustomerTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCREVENUE" ], "xbrltype": "textBlockItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r224", "r236", "r277", "r278", "r289", "r294", "r295", "r301", "r303", "r304", "r344", "r399", "r400", "r401", "r402", "r403", "r404", "r405", "r406", "r407", "r551", "r645", "r940" ], "calculation": { "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 2.0, "parentTag": "us-gaap_GrossProfit", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "totalLabel": "Total revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/SEGMENTREPORTINGRevenuebySegmentDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenuesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Revenues [Abstract]", "terseLabel": "REVENUES:" } } }, "localname": "RevenuesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r571", "r851" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "ROU assets obtained in exchange for new lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESSupplementalCashFlowInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SalesRevenueNetMember": { "auth_ref": [ "r304", "r875" ], "lang": { "en-us": { "role": { "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.", "label": "Revenue Benchmark [Member]", "terseLabel": "Revenue Benchmark" } } }, "localname": "SalesRevenueNetMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r43" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/EARNINGSPERSHARENarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r73", "r74", "r518" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]", "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONProFormaFinancialInformationDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONPurchasePriceAllocationDetails", "http://abacuslife.com/role/BUSINESSCOMBINATIONValueConveyedDetails", "http://abacuslife.com/role/DESCRIPTIONOFBUSINESSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "auth_ref": [ "r73", "r74" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts.", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "terseLabel": "Value conveyed" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.", "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]", "terseLabel": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments" } } }, "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "auth_ref": [ "r905" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of Earnings Per Share, Basic and Diluted" } } }, "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/EARNINGSPERSHARETables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r59", "r62", "r624" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.", "label": "Schedule of Finite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r59", "r62" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Finite-Lived Intangible Assets" } } }, "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfGoodwillTable": { "auth_ref": [ "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r828" ], "lang": { "en-us": { "role": { "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.", "label": "Schedule of Goodwill [Table]", "terseLabel": "Schedule of Goodwill [Table]" } } }, "localname": "ScheduleOfGoodwillTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSChangesinGoodwillbyReportableSegmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfGoodwillTextBlock": { "auth_ref": [ "r828", "r924", "r925", "r926", "r927", "r928", "r929", "r930", "r931", "r932", "r933", "r934" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.", "label": "Schedule of Goodwill [Table Text Block]", "terseLabel": "Schedule of Goodwill" } } }, "localname": "ScheduleOfGoodwillTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": { "auth_ref": [ "r17", "r141" ], "lang": { "en-us": { "role": { "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "auth_ref": [ "r17", "r141" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "terseLabel": "Schedule of Indefinite-Lived Intangible Assets" } } }, "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLifeSettlementContractsFairValueMethodTextBlock": { "auth_ref": [ "r921", "r922", "r923" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of life settlement contracts based on the remaining life expectancy for each of the first five succeeding years from the date of the statement of financial position and thereafter, as well as in the aggregate including: (a) the number of life settlement contracts, (b) the carrying value of the life settlement contracts, and (c) the face value (death benefits) of the life insurance policies underlying the contracts.", "label": "Schedule of Life Settlement Contracts, Fair Value Method [Table Text Block]", "terseLabel": "Schedule of Life Settlement Contracts, Fair Value Method" } } }, "localname": "ScheduleOfLifeSettlementContractsFairValueMethodTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfLifeSettlementContractsInvestmentMethodTextBlock": { "auth_ref": [ "r917", "r918", "r919", "r920" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of life settlement contracts based on the remaining life expectancy for each of the first five succeeding years from the date of the statement of financial position and thereafter, as well as in the aggregate including: (a) the number of life settlement contracts, (b) the carrying value of the life settlement contracts, and (c) the face value (death benefits) of the life insurance policies underlying the contracts, and (d) the life insurance premiums anticipated to be paid for each of the five succeeding fiscal years to keep the life settlement contracts in force as of the date of the most recent statement of financial position presented.", "label": "Schedule of Life Settlement Contracts, Investment Method [Table Text Block]", "terseLabel": "Schedule of Life Settlement Contracts, Investment Method" } } }, "localname": "ScheduleOfLifeSettlementContractsInvestmentMethodTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LIFEINSURANCESETTLEMENTPOLICIESTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]", "terseLabel": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/PROPERTYANDEQUIPMENTNETDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r155" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]", "terseLabel": "Purchase price allocation" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r111", "r112", "r764", "r765", "r768" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]", "terseLabel": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSNarrativeDetails", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSRevenueEarnedandContractsOriginatedDetails", "http://abacuslife.com/role/RELATEDPARTYTRANSACTIONSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates.", "label": "Schedule of Related Party Transactions [Table Text Block]", "terseLabel": "Schedule of Related Party Transactions" } } }, "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r52", "r53", "r54", "r57" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]", "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTINGDetails", "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails", "http://abacuslife.com/role/SEGMENTREPORTINGRevenuebySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r52", "r53", "r54", "r57" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Summary of Segment Information" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SEGMENTREPORTINGTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This table describes the key aspects of a subsidiary (partnership, corporation, or other entity) of the Limited Liability Company (LLC) or Limited Partnership (LP).", "label": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership [Table]", "terseLabel": "Schedule of Subsidiary of Limited Liability Company or Limited Partnership [Table]" } } }, "localname": "ScheduleOfSubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESS", "http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXES", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONS", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSTables", "http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLAN", "http://abacuslife.com/role/AbacusSettlementsLLCREVENUE", "http://abacuslife.com/role/AbacusSettlementsLLCREVENUETables", "http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTING", "http://abacuslife.com/role/AbacusSettlementsLLCSUBSEQUENTEVENT", "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfVariableInterestEntitiesTable": { "auth_ref": [ "r84", "r85", "r87", "r91", "r92", "r520", "r521", "r525", "r526", "r602", "r603", "r604" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of qualitative and quantitative information related to variable interests the entity holds, whether or not such variable interest entity (VIE) is included in the reporting entity's consolidated financial statements. Includes, but is not limited to, description of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a tabular comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.", "label": "Schedule of Variable Interest Entities [Table]", "terseLabel": "Schedule of Variable Interest Entities [Table]" } } }, "localname": "ScheduleOfVariableInterestEntitiesTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONSOLIDATIONOFVARIABLEINTERESTENTITIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": { "auth_ref": [ "r44", "r45", "r47", "r48", "r102", "r160" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.", "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]", "terseLabel": "Schedules of Concentration of Risk, by Risk Factor" } } }, "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets.", "label": "Secured Debt [Member]", "terseLabel": "Secured borrowing" } } }, "localname": "SecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesIILPandLMAIncomeSeriesIIGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLMAIncomeSeriesLPandLMAIncomeSeriesGPLLCSecuredBorrowingDetails", "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails", "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SecuredLongTermDebt": { "auth_ref": [ "r27" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of collateralized debt obligations with maturities initially due after one year or beyond the operating cycle, if longer, excluding the current portion. Obligations include, but not limited to, mortgage loans, chattel loans, and other borrowings secured by assets.", "label": "Secured Long-Term Debt, Noncurrent", "terseLabel": "SPV purchase and sale note" } } }, "localname": "SecuredLongTermDebt", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember": { "auth_ref": [ "r951" ], "lang": { "en-us": { "role": { "documentation": "Fixed rate on U.S. dollar, constant-notional interest rate swap that has its variable-rate leg referenced to Secured Overnight Financing Rate (SOFR) with no additional spread over SOFR on variable-rate leg.", "label": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate [Member]", "terseLabel": "Secured Overnight Financing Rate (SOFR) Overnight Index Swap Rate" } } }, "localname": "SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r273", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r304", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r391", "r392", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r828", "r879", "r970" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.", "label": "Segments [Domain]", "terseLabel": "Segments [Domain]" } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails", "http://abacuslife.com/role/SEGMENTREPORTINGRevenuebySegmentDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r272", "r273", "r274", "r275", "r276", "r288", "r293", "r297", "r298", "r299", "r300", "r301", "r302", "r304" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "SEGMENT REPORTING" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTING", "http://abacuslife.com/role/SEGMENTREPORTING" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTINGDetails", "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails", "http://abacuslife.com/role/SEGMENTREPORTINGRevenuebySegmentDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingAndMarketingExpense": { "auth_ref": [], "calculation": { "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 }, "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 3.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services.", "label": "Selling and Marketing Expense", "negatedTerseLabel": "Sales and marketing", "terseLabel": "Sales and marketing" } } }, "localname": "SellingAndMarketingExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r138", "r234" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]", "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r195", "r273", "r276", "r277", "r278", "r279", "r280", "r281", "r282", "r283", "r284", "r285", "r286", "r287", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r299", "r304", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r380", "r381", "r390", "r391", "r392", "r669", "r670", "r671", "r672", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "r828", "r879", "r970" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]", "terseLabel": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails", "http://abacuslife.com/role/SEGMENTREPORTINGRevenuebySegmentDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConcentrationsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementClassOfStockAxis": { "auth_ref": [ "r191", "r206", "r207", "r208", "r236", "r259", "r260", "r262", "r264", "r270", "r271", "r344", "r399", "r401", "r402", "r403", "r406", "r407", "r426", "r427", "r430", "r433", "r440", "r551", "r696", "r697", "r698", "r699", "r707", "r708", "r709", "r711", "r712", "r713", "r714", "r715", "r716", "r717", "r718", "r719", "r740", "r761", "r785", "r804", "r805", "r806", "r807", "r808", "r873", "r895", "r904" ], "lang": { "en-us": { "role": { "documentation": "Information by the different classes of stock of the entity.", "label": "Class of Stock [Axis]", "terseLabel": "Class of Stock [Axis]" } } }, "localname": "StatementClassOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESSDetails", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEBALANCESHEETSParenthetical", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/COVER", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r13", "r29", "r193", "r220", "r221", "r222", "r243", "r244", "r245", "r247", "r253", "r255", "r269", "r360", "r361", "r442", "r489", "r490", "r491", "r507", "r508", "r527", "r528", "r529", "r530", "r531", "r532", "r535", "r552", "r554", "r555", "r556", "r557", "r558", "r575", "r687", "r688", "r689", "r707", "r785" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r243", "r244", "r245", "r269", "r623", "r694", "r719", "r730", "r732", "r733", "r734", "r735", "r736", "r740", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r757", "r759", "r762", "r763", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r785", "r858" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEBALANCESHEETSParenthetical", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r243", "r244", "r245", "r269", "r623", "r694", "r719", "r730", "r732", "r733", "r734", "r735", "r736", "r740", "r743", "r744", "r745", "r746", "r747", "r748", "r749", "r750", "r751", "r753", "r754", "r755", "r756", "r757", "r759", "r762", "r763", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r778", "r779", "r780", "r781", "r782", "r785", "r858" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY", "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDINTERIMCONDENSEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEBALANCESHEETSParenthetical", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "auth_ref": [ "r13", "r29", "r149" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of stock issued pursuant to acquisitions during the period.", "label": "Stock Issued During Period, Value, Acquisitions", "terseLabel": "Marger/Acquisition" } } }, "localname": "StockIssuedDuringPeriodValueAcquisitions", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r79", "r80", "r93", "r193", "r194", "r221", "r243", "r244", "r245", "r247", "r253", "r360", "r361", "r442", "r489", "r490", "r491", "r507", "r508", "r527", "r528", "r529", "r530", "r531", "r532", "r535", "r552", "r554", "r558", "r575", "r688", "r689", "r705", "r742", "r758", "r786", "r787", "r809", "r864", "r897", "r916", "r955", "r976" ], "calculation": { "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total shareholders' equity (deficit)" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDSTATEMENTSOFCHANGESINMEMBERSEQUITY", "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCHANGESINSHAREHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity, Including Portion Attributable to Noncontrolling Interest [Abstract]", "terseLabel": "SHAREHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONDENSEDCONSOLIDATEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r146", "r235", "r425", "r427", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r437", "r439", "r442", "r534", "r788", "r790", "r810" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]", "terseLabel": "SHAREHOLDERS' EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SHAREHOLDERSEQUITY" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [ "r559", "r586" ], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r559", "r586" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Event" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r559", "r586" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]", "terseLabel": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r559", "r586" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]", "terseLabel": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r559", "r586" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]", "terseLabel": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/LONGTERMDEBTSPVPurchaseandSaleandSPVInvestmentFacilityDetails", "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r585", "r587" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]", "terseLabel": "SUBSEQUENT EVENTS", "verboseLabel": "SUBSEQUENT EVENT" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCSUBSEQUENTEVENT", "http://abacuslife.com/role/SUBSEQUENTEVENTS" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Subsidiary of Limited Liability Company or Limited Partnership [Line Items]", "terseLabel": "Subsidiary of Limited Liability Company or Limited Partnership [Line Items]" } } }, "localname": "SubsidiaryOfLimitedLiabilityCompanyOrLimitedPartnershipLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCDESCRIPTIONOFTHEBUSINESS", "http://abacuslife.com/role/AbacusSettlementsLLCINCOMETAXES", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONS", "http://abacuslife.com/role/AbacusSettlementsLLCRELATEDPARTYTRANSACTIONSTables", "http://abacuslife.com/role/AbacusSettlementsLLCRETIREMENTPLAN", "http://abacuslife.com/role/AbacusSettlementsLLCREVENUE", "http://abacuslife.com/role/AbacusSettlementsLLCREVENUETables", "http://abacuslife.com/role/AbacusSettlementsLLCSEGMENTREPORTING", "http://abacuslife.com/role/AbacusSettlementsLLCSUBSEQUENTEVENT", "http://abacuslife.com/role/AbacusSettlementsLLCSUMMARYOFSIGNIFICANTACCOUNTINGPOLICIES", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "stringItemType" }, "us-gaap_TradeNamesMember": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.", "label": "Trade Names [Member]", "terseLabel": "Trade Name" } } }, "localname": "TradeNamesMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONIntangibleAssetsAcquiredDetails", "http://abacuslife.com/role/GOODWILLANDOTHERINTANGIBLEASSETSIntangibleAssetsAcquiredDetails" ], "xbrltype": "domainItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r424", "r438", "r533", "r588", "r589", "r590", "r591", "r592", "r593", "r594", "r595", "r596", "r597", "r598", "r599", "r600", "r601", "r605", "r606", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r661", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r912", "r913", "r914", "r915" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/OTHERINVESTMENTSANDOTHERNONCURRENTASSETSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UnrealizedGainLossOnInvestments": { "auth_ref": [ "r7" ], "calculation": { "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails": { "order": 5.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 }, "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 }, "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of unrealized gain (loss) on investment.", "label": "Unrealized Gain (Loss) on Investments", "negatedLabel": "Unrealized loss (gain) on investments", "negatedTerseLabel": "Unrealized (gain) loss on investments", "terseLabel": "Unrealized gain (loss) on investments" } } }, "localname": "UnrealizedGainLossOnInvestments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SEGMENTREPORTINGReconciliationofNetIncomeDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFCASHFLOWS", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "monetaryItemType" }, "us-gaap_UnsecuredDebtMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.", "label": "Unsecured Debt [Member]", "terseLabel": "Unsecured borrowing" } } }, "localname": "UnsecuredDebtMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LONGTERMDEBTLongTermDebtDetails", "http://abacuslife.com/role/LONGTERMDEBTSponsorPIKNoteDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r49", "r50", "r51", "r179", "r180", "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDiscountedCashFlowMember": { "auth_ref": [ "r953" ], "lang": { "en-us": { "role": { "documentation": "Valuation technique calculating present value of future cash flows.", "label": "Valuation Technique, Discounted Cash Flow [Member]", "terseLabel": "Discounted cash flow method" } } }, "localname": "ValuationTechniqueDiscountedCashFlowMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/BUSINESSCOMBINATIONNarrativeDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableInterestEntityDisclosureTextBlock": { "auth_ref": [ "r156" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a variable interest entity (VIE), including but not limited to, judgments and assumptions in determining whether to consolidate and in identifying the primary beneficiary, gain (loss) recognized on the initial consolidation of the VIE, terms of arrangements, amounts and classification of the VIE's assets and liabilities, and the entity's maximum exposure to loss.", "label": "Variable Interest Entity Disclosure [Text Block]", "terseLabel": "CONSOLIDATION OF VARIABLE INTEREST ENTITIES" } } }, "localname": "VariableInterestEntityDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONSOLIDATIONOFVARIABLEINTERESTENTITIES" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableInterestEntityFinancialOrOtherSupportAmount": { "auth_ref": [ "r89" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of financial or other support the reporting entity has provided (explicitly or implicitly) to the Variable Interest Entity (VIE) that it was not previously contractually required to provide or that the reporting entity intends to provide, including, for example, situations in which the reporting entity assisted the VIE in obtaining another type of support.", "label": "Variable Interest Entity, Financial or Other Support, Amount", "terseLabel": "Contribution amount" } } }, "localname": "VariableInterestEntityFinancialOrOtherSupportAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableInterestEntityLineItems": { "auth_ref": [ "r520", "r521", "r525", "r526", "r602", "r603", "r604" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Variable Interest Entity [Line Items]", "terseLabel": "Variable Interest Entity [Line Items]" } } }, "localname": "VariableInterestEntityLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONSOLIDATIONOFVARIABLEINTERESTENTITIESDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableInterestEntityNotPrimaryBeneficiaryMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity does not have a controlling financial interest (as defined) and of which it is therefore not the primary beneficiary. VIEs of which the entity is not the primary beneficiary because it does not have the power to direct the activities of the VIE that most significantly impact the VIE's economic performance and for which it does not have the obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE are not included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Not Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Not Primary Beneficiary" } } }, "localname": "VariableInterestEntityNotPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://abacuslife.com/role/CONSOLIDATIONOFVARIABLEINTERESTENTITIESDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableInterestEntityOwnershipPercentage": { "auth_ref": [ "r90" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the Variable Interest Entity's (VIE) voting interest owned by (or beneficial interest in) the reporting entity (directly or indirectly).", "label": "Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage", "terseLabel": "Ownership percentage" } } }, "localname": "VariableInterestEntityOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_VariableInterestEntityPrimaryBeneficiaryMember": { "auth_ref": [ "r84", "r520", "r521", "r525", "r526" ], "lang": { "en-us": { "role": { "documentation": "Variable Interest Entities (VIE) in which the entity has a controlling financial interest (as defined) and of which it is therefore the primary beneficiary. A controlling financial interest is determined based on both: (a) the entity's power to direct activities of the VIE that most significantly impact the VIE's economic performance and (b) the entity's obligation to absorb losses of the VIE that could potentially be significant to the VIE or the right to receive benefits from the VIE that could potentially be significant to the VIE. VIEs of which the entity is the primary beneficiary are included in the consolidated financial statements of the entity.", "label": "Variable Interest Entity, Primary Beneficiary [Member]", "terseLabel": "Variable Interest Entity, Primary Beneficiary" } } }, "localname": "VariableInterestEntityPrimaryBeneficiaryMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/CONSOLIDATIONOFVARIABLEINTERESTENTITIESDetails", "http://abacuslife.com/role/SUMMARYOFSIGNIFICANTACCOUNTINGPOLICIESConsolidationofVariableInterestEntitiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r569", "r851" ], "calculation": { "http://abacuslife.com/role/LEASESLeaseExpenseDetails": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable Lease, Cost", "terseLabel": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/LEASESLeaseExpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_VariableRateAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of variable rate.", "label": "Variable Rate [Axis]", "terseLabel": "Variable Rate [Axis]" } } }, "localname": "VariableRateAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "stringItemType" }, "us-gaap_VariableRateDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.", "label": "Variable Rate [Domain]", "terseLabel": "Variable Rate [Domain]" } } }, "localname": "VariableRateDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/SUBSEQUENTEVENTSDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantMember": { "auth_ref": [ "r855", "r856", "r859", "r860", "r861", "r862" ], "lang": { "en-us": { "role": { "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.", "label": "Warrant [Member]", "terseLabel": "Warrant" } } }, "localname": "WarrantMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/COVER" ], "xbrltype": "domainItemType" }, "us-gaap_WarrantsAndRightsOutstanding": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.", "label": "Warrants and Rights Outstanding", "terseLabel": "Warrants outstanding" } } }, "localname": "WarrantsAndRightsOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r543" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants and rights outstanding, measurement input" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSAssumptionsDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "decimalItemType" }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "auth_ref": [ "r954" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Warrants and Rights Outstanding, Term", "verboseLabel": "Warrants term" } } }, "localname": "WarrantsAndRightsOutstandingTerm", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://abacuslife.com/role/SHAREHOLDERSEQUITYDetails" ], "xbrltype": "durationItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r258", "r264" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares used in computing net income per share, diluted (in shares)", "verboseLabel": "Diluted weighted average shares outstanding (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/EARNINGSPERSHAREBasicandDilutedDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r257", "r264" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic weighted average shares outstanding (in shares)", "verboseLabel": "Weighted-average shares used in computing net income per share, basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME", "http://abacuslife.com/role/EARNINGSPERSHAREBasicandDilutedDetails", "http://abacuslife.com/role/UNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "WEIGHTED-AVERAGE UNITS USED IN COMPUTING NET INCOME (LOSS) PER UNIT:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://abacuslife.com/role/AbacusSettlementsLLCUNAUDITEDCONDENSEDCONSOLIDATEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVEINCOME" ], "xbrltype": "stringItemType" } }, "unitCount": 13 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "30", "SubTopic": "30", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479637/805-30-30-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-22", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-30", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "470", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480848/942-470-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//205-20/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(20))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(8))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.1,2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.18)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.2)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(b))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "350", "URI": "https://asc.fasb.org//350/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(3)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org//360/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "470", "URI": "https://asc.fasb.org//470/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-7", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.F)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "15A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-15A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org//805/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org//810/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-23", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org//940-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(15)(1))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(16))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b),(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.9)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org//942-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r172": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org//946-320/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482739/220-10-55-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org//606/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(22))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(12))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(13))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(14))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(27)(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(4))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(210.5-03(11))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(22))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org//260/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org//280/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-26", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-34", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org//320/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aaa)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(3)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(4)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "30", "Topic": "325", "URI": "https://asc.fasb.org//325-30/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481493/325-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479130/326-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479106/326-30-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147479823/420-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "405", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147481071/942-405-45-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1E", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "1F", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r465": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "715", "URI": "https://asc.fasb.org//715/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(l)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r475": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r476": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(o)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r477": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(p)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r478": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(q)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r479": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(1)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(r)(2)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r481": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480126/715-20-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r482": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "60", "Subparagraph": "(c)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480266/715-60-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r483": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org//715-70/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r484": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "70", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480794/715-70-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r485": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r486": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r487": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r488": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r489": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r491": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r492": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org//1943274/2147483406/720-35-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r493": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r494": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "6B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "6B", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482736/825-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r554": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r555": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r556": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r557": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r558": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r559": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r560": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r561": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r562": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "835", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r563": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//842-20/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r564": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r565": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r566": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r567": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r568": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r569": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r570": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r571": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r572": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(3)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r573": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(4)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r574": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r575": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r576": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org//850/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r577": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r578": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r579": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482686/350-30-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r580": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r581": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r582": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r583": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r584": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r585": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r586": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r587": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r588": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r589": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r590": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r591": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r592": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r593": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r594": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r595": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r596": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r597": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r598": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r599": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r600": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r601": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481444/860-30-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r602": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r603": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)(ii)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r604": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r605": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r606": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r607": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r608": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r609": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "((a)(1),(b))", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r610": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r611": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r612": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r613": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r614": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r615": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r616": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r617": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r618": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r619": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r620": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481229/860-50-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r621": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r622": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r623": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r624": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r625": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r626": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r627": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r628": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r629": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(2)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r630": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r631": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r632": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r633": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r634": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r635": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r636": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r637": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r638": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r639": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r640": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r641": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(24))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r642": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r643": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r644": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r645": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r646": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r647": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r648": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(15)(b)(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r649": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r650": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r651": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r652": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r653": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r654": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r655": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r656": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r657": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(16))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r658": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(17))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r659": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481544/470-10-50-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r660": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r661": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(a))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r662": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2)(d))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r663": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(2))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r664": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(20))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r665": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r666": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r667": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r668": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r669": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r670": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r671": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r672": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r673": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r674": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r675": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column G))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r676": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column H))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r677": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column I))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r678": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column J))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r679": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-16(Column K))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r680": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column A))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r681": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column B))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r682": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column C))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r683": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column D))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r684": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column E))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r685": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.12-17(Column F))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480149/944-235-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r686": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r687": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r688": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r689": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r690": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r691": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r692": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r693": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r694": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r695": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(h)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r696": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r697": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r698": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r699": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 4.F)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r700": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r701": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r702": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r703": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r704": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r705": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r706": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r707": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r708": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r709": { "Name": "Accounting Standards Codification", "Paragraph": "27", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-27", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r710": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r711": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r712": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r713": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r714": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r715": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r716": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r717": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(g)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r718": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "205", "Subparagraph": "(h)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480737/946-205-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r719": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "217", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482663/740-10-55-217", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r720": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r721": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r722": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r723": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(c)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r724": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r725": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r726": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(2)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r727": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(4)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r728": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r729": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r730": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r731": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(11))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r732": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r733": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r734": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r735": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r736": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r737": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r738": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r739": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r740": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r741": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r742": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r743": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r744": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r745": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r746": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r747": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r748": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r749": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r750": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r751": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r752": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r753": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r754": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r755": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r756": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r757": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r758": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r759": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r760": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r761": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483580/946-220-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r762": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r763": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r764": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r765": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r766": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r767": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r768": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r769": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r770": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r771": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r772": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r773": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r774": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r775": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r776": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r777": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r778": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r779": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r780": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r781": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r782": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r783": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r784": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r785": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r786": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r787": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r788": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r789": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r790": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r791": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r792": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r793": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r794": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r795": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r796": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r797": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13(Column A)(Footnote 3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r798": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13A(Column E))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r799": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E)(Footnote 4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r800": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13B(Column E))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r801": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H)(Footnote 7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r802": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-13C(Column H))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-5C", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r803": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r804": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r805": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r806": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r807": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r808": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r809": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-21", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r810": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r811": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147481027/954-310-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r812": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r813": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r814": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r815": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r816": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r817": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r818": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r819": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r820": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r821": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r822": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r823": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r824": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r825": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r826": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r827": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479081/326-30-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r828": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r829": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "2AA", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "a", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-2AA", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r830": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r831": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r832": { "Name": "Accounting Standards Codification", "Paragraph": "69E", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r833": { "Name": "Accounting Standards Codification", "Paragraph": "69F", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r834": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r835": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r836": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r837": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r838": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r839": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r840": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r841": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r842": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r843": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r844": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r845": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r846": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r847": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r848": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r849": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r850": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r851": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r852": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r853": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479401/944-30-55-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r854": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r855": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r856": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r857": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r858": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r859": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r860": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r861": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r862": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r863": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r864": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r865": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r866": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r867": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r868": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r869": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r870": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r871": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r872": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r873": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r874": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r875": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r876": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479383/944-825-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r877": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r878": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(3)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r879": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-4H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r880": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r881": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r882": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r883": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r884": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r885": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r886": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r887": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r888": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r889": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r890": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r891": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r892": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r893": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r894": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r895": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(d))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r896": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(f))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r897": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r898": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r899": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-5A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r900": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r901": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r902": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r903": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r904": { "Name": "Accounting Standards Codification", "Paragraph": "55", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-55", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r905": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r906": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r907": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r908": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r909": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-6", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r910": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r911": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481830/320-10-45-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r912": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org//1943274/2147481800/320-10-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r913": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r914": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r915": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r916": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r917": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r918": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r919": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r920": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r921": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r922": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r923": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "325", "URI": "https://asc.fasb.org//1943274/2147481463/325-30-50-8", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r924": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r925": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r926": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r927": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r928": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r929": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r930": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r931": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r932": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r933": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r934": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r935": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r936": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r937": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r938": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r939": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r940": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r941": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r942": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r943": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r944": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r945": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r946": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r947": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147483041/730-20-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r948": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147480060/805-50-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r949": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r950": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "30", "SubTopic": "50", "Topic": "805", "URI": "https://asc.fasb.org//1943274/2147480027/805-50-30-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r951": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480682/815-20-25-6A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r952": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r953": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r954": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r955": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r956": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r957": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r958": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r959": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4M", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4M", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r960": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r961": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r962": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r963": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r964": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r965": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r966": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r967": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r968": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r969": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481420/860-30-50-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r970": { "Name": "Accounting Standards Codification", "Paragraph": "2B", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r971": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(c)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r972": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r973": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(3)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r974": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(18))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r975": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(i)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r976": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r977": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 121 0001814287-23-000007-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001814287-23-000007-xbrl.zip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end

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�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